<SEC-DOCUMENT>0001724521-23-000021.txt : 20231107
<SEC-HEADER>0001724521-23-000021.hdr.sgml : 20231107
<ACCEPTANCE-DATETIME>20231107161143
ACCESSION NUMBER:		0001724521-23-000021
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231107
DATE AS OF CHANGE:		20231107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38419
		FILM NUMBER:		231384040

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 694-6200

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>rcus-20230930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:805eb66e-844e-45f5-86a8-527ac86fecd7,g:7538c7a3-a72e-4e53-a8d0-2829fb9c9dc2,d:f2f5ba682505427b80ca0ea888ebdc11--><html xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:rcus="http://arcusbio.com/20230930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rcus-20230930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001724521</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-27">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-69" name="us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" id="f-615">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-26" name="us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" id="f-616">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-322" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-754">458</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rcus-20230930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:SecondStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:SecondStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:SecondStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>rcus:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rcus:CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedInvestorRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>rcus:Program</xbrli:measure></xbrli:unit><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiPDOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:AbmunoLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationLicenseAndRDServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationLicenseAndRDServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationLicenseAndRDServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationLicenseAndRDServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationAccessRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationAccessRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationAccessRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationAccessRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationRDServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationRDServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationRDServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationRDServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationAccessRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationAccessRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationAccessRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationAccessRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rcus:InflammationTarget1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rcus:InflammationTarget2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForInflammationProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForInflammationProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForInflammationProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForDomvanalimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForDomvanalimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForDomvanalimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForDomvanalimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR221DevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR221DevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR221DevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR221DevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>rcus:position</xbrli:measure></xbrli:unit><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:SecondStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:SecondStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rcus:AtTheMarketFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rcus:AtTheMarketFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:UsGovernmentAgencyObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:UsGovernmentAgencyObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:UsGovernmentAgencyObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:UsGovernmentAgencyObligationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">rcus:OfficersAndDirectorsTradingArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:JuanCJaenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:JuanCJaenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if2f5ba682505427b80ca0ea888ebdc11_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2023</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from _____________to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_______________ </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38419</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Arcus Biosciences, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">47-3898435</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">3928 Point Eden Way</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Hayward</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">94545</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">510</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">694-6200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:37.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Titles of Each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Name of Each Exchange on which Registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, Par Value $0.0001 Per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">RCUS</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">x</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of November&#160;1, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">74,855,565</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:18pt;padding-left:6pt;padding-right:6pt;text-align:center"><span><br/></span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_10">RISK FACTOR SUMMARY</a></span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_10">i</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_13">PART I.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_22">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_22">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_25">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_28">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_28">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_31">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_34">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_76">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_76">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_76">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_103">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_103">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_103">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_106">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_106">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_106">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_109">PART II.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_109">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_112">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_112">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_112">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_115">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_115">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_115">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_118">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_118">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_118">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_121">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_121">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_121">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_124">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_124">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_124">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_127">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_127">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_127">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_130">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_130">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_130">59</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_133">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2f5ba682505427b80ca0ea888ebdc11_133">60</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:18pt;padding-left:6pt;padding-right:6pt;text-align:center"><span><br/></span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the key risks and uncertainties that make an investment in our securities speculative and risky. This does not contain all of the information that may be important to you, and you should read this summary together with the more detailed description risks related to an investment in our securities set forth in this report under "Part II. Item 1A. Risk Factors". </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Limited Operating History, Financial Position and Capital Requirements </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We have a history of operating losses, have never generated any revenue from product sales and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We may need to obtain additional funding to finance our operations and complete the development and any commercialization of our investigational products. If we do not receive substantial capital when needed, we may be forced to restrict our operations or delay, reduce or eliminate our product development programs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of our Investigational Products </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Clinical drug development is a lengthy, expensive and uncertain process, if we are unable to develop, obtain regulatory approval for and commercialize our investigational products, or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The results of preclinical studies and early clinical trials are not always predictive of future results. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Enrollment and retention of subjects in clinical trials is expensive and time consuming, can be made more difficult or rendered impossible by competing treatments, clinical trials of competing investigational products, geopolitical instability and public health epidemics, each of which could result in significant delays and additional costs in our product development activities, or in the failure of such activities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Preliminary and interim data from our clinical studies that we announce or publish from time to time could materially change due to audit and verification procedures or as more patient data become available.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Serious adverse events, undesirable side effects or other unexpected properties of our investigational products may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our investigational products or limitations on the use of our investigational products or revocation of any marketing authorizations or subsequent limitations on the use of our investigational products.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If we are not successful in discovering, developing and commercializing investigational products that take advantage of different mechanisms of action to achieve superior outcomes relative to the use of single agents or other combination therapies, our ability to achieve our strategic objectives would be impaired.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Development of combination therapies may present more or different challenges than other therapies.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Failure to successfully develop, validate and obtain regulatory clearance or approval for any required companion diagnostics could prevent us from realizing the commercial potential of our investigational products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties, Manufacturing and Commercialization</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If our collaboration with Gilead is not successful, our business could be adversely affected.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We rely on third parties to conduct our clinical trials, to manufacture and supply us with sufficient quantities of our investigational products, standard of care and comparator products used in our clinical trials, and to perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Even if we receive marketing approval, we may not be successful in commercializing our investigational products or obtaining coverage and reimbursement approval for a product from a government or other third-party payor, which coverage may be delayed or may not be sufficient to cover our costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our investigational products may never be approved or commercialized outside the United States, which would limit our ability to realize their full market potential.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Any investigational products for which we intend to seek approval as biologic products may face competition sooner than anticipated. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to In-Licenses, Strategic Arrangements and Intellectual Property</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We are currently party to several in-license agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our investigational products. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these investigational products or both, which would adversely affect our business and prospects.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If we are unable to obtain and maintain sufficient intellectual property protection for our investigational products, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We may need to obtain additional licenses of third-party technology which may cause us to operate our business in a more costly or otherwise adverse manner than anticipated.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We may become involved in lawsuits alleging that we have infringed the intellectual property rights of third parties or to protect or enforce our patents or other intellectual property, which litigation could affect our ability to develop or commercialize our investigational products.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our investigational products. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business Operations and Industry</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We expect to expand our business operations and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their investigational products are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our internal information technology systems, and those of the third parties upon which we rely, are subject to failure, security breaches and other disruptions, which could result in a material disruption of our investigational products&#8217; development programs, jeopardize sensitive information, or prevent us from accessing critical information or result in a loss of our assets, and potentially expose us to notification obligations, loss, liability or reputational damage and otherwise adversely affect our business.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per share amounts)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">License and development service revenue </span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Includes $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-30">18</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-31">23</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-32">54</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-33">48</ix:nonFraction> from a related party)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-34">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-35">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-36">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-37">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other collaboration revenue </span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Includes $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-38">10</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-39">8</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-40">28</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-41">25</ix:nonFraction> from a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-42">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-43">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-44">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-45">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-46">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-47">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-48">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-49">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development </span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Net of recoveries of $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="rcus:ResearchAndDevelopmentExpenseRecoveries" scale="6" id="f-50">22</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-6" name="rcus:ResearchAndDevelopmentExpenseRecoveries" scale="6" id="f-51">27</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="rcus:ResearchAndDevelopmentExpenseRecoveries" scale="6" id="f-52">89</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="rcus:ResearchAndDevelopmentExpenseRecoveries" scale="6" id="f-53">93</ix:nonFraction> from a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-54">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-55">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-56">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-57">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-58">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-59">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-60">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-61">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:OperatingExpenses" scale="6" id="f-62">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:OperatingExpenses" scale="6" id="f-63">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingExpenses" scale="6" id="f-64">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:OperatingExpenses" scale="6" id="f-65">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-66">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-67">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-68">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-69">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-operating income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="rcus:InterestAndOtherIncomeExpenseNonoperatingNet" scale="6" id="f-70">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="rcus:InterestAndOtherIncomeExpenseNonoperatingNet" scale="6" id="f-71">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:InterestAndOtherIncomeExpenseNonoperatingNet" scale="6" id="f-72">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="rcus:InterestAndOtherIncomeExpenseNonoperatingNet" scale="6" id="f-73">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Effective interest on liability for sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="rcus:EffectiveInterestOnLiabilityForSaleOfFutureRoyalties" scale="6" id="f-74">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="rcus:EffectiveInterestOnLiabilityForSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="6" id="f-75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:EffectiveInterestOnLiabilityForSaleOfFutureRoyalties" scale="6" id="f-76">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="rcus:EffectiveInterestOnLiabilityForSaleOfFutureRoyalties" scale="6" id="f-77">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total non-operating income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-78">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-79">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-80">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-81">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-82">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-83">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-84">221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-85">199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-86">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-88">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-89">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-90">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-91">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-92">226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-93">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-94"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-95">0.94</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-96"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-97">0.90</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-98"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-99">3.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-100"><ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-101">2.78</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Shares used to compute net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-102"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-103">74.6</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-104"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-105">72.2</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-106"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-107">73.6</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-108"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-109">71.8</ix:nonFraction></ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-110">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-111">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-112">226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-113">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-114">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-115">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-116">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-117">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-118">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-119">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-120">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-121">208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per share amounts)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ASSETS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-122">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-123">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="f-124">615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="f-125">803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Receivable from collaboration partners ($<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="f-126">22</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="f-127">39</ix:nonFraction> from a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="f-128">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="f-129">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-130">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-131">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AssetsCurrent" scale="6" id="f-132">882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-133">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-134">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-135">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-136">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-137">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other noncurrent assets ($<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-138">6</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-139">2</ix:nonFraction> from a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-140">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-141">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-142">1,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-143">1,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS' EQUITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-144">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-145">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Deferred revenue ($<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-146">96</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-147">97</ix:nonFraction> to a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-148">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-149">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-150">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-151">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-152">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-153">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Deferred revenue, noncurrent ($<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-154">309</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-155">355</ix:nonFraction> to a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-156">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-157">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-158">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-159">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-26" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-160"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-27" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-161"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-162"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-163">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-164"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-165">10.0</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-166"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-167"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-168"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-169">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock and additional paid-in capital: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-172"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-173">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-174"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-175">400.0</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-176"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-177">74.8</ix:nonFraction></ix:nonFraction> shares in 2023 and <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-178"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-179">72.9</ix:nonFraction></ix:nonFraction> shares in 2022 issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="f-180">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="f-181">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-182">768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-183">542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-184">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-185">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-186">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-187">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-188">1,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-189">1,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Number of shares of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Common stock and additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Accumulated deficit </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">comprehensive loss </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">stockholders&#8217; equity </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-190">70.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-191">1,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-192">275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-193">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-194">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Issuance of common stock in connection with our equity award programs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-195">0.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-196">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-197">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-198">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-199">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-200">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-201">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-202">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-203">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-204">71.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-205">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-206">343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-207">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-208">797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Issuance of common stock in connection with our equity award programs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-209">0.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-210">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-211">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-212">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-213">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-214">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-215">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-216">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-217">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-218">72.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-219">1,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-220">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-221">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-222">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Issuance of common stock in connection with our equity award programs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-223">0.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-224">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-225">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-226">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-227">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-228">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-229">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-230">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-231">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-232">72.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-233">1,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-234">475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-235">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-236">699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-237">72.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-238">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-239">542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-240">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-241">657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Issuance of common stock in connection with our equity award programs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-74" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-242">0.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-243">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-244">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-245">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-246">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other comprehensive gain</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-247">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-248">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-249">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-250">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-81" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-251">73.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-252">1,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-253">622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-254">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-255">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc.)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-86" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-256">1.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-257">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-258">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Issuance of common stock in connection with our equity award programs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-89" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-259">0.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-260">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-261">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-262">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-263">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-264">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-265">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance at June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-95" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-266">74.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-267">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-268">697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-269">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-270">566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Issuance of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-100" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-271">0.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-272">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-273">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Issuance of common stock in connection with our equity award programs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-102" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-274">0.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-275">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-276">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-277">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-278">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other comprehensive gain</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-279">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-280">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-281">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-282">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-283">74.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-284">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-285">768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-286">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-287">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-288">226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-289">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-290">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-291">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-292">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-293">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Noncash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-294">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-295">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amortization of premiums (discounts) on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="f-296">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="f-297">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="f-298">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="f-299">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Receivable from collaboration partners ($<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="f-300">17</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="f-301">718</ix:nonFraction> from a related party)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="f-302">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="f-303">716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other assets (($<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="f-304">4</ix:nonFraction>) and ($<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="f-305">2</ix:nonFraction>) from a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="f-306">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="f-307">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="f-308">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:fixed-zero" scale="6" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Deferred revenue (($<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-310">47</ix:nonFraction>) and ($<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-311">73</ix:nonFraction>) to a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-312">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-313">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="6" id="f-314">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="6" id="f-315">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-316">218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-317">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="f-318">673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="f-319">1,085</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:ProceedsFromMaturityOfMarketableSecurities" scale="6" id="f-320">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="rcus:ProceedsFromMaturityOfMarketableSecurities" scale="6" id="f-321">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Proceeds from sales of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:ProceedsFromSaleOfMarketableSecurities" scale="6" id="f-322">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="rcus:ProceedsFromSaleOfMarketableSecurities" scale="6" id="f-323">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-324">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-325">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Purchases of in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="6" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="f-327">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Collaboration reimbursements of in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty" format="ixt:fixed-zero" scale="6" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="rcus:CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty" scale="6" id="f-329">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-330">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-331">460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock ($<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-332">20</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-333">&#8212;</ix:nonFraction> from a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-334">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock pursuant to equity award plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="f-336">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="f-337">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Proceeds from sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:ProceedsFromSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="6" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="rcus:ProceedsFromSaleOfFutureRoyalties" scale="6" id="f-339">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-340">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-341">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-342">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-343">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-344">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-345">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-346">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-347">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Unpaid portion of property and equipment purchases included in Accounts payable and Other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-348">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-349">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-350" continuedAt="f-350-1" escape="true">Organization, liquidity and capital resources</ix:nonNumeric></span></div><ix:continuation id="f-350-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arcus Biosciences, Inc. (referred to as "Arcus," "we," "our," "us," or the "Company") is a clinical-stage, biopharmaceutical company focused on creating best-in-class therapies. Using our robust and highly efficient drug discovery capability, we have created a significant portfolio of investigational products which are in clinical development, with our most advanced molecule, an anti-TIGIT antibody, now in four Phase 3 registrational studies targeting lung and gastrointestinal cancers. Our deep portfolio of novel small molecules and enabling antibodies allows us to create highly differentiated therapies, which we are developing to treat multiple large indications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate and manage our business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-351"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-352">one</ix:nonFraction></ix:nonFraction> reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, we had cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="6" id="f-353">950</ix:nonFraction> million, which we believe will be sufficient to fund our planned operations for a period of at least twelve months following the date of filing of this report.</span></div></ix:continuation><div id="if2f5ba682505427b80ca0ea888ebdc11_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-354" continuedAt="f-354-1" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="f-354-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-355" continuedAt="f-355-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2022 included in our Annual Report on Form 10-K filed with the SEC on February&#160;28, 2023. There have been no significant changes to our accounting policies as described in Note 2, Summary of significant accounting policies, in the notes to Consolidated Financial Statements in Item 8 of Part II of the Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and include all adjustments consisting of normal recurring adjustments that management believes are necessary for a fair presentation of the periods presented. The Condensed Consolidated Balance Sheet as of December&#160;31, 2022 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-355-1">Operating results for the nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023 or for any future period.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-356" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed and updated each period to reflect current information. Actual results may differ materially from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-357" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements issued or adopted during the period with a significant impact to our financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-358" continuedAt="f-358-1" escape="true">Related party - Gilead Sciences, Inc.</ix:nonNumeric></span></div><ix:continuation id="f-358-1" continuedAt="f-358-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we and Gilead Sciences, Inc. (Gilead) entered into an Option, License and Collaboration Agreement (the Gilead Collaboration Agreement), Common Stock Purchase Agreement (the Stock Purchase Agreement), and Investor Rights Agreement (Investor Rights Agreement). In 2021, we amended the Gilead Collaboration Agreement (the First Gilead Collaboration Agreement Amendment) and the Stock Purchase Agreement (the First Stock Purchase Agreement Amendment), and in 2022 we amended the Investor Rights Agreement (Amended Investor Rights Agreement). In the second quarter of 2023, we expanded our collaboration to include research-stage inflammation programs (the Second Gilead Collaboration Agreement Amendment) and further amended the Stock Purchase Agreement (the Second Stock Purchase Agreement Amendment). We refer to these agreements collectively as the Gilead Agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase Agreement and Investor Rights Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, under the Stock Purchase Agreement, Gilead purchased <ix:nonFraction unitRef="shares" contextRef="c-112" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-359">6.0</ix:nonFraction> million shares of our common stock for a total cost of $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="rcus:FundsReceivedForStockPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="f-360">200</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="rcus:StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-361">91</ix:nonFraction> million was allocated to the revenue related performance obligations created by the Gilead Collaboration Agreement (See Note 5, Revenues for more information).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, under the First Stock Purchase Agreement Amendment, Gilead purchased <ix:nonFraction unitRef="shares" contextRef="c-113" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-362">5.7</ix:nonFraction> million shares of our common stock for a total cost of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-363">220</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, under the Second Stock Purchase Agreement Amendment, Gilead purchased <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-364">1.0</ix:nonFraction> million shares of our common stock for a total cost of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-365">20</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead has the right, at its option until July 2025, to purchase up to a maximum of <ix:nonFraction unitRef="number" contextRef="c-115" decimals="2" name="rcus:RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage" scale="-2" id="f-366">35</ix:nonFraction>% of the Company&#8217;s then-outstanding voting common stock, at a purchase price equal to the greater of a <ix:nonFraction unitRef="number" contextRef="c-116" decimals="2" name="rcus:PercentageOfPremiumPurchasePriceOfCommonStock" scale="-2" id="f-367">20</ix:nonFraction>% premium to market (based on a trailing <ix:nonNumeric contextRef="c-116" name="rcus:TrailingDaysAverageClosingPrice" format="ixt-sec:durwordsen" id="f-368">five-day</ix:nonNumeric> average closing price at option exercise) or the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-369">33.54</ix:nonFraction> initial purchase price. Based on the value of our common stock at each contract closing, the right to purchase additional shares had no value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Investor Rights Agreement, Gilead has the right, which they have exercised, to designate two members of our Board of Directors. This agreement also included a three-year standstill and a two-year lockup, provided Gilead with registration rights commencing at the end of the lockup period and provides Gilead with pro rata participation rights in certain future financings. In October 2022, we registered Gilead&#8217;s shares and entered into the Amended Investor Rights Agreement, primarily to extend the <ix:nonNumeric contextRef="c-118" name="rcus:LockupPeriod" format="ixt-sec:durwordsen" id="f-370">two-year</ix:nonNumeric> lockup period to <ix:nonNumeric contextRef="c-118" name="rcus:ExtendedLockupPeriod" format="ixt-sec:durwordsen" id="f-371">three-years</ix:nonNumeric> which expired on July 13, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, Gilead held approximately <ix:nonFraction unitRef="number" contextRef="c-28" decimals="3" name="rcus:PercentageOfOutstandingCommonStockOwned" scale="-2" id="f-372">19.8</ix:nonFraction>% of the Company&#8217;s outstanding common stock arising from purchases in our May 2020 public offering and purchases under the Stock Purchase Agreement and the First and Second Amended Stock Purchase Agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into the Gilead Collaboration Agreement, which gave Gilead an exclusive license to develop and commercialize zimberelimab (the anti PD-1 program) in certain markets and time-limited options to acquire exclusive licenses to develop and commercialize any of our then-current and future clinical programs arising during the <ix:nonNumeric contextRef="c-119" name="rcus:CollaborationTermForCurrentAndFutureClinicalPrograms" format="ixt-sec:durwordsen" id="f-373">10-year</ix:nonNumeric> collaboration term, contingent upon $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="rcus:OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" format="ixt:num-dot-decimal" scale="6" id="f-374">100</ix:nonFraction> million option continuation payments payable on each of the second, fourth, sixth and eighth anniversaries of the agreement. Upon closing of the transaction in July 2020, Gilead made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-6" name="rcus:UpfrontCashPayment" format="ixt:num-dot-decimal" scale="6" id="f-375">175</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we entered into the First Gilead Collaboration Agreement Amendment pursuant to which Gilead exercised its option to <ix:nonFraction unitRef="program" contextRef="c-121" decimals="INF" name="rcus:NumberOfExerciseOptionToPrograms" format="ixt-sec:numwordsen" scale="0" id="f-376">three</ix:nonFraction> programs&#8212;providing Gilead with exclusive licenses to develop and commercialize domvanalimab and AB308 (collectively, the anti-TIGIT program), etrumadenant (the adenosine receptor antagonist program) and quemliclustat (the CD73 program), in certain markets&#8212;for a total payment of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-6" name="rcus:OptionPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-377">725</ix:nonFraction> million that was received in 2022. The amendment also (i) provided for a slight reduction in the royalties for these three programs, such that Gilead will pay us tiered royalties as a percentage of revenues ranging from the mid-teens to the low twenties; and (ii) removed the $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-6" name="rcus:RemoveOptionContinuationPaymentUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-378">100</ix:nonFraction> million option continuation payment that was otherwise due on the second anniversary of the Gilead Collaboration Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead's option, on a program-by-program basis, will expire after a prescribed period following the achievement of a clinical development milestone in such program and our delivery to Gilead of the requisite data package. Gilead may exercise its option to any program at any time prior to expiration of the option and will pay Arcus an option fee of $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-6" name="rcus:OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" format="ixt:num-dot-decimal" scale="6" id="f-379">150</ix:nonFraction> million per program. With respect to domvanalimab, we are also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-6" name="rcus:PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" format="ixt:num-dot-decimal" scale="6" id="f-380">500</ix:nonFraction> million in potential U.S. regulatory approval milestones.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><ix:continuation id="f-358-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each program that Gilead opts in to, both companies will co-develop and equally share global development costs, subject to certain opt-out rights that we have, and caps on our spending and related subsequent adjustments. For each program, provided we have not exercised our opt-out rights, we have the option to co-promote in the United States with equal sharing of related profits and losses. Gilead has the right to exclusively commercialize outside of the U.S., subject to the rights of our existing partners in any territories and will pay us tiered royalties as a percentage of revenues ranging from the high teens to the low twenties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, Gilead also has option rights to <ix:nonFraction unitRef="usd" contextRef="c-122" decimals="INF" name="rcus:NumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="f-381">two</ix:nonFraction> immuno-oncology research programs for which we will lead discovery and early development activities. With respect to these two research programs, Gilead has the right to exercise its option, on a program-by-program basis, either (i) upon our completion of certain IND-enabling activities for an option payment of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-6" name="rcus:OptionPaymentUponCompletionOfCertainIndEnablingActivities" format="ixt:num-dot-decimal" scale="6" id="f-382">60</ix:nonFraction> million or (ii) following the achievement of a clinical development milestone for an option payment of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-6" name="rcus:OptionPaymentUponAchievementOfCertainDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="f-383">150</ix:nonFraction> million. These research programs were not determined to be performance obligations at contract inception, due to the very early stages of the programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we entered into the Second Gilead Collaboration Agreement Amendment pursuant to which we expanded our collaboration to provide Gilead with options to license up to four jointly selected research-stage programs that target inflammatory diseases for which we will lead discovery and early development activities. We will receive an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="rcus:UpfrontCashPayment" format="ixt:num-dot-decimal" scale="6" id="f-384">17.5</ix:nonFraction> million for each initiated program and Gilead will have an option to license each program at two separate, prespecified time points. For the first two research programs, Gilead has the right to exercise its option, on a program-by-program basis, either (i) upon our completion of certain IND-enabling activities for an option payment of $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-6" name="rcus:OptionPaymentUponCompletionOfCertainIndEnablingActivities" format="ixt:num-dot-decimal" scale="6" id="f-385">45</ix:nonFraction> million or (ii) following the achievement of a clinical development milestone for an option payment of $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="rcus:OptionPaymentUponAchievementOfCertainDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="f-386">150</ix:nonFraction> million. If Gilead exercises its option at the earlier time point for the first <ix:nonFraction unitRef="program" contextRef="c-126" decimals="INF" name="rcus:NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" format="ixt-sec:numwordsen" scale="0" id="f-387">two</ix:nonFraction> programs, we would be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-6" name="rcus:RegulatoryAndCommercialMilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="f-388">375</ix:nonFraction> million in regulatory and commercial milestone payments as well as tiered royalties for each optioned program. For any other program option exercise by Gilead, the parties would have rights to co-develop and share global development costs and to co-commercialize and share profits in the US for that program. We received a total upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-6" name="rcus:UpfrontCashPayment" format="ixt:num-dot-decimal" scale="6" id="f-389">35</ix:nonFraction> million for an initial <ix:nonFraction unitRef="program" contextRef="c-128" decimals="INF" name="rcus:NumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="f-390">two</ix:nonFraction> research programs in June 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, Gilead has licenses to domvanalimab, AB308, etrumadenant, quemliclustat and zimberelimab.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2023 and 2022, we recognized revenue under the Gilead Agreements of $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-391">28</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-392">31</ix:nonFraction> million, respectively, and net reimbursements from Gilead recognized as reductions in research and development (R&amp;D) expense of $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-6" name="rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" format="ixt:num-dot-decimal" scale="6" id="f-393">22</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-6" name="rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" format="ixt:num-dot-decimal" scale="6" id="f-394">27</ix:nonFraction> million, respectively. For the nine months ended September&#160;30, 2023 and 2022, we recognized revenue under the Gilead Agreements of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-395">82</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-396">73</ix:nonFraction> million, respectively, and net reimbursements from Gilead recognized as reductions in R&amp;D expense of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" format="ixt:num-dot-decimal" scale="6" id="f-397">89</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" format="ixt:num-dot-decimal" scale="6" id="f-398">93</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more detailed discussion on revenues recognized under the Gilead Agreements, see Note 5, Revenues.</span></div></ix:continuation><div id="if2f5ba682505427b80ca0ea888ebdc11_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-399" continuedAt="f-399-1" escape="true">License and collaborations</ix:nonNumeric></span></div><ix:continuation id="f-399-1" continuedAt="f-399-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into licensing agreements, strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain investigational products. These arrangements may be collaborative and involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include: non-refundable upfront payments; payments for options to acquire certain rights; potential development and regulatory milestone payments and/or sales-based milestone payments; royalty payments; revenue or profit-sharing arrangements; expense reimbursements; and cost-sharing arrangements. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Condensed Consolidated Statements of Operations, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant arrangements are discussed below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gilead Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3, Related party - Gilead Sciences, Inc.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><ix:continuation id="f-399-2" continuedAt="f-399-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taiho Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an agreement with Taiho Pharmaceutical Co., Ltd (Taiho) under which we granted Taiho exclusive options to programs arising over a <ix:nonNumeric contextRef="c-137" name="rcus:OptionPeriod" format="ixt-sec:durwordsen" id="f-400">five-year</ix:nonNumeric> period which ended in September 2022 (the Option Period) for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="rcus:NonRefundableAndNonCreditableCashPayments" format="ixt:num-dot-decimal" scale="6" id="f-401">35</ix:nonFraction> million. Upon an option exercise of a program, Taiho would obtain exclusive development and commercialization rights to investigational products under the program for Japan and certain other territories in Asia (excluding China) (the Taiho Territory). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each option that Taiho exercises, they will be obligated to make a payment of $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="rcus:PaymentForOptionExercise" format="ixt:num-dot-decimal" scale="6" id="f-402">3</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="rcus:PaymentForOptionExercise" format="ixt:num-dot-decimal" scale="6" id="f-403">15</ix:nonFraction> million, depending on the development stage of the optioned program. Upon exercise, Taiho is solely responsible for continued development and commercialization in the Taiho Territory. In addition, for each optioned program we would be eligible to receive clinical and regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="rcus:AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="f-404">130</ix:nonFraction> million and commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="rcus:ContingentMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-405">145</ix:nonFraction> million with the achievement of certain sales thresholds in the Taiho Territory. We will also receive royalties ranging from high single-digits to mid-teens on net sales of licensed products in the Taiho Territory. Royalties will be payable by product and country commencing on the first commercial sale and ending upon the later of: (a) <ix:nonNumeric contextRef="c-141" name="rcus:RoyaltiesPayableTerm" format="ixt-sec:duryear" id="f-406">10</ix:nonNumeric> years; and (b) expiration of the last-to-expire valid claim of our patents covering the manufacture, use or sale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, Taiho opted to participate in two global Phase 3 trials of domvanalimab and zimberelimab combinations, STAR-121 and STAR-221, and is obligated to make certain milestone payments contingent upon successfully satisfying the related clinical milestones. During the three months ended September 30, 2023, the clinical milestones for domvanalimab and zimberelimab for the STAR-221 study were met and Taiho became obligated to pay us $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="rcus:PaymentForOptionExercise" format="ixt:num-dot-decimal" scale="6" id="f-407">28</ix:nonFraction> million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, Taiho has licenses for the Taiho Territory to (i) etrumadenant (the adenosine receptor antagonist program); (ii) zimberelimab (the anti PD-1 program); and (iii) domvanalimab and AB308 (collectively, the anti-TIGIT program).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2023 and 2022, we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-408">4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-409">2</ix:nonFraction> million, respectively, and we recognized net reimbursements from Taiho as a reduction in R&amp;D expense of $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="rcus:ReimbursementOfResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-410">2</ix:nonFraction> million for the three months ended September&#160;30, 2023. For the nine months ended September 30, 2023 and 2022, we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-411">4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-412">5</ix:nonFraction> million, respectively and we recognized net reimbursements from Taiho as a reduction in R&amp;D expense of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" name="rcus:ReimbursementOfResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-413">4</ix:nonFraction>&#160;million for the nine months ended September 30, 2023. For a more detailed discussion on revenues see Note 5, Revenues.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a collaboration with AstraZeneca to evaluate domvanalimab, our investigational anti-TIGIT antibody, in combination with AstraZeneca&#8217;s durvalumab in a registrational Phase 3 clinical trial in patients with unresectable Stage 3 non-small cell lung cancer (NSCLC), known as the PACIFIC-8 trial. Under the collaboration, each company will retain existing rights to their respective molecules and any future commercial economics. AstraZeneca will conduct the trial, and each company will supply their respective investigational product to support the trial. Under the terms of the agreement, we will reimburse AstraZeneca for its share of the trial costs upon the achievement of certain milestones or under certain circumstances if the agreement is terminated early. The portion of the costs that we consider to be unavoidable are accrued in advance of the achievement of the milestone.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2023 and 2022, we recognized as R&amp;D expense $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-414">1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-415">1</ix:nonFraction> million, respectively, before expected recoveries from our cost-sharing agreement with Gilead. For the nine months ended September&#160;30, 2023 and 2022, we recognized as R&amp;D expense $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-416">6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-417">3</ix:nonFraction> million, respectively, before expected recoveries from our cost-sharing agreement with Gilead. At September&#160;30, 2023 and December&#160;31, 2022, we have recognized a liability of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-418">11</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-419">5</ix:nonFraction> million, respectively, related to our obligation to AstraZeneca which is recorded in Other noncurrent liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PACIFIC-8 trial forms part of the Arcus and Gilead joint development program for domvanalimab and our portion of the trial costs are shared with Gilead. At September&#160;30, 2023 and December&#160;31, 2022, we have recognized a receivable due from Gilead for these shared costs of $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-420">6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-421">2</ix:nonFraction> million, respectively, which is recorded in Other noncurrent assets. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><ix:continuation id="f-399-3" continuedAt="f-399-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WuXi Biologics License - anti-PD-1 </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an agreement with WuXi Biologics Ireland Limited (WuXi Biologics) which, as amended, provides us with exclusive rights to (i) develop, use and manufacture products that include an anti-PD-1 antibody, including zimberelimab, worldwide and (ii) commercialize any such products worldwide, except in Greater China. Under the agreement, as of September&#160;30, 2023, we may incur (i) clinical and regulatory milestone payments, and commercialization milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="rcus:ClinicalRegulatoryAndCommercializationMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-422">375</ix:nonFraction> million, (ii) tiered royalties that range from the high single-digits to low teens on net sales of the licensed products and (iii) fees related to any sublicenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2023 and 2022, we did not have any transactions nor were any amounts due under this arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WuXi Biologics License - anti-CD39</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into an agreement with WuXi Biologics, under which we obtained the exclusive worldwide license to develop and commercialize anti-CD39 antibodies discovered under the agreement. As of September&#160;30, 2023, we may incur additional clinical and regulatory milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="rcus:AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-423">14</ix:nonFraction> million and royalty payments in the low single digits on net sales of the licensed products under this agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2023 and 2022, we incurred <ix:nonFraction unitRef="usd" contextRef="c-155" decimals="INF" name="rcus:MilestoneExpense" format="ixt:fixed-zero" scale="0" id="f-424"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="INF" name="rcus:MilestoneExpense" format="ixt:fixed-zero" scale="0" id="f-425">no</ix:nonFraction></ix:nonFraction> development milestones nor were any amounts due under this arrangement. For the nine months ended September&#160;30, 2023 and 2022, we incurred development milestones under this arrangement of $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="rcus:MilestoneExpense" format="ixt:num-dot-decimal" scale="6" id="f-426">1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="rcus:MilestoneExpense" format="ixt:num-dot-decimal" scale="6" id="f-427">2</ix:nonFraction> million, respectively, which were recognized as R&amp;D expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Abmuno License</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into an agreement with Abmuno Therapeutics LLC (Abmuno), under which we obtained the exclusive worldwide license to develop, use, manufacture, and commercialize products that include an anti-TIGIT antibody, including domvanalimab. As of September&#160;30, 2023 we may incur additional clinical, regulatory and commercialization milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="rcus:AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-428">88</ix:nonFraction> million under this agreement.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-399-4">For the three and nine months ended September&#160;30, 2023 and 2022, we did not have any transactions nor were any amounts due under this arrangement.</ix:continuation> </span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-429" continuedAt="f-429-1" escape="true">Revenues </ix:nonNumeric></span></div><ix:continuation id="f-429-1" continuedAt="f-429-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-430" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenues by collaboration, category of revenue, and the method of recognition (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Over time</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Point in time</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Collaboration</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License and R&amp;D services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-431">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-432">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-433">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-434">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Access rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-435">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-436">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-437">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-438">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taiho Collaboration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-439">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-441">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Access rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-444">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-446">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-447">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-448">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-449">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-450">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from Gilead accounted for <ix:nonFraction unitRef="number" contextRef="c-176" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-451">88</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-177" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-452">94</ix:nonFraction>% of Total revenues for the three months ended September&#160;30, 2023 and 2022, respectively and <ix:nonFraction unitRef="number" contextRef="c-178" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-453">95</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-179" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-454">94</ix:nonFraction>% for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredRevenueByArrangementDisclosureTextBlock" id="f-455" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue recognized as a result of changes in the deferred revenue balance (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from amounts included in deferred revenue at the beginning of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="6" id="f-456">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="6" id="f-457">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="6" id="f-458">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="6" id="f-459">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><ix:continuation id="f-429-2" continuedAt="f-429-3"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the nine months ended September&#160;30, 2023 includes a net $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-460">1</ix:nonFraction>&#160;million cumulative catch-up of revenue due to changes in the total estimated effort to be incurred in the future to satisfy the Gilead license and R&amp;D services performance obligations, primarily related to lower estimated late-stage clinical trial costs for etrumadenant, partially offset by higher estimated late-stage clinical trial costs for quemliclustat.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-461">429</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-462">452</ix:nonFraction> million of deferred revenue remaining on our Condensed Consolidated Balance Sheets at September&#160;30, 2023 and December&#160;31, 2022, respectively, allocated between current and noncurrent based on the expected timing of future recognition. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from the Gilead Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for performance obligations under this arrangement for the periods presented herein was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflammation Programs - R&amp;D Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we entered into the Second Gilead Collaboration Agreement Amendment pursuant to which we expanded our collaboration to provide Gilead with options to license up to four jointly selected research-stage programs that target inflammatory diseases for which we will lead discovery and early development activities (see Note 3, Related party - Gilead Sciences, Inc., for more information). In June 2023, we received a total upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="rcus:UpfrontCashPayment" format="ixt:num-dot-decimal" scale="6" id="f-463">35</ix:nonFraction> million for an initial two jointly selected research-stage programs. We determined that the Second Gilead Collaboration Agreement Amendment represented a separate contract and, at the amendment closing date, we allocated the transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="rcus:AllocationToPerformanceObligations" format="ixt:num-dot-decimal" scale="6" id="f-464">35</ix:nonFraction> million to the performance obligations created as of the date of this amendment. <ix:nonNumeric contextRef="c-1" name="rcus:ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" id="f-465" continuedAt="f-465-1" escape="true">The following table summarizes the allocation of the transaction price to the distinct performance obligations (in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="f-465-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation to performance obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Distinct</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflammation target 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="rcus:AllocationToPerformanceObligations" scale="6" id="f-466">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflammation target 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-6" name="rcus:AllocationToPerformanceObligations" scale="6" id="f-467">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total allocated transaction price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:AllocationToPerformanceObligations" scale="6" id="f-468">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that we have separate performance obligations to perform R&amp;D services for Gilead related to discovery and early development activities for each research program for which they have made an upfront payment. The standalone selling price of these obligations was determined using an expected cost-plus margin approach. We recognize the amounts allocated to these services as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. The options to acquire additional licenses or services did not result in additional performance obligations because they did not provide a material right at contract inception, primarily due to the very early stages of the programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-469">2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-470">3</ix:nonFraction> million for the three and nine months ended September&#160;30, 2023, respectively, within Other collaboration revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-471">32</ix:nonFraction> million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to these performance obligations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Etrumadenant - License and R&amp;D Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, Gilead has an exclusive license and we are also obligated to perform further R&amp;D services for Gilead related to etrumadenant. We determined that the license and R&amp;D services were combined based on an evaluation of the delivery of the license, due to the early stage of the technology and the specialized nature of our know-how. We allocated arrangement consideration of $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-6" name="us-gaap:DeferredRevenueRevenueRecognized1" format="ixt:num-dot-decimal" scale="6" id="f-472">219</ix:nonFraction> million to the combined license and R&amp;D services performance obligation and recognize the amounts allocated as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-473">21</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-474">3</ix:nonFraction> million for the three months ended September&#160;30, 2023 and 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-475">39</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-476">21</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively, within License and development service revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-477">146</ix:nonFraction> million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to this performance obligation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><ix:continuation id="f-429-3" continuedAt="f-429-4"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Quemliclustat - License and R&amp;D Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, Gilead has an exclusive license and we are also obligated to perform further R&amp;D services for Gilead related to quemliclustat. We determined that the license and R&amp;D services were combined based on an evaluation of the delivery of the license, due to the early stage of the technology and the specialized nature of our know-how. We allocated arrangement consideration of $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:DeferredRevenueRevenueRecognized1" format="ixt:num-dot-decimal" scale="6" id="f-478">176</ix:nonFraction> million to the combined license and R&amp;D services performance obligation and recognize the amounts allocated as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a reversal of revenue of $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-479">4</ix:nonFraction> million for the three months ended September&#160;30, 2023 due to changes in the total estimated effort to be incurred in the future to satisfy the performance obligations, primarily related to revised clinical trial assumptions and revenue of $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-480">12</ix:nonFraction> million for the three months ended September 30, 2022. We recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-481">11</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-482">16</ix:nonFraction> million for the nine months ended September&#160;30, 2023 and 2022, respectively, within License and development service revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-483">138</ix:nonFraction> million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to this performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Domvanalimab - R&amp;D Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, we have an obligation to perform further R&amp;D services for Gilead related to domvanalimab. We determined that these services are distinct based on an evaluation of the delivery of the related license, noting that the program was in the later stages of development and license met the criteria for being distinct from the R&amp;D services required. We allocated arrangement consideration of $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:DeferredRevenueRevenueRecognized1" format="ixt:num-dot-decimal" scale="6" id="f-484">34</ix:nonFraction> million to the R&amp;D services performance obligation and recognize the amounts allocated as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-485">1</ix:nonFraction> million for the three months ended September&#160;30, 2023, and $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-486">3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-487">2</ix:nonFraction> million for the nine months ended September&#160;30, 2023 and 2022, respectively, within License and development service revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-488">27</ix:nonFraction> million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to this performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zimberelimab - R&amp;D and Commercialization Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, we have an obligation to perform further R&amp;D and commercialization services for Gilead related to zimberelimab, as a monotherapy and in combination with other agents. We determined that these services are distinct based on an evaluation of the delivery of the related license, noting that the program was in the later stages of development and license met the criteria for being distinct from the R&amp;D and commercialization services required. We allocated arrangement consideration of $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-6" name="us-gaap:DeferredRevenueRevenueRecognized1" format="ixt:num-dot-decimal" scale="6" id="f-489">11</ix:nonFraction> million to the R&amp;D and commercialization services performance obligation and recognize the amounts allocated as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized <ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-490">no</ix:nonFraction> revenue for the three months ended September&#160;30, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-491">8</ix:nonFraction> million for the three months ended September 30, 2022. We recognized $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-492">1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-493">9</ix:nonFraction> million for the nine months ended September 30, 2023 and 2022, respectively, within License and development service revenue in our Condensed Consolidated Statements of Operations. As of December 31, 2022, substantially all the revenue related to this performance obligation had been recognized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Access Rights and Option Continuation Periods</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, Gilead has exclusive access to our current programs as well as the future programs for a period of <ix:nonNumeric contextRef="c-206" name="rcus:CurrentAndFutureProgramsExclusiveAccessPeriod" format="ixt-sec:durwordsen" id="f-494">ten years</ix:nonNumeric>, contingent upon option continuation payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-6" name="rcus:ContingentMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-495">300</ix:nonFraction> million, consisting of a $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-6" name="rcus:OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" format="ixt:num-dot-decimal" scale="6" id="f-496">100</ix:nonFraction> million payment on each of the fourth, sixth, and eighth anniversaries of the agreement. We allocated arrangement consideration of $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-6" name="us-gaap:DeferredRevenueRevenueRecognized1" format="ixt:num-dot-decimal" scale="6" id="f-497">121</ix:nonFraction> million to this performance obligation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a time-elapsed input method to measure progress toward satisfying this obligation, which is the method we believe most faithfully depicts our performance in transferring the promised services during the time period in which Gilead has access to our R&amp;D pipeline. Accordingly, the revenue allocated to this performance obligation is being recognized using this input method over the minimum <ix:nonNumeric contextRef="c-206" name="rcus:PerformanceObligationPeriod" format="ixt-sec:durwordsen" id="f-498">four-year</ix:nonNumeric> period. We have determined that Gilead is not obligated to pay the remaining $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-6" name="rcus:ContingentMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-499">300</ix:nonFraction> million due over the remainder of the term and excluded these payments from the transaction price. Failure to pay the non-obligatory option continuation payments will result in Gilead&#8217;s loss of certain rights to access and obtain licenses to the programs arising from our R&amp;D pipeline.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><ix:continuation id="f-429-4"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-500"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-501">8</ix:nonFraction></ix:nonFraction> million associated with the performance of this obligation for each of the three months ended September&#160;30, 2023 and 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-502"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-503">25</ix:nonFraction></ix:nonFraction> million for each of the nine months ended September&#160;30, 2023 and 2022, within Other collaboration revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-504">62</ix:nonFraction> million of deferred revenue on our Condensed Consolidated Balance Sheet related to this performance obligation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from the Taiho Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, under the Taiho collaboration, certain clinical milestones for domvanalimab and zimberelimab were met through the STAR-221 study and Taiho became obligated to pay us $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-505">28</ix:nonFraction>&#160;million, which is recorded in Receivable from collaboration partners at September&#160;30, 2023 on our Condensed Consolidated Balance Sheet. We determined that we have a performance obligation to perform R&amp;D services for Taiho related to the global development activities for the STAR-221 study in support of the Taiho Territory. We allocated the $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-506">28</ix:nonFraction>&#160;million to this single performance obligation and recognize the amounts allocated to this service as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-507"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-508">4</ix:nonFraction></ix:nonFraction>&#160;million for both the three and nine months ended September&#160;30, 2023 within License and development service revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-509">24</ix:nonFraction>&#160;million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to this performance obligation, allocated between current and noncurrent based on the expected timing of future recognition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalized Costs to Obtain Contracts</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred certain costs to obtain the Gilead Collaboration Agreement in 2020 and the First Gilead Collaboration Agreement Amendment in 2021, which consisted of consultant and legal fees. We allocated these costs to the various performance obligations, to be recognized as the underlying performance obligations are satisfied and revenue is recognized. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2023 and 2022, the recognized expense was not significant. For each of the nine months ended September&#160;30, 2023 and 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="f-510"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="f-511">1</ix:nonFraction></ix:nonFraction>&#160;million expense related to these capitalized costs in G&amp;A expense. At September&#160;30, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="f-512">3</ix:nonFraction> million in capitalized costs to obtain the contracts, of which $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="us-gaap:CapitalizedContractCostNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-513">1</ix:nonFraction> million was recorded as Prepaid expenses and other current assets and $<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-514">2</ix:nonFraction> million was recorded as Other noncurrent assets in our Condensed Consolidated Balance Sheet.</span></div></ix:continuation><div id="if2f5ba682505427b80ca0ea888ebdc11_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-515" continuedAt="f-515-1" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="f-515-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision or benefit for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into consideration in the relevant period. Each quarter, we update the estimate of the annual effective tax rate, and if the estimated tax rate changes, we record a cumulative adjustment to the provision or benefit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense was $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-516">2</ix:nonFraction> million for the three months ended September&#160;30, 2023, with an effective tax rate of (<ix:nonFraction unitRef="number" contextRef="c-19" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-517">2.4</ix:nonFraction>%). We did <ix:nonFraction unitRef="usd" contextRef="c-20" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-518">no</ix:nonFraction>t record a provision for income taxes for the three months ended September&#160;30, 2022. The income tax expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-519">5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-520">1</ix:nonFraction> million for the nine months ended September&#160;30, 2023 and 2022, with an effective tax rate of (<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-521">2.2</ix:nonFraction>%) and (<ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-522">0.5</ix:nonFraction>%), respectively. The year-over-year increase in the income tax provision was due to an increase in taxable income. We have taxable income compared to book losses before income taxes due to the timing of recognition of deferred revenue for tax purposes and the effects of the mandatory capitalization and amortization of research and development expenses starting in 2022, as required by the 2017 Tax Cuts and Jobs Act. The effective tax rate differs from the U.S. statutory tax rate primarily due to the valuation allowances on our deferred tax assets and state income taxes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023 and December&#160;31, 2022, we have provided a valuation allowance against U.S. federal and state deferred tax assets. We continue to evaluate the realizability of deferred tax assets and the related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties associated with uncertain tax benefits as part of the income tax provision. To date, we have not recognized any interest and penalties, nor have we accrued for or made payments for interest and penalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been audited by the Internal Revenue Service, or any state or foreign tax authority. We are subject to taxation in the United States and in Australia. Due to net operating loss and research credit carryforwards, all of our tax years, from 2015 to 2022, remain open to U.S. federal and California state tax examinations. In addition, our fiscal years from 2018 to 2022 are open to examination in Australia.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-523" continuedAt="f-523-1" escape="true">Net loss per share</ix:nonNumeric></span></div><ix:continuation id="f-523-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-524" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potentially dilutive securities excluded from the computation of diluted net loss per share calculations because they would have been antidilutive (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock options issued and outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-222" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-525">13.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-223" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-526">12.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-224" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-527">1.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-225" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-528">1.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-226" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-529">0.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-227" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-530">0.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total potential dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-531">15.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-532">13.8</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also excluded the effect of Gilead&#8217;s right to purchase additional shares of our common stock from the calculation as these rights had no intrinsic value at either September&#160;30, 2023 or 2022.</span></div></ix:continuation><div id="if2f5ba682505427b80ca0ea888ebdc11_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-533" continuedAt="f-533-1" escape="true">Stock-based compensation </ix:nonNumeric></span></div><ix:continuation id="f-533-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-534" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Condensed Consolidated Statements of Operations (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-535">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-536">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-537">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-538">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-539">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-540">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-541">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-542">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-543">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-544">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-545">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-546">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if2f5ba682505427b80ca0ea888ebdc11_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-547" continuedAt="f-547-1" escape="true">Cash, cash equivalents and marketable securities </ix:nonNumeric></span></div><ix:continuation id="f-547-1" continuedAt="f-547-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-548" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, gross unrealized gains and losses and the fair value of our cash, cash equivalents and marketable securities, all of which are considered available for sale, by type of securities (in millions): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Types of securities as of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-549">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-552">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-553">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-554">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-555">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-556">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-557">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-559">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-560">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-561">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-564">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-565">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-568">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-569">953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-571">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-572">950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Types of securities as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-573">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-576">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-577">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-578">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-579">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-580">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-581">635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-583">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-584">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-585">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-588">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-589">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-590">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-592">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-593">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-595">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-596">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-597" continuedAt="f-597-1" escape="true">The following table summarizes the fair values of our cash, cash equivalents and marketable securities by location in the Condensed Consolidated Balance Sheets and contractual maturity (in millions):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><ix:continuation id="f-547-2"><div style="margin-top:6pt"><ix:continuation id="f-597-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Location in Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-598">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-599">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="f-600">615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="f-601">803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between one and three years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-602">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-603">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="rcus:CashCashEquivalentsAndAvailableForSaleInvestments" scale="6" id="f-604">950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="rcus:CashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="6" id="f-605">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses recognized on the sale of available-for-sale marketable securities were not material for the three and nine months ended September&#160;30, 2023 and 2022. Realized gains and losses are included in Interest and other income, net, in the Condensed Consolidated Statements of Operations. The cost of a security sold is determined using the specific-identification method.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We limit the credit risk associated with our investments by placing them with banks and institutions we believe are highly credit worthy and investing in highly rated investments. We held a total of <ix:nonFraction unitRef="position" contextRef="c-26" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-606">159</ix:nonFraction> and <ix:nonFraction unitRef="position" contextRef="c-27" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-607">219</ix:nonFraction> positions in securities which were in unrealized loss positions as of September&#160;30, 2023 and December&#160;31, 2022, respectively. We do not intend to sell our securities with unrealized loss positions and have concluded we will not be required to sell the securities before recovery of the amortized cost for the investment at maturity. <ix:nonFraction unitRef="usd" contextRef="c-21" decimals="INF" name="us-gaap:ProvisionForLoanLossesExpensed" format="ixt:fixed-zero" scale="0" id="f-608"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ProvisionForLoanLossesExpensed" format="ixt:fixed-zero" scale="0" id="f-609"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="INF" name="us-gaap:ProvisionForLoanLossesExpensed" format="ixt:fixed-zero" scale="0" id="f-610">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> credit related losses have been recognized for any of the periods presented.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-611" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-612" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-613">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-614">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-615"><span style="-sec-ix-hidden:f-616">Restricted cash (included in Other noncurrent assets)</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="f-617">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="f-618">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-619">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-620">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div id="if2f5ba682505427b80ca0ea888ebdc11_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-621" continuedAt="f-621-1" escape="true">Condensed consolidated balance sheet components</ix:nonNumeric></span></div><ix:continuation id="f-621-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-622" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="rcus:PrepaidExpensesAndOtherCurrentAssets" scale="6" id="f-623">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="rcus:PrepaidExpensesAndOtherCurrentAssets" scale="6" id="f-624">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="f-625">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="f-626">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-627">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-628">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="f-629" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="rcus:AccruedResearchAndDevelopmentExpensesCurrent" scale="6" id="f-630">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="rcus:AccruedResearchAndDevelopmentExpensesCurrent" scale="6" id="f-631">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-632">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-633">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-634">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-635">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="f-636">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:fixed-zero" scale="6" id="f-637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="6" id="f-638">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="6" id="f-639">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-640">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-641">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-642" continuedAt="f-642-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-642-1"><ix:nonNumeric contextRef="c-1" name="rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" id="f-643" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash and non-cash information related to our operating leases (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" scale="6" id="f-644">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" scale="6" id="f-645">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from tenant improvement allowances</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:CashReceivedFromTenantImprovementAllowances" scale="6" id="f-646">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="rcus:CashReceivedFromTenantImprovementAllowances" scale="6" id="f-647">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="6" id="f-648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-649">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of tenant improvement allowance receivable included in Other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:RecognitionOfTenantImprovementAllowanceReceivable" scale="6" id="f-650">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="rcus:RecognitionOfTenantImprovementAllowanceReceivable" scale="6" id="f-651">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023 and December&#160;31, 2022, we have provided deposits for letters of credit totaling $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="6" id="f-652"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="6" id="f-653">3</ix:nonFraction></ix:nonFraction> million to secure our obligations under our leases, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets.</span></div></ix:continuation><div id="if2f5ba682505427b80ca0ea888ebdc11_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-654" continuedAt="f-654-1" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="f-654-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gilead Stock Purchase</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, under the Second Stock Purchase Agreement, Gilead purchased <ix:nonFraction unitRef="shares" contextRef="c-247" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-655">1.0</ix:nonFraction> million shares of our common stock at the closing day purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-248" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-656">19.26</ix:nonFraction> per share for a total cost of $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-657">20</ix:nonFraction> million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Facility</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we entered into an equity distribution agreement pursuant to which we may, from time to time, sell shares of our common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-249" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-658">0.0001</ix:nonFraction> per share, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-6" name="rcus:SaleOfStockAuthorizedConsiderationOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-659">200</ix:nonFraction>&#160;million. In August 2023, we issued and sold <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-660">0.2</ix:nonFraction>&#160;million shares of our common stock under this agreement for total net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-661">5</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="if2f5ba682505427b80ca0ea888ebdc11_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-662" continuedAt="f-662-1" escape="true">Fair value measurements</ix:nonNumeric></span></div><ix:continuation id="f-662-1" continuedAt="f-662-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1 inputs include unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><ix:continuation id="f-662-2" continuedAt="f-662-3"><ix:nonNumeric contextRef="c-1" name="rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-663" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement as of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-664">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-666">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-667">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-669">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-670">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-671">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-672">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-673">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-675">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-677">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-679">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-680">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-681">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-683">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-684">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-685">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-686">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-687">950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability for sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-689">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-690">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-691">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities measured at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-694">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-695">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-696">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-697">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-698">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-699">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-701">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-702">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-703">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-705">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-706">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-707">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-709">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-710">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-711">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-713">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-715">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-716">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-717">969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-719">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability for sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-722">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-723">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities measured at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-724">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-726">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-727">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability for Sale of Future Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we entered into an agreement with BVF Partners L.P. (BVF), under which BVF funded the discovery and development of compounds for the treatment of inflammatory diseases (the BVF Program) for $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" name="rcus:NonRefundablePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="f-728"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-6" name="rcus:NonRefundablePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="f-729">15</ix:nonFraction></ix:nonFraction> million in non-refundable payments which were paid in 2021 and 2022. In return, we are obligated to: perform research and development activities in the Program; make contingent payments upon the achievement of certain clinical and regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-6" name="rcus:ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones" format="ixt:num-dot-decimal" scale="6" id="f-730">73</ix:nonFraction> million or $<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" name="rcus:ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones" format="ixt:num-dot-decimal" scale="6" id="f-731">160</ix:nonFraction> million depending on whether the program is solely developed by us or with Gilead if they opt-in under the Gilead Collaboration Agreement; and pay mid- to high-single digit royalties on any net product sales generated by the BVF Program. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the BVF Agreement as a liability primarily because we have significant continuing involvement in generating the cash flows due to BVF. The liability is recorded at fair value by using probability-adjusted discounted cash flows and is revalued each reporting period until the related contingencies have been resolved. The fair value measurement is based on significant unobservable inputs that are reviewed quarterly by management and include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair value of this liability related to interest accretion are recognized in Non-operating income (expense) in the Condensed Consolidated Statements of Operations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><ix:continuation id="f-662-3"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, new preclinical information from our BVF Program led to revised assumptions which decreased the estimated probabilities of success and delayed the projected timing of achieving specified development, regulatory and commercial milestones and commercial sales. These changes in estimates are accounted for prospectively and resulted in a decrease in the imputed effective interest rate on the unamortized portion of the liability to <ix:nonFraction unitRef="number" contextRef="c-312" decimals="3" name="rcus:ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability" scale="-2" id="f-732">10.1</ix:nonFraction>% commencing with the quarter ended June 30, 2023, compared to <ix:nonFraction unitRef="number" contextRef="c-313" decimals="3" name="rcus:ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability" scale="-2" id="f-733"><ix:nonFraction unitRef="number" contextRef="c-314" decimals="3" name="rcus:ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability" scale="-2" id="f-734"><ix:nonFraction unitRef="number" contextRef="c-315" decimals="3" name="rcus:ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability" scale="-2" id="f-735">20.6</ix:nonFraction></ix:nonFraction></ix:nonFraction>% for the quarters ended March 31, 2023 and prior. The impact of this change on the non-cash interest expense for the quarter and nine months ended September&#160;30, 2023 was not material when compared to the prior year periods. <ix:nonNumeric contextRef="c-1" name="rcus:SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock" id="f-736" continuedAt="f-736-1" escape="true">The liability for sale of future royalties is reported in Other noncurrent liabilities in the Condensed Consolidated Balance Sheets and changes were as follows (in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="f-736-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-6" name="rcus:LiabilityForSaleOfFutureRoyalties" scale="6" id="f-737">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-6" name="rcus:LiabilityForSaleOfFutureRoyalties" scale="6" id="f-738">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-6" name="rcus:IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived" format="ixt:fixed-zero" scale="6" id="f-739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-6" name="rcus:IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived" scale="6" id="f-740">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-6" name="rcus:IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion" scale="6" id="f-741">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-6" name="rcus:IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion" scale="6" id="f-742">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-6" name="rcus:LiabilityForSaleOfFutureRoyalties" scale="6" id="f-743">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-6" name="rcus:LiabilityForSaleOfFutureRoyalties" scale="6" id="f-744">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited Condensed Consolidated Financial Statements and related notes in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited Consolidated Financial Statements and related notes thereto for the year ended December&#160;31, 2022, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February&#160;28, 2023. This discussion and other parts of this report contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations, and intentions. Further, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Our actual results could differ materially from those discussed in these forward-looking and other statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report titled &#8220;Risk Factors.&#8221; </span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on creating best-in-class therapies. Using our robust and highly efficient drug discovery capability, we have created a significant portfolio of investigational products which are in clinical development, with our most advanced molecule, an anti-TIGIT antibody, now in four Phase 3 registrational studies targeting lung and gastrointestinal cancers. Our deep portfolio of novel small molecules and enabling antibodies allows us to create highly differentiated therapies, which we are developing to treat multiple large indications. We expect our clinical-stage portfolio to continue to expand and to include molecules targeting immuno-oncology, cancer cell-intrinsic and immunological pathways. Our vision is to create, develop and commercialize highly differentiated therapies that have a meaningful impact on patients. </span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_82"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Clinical Product Portfolio</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently developing multiple investigational products in clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and HIF-2a. We have entered into an Option, License and Collaboration Agreement (as amended, the Gilead Collaboration Agreement) with Gilead Sciences, Inc. (Gilead) to strategically advance our portfolio through a collaborative relationship. The Gilead Collaboration Agreement provides Gilead with an exclusive license to our anti-PD-1 program (including zimberelimab) and time-limited exclusive option rights to our clinical programs, which they have exercised for our anti-TIGIT program (including domvanalimab), adenosine receptor antagonist program (including etrumadenant) and CD73 program (including quemliclustat). For all such optioned programs, we are co-developing investigational products with Gilead. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart summarizes our clinical pipeline:</span></div><div style="margin-top:6pt;text-align:center"><img src="rcus-20230930_g1.jpg" alt="img116678624_0.jpg" style="height:352px;margin-bottom:5pt;vertical-align:text-bottom;width:529px"/></div><div style="text-align:center"><img src="rcus-20230930_g2.jpg" alt="img116678624_1.jpg" style="height:152px;margin-bottom:5pt;vertical-align:text-bottom;width:525px"/></div><div style="text-align:center"><img src="rcus-20230930_g3.jpg" alt="Etruma Pipeline.jpg" style="height:121px;margin-bottom:5pt;vertical-align:text-bottom;width:530px"/></div><div style="text-align:center"><img src="rcus-20230930_g4.jpg" alt="img116678624_3.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:530px"/></div><div style="text-align:center"><img src="rcus-20230930_g5.jpg" alt="img116678624_4.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:530px"/></div><div style="text-align:center"><img src="rcus-20230930_g6.jpg" alt="AB801 Pipeline.jpg" style="height:31px;margin-bottom:5pt;vertical-align:text-bottom;width:530px"/></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">dom: domvanalimab; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; nivo: nivolumab; pembro: pembrolizumab; quemli: quemliclustat; rego: regorafenib; zim: zimberelimab</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">*+/- biologic, e.g. bevacizumab or biosimilar, will be included for all patients in whom it is not contraindicated</span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_85"></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the recent significant developments affecting our business: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">In November 2023, we presented p</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reliminary data from Arm A1 of the Phase 2 EDGE-Gastric study, evaluating domvanalimab plus zimberelimab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic upper gastrointestinal (GI) cancers. These data were from the cohort that includes a similar patient population and dosing regimen as the ongoing Phase 3 study, STAR-221. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Domvanalimab plus zimberelimab and chemotherapy showed encouraging objective response rates (ORR) of 80% (confirmed ORR (cORR) of 73%) in patients with PD-L1-high tumors (tumor activity positivity (TAP) &#8805;5%), 46% (all confirmed) in patients with PD-L1-low (TAP &lt;5%) tumors and 59%  (cORR of 56%) for patients overall. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Six-month landmark progression-free survival (PFS) was 93% for patients with PD-L1-high tumors (TAP &#8805;5%), 68% for patients with PD-L1-low tumors (TAP &lt;5%) and 77% for patients overall. Mature PFS has not been reached and data are expected in the second half of 2024. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Domvanalimab plus zimberelimab and chemotherapy was well tolerated, with a similar safety profile to what has been reported for anti-PD1 plus chemotherapy in this setting.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Pharmacokinetic and pharmacodynamic data from the dose-escalation phase of ARC-20, a Phase 1b study in cancer patients of AB521, a potential best-in-class HIF-2a inhibitor, is consistent with results seen in healthy volunteers.</span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Operating Results </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future. All revenue recognized to date has been through research, collaboration and license arrangements with strategic partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Development Services Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license and development services revenue consists of amounts recognized from the portions of the nonrefundable upfront and milestone payments received from Gilead and Taiho and allocated to performance obligations for licenses or R&amp;D activities performed by us as we develop our investigational products under the terms of our collaboration agreements. License and development services revenues are recognized based upon the timing of the delivery of a license or service if delivery is complete, or based on estimates of each performance obligation's percentage of completion at the period end if it is still in process. We calculate percentage of completion as a ratio of effort incurred to date on each performance obligation to the total estimated effort to be incurred to satisfy that performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Collaboration Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other collaboration revenue consists primarily of amounts recognized from the portions of the nonrefundable upfront payments received from Gilead and Taiho and allocated to performance obligations relating to access to our investigational pipeline recognized over the period of access. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist of expenses incurred in connection with the research and development of our pipeline programs. These expenses include preclinical and clinical expenses, payroll and personnel expenses, including stock-based compensation for our employees, laboratory supplies, product licenses, consulting costs, contract research, and depreciation. Shared facility expenses are allocated to functional groups proportionally based on usage. Under certain collaboration agreements we agree to share research and development expenses with our partners. Such cost sharing arrangements may result in receiving reimbursement from our partners or require that we reimburse our partners for qualified expenses. We expense both internal and external research and development costs as they are incurred. We record advance payments for services that will be used or rendered for future research and development activities as prepaid expenses and recognize them as an expense as the related services are performed. We recognize reimbursement for shared costs incurred by us and reimbursed by our partners as a reduction in research and development expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate our costs by investigational product, as a significant amount of research and development expenses include internal costs, such as payroll and other personnel expenses, and certain external costs that are not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded at the investigational product level. In particular, with respect to internal costs, several of our departments support multiple research and development programs, and we do not allocate those costs by investigational product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The level of our future research and development investment will depend on a number of factors and uncertainties, including the breadth of the joint development program agreed to with Gilead for the optioned programs, the outcome of our efforts, and the amount of cost reimbursements or milestone payments we receive from our collaborators. We expect our research and development expenses to increase substantially during the next few years as we pursue joint development programs with Gilead and advance these programs towards regulatory approval. We also expect to advance new programs into the clinic. All of this will require significant growth in our development capabilities and infrastructure. In addition, our joint development programs with Gilead for the optioned molecules are anticipated to include a significant number of later-stage clinical trials, which typically include a larger number of subjects, are of a longer duration and include more geographic regions. As we advance our clinical-stage programs and prepare to seek regulatory approval, we will also need to increase our late-stage manufacturing activities. As a result, we expect our preclinical, clinical, and contract manufacturing expenses to increase significantly relative to what we have incurred to date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under our arrangements with WuXi Biologics, Abmuno, AstraZeneca and BVF, we may incur additional clinical and regulatory milestone payments based on the development progress of our investigational products. We may also be required to pay royalties in the event of a successful product launch and our receipt of commercial revenues. Therefore, we are unable to predict the timing or the final cost to complete our clinical programs or validation of our manufacturing and supply processes and delays may occur due to numerous factors. Factors that could cause or contribute to delays or additional costs include, but are not limited to, those discussed in &#8220;Item 1A. Risk Factors.&#8221; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist principally of personnel-related costs including payroll and stock-based compensation for personnel in executive, finance, human resources, information technology, business and corporate development, and other administrative functions. Shared facility expenses are allocated to functional groups proportionally based on usage. Our general and administrative expenses also include professional fees for legal, consulting, and accounting services, rent and other facilities costs, fixed asset depreciation, and other general operating expenses not otherwise classified as research and development expenses. We do not receive significant reimbursements of these costs through our collaboration with Gilead.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase during the next few years as we support our growing research and development activities, including due to staff expansion, and other costs associated with increased infrastructure needs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating Income, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income, net consists primarily of interest earned on our investments in fixed-income marketable securities and non-cash interest expense incurred under the effective interest method on our liability for sale of future royalties to BVF.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License and development service revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">335&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">284&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(249)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(206)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(69)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(221)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(199)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(71)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(226)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(200)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.5pt">Not meaningful</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Total revenues for the three months ended September&#160;30, 2023 was primarily driven by decreased revenues from license and development services due to the progress in research and development activities for our programs, primarily zimberelimab, partially offset by an increase in revenue related to our Taiho collaboration.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Total revenues for the nine months ended September&#160;30, 2023 was primarily driven by increased revenues from license and development services due to the progress in the research and development activities for our programs, primarily etrumadenant, partially offset by a decrease in revenue recognized for zimberelimab.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5, Revenues to our Condensed Consolidated Financial Statements in Part I, Item 1 for further discussion of the amount and timing of revenues recognized from our license and collaboration agreements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of 6% or $5&#160;million in Research and development expenses for the three months ended September&#160;30, 2023 was primarily driven by: $7&#160;million of higher spend for Arcus programs not under a cost-sharing collaboration due to our expanding clinical and development activities; partially offset by a net decrease of $2&#160;million in shared costs for programs optioned by our collaboration partners, primarily from the Gilead collaboration. The net decrease of $2&#160;million was due to a decrease in shared collaboration costs of $10&#160;million primarily from the timing of clinical manufacturing; with a corresponding decrease in reimbursements for shared expenses of $8&#160;million. Non-cash stock-based compensation expense was $8 million for each of the third quarter 2023 and 2022. The net increase was primarily driven by: $3 million in net clinical costs due to our expanding clinical and development activities as we enrolled more patients in our existing and new studies; and $3 million increase in net employee compensation costs due to our growing headcount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of 19% or $39&#160;million in Research and development expenses for the nine months ended September&#160;30, 2023 was primarily driven by: $47&#160;million in higher costs incurred to support our expanded clinical and development activities including $19 million in higher costs due to the timing of standard-of-care therapeutic purchases and $17 million in lower costs due to the timing of clinical manufacturing; partially offset by $8&#160;million in higher reimbursements for shared expenses from our collaborations, primarily the Gilead collaboration. The net increase was primarily driven by $21 million in net clinical costs due to our expanding clinical and development activities as we enrolled more patients in our existing and new studies and $19 million increase in net employee compensation costs due to our growing headcount, including $2 million in increased non-cash stock-based compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2023 and 2022, we recognized reimbursements for shared expenses from our collaborations of $33 million and $41 million, respectively. For the nine months ended September&#160;30, 2023 and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, we recognized reimbursements for shared expenses from our collaborations of $119 million and $111 million, respectively. Reimbursements are driven primarily by the Gilead collaboration.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense by quarter may fluctuate due to the timing of clinical manufacturing and standard-of-care therapeutic purchases with a corresponding impact on reimbursements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of 15% or $4&#160;million in General and administrative expenses for the three months ended September&#160;30, 2023 was primarily driven by the increased complexity of supporting our expanding clinical pipeline and partnership obligations. Our growing headcount and our 2023 stock awards drove a $2 million increase in employee compensation costs, primarily due to increased non-cash stock-based compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of 16% or $12&#160;million in General and administrative expenses for the nine months ended September&#160;30, 2023 was primarily driven by the increased complexity of supporting our expanding clinical pipeline and partnership obligations. Our growing headcount and our 2023 stock awards drove a $9 million increase in employee compensation costs, including $5 million in increased non-cash stock-based compensation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Operating Income, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $6&#160;million and $21&#160;million in Non-operating income, net for the three and nine months ended September&#160;30, 2023, respectively, was primarily due to higher interest income resulting from increased investment yields as compared to the prior year.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $2&#160;million and $4&#160;million in Income tax expense for the three and nine months ended September&#160;30, 2023, respectively was primarily due to an increase in taxable income compared to the prior year.</span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily from the sale of our equity securities and payments received under our research, collaboration and license agreements with our strategic partners including Gilead. We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of our investigational products and ongoing internal research and development programs. At this time, we cannot reasonably estimate the nature, timing or aggregate amount of costs for our development, potential commercialization, and internal research and development programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, we had $950&#160;million of cash, cash equivalents, and marketable securities, compared to $1.1&#160;billion as of December&#160;31, 2022. The decrease in cash from the prior year end is primarily due to the use of cash in our research and development activities. Our cash and investments are held in a variety of interest-bearing instruments, including money market funds, U.S. government treasury obligations, investments in corporate securities and certificates of deposit. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our existing business plan, we believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our planned level of operations into 2026.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash flow and financing requirements are determined by analyses of operating and capital spending budgets. It is challenging to predict the nature, timing and estimated long-range costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our investigational products. This is made more challenging by events outside of our control. Accordingly, our operating plan may change, including as a result of factors currently unknown to us, and we may need to seek additional funds sooner than planned. Such financing may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may adversely affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Part II, Item 1A. Risk Factors&#8221; for additional risks associated with our substantial capital requirements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activities for each of the periods presented below (in millions): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net cash provided by (used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(218)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">508&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $218 million for the nine months ended September&#160;30, 2023 as compared to net cash provided by operating activities of $508 million for the same period in the prior year. The change in operating cash flows is primarily due to $725 million received from Gilead in January 2022 under the Gilead Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities for the nine months ended September&#160;30, 2023 was primarily due to net proceeds from marketable securities of $184&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for the nine months ended September&#160;30, 2022 was primarily due to net purchases of short-term and long-term securities as we invested a portion of the $725 million received from Gilead in January 2022 under the Gilead Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the nine months ended September&#160;30, 2023 was due to net proceeds of $25 million from issuance of our common stock and proceeds of $5 million for stock issued under our equity award plans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the nine months ended September&#160;30, 2022 was due to net proceeds of $17 million for stock issued under our equity award plans and $5 million received under the BVF agreement.</span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Judgments and Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these Condensed Consolidated Financial Statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements, as well as the reported revenue and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting policies and estimates, from those disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2022. </span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our contractual obligations outside the ordinary course of business during the nine months ended September&#160;30, 2023, as compared to those disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from changes in interest rates and foreign currency exchange rates. Our market risks have not changed materially from those discussed in our Annual Report on Form 10-K filed with the SEC on February&#160;28, 2023.</span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended September&#160;30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.</span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should consider carefully the following risk factors, together with all the other information in this report, including our Condensed Consolidated Financial Statements and notes thereto, and in our other public filings with the SEC, including our Annual Report on Form 10-K filed with the SEC on February&#160;28, 2023. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Limited Operating History, Financial Position and Capital Requirements </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of operating losses, have never generated any revenue from product sales and anticipate that we will continue to incur significant losses for the foreseeable future. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a pre-commercial immuno-oncology company with a limited operating history that may make it difficult to evaluate the success of our business to date and to assess our future viability. All of our investigational products are in development, and none have been approved for commercial sale nor have we ever generated any revenue from product sales. Our revenues to date have been primarily from upfront and milestone payments, research and development support and clinical materials reimbursement from our strategic partners. For the nine months ended September&#160;30, 2023 and the year ended December&#160;31, 2022 we had net losses of $226&#160;million and $267 million, respectively. As of September&#160;30, 2023, we had an accumulated deficit of $768&#160;million. We expect that it will be several years, if ever, before we have an investigational product ready for commercialization. While we may receive income from year to year under the Gilead Agreement and Taiho Agreement, we generally expect to incur substantial and increasing levels of operating losses over the next several years and for the foreseeable future as we advance our investigational products. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable on a sustained basis, we must develop and eventually commercialize a product with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our investigational products, obtaining marketing approval for these investigational products, manufacturing, marketing and selling those products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we succeed in commercializing one or more of our investigational products, we may never generate revenues that are significant or large enough to achieve sustained profitability. In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. If we do achieve profitability from product sales, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional investigational products. Our failure to become and remain profitable on a sustained basis would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to obtain additional funding to finance our operations and complete the development and any commercialization of our investigational products. If we do not receive substantial opt-in, milestone or royalty payments from our existing collaboration agreements, or are unable to raise additional capital when needed, we may be forced to restrict our operations or delay, reduce or eliminate our product development programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of biopharmaceutical investigational products is capital intensive. Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially during the next few years as our investigational products enter and advance into and through large late-stage or registrational clinical trials and we expand our clinical, regulatory, quality and manufacturing capabilities. In addition, if we obtain marketing approval for any of our investigational products, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, we had $950 million of cash, cash equivalents and marketable securities. While we believe that our cash position will be sufficient to fund our anticipated level of operations into 2026, our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number, scope, rate of progress and costs of clinical programs and investigational products as well as drug discovery, preclinical development activities, and laboratory testing; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope and costs of manufacturing development and commercial manufacturing activities; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope and costs of developing and supporting new non-oncology programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope of any cost sharing arrangements with our strategic partners; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and amount of milestone payments and option fees we receive under the Gilead Collaboration Agreement and Taiho Agreement; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent to which we acquire or in-license other investigational products and technologies; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost, timing and outcome of regulatory review of our investigational products; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost and timing of establishing sales and marketing capabilities, if any of our investigational products receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs associated with being a public company; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost associated with commercializing our investigational products, if they receive marketing approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our investigational products. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. In addition, if we are able to raise additional capital, raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or investigational products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of our Investigational Products </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain regulatory approval for our investigational products, or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for sale and our investigational products must be approved by the Food and Drug Administration (FDA) in the United States and similar regulatory authorities outside the United States, such as the EMA, prior to commercialization. The process of obtaining marketing approvals, both in the United States and abroad, is expensive and takes many years, if approval is obtained at all, and can vary substantially based upon a variety of factors. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the investigational product&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities, among other requirements. Our investigational products may not be effective, may be only moderately effective, may not have an acceptable durability of response, may not have an acceptable risk-benefit profile or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude us from obtaining marketing approval or limit their commercial use. Our investigational products may not be approved even if they achieve their primary endpoints in any Phase 3 clinical trials or registrational trials we or our collaborators conduct.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and in determining when or whether marketing approval will be obtained for any of our investigational products. Regulatory authorities may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of an investigational product. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may also cause delays in or prevent the approval of an application. For example, since a key element of our strategy is the development of intra-portfolio combinations, regulatory authorities may disagree that we have sufficiently demonstrated the contribution of each investigational product or other agent in our combination trials and require further studies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to obtain marketing approvals for any of our investigational products, those approvals may be for indications that are not as broad as desired or may contain other limitations that would adversely affect our ability to generate revenue from sales of those products. Moreover, if we are not able to differentiate our product against other approved products within the same class of drugs, or if any of the other circumstances described above occur, our business would be materially harmed and our ability to generate revenue from that class of drugs would be severely impaired. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining approval or if we fail to obtain approval of our investigational products, the commercial prospects for our investigational products may be harmed and our ability to generate revenues will be materially impaired.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development is a lengthy, expensive and uncertain process. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development of drugs and biological products is an extremely risky industry. Only a small percentage of investigational products that enter the development process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any investigational product, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our investigational products in humans. Clinical testing is expensive, can take many years to complete and its outcome is uncertain. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of preclinical studies and early clinical trials are not always predictive of future results. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of preclinical and early clinical trials of our investigational products and other products with the same mechanism of action may not be predictive of the results of later-stage clinical trials. Clinical trial failure may result from a multitude of factors including flaws in study design, dose selection, placebo effect, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the biopharmaceutical industry have suffered setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from clinical trials are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may further delay, limit or prevent marketing approval. In particular, results from uncontrolled trials, meaning trials in which there is no control group such as a placebo group, are inherently difficult to interpret. This difficulty is compounded in clinical trials such as ours, in which two or more investigational products that have not yet been approved are being evaluated. Accordingly, the preliminary data from clinical trials of certain of our investigational products may not be predictive of future clinical trial results for these or other investigational products when studied in a randomized environment or larger patient populations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Most of our clinical trials are open-label studies and may be susceptible to bias.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our clinical trials, including our Phase 3 trials, are open-label studies in which both the patient and investigator know whether the patient is receiving the investigational products or either an existing approved drug or placebo. Open-label clinical trials are susceptible to bias that may exaggerate any therapeutic effect or overestimate the risk associated with the investigational product. Patients may perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Investigators may interpret the information of the treated group more favorably given their awareness of the treatment regimen or may attribute safety risks to the investigational product. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enrollment and retention of subjects in clinical trials is expensive and time consuming, can be made more difficult or rendered impossible by competing treatments, clinical trials of competing investigational products, geopolitical instability and public health epidemics, each of which could result in significant delays and additional costs in our product development activities, or in the failure of such activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter delays in enrolling, or be unable to enroll and maintain, a sufficient number of subjects to complete any of our clinical trials. Patient enrollment and retention in clinical trials is a significant factor in the timing and cost of clinical trials and depends on many factors, including the size of the patient population required for analysis of the trial&#8217;s primary endpoints, the nature of the trial protocol, our ability to recruit clinical trial investigators with the appropriate competencies and experience, the existing body of safety and efficacy data with respect to the investigational product, the number and nature of competing products or investigational products and ongoing clinical trials of competing investigational products for the same indication, the proximity of subjects to clinical trial sites, the eligibility criteria for the clinical trial and our ability to obtain and maintain subject consents. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, enrollment of oncology subjects in our clinical trials evaluating zimberelimab may be hampered by nivolumab from Bristol-Myers Squibb and pembrolizumab from Merck, both of which are approved and on the market. Subjects may opt to be treated with an approved product rather than our anti-PD-1 antibody investigational product. In addition, Roche/Genentech, Merck and Beigene have initiated numerous Phase 3 trials with their respective anti-TIGIT antibodies, which could reduce the number of clinical sites and subjects available for our registrational program for domvanalimab (our anti-TIGIT antibody), including ARC-10 and STAR-121, each Phase 3 trials in lung cancer, and STAR-221, our Phase 3 trial in upper gastrointestinal tract cancer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Geopolitical instability and public health outbreaks may have an adverse impact our clinical trial operations. For example, we suspended clinical trial activities, including the enrollment of subjects, following the outbreak of war in Israel. If there are other geopolitical conflicts, a resurgence of the COVID-19 pandemic or additional public health outbreaks, we may further suspend or redirect our clinical trial activities, regulatory authorities and ethics committees may choose to divert resources and the time for review of new studies and any protocol or other amendments for ongoing studies may be prolonged. Our investigational sites may intermittently divert resources in order to respond to an ongoing health or humanitarian crisis, which could cause delays and limit their ability to initiate new studies. The limited resources at investigational sites in these situations would further hinder their ability to screen and enroll subjects, conduct and report all patient assessments and collect all patients' samples, thereby impacting our ability to assess the activity of our investigational products in a timely manner. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, recruiting and retaining subjects in our clinical trials may be adversely impacted by negative results that we report in our other clinical trials using the same investigational products or by negative results reported by others using investigational products with the same mechanism of action as our investigational products. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our investigational products. Failures in planned subject enrollment or retention may result in increased costs or program delays and could render further development impossible. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our product development goals in the time frames we announce and expect, the commercialization of our investigational products may be delayed, our share price may decline and our commercial prospects may be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development is inherently risky and uncertain. The actual timing of our development milestones can vary significantly compared to our estimates, in some cases for reasons beyond our control, for any number of reasons, including: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in completing IND-enabling preclinical studies or developing manufacturing processes and associated analytical methods that meet good manufacturing practice (cGMP) requirements; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA placing a clinical trial on hold; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA requesting additional information, which could necessitate generating additional information at significant cost in terms of both time and expenses;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our prioritization of other of our investigational products for advancement or the emergence of competing investigational products developed by others;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">challenges and delays in trial execution associated with our testing of multiple investigational products in the same indication in different clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects failing to enroll or remain in our trial at the rate we expect; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects choosing an alternative treatment or other investigational products, or participating in competing clinical trials; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">lack of adequate funding to continue our clinical trials; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects experiencing severe or unexpected drug-related adverse effects; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any interruptions or delays in the supply of our investigational products for our clinical trials; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a facility manufacturing any of our investigational products or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements, or infections or cross-contaminations of investigational products in the manufacturing process; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any changes to our manufacturing process or product specifications that may be necessary or desired; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any failure or delay in reaching an agreement with contract research organizations (CROs) and clinical trial sites; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices (GCP) or regulatory requirements or other third parties not performing data collection or analysis in a timely or accurate manner; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other comparable foreign regulatory authorities for violations of applicable regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">one or more Institutional Review Boards (IRBs) refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in regulatory requirements and policies which may require us to amend clinical trial protocols to comply with these changes and resubmit our clinical trial protocols to IRBs for reexamination; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays due to new regulatory requirements which may take time for us and the third-parties we engage to incorporate into our operations to ensure compliance; or</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">health crises, such as COVID-19, which may restrict the ability of trial sites to initiate new trials, screen patients for enrollment or treat enrolled patients, and divert clinical trial site resources away from the conduct of our clinical trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors may also lead to the suspension or termination of clinical trials, and ultimately the denial of regulatory approval of an investigational product. Any delays in achieving our development goals may allow our competitors to bring products to market before we do and adversely affect our commercial prospects and cause our stock price to decline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, topline results that we report may differ from future results of the same studies and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our business prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serious adverse events, undesirable side effects or other unexpected properties of our investigational products may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our investigational products or limitations on the use of our investigational products or, if discovered following marketing approval, revocation of marketing authorizations or subsequent limitations on the use of our investigational products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to develop our investigational products and initiate clinical trials of additional investigational products, serious adverse events, undesirable side effects or unexpected characteristics may emerge causing us to abandon these investigational products or limit their development to more narrow uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Even if our investigational products initially show promise in early clinical trials, the side effects of drugs are frequently only detectable after they are tested in large, Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the investigational product or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications. If serious adverse or unexpected side effects are identified during development and are determined to be attributed to our investigational product, we may be required to develop a Risk Evaluation and Mitigation Strategy (REMS) to mitigate those serious safety risks, which could impose significant distribution and use restrictions on our products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug-related side effects could also affect subject recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business prospects significantly. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if one or more of our investigational products receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may withdraw approvals of such product; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may require additional warnings on the label; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may impose subsequent limitations on the use of the product; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we could be sued and held liable for harm caused to patients; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reputation may suffer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of the particular investigational product, if approved, and could significantly harm our business, results of operations and prospects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse findings from clinical trials conducted by third parties investigating the same investigational products as us in different territories or different investigational products directed to the same target as one of our programs could adversely affect our development program. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lack of efficacy, adverse events, undesirable side effects or other adverse findings may emerge in clinical trials conducted by third parties investigating the same investigational products as us in different territories or different investigational products directed to the same target as one of our programs. For example, we and Gloria Biosciences, each licensed our rights to the same anti-PD-1 antibody (which we refer to as zimberelimab) from WuXi Biologics (Cayman) Inc. (WuXi Biologics). Gloria Biosciences refers to this antibody as GLS-010 and is conducting clinical trials with GLS-010 in China. We have no control over their clinical trials or development program, and adverse findings from the results or their conduct of clinical trials could adversely affect our development of zimberelimab or even the viability of zimberelimab as an investigational product. We may be required to report Gloria Biosciences' adverse events or unexpected side effects to the FDA or comparable foreign regulatory authorities, which could, among other things, order us to cease further development of zimberelimab. We may face similar risks from any independent development conducted with our investigational products by Gilead and Taiho, following any exercise of their respective options to our programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we have no control over the clinical trials or development program of third parties developing investigational products directed to the same target as one of our programs. Adverse findings or results from any of their clinical trials could adversely affect the commercial prospects of our investigational products and cause our stock price to fluctuate or decline. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A key element of our strategy is the development of intra-portfolio combinations. If we are not successful in discovering, developing and commercializing investigational products that take advantage of different mechanisms of action to achieve superior outcomes relative to the use of single agents or other combination therapies, our ability to achieve our strategic objectives would be impaired. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to build a broad portfolio of investigational products that will allow for the development of intra-portfolio combinations. We believe that by developing or licensing these investigational products, we can control the combinations we pursue and, if and when approved, maximize the commercial potential of these combinations. However, these combinations have not been tested before and may fail to demonstrate synergistic activity against immunological targets, may fail to achieve superior outcomes relative to the use of single agents or other combination therapies, may exacerbate adverse events associated with one of the investigational products when used as monotherapy, or may fail to demonstrate sufficient safety or efficacy traits in clinical trials to enable us to complete those clinical trials or obtain marketing approval for the combination therapy. In addition, our early clinical trials may test more than one investigational product in uncontrolled studies, and it may be difficult to interpret the results of those uncontrolled trials or evaluate the contribution of each investigational agent in such combination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in developing combination therapies, competition from other investigational products in the same class which are either already approved or further along in development than ours may prevent us from realizing the commercial potential of our combination therapies and prevent us from achieving our strategic objectives. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development of combination therapies may present more or different challenges than development of single agent therapies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our investigational products are being pursued in combination with one or more additional products or investigational products. The development of combination therapies may be more complex than the development of single agent therapies and generally requires that sponsors demonstrate the contribution of each investigational product to the claimed effect and the safety and efficacy of the combination as a whole. This requirement may make the design and conduct of clinical trials more complex, requiring more clinical trial subjects. We also may not be able to meet the FDA&#8217;s current or future approval standards required for combination therapies or combination products, if we decided to administer or package a combination therapy as a single drug product. For example, under the "combination rule", the FDA may not file or approve a fixed-dose combination product unless each component of a proposed drug product is shown to make a contribution to the claimed effects and the dosage of each component (amount, frequency, duration) is safe and effective for the intended population. To satisfy these requirements, the FDA typically requires a clinical factorial study, designed to assess the effects attributable to each drug in the combination product. This is particularly true when the ingredients are directed at the same sign or symptom of the disease or condition. The FDA has accepted a variety of approaches to satisfy the combination rule but the FDA has stated that factorial studies may be unethical (e.g., omitting a drug known to improve survival) or impractical (there may be too many components to conduct a factorial study, meaning the trial cannot be conducted). The FDA has also stated that it may be possible to use other types of clinical and nonclinical data and mechanistic information available to demonstrate the contributions of the individual active ingredients to the effect of the combination. Moreover, the applicable requirements for approval of a combination therapy may differ from country to country.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that one of our investigational products were to fail to demonstrate sufficient safety and efficacy or establish its contribution to the claimed effects of a combination therapies, we would need to identify alternatives. For example, we expect that our anti-PD-1 antibody, zimberelimab, will form the backbone of many of the combination therapies we are pursuing. If we are unable to demonstrate the contribution of zimberelimab to the claimed effects of a combination therapy, we would need to identify an anti-PD-1 antibody for use in such combination therapy. In the event we are unable to do so or are unable to do so on commercially reasonable terms, our business and prospects would be materially harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of our investigational products may require companion diagnostics in certain indications. Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our investigational products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as a medical device and may require separate regulatory authorization prior to commercialization. Certain clinical trials that we are conducting, such as our Phase 2 ARC-7 trial and our Phase 3 ARC-10 trial, which are each being conducted in patients with PD-L1&#8805;50% NSCLC, include the use of a diagnostic test to help identify eligible patients. Our future trials may also use a diagnostic test to help identify eligible patients. In addition, we have significant efforts directed to identifying changes in various cells and proteins to understand their relationship, if any, to the clinical activity observed in our clinical trials and to assess if such cells and/or proteins could be used as predictive biomarkers to select for patients more likely to respond to our investigational products. However, we cannot be certain that we will be able to identify any such biomarkers, that such biomarkers will result in us identifying the appropriate patients for our investigational products or that we or any third-party collaborators will be able to validate any diagnostic tests incorporating any predictive biomarkers we may identify. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have any plans to develop diagnostic tests internally. We are therefore dependent on the sustained cooperation and effort of third-party collaborators in developing and, if our investigational products are approved for use only with an approved companion diagnostic test, obtaining approval and commercializing these tests. If these parties are unable to successfully develop companion diagnostics for these investigational products, or experience delays in doing so, the development of our investigational products may be adversely affected and we may not be able to obtain marketing authorization for these investigational products. Furthermore, our ability to market and sell, as well as the commercial success, of any of our investigational products that require a companion diagnostic will be tied to, and dependent upon, the receipt of required regulatory authorization and the continued ability of such third parties to make the companion diagnostic commercially available on reasonable terms in the relevant geographies. Any failure to develop, validate, obtain and maintain marketing authorization and supply for a companion diagnostic we need will harm our business prospects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The design or our execution of our ongoing and future clinical trials may not support marketing approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design or execution of a clinical trial can determine whether its results will support marketing approval, and flaws in the design or execution of a clinical trial may not become apparent until the clinical trial is well advanced. In some instances, there can be significant variability in safety or efficacy results between different trials with the same investigational product due to numerous factors, including differences in trial protocols, size and type of the patient populations, variable adherence to the dosing regimen or other protocol requirements and the rate of dropout among clinical trial participants. The FDA or comparable foreign regulatory authorities may disagree with our trial designs and our interpretation of data from preclinical studies or clinical trials. Even if we adhere to guidance or advice given by the FDA or comparable foreign regulatory authorities, such adherence does not guarantee that the FDA will agree with our trial designs or data interpretations or prevent the FDA from changing the requirements for the approval of any investigational product. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have conducted, and continue to conduct, portions of our clinical trials outside the United States, and the FDA may not accept data from trials conducted in foreign locations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted, and we expect to continue to conduct, portions of our clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In general, the patient population for any clinical trials conducted outside the United States must be representative of the population for which we intend to label the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. We cannot assure you that the FDA will accept data from trials conducted outside the United States. If the FDA does not accept the data from such clinical trials, we would likely need to conduct additional trials, which would be costly and time-consuming and delay or permanently halt our development of our investigational products. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties, Manufacturing and Commercialization </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to depend on our collaboration with Gilead for the research, development, manufacture and commercialization of our investigational products. If this collaboration is not successful, our business could be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy for fully developing and commercializing our investigational products is dependent upon maintaining our current arrangements with Gilead and our other strategic partners. Our ability to leverage these arrangements to produce commercial success will depend, among other things, on our collaborators' cooperation and ability to successfully meet their responsibilities with regards to a clinical program. We cannot predict the success of any collaboration that we enter into. Our partnership with Gilead poses a number of risks including, but not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">conflicts may arise between us and Gilead, such as conflicts regarding the combinations or indications to pursue or concerning the interpretation of clinical data, the commercial potential of any optioned investigational products, the interpretation of financial provisions or the ownership of intellectual property developed during the collaboration. Any such conflicts could slow or prevent the development or commercialization of our investigational products; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if our joint development program does not result in the successful development and commercialization of products or if Gilead terminates the collaboration agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our investigational products could be delayed and we may need additional resources to develop our investigational products;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we will be heavily dependent on Gilead for its further development and commercialization of the investigational products from the programs that it opts in to;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may not be successful in this collaboration due to various other factors, including our ability to demonstrate proof of concept in one or more clinical studies so that Gilead will exercise its option to these programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we have appointed two individuals designated by Gilead to our board of directors pursuant to the terms of the investor rights agreement, and Gilead owns approximately 19.9% of our outstanding common stock and has the right (but not the obligation) to acquire additional shares from us up to an amount resulting in Gilead owning a total of 35% of our outstanding common stock and, as a result, may be able to exert significant influence over our company; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Gilead could independently develop, or develop with third parties, products that compete directly or indirectly with our investigational products if Gilead believes that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">because Gilead has an option to all of our programs, it will be difficult for us to enter into new collaborations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we are and expect to remain dependent on third parties to conduct our ongoing clinical trials and any future clinical trials of our investigational products. The timing of the initiation and completion of these trials will therefore be partially controlled by such third parties and may result in delays to our development programs. Specifically, we expect CROs, clinical investigators, and consultants to play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, we will not be able to control all aspects of their activities. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines controlling how clinical trials should be conducted and are applicable to all of our investigational products in clinical development. The FDA and comparable foreign regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites fail to comply with applicable GCP requirements, the data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. Many of these third parties have and continue to suffer from personnel constraints resulting from COVID-19 and other economic factors which may impact their ability to perform their contractual obligations. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trials unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or comparable foreign regulatory authorities concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit by the FDA or any comparable foreign regulatory authority. Any such delay or rejection could prevent us from commercializing our investigational products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our investigational products and will not be able to, or may be delayed in our efforts to, successfully commercialize our products. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply by third parties of the investigational products, standard-of-care drugs or comparator agents used in our clinical trials may become limited or interrupted which could delay, prevent or impair our development efforts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any manufacturing facilities. We produce in our laboratory relatively small quantities of compounds for evaluation in our research programs. We rely, and expect to continue to rely, on third parties for the manufacture and supply of our investigational products for preclinical and clinical testing, as well as for commercial manufacture if any of our investigational products are approved. If any of these third-parties fail to perform these activities for us, nonclinical or clinical development of our investigational products could be delayed, which could have an adverse effect on our business, financial condition, results of operations, and/or growth prospects. Further, we currently have limited manufacturing arrangements for our investigational products and expect that each of our investigational products will only be covered by single source suppliers for the foreseeable future. In particular, we have an exclusive relationship with WuXi Biologics, located in China, for the manufacture of zimberelimab drug substance. Our reliance on limited manufacturing arrangements increases the risk that we will not have and may not be able to obtain sufficient quantities of our investigational products for use in our clinical trials, which could delay, prevent or impair our development efforts. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any supply chain challenges may affect our ability to supply clinical sites with our investigational products and any standard-of-care drugs and comparator agents that we use in our clinical trials. These supply chain challenges can include longer lead times for the manufacturers of our investigational products to obtain raw materials, longer timeframes to procure or lack of supply for standard-of-care drugs or comparator agents used in our clinical trials, and transit delays at each point in the manufacturing, supply or distribution chain. For example, carboplatin and 5-flourouracil are used in certain of our clinical trials as the standard-of-care chemotherapy agent. However, certain of the countries where we conduct these clinical trials are experiencing a shortage in the supply of carboplatin. These supply chain challenges may delay, prevent or impair our development efforts, or result in increased costs for our clinical trials. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing partners are subject to extensive regulation. In the event any of our manufacturers fail to comply with such regulations or perform its obligations, our business may be adversely affected could negatively and we may need to delay or halt the development of our investigational products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for our investigational products, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants, or to inadvertent changes in the properties or stability of our investigational products that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA or Biologics License Application (BLA) on a timely basis and must adhere to the FDA&#8217;s Good Laboratory Practice regulations and cGMP regulations enforced by the FDA through its facilities inspection program. Comparable foreign regulatory authorities may require compliance with similar requirements. The facilities and quality systems of our third-party contractor manufacturers must pass a pre-approval inspection for compliance with the applicable regulations as a condition of marketing approval of our investigational products. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMP regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our investigational products may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our investigational products. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop investigational products in a timely manner or within budget. Our or a third party&#8217;s failure to execute on our manufacturing requirements, to do so on commercially reasonable terms and comply with cGMP could adversely affect our business in a number of ways, including: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an inability to initiate or continue clinical trials of our investigational products under development; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delay in submitting regulatory applications, or receiving marketing approvals, for our investigational products; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">loss of the cooperation of an existing or future collaborator, including option exercises by Gilead or Taiho under the Gilead Collaboration Agreement or Taiho Agreement, respectively; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">requirements to cease development or to recall batches of our investigational products; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">in the event of approval to market and commercialize our investigational products, an inability to meet commercial demands for our product or any other future investigational products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in methods of investigational product manufacturing or formulation may result in additional costs or delay. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As investigational products progress through preclinical to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as the investigational product&#8217;s specifications, manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our investigational products to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our investigational products and jeopardize our ability to commercialize our investigational products and generate revenue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, clinical trial investigators, CROs, consultants, vendors, collaboration partners and any potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, clinical trial investigators, CROs, consultants, vendors, collaboration partners and any potential commercial partners. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i) FDA laws and regulations or those of comparable foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information, (ii) manufacturing standards, (iii) federal and state health and data privacy, security, fraud and abuse, government price reporting, transparency reporting requirements, and other healthcare laws and regulations in the United States and abroad, or (iv) laws that require the true, complete and accurate reporting of financial information or data. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, as well as a disclosure program and other applicable policies and procedures, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive marketing approval, we may not be successful in commercializing our investigational products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no sales, marketing or distribution capabilities or experience. If any of our investigational products ultimately obtains regulatory approval, we, whether alone or in collaboration with Gilead for programs that we commercialize together, may not be able to effectively or successfully market the product due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the imposition by regulatory authorities of significant restrictions on a product&#8217;s indicated uses, marketing or distribution;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the imposition by regulatory authorities of costly and time-consuming post-approval studies, post-market surveillance or additional clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our failure to establish sales and marketing capabilities; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the failure of our products to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, healthcare payors and others in the medical community necessary for commercial success; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unfavorable pricing regulations or third-party coverage and reimbursement policies; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inaccuracies in our estimates of the addressable patient population resulting in a smaller market opportunity than we believed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our investigational products for which we have or retain sales and marketing responsibilities are approved, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third parties. We may be unable to recruit and retain adequate numbers of effective sales and marketing personnel, and if we enter into arrangements with third parties to perform sales, marketing and distribution services our product revenue or the profitability of these product revenue to us are likely to be lower than if we were to market and sell any medicines that we develop ourselves.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our or our collaborators&#8217; inability to successfully market and sell any of our investigational products, if approved, could have a material adverse effect on our business and our overall financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive marketing approval for one or more of our investigational products, our commercial success is dependent on obtaining coverage and reimbursement approval for a product from a government or other third-party payor, which coverage may be delayed or may not be sufficient to cover our costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success is dependent on obtaining coverage and reimbursement approval for a product from a government or other third-party payor, which is a time-consuming and costly process that could require us and any collaborators to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded therapeutics and therapeutics administered under the supervision of a physician. Additionally, our collaborators will be required to obtain coverage and reimbursement for any related companion diagnostics tests they develop separate and apart from the coverage and reimbursement we seek for our investigational products, once approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement may also impact the demand for, and the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance and we expect to experience pricing pressures in connection with the sale of any of our investigational products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to obtain coverage and reimbursement approval for any of our investigational products, if approved, could have a material adverse effect on the demand for that investigational product, and on our business and our overall financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our investigational products are approved by the FDA, they may never be approved or commercialized outside the United States, which would limit our ability to realize their full market potential. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products outside the United States, we or our collaborators must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. For example, the approval of zimberelimab for the treatment of recurrent or refractory classical Hodgkin&#8217;s Lymphoma in China by Gloria Biosciences does not improve the chances of FDA approval for any BLA that we may submit for zimberelimab in the United States in any indication. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us or our collaborators and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our or our collaborators&#8217; failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any investigational products approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or fail to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any investigational products for which we intend to seek approval as biologic products may face competition sooner than anticipated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until twelve years from the date on which the reference product was first licensed. During this twelve-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The law is complex and is still being interpreted and implemented by the FDA. As a result, any such processes could have a material adverse effect on the future commercial prospects for our biological products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zimberelimab and domvanalimab are biological products and we may develop additional biological products in the future. We believe that any of our current and future investigational products approved as a biological product under a BLA should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our investigational products to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our In-Licenses and Other Strategic Agreements </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently party to several in-license agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our investigational products. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these investigational products or both, which would adversely affect our business and prospects. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, in part, on license and other strategic agreements, which subject us to various obligations, including diligence obligations with respect to development and commercialization activities, reporting and notification obligations, payment obligations for achievement of certain milestones and royalties on product sales, negative covenants and other material obligations. We may need to devote substantial time and attention to ensuring that we are compliant with our obligations under these agreements. If we fail to comply with the obligations under our license agreements or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and our licensors may have the right to terminate the license. If our license agreements are terminated, we may not be able to develop, manufacture, market or sell the products covered by our agreements and those being tested or approved in combination with such products. Such an occurrence could materially adversely affect the value of the investigational product being developed under any such agreement and any other investigational products being developed or tested in combination. For example, zimberelimab, which we in-licensed from WuXi Biologics, is intended to be used as the cornerstone of our combination strategy. Domvanalimab, which we in-licensed from Abmuno Therapeutics, is being evaluated in four registrational studies: ARC-10, PACIFIC-8 (in collaboration with AstraZeneca), STAR-121 (being operationalized by Gilead) and STAR-221. In the event we breach our license agreement with WuXi Biologics and/or Abmuno Therapeutics, and our license agreements are terminated, we would be unable to pursue our intra-portfolio combination strategy, or we would have to negotiate a new or reinstated agreement, which may not be available to us on equally favorable terms, or at all. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our collaborations or other strategic partnerships on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected investigational products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not realize the benefits of any acquisitions, in-license or other collaborations or strategic alliances that we enter into. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into in-license agreements with multiple licensors and option agreements to enable the development and commercialization of our investigational products worldwide. In the future, we may seek to enter into acquisitions or additional licensing arrangements with third parties to expand our pipeline or that we believe will complement or augment our development and commercialization efforts with respect to our investigational products and any future investigational products that we may develop. These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, investigational products or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into in-license, acquisition or collaboration agreements, or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction or such other benefits that led us to enter into the arrangement. For example, under the Gilead Collaboration Agreement, for each additional clinical program that Gilead exercises its option to, it will pay an option-exercise fee. Furthermore, we and Gilead will equally share global co-development costs for the joint development program, as well as profits and losses for the United States, subject to opt-out rights applicable to certain programs, and expense caps on our spending and true-up adjustments. If Gilead does not exercise its option to develop a program, our capital requirements relating to that development program will significantly increase and we may need to seek a new partner in order to develop and commercialize our investigational products from that program. Failure to realize the benefits of any collaborations or strategic alliances may further cause us to curtail the development of an investigational product, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any planned sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we will need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our investigational products or bring them to market and generate product sales revenue, which would harm our business prospects, financial condition and results of operations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may wish to acquire rights to future assets through in-licensing or may attempt to form collaborations in the future with respect to our investigational products, but may not be able to do so, which may cause us to alter or delay our development and commercialization plans. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and potential commercialization of our investigational products may require substantial additional capital to fund expenses. Pursuant to the Gilead Collaboration Agreement, Gilead has an exclusive option to acquire an exclusive license to all of our then-current and future clinical programs during the 10-year collaboration term. Given the breadth of the collaboration, our ability to form new collaborations in the future will be limited. If Gilead declines to exercise its option to a program, we may need to enter into new collaborations for such programs with companies that have more resources and experience than us. We may not be successful in these efforts because third parties may not view our investigational products as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third party for development and commercialization of an investigational product, we can expect to relinquish some or all of the control over the future success of that investigational product to the third party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the design or results of clinical trials; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the likelihood of approval by the FDA or comparable foreign regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential market for the investigational product; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs and complexities of manufacturing and delivering such investigational product to patients; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential of competing products; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the existence of uncertainty with respect to our ownership of technology or other rights, which can exist if there is a challenge to such ownership without regard to the merits of the challenge; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">industry and market conditions generally. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaborator may also consider alternative investigational products or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our investigational product. We may also be restricted under any license agreements by one or more negative covenants or otherwise. For example, we may be restricted from entering into agreements on certain terms or at all with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such investigational product, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such investigational product, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense and may be prevented from or limited in forming additional strategic collaborations. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our investigational products or bring them to market and generate product revenue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain sufficient intellectual property protection for our investigational products, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our investigational products and research programs. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business, however, we cannot predict: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if and when patents may issue based on our patent applications; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope of protection of any patent issuing based on our patent applications; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether the claims of any patent issuing based on our patent applications will protect our investigational products and their intended uses or prevent others from commercializing competitive technologies or products; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether or not third parties will find ways to invalidate or circumvent our patent rights; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; and/or</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and enforcing patents is expensive and time-consuming and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Even if we successfully file and prosecute a patent application, we may not be able to maintain and/or enforce the issued patent. We may determine that filing or maintaining such a patent or any action to enforce a patent may be too high or not in the best interest of our company or our stockholders. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot be certain that the claims in our pending patent applications directed to our investigational products and/or technologies will be considered patentable by the U.S. Patent and Trademark Office (USPTO) or by patent offices in foreign countries. One aspect of the determination of patentability of our inventions depends on the scope and content of the &#8220;prior art,&#8221; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Even if the patents do issue based on our patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to our investigational products is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our investigational products. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner than anticipated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time we may be required to license technology from additional third parties to further develop or commercialize our investigational products. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our investigational products, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our investigational products could cause us to abandon any related efforts, which could seriously harm our business and operations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits alleging that we have infringed the intellectual property rights of third parties or to protect or enforce our patents or other intellectual property, which litigation could be expensive, time consuming and adversely affect our ability to develop or commercialize our investigational products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates. Third parties may assert infringement claims against us based on existing or future intellectual property rights. For example, we are aware of certain patents owned or licensed by Bristol-Myers Squibb having claims directed broadly to treating cancer with anti-PD-1 antibodies (the BMS Patents), which expire in 2023 and 2024. The BMS Patents have been and may in the future be the subject of litigation. In addition, we are aware of certain patents held by Genentech relating to methods of using an anti-PD-1 or anti-PD-L1 antibody in combination with an anti-TIGIT antibody for the treatment of cancer (the Genentech Patents), which expire in 2034, two of which were recently statutorily disclaimed. These patents are, or have been, the subject of post-grant proceedings at the United States Patent and Trademark Office &#8220;USPTO&#8221; and other global patent offices. If the validity of the BMS Patents and Genentech Patents are upheld following all challenges, and if we receive regulatory approval for zimberelimab prior to expiration of the BMS Patents or domvanalimab in combination with zimberelimab in a territory with standing intellectual property rights prior to expiration of the BMS or Genentech Patents, then we may need to delay commercialization or we may need to obtain a license, which license may not be available on commercially reasonable terms, or at all. If we were sued for patent infringement, we would need to demonstrate that our investigational products, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. If we are found to infringe a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing investigational product or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing investigational product. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our investigational products or force us to cease some of our business operations, which could materially harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may find that competitors are infringing our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against which we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to defend or pursue such litigation, which typically last for years before they are concluded. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our investigational products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights outside of the U.S. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents are of national or regional effect, and filing, prosecuting and defending patents on all of our investigational products throughout the world would be prohibitively expensive. As such, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Further, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals or biologics, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. In addition, certain developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Further, we file patent applications in Russia and the Eurasian patent office, which is headquartered in Moscow. Sanctions against Russia may make it difficult to file and maintain patents in these countries, and Russia has begun taking actions against "unfriendly" countries, including the U.S., which may adversely affect the scope of and/or our ability to enforce our intellectual property rights. In any of these countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our investigational products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. However, the patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, which have increased uncertainties as to the ability to obtain and enforce patent rights in the future. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries could increase the uncertainties and costs. For example, in September 2011 the Leahy-Smith America Invents Act (the America Invents Act) was signed into law and included a number of significant changes to U.S. patent law as then existed. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review, and derivation proceedings. After March 2013, under the America Invents Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may rely on trade secret and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and investigational products, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Elements of our investigational product, including processes for their preparation and manufacture, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, third parties with which we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets and know-how can be difficult to protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We and any third parties with which we share facilities enter into written agreements that include confidentiality and intellectual property obligations to protect each party&#8217;s property, potential trade secrets, proprietary know-how, and information. We further seek to protect our potential trade secrets, proprietary know-how, and information in part, by entering into non-disclosure and confidentiality agreements with parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our investigational products or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our investigational products for an adequate amount of time. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent rights are of limited duration. Given the amount of time required for the development, testing and regulatory review of new investigational products, patents protecting such candidates might expire before or shortly after such investigational products are commercialized. Even if patents covering our investigational products are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. A patent term extension based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business Operations </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our business operations and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to grow our business operations, including, if any of our investigational products receives marketing approval, adding employees in sales and marketing. To manage our anticipated future growth, we must: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">identify, recruit, integrate, maintain and motivate additional qualified personnel; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">manage our development efforts effectively, including the initiation and conduct of clinical trials for our investigational products; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">improve our operational, financial and management controls, reporting systems and procedures. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to develop, manufacture and commercialize our investigational products will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time, to managing these growth activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our investigational products and, accordingly, may not achieve our research, development and commercialization goals. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biopharmaceuticals industry depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific, medical, regulatory, manufacturing and management skills and experience. We conduct our operations in the San Francisco Bay Area, a region that is home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel and rapidly increasing wages. Our industry also has experienced a high rate of turnover in recent years. While we have expanded a number of our in-office roles to permit remote work arrangements, allowing us to seek talent from outside the San Francisco Bay Area, we still may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number of qualified personnel among biopharmaceutical companies. Many of the other biopharmaceutical companies against which we compete have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better opportunities for career advancement. Any or all of these competing factors may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize our investigational products and to grow our business and operations as currently contemplated. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the services of our founders, Terry Rosen, Ph.D., who serves as our Chief Executive Officer, and Juan Jaen, Ph.D., who serves as our President. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the services of our founders, Terry Rosen, Ph.D., who serves as our Chief Executive Officer, and Juan Jaen, Ph.D., who serves as our President. Although we have entered into employment agreements with them, they are not for a specific term and each of them may terminate their employment with us at any time, though we are not aware of any present intention of either of these individuals to leave us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drs. Rosen and Jaen have significant experience identifying and developing biopharmaceuticals. We believe that their drug discovery and development experience, and overall biopharmaceutical company management experience, would be difficult to replace. However, the historical results, past performance and/or acquisitions of companies with which they were affiliated do not necessarily predict or guarantee similar results for our company. Further, Drs. Rosen and Jaen have certain other business and personal commitments outside of serving as the Chief Executive Officer and President of Arcus, including serving on the boards of other companies and foundations, which may result in diversion of their focus and attention on our company.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their investigational products are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer, which is highly competitive with rapidly changing standards of care. As such, our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or non-competitive. Our competitors also may obtain marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several pharmaceutical companies developing products in the same class as our investigational products, some of which are further along in development than our corresponding assets. For additional information regarding our competitors, see &#8220;Item 1. Business&#8212;Competition&#8221; in our Annual Report on Form 10-K filed with the SEC on February&#160;28, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more investigational products within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Consequently, the results of our clinical trials for investigational products in that class will likely need to show a risk benefit profile that is competitive with or more favorable than those products and investigational products in order to obtain marketing approval or, if approved, a product label that is favorable for commercialization. If the risk benefit profile is not competitive with those products or investigational products, or if the approval of other agents for an indication or patient population significantly alters the standard of care with which we tested our investigational products, we may have developed a product that is not commercially viable, that we are not able to sell profitably or that is unable to achieve favorable pricing or reimbursement. In such circumstances, our future product revenue and financial condition would be materially and adversely affected. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal information technology systems, and those of our third-party CROs and other third parties upon which we rely, are subject to failure, security breaches and other disruptions, which could result in a material disruption of our investigational products&#8217; development programs, jeopardize sensitive information, prevent us from accessing critical information or result in a loss of our assets, and potentially expose us to notification obligations, loss, liability or reputational damage and otherwise adversely affect our business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information, including but not limited to intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party contractors who have access to our confidential information. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, given their size and complexity and the increasing amounts of confidential information that they maintain, our internal information technology systems and those of our third-party CROs and other third parties upon which we rely are vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyberattacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information and other assets), which may compromise our system infrastructure, lead to data leakage, impair key business processes or other critical business operations, delay our development programs, or result in the loss of assets or other liability. We have monitoring systems in place and have detected at least one intrusion into our computer systems and attempts to exfiltrate our data. Although our investigation in each case indicates that it did not have a material adverse effect on our operations nor result in any compromise of our information, there can be no assurance of a similar result in the future. Our reliance on internet technology and the number of our employees who are working remotely has increased the opportunities for cybercriminals to exploit vulnerabilities. Overall, there has been a significant increase in fraud schemes, including a successful social engineering attack against us through one of our employees. We cannot assure you that our data protection efforts and our investment in information technology will prevent breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, as the cyber threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and becoming increasingly difficult to detect. There can be no assurance that we and our third-party CROs and other third parties upon which we rely will be successful in detecting, preventing or fully recovering systems or data from all breakdowns, service interruptions, attacks or breaches of systems that could adversely affect our business and operations and/or result in the loss or disclosure of critical or sensitive data or other assets, which could result in financial, legal, business or reputational harm to us. Ransomware attacks have risen dramatically and we may be forced to pay to unlock our data and information, re-access our systems and resume our ability to conduct business operations. The loss of clinical trial data for our investigational products could significantly increase our costs to recover or reproduce the data and result in delays in our development programs, impair our ability to obtain marketing approval and reduce the commercial opportunity for our investigational products. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. In particular, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain insurance coverage to insure against losses suffered as a result of malicious intrusions and cyberattacks, such coverage may be insufficient to fully compensate us for the loss or there may be disputes with our insurers about the availability of insurance coverage for our claims. Cyber insurance may become increasingly difficult to maintain and we may not be able to maintain coverage at a reasonable cost or in an amount adequate to compensate for any loss or satisfy any liability that may arise.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic, political and trade conditions could adversely affect our business, financial condition or results of operations and may exacerbate the effects of the risks described herein. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current global economic conditions are highly volatile due to a number of reasons, including geopolitical instability, such as the ongoing military conflict between Russia and Ukraine and the recent eruption of war between Israel and Hamas, rising inflation that has increased our operating expenses and disruptions in the capital and credit markets that may reduce our ability to raise additional capital when needed on acceptable terms, if at all. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging international trade relations may also adversely impact our operations and/or financial condition by limiting or preventing the activities of third parties that we engage or increasing the cost of our operations. For example, WuXi Biologics, located in China, is our sole manufacturer of our investigational biologics, including zimberelimab, domvanalimab. In addition, if tariffs were to be imposed on the investigational products they manufacture for us, such tariffs would have an adverse impact on our operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the current inflationary environment related to increased aggregate demand and supply chain constraints has increased our operating expenses and may continue to affect our operating expenses. Economic conditions may also strain our suppliers, possibly resulting in supply disruptions that impact our ongoing clinical trials and other operations. A significant worsening of global economic conditions could materially increase these risks we face.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any new or prolonged downturn of global economic conditions could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future profitability may depend, in part, on our ability to commercialize our investigational products in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our investigational products before we receive marketing approval from the applicable regulatory authority in that foreign market, and we may never receive such marketing approval for any of our investigational products. To obtain marketing approval in many foreign countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our investigational products, and we cannot predict success in these jurisdictions. If we obtain approval of our investigational products and ultimately commercialize our investigational products in foreign markets, we would be subject to additional risks and uncertainties, including: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our customers&#8217; ability to obtain reimbursement for our investigational products in foreign markets; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our inability to directly control commercial activities because we are relying on third parties;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">import or export licensing requirements; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">longer accounts receivable collection times; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">longer lead times for shipping; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">language barriers for technical training; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reduced protection of intellectual property rights in some foreign countries; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the existence of additional potentially relevant third-party intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">foreign currency exchange rate fluctuations; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign sales of our investigational products could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or the third parties upon which we depend may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our headquarters and main research facility are located in the San Francisco Bay Area, which in the past has experienced severe earthquakes and fires. In addition, fires and other natural disasters may increase in frequency and severity over time due to climate change. If these earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us from using all or a significant portion of our headquarters or research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our clinical trials, our development plans and business. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and our ability to generate profits in the future is uncertain. Unused net operating loss carryforwards (NOLs) for the tax year ended December 31, 2017 and prior tax years will carry forward to offset future taxable income, if any, until such unused NOLs expire. Unused NOLs generated after December 31, 2017, under current tax law, will not expire. Our NOLs may be carried forward indefinitely. In addition, the future deductibility of such NOLs will be limited to 80% of current year taxable income in any given year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both our current and our future unused losses (and tax credit carryforwards) may be subject to further limitation under Sections 382 and 383 of the Internal Revenue Code (IRC) of 1986, as amended, if we undergo an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period. We performed an analysis under IRC Section 382 and 383 through October 31, 2020 with respect to our net operating loss and credit carryforwards. We concluded that an ownership change, as defined under IRC Section 382, occurred in previous years but that such ownership change did not result in the expiration of our net operating loss or credit carryforwards prior to utilization. We may incur additional ownership changes in the future in connection with any equity issuance, including any additional issuances to Gilead. If we experience any such ownership change, we may be limited in our ability to use our net operating loss and credit carryforwards and be required to make material cash tax payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited. For example, while California recently enacted a franchise tax law restoring the usability of California state NOLs to offset taxable income for tax years beginning on January 1, 2022, previous law significantly limited the use of California state NOLs for taxable years 2020 and 2021. Similar laws in the future could accelerate or permanently increase state taxes owed. Therefore, even if we attain sustained profitability, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws and regulations or exposure to additional tax liabilities could adversely affect our financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, or IRS, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to currently deduct research and development expenditures and requires taxpayers to capitalize and amortize U.S. based and non-U.S. based research and development expenditures over five and fifteen years, respectively, pursuant to IRC Section 174. We cannot predict whether, when, in what form, or with what effective dates, tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit our commercialization of any investigational products that we may develop. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our investigational products in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our investigational products or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delay or termination of clinical trials; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">decreased demand for any investigational products or products that we may develop; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injury to our reputation and significant negative media attention; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">withdrawal of clinical trial subjects; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">initiation of investigations by regulators; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant costs to defend the related litigation and diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">substantial monetary awards to study subjects or patients; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">loss of revenue; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the inability to commercialize any products that we may develop. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as our investigational products advance through clinical trials and if we successfully commercialize any products. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and any potential collaborators may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH). Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative and regulatory landscape for privacy and data security continues to evolve, and we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data security in the United States, the EU and other jurisdictions. This increased focus on privacy and data security issues may negatively affect our operating results and our business. For example, the California Consumer Privacy Act of 2018 (CCPA), which took effect on January 1, 2020 and was amended by the California Privacy Rights Act of 2020 effective on January 1, 2023, gives California residents expanded rights to access, correct and require deletion of their personal information, limit disclosure of sensitive personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. In addition, the CCPA authorizes private lawsuits to recover statutory damages for certain data breaches. While it exempts some data regulated by HIPAA and certain clinical trials data, the CCPA may increase our compliance costs and potential liability with respect to other personal information we collect about California residents. Some observers note that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign data protection laws also apply to health-related and other personal data obtained outside the United States. In the European Union, Regulation (EU) 2016/679 (General Data Protection Regulation) took effect in May 2018 and imposes, in some cases, stricter obligations than data protection laws in the United States on the use of health-related and other personal data. These requirements include the obligation to appoint data protection officers in certain circumstances, rights for individuals to be &#8220;forgotten&#8221; and to data portability, and the obligation to make public notification of significant data breaches. Under the General Data Protection Regulation, data protection authorities can also impose administrative fines of up to 4% of our total worldwide turnover or up to &#8364;20 million (whichever is higher). In addition, the General Data Protection Regulation only permits the transfer of personal data outside the European Economic Area (EEA) to countries that offer a level of data protection deemed adequate by the European Commission, unless an approved data transfer mechanism is in place. One such mechanism was invalidated by the European Court of Justice, adding to the complexity of transferring personal data outside the EEA. The General Data Protection Regulation increases our responsibility and liability in relation to personal data that we process, and we must put in place additional mechanisms to ensure compliance with the new EU data protection rules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with U.S. and foreign data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations expose us to broadly applicable fraud and abuse, transparency, government price reporting, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject, either directly or indirectly through our customers and third-party payors, to various U.S. federal and state health care laws, including fraud and abuse, transparency and other healthcare laws and regulations, and similar laws in other jurisdictions in which we conduct our business. These laws may impact, among other things, our research and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers, physicians and other parties through which we market, sell and distribute our products for which we obtain marketing approval. The laws that may affect our ability to operate include, but are not limited to the federal Anti-Kickback Statute; federal civil and criminal false claims laws, such as the False Claims Act (FCA); HIPAA; federal and state consumer protection and unfair competition laws; the federal transparency requirements under the Physician Payments Sunshine Act; state and foreign law equivalents of each of these federal laws; and state and foreign laws that require pharmaceutical companies to implement compliance programs. Many of these laws are discussed in detail in &#8220;Item 1. Business&#8212;Government Regulation&#8212;Other U.S. Healthcare Laws and Compliance Requirements&#8221; in our Annual Report on Form 10-K filed with the SEC on February 28, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have continued their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. We have entered into consulting and advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our investigational products, if approved. Because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant civil, criminal and administrative penalties such as fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. If any of the physicians or other healthcare providers or entities with which we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of investigational products, restrict or regulate post-approval activities, and affect the ability to profitably sell investigational products for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, on August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022 (IRA), which, among other things, (1) directs the U.S. Department of Health and Human Services to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025 and eliminates the &#8220;donut hole&#8221; under the Medicare Part D program by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. These provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. The United States Department of Health and Human Services has and will continue to issue and update guidance as these programs are implemented. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. We expect that other healthcare reform measures may be adopted in the future, and that any such health reform measures could have an adverse effect on our business and/or results of operation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, Trade Laws) prohibit, among other things, companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies, and clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and the third parties with which we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with which we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Owning our Common Stock </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The stock price of our common stock has been and may continue to be volatile or may decline regardless of our operating performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has fluctuated and may fluctuate significantly in response to numerous factors, many of which are beyond our control, including: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">overall performance of the equity markets; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our operating performance and the performance of other similar companies; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">results from our ongoing clinical trials and future clinical trials with our current and future investigational products or of our competitors; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory, trade or legal developments in the United States and other countries, including changes in tariffs or other trade restrictions and the changes in the structure of healthcare payment systems; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the level of expenses related to future investigational products or clinical development programs; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our failure to achieve product development goals in the timeframe we announce; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcements of acquisitions, strategic alliances or significant agreements by us or by our competitors; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">recruitment or departure of key personnel; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the economy as a whole and market conditions in our industry; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">trading activity by a limited number of stockholders who together beneficially own a majority of our outstanding common stock; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the size of our market float; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any other factors discussed in this report. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many immuno-oncology companies. Stock prices of many immuno-oncology companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The amount of our future losses is uncertain and our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and success or failure of clinical trials for our investigational products or competing investigational products, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our progress towards the achievement of any product development goals or milestones we announce, including any delays or failures which lead to the suspension or termination of any clinical trial or development program;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and cost of, and level of investment in, research and development activities relating to our investigational products, which may change from time to time; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">option fees received by us in connection with option exercises by Gilead and/or Taiho pursuant to their respective option agreements and/or payments received by us from Gilead or Taiho in connection with the achievement of certain development and/or regulatory milestones;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">amounts payable by us in connection with the achievement of development, regulatory and commercial milestones under our in-license and other strategic agreements; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract, hire and retain qualified personnel; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenditures that we will or may incur to develop additional investigational products; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain marketing approval for our investigational products, and the timing and scope of any such approvals we may receive; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the changing and volatile U.S. and global economic environments; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">future accounting pronouncements or changes in our accounting policies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The concentration of our stock ownership will likely limit our stockholders&#8217; ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon shares outstanding as of September&#160;30, 2023, our executive officers, directors and the holders of more than 5% of our outstanding common stock, in the aggregate, beneficially owned approximately 47.6% of our common stock. In particular, Gilead owns approximately 19.8% of our outstanding common stock (and has the right to acquire additional shares of our common stock from us to enable it to own up to 35% of our outstanding common stock), and we have appointed its two designees to our board of directors pursuant to the terms of the Investor Rights Agreement. As a result, these stockholders, acting together, will have significant influence over all matters that require approval by our stockholders, including the election of directors and approval of significant corporate transactions. Corporate actions might be taken even if other stockholders oppose them. This concentration of ownership might also have the effect of delaying or preventing a change of control of our company that other stockholders may view as beneficial. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may make the acquisition of our company more difficult, including the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our board of directors; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors or our chief executive officer, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the requirement for the affirmative vote of holders of at least 66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8260;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">% of the voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend the provisions of our amended and restated certificate of incorporation relating to the management of our business or our amended and restated bylaws, which may inhibit the ability of an acquirer to effect such amendments to facilitate an unsolicited takeover attempt; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for our stockholders to realize value in a corporate transaction. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws or any action asserting a claim against us that is governed by the internal affairs doctrine. In addition, to prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our bylaws provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits. While the Delaware courts have determined that these types of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of these provisions, which may require significant additional costs associated with resolving such action in other jurisdictions, and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of substantial amounts of our shares may cause the price of our common stock to decline. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price of our common stock could decline if there are substantial sales of our common stock, including any sales by us, our directors, executive officers, significant stockholders or the sales agents under the equity distribution agreement, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. We have also registered shares of common stock that we have issued and may issue under our employee equity incentive plans. These shares can be sold freely in the public market upon issuance, subject to vesting conditions and, in the case of our affiliates, volume limitations under Rule 144 under the Securities Act of 1933, as amended.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could result in sanctions or other penalties that would harm our business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of the New York Stock Exchange. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal controls over financial reporting. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. Accordingly, we cannot assure you that we will not in the future identify one or more material weaknesses in our internal control over financial reporting, which may have a negative impact on our ability to timely and accurately produce financial statements, may result in a material misstatement of our Consolidated Financial Statements or may negatively impact the confidence level of our stockholders and other market participants with respect to our reported financial information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that we have adequate internal controls over financial reporting is a costly and time-consuming effort that needs to be re-evaluated frequently. Recent trends in remote work arrangements have led to changes in work patterns that can make it more difficult to properly perform our controls and may create risks that result in deficiencies in the design of our controls. To the extent necessary, implementing any changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. </span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if2f5ba682505427b80ca0ea888ebdc11_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 10b5-1 Trading Arrangements</span></div><ix:nonNumeric contextRef="c-321" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-745" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonNumeric contextRef="c-19" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-746"><ix:nonNumeric contextRef="c-19" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-747">adoption, modification</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-19" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-748"><ix:nonNumeric contextRef="c-19" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-749">termination</ix:nonNumeric></ix:nonNumeric> of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended September&#160;30, 2023, which are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:37.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.877%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.003%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name and Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Action</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Shares to be Sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-19" name="ecd:TrdArrIndName" id="f-750">Juan C. Jaen</ix:nonNumeric></span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-19" name="ecd:TrdArrIndTitle" id="f-751">President and Director</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adopted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-322" name="ecd:TrdArrAdoptionDate" id="f-752">August 8, 2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-323" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="6" id="f-753">300,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 8, 2024</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:-40.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The documents listed below are incorporated by reference or are filed with this Quarterly Report on Form 10-Q, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.995%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Incorporated by Reference</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1724521/000156459018012447/rcus-ex31_541.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">001-38419</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 9, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1724521/000156459020026867/rcus-ex31_7.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">001-38419</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 26, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit101arcustaihomemora.htm">Memorandum, dated July 27, 2023, between Arcus Biosciences, Inc. and Taiho Pharmaceutical Co., LTD.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2023q3exhibit311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2023q3exhibit312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2023q3exhibit321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2023q3exhibit322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document &#8211; The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as inline XBRL and contained in exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.5pt">Filed herewith.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.5pt">This certification is deemed furnished but not filed for purposes of section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.28pt">This exhibit omits certain information the Company deems immaterial and of the type that it treats as confidential.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="if2f5ba682505427b80ca0ea888ebdc11_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2f5ba682505427b80ca0ea888ebdc11_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 7, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Terry Rosen</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Terry Rosen, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 7, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Alexander Azoy</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alexander Azoy</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Accounting Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Principal Accounting Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101arcustaihomemora.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9c911805c98c4518859f0f1e5062d8d4_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; &#61; INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT ARCUS BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL</font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">MEMORANDUM</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">This memorandum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Memorandum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is made and entered into effective as of July 27, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Arcus Biosciences, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a company organized under the laws of State of Delaware, U.S.A., having a business address at 3928 Point Eden Way, Hayward, CA 94545, U.S.A. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Arcus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TAIHO Pharmaceutical Co., Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a corporation organized under the laws of Japan, having a business address at 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">TAIHO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Arcus and TAIHO are sometimes collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and separately as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221;  Capitalized terms used herein but not defined herein shall have the meaning set forth in that certain Option and License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreement made and entered into effective as of September 19, 2017,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">by and between Arcus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and TAIHO,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as amended September 1, 2018 and as may be further amended from time to time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, pursuant to the Agreement, Arcus granted to TAIHO, with respect to each Arcus Program, (a) during the Exercise Period for such Arcus Program, an exclusive option to obtain an exclusive license to Develop and Commercialize the Option Products in such Arcus Program in the Field in and for the Territory and (b) upon TAIHO&#8217;s exercise of the Option, an exclusive license to Develop and Commercialize Licensed Products in the Field in and for the Territory during the Term.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, TAIHO exercised its Option with respect to that certain Arcus Program, Antibodies to PD-1, including but not limited to AB122 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">PD-1 Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and that certain Arcus Program, Antibodies to TIGIT, including but not limited to AB154 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">TIGIT Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and obtained the License with respect thereto. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties now desire to clarify certain matters with respect to the Development and Regulatory Milestones of PD-1 Program and TIGIT Program, as set forth below.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Now, Therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in consideration of the mutual covenants, agreements and stipulations set forth herein, the receipt and legal sufficiency of which are hereby mutually acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE I</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SKIPPED MILESTONES</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TAIHO is joining two Phase III Clinical Trials the titles of which are &#8220;A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously-Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma&#8221; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">STAR-221 Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and &#8220;A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations&#8221; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">STAR-121 Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), both of which are Global Studies and also Phase III Clinical Trials to ascertain efficacy and safety of combination therapy of AB122 and AB154. Arcus and TAIHO acknowledge and agree that, pursuant to Section 5.2(d)(iii) of the Agreement,  milestone 1 of the Global Study Pathway for &#91;***&#93; will be deemed to have been met upon &#91;***&#93;, respectively, for each of the PD-1 Program and the TIGIT Program and such milestone amounts payable by Taiho to Arcus in accordance with Section 5.2(d)(iii) of the Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><div id="i9c911805c98c4518859f0f1e5062d8d4_133"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE II</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INITIATION OF THE FIRST PHASE III STUDY WITH RESPECT TO PD-1 PROGRAM AND TIGIT PROGRAM</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the protocol of the STAR-221 Study in Japan, &#91;***&#93;. Given the purpose of the &#91;***&#93; as above, Arcus and TAIHO acknowledge and agree that, with respect to the Development and Regulatory Milestones corresponding to the STAR-221 Study, the timing of milestone 2 &#91;***&#93; under Section 5.2(a) of the Agreement, shall be &#91;***&#93;.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE III</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DEVELOPMENT AND REGULATORY MILESTONE PAYMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WITH RESPECT TO PD-1 PROGRAM AND TIGIT PROGRAM</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Parties hereby agree that solely for the first Development and Regulatory Milestone paid by Taiho to Arcus for the PD-1 Program and TIGIT Program pursuant to Section 5.2(a) of the Agreement, Taiho may &#91;***&#93;. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE IV<br>GENERAL</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1&#160;&#160;&#160;&#160;No Modifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as specifically set forth in this Memorandum, the terms and conditions of the Agreement shall remain in full force and effect. No waiver, alteration or modification of any of the provisions of this Memorandum shall be binding unless made in writing and signed by the Parties by their respective officers thereunto duly authorized.  The waiver by either Party of a breach or a default of any provision of this Memorandum by the other Party shall not be construed as a waiver of any succeeding breach of the same or any other provision, nor shall any delay or omission on the part of either Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such Party.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.2&#160;&#160;&#160;&#160;Miscellaneous.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Memorandum may be executed in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.  This Memorandum, once executed by a Party may be delivered via electronic means of transmission and shall have the same force and effect as if it were executed and delivered by the Parties in the presence of one another.  This Memorandum shall be governed by and construed in accordance with the laws of the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">State of California, United States without regard to its conflicts of laws principles.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Remainder of Page Intentionally Left Blank&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><div id="i9c911805c98c4518859f0f1e5062d8d4_4"></div><hr style="page-break-after:always"><div style="min-height:86.4pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties hereto have caused this Memorandum to be executed as of the Effective Date by their duly authorized representatives.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Arcus Biosciences, Inc.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; Terry Rosen&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  Terry Rosen&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  7&#47;27&#47;2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TAIHO Pharmaceutical Co., Ltd.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; Atsushi Azuma&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  Atsushi Azuma&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  Managing Director, Board Member, Business&#160;&#160;&#160;&#160; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Development&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">  8&#47;1&#47;2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;-2-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a2023q3exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if1ade4bbed0545feb7f446b360eb7b47_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Terry Rosen, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Form 10-Q of Arcus Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;7, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Terry Rosen</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terry Rosen, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a2023q3exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6bf7697d2a804defb6dd4212d699c802_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert C. Goeltz II, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Form 10-Q of Arcus Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;7, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert C. Goeltz II</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Robert C. Goeltz II</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a2023q3exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i575d849160c6478bb0dcd5e742e47911_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Arcus Biosciences, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending September&#160;30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;7, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Terry Rosen</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terry Rosen, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>a2023q3exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icc16864d6c0e4f99b164c0238ab90343_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Arcus Biosciences, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending September&#160;30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;7, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert C. Goeltz II</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Robert C. Goeltz II</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>rcus-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:805eb66e-844e-45f5-86a8-527ac86fecd7,g:7538c7a3-a72e-4e53-a8d0-2829fb9c9dc2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rcus="http://arcusbio.com/20230930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://arcusbio.com/20230930">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://arcusbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000002 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsParenthetical" roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000005 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationLiquidityandCapitalResources" roleURI="http://arcusbio.com/role/OrganizationLiquidityandCapitalResources">
        <link:definition>0000010 - Disclosure - Organization, Liquidity, and Capital Resources</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://arcusbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyGileadSciencesInc" roleURI="http://arcusbio.com/role/RelatedPartyGileadSciencesInc">
        <link:definition>0000012 - Disclosure - Related Party - Gilead Sciences, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborations" roleURI="http://arcusbio.com/role/LicenseandCollaborations">
        <link:definition>0000013 - Disclosure - License and Collaborations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://arcusbio.com/role/Revenues">
        <link:definition>0000014 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://arcusbio.com/role/IncomeTaxes">
        <link:definition>0000015 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://arcusbio.com/role/NetLossPerShare">
        <link:definition>0000016 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://arcusbio.com/role/StockBasedCompensation">
        <link:definition>0000017 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecurities" roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities">
        <link:definition>0000018 - Disclosure - Cash, Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponents" roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents">
        <link:definition>0000019 - Disclosure - Condensed Consolidated Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://arcusbio.com/role/Leases">
        <link:definition>0000020 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://arcusbio.com/role/StockholdersEquity">
        <link:definition>0000021 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://arcusbio.com/role/FairValueMeasurements">
        <link:definition>0000022 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://arcusbio.com/role/RevenuesTables">
        <link:definition>9954472 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://arcusbio.com/role/NetLossPerShareTables">
        <link:definition>9954473 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://arcusbio.com/role/StockBasedCompensationTables">
        <link:definition>9954474 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecuritiesTables" roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables">
        <link:definition>9954475 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsTables" roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables">
        <link:definition>9954476 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://arcusbio.com/role/LeasesTables">
        <link:definition>9954477 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://arcusbio.com/role/FairValueMeasurementsTables">
        <link:definition>9954478 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails" roleURI="http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails">
        <link:definition>9954479 - Disclosure - Organization, Liquidity, and Capital Resources - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyGileadSciencesIncAdditionalInformationDetails" roleURI="http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails">
        <link:definition>9954480 - Disclosure - Related Party - Gilead Sciences, Inc. - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationsAdditionalInformationDetails" roleURI="http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails">
        <link:definition>9954481 - Disclosure - License and Collaborations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails" roleURI="http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails">
        <link:definition>9954482 - Disclosure - Revenues - Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesAdditionalInformationDetails" roleURI="http://arcusbio.com/role/RevenuesAdditionalInformationDetails">
        <link:definition>9954483 - Disclosure - Revenues - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails" roleURI="http://arcusbio.com/role/RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails">
        <link:definition>9954484 - Disclosure - Revenues - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails" roleURI="http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails">
        <link:definition>9954485 - Disclosure - Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://arcusbio.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9954486 - Disclosure - Income Taxes - Additional Information - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails" roleURI="http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails">
        <link:definition>9954487 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" roleURI="http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails">
        <link:definition>9954488 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails" roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails">
        <link:definition>9954489 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities Considered as Available for Sale by Type of Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails" roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails">
        <link:definition>9954490 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Schedule of Fair Values of Our Cash, Cash Equivalents and Marketable Securities by Location in Condensed Consolidated Balance Sheets and Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails" roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>9954491 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>9954492 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails" roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails">
        <link:definition>9954493 - Disclosure - Condensed Consolidated Balance Sheet Components - Summary of Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails" roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails">
        <link:definition>9954494 - Disclosure - Condensed Consolidated Balance Sheet Components - Summary of Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails" roleURI="http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails">
        <link:definition>9954495 - Disclosure - Leases - Summary of Cash and Non-cash Information Related to Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://arcusbio.com/role/LeasesAdditionalInformationDetails">
        <link:definition>9954496 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>9954497 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9954498 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>9954499 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails" roleURI="http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails">
        <link:definition>9954500 - Disclosure - Fair Value Measurements - Summary of Changes of Liabilities for Sale of Future Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="rcus_PercentageOfOutstandingCommonStockOwned" abstract="false" name="PercentageOfOutstandingCommonStockOwned" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="rcus_GileadCollaborationAgreementMember" abstract="true" name="GileadCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties" abstract="false" name="EffectiveInterestOnLiabilityForSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" abstract="false" name="ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rcus_AmendedInvestorRightsAgreementMember" abstract="true" name="AmendedInvestorRightsAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_CorporateSecuritiesAndCommercialPaperMember" abstract="true" name="CorporateSecuritiesAndCommercialPaperMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" abstract="true" name="CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" abstract="false" name="NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rcus_LockupPeriod" abstract="false" name="LockupPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rcus_RecognitionOfTenantImprovementAllowanceReceivable" abstract="false" name="RecognitionOfTenantImprovementAllowanceReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_PrepaidExpensesAndOtherCurrentAssets" abstract="false" name="PrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_PerformanceObligationPeriod" abstract="false" name="PerformanceObligationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities" abstract="false" name="OptionPaymentUponCompletionOfCertainIndEnablingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" abstract="true" name="CashCashEquivalentsAndMarketableSecuritiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rcus_AntiCDThirtyNineMember" abstract="true" name="AntiCDThirtyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_AccruedResearchAndDevelopmentExpensesCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember" abstract="true" name="QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_NumberOfExerciseOptionToPrograms" abstract="false" name="NumberOfExerciseOptionToPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rcus_OptionPaymentReceived" abstract="false" name="OptionPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_SecondStockPurchaseAgreementMember" abstract="true" name="SecondStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_LiabilityForSaleOfFutureRoyaltiesMember" abstract="true" name="LiabilityForSaleOfFutureRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_TaihoPharmaceuticalCoLtdMember" abstract="true" name="TaihoPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_CashCashEquivalentsAndAvailableForSaleInvestments" abstract="false" name="CashCashEquivalentsAndAvailableForSaleInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_BvfPartnersLPMember" abstract="true" name="BvfPartnersLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_OfficersAndDirectorsTradingArrangementMember" abstract="true" name="OfficersAndDirectorsTradingArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_SaleOfStockAuthorizedConsiderationOnTransaction" abstract="false" name="SaleOfStockAuthorizedConsiderationOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_TrailingDaysAverageClosingPrice" abstract="false" name="TrailingDaysAverageClosingPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rcus_ExtendedLockupPeriod" abstract="false" name="ExtendedLockupPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" abstract="false" name="AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ProceedsFromSaleOfMarketableSecurities" abstract="false" name="ProceedsFromSaleOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ResearchAndDevelopmentExpenseRecoveries" abstract="false" name="ResearchAndDevelopmentExpenseRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_NonRefundableAndNonCreditableCashPayments" abstract="false" name="NonRefundableAndNonCreditableCashPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" abstract="false" name="AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_BvfAgreementMember" abstract="true" name="BvfAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_UsGovernmentAgencyObligationMember" abstract="true" name="UsGovernmentAgencyObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_OptionPeriod" abstract="false" name="OptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rcus_GileadSciencesIncMember" abstract="true" name="GileadSciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" abstract="false" name="CollaborationTermForCurrentAndFutureClinicalPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" abstract="false" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rcus_TaihoCollaborationAccessRightsMember" abstract="true" name="TaihoCollaborationAccessRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_AllocationToPerformanceObligations" abstract="false" name="AllocationToPerformanceObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" abstract="false" name="OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_GileadCollaborationAccessRightsMember" abstract="true" name="GileadCollaborationAccessRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_LicenseAndCollaborationAgreementsTable" abstract="true" name="LicenseAndCollaborationAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="rcus_GileadCollaborationLicenseAndRDServicesMember" abstract="true" name="GileadCollaborationLicenseAndRDServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_AntiPDOneMember" abstract="true" name="AntiPDOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_LicenseAndCollaborationAgreementsAbstract" abstract="true" name="LicenseAndCollaborationAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rcus_NonRefundablePaymentsReceived" abstract="false" name="NonRefundablePaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage" abstract="false" name="RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" abstract="false" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" abstract="true" name="ResearchAndDevelopmentActivitiesForInflammationProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation" abstract="false" name="StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" abstract="false" name="OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_WuXiBiologicsLicenseAgreementMember" abstract="true" name="WuXiBiologicsLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_TaihoCollaborationAgreementMember" abstract="true" name="TaihoCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_AccessRightsAndOptionContinuationPeriodsMember" abstract="true" name="AccessRightsAndOptionContinuationPeriodsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" abstract="false" name="OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_CashReceivedFromTenantImprovementAllowances" abstract="false" name="CashReceivedFromTenantImprovementAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_AtTheMarketFacilityMember" abstract="true" name="AtTheMarketFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember" abstract="true" name="EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_ProceedsFromSaleOfFutureRoyalties" abstract="false" name="ProceedsFromSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ProceedsFromMaturityOfMarketableSecurities" abstract="false" name="ProceedsFromMaturityOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_EquityAwardProgramsMember" abstract="true" name="EquityAwardProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_OptionLicenseAndCollaborationAgreementMember" abstract="true" name="OptionLicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember" abstract="true" name="ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_UpfrontCashPayment" abstract="false" name="UpfrontCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_OptionAndLicenseAgreementMember" abstract="true" name="OptionAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_InflammationTarget1Member" abstract="true" name="InflammationTarget1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_RemoveOptionContinuationPaymentUnderAgreement" abstract="false" name="RemoveOptionContinuationPaymentUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_CommonStockPurchaseAgreementMember" abstract="true" name="CommonStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" abstract="false" name="PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_LiabilityForSaleOfFutureRoyalties" abstract="false" name="LiabilityForSaleOfFutureRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_LicenseAndDevelopmentServicesRevenueMember" abstract="true" name="LicenseAndDevelopmentServicesRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_RoyaltiesPayableTerm" abstract="false" name="RoyaltiesPayableTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" abstract="false" name="CurrentAndFutureProgramsExclusiveAccessPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty" abstract="false" name="CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ContingentMilestonePaymentsReceivable" abstract="false" name="ContingentMilestonePaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" abstract="false" name="RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones" abstract="false" name="ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_MilestoneExpense" abstract="false" name="MilestoneExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock" abstract="false" name="SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rcus_PaymentForOptionExercise" abstract="false" name="PaymentForOptionExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_OtherCollaborationRevenueMember" abstract="true" name="OtherCollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_OrganizationTable" abstract="true" name="OrganizationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="rcus_ReimbursementOfResearchAndDevelopmentExpense" abstract="false" name="ReimbursementOfResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_OrganizationLineItems" abstract="true" name="OrganizationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion" abstract="false" name="IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_AbmunoLicenseAgreementMember" abstract="true" name="AbmunoLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_RegulatoryAndCommercialMilestonePaymentsReceived" abstract="false" name="RegulatoryAndCommercialMilestonePaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_InterestAndOtherIncomeExpenseNonoperatingNet" abstract="false" name="InterestAndOtherIncomeExpenseNonoperatingNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability" abstract="false" name="ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="rcus_AstraZenecaAgreementMember" abstract="true" name="AstraZenecaAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_NumberOfResearchPrograms" abstract="false" name="NumberOfResearchPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rcus_AmendedGileadCollaborationAgreementMember" abstract="true" name="AmendedGileadCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_PercentageOfPremiumPurchasePriceOfCommonStock" abstract="false" name="PercentageOfPremiumPurchasePriceOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="rcus_LicenseAndCollaborationAgreementsLineItems" abstract="true" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rcus_STAR221DevelopmentActivitiesMember" abstract="true" name="STAR221DevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember" abstract="true" name="ResearchAndDevelopmentActivitiesForDomvanalimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rcus_JuanCJaenMember" abstract="true" name="JuanCJaenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived" abstract="false" name="IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_FundsReceivedForStockPurchaseAgreement" abstract="false" name="FundsReceivedForStockPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" abstract="false" name="ClinicalRegulatoryAndCommercializationMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_TaihoCollaborationRDServicesMember" abstract="true" name="TaihoCollaborationRDServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" abstract="false" name="OptionPaymentUponAchievementOfCertainDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_InflammationTarget2Member" abstract="true" name="InflammationTarget2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>rcus-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:805eb66e-844e-45f5-86a8-527ac86fecd7,g:7538c7a3-a72e-4e53-a8d0-2829fb9c9dc2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_de0cf829-1b12-43d4-b5fa-6c90a4bc2c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_09b57183-7752-4a0c-9ab9-fb54d5427666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_de0cf829-1b12-43d4-b5fa-6c90a4bc2c3b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_09b57183-7752-4a0c-9ab9-fb54d5427666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ebcc756c-6d9c-4912-be30-db4aee19ddca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_de0cf829-1b12-43d4-b5fa-6c90a4bc2c3b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ebcc756c-6d9c-4912-be30-db4aee19ddca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_db24b661-7f63-42d7-bb71-978d3d39a722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_48a07df0-7ee6-4f35-8613-d771a90b09db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_db24b661-7f63-42d7-bb71-978d3d39a722" xlink:to="loc_us-gaap_OperatingIncomeLoss_48a07df0-7ee6-4f35-8613-d771a90b09db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6af0824e-1b28-428a-bcac-d8a841c8a750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_db24b661-7f63-42d7-bb71-978d3d39a722" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6af0824e-1b28-428a-bcac-d8a841c8a750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_32755465-d681-409e-bf7d-5be32d88ccb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties_fbba688d-6143-4cff-a1c3-c562c8b85052" xlink:href="rcus-20230930.xsd#rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_32755465-d681-409e-bf7d-5be32d88ccb5" xlink:to="loc_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties_fbba688d-6143-4cff-a1c3-c562c8b85052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_429ecd3e-e99e-4bcf-8ae4-c36434063102" xlink:href="rcus-20230930.xsd#rcus_InterestAndOtherIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_32755465-d681-409e-bf7d-5be32d88ccb5" xlink:to="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_429ecd3e-e99e-4bcf-8ae4-c36434063102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c9b7a72-ac97-484d-abdf-2f4712a1c218" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_23f2e5ce-3433-461b-a11a-3cc753947187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5c9b7a72-ac97-484d-abdf-2f4712a1c218" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_23f2e5ce-3433-461b-a11a-3cc753947187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ae1cfa9b-8aec-4bd2-b771-41330fc09c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5c9b7a72-ac97-484d-abdf-2f4712a1c218" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ae1cfa9b-8aec-4bd2-b771-41330fc09c17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0aee2b58-25fb-4d05-b81e-da532ecac079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_082b9329-893d-491d-9ccc-28ef9c12be56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0aee2b58-25fb-4d05-b81e-da532ecac079" xlink:to="loc_us-gaap_OperatingExpenses_082b9329-893d-491d-9ccc-28ef9c12be56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93f865dd-612a-47bb-9d70-acf6deba6ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0aee2b58-25fb-4d05-b81e-da532ecac079" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93f865dd-612a-47bb-9d70-acf6deba6ca1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ec5d73cb-0ac5-48af-b194-1c666c96b4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_28694d78-b08d-45b5-b591-12757aa002fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ec5d73cb-0ac5-48af-b194-1c666c96b4e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_28694d78-b08d-45b5-b591-12757aa002fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_888c4c88-ec9a-4635-8370-98f255e3f16f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ec5d73cb-0ac5-48af-b194-1c666c96b4e5" xlink:to="loc_us-gaap_NetIncomeLoss_888c4c88-ec9a-4635-8370-98f255e3f16f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_49343a1f-b6b7-46f4-ad9d-8f66e86a2e82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e848760f-2425-4135-984a-2d4ad4fec0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_49343a1f-b6b7-46f4-ad9d-8f66e86a2e82" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e848760f-2425-4135-984a-2d4ad4fec0bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8751cbf3-c829-4a43-9e90-19317522f41d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_49343a1f-b6b7-46f4-ad9d-8f66e86a2e82" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8751cbf3-c829-4a43-9e90-19317522f41d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b738b631-5bdd-4043-a696-b4498c300c32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_49343a1f-b6b7-46f4-ad9d-8f66e86a2e82" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b738b631-5bdd-4043-a696-b4498c300c32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a4587b0d-b5c4-4186-82bb-75aefd5d5fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_49343a1f-b6b7-46f4-ad9d-8f66e86a2e82" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a4587b0d-b5c4-4186-82bb-75aefd5d5fbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d81c9999-d328-4f07-a81e-5a9aba9f6cee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_20755fa4-837f-43a5-8477-0b0df8f5f053" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d81c9999-d328-4f07-a81e-5a9aba9f6cee" xlink:to="loc_us-gaap_LiabilitiesCurrent_20755fa4-837f-43a5-8477-0b0df8f5f053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9c0d4638-d335-46a2-a117-fe4a9112dddb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d81c9999-d328-4f07-a81e-5a9aba9f6cee" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9c0d4638-d335-46a2-a117-fe4a9112dddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6bf7e439-03db-40de-8f99-92443a4311d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d81c9999-d328-4f07-a81e-5a9aba9f6cee" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6bf7e439-03db-40de-8f99-92443a4311d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_725f7091-9ef5-43e7-a565-c8b9d4aa80ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d81c9999-d328-4f07-a81e-5a9aba9f6cee" xlink:to="loc_us-gaap_StockholdersEquity_725f7091-9ef5-43e7-a565-c8b9d4aa80ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1121b93a-e5ad-424e-a1f3-54835ec364ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d81c9999-d328-4f07-a81e-5a9aba9f6cee" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1121b93a-e5ad-424e-a1f3-54835ec364ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_be5c1a28-93f6-4811-8e53-4f0e492eddee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9f8300a9-326b-4816-9f4f-f17252a6919f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_be5c1a28-93f6-4811-8e53-4f0e492eddee" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9f8300a9-326b-4816-9f4f-f17252a6919f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d90db53b-2430-4950-b4f3-23af2245b403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_be5c1a28-93f6-4811-8e53-4f0e492eddee" xlink:to="loc_us-gaap_PreferredStockValue_d90db53b-2430-4950-b4f3-23af2245b403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_174d6c03-2f04-4dc5-9a27-b8e953a480d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_be5c1a28-93f6-4811-8e53-4f0e492eddee" xlink:to="loc_us-gaap_CommonStockValue_174d6c03-2f04-4dc5-9a27-b8e953a480d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1e7ce305-4647-4cf5-9504-bffc8710fa7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_be5c1a28-93f6-4811-8e53-4f0e492eddee" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1e7ce305-4647-4cf5-9504-bffc8710fa7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3c7610b1-37ad-46e1-9104-d2318c3550ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b96d514c-5586-4a6f-b755-efc86d7233d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c7610b1-37ad-46e1-9104-d2318c3550ee" xlink:to="loc_us-gaap_AssetsCurrent_b96d514c-5586-4a6f-b755-efc86d7233d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_06e9d32b-80d5-48bb-95b3-01d1cf0a5c83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c7610b1-37ad-46e1-9104-d2318c3550ee" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_06e9d32b-80d5-48bb-95b3-01d1cf0a5c83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d2222c7b-942b-4516-838c-d28e0a4d5584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c7610b1-37ad-46e1-9104-d2318c3550ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d2222c7b-942b-4516-838c-d28e0a4d5584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dec36c6b-4a79-49c8-855f-94f0959866d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c7610b1-37ad-46e1-9104-d2318c3550ee" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dec36c6b-4a79-49c8-855f-94f0959866d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5bb7d777-c929-4d63-a975-f909f47673a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_202d799e-8999-4aae-b45c-de9e9d46435c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5bb7d777-c929-4d63-a975-f909f47673a4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_202d799e-8999-4aae-b45c-de9e9d46435c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7bc40856-7a9d-440b-baee-0535afb4d9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5bb7d777-c929-4d63-a975-f909f47673a4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7bc40856-7a9d-440b-baee-0535afb4d9b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6a27f24b-39bf-4c25-bca5-f97862734ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5bb7d777-c929-4d63-a975-f909f47673a4" xlink:to="loc_us-gaap_AccountsPayableCurrent_6a27f24b-39bf-4c25-bca5-f97862734ea0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b30fce99-04eb-4721-b421-09a278496692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c1c024b5-8dc3-46db-a06e-b77b2e3a66ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b30fce99-04eb-4721-b421-09a278496692" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c1c024b5-8dc3-46db-a06e-b77b2e3a66ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1b6438ae-3dfa-42ef-a7c0-b76d5acb9b10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b30fce99-04eb-4721-b421-09a278496692" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1b6438ae-3dfa-42ef-a7c0-b76d5acb9b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromSaleOfFutureRoyalties_13a6b506-bcdc-4dec-98c8-58dd3587c71a" xlink:href="rcus-20230930.xsd#rcus_ProceedsFromSaleOfFutureRoyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b30fce99-04eb-4721-b421-09a278496692" xlink:to="loc_rcus_ProceedsFromSaleOfFutureRoyalties_13a6b506-bcdc-4dec-98c8-58dd3587c71a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7eb9aa8-86e2-4b2f-bd09-4911a55073e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_71ed0010-05d0-47c1-b98e-036758d3cc91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7eb9aa8-86e2-4b2f-bd09-4911a55073e5" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_71ed0010-05d0-47c1-b98e-036758d3cc91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_2523f89e-3c39-481b-b73e-1dcb5590df65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7eb9aa8-86e2-4b2f-bd09-4911a55073e5" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_2523f89e-3c39-481b-b73e-1dcb5590df65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_98d46f96-97bc-406a-8b83-5446b253d9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7eb9aa8-86e2-4b2f-bd09-4911a55073e5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_98d46f96-97bc-406a-8b83-5446b253d9ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2d54a7bb-5419-4ac6-a548-2ce3988ebdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7eb9aa8-86e2-4b2f-bd09-4911a55073e5" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2d54a7bb-5419-4ac6-a548-2ce3988ebdd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_23f68491-10ae-4aa7-9050-bcb803890cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7eb9aa8-86e2-4b2f-bd09-4911a55073e5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_23f68491-10ae-4aa7-9050-bcb803890cd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7300ab5d-7c14-4f4a-82cf-70ce54a61703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7eb9aa8-86e2-4b2f-bd09-4911a55073e5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7300ab5d-7c14-4f4a-82cf-70ce54a61703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6f4745a5-ef1f-4942-bdf3-37fce6c4e388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7eb9aa8-86e2-4b2f-bd09-4911a55073e5" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6f4745a5-ef1f-4942-bdf3-37fce6c4e388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7c7e7119-74c6-4fa2-bb3f-1fbc6db09f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7eb9aa8-86e2-4b2f-bd09-4911a55073e5" xlink:to="loc_us-gaap_ProfitLoss_7c7e7119-74c6-4fa2-bb3f-1fbc6db09f9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_e14abbbd-2725-4eea-8577-56194af0a8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7eb9aa8-86e2-4b2f-bd09-4911a55073e5" xlink:to="loc_us-gaap_DepreciationAndAmortization_e14abbbd-2725-4eea-8577-56194af0a8b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cdc3a5e5-f20c-4a9c-a225-6bd45285c863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7eb9aa8-86e2-4b2f-bd09-4911a55073e5" xlink:to="loc_us-gaap_ShareBasedCompensation_cdc3a5e5-f20c-4a9c-a225-6bd45285c863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_97b0b083-5baf-45f5-b18a-6a7d13319208" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7eb9aa8-86e2-4b2f-bd09-4911a55073e5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_97b0b083-5baf-45f5-b18a-6a7d13319208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dcea2796-9667-4c30-803f-e4f1bde5ea6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc82fa9c-25be-4528-8476-8050ca44e56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dcea2796-9667-4c30-803f-e4f1bde5ea6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc82fa9c-25be-4528-8476-8050ca44e56c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c6fd16b3-492f-4a5b-9f9f-944174423c23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dcea2796-9667-4c30-803f-e4f1bde5ea6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c6fd16b3-492f-4a5b-9f9f-944174423c23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_617f1cc2-df29-4deb-b86c-baba2bbc8f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dcea2796-9667-4c30-803f-e4f1bde5ea6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_617f1cc2-df29-4deb-b86c-baba2bbc8f41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a498c44-0656-4e0e-99f9-c017ec46ed55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6bf0c00c-0c60-4154-b5d0-25b6a5e4db5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a498c44-0656-4e0e-99f9-c017ec46ed55" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6bf0c00c-0c60-4154-b5d0-25b6a5e4db5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dd58a415-03cc-4957-8815-364ac27cd66f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a498c44-0656-4e0e-99f9-c017ec46ed55" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dd58a415-03cc-4957-8815-364ac27cd66f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_f42d6a85-8602-431b-8ed4-8bdd5a2fb9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a498c44-0656-4e0e-99f9-c017ec46ed55" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_f42d6a85-8602-431b-8ed4-8bdd5a2fb9ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromSaleOfMarketableSecurities_fff89f29-1d43-480b-911d-47937fdcd0d8" xlink:href="rcus-20230930.xsd#rcus_ProceedsFromSaleOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a498c44-0656-4e0e-99f9-c017ec46ed55" xlink:to="loc_rcus_ProceedsFromSaleOfMarketableSecurities_fff89f29-1d43-480b-911d-47937fdcd0d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromMaturityOfMarketableSecurities_172193ed-b11b-4d54-a531-4903b4848807" xlink:href="rcus-20230930.xsd#rcus_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a498c44-0656-4e0e-99f9-c017ec46ed55" xlink:to="loc_rcus_ProceedsFromMaturityOfMarketableSecurities_172193ed-b11b-4d54-a531-4903b4848807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty_8267c329-df3f-4c83-93a9-f8c7446dbf99" xlink:href="rcus-20230930.xsd#rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a498c44-0656-4e0e-99f9-c017ec46ed55" xlink:to="loc_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty_8267c329-df3f-4c83-93a9-f8c7446dbf99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ff238e78-2003-4a4a-a92b-ab9417d5c4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7ec93a3f-bb8e-499a-9535-1191e8a896ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ff238e78-2003-4a4a-a92b-ab9417d5c4e1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7ec93a3f-bb8e-499a-9535-1191e8a896ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_91b1b189-67af-441c-b4ef-308fd556542c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ff238e78-2003-4a4a-a92b-ab9417d5c4e1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_91b1b189-67af-441c-b4ef-308fd556542c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f2b179b5-5ffe-4589-b639-6ed0024fc002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ff238e78-2003-4a4a-a92b-ab9417d5c4e1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f2b179b5-5ffe-4589-b639-6ed0024fc002" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_036b8f02-3d5b-47d3-9b88-5b3fb30cf4c6" xlink:href="rcus-20230930.xsd#rcus_CashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e929f86c-5880-4062-8f4b-014fdf1f7db2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_036b8f02-3d5b-47d3-9b88-5b3fb30cf4c6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e929f86c-5880-4062-8f4b-014fdf1f7db2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2125fb38-463b-496e-9ee4-a38972e3e3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_036b8f02-3d5b-47d3-9b88-5b3fb30cf4c6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2125fb38-463b-496e-9ee4-a38972e3e3a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3f1862fe-dcb9-4b26-a8e0-5e0aa0e5b5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_036b8f02-3d5b-47d3-9b88-5b3fb30cf4c6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3f1862fe-dcb9-4b26-a8e0-5e0aa0e5b5ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_971be69e-bb76-4b1c-a4e7-2c66fdc00cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_55ff7840-93ea-4cd2-9509-88c1ba568179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_971be69e-bb76-4b1c-a4e7-2c66fdc00cdf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_55ff7840-93ea-4cd2-9509-88c1ba568179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_7e6e0a7f-54dc-41fc-b5c2-1c74ccf77e82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_971be69e-bb76-4b1c-a4e7-2c66fdc00cdf" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_7e6e0a7f-54dc-41fc-b5c2-1c74ccf77e82" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_246d8de1-2166-4e14-b120-263d153fe2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_d8b7679f-89b1-4062-8654-0d174ed81418" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_246d8de1-2166-4e14-b120-263d153fe2bd" xlink:to="loc_us-gaap_InterestReceivableCurrent_d8b7679f-89b1-4062-8654-0d174ed81418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PrepaidExpensesAndOtherCurrentAssets_8d0809f3-21df-4a7f-bd58-6f9c3552f99b" xlink:href="rcus-20230930.xsd#rcus_PrepaidExpensesAndOtherCurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_246d8de1-2166-4e14-b120-263d153fe2bd" xlink:to="loc_rcus_PrepaidExpensesAndOtherCurrentAssets_8d0809f3-21df-4a7f-bd58-6f9c3552f99b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4a67a9f0-49ac-4932-8d3a-95045d08acbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_7c9ff3b1-0c00-4633-8c92-a05592513858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4a67a9f0-49ac-4932-8d3a-95045d08acbf" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_7c9ff3b1-0c00-4633-8c92-a05592513858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3310ba70-7f02-44b2-8b20-bfd8c5ba386d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4a67a9f0-49ac-4932-8d3a-95045d08acbf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3310ba70-7f02-44b2-8b20-bfd8c5ba386d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccruedResearchAndDevelopmentExpensesCurrent_386bfe20-d449-471b-91ed-d08474c0e2f7" xlink:href="rcus-20230930.xsd#rcus_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4a67a9f0-49ac-4932-8d3a-95045d08acbf" xlink:to="loc_rcus_AccruedResearchAndDevelopmentExpensesCurrent_386bfe20-d449-471b-91ed-d08474c0e2f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_1a0ee8bf-8f4f-4bec-aa9d-bedcf674abde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4a67a9f0-49ac-4932-8d3a-95045d08acbf" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_1a0ee8bf-8f4f-4bec-aa9d-bedcf674abde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6dc0986e-0408-4658-8a3a-43fb04542301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4a67a9f0-49ac-4932-8d3a-95045d08acbf" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6dc0986e-0408-4658-8a3a-43fb04542301" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>rcus-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:805eb66e-844e-45f5-86a8-527ac86fecd7,g:7538c7a3-a72e-4e53-a8d0-2829fb9c9dc2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_22d63d1e-8a7e-47ea-b689-504d6772e920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_RevenuesAbstract_22d63d1e-8a7e-47ea-b689-504d6772e920" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f367fd8-aa03-4b45-bc37-2225af1790bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_22d63d1e-8a7e-47ea-b689-504d6772e920" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f367fd8-aa03-4b45-bc37-2225af1790bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_fa8518ef-a9cc-41b2-94e3-da8c721d4ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_OperatingExpensesAbstract_fa8518ef-a9cc-41b2-94e3-da8c721d4ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e30a2c35-ea0d-48bb-9b5a-2fad8c8c3854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fa8518ef-a9cc-41b2-94e3-da8c721d4ca9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e30a2c35-ea0d-48bb-9b5a-2fad8c8c3854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3ec07ccb-a1e1-4cc0-b782-690c1967efb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fa8518ef-a9cc-41b2-94e3-da8c721d4ca9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3ec07ccb-a1e1-4cc0-b782-690c1967efb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ec9c2de9-3d13-4f79-9147-b6971d944512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fa8518ef-a9cc-41b2-94e3-da8c721d4ca9" xlink:to="loc_us-gaap_OperatingExpenses_ec9c2de9-3d13-4f79-9147-b6971d944512" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9282cabd-41c3-42c5-8498-b512f951f44f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_OperatingIncomeLoss_9282cabd-41c3-42c5-8498-b512f951f44f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_7e36f0b7-8653-4906-8603-3b378985ac6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_7e36f0b7-8653-4906-8603-3b378985ac6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_d5785810-71b4-4089-a18f-49fe0a0f0ced" xlink:href="rcus-20230930.xsd#rcus_InterestAndOtherIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_7e36f0b7-8653-4906-8603-3b378985ac6c" xlink:to="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_d5785810-71b4-4089-a18f-49fe0a0f0ced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties_ff43e319-0bc9-4477-ab7f-de23363f6352" xlink:href="rcus-20230930.xsd#rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_7e36f0b7-8653-4906-8603-3b378985ac6c" xlink:to="loc_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties_ff43e319-0bc9-4477-ab7f-de23363f6352" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e22e54a8-715b-441e-a97a-60b5924c03f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_7e36f0b7-8653-4906-8603-3b378985ac6c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e22e54a8-715b-441e-a97a-60b5924c03f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d86fa16-a7c9-40ad-8dc4-698973cca72c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d86fa16-a7c9-40ad-8dc4-698973cca72c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e3949b5e-b722-4ea9-a46f-ab58f0abf0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e3949b5e-b722-4ea9-a46f-ab58f0abf0f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_da1e20b7-c552-4a7b-94fc-a80ef69ba08a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_NetIncomeLoss_da1e20b7-c552-4a7b-94fc-a80ef69ba08a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_07c27aca-0917-4f44-99fc-f9a4d4e62597" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_07c27aca-0917-4f44-99fc-f9a4d4e62597" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_c4810057-e205-43b7-8a99-f52c848a38e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_c4810057-e205-43b7-8a99-f52c848a38e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_64a3989b-014a-49ee-aeb3-b7dbc829eca8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_64a3989b-014a-49ee-aeb3-b7dbc829eca8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b330cf5e-bbae-4243-9899-2ecc088e02e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b330cf5e-bbae-4243-9899-2ecc088e02e3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_193c7699-ce4a-447a-88c1-f5ead741f06c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_StatementTable_193c7699-ce4a-447a-88c1-f5ead741f06c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f062fa20-a279-4966-9aa8-d1de083dcdd0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_193c7699-ce4a-447a-88c1-f5ead741f06c" xlink:to="loc_srt_ProductOrServiceAxis_f062fa20-a279-4966-9aa8-d1de083dcdd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f062fa20-a279-4966-9aa8-d1de083dcdd0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f062fa20-a279-4966-9aa8-d1de083dcdd0" xlink:to="loc_srt_ProductsAndServicesDomain_f062fa20-a279-4966-9aa8-d1de083dcdd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f01f9433-3795-4ad7-aa10-bb02181af8d5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f062fa20-a279-4966-9aa8-d1de083dcdd0" xlink:to="loc_srt_ProductsAndServicesDomain_f01f9433-3795-4ad7-aa10-bb02181af8d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesRevenueMember_0b1bd505-1c4a-46ff-b90c-7c4efb941c54" xlink:href="rcus-20230930.xsd#rcus_LicenseAndDevelopmentServicesRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f01f9433-3795-4ad7-aa10-bb02181af8d5" xlink:to="loc_rcus_LicenseAndDevelopmentServicesRevenueMember_0b1bd505-1c4a-46ff-b90c-7c4efb941c54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherCollaborationRevenueMember_0d731bb5-a469-4f42-af30-06e85e5409a1" xlink:href="rcus-20230930.xsd#rcus_OtherCollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f01f9433-3795-4ad7-aa10-bb02181af8d5" xlink:to="loc_rcus_OtherCollaborationRevenueMember_0d731bb5-a469-4f42-af30-06e85e5409a1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedStatementsofOperationsParenthetical"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7c2a361f-2a25-47f5-9cd4-24c94bbd69fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee4347a2-9f61-4307-9e35-65aa86f2e499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c2a361f-2a25-47f5-9cd4-24c94bbd69fd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee4347a2-9f61-4307-9e35-65aa86f2e499" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentExpenseRecoveries_01492c6c-da3b-4cee-9a87-679a6fd6ac86" xlink:href="rcus-20230930.xsd#rcus_ResearchAndDevelopmentExpenseRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c2a361f-2a25-47f5-9cd4-24c94bbd69fd" xlink:to="loc_rcus_ResearchAndDevelopmentExpenseRecoveries_01492c6c-da3b-4cee-9a87-679a6fd6ac86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_54ecc98f-5c7f-44c1-8161-f2894f4bbd16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7c2a361f-2a25-47f5-9cd4-24c94bbd69fd" xlink:to="loc_us-gaap_StatementTable_54ecc98f-5c7f-44c1-8161-f2894f4bbd16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1a5fb827-6935-4fc4-a4c3-5203c3510a1a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_54ecc98f-5c7f-44c1-8161-f2894f4bbd16" xlink:to="loc_srt_ProductOrServiceAxis_1a5fb827-6935-4fc4-a4c3-5203c3510a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a5fb827-6935-4fc4-a4c3-5203c3510a1a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1a5fb827-6935-4fc4-a4c3-5203c3510a1a" xlink:to="loc_srt_ProductsAndServicesDomain_1a5fb827-6935-4fc4-a4c3-5203c3510a1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e7860977-649e-4ff6-8e34-cf8d3b34367a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1a5fb827-6935-4fc4-a4c3-5203c3510a1a" xlink:to="loc_srt_ProductsAndServicesDomain_e7860977-649e-4ff6-8e34-cf8d3b34367a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesRevenueMember_b514578f-77a8-44a9-ac78-0b7c36f53909" xlink:href="rcus-20230930.xsd#rcus_LicenseAndDevelopmentServicesRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e7860977-649e-4ff6-8e34-cf8d3b34367a" xlink:to="loc_rcus_LicenseAndDevelopmentServicesRevenueMember_b514578f-77a8-44a9-ac78-0b7c36f53909" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherCollaborationRevenueMember_2ba9a33c-89e1-4a42-92b1-46fd61730330" xlink:href="rcus-20230930.xsd#rcus_OtherCollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e7860977-649e-4ff6-8e34-cf8d3b34367a" xlink:to="loc_rcus_OtherCollaborationRevenueMember_2ba9a33c-89e1-4a42-92b1-46fd61730330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ce5fbe12-f2da-4342-bf2d-2054a73793e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_54ecc98f-5c7f-44c1-8161-f2894f4bbd16" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ce5fbe12-f2da-4342-bf2d-2054a73793e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ce5fbe12-f2da-4342-bf2d-2054a73793e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ce5fbe12-f2da-4342-bf2d-2054a73793e0" xlink:to="loc_us-gaap_RelatedPartyDomain_ce5fbe12-f2da-4342-bf2d-2054a73793e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_01618040-310b-41bf-ad4a-97056a03884f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ce5fbe12-f2da-4342-bf2d-2054a73793e0" xlink:to="loc_us-gaap_RelatedPartyDomain_01618040-310b-41bf-ad4a-97056a03884f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_0bfff693-6456-4986-acb2-dfcbe4d439d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_01618040-310b-41bf-ad4a-97056a03884f" xlink:to="loc_us-gaap_RelatedPartyMember_0bfff693-6456-4986-acb2-dfcbe4d439d1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_6eb6bc64-7f46-45c8-a654-3e07642363e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_6eb6bc64-7f46-45c8-a654-3e07642363e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c5135878-4fc1-490a-9f7e-2e024a46f123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c5135878-4fc1-490a-9f7e-2e024a46f123" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_db6f6f44-79ee-4d34-b068-1f46989cf279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_db6f6f44-79ee-4d34-b068-1f46989cf279" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_70c82c4c-919b-4a19-94c3-581c005c0bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_70c82c4c-919b-4a19-94c3-581c005c0bc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_42004903-7c6a-4baf-9b53-8c6bb3e13947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_42004903-7c6a-4baf-9b53-8c6bb3e13947" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1a8abebc-c4cb-489f-9b8f-99b0fb888f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1a8abebc-c4cb-489f-9b8f-99b0fb888f80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f04604a8-e8cd-46df-8242-99403c81a60c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f04604a8-e8cd-46df-8242-99403c81a60c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4f4a49c9-8e78-407b-b010-738c059e52c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4f4a49c9-8e78-407b-b010-738c059e52c2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8ee1f610-ded0-4f73-bd17-ae6640f60ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8ee1f610-ded0-4f73-bd17-ae6640f60ab1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a8b23046-54d0-4523-a7dc-dc972ef41dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a8b23046-54d0-4523-a7dc-dc972ef41dec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_749f9d80-c413-41fe-93e1-f29b31cd4f48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_CommonStockSharesIssued_749f9d80-c413-41fe-93e1-f29b31cd4f48" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d14f1f3e-9c68-4c5c-9078-480ec3c61c06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d14f1f3e-9c68-4c5c-9078-480ec3c61c06" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c4fb16c6-fb61-41b1-8f63-96134686fd76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_StatementTable_c4fb16c6-fb61-41b1-8f63-96134686fd76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca8eb3a-491a-492b-8f32-f560be852a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c4fb16c6-fb61-41b1-8f63-96134686fd76" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca8eb3a-491a-492b-8f32-f560be852a87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5ca8eb3a-491a-492b-8f32-f560be852a87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca8eb3a-491a-492b-8f32-f560be852a87" xlink:to="loc_us-gaap_RelatedPartyDomain_5ca8eb3a-491a-492b-8f32-f560be852a87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ef5fd612-61cf-49b1-8584-466dcf0a6398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca8eb3a-491a-492b-8f32-f560be852a87" xlink:to="loc_us-gaap_RelatedPartyDomain_ef5fd612-61cf-49b1-8584-466dcf0a6398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_ca0a5d31-72f4-4fc9-aa4e-7a32886ede9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ef5fd612-61cf-49b1-8584-466dcf0a6398" xlink:to="loc_us-gaap_RelatedPartyMember_ca0a5d31-72f4-4fc9-aa4e-7a32886ede9b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dbbc2b52-1177-4605-ad2e-0aef25189b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dbbc2b52-1177-4605-ad2e-0aef25189b62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_df0cfc2c-667e-4b35-b239-e7b672420043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_StockholdersEquity_df0cfc2c-667e-4b35-b239-e7b672420043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c3922219-d33d-40b2-8611-60d76bc6fd67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c3922219-d33d-40b2-8611-60d76bc6fd67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27581d50-66c9-4c19-af89-0135573c8310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27581d50-66c9-4c19-af89-0135573c8310" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_020cb3c8-ea7f-43be-916b-f810e436aa5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_020cb3c8-ea7f-43be-916b-f810e436aa5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a1aa440a-e7f2-49c4-9f9e-00b9b08a891f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a1aa440a-e7f2-49c4-9f9e-00b9b08a891f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_44cf9f59-d93c-452e-b5c7-688e3d452d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_NetIncomeLoss_44cf9f59-d93c-452e-b5c7-688e3d452d9a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_81c64402-1c31-4733-ab58-d189a8292b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fb9b230a-90b5-4ce5-bd5a-affe618dcf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8025f4df-5a94-40ff-a972-3d3315d4062c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_StatementTable_8025f4df-5a94-40ff-a972-3d3315d4062c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40efc704-4d00-4424-8711-a74b64c229bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8025f4df-5a94-40ff-a972-3d3315d4062c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40efc704-4d00-4424-8711-a74b64c229bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_40efc704-4d00-4424-8711-a74b64c229bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40efc704-4d00-4424-8711-a74b64c229bd" xlink:to="loc_us-gaap_EquityComponentDomain_40efc704-4d00-4424-8711-a74b64c229bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87e5d0cc-190c-45de-ba38-2122cd67a13f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40efc704-4d00-4424-8711-a74b64c229bd" xlink:to="loc_us-gaap_EquityComponentDomain_87e5d0cc-190c-45de-ba38-2122cd67a13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_064a67ec-3149-4769-976b-047736a3635c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87e5d0cc-190c-45de-ba38-2122cd67a13f" xlink:to="loc_us-gaap_CommonStockMember_064a67ec-3149-4769-976b-047736a3635c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_a3b0c59b-d204-4e7e-bc97-d2bc74cc8cff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87e5d0cc-190c-45de-ba38-2122cd67a13f" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_a3b0c59b-d204-4e7e-bc97-d2bc74cc8cff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1803e84a-741d-431c-8e8e-eb5159ec1967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87e5d0cc-190c-45de-ba38-2122cd67a13f" xlink:to="loc_us-gaap_RetainedEarningsMember_1803e84a-741d-431c-8e8e-eb5159ec1967" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f52eb671-38b0-46bf-8e04-4cc5e862867a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87e5d0cc-190c-45de-ba38-2122cd67a13f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f52eb671-38b0-46bf-8e04-4cc5e862867a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d8fb6355-d76a-4093-91bb-9ffd00315398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8025f4df-5a94-40ff-a972-3d3315d4062c" xlink:to="loc_us-gaap_PlanNameAxis_d8fb6355-d76a-4093-91bb-9ffd00315398" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d8fb6355-d76a-4093-91bb-9ffd00315398_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d8fb6355-d76a-4093-91bb-9ffd00315398" xlink:to="loc_us-gaap_PlanNameDomain_d8fb6355-d76a-4093-91bb-9ffd00315398_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dd141c39-6371-45b3-b425-85d8a4263e09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d8fb6355-d76a-4093-91bb-9ffd00315398" xlink:to="loc_us-gaap_PlanNameDomain_dd141c39-6371-45b3-b425-85d8a4263e09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EquityAwardProgramsMember_f6d0ebbb-4eeb-4678-8e97-c028c3a49e3b" xlink:href="rcus-20230930.xsd#rcus_EquityAwardProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dd141c39-6371-45b3-b425-85d8a4263e09" xlink:to="loc_rcus_EquityAwardProgramsMember_f6d0ebbb-4eeb-4678-8e97-c028c3a49e3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_116b2611-34e8-4ec1-b688-6149151b23f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8025f4df-5a94-40ff-a972-3d3315d4062c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_116b2611-34e8-4ec1-b688-6149151b23f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_116b2611-34e8-4ec1-b688-6149151b23f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_116b2611-34e8-4ec1-b688-6149151b23f2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_116b2611-34e8-4ec1-b688-6149151b23f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3377b0de-e72a-40df-868f-046ff7c72bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_116b2611-34e8-4ec1-b688-6149151b23f2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3377b0de-e72a-40df-868f-046ff7c72bc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SecondStockPurchaseAgreementMember_018ca0c1-1197-44d6-81cd-b4fcfdd5c4d9" xlink:href="rcus-20230930.xsd#rcus_SecondStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3377b0de-e72a-40df-868f-046ff7c72bc1" xlink:to="loc_rcus_SecondStockPurchaseAgreementMember_018ca0c1-1197-44d6-81cd-b4fcfdd5c4d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1325bbfb-5e26-480a-9105-a7978af5c1d6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8025f4df-5a94-40ff-a972-3d3315d4062c" xlink:to="loc_srt_CounterpartyNameAxis_1325bbfb-5e26-480a-9105-a7978af5c1d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1325bbfb-5e26-480a-9105-a7978af5c1d6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1325bbfb-5e26-480a-9105-a7978af5c1d6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1325bbfb-5e26-480a-9105-a7978af5c1d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31b48067-66ba-456b-80c0-14bc535cfc63" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1325bbfb-5e26-480a-9105-a7978af5c1d6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31b48067-66ba-456b-80c0-14bc535cfc63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_87691920-5de5-487b-81fb-a3f44c5f457d" xlink:href="rcus-20230930.xsd#rcus_GileadSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31b48067-66ba-456b-80c0-14bc535cfc63" xlink:to="loc_rcus_GileadSciencesIncMember_87691920-5de5-487b-81fb-a3f44c5f457d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_183e6186-c6b2-4869-8850-7dcd80719602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_43b48e2e-b409-48d0-93e8-ccdaf5155ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_183e6186-c6b2-4869-8850-7dcd80719602" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_43b48e2e-b409-48d0-93e8-ccdaf5155ae8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d2ecd068-e3b7-4609-862f-93c925b9c0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_183e6186-c6b2-4869-8850-7dcd80719602" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d2ecd068-e3b7-4609-862f-93c925b9c0a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_36f2a563-31a2-4a2f-9364-d73f34b42df5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_183e6186-c6b2-4869-8850-7dcd80719602" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_36f2a563-31a2-4a2f-9364-d73f34b42df5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0c466600-9951-4ebb-bcae-f4990c0f3cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_183e6186-c6b2-4869-8850-7dcd80719602" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0c466600-9951-4ebb-bcae-f4990c0f3cab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f7bf5eca-2762-4c11-a9f1-2b76a3786b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_183e6186-c6b2-4869-8850-7dcd80719602" xlink:to="loc_us-gaap_StatementTable_f7bf5eca-2762-4c11-a9f1-2b76a3786b4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_30167fff-a1bf-4a37-8f1e-a1d739e95a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f7bf5eca-2762-4c11-a9f1-2b76a3786b4d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_30167fff-a1bf-4a37-8f1e-a1d739e95a4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_30167fff-a1bf-4a37-8f1e-a1d739e95a4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_30167fff-a1bf-4a37-8f1e-a1d739e95a4c" xlink:to="loc_us-gaap_RelatedPartyDomain_30167fff-a1bf-4a37-8f1e-a1d739e95a4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cc76c575-d8cf-4a56-a18f-092ffa0501f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_30167fff-a1bf-4a37-8f1e-a1d739e95a4c" xlink:to="loc_us-gaap_RelatedPartyDomain_cc76c575-d8cf-4a56-a18f-092ffa0501f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_8ae98add-2695-48df-bd6a-d5b2b1989811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cc76c575-d8cf-4a56-a18f-092ffa0501f1" xlink:to="loc_us-gaap_RelatedPartyMember_8ae98add-2695-48df-bd6a-d5b2b1989811" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OrganizationLineItems_1540ce45-df18-48ef-99c3-7322d57ec5b5" xlink:href="rcus-20230930.xsd#rcus_OrganizationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_be1fa21d-925e-43bf-a878-a7dcbb133af0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_OrganizationLineItems_1540ce45-df18-48ef-99c3-7322d57ec5b5" xlink:to="loc_us-gaap_NumberOfReportableSegments_be1fa21d-925e-43bf-a878-a7dcbb133af0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_51064459-0c00-41f6-80a5-2f3e012e2161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_OrganizationLineItems_1540ce45-df18-48ef-99c3-7322d57ec5b5" xlink:to="loc_us-gaap_NumberOfOperatingSegments_51064459-0c00-41f6-80a5-2f3e012e2161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_9826e14b-8b16-41f4-ab1c-bf461aa55b17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_OrganizationLineItems_1540ce45-df18-48ef-99c3-7322d57ec5b5" xlink:to="loc_us-gaap_InvestmentsAndCash_9826e14b-8b16-41f4-ab1c-bf461aa55b17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OrganizationTable_ee6fb5d8-8c19-4f03-8207-ca11861ede06" xlink:href="rcus-20230930.xsd#rcus_OrganizationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rcus_OrganizationLineItems_1540ce45-df18-48ef-99c3-7322d57ec5b5" xlink:to="loc_rcus_OrganizationTable_ee6fb5d8-8c19-4f03-8207-ca11861ede06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8a1098bf-5769-4e1d-9715-e825e1706c46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rcus_OrganizationTable_ee6fb5d8-8c19-4f03-8207-ca11861ede06" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8a1098bf-5769-4e1d-9715-e825e1706c46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8a1098bf-5769-4e1d-9715-e825e1706c46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8a1098bf-5769-4e1d-9715-e825e1706c46" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8a1098bf-5769-4e1d-9715-e825e1706c46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8445bcbb-a6b8-4f43-8e85-1dd09bdaa0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8a1098bf-5769-4e1d-9715-e825e1706c46" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8445bcbb-a6b8-4f43-8e85-1dd09bdaa0ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_6e71d93a-353c-40ba-ac08-7486c9315be7" xlink:href="rcus-20230930.xsd#rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8445bcbb-a6b8-4f43-8e85-1dd09bdaa0ae" xlink:to="loc_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_6e71d93a-353c-40ba-ac08-7486c9315be7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#RelatedPartyGileadSciencesIncAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2bc46066-1450-4dd1-8a16-00468f431435" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2bc46066-1450-4dd1-8a16-00468f431435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_FundsReceivedForStockPurchaseAgreement_098aa783-7573-4d0c-ba59-3798fa1fac84" xlink:href="rcus-20230930.xsd#rcus_FundsReceivedForStockPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_FundsReceivedForStockPurchaseAgreement_098aa783-7573-4d0c-ba59-3798fa1fac84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation_052863c2-e63c-484f-9bc5-f70d17df6fe1" xlink:href="rcus-20230930.xsd#rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation_052863c2-e63c-484f-9bc5-f70d17df6fe1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e71bc42e-865b-4dd9-85be-eb834fbd9787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e71bc42e-865b-4dd9-85be-eb834fbd9787" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage_692f01c8-a855-43c9-9b28-7b90cc8e6dcf" xlink:href="rcus-20230930.xsd#rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage_692f01c8-a855-43c9-9b28-7b90cc8e6dcf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PercentageOfPremiumPurchasePriceOfCommonStock_9702db27-d13e-4266-b60a-01b457430b8a" xlink:href="rcus-20230930.xsd#rcus_PercentageOfPremiumPurchasePriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_PercentageOfPremiumPurchasePriceOfCommonStock_9702db27-d13e-4266-b60a-01b457430b8a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_d7cbe0f8-0a34-467e-adde-df9bd2d9bc32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_us-gaap_SharePrice_d7cbe0f8-0a34-467e-adde-df9bd2d9bc32" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TrailingDaysAverageClosingPrice_71878ee4-ff4c-4548-90cd-5adaeb973f1f" xlink:href="rcus-20230930.xsd#rcus_TrailingDaysAverageClosingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_TrailingDaysAverageClosingPrice_71878ee4-ff4c-4548-90cd-5adaeb973f1f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LockupPeriod_52a331cf-439a-44da-9cb7-3ef6960fbaf3" xlink:href="rcus-20230930.xsd#rcus_LockupPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_LockupPeriod_52a331cf-439a-44da-9cb7-3ef6960fbaf3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ExtendedLockupPeriod_b92a5a5e-e80d-4997-ba57-c4c5c9cc509d" xlink:href="rcus-20230930.xsd#rcus_ExtendedLockupPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_ExtendedLockupPeriod_b92a5a5e-e80d-4997-ba57-c4c5c9cc509d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PercentageOfOutstandingCommonStockOwned_a8303d03-2306-44da-ab42-62123091b629" xlink:href="rcus-20230930.xsd#rcus_PercentageOfOutstandingCommonStockOwned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_PercentageOfOutstandingCommonStockOwned_a8303d03-2306-44da-ab42-62123091b629" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_acb652be-7104-4bdf-82de-6da37eedb3c2" xlink:href="rcus-20230930.xsd#rcus_CollaborationTermForCurrentAndFutureClinicalPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_acb652be-7104-4bdf-82de-6da37eedb3c2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_20c2ce57-45e3-4624-9921-0d8aa2fae174" xlink:href="rcus-20230930.xsd#rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_20c2ce57-45e3-4624-9921-0d8aa2fae174" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_UpfrontCashPayment_b1170fa7-ffb6-4b34-be7b-24354f8973b0" xlink:href="rcus-20230930.xsd#rcus_UpfrontCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_UpfrontCashPayment_b1170fa7-ffb6-4b34-be7b-24354f8973b0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfExerciseOptionToPrograms_0d31608d-3eca-4f36-936d-6b28c9515889" xlink:href="rcus-20230930.xsd#rcus_NumberOfExerciseOptionToPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_NumberOfExerciseOptionToPrograms_0d31608d-3eca-4f36-936d-6b28c9515889" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentReceived_075cc8ff-5f15-4259-b528-822dcb72064f" xlink:href="rcus-20230930.xsd#rcus_OptionPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_OptionPaymentReceived_075cc8ff-5f15-4259-b528-822dcb72064f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RemoveOptionContinuationPaymentUnderAgreement_6b120b77-a9fb-4cba-8e08-9b609722b490" xlink:href="rcus-20230930.xsd#rcus_RemoveOptionContinuationPaymentUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_RemoveOptionContinuationPaymentUnderAgreement_6b120b77-a9fb-4cba-8e08-9b609722b490" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_e39024de-f320-4889-9d65-ddd876f7bfe4" xlink:href="rcus-20230930.xsd#rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_e39024de-f320-4889-9d65-ddd876f7bfe4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_57af7d5e-b3b9-428d-b0a8-cb0b096a4097" xlink:href="rcus-20230930.xsd#rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_57af7d5e-b3b9-428d-b0a8-cb0b096a4097" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfResearchPrograms_fc4d5ac8-2e1f-4549-b767-036e84b19015" xlink:href="rcus-20230930.xsd#rcus_NumberOfResearchPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_NumberOfResearchPrograms_fc4d5ac8-2e1f-4549-b767-036e84b19015" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities_3233e909-69ae-4305-8a2f-63d5e2bf87a3" xlink:href="rcus-20230930.xsd#rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities_3233e909-69ae-4305-8a2f-63d5e2bf87a3" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_47a79d88-34a7-4c57-b051-bfff647b9572" xlink:href="rcus-20230930.xsd#rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_47a79d88-34a7-4c57-b051-bfff647b9572" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_70ba06c1-af0d-42eb-b3ce-f69e486df05a" xlink:href="rcus-20230930.xsd#rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_70ba06c1-af0d-42eb-b3ce-f69e486df05a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_691daf7f-06df-4cf2-8a40-bd0249ed5749" xlink:href="rcus-20230930.xsd#rcus_RegulatoryAndCommercialMilestonePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_691daf7f-06df-4cf2-8a40-bd0249ed5749" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5291f8cf-1715-4a05-a1f4-943245555b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5291f8cf-1715-4a05-a1f4-943245555b8b" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_ddd98f1c-941b-49dd-b396-9e40f28e020c" xlink:href="rcus-20230930.xsd#rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_ddd98f1c-941b-49dd-b396-9e40f28e020c" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_456de4ac-1ecb-4e60-91e1-57c6d3fa47a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_456de4ac-1ecb-4e60-91e1-57c6d3fa47a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1dde1a24-c476-4699-9fa8-932ac38b37d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_456de4ac-1ecb-4e60-91e1-57c6d3fa47a7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1dde1a24-c476-4699-9fa8-932ac38b37d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1dde1a24-c476-4699-9fa8-932ac38b37d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1dde1a24-c476-4699-9fa8-932ac38b37d7" xlink:to="loc_us-gaap_RelatedPartyDomain_1dde1a24-c476-4699-9fa8-932ac38b37d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_203eda47-0be2-4eed-8e26-b5f97b33d166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1dde1a24-c476-4699-9fa8-932ac38b37d7" xlink:to="loc_us-gaap_RelatedPartyDomain_203eda47-0be2-4eed-8e26-b5f97b33d166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_952dbcfa-22c2-4ab6-9dc0-b3782fed6ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_203eda47-0be2-4eed-8e26-b5f97b33d166" xlink:to="loc_us-gaap_RelatedPartyMember_952dbcfa-22c2-4ab6-9dc0-b3782fed6ad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_33ab0d89-d850-4882-87ed-60161e75228a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_456de4ac-1ecb-4e60-91e1-57c6d3fa47a7" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_33ab0d89-d850-4882-87ed-60161e75228a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_33ab0d89-d850-4882-87ed-60161e75228a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_33ab0d89-d850-4882-87ed-60161e75228a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_33ab0d89-d850-4882-87ed-60161e75228a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a85867f1-bebe-4b9d-8f87-60b4e9568f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_33ab0d89-d850-4882-87ed-60161e75228a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a85867f1-bebe-4b9d-8f87-60b4e9568f16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CommonStockPurchaseAgreementMember_7ed57a97-78bf-4aff-9502-365ab0bc3160" xlink:href="rcus-20230930.xsd#rcus_CommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a85867f1-bebe-4b9d-8f87-60b4e9568f16" xlink:to="loc_rcus_CommonStockPurchaseAgreementMember_7ed57a97-78bf-4aff-9502-365ab0bc3160" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AmendedInvestorRightsAgreementMember_d746b1d2-82c6-4909-a8d7-038a9c845f7c" xlink:href="rcus-20230930.xsd#rcus_AmendedInvestorRightsAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a85867f1-bebe-4b9d-8f87-60b4e9568f16" xlink:to="loc_rcus_AmendedInvestorRightsAgreementMember_d746b1d2-82c6-4909-a8d7-038a9c845f7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionLicenseAndCollaborationAgreementMember_dd83fff8-8dd7-4ad5-ac5a-ff69d0337bd9" xlink:href="rcus-20230930.xsd#rcus_OptionLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a85867f1-bebe-4b9d-8f87-60b4e9568f16" xlink:to="loc_rcus_OptionLicenseAndCollaborationAgreementMember_dd83fff8-8dd7-4ad5-ac5a-ff69d0337bd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AmendedGileadCollaborationAgreementMember_fd86273e-edc0-4613-b010-38c217955a55" xlink:href="rcus-20230930.xsd#rcus_AmendedGileadCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a85867f1-bebe-4b9d-8f87-60b4e9568f16" xlink:to="loc_rcus_AmendedGileadCollaborationAgreementMember_fd86273e-edc0-4613-b010-38c217955a55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa973925-0e3c-44a9-98fb-92cd932f9e0b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_456de4ac-1ecb-4e60-91e1-57c6d3fa47a7" xlink:to="loc_srt_RangeAxis_aa973925-0e3c-44a9-98fb-92cd932f9e0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aa973925-0e3c-44a9-98fb-92cd932f9e0b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aa973925-0e3c-44a9-98fb-92cd932f9e0b" xlink:to="loc_srt_RangeMember_aa973925-0e3c-44a9-98fb-92cd932f9e0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e873d81-dbdc-4ccc-88a9-1de9cd3e3a94" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aa973925-0e3c-44a9-98fb-92cd932f9e0b" xlink:to="loc_srt_RangeMember_7e873d81-dbdc-4ccc-88a9-1de9cd3e3a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_43ccd4e5-4fc2-4cb3-ae31-0790774d7a75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7e873d81-dbdc-4ccc-88a9-1de9cd3e3a94" xlink:to="loc_srt_MaximumMember_43ccd4e5-4fc2-4cb3-ae31-0790774d7a75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cb32cc10-29f9-4902-b4d0-9dbf96681435" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_456de4ac-1ecb-4e60-91e1-57c6d3fa47a7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cb32cc10-29f9-4902-b4d0-9dbf96681435" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cb32cc10-29f9-4902-b4d0-9dbf96681435_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cb32cc10-29f9-4902-b4d0-9dbf96681435" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cb32cc10-29f9-4902-b4d0-9dbf96681435_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a26cf6e8-dd1b-46fb-a9c9-3d8a62182993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cb32cc10-29f9-4902-b4d0-9dbf96681435" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a26cf6e8-dd1b-46fb-a9c9-3d8a62182993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_26d60c8b-2955-432d-91b0-2241421d0e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a26cf6e8-dd1b-46fb-a9c9-3d8a62182993" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_26d60c8b-2955-432d-91b0-2241421d0e05" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#LicenseandCollaborationsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:href="rcus-20230930.xsd#rcus_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPeriod_ff8b09e4-5d9a-4aea-95b2-c286114f9442" xlink:href="rcus-20230930.xsd#rcus_OptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_OptionPeriod_ff8b09e4-5d9a-4aea-95b2-c286114f9442" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NonRefundableAndNonCreditableCashPayments_88865cc3-ba18-48ab-ae39-3ad5eb2e6586" xlink:href="rcus-20230930.xsd#rcus_NonRefundableAndNonCreditableCashPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_NonRefundableAndNonCreditableCashPayments_88865cc3-ba18-48ab-ae39-3ad5eb2e6586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PaymentForOptionExercise_7efe035a-890c-4088-9ae9-bf107565196d" xlink:href="rcus-20230930.xsd#rcus_PaymentForOptionExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_PaymentForOptionExercise_7efe035a-890c-4088-9ae9-bf107565196d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_01ec51e3-4ec3-46ca-80ec-6b78ce7aff1a" xlink:href="rcus-20230930.xsd#rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_01ec51e3-4ec3-46ca-80ec-6b78ce7aff1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContingentMilestonePaymentsReceivable_0daf72ec-0ced-4142-ad2e-d903cf255183" xlink:href="rcus-20230930.xsd#rcus_ContingentMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_ContingentMilestonePaymentsReceivable_0daf72ec-0ced-4142-ad2e-d903cf255183" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RoyaltiesPayableTerm_1dd2d123-23a2-4ca0-8fab-b2d592ad468a" xlink:href="rcus-20230930.xsd#rcus_RoyaltiesPayableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_RoyaltiesPayableTerm_1dd2d123-23a2-4ca0-8fab-b2d592ad468a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_faa780c7-d7af-4647-b12f-ad1933335119" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_faa780c7-d7af-4647-b12f-ad1933335119" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ReimbursementOfResearchAndDevelopmentExpense_6902b8d2-36f0-4888-8ebb-37b79f95e37f" xlink:href="rcus-20230930.xsd#rcus_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_ReimbursementOfResearchAndDevelopmentExpense_6902b8d2-36f0-4888-8ebb-37b79f95e37f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_969ee8ba-c5e0-4bc2-9edd-d39660f6cca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_969ee8ba-c5e0-4bc2-9edd-d39660f6cca4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b65eb925-2c90-4286-b2d8-f2b8959bca87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b65eb925-2c90-4286-b2d8-f2b8959bca87" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b849fbe7-f5c3-4c5c-a611-bd0d425bd845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b849fbe7-f5c3-4c5c-a611-bd0d425bd845" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_a9b04298-f3c5-4f6b-b02f-e1b3171e8039" xlink:href="rcus-20230930.xsd#rcus_ClinicalRegulatoryAndCommercializationMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_a9b04298-f3c5-4f6b-b02f-e1b3171e8039" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_499e113f-f656-479e-bde3-d2608884e677" xlink:href="rcus-20230930.xsd#rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_499e113f-f656-479e-bde3-d2608884e677" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_MilestoneExpense_aeaff702-2c84-44f0-9f70-88944e145268" xlink:href="rcus-20230930.xsd#rcus_MilestoneExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_MilestoneExpense_aeaff702-2c84-44f0-9f70-88944e145268" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:href="rcus-20230930.xsd#rcus_LicenseAndCollaborationAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0d9454ee-570f-4f82-a4b3-741272317726" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:to="loc_srt_CounterpartyNameAxis_0d9454ee-570f-4f82-a4b3-741272317726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0d9454ee-570f-4f82-a4b3-741272317726_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0d9454ee-570f-4f82-a4b3-741272317726" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0d9454ee-570f-4f82-a4b3-741272317726_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_481eee06-b5a6-432e-86d3-c9cee1ba2ff8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0d9454ee-570f-4f82-a4b3-741272317726" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_481eee06-b5a6-432e-86d3-c9cee1ba2ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoPharmaceuticalCoLtdMember_a967eac1-af61-4903-9cc5-0b4fbdac48fb" xlink:href="rcus-20230930.xsd#rcus_TaihoPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_481eee06-b5a6-432e-86d3-c9cee1ba2ff8" xlink:to="loc_rcus_TaihoPharmaceuticalCoLtdMember_a967eac1-af61-4903-9cc5-0b4fbdac48fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_WuXiBiologicsLicenseAgreementMember_9d0806a2-f248-4286-87c4-31a266372ca9" xlink:href="rcus-20230930.xsd#rcus_WuXiBiologicsLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_481eee06-b5a6-432e-86d3-c9cee1ba2ff8" xlink:to="loc_rcus_WuXiBiologicsLicenseAgreementMember_9d0806a2-f248-4286-87c4-31a266372ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AbmunoLicenseAgreementMember_19bf1559-d996-4cce-95eb-d3aee84e75ad" xlink:href="rcus-20230930.xsd#rcus_AbmunoLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_481eee06-b5a6-432e-86d3-c9cee1ba2ff8" xlink:to="loc_rcus_AbmunoLicenseAgreementMember_19bf1559-d996-4cce-95eb-d3aee84e75ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0c6975fa-4c9b-4b9d-b32c-3c1449641412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0c6975fa-4c9b-4b9d-b32c-3c1449641412" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c6975fa-4c9b-4b9d-b32c-3c1449641412_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0c6975fa-4c9b-4b9d-b32c-3c1449641412" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c6975fa-4c9b-4b9d-b32c-3c1449641412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bc6e364-d944-4217-8847-12007b361743" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0c6975fa-4c9b-4b9d-b32c-3c1449641412" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bc6e364-d944-4217-8847-12007b361743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionAndLicenseAgreementMember_20e921a1-2ba0-467b-8c2b-812eaf6e42d1" xlink:href="rcus-20230930.xsd#rcus_OptionAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bc6e364-d944-4217-8847-12007b361743" xlink:to="loc_rcus_OptionAndLicenseAgreementMember_20e921a1-2ba0-467b-8c2b-812eaf6e42d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AstraZenecaAgreementMember_ffdc022a-ae8a-42c5-a757-f8ac6942f147" xlink:href="rcus-20230930.xsd#rcus_AstraZenecaAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bc6e364-d944-4217-8847-12007b361743" xlink:to="loc_rcus_AstraZenecaAgreementMember_ffdc022a-ae8a-42c5-a757-f8ac6942f147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionLicenseAndCollaborationAgreementMember_8f49f955-c566-4dfa-a390-8f0918655d47" xlink:href="rcus-20230930.xsd#rcus_OptionLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bc6e364-d944-4217-8847-12007b361743" xlink:to="loc_rcus_OptionLicenseAndCollaborationAgreementMember_8f49f955-c566-4dfa-a390-8f0918655d47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b159544-ecb5-4f51-9eb2-f37f0519a8f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:to="loc_srt_RangeAxis_7b159544-ecb5-4f51-9eb2-f37f0519a8f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b159544-ecb5-4f51-9eb2-f37f0519a8f8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7b159544-ecb5-4f51-9eb2-f37f0519a8f8" xlink:to="loc_srt_RangeMember_7b159544-ecb5-4f51-9eb2-f37f0519a8f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7d076581-d3c8-477e-afdd-29f7da4c1de6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7b159544-ecb5-4f51-9eb2-f37f0519a8f8" xlink:to="loc_srt_RangeMember_7d076581-d3c8-477e-afdd-29f7da4c1de6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4f5d92ed-7353-4a1d-a8d5-7e66416c5368" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7d076581-d3c8-477e-afdd-29f7da4c1de6" xlink:to="loc_srt_MinimumMember_4f5d92ed-7353-4a1d-a8d5-7e66416c5368" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f5a6547c-94e1-455d-9c88-a3bc649203dd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7d076581-d3c8-477e-afdd-29f7da4c1de6" xlink:to="loc_srt_MaximumMember_f5a6547c-94e1-455d-9c88-a3bc649203dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2c5cc149-cea9-4e9e-9d2f-9cc1da4271a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:to="loc_srt_ProductOrServiceAxis_2c5cc149-cea9-4e9e-9d2f-9cc1da4271a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2c5cc149-cea9-4e9e-9d2f-9cc1da4271a8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2c5cc149-cea9-4e9e-9d2f-9cc1da4271a8" xlink:to="loc_srt_ProductsAndServicesDomain_2c5cc149-cea9-4e9e-9d2f-9cc1da4271a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1acc93e3-7e29-47bc-a768-5209959d9063" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2c5cc149-cea9-4e9e-9d2f-9cc1da4271a8" xlink:to="loc_srt_ProductsAndServicesDomain_1acc93e3-7e29-47bc-a768-5209959d9063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AntiPDOneMember_6db1d61d-24da-4b37-b76b-80ef4234138b" xlink:href="rcus-20230930.xsd#rcus_AntiPDOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1acc93e3-7e29-47bc-a768-5209959d9063" xlink:to="loc_rcus_AntiPDOneMember_6db1d61d-24da-4b37-b76b-80ef4234138b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AntiCDThirtyNineMember_bed55ac7-afec-44d4-b5b4-ac8c414a0f28" xlink:href="rcus-20230930.xsd#rcus_AntiCDThirtyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1acc93e3-7e29-47bc-a768-5209959d9063" xlink:to="loc_rcus_AntiCDThirtyNineMember_bed55ac7-afec-44d4-b5b4-ac8c414a0f28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_13cc2e8b-c7bc-4bdc-9137-9285b68dd59c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_13cc2e8b-c7bc-4bdc-9137-9285b68dd59c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_13cc2e8b-c7bc-4bdc-9137-9285b68dd59c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13cc2e8b-c7bc-4bdc-9137-9285b68dd59c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_13cc2e8b-c7bc-4bdc-9137-9285b68dd59c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fbc94661-ef06-4e19-9c4d-a1fa496b3d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13cc2e8b-c7bc-4bdc-9137-9285b68dd59c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fbc94661-ef06-4e19-9c4d-a1fa496b3d0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f562b10d-2a2a-48c0-8dff-565aa0549d80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fbc94661-ef06-4e19-9c4d-a1fa496b3d0c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f562b10d-2a2a-48c0-8dff-565aa0549d80" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsLineItems_f5caf771-2073-463f-8932-a9004af2db89" xlink:href="rcus-20230930.xsd#rcus_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63d42f86-15ba-4433-a27f-caa6f335a525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_f5caf771-2073-463f-8932-a9004af2db89" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63d42f86-15ba-4433-a27f-caa6f335a525" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_60361001-e0ac-40bc-9f0b-bd43fd09d3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_f5caf771-2073-463f-8932-a9004af2db89" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_60361001-e0ac-40bc-9f0b-bd43fd09d3ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e704328b-96a6-420f-b940-97c11a5fd1e2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_60361001-e0ac-40bc-9f0b-bd43fd09d3ba" xlink:to="loc_srt_ProductOrServiceAxis_e704328b-96a6-420f-b940-97c11a5fd1e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e704328b-96a6-420f-b940-97c11a5fd1e2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e704328b-96a6-420f-b940-97c11a5fd1e2" xlink:to="loc_srt_ProductsAndServicesDomain_e704328b-96a6-420f-b940-97c11a5fd1e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f247b0fb-0e76-4d07-93b1-0f68a5b8d6fd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e704328b-96a6-420f-b940-97c11a5fd1e2" xlink:to="loc_srt_ProductsAndServicesDomain_f247b0fb-0e76-4d07-93b1-0f68a5b8d6fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationLicenseAndRDServicesMember_5b907266-8fd2-405d-a8b6-8a96e4d33c08" xlink:href="rcus-20230930.xsd#rcus_GileadCollaborationLicenseAndRDServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f247b0fb-0e76-4d07-93b1-0f68a5b8d6fd" xlink:to="loc_rcus_GileadCollaborationLicenseAndRDServicesMember_5b907266-8fd2-405d-a8b6-8a96e4d33c08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationAccessRightsMember_3a119fd0-e60e-4982-8a72-f89e5f2843be" xlink:href="rcus-20230930.xsd#rcus_GileadCollaborationAccessRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f247b0fb-0e76-4d07-93b1-0f68a5b8d6fd" xlink:to="loc_rcus_GileadCollaborationAccessRightsMember_3a119fd0-e60e-4982-8a72-f89e5f2843be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationRDServicesMember_ee79149b-e12f-4a38-b8ab-7364a7e104d0" xlink:href="rcus-20230930.xsd#rcus_TaihoCollaborationRDServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f247b0fb-0e76-4d07-93b1-0f68a5b8d6fd" xlink:to="loc_rcus_TaihoCollaborationRDServicesMember_ee79149b-e12f-4a38-b8ab-7364a7e104d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationAccessRightsMember_dcadadf4-94d1-438c-97a8-9b7ed3bc65b4" xlink:href="rcus-20230930.xsd#rcus_TaihoCollaborationAccessRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f247b0fb-0e76-4d07-93b1-0f68a5b8d6fd" xlink:to="loc_rcus_TaihoCollaborationAccessRightsMember_dcadadf4-94d1-438c-97a8-9b7ed3bc65b4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#RevenuesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/RevenuesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8b04f663-45ea-49fa-91f0-fcb5beb7d5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8b04f663-45ea-49fa-91f0-fcb5beb7d5bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee984f1f-9ff3-4266-9fe6-84df40d9d1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee984f1f-9ff3-4266-9fe6-84df40d9d1ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_13993935-1d37-4f8d-b206-0126c8df19a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_ContractWithCustomerLiability_13993935-1d37-4f8d-b206-0126c8df19a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_UpfrontCashPayment_da6f5aa1-cec6-4839-b9a6-820b1724017a" xlink:href="rcus-20230930.xsd#rcus_UpfrontCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_rcus_UpfrontCashPayment_da6f5aa1-cec6-4839-b9a6-820b1724017a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AllocationToPerformanceObligations_18059f5c-80c7-4a7e-8e57-6ca131b312b0" xlink:href="rcus-20230930.xsd#rcus_AllocationToPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_rcus_AllocationToPerformanceObligations_18059f5c-80c7-4a7e-8e57-6ca131b312b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_04c24fb9-c97d-4362-96e0-b07c99df5693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_04c24fb9-c97d-4362-96e0-b07c99df5693" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_7245312f-d199-4114-9b66-8162a1caaeaf" xlink:href="rcus-20230930.xsd#rcus_CurrentAndFutureProgramsExclusiveAccessPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_7245312f-d199-4114-9b66-8162a1caaeaf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContingentMilestonePaymentsReceivable_515cc7fd-f964-4a94-99bb-fdcf4817b20c" xlink:href="rcus-20230930.xsd#rcus_ContingentMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_rcus_ContingentMilestonePaymentsReceivable_515cc7fd-f964-4a94-99bb-fdcf4817b20c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_58441cdd-0d46-44e6-8c6b-0003ef2645bf" xlink:href="rcus-20230930.xsd#rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_58441cdd-0d46-44e6-8c6b-0003ef2645bf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PerformanceObligationPeriod_30e311d0-e7c2-4264-a9b3-02deb2b9042c" xlink:href="rcus-20230930.xsd#rcus_PerformanceObligationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_rcus_PerformanceObligationPeriod_30e311d0-e7c2-4264-a9b3-02deb2b9042c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2410be4a-3c58-4747-b4cd-322053032e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2410be4a-3c58-4747-b4cd-322053032e3b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_19ba808d-ee48-4841-a121-d91d3309bd56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_19ba808d-ee48-4841-a121-d91d3309bd56" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_22d4cc10-67b2-4e41-a21d-a02ef4ad6833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_22d4cc10-67b2-4e41-a21d-a02ef4ad6833" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent_9435c064-eb49-4f59-97a5-8e8b6c7985b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_CapitalizedContractCostNetCurrent_9435c064-eb49-4f59-97a5-8e8b6c7985b9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_73f506cd-9b8c-42c1-a568-e0d994610e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_73f506cd-9b8c-42c1-a568-e0d994610e80" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0d25dac3-445b-4993-a033-9f90d0eae723" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:to="loc_srt_CounterpartyNameAxis_0d25dac3-445b-4993-a033-9f90d0eae723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0d25dac3-445b-4993-a033-9f90d0eae723_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0d25dac3-445b-4993-a033-9f90d0eae723" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0d25dac3-445b-4993-a033-9f90d0eae723_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b4b844f-3577-4835-bd42-dd1fe7af4a6a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0d25dac3-445b-4993-a033-9f90d0eae723" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b4b844f-3577-4835-bd42-dd1fe7af4a6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_aec233df-480f-48c9-b1ac-87d07eb29778" xlink:href="rcus-20230930.xsd#rcus_GileadSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b4b844f-3577-4835-bd42-dd1fe7af4a6a" xlink:to="loc_rcus_GileadSciencesIncMember_aec233df-480f-48c9-b1ac-87d07eb29778" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_STAR221DevelopmentActivitiesMember_01cb6781-e61a-4e46-ba62-b0163d11f71a" xlink:href="rcus-20230930.xsd#rcus_STAR221DevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b4b844f-3577-4835-bd42-dd1fe7af4a6a" xlink:to="loc_rcus_STAR221DevelopmentActivitiesMember_01cb6781-e61a-4e46-ba62-b0163d11f71a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_47baaa1a-b0c9-415d-a0ef-7274d58a189a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_47baaa1a-b0c9-415d-a0ef-7274d58a189a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_47baaa1a-b0c9-415d-a0ef-7274d58a189a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_47baaa1a-b0c9-415d-a0ef-7274d58a189a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_47baaa1a-b0c9-415d-a0ef-7274d58a189a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19266558-e675-4a30-916c-c8ce0a009180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_47baaa1a-b0c9-415d-a0ef-7274d58a189a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19266558-e675-4a30-916c-c8ce0a009180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_04e6c0e7-7003-44d4-b1d8-6a42228aece4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19266558-e675-4a30-916c-c8ce0a009180" xlink:to="loc_us-gaap_SalesRevenueNetMember_04e6c0e7-7003-44d4-b1d8-6a42228aece4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b2ef0120-a763-4507-9e3d-a57d7ddfa300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b2ef0120-a763-4507-9e3d-a57d7ddfa300" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b2ef0120-a763-4507-9e3d-a57d7ddfa300_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b2ef0120-a763-4507-9e3d-a57d7ddfa300" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b2ef0120-a763-4507-9e3d-a57d7ddfa300_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_28faad5c-1c09-48c0-8b6a-0c64419585eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b2ef0120-a763-4507-9e3d-a57d7ddfa300" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_28faad5c-1c09-48c0-8b6a-0c64419585eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_887f6502-6ad0-4370-a609-7b705a8f7bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_28faad5c-1c09-48c0-8b6a-0c64419585eb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_887f6502-6ad0-4370-a609-7b705a8f7bb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_73694dd2-04e4-4cd3-af79-96e70cf8d41a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:to="loc_us-gaap_TypeOfArrangementAxis_73694dd2-04e4-4cd3-af79-96e70cf8d41a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73694dd2-04e4-4cd3-af79-96e70cf8d41a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_73694dd2-04e4-4cd3-af79-96e70cf8d41a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73694dd2-04e4-4cd3-af79-96e70cf8d41a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_73694dd2-04e4-4cd3-af79-96e70cf8d41a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionLicenseAndCollaborationAgreementMember_62e60355-a8cf-4fa8-8871-478916883aa4" xlink:href="rcus-20230930.xsd#rcus_OptionLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_OptionLicenseAndCollaborationAgreementMember_62e60355-a8cf-4fa8-8871-478916883aa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_2e9d46be-ec42-4d05-8e20-c8eab19c59da" xlink:href="rcus-20230930.xsd#rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_2e9d46be-ec42-4d05-8e20-c8eab19c59da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember_06dd0c88-f20e-4721-af56-aa77d85f2c5e" xlink:href="rcus-20230930.xsd#rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember_06dd0c88-f20e-4721-af56-aa77d85f2c5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember_72255d19-2090-48a5-ab89-72107432d5ed" xlink:href="rcus-20230930.xsd#rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember_72255d19-2090-48a5-ab89-72107432d5ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember_d3277e75-06ee-494b-aa11-ef56f4e407ab" xlink:href="rcus-20230930.xsd#rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember_d3277e75-06ee-494b-aa11-ef56f4e407ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember_753fde11-5740-49dc-b71c-60487c4e75a6" xlink:href="rcus-20230930.xsd#rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember_753fde11-5740-49dc-b71c-60487c4e75a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember_f08c9082-2ef9-40fa-b96b-fe301d30d3bf" xlink:href="rcus-20230930.xsd#rcus_AccessRightsAndOptionContinuationPeriodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember_f08c9082-2ef9-40fa-b96b-fe301d30d3bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationAgreementMember_4d1692d4-3125-4412-9a1a-43fb42a39655" xlink:href="rcus-20230930.xsd#rcus_TaihoCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_TaihoCollaborationAgreementMember_4d1692d4-3125-4412-9a1a-43fb42a39655" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_18d7f194-e924-41cf-9467-a7844651fcac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_18d7f194-e924-41cf-9467-a7844651fcac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_18d7f194-e924-41cf-9467-a7844651fcac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_18d7f194-e924-41cf-9467-a7844651fcac" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_18d7f194-e924-41cf-9467-a7844651fcac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_744ad76f-dd48-4fe3-a44b-d5aec6c866af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_18d7f194-e924-41cf-9467-a7844651fcac" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_744ad76f-dd48-4fe3-a44b-d5aec6c866af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_486b49e6-a26e-4c57-96d0-6a9f5f8e2268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_744ad76f-dd48-4fe3-a44b-d5aec6c866af" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_486b49e6-a26e-4c57-96d0-6a9f5f8e2268" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_b54d17a0-b1b4-4f8c-a04e-5e1f0c21c51a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_744ad76f-dd48-4fe3-a44b-d5aec6c866af" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_b54d17a0-b1b4-4f8c-a04e-5e1f0c21c51a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsLineItems_c12f2281-e907-4ca3-836c-99301de5c6fc" xlink:href="rcus-20230930.xsd#rcus_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AllocationToPerformanceObligations_1fe21a38-b88d-474a-b9dd-43668382c485" xlink:href="rcus-20230930.xsd#rcus_AllocationToPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_c12f2281-e907-4ca3-836c-99301de5c6fc" xlink:to="loc_rcus_AllocationToPerformanceObligations_1fe21a38-b88d-474a-b9dd-43668382c485" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1189627e-a07d-472b-a065-b5bf70b08a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_c12f2281-e907-4ca3-836c-99301de5c6fc" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1189627e-a07d-472b-a065-b5bf70b08a7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_65260505-c30d-4757-915c-240691c123a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1189627e-a07d-472b-a065-b5bf70b08a7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_65260505-c30d-4757-915c-240691c123a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_65260505-c30d-4757-915c-240691c123a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_65260505-c30d-4757-915c-240691c123a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_65260505-c30d-4757-915c-240691c123a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1d595712-9f56-4b36-83e8-9fb349346fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_65260505-c30d-4757-915c-240691c123a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1d595712-9f56-4b36-83e8-9fb349346fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InflammationTarget1Member_08273c45-3fe9-4e29-bf95-b868bb58c12a" xlink:href="rcus-20230930.xsd#rcus_InflammationTarget1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1d595712-9f56-4b36-83e8-9fb349346fc6" xlink:to="loc_rcus_InflammationTarget1Member_08273c45-3fe9-4e29-bf95-b868bb58c12a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InflammationTarget2Member_a786f319-3f11-4ed2-905a-1e6b95b75a6d" xlink:href="rcus-20230930.xsd#rcus_InflammationTarget2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1d595712-9f56-4b36-83e8-9fb349346fc6" xlink:to="loc_rcus_InflammationTarget2Member_a786f319-3f11-4ed2-905a-1e6b95b75a6d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_56d68774-faec-4ba7-a282-2b51f95a4e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c7ae6d51-2790-4245-adf9-02eb6e7f7663" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_56d68774-faec-4ba7-a282-2b51f95a4e98" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c7ae6d51-2790-4245-adf9-02eb6e7f7663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d86dbdf5-5c59-47b1-9104-78b515db15b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_56d68774-faec-4ba7-a282-2b51f95a4e98" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d86dbdf5-5c59-47b1-9104-78b515db15b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a980e966-0114-4b6e-846d-b422162670a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d86dbdf5-5c59-47b1-9104-78b515db15b0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a980e966-0114-4b6e-846d-b422162670a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a980e966-0114-4b6e-846d-b422162670a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a980e966-0114-4b6e-846d-b422162670a6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a980e966-0114-4b6e-846d-b422162670a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd6bd39-8d36-4904-8ce2-30de85446d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a980e966-0114-4b6e-846d-b422162670a6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd6bd39-8d36-4904-8ce2-30de85446d7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_9168588d-c845-4905-a27b-eb094171f364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd6bd39-8d36-4904-8ce2-30de85446d7b" xlink:to="loc_us-gaap_StockCompensationPlanMember_9168588d-c845-4905-a27b-eb094171f364" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a3ce3605-3799-4c52-b82d-5a524d1c0e59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd6bd39-8d36-4904-8ce2-30de85446d7b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a3ce3605-3799-4c52-b82d-5a524d1c0e59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2fe6992c-0f4b-4b18-9f07-42029b09964d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd6bd39-8d36-4904-8ce2-30de85446d7b" xlink:to="loc_us-gaap_EmployeeStockMember_2fe6992c-0f4b-4b18-9f07-42029b09964d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ff8add99-dbff-4343-9228-203b188f5628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d037b9f1-01bb-48a3-b536-a6aed328b003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ff8add99-dbff-4343-9228-203b188f5628" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d037b9f1-01bb-48a3-b536-a6aed328b003" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_211f2568-539f-4d37-a19e-f4ba763178c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ff8add99-dbff-4343-9228-203b188f5628" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_211f2568-539f-4d37-a19e-f4ba763178c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_734e292c-8ed3-4786-aa10-5ba825b210a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_211f2568-539f-4d37-a19e-f4ba763178c9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_734e292c-8ed3-4786-aa10-5ba825b210a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_734e292c-8ed3-4786-aa10-5ba825b210a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_734e292c-8ed3-4786-aa10-5ba825b210a0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_734e292c-8ed3-4786-aa10-5ba825b210a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3038f968-4e6b-49bd-8e71-d08f778e8b61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_734e292c-8ed3-4786-aa10-5ba825b210a0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3038f968-4e6b-49bd-8e71-d08f778e8b61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_50d9788a-9f6f-4c89-b672-2d3bd2b657bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3038f968-4e6b-49bd-8e71-d08f778e8b61" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_50d9788a-9f6f-4c89-b672-2d3bd2b657bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1bcafff7-6e9c-45ca-bf98-e6afcacb7e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3038f968-4e6b-49bd-8e71-d08f778e8b61" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1bcafff7-6e9c-45ca-bf98-e6afcacb7e24" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa97a8a5-884b-4559-bc12-0bc515afaf69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1fe0a367-ea27-4675-9e80-ad9a0405f455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa97a8a5-884b-4559-bc12-0bc515afaf69" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1fe0a367-ea27-4675-9e80-ad9a0405f455" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_51de150c-1312-4c5b-80e3-7b6c4332c95e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa97a8a5-884b-4559-bc12-0bc515afaf69" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_51de150c-1312-4c5b-80e3-7b6c4332c95e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6578f0a2-867d-450b-ab52-5a29a026ff62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa97a8a5-884b-4559-bc12-0bc515afaf69" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6578f0a2-867d-450b-ab52-5a29a026ff62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a35dfd17-48ac-4aa6-b5bc-3ef80251c9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa97a8a5-884b-4559-bc12-0bc515afaf69" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a35dfd17-48ac-4aa6-b5bc-3ef80251c9ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1bc1ad48-53c5-432c-8049-e89d61e9119f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa97a8a5-884b-4559-bc12-0bc515afaf69" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1bc1ad48-53c5-432c-8049-e89d61e9119f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_132aaba9-06c2-4f8a-92f6-0d15d3f7670f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1bc1ad48-53c5-432c-8049-e89d61e9119f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_132aaba9-06c2-4f8a-92f6-0d15d3f7670f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_132aaba9-06c2-4f8a-92f6-0d15d3f7670f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_132aaba9-06c2-4f8a-92f6-0d15d3f7670f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_132aaba9-06c2-4f8a-92f6-0d15d3f7670f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_132aaba9-06c2-4f8a-92f6-0d15d3f7670f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_32c85ebb-2a8a-4781-bf88-3004642ab547" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_32c85ebb-2a8a-4781-bf88-3004642ab547" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8973c201-0d71-4875-87fe-f3feca3b1f25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8973c201-0d71-4875-87fe-f3feca3b1f25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_ca8a4ca9-f63d-4440-8160-34fad52bb9ff" xlink:href="rcus-20230930.xsd#rcus_CorporateSecuritiesAndCommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:to="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_ca8a4ca9-f63d-4440-8160-34fad52bb9ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e29c50f7-10f2-4ce1-9036-bd51a3353b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e29c50f7-10f2-4ce1-9036-bd51a3353b3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d8d8b7d3-1617-4373-835c-0405e104db1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d8d8b7d3-1617-4373-835c-0405e104db1a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0d29528f-01f0-47d2-b040-bb02cc4e17a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0d29528f-01f0-47d2-b040-bb02cc4e17a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_5bfd94a1-96e2-4772-ae67-a4a174fcfc90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_us-gaap_SharePrice_5bfd94a1-96e2-4772-ae67-a4a174fcfc90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0b8c9502-6eb5-401b-8230-23084af7aa22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0b8c9502-6eb5-401b-8230-23084af7aa22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d8bcc002-2b03-4c55-9824-968c1e6a7908" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d8bcc002-2b03-4c55-9824-968c1e6a7908" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SaleOfStockAuthorizedConsiderationOnTransaction_215988c8-a08f-44e4-af10-c8be09feab99" xlink:href="rcus-20230930.xsd#rcus_SaleOfStockAuthorizedConsiderationOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_rcus_SaleOfStockAuthorizedConsiderationOnTransaction_215988c8-a08f-44e4-af10-c8be09feab99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c7721872-d891-4ca7-a6a5-9b94bc5dd09b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c7721872-d891-4ca7-a6a5-9b94bc5dd09b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fdf003c3-ee60-47b0-8c4a-981cd9a2652b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fdf003c3-ee60-47b0-8c4a-981cd9a2652b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ec7fb4d9-8913-41e7-ac78-e6c177c5389f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ec7fb4d9-8913-41e7-ac78-e6c177c5389f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8c7d5716-358a-4ee9-ac74-ab2cd7ceb2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ec7fb4d9-8913-41e7-ac78-e6c177c5389f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8c7d5716-358a-4ee9-ac74-ab2cd7ceb2d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8c7d5716-358a-4ee9-ac74-ab2cd7ceb2d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8c7d5716-358a-4ee9-ac74-ab2cd7ceb2d3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8c7d5716-358a-4ee9-ac74-ab2cd7ceb2d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3e8d43e-dce9-404f-9043-d0588c303b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8c7d5716-358a-4ee9-ac74-ab2cd7ceb2d3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3e8d43e-dce9-404f-9043-d0588c303b0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SecondStockPurchaseAgreementMember_1f77c57b-d31a-4fee-8bc2-512103f0fb94" xlink:href="rcus-20230930.xsd#rcus_SecondStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3e8d43e-dce9-404f-9043-d0588c303b0d" xlink:to="loc_rcus_SecondStockPurchaseAgreementMember_1f77c57b-d31a-4fee-8bc2-512103f0fb94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e25aad8b-86aa-48e4-88ee-679bb79f99e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ec7fb4d9-8913-41e7-ac78-e6c177c5389f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e25aad8b-86aa-48e4-88ee-679bb79f99e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e25aad8b-86aa-48e4-88ee-679bb79f99e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e25aad8b-86aa-48e4-88ee-679bb79f99e0" xlink:to="loc_us-gaap_RelatedPartyDomain_e25aad8b-86aa-48e4-88ee-679bb79f99e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9a30c48b-dc8c-4acf-b2e1-cfa255dafc52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e25aad8b-86aa-48e4-88ee-679bb79f99e0" xlink:to="loc_us-gaap_RelatedPartyDomain_9a30c48b-dc8c-4acf-b2e1-cfa255dafc52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_3933336b-9290-47c5-8db6-9704d3ae22d1" xlink:href="rcus-20230930.xsd#rcus_GileadSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9a30c48b-dc8c-4acf-b2e1-cfa255dafc52" xlink:to="loc_rcus_GileadSciencesIncMember_3933336b-9290-47c5-8db6-9704d3ae22d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_08f4b474-f659-4088-9fce-b0aa59c7975f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ec7fb4d9-8913-41e7-ac78-e6c177c5389f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_08f4b474-f659-4088-9fce-b0aa59c7975f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_08f4b474-f659-4088-9fce-b0aa59c7975f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_08f4b474-f659-4088-9fce-b0aa59c7975f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_08f4b474-f659-4088-9fce-b0aa59c7975f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_72f2c56e-5599-493c-b17c-467c48d76455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_08f4b474-f659-4088-9fce-b0aa59c7975f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_72f2c56e-5599-493c-b17c-467c48d76455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AtTheMarketFacilityMember_fc00313f-963c-4944-9209-7ac788a1fe46" xlink:href="rcus-20230930.xsd#rcus_AtTheMarketFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_72f2c56e-5599-493c-b17c-467c48d76455" xlink:to="loc_rcus_AtTheMarketFacilityMember_fc00313f-963c-4944-9209-7ac788a1fe46" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc39747d-07c4-4259-9e5a-4458ad824dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b7c3ccd8-b242-4bba-bc9b-b76fbfa64eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc39747d-07c4-4259-9e5a-4458ad824dbe" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b7c3ccd8-b242-4bba-bc9b-b76fbfa64eac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8ee7eb6b-20b2-4b28-a6a2-2109898ae56a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc39747d-07c4-4259-9e5a-4458ad824dbe" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_8ee7eb6b-20b2-4b28-a6a2-2109898ae56a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b121ff51-8022-441c-868a-df0aaafef4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc39747d-07c4-4259-9e5a-4458ad824dbe" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b121ff51-8022-441c-868a-df0aaafef4b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e881ae2c-bfdc-41cc-af7e-6bb08ad24cba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b121ff51-8022-441c-868a-df0aaafef4b1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e881ae2c-bfdc-41cc-af7e-6bb08ad24cba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e881ae2c-bfdc-41cc-af7e-6bb08ad24cba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e881ae2c-bfdc-41cc-af7e-6bb08ad24cba" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e881ae2c-bfdc-41cc-af7e-6bb08ad24cba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b96de93-a72d-4e1e-8b31-2b49a44ad288" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e881ae2c-bfdc-41cc-af7e-6bb08ad24cba" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b96de93-a72d-4e1e-8b31-2b49a44ad288" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bfa02e21-c670-40e9-be52-0ddc8a1b00fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b96de93-a72d-4e1e-8b31-2b49a44ad288" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bfa02e21-c670-40e9-be52-0ddc8a1b00fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beba0a8c-8ed3-4a11-8504-1444ba6020f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b121ff51-8022-441c-868a-df0aaafef4b1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beba0a8c-8ed3-4a11-8504-1444ba6020f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_beba0a8c-8ed3-4a11-8504-1444ba6020f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beba0a8c-8ed3-4a11-8504-1444ba6020f5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_beba0a8c-8ed3-4a11-8504-1444ba6020f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51a94b2f-6d34-47e2-a20e-88099f8aa632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beba0a8c-8ed3-4a11-8504-1444ba6020f5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51a94b2f-6d34-47e2-a20e-88099f8aa632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4c0a934e-9c81-44ff-881b-f40528bb4bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51a94b2f-6d34-47e2-a20e-88099f8aa632" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4c0a934e-9c81-44ff-881b-f40528bb4bdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9d9f3792-bfd9-4130-bdbf-369661b5b7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51a94b2f-6d34-47e2-a20e-88099f8aa632" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9d9f3792-bfd9-4130-bdbf-369661b5b7ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f1e443c7-4fa7-4ee0-8bc7-e163aff7ff3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51a94b2f-6d34-47e2-a20e-88099f8aa632" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f1e443c7-4fa7-4ee0-8bc7-e163aff7ff3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_75bd78a1-361d-4101-90c7-e4d99d209ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b121ff51-8022-441c-868a-df0aaafef4b1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_75bd78a1-361d-4101-90c7-e4d99d209ca7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_75bd78a1-361d-4101-90c7-e4d99d209ca7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_75bd78a1-361d-4101-90c7-e4d99d209ca7" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_75bd78a1-361d-4101-90c7-e4d99d209ca7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_75bd78a1-361d-4101-90c7-e4d99d209ca7" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4b1463a6-a474-4f4f-a948-a935380aee35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4b1463a6-a474-4f4f-a948-a935380aee35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b99c22e7-1c3a-49e9-bd1f-7bb410a919f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b99c22e7-1c3a-49e9-bd1f-7bb410a919f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_88e106b7-a515-40c7-bacb-87a39dfe41df" xlink:href="rcus-20230930.xsd#rcus_CorporateSecuritiesAndCommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:to="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_88e106b7-a515-40c7-bacb-87a39dfe41df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_UsGovernmentAgencyObligationMember_b5f21e6c-c7f2-4abd-8b82-ac90f95dea78" xlink:href="rcus-20230930.xsd#rcus_UsGovernmentAgencyObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:to="loc_rcus_UsGovernmentAgencyObligationMember_b5f21e6c-c7f2-4abd-8b82-ac90f95dea78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9e8f7c54-0c08-4a28-b3ab-c4657dbcd697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9e8f7c54-0c08-4a28-b3ab-c4657dbcd697" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_66ee8a2f-9c03-4516-8966-20246567c4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:to="loc_us-gaap_CertificatesOfDepositMember_66ee8a2f-9c03-4516-8966-20246567c4e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1997ff5a-6d81-4835-b76f-c786ac697674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b121ff51-8022-441c-868a-df0aaafef4b1" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1997ff5a-6d81-4835-b76f-c786ac697674" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1997ff5a-6d81-4835-b76f-c786ac697674_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1997ff5a-6d81-4835-b76f-c786ac697674" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1997ff5a-6d81-4835-b76f-c786ac697674_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_82768542-0f20-45fe-9f9f-bc9d57891dab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1997ff5a-6d81-4835-b76f-c786ac697674" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_82768542-0f20-45fe-9f9f-bc9d57891dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LiabilityForSaleOfFutureRoyaltiesMember_a9e68cf7-c9af-462f-aeed-44cd2e5b0a98" xlink:href="rcus-20230930.xsd#rcus_LiabilityForSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_82768542-0f20-45fe-9f9f-bc9d57891dab" xlink:to="loc_rcus_LiabilityForSaleOfFutureRoyaltiesMember_a9e68cf7-c9af-462f-aeed-44cd2e5b0a98" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aa8d980e-01e9-432c-85e1-711252e11f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NonRefundablePaymentsReceived_54383bad-aebe-4528-bca5-6a9f9ee96c62" xlink:href="rcus-20230930.xsd#rcus_NonRefundablePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aa8d980e-01e9-432c-85e1-711252e11f20" xlink:to="loc_rcus_NonRefundablePaymentsReceived_54383bad-aebe-4528-bca5-6a9f9ee96c62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones_d0c91e3d-5d4e-4778-9dba-807ebf9847ef" xlink:href="rcus-20230930.xsd#rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aa8d980e-01e9-432c-85e1-711252e11f20" xlink:to="loc_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones_d0c91e3d-5d4e-4778-9dba-807ebf9847ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability_2f3df560-2b86-43b7-bd3c-c8a72f30c9bf" xlink:href="rcus-20230930.xsd#rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aa8d980e-01e9-432c-85e1-711252e11f20" xlink:to="loc_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability_2f3df560-2b86-43b7-bd3c-c8a72f30c9bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4401f4c1-6fb0-4561-82f3-516dbd7a5b75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aa8d980e-01e9-432c-85e1-711252e11f20" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4401f4c1-6fb0-4561-82f3-516dbd7a5b75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_48e4eb33-27e3-4076-9da2-87e8bc36de00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4401f4c1-6fb0-4561-82f3-516dbd7a5b75" xlink:to="loc_srt_CounterpartyNameAxis_48e4eb33-27e3-4076-9da2-87e8bc36de00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_48e4eb33-27e3-4076-9da2-87e8bc36de00_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_48e4eb33-27e3-4076-9da2-87e8bc36de00" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_48e4eb33-27e3-4076-9da2-87e8bc36de00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c20c04d-f33b-4b25-8ffc-80d8061c874c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_48e4eb33-27e3-4076-9da2-87e8bc36de00" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c20c04d-f33b-4b25-8ffc-80d8061c874c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_BvfPartnersLPMember_fb85685a-81a2-4326-a0b5-8ca880af2f67" xlink:href="rcus-20230930.xsd#rcus_BvfPartnersLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c20c04d-f33b-4b25-8ffc-80d8061c874c" xlink:to="loc_rcus_BvfPartnersLPMember_fb85685a-81a2-4326-a0b5-8ca880af2f67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a0c7197d-7080-44c3-aa8a-dfb6adc2116c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4401f4c1-6fb0-4561-82f3-516dbd7a5b75" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a0c7197d-7080-44c3-aa8a-dfb6adc2116c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0c7197d-7080-44c3-aa8a-dfb6adc2116c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a0c7197d-7080-44c3-aa8a-dfb6adc2116c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0c7197d-7080-44c3-aa8a-dfb6adc2116c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_873e3736-d68a-423d-9f81-b1ff5668abbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a0c7197d-7080-44c3-aa8a-dfb6adc2116c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_873e3736-d68a-423d-9f81-b1ff5668abbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_BvfAgreementMember_74a554cb-c39c-4b2f-bc36-2fe946e43be7" xlink:href="rcus-20230930.xsd#rcus_BvfAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_873e3736-d68a-423d-9f81-b1ff5668abbd" xlink:to="loc_rcus_BvfAgreementMember_74a554cb-c39c-4b2f-bc36-2fe946e43be7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationAgreementMember_9ec629bd-bbd1-432b-9d1f-3e36e75bb44a" xlink:href="rcus-20230930.xsd#rcus_GileadCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_873e3736-d68a-423d-9f81-b1ff5668abbd" xlink:to="loc_rcus_GileadCollaborationAgreementMember_9ec629bd-bbd1-432b-9d1f-3e36e75bb44a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e4e00dcd-09d8-4b86-958d-a148570bb29d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4401f4c1-6fb0-4561-82f3-516dbd7a5b75" xlink:to="loc_srt_RangeAxis_e4e00dcd-09d8-4b86-958d-a148570bb29d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e4e00dcd-09d8-4b86-958d-a148570bb29d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e4e00dcd-09d8-4b86-958d-a148570bb29d" xlink:to="loc_srt_RangeMember_e4e00dcd-09d8-4b86-958d-a148570bb29d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27de2269-7ab1-4eff-8df6-48baeb7255c7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e4e00dcd-09d8-4b86-958d-a148570bb29d" xlink:to="loc_srt_RangeMember_27de2269-7ab1-4eff-8df6-48baeb7255c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_702f030a-4e34-4a05-bf56-c66689f154a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_27de2269-7ab1-4eff-8df6-48baeb7255c7" xlink:to="loc_srt_MaximumMember_702f030a-4e34-4a05-bf56-c66689f154a8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8c721385-2bd4-4c59-b6a8-ddd85af52200" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_19781b0a-d327-447a-a704-29088f5a5ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8c721385-2bd4-4c59-b6a8-ddd85af52200" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_19781b0a-d327-447a-a704-29088f5a5ce7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LiabilityForSaleOfFutureRoyalties_1e4c28c9-bdda-4995-a394-4033c113d92c" xlink:href="rcus-20230930.xsd#rcus_LiabilityForSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_19781b0a-d327-447a-a704-29088f5a5ce7" xlink:to="loc_rcus_LiabilityForSaleOfFutureRoyalties_1e4c28c9-bdda-4995-a394-4033c113d92c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived_239fde6e-7297-44c9-aa56-2e831767770a" xlink:href="rcus-20230930.xsd#rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_19781b0a-d327-447a-a704-29088f5a5ce7" xlink:to="loc_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived_239fde6e-7297-44c9-aa56-2e831767770a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion_f1c12604-98d0-44cc-929f-6dad92121cb3" xlink:href="rcus-20230930.xsd#rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_19781b0a-d327-447a-a704-29088f5a5ce7" xlink:to="loc_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion_f1c12604-98d0-44cc-929f-6dad92121cb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LiabilityForSaleOfFutureRoyalties_a3905f1c-446f-4574-8f63-d6d97255b077" xlink:href="rcus-20230930.xsd#rcus_LiabilityForSaleOfFutureRoyalties"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_59d590df-cd0d-453e-a050-ed1c8b0f777b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8c721385-2bd4-4c59-b6a8-ddd85af52200" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_59d590df-cd0d-453e-a050-ed1c8b0f777b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_664b4f3f-37a5-4c1b-88b3-9e466f97195e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_59d590df-cd0d-453e-a050-ed1c8b0f777b" xlink:to="loc_srt_CounterpartyNameAxis_664b4f3f-37a5-4c1b-88b3-9e466f97195e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_664b4f3f-37a5-4c1b-88b3-9e466f97195e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_664b4f3f-37a5-4c1b-88b3-9e466f97195e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_664b4f3f-37a5-4c1b-88b3-9e466f97195e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e75a0bc-f08c-40c5-aa78-1f36dc8f9da5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_664b4f3f-37a5-4c1b-88b3-9e466f97195e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e75a0bc-f08c-40c5-aa78-1f36dc8f9da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_BvfPartnersLPMember_40bd70ef-4f89-4234-a57a-506680040c93" xlink:href="rcus-20230930.xsd#rcus_BvfPartnersLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e75a0bc-f08c-40c5-aa78-1f36dc8f9da5" xlink:to="loc_rcus_BvfPartnersLPMember_40bd70ef-4f89-4234-a57a-506680040c93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f4b32ef8-1638-480d-ab77-365aff4afcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_59d590df-cd0d-453e-a050-ed1c8b0f777b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f4b32ef8-1638-480d-ab77-365aff4afcd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f4b32ef8-1638-480d-ab77-365aff4afcd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f4b32ef8-1638-480d-ab77-365aff4afcd9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f4b32ef8-1638-480d-ab77-365aff4afcd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f06d3c4-df69-40ba-9ace-938347cf2ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f4b32ef8-1638-480d-ab77-365aff4afcd9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f06d3c4-df69-40ba-9ace-938347cf2ef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_BvfAgreementMember_66853d4d-b342-4089-961b-e4236bb42434" xlink:href="rcus-20230930.xsd#rcus_BvfAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f06d3c4-df69-40ba-9ace-938347cf2ef1" xlink:to="loc_rcus_BvfAgreementMember_66853d4d-b342-4089-961b-e4236bb42434" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TradingArrangmentsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OfficersAndDirectorsTradingArrangementMember_d474e282-f799-427d-8463-e244780828e7" xlink:href="rcus-20230930.xsd#rcus_OfficersAndDirectorsTradingArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_rcus_OfficersAndDirectorsTradingArrangementMember_d474e282-f799-427d-8463-e244780828e7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_JuanCJaenMember_a845a59f-9790-4e13-b71d-9c676a0c4ed6" xlink:href="rcus-20230930.xsd#rcus_JuanCJaenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rcus_JuanCJaenMember_a845a59f-9790-4e13-b71d-9c676a0c4ed6" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>rcus-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:805eb66e-844e-45f5-86a8-527ac86fecd7,g:7538c7a3-a72e-4e53-a8d0-2829fb9c9dc2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsLineItems_22a5458c-98f4-417c-b4dc-d0fec9c6000f_terseLabel_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsLineItems_label_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsLineItems_documentation_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsLineItems" xlink:href="rcus-20230930.xsd#rcus_LicenseAndCollaborationAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems" xlink:to="lab_rcus_LicenseAndCollaborationAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_88a7bb4f-9920-421f-80af-bac7cf1d81b7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_a38e34f5-274b-4bb9-b334-de9a5477aaae_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Revenue Recognized as a Result of Changes in Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6b301495-55d5-4ec9-aed3-2ebb38d74d0a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development (Net of recoveries of $22, $27, $89 and $93 from a related party)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e9808244-78b6-4b6c-8a43-c65695fe7e6b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_5f79d144-5a59-4347-849b-fda57a74a042_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_02d0b8c2-2b09-4cb4-ae1d-5cc9454e672a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Including Additional Paid in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_bf2e4405-2257-4e86-a0ae-871107c6d0d6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_dc56fb4a-4f30-402b-a50e-a37d17220445_terseLabel_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments in Marketable Securities</link:label>
    <link:label id="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_label_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Investments In Marketable Securities [Member]</link:label>
    <link:label id="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and investments in marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" xlink:href="rcus-20230930.xsd#rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" xlink:to="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_f154f047-4ebc-41b4-aee6-070a0fd97e8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Values of Our Cash, Cash Equivalents and Marketable Securities by Location in Condensed Consolidated Balance Sheets and Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8f271e50-bfee-40a9-8469-2c75309050e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_d791ec3d-23c5-4f28-923c-216c07ffefa5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_e03bd85c-8eb2-4ecc-bc79-c995fe7ae234_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_01ab5b78-b8b7-4380-bf1e-23afcee3a946_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-operating income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d6e4c5f2-b720-44f8-a3f7-863ec4e7a4e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_2244e97a-4f56-4d5d-980b-6f26fe426dd8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_InflammationTarget1Member_ed8626f3-6f27-4046-a25d-654b1ef51a29_terseLabel_en-US" xlink:label="lab_rcus_InflammationTarget1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflammation target 1</link:label>
    <link:label id="lab_rcus_InflammationTarget1Member_label_en-US" xlink:label="lab_rcus_InflammationTarget1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflammation Target 1 [Member]</link:label>
    <link:label id="lab_rcus_InflammationTarget1Member_documentation_en-US" xlink:label="lab_rcus_InflammationTarget1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflammation target 1 member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InflammationTarget1Member" xlink:href="rcus-20230930.xsd#rcus_InflammationTarget1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_InflammationTarget1Member" xlink:to="lab_rcus_InflammationTarget1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f93f8073-071f-43be-9808-6fc69933ef5d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1c947828-f2d8-41bb-b0e7-1c401cfc3b07_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock ($20 and $&#8212; from a related party)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1009828c-0412-451c-8934-98c7b1f1c011_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_71913c9a-2b1f-4ce0-b8d6-93635f512ff3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets (($4) and ($2) from a related party)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3deb5a56-b699-48b5-ba40-dcc9584788ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_BvfPartnersLPMember_97937689-0cad-4676-bd38-2a635068e762_terseLabel_en-US" xlink:label="lab_rcus_BvfPartnersLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BVF Partners L.P.</link:label>
    <link:label id="lab_rcus_BvfPartnersLPMember_label_en-US" xlink:label="lab_rcus_BvfPartnersLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BVF Partners L.P. [Member]</link:label>
    <link:label id="lab_rcus_BvfPartnersLPMember_documentation_en-US" xlink:label="lab_rcus_BvfPartnersLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BVF Partners L.P.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_BvfPartnersLPMember" xlink:href="rcus-20230930.xsd#rcus_BvfPartnersLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_BvfPartnersLPMember" xlink:to="lab_rcus_BvfPartnersLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_eaccdd88-902d-4384-92ba-018fbf9d57d7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ebf3b014-a792-4fcf-9830-0af155cb3f80_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_102bd4c6-07c6-4520-8c04-3c96795ec122_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue (($47) and ($73) to a related party)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_06303ae9-34f5-4fa6-90dc-ccfee4d8e983_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7be89ed8-e25c-4873-b209-27c81eecf9cf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember_962140e7-0f58-4958-9139-65488a430b31_terseLabel_en-US" xlink:label="lab_rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Etrumadenant License and research and Development Services Agreement</link:label>
    <link:label id="lab_rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember_label_en-US" xlink:label="lab_rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Etrumadenant License And Research And Development Services Agreement [Member]</link:label>
    <link:label id="lab_rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember_documentation_en-US" xlink:label="lab_rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Etrumadenant License And Research And Development Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember" xlink:href="rcus-20230930.xsd#rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember" xlink:to="lab_rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_aac92432-25d0-4fbe-a3b3-3d5b8985569c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e87264eb-c002-4d83-96a0-6d5a6fd7a409_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_164c9512-b72e-45fd-8c65-50de4f96bdba_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value per share; 10.0 shares authorized; no shares issued and outstanding.</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AllocationToPerformanceObligations_f505386e-725a-4cd4-968e-ff66c75a6eea_terseLabel_en-US" xlink:label="lab_rcus_AllocationToPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allocated transaction price</link:label>
    <link:label id="lab_rcus_AllocationToPerformanceObligations_label_en-US" xlink:label="lab_rcus_AllocationToPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation To Performance Obligations</link:label>
    <link:label id="lab_rcus_AllocationToPerformanceObligations_documentation_en-US" xlink:label="lab_rcus_AllocationToPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation to performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AllocationToPerformanceObligations" xlink:href="rcus-20230930.xsd#rcus_AllocationToPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AllocationToPerformanceObligations" xlink:to="lab_rcus_AllocationToPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2538606e-12e3-495d-a091-22d0dcc46f54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_408004fc-1150-488d-a7fe-281d114fe26b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent_f016cdef-3583-42f5-b02e-ffe0f31b915d_terseLabel_en-US" xlink:label="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development</link:label>
    <link:label id="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent_label_en-US" xlink:label="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expenses Current</link:label>
    <link:label id="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent_documentation_en-US" xlink:label="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:href="rcus-20230930.xsd#rcus_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_2bf8392f-9a22-410f-89d0-b50887473e0e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_81ccca96-4e7d-4c34-8c92-c89a8a93573a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_293b326c-22ab-4e8f-a0f4-8b7a6838294b_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_PerformanceObligationPeriod_28cdbe50-eb47-4cdf-86f6-90e66ff7203f_terseLabel_en-US" xlink:label="lab_rcus_PerformanceObligationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation period</link:label>
    <link:label id="lab_rcus_PerformanceObligationPeriod_label_en-US" xlink:label="lab_rcus_PerformanceObligationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Obligation Period</link:label>
    <link:label id="lab_rcus_PerformanceObligationPeriod_documentation_en-US" xlink:label="lab_rcus_PerformanceObligationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PerformanceObligationPeriod" xlink:href="rcus-20230930.xsd#rcus_PerformanceObligationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_PerformanceObligationPeriod" xlink:to="lab_rcus_PerformanceObligationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_62b279f4-3281-418c-a5f1-b26a25dac577_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3725ce3e-69fc-4b57-b268-6a49235076fc_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_LiabilityForSaleOfFutureRoyalties_cb9b2cbc-6562-4ec1-82a5-1e72e18cb67a_periodStartLabel_en-US" xlink:label="lab_rcus_LiabilityForSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_rcus_LiabilityForSaleOfFutureRoyalties_d5abf8ef-d19b-44b9-98a3-1f3121e2efd7_periodEndLabel_en-US" xlink:label="lab_rcus_LiabilityForSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_rcus_LiabilityForSaleOfFutureRoyalties_label_en-US" xlink:label="lab_rcus_LiabilityForSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Sale of Future Royalties</link:label>
    <link:label id="lab_rcus_LiabilityForSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_rcus_LiabilityForSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LiabilityForSaleOfFutureRoyalties" xlink:href="rcus-20230930.xsd#rcus_LiabilityForSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_LiabilityForSaleOfFutureRoyalties" xlink:to="lab_rcus_LiabilityForSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_75c742a5-5da1-4bdf-84ab-555e1bb6a6b5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_6b54559b-71c7-441f-a2bb-c01e25d5122b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_058aa865-c869-4f34-832b-1e64d3ea1b29_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_57a19801-207d-4b2a-bcce-7ddfb590b031_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_ba27fbf4-55b4-4931-b826-08bf35e8b8e7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan shares</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_SecondStockPurchaseAgreementMember_133f4df8-3cef-4988-bcaa-70642266e40d_terseLabel_en-US" xlink:label="lab_rcus_SecondStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Stock Purchase Agreement</link:label>
    <link:label id="lab_rcus_SecondStockPurchaseAgreementMember_label_en-US" xlink:label="lab_rcus_SecondStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_rcus_SecondStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_rcus_SecondStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Stock Purchase Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SecondStockPurchaseAgreementMember" xlink:href="rcus-20230930.xsd#rcus_SecondStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_SecondStockPurchaseAgreementMember" xlink:to="lab_rcus_SecondStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement_a3488c47-4063-4b66-959f-edb0dba7f068_terseLabel_en-US" xlink:label="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Removal of option continuation payment under agreement</link:label>
    <link:label id="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement_label_en-US" xlink:label="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remove Option Continuation Payment Under Agreement</link:label>
    <link:label id="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement_documentation_en-US" xlink:label="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remove option continuation payment under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RemoveOptionContinuationPaymentUnderAgreement" xlink:href="rcus-20230930.xsd#rcus_RemoveOptionContinuationPaymentUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_RemoveOptionContinuationPaymentUnderAgreement" xlink:to="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_TrailingDaysAverageClosingPrice_daa41fcf-443e-4b03-82f9-10706850688a_terseLabel_en-US" xlink:label="lab_rcus_TrailingDaysAverageClosingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing days average closing price</link:label>
    <link:label id="lab_rcus_TrailingDaysAverageClosingPrice_label_en-US" xlink:label="lab_rcus_TrailingDaysAverageClosingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing Days Average Closing Price</link:label>
    <link:label id="lab_rcus_TrailingDaysAverageClosingPrice_documentation_en-US" xlink:label="lab_rcus_TrailingDaysAverageClosingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing days average closing price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TrailingDaysAverageClosingPrice" xlink:href="rcus-20230930.xsd#rcus_TrailingDaysAverageClosingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_TrailingDaysAverageClosingPrice" xlink:to="lab_rcus_TrailingDaysAverageClosingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_358b30da-0115-426a-b5c0-505696e6dd5f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c69e7a22-4057-4ce4-bbf6-0b9f7b876117_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_8370c8ba-02c4-4ec8-a38c-10f1103d6001_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_509090ef-14bf-4617-901d-e801c78699f6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_STAR221DevelopmentActivitiesMember_9ac1c53f-9d17-4c05-a0ca-a7657b274abf_terseLabel_en-US" xlink:label="lab_rcus_STAR221DevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STAR-221 Development Activities</link:label>
    <link:label id="lab_rcus_STAR221DevelopmentActivitiesMember_label_en-US" xlink:label="lab_rcus_STAR221DevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STAR-221 Development Activities [Member]</link:label>
    <link:label id="lab_rcus_STAR221DevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_rcus_STAR221DevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STAR-221 Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_STAR221DevelopmentActivitiesMember" xlink:href="rcus-20230930.xsd#rcus_STAR221DevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_STAR221DevelopmentActivitiesMember" xlink:to="lab_rcus_STAR221DevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ProceedsFromMaturityOfMarketableSecurities_7c748cdc-0c2a-473c-9530-78000b54aa83_terseLabel_en-US" xlink:label="lab_rcus_ProceedsFromMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_rcus_ProceedsFromMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_rcus_ProceedsFromMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity of Marketable Securities</link:label>
    <link:label id="lab_rcus_ProceedsFromMaturityOfMarketableSecurities_documentation_en-US" xlink:label="lab_rcus_ProceedsFromMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturity of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromMaturityOfMarketableSecurities" xlink:href="rcus-20230930.xsd#rcus_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ProceedsFromMaturityOfMarketableSecurities" xlink:to="lab_rcus_ProceedsFromMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_681c83ba-114c-417f-ba96-7648612045ed_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4742fa5d-e29b-45b1-82a6-bc6e80d53344_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ec641c1c-0115-4b47-b66e-7136cc4278e2_terseLabel_en-US" xlink:label="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets and Liabilities Measured On Recurring Basis [Table Text Block]</link:label>
    <link:label id="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_documentation_en-US" xlink:label="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value assets and liabilities measured on recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="rcus-20230930.xsd#rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_97d21a19-c168-435f-a3dd-99babf5e30f5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_065ec6c8-11c9-42cd-ad3c-57a18e5b411e_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_UsGovernmentAgencyObligationMember_c72756e9-52c6-46c0-a8f5-6783be6b0f94_terseLabel_en-US" xlink:label="lab_rcus_UsGovernmentAgencyObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency obligations</link:label>
    <link:label id="lab_rcus_UsGovernmentAgencyObligationMember_label_en-US" xlink:label="lab_rcus_UsGovernmentAgencyObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agency Obligation [Member]</link:label>
    <link:label id="lab_rcus_UsGovernmentAgencyObligationMember_documentation_en-US" xlink:label="lab_rcus_UsGovernmentAgencyObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government agency obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_UsGovernmentAgencyObligationMember" xlink:href="rcus-20230930.xsd#rcus_UsGovernmentAgencyObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_UsGovernmentAgencyObligationMember" xlink:to="lab_rcus_UsGovernmentAgencyObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_538f26a5-3534-4947-804a-10ea03535c7b_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_LockupPeriod_79ac30a7-242a-46a0-87bc-39b264e648a6_terseLabel_en-US" xlink:label="lab_rcus_LockupPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lockup period</link:label>
    <link:label id="lab_rcus_LockupPeriod_label_en-US" xlink:label="lab_rcus_LockupPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lockup Period</link:label>
    <link:label id="lab_rcus_LockupPeriod_documentation_en-US" xlink:label="lab_rcus_LockupPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lockup period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LockupPeriod" xlink:href="rcus-20230930.xsd#rcus_LockupPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_LockupPeriod" xlink:to="lab_rcus_LockupPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AstraZenecaAgreementMember_e0f1303a-8530-4b14-bb9b-eec194ef6b58_terseLabel_en-US" xlink:label="lab_rcus_AstraZenecaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca Agreement</link:label>
    <link:label id="lab_rcus_AstraZenecaAgreementMember_label_en-US" xlink:label="lab_rcus_AstraZenecaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astra Zeneca Agreement [Member]</link:label>
    <link:label id="lab_rcus_AstraZenecaAgreementMember_documentation_en-US" xlink:label="lab_rcus_AstraZenecaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AstraZenecaAgreementMember" xlink:href="rcus-20230930.xsd#rcus_AstraZenecaAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AstraZenecaAgreementMember" xlink:to="lab_rcus_AstraZenecaAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3bbc222a-5540-4143-9f40-c8000cd0d85b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c39e714a-738a-49f1-96eb-1144a1b6c9d7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_45bb8ce0-7e49-4d0a-9f3d-bf4c3edee4a6_terseLabel_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities [Abstract]</link:label>
    <link:label id="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_label_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities [Abstract]</link:label>
    <link:label id="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_documentation_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="rcus-20230930.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionLicenseAndCollaborationAgreementMember_7321a9e8-db54-4cb4-95dd-61e9f7408cd6_terseLabel_en-US" xlink:label="lab_rcus_OptionLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Collaboration Agreement</link:label>
    <link:label id="lab_rcus_OptionLicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_rcus_OptionLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_rcus_OptionLicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_rcus_OptionLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option, license and collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionLicenseAndCollaborationAgreementMember" xlink:href="rcus-20230930.xsd#rcus_OptionLicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionLicenseAndCollaborationAgreementMember" xlink:to="lab_rcus_OptionLicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_035a521e-6e4b-41c1-9d8e-089c68a0ff79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList_b8473fa3-a5b2-4179-b19d-7ea3b77315da_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5443cf9a-9010-45ee-bf72-141d3a3aed15_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units issued</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_TaihoPharmaceuticalCoLtdMember_e5c054bd-d0ae-4726-8416-22642c229083_terseLabel_en-US" xlink:label="lab_rcus_TaihoPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taiho Pharmaceutical Co., Ltd</link:label>
    <link:label id="lab_rcus_TaihoPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_rcus_TaihoPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taiho Pharmaceutical Co Ltd [Member]</link:label>
    <link:label id="lab_rcus_TaihoPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_rcus_TaihoPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taiho Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoPharmaceuticalCoLtdMember" xlink:href="rcus-20230930.xsd#rcus_TaihoPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_TaihoPharmaceuticalCoLtdMember" xlink:to="lab_rcus_TaihoPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_9a56a755-fa30-46bc-b2bb-4e1743104248_terseLabel_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option continuation payment due upon sixth anniversary of agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_label_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Continuation Payment Due Upon Sixth Anniversary of Agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_documentation_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option continuation payment due upon Sixth anniversary of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" xlink:href="rcus-20230930.xsd#rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" xlink:to="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6baa7e12-e2a3-47fa-9173-0c1b117b15e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_d23c583d-d8e6-40ca-9ab4-4c139839d20a_terseLabel_en-US" xlink:label="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional clinical, regulatory and commercialization milestone payments</link:label>
    <link:label id="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_label_en-US" xlink:label="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Clinical Regulatory And Commercialization Milestone Payments</link:label>
    <link:label id="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_documentation_en-US" xlink:label="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional clinical regulatory and commercialization milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" xlink:href="rcus-20230930.xsd#rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" xlink:to="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_60c8fa12-096d-4be7-bd70-a783f5fbde29_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6746c6d8-cc9b-458e-bd4b-8e9adce71a8f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development cost recorded within research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4f8e86b-796e-4dc6-9b53-3d2a362ac4b3_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_FundsReceivedForStockPurchaseAgreement_d136257d-165a-45e8-858a-558653e63712_terseLabel_en-US" xlink:label="lab_rcus_FundsReceivedForStockPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds received for stock purchase agreement</link:label>
    <link:label id="lab_rcus_FundsReceivedForStockPurchaseAgreement_label_en-US" xlink:label="lab_rcus_FundsReceivedForStockPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds Received For Stock Purchase Agreement</link:label>
    <link:label id="lab_rcus_FundsReceivedForStockPurchaseAgreement_documentation_en-US" xlink:label="lab_rcus_FundsReceivedForStockPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds received for stock purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_FundsReceivedForStockPurchaseAgreement" xlink:href="rcus-20230930.xsd#rcus_FundsReceivedForStockPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_FundsReceivedForStockPurchaseAgreement" xlink:to="lab_rcus_FundsReceivedForStockPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage_d617028a-6941-40f2-b9af-0192405f50dd_terseLabel_en-US" xlink:label="lab_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right to purchase additional outstanding voting common stock percentage</link:label>
    <link:label id="lab_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage_label_en-US" xlink:label="lab_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right To Purchase Additional Outstanding Voting Common Stock Percentage</link:label>
    <link:label id="lab_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage_documentation_en-US" xlink:label="lab_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right to purchase additional outstanding voting common stock percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage" xlink:href="rcus-20230930.xsd#rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage" xlink:to="lab_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_e698dd66-f95f-42f1-a472-33eae3c1f91d_terseLabel_en-US" xlink:label="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of programs, eligible to receive regulatory and commercial milestone payments</link:label>
    <link:label id="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_label_en-US" xlink:label="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Programs, Eligible To Receive Regulatory And Commercial Milestone Payments</link:label>
    <link:label id="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_documentation_en-US" xlink:label="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of programs, eligible to receive regulatory and commercial milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" xlink:href="rcus-20230930.xsd#rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" xlink:to="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_97317424-4bb7-42ce-90ed-00450a30dbd2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_2b255f78-65e8-4d58-a16a-524bbaf93462_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_90a8d823-edce-4309-9183-78ab532bd2db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_899ff196-b19c-4db7-99dc-571a68194007_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_330ae011-760e-4429-a492-ec568ce945f9_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CorporateSecuritiesAndCommercialPaperMember_acd981ca-c70c-4210-971a-6b692c30e364_terseLabel_en-US" xlink:label="lab_rcus_CorporateSecuritiesAndCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate securities and commercial paper</link:label>
    <link:label id="lab_rcus_CorporateSecuritiesAndCommercialPaperMember_label_en-US" xlink:label="lab_rcus_CorporateSecuritiesAndCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Securities And Commercial Paper [Member]</link:label>
    <link:label id="lab_rcus_CorporateSecuritiesAndCommercialPaperMember_documentation_en-US" xlink:label="lab_rcus_CorporateSecuritiesAndCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate securities and commercial paper.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CorporateSecuritiesAndCommercialPaperMember" xlink:href="rcus-20230930.xsd#rcus_CorporateSecuritiesAndCommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CorporateSecuritiesAndCommercialPaperMember" xlink:to="lab_rcus_CorporateSecuritiesAndCommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_0478c1d7-a170-4c66-9fc0-4bc6e585b22d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from collaboration partners ($22 and $39 from a related party)</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_c1ab671d-f57a-43fc-97d7-76c3e12bb934_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from collaboration partners, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_455f17a3-a2c9-478b-bc25-76e2a8eea6a9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_586f5ee1-dcf9-4e9f-8a67-65b1cf10e549_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cb86ccb2-8a0e-4211-a1ab-3a95b6ec4af8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AntiPDOneMember_b34b5b13-da87-41ff-82a0-ba974fad5556_terseLabel_en-US" xlink:label="lab_rcus_AntiPDOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">anti-PD-1</link:label>
    <link:label id="lab_rcus_AntiPDOneMember_label_en-US" xlink:label="lab_rcus_AntiPDOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti P D One [Member]</link:label>
    <link:label id="lab_rcus_AntiPDOneMember_documentation_en-US" xlink:label="lab_rcus_AntiPDOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti PD one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AntiPDOneMember" xlink:href="rcus-20230930.xsd#rcus_AntiPDOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AntiPDOneMember" xlink:to="lab_rcus_AntiPDOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_555fd37e-0518-4d53-8b34-5b2b5a4e0446_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_fcd2a985-5860-4571-9d86-0a563c975994_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_402077c6-7163-4297-b3e7-bd615a85e35a_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_JuanCJaenMember_label_en-US" xlink:label="lab_rcus_JuanCJaenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juan C. Jaen [Member]</link:label>
    <link:label id="lab_rcus_JuanCJaenMember_documentation_en-US" xlink:label="lab_rcus_JuanCJaenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juan C. Jaen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_JuanCJaenMember" xlink:href="rcus-20230930.xsd#rcus_JuanCJaenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_JuanCJaenMember" xlink:to="lab_rcus_JuanCJaenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_78bcf7d7-e2c8-4c7a-8332-fd04c370c09e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_UpfrontCashPayment_0f9ff604-35bb-434a-96dd-7d4640f9eda8_terseLabel_en-US" xlink:label="lab_rcus_UpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment</link:label>
    <link:label id="lab_rcus_UpfrontCashPayment_label_en-US" xlink:label="lab_rcus_UpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Cash Payment</link:label>
    <link:label id="lab_rcus_UpfrontCashPayment_documentation_en-US" xlink:label="lab_rcus_UpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_UpfrontCashPayment" xlink:href="rcus-20230930.xsd#rcus_UpfrontCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_UpfrontCashPayment" xlink:to="lab_rcus_UpfrontCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3aed7931-3f76-4d1a-8d8c-d989eadb16e8_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid portion of property and equipment purchases included in Accounts payable and Other current liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab1abd89-3d9c-4829-9d01-42b9d57df9c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_47762319-682e-46d8-9cf2-fcead88cf38e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1dd72ca2-918e-40cc-a055-9d8203d2e6d1_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_d4aff96b-f230-476a-a88b-d941d8842b1d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6aee04a9-2e74-4cd2-8d89-9506d645082d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party - Gilead Sciences, Inc.</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_c54a76be-1d43-4c66-8ba5-eb3b2976b899_terseLabel_en-US" xlink:label="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and commercial milestone payments received</link:label>
    <link:label id="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_label_en-US" xlink:label="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory And Commercial Milestone Payments Received</link:label>
    <link:label id="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_documentation_en-US" xlink:label="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and commercial milestone payments received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RegulatoryAndCommercialMilestonePaymentsReceived" xlink:href="rcus-20230930.xsd#rcus_RegulatoryAndCommercialMilestonePaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_RegulatoryAndCommercialMilestonePaymentsReceived" xlink:to="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_LiabilityForSaleOfFutureRoyaltiesMember_f363899c-7a38-4014-b23e-474ca5a90c3e_terseLabel_en-US" xlink:label="lab_rcus_LiabilityForSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for sale of future royalties</link:label>
    <link:label id="lab_rcus_LiabilityForSaleOfFutureRoyaltiesMember_label_en-US" xlink:label="lab_rcus_LiabilityForSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Sale of Future Royalties [Member]</link:label>
    <link:label id="lab_rcus_LiabilityForSaleOfFutureRoyaltiesMember_documentation_en-US" xlink:label="lab_rcus_LiabilityForSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LiabilityForSaleOfFutureRoyaltiesMember" xlink:href="rcus-20230930.xsd#rcus_LiabilityForSaleOfFutureRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_LiabilityForSaleOfFutureRoyaltiesMember" xlink:to="lab_rcus_LiabilityForSaleOfFutureRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_09081940-8010-4acb-9595-ade0cb5d7256_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a0eff042-48ed-4d3f-90cc-1018f096e7c1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ecf24c7b-df96-4500-a2fe-389051d85166_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetCurrent_ef84b9ef-8472-44ab-afa6-bfdca8da8749_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, net, current</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetCurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetCurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f88ddf08-d8e9-4d16-9f16-4c099671549c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_26d194a2-865a-40b4-8a42-0e2cb3a7bfdb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4f5aeef1-bb64-403e-9ca8-3fb9626a93fe_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_00c0ab54-2bd9-4cc6-b490-8cf72c5e12cf_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_19ccaebc-fbcf-49e3-959e-35428115dcd1_terseLabel_en-US" xlink:label="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current and future programs exclusive access period</link:label>
    <link:label id="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_label_en-US" xlink:label="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current And Future Programs Exclusive Access Period</link:label>
    <link:label id="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_documentation_en-US" xlink:label="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current and future programs exclusive access period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" xlink:href="rcus-20230930.xsd#rcus_CurrentAndFutureProgramsExclusiveAccessPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" xlink:to="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_2b08a1ed-7436-423a-a2ba-f848c2852bcb_terseLabel_en-US" xlink:label="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement from related party for shared costs</link:label>
    <link:label id="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_label_en-US" xlink:label="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction Reimbursement From Related Party For Shared Costs</link:label>
    <link:label id="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_documentation_en-US" xlink:label="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction reimbursement from related party for shared costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" xlink:href="rcus-20230930.xsd#rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" xlink:to="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9b1563f7-a673-4304-adc9-8590abd70a1f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_68415dbd-c230-4239-b69d-e9bcc6881a02_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_a8a4e9a2-88a7-42e2-a336-281c4f311c20_terseLabel_en-US" xlink:label="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</link:label>
    <link:label id="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_label_en-US" xlink:label="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:label id="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_documentation_en-US" xlink:label="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:href="rcus-20230930.xsd#rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9f51d2cc-3b07-4b1b-b85e-71be96aae60a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_c5d4b44f-d913-4ef2-9dd5-17b23b092b94_terseLabel_en-US" xlink:label="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, regulatory and commercialization milestone payments</link:label>
    <link:label id="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_label_en-US" xlink:label="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Regulatory And Commercialization Milestone Payments</link:label>
    <link:label id="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_documentation_en-US" xlink:label="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical regulatory and commercialization milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" xlink:href="rcus-20230930.xsd#rcus_ClinicalRegulatoryAndCommercializationMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" xlink:to="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_f61224a4-d497-4e48-9c15-7521e0426e7b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue ($96 and $97 to a related party)</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_35a0f294-8c63-4bbb-96d1-c2e5d0038f23_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1d5a372b-2449-47bb-b680-c1930dccbb80_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_9b0f619c-3b97-4d7a-a19f-2f0dff4867b4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c21946bd-31d5-43d9-ac9e-04d96552de4f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_91037f82-11be-475f-a5ad-abedb22fb409_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsTable_c0b764c8-45d9-4bc6-98e0-c49966dc17a0_terseLabel_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsTable_label_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements [Table]</link:label>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsTable_documentation_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsTable" xlink:href="rcus-20230930.xsd#rcus_LicenseAndCollaborationAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable" xlink:to="lab_rcus_LicenseAndCollaborationAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock_9e243deb-2e1e-412b-91fc-03c1d25c8053_terseLabel_en-US" xlink:label="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations</link:label>
    <link:label id="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock_label_en-US" xlink:label="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Transaction Price and Allocated To Transaction Price to Performance Obligations [Table Text Block]</link:label>
    <link:label id="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock_documentation_en-US" xlink:label="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of transaction price and allocated to transaction price to performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" xlink:href="rcus-20230930.xsd#rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" xlink:to="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_060794e4-9e1c-4f09-9cb0-e1f762ba5198_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaborations</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_34eb215e-56b5-47f1-9589-95e934e2c150_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones_e35603ad-a991-494d-bd63-cbe484c3309a_terseLabel_en-US" xlink:label="lab_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payments upon achievement of certain clinical and regulatory milestones</link:label>
    <link:label id="lab_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones_label_en-US" xlink:label="lab_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payments Upon Achievement Of Certain Clinical And Regulatory Milestones</link:label>
    <link:label id="lab_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payments upon achievement of certain clinical and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones" xlink:href="rcus-20230930.xsd#rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones" xlink:to="lab_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_GileadCollaborationAgreementMember_15a3189f-84ec-4914-9808-879c701b6d7c_terseLabel_en-US" xlink:label="lab_rcus_GileadCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Collaboration Agreement</link:label>
    <link:label id="lab_rcus_GileadCollaborationAgreementMember_label_en-US" xlink:label="lab_rcus_GileadCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Collaboration Agreement [Member]</link:label>
    <link:label id="lab_rcus_GileadCollaborationAgreementMember_documentation_en-US" xlink:label="lab_rcus_GileadCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationAgreementMember" xlink:href="rcus-20230930.xsd#rcus_GileadCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_GileadCollaborationAgreementMember" xlink:to="lab_rcus_GileadCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d438f721-cbf0-4a1d-8c87-446fb75b9486_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a33d1f76-65c0-4148-9917-db889c71d716_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c1da5923-6f00-47a8-b909-35f475c4cf28_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties_691b94a7-bfaa-4545-b5a6-0b7cbc4cbe2a_negatedLabel_en-US" xlink:label="lab_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest on liability for sale of future royalties</link:label>
    <link:label id="lab_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties_label_en-US" xlink:label="lab_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Interest on Liability for Sale of Future Royalties</link:label>
    <link:label id="lab_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest on liability for sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties" xlink:href="rcus-20230930.xsd#rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties" xlink:to="lab_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_a34129cb-e445-4fb5-ab6b-ac133341dc49_terseLabel_en-US" xlink:label="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional clinical and regulatory milestone payments receivable</link:label>
    <link:label id="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_label_en-US" xlink:label="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Clinical And Milestone Payments Received Under License Agreement</link:label>
    <link:label id="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional clinical and milestone payments received under license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:href="rcus-20230930.xsd#rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:to="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_NumberOfResearchPrograms_b63c8d2c-a493-4995-b5fc-b78b24a80fa9_terseLabel_en-US" xlink:label="lab_rcus_NumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research programs</link:label>
    <link:label id="lab_rcus_NumberOfResearchPrograms_label_en-US" xlink:label="lab_rcus_NumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Research Programs</link:label>
    <link:label id="lab_rcus_NumberOfResearchPrograms_documentation_en-US" xlink:label="lab_rcus_NumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfResearchPrograms" xlink:href="rcus-20230930.xsd#rcus_NumberOfResearchPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_NumberOfResearchPrograms" xlink:to="lab_rcus_NumberOfResearchPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ef9497b7-58d3-4310-8e8d-9fd3e078e29f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_e05c8dc8-0546-4882-9ece-e77f98ca08c2_terseLabel_en-US" xlink:label="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest And Other Income Expense Nonoperating Net</link:label>
    <link:label id="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_documentation_en-US" xlink:label="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income (expense) nonoperating net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet" xlink:href="rcus-20230930.xsd#rcus_InterestAndOtherIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet" xlink:to="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_TaihoCollaborationAgreementMember_48b2030d-ef36-486b-868d-38c00477ba4a_terseLabel_en-US" xlink:label="lab_rcus_TaihoCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taiho Collaboration Agreement</link:label>
    <link:label id="lab_rcus_TaihoCollaborationAgreementMember_label_en-US" xlink:label="lab_rcus_TaihoCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taiho Collaboration Agreement [Member]</link:label>
    <link:label id="lab_rcus_TaihoCollaborationAgreementMember_documentation_en-US" xlink:label="lab_rcus_TaihoCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taiho Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationAgreementMember" xlink:href="rcus-20230930.xsd#rcus_TaihoCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_TaihoCollaborationAgreementMember" xlink:to="lab_rcus_TaihoCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_7aeb5420-affb-443a-a67f-59186c81f40b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_526526ca-6646-4abc-a44c-12e388b9e2be_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_52a40fec-fd95-4321-8d57-ca8a43c35dc6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AmendedGileadCollaborationAgreementMember_ce804a11-6804-49ad-af6b-e8d52f35861b_terseLabel_en-US" xlink:label="lab_rcus_AmendedGileadCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Gilead Collaboration Agreement</link:label>
    <link:label id="lab_rcus_AmendedGileadCollaborationAgreementMember_label_en-US" xlink:label="lab_rcus_AmendedGileadCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Gilead Collaboration Agreement [Member]</link:label>
    <link:label id="lab_rcus_AmendedGileadCollaborationAgreementMember_documentation_en-US" xlink:label="lab_rcus_AmendedGileadCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended gilead collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AmendedGileadCollaborationAgreementMember" xlink:href="rcus-20230930.xsd#rcus_AmendedGileadCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AmendedGileadCollaborationAgreementMember" xlink:to="lab_rcus_AmendedGileadCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_eeafded9-085a-4e1c-8421-e75cd5a9d60f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_eebccb71-baa7-41e9-b379-135a125a9f1d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash (included in Other noncurrent assets)</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_d7c704dc-dd87-4f9c-ade7-32992c020523_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_90e21d92-b90c-431a-a2e6-965e94600dc2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_c6ffaba1-7b7a-4cdf-9c5f-125b1d4048c2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_2a240fc5-5c70-4c1c-bcf9-a76bd3759297_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_0908707a-23e0-41f9-92e4-4055a75fabbb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from collaboration partners ($17 and $718 from a related party)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_64864ed7-6b3e-4984-9839-3e67f3f8d9ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from collaboration partners</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4fa0be0c-cd3f-4678-92dc-f328bd549bf9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a9526f7c-18e1-474d-b5bb-604f5e1ee48c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bb946433-d7c0-474c-b062-405919bf6926_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_3738bb83-4205-4ad9-ac88-cc0189c8ed70_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ExtendedLockupPeriod_ed82bdd8-e281-4800-9b7e-5cb3b5122bb8_terseLabel_en-US" xlink:label="lab_rcus_ExtendedLockupPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended lockup period</link:label>
    <link:label id="lab_rcus_ExtendedLockupPeriod_label_en-US" xlink:label="lab_rcus_ExtendedLockupPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Lockup Period</link:label>
    <link:label id="lab_rcus_ExtendedLockupPeriod_documentation_en-US" xlink:label="lab_rcus_ExtendedLockupPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended lockup period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ExtendedLockupPeriod" xlink:href="rcus-20230930.xsd#rcus_ExtendedLockupPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ExtendedLockupPeriod" xlink:to="lab_rcus_ExtendedLockupPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_1b919a30-23bc-4ae7-9ad8-bb2d49960144_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_37e31b48-c781-47fb-822f-82f191154791_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32bf7b31-c30f-4086-a8a2-cba4e2f08777_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1cdfaba2-1920-4c8b-b132-f1e3331fe7aa_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_df8ac277-5be9-49d3-867f-cacd70c9445a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember_2157e663-3318-4ae9-9472-1059db5eed6c_terseLabel_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Activities for Domvanalimab</link:label>
    <link:label id="lab_rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember_label_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Activities For Domvanalimab [Member]</link:label>
    <link:label id="lab_rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember_documentation_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development activities for domvanalimab.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember" xlink:href="rcus-20230930.xsd#rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember" xlink:to="lab_rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_5db11e4e-5340-4d62-af67-fde896bba73c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_31781a67-7b2a-4f83-94c8-eb73e14f4ffc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b09c2f62-f4dd-473e-bf85-7fdf11cf8b86_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_ba8cf89f-1379-4c0b-8322-c75b3b7ab786_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_72d28eeb-dcec-476f-be31-80ca04eef210_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_5706cd69-8f4a-4cbb-a26d-d2734142c5a2_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_7d1d1c36-ffd9-4ebb-b925-fbe414965637_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a18c68ff-0023-4e89-9175-6b2e9962a789_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4f97bbbf-94b2-4b81-995e-11302fd7edda_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ContingentMilestonePaymentsReceivable_30ae32f9-c690-4f3e-bdb8-daa3f75911d9_terseLabel_en-US" xlink:label="lab_rcus_ContingentMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent milestone payments receivable</link:label>
    <link:label id="lab_rcus_ContingentMilestonePaymentsReceivable_label_en-US" xlink:label="lab_rcus_ContingentMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Milestone Payments Receivable</link:label>
    <link:label id="lab_rcus_ContingentMilestonePaymentsReceivable_documentation_en-US" xlink:label="lab_rcus_ContingentMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent milestone payments receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContingentMilestonePaymentsReceivable" xlink:href="rcus-20230930.xsd#rcus_ContingentMilestonePaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ContingentMilestonePaymentsReceivable" xlink:to="lab_rcus_ContingentMilestonePaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5bd1386f-2679-48b6-9ad1-5c601db650cf_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2d9c7daf-0053-4915-b6e0-b459af68d2fe_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3215a2f2-f4c7-450c-98c2-e344a1eb41bc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_e799046e-f08e-4347-b44a-7d709a26536d_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_de991102-a20d-4bef-8b2a-e65ba5e8bc2a_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits for letters of credit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f7eabba8-3dbc-4aba-acad-f907ef1980dc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_8f4f4906-3605-4d71-b8b4-4126e88c947a_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability_aac6dafb-4da2-49e5-92be-fd3660e0bbbb_terseLabel_en-US" xlink:label="lab_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed effective rate of interest on unamortized portion of liability</link:label>
    <link:label id="lab_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability_label_en-US" xlink:label="lab_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed Effective Rate of Interest on Unamortized Portion of Liability</link:label>
    <link:label id="lab_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability_documentation_en-US" xlink:label="lab_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed effective rate of interest on unamortized portion of liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability" xlink:href="rcus-20230930.xsd#rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability" xlink:to="lab_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cd345811-fe83-4dca-b3c8-733309978bb4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_79b83820-4353-4f14-bcb3-4966ebd9d227_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_8c38dd3c-3c53-4031-ba6d-e4b7268e012a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f8cd3f8a-1242-44d1-997f-2fb38a11b15b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2a514880-3d8c-48a9-887e-b571d04e5e93_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_84f36c1b-7da7-4fd6-aa62-b3aa386256bd_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fd35b8c8-f960-4304-bfaa-63731b0a698a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion_cce27dfa-7280-454a-bc6a-bf85784e4931_terseLabel_en-US" xlink:label="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest accretion</link:label>
    <link:label id="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion_label_en-US" xlink:label="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Liability for Sale of Future Royalties Interest Accretion</link:label>
    <link:label id="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion_documentation_en-US" xlink:label="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in liability for sale of future royalties interest accretion.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion" xlink:href="rcus-20230930.xsd#rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion" xlink:to="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_WuXiBiologicsLicenseAgreementMember_fb53b833-d0e3-42fc-a016-ce6ac5a1c89b_terseLabel_en-US" xlink:label="lab_rcus_WuXiBiologicsLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WuXi Biologics License Agreement</link:label>
    <link:label id="lab_rcus_WuXiBiologicsLicenseAgreementMember_label_en-US" xlink:label="lab_rcus_WuXiBiologicsLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wu Xi Biologics License Agreement [Member]</link:label>
    <link:label id="lab_rcus_WuXiBiologicsLicenseAgreementMember_documentation_en-US" xlink:label="lab_rcus_WuXiBiologicsLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WuXi Biologics license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_WuXiBiologicsLicenseAgreementMember" xlink:href="rcus-20230930.xsd#rcus_WuXiBiologicsLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_WuXiBiologicsLicenseAgreementMember" xlink:to="lab_rcus_WuXiBiologicsLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember_0de73f8a-1176-47ee-b393-03f9f07b59c9_terseLabel_en-US" xlink:label="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Rights and Option Continuation Periods</link:label>
    <link:label id="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember_label_en-US" xlink:label="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Rights and Option Continuation Periods [Member]</link:label>
    <link:label id="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember_documentation_en-US" xlink:label="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access rights and option continuation periods.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember" xlink:href="rcus-20230930.xsd#rcus_AccessRightsAndOptionContinuationPeriodsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember" xlink:to="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_15df9f0e-9470-4185-8fec-7916ed045a0d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities_3f8ba496-3c02-4df2-af26-49e7f44e18c4_terseLabel_en-US" xlink:label="lab_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option payment upon completion of certain IND-enabling activities</link:label>
    <link:label id="lab_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities_label_en-US" xlink:label="lab_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Payment Upon Completion of certain IND-enabling Activities</link:label>
    <link:label id="lab_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities_documentation_en-US" xlink:label="lab_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option payment upon completion of certain IND-enabling activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities" xlink:href="rcus-20230930.xsd#rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities" xlink:to="lab_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_337413d3-dbf4-4c4f-ac28-35c41e1d7bca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3895192b-daa3-4ad8-a8ea-f563e005e30d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_05e83dfc-fc3c-4bd7-8ab8-d703da56d111_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_eaa6bddf-eba8-48a0-8657-ebbcbf244611_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_NonRefundableAndNonCreditableCashPayments_d2ed9d9f-d864-4577-8c0a-22874a5ede46_terseLabel_en-US" xlink:label="lab_rcus_NonRefundableAndNonCreditableCashPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non refundable and non creditable cash payments</link:label>
    <link:label id="lab_rcus_NonRefundableAndNonCreditableCashPayments_label_en-US" xlink:label="lab_rcus_NonRefundableAndNonCreditableCashPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Refundable And Non Creditable Cash Payments</link:label>
    <link:label id="lab_rcus_NonRefundableAndNonCreditableCashPayments_documentation_en-US" xlink:label="lab_rcus_NonRefundableAndNonCreditableCashPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non refundable and non creditable cash payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NonRefundableAndNonCreditableCashPayments" xlink:href="rcus-20230930.xsd#rcus_NonRefundableAndNonCreditableCashPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_NonRefundableAndNonCreditableCashPayments" xlink:to="lab_rcus_NonRefundableAndNonCreditableCashPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived_b452f154-e379-488a-9fc2-93e89f62dd34_terseLabel_en-US" xlink:label="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received</link:label>
    <link:label id="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived_label_en-US" xlink:label="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Liability for Sale of Future Royalties Cash Received</link:label>
    <link:label id="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived_documentation_en-US" xlink:label="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in liability for sale of future royalties cash received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived" xlink:href="rcus-20230930.xsd#rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived" xlink:to="lab_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_1bd82c1b-830b-48a2-920b-9b1aa3e079fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions in securities in unrealized loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_64d19d93-48cb-4988-aaf3-a2a9bce0dcdb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98a61d7b-816f-4114-bd21-c30a3eb04b8f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_9e5d6006-148e-42c8-a56e-38fe19f460ad_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7d12971-5298-4e1b-8e12-46a866be2622_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b0f80333-ec57-4b65-8da0-7c5d7a7ca038_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_34ee19d9-827e-4d9b-8308-434e7fc7f6a2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, noncurrent ($309 and $355 to a related party)</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7aa94765-f6e5-4061-b1ba-c8fa817ec956_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_MilestoneExpense_2e76a02d-df05-4ced-a74f-bcf5b4cdb992_terseLabel_en-US" xlink:label="lab_rcus_MilestoneExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone expense</link:label>
    <link:label id="lab_rcus_MilestoneExpense_label_en-US" xlink:label="lab_rcus_MilestoneExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Expense</link:label>
    <link:label id="lab_rcus_MilestoneExpense_documentation_en-US" xlink:label="lab_rcus_MilestoneExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_MilestoneExpense" xlink:href="rcus-20230930.xsd#rcus_MilestoneExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_MilestoneExpense" xlink:to="lab_rcus_MilestoneExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_2bde9eb3-3a09-442b-990b-c6258ca2970f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_5f1f3485-81e6-4f1b-a840-4c9e9ee17f77_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_67c95bab-595e-4be3-b150-ebbeed154266_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3a2cd787-2598-4607-95ca-eb430f45ac39_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ef4dd940-5f37-42fe-a04e-7cd463086f55_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 74.8 shares in 2023 and 72.9 shares in 2022 issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_cc2e37dd-5dff-4d20-a47f-24bd75db8166_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_NumberOfExerciseOptionToPrograms_551d8407-c846-473a-a56a-bcc4617b4bac_terseLabel_en-US" xlink:label="lab_rcus_NumberOfExerciseOptionToPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of exercise option to programs</link:label>
    <link:label id="lab_rcus_NumberOfExerciseOptionToPrograms_label_en-US" xlink:label="lab_rcus_NumberOfExerciseOptionToPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Exercise Option to Programs</link:label>
    <link:label id="lab_rcus_NumberOfExerciseOptionToPrograms_documentation_en-US" xlink:label="lab_rcus_NumberOfExerciseOptionToPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of exercise option to programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfExerciseOptionToPrograms" xlink:href="rcus-20230930.xsd#rcus_NumberOfExerciseOptionToPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_NumberOfExerciseOptionToPrograms" xlink:to="lab_rcus_NumberOfExerciseOptionToPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88a8c7b5-bbbc-4416-bec3-0a7b58f5ac69_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c30c683b-347f-45a4-a47c-eeb40a421a17_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_1f661ab2-72cd-4ce4-9aac-166f370542f7_terseLabel_en-US" xlink:label="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option continuation payment receivable upon sixth anniversary of agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_label_en-US" xlink:label="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Continuation Payment Receivable Upon Sixth Anniversary Of Agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_documentation_en-US" xlink:label="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option continuation payment receivable upon sixth anniversary of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" xlink:href="rcus-20230930.xsd#rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" xlink:to="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_PaymentForOptionExercise_965317ec-8c99-4d38-ad51-b0201a81af67_terseLabel_en-US" xlink:label="lab_rcus_PaymentForOptionExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for option exercise</link:label>
    <link:label id="lab_rcus_PaymentForOptionExercise_label_en-US" xlink:label="lab_rcus_PaymentForOptionExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Option Exercise</link:label>
    <link:label id="lab_rcus_PaymentForOptionExercise_documentation_en-US" xlink:label="lab_rcus_PaymentForOptionExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for option exercise.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PaymentForOptionExercise" xlink:href="rcus-20230930.xsd#rcus_PaymentForOptionExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_PaymentForOptionExercise" xlink:to="lab_rcus_PaymentForOptionExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_bb97f251-d1dc-4a9b-9ce2-f30ce274a5f6_terseLabel_en-US" xlink:label="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration term for current and future clinical programs</link:label>
    <link:label id="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_label_en-US" xlink:label="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Term For Current And Future Clinical Programs</link:label>
    <link:label id="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_documentation_en-US" xlink:label="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration term for current and future clinical programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" xlink:href="rcus-20230930.xsd#rcus_CollaborationTermForCurrentAndFutureClinicalPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" xlink:to="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_bcce8a2a-33ca-4a4c-8d41-6cb165d2a2d4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_4816a790-0866-47ca-b691-9072d0915e02_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_2d2420dd-29f0-45a3-bd68-5ee52079bb2b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_cb42fdf7-7a2b-4d7a-bb0b-93b917bbb797_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_401c59a9-76f8-4bb8-93b5-65460305323c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_0fd51e2f-831e-42af-9832-cc017a9eed03_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_35136636-5cbf-4270-9777-87e022dd912b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_bac74866-c6fe-4265-b6d3-e3d6ac95efb8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f8d64961-9d43-4f8d-a86a-f931215860e8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_eeb54553-934c-4bcb-80a2-9609a99b253c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_75bd0882-7f65-4208-b782-000f2ff19a02_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Prepaid and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f62cd129-a888-4884-a102-d52c0f23b960_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AtTheMarketFacilityMember_76ae372a-27ea-42c7-93ae-4b72a612426f_terseLabel_en-US" xlink:label="lab_rcus_AtTheMarketFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-Market Facility</link:label>
    <link:label id="lab_rcus_AtTheMarketFacilityMember_label_en-US" xlink:label="lab_rcus_AtTheMarketFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-Market Facility [Member]</link:label>
    <link:label id="lab_rcus_AtTheMarketFacilityMember_documentation_en-US" xlink:label="lab_rcus_AtTheMarketFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-Market Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AtTheMarketFacilityMember" xlink:href="rcus-20230930.xsd#rcus_AtTheMarketFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AtTheMarketFacilityMember" xlink:to="lab_rcus_AtTheMarketFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_36e1d430-04e6-4255-98ab-5c9c62477b9f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_5999fea2-4b17-4ce5-9c19-01957c152202_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Liquidity, and Capital Resources</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AntiCDThirtyNineMember_3e3cb1f3-224c-4ee0-9a18-cb022d2dc37f_terseLabel_en-US" xlink:label="lab_rcus_AntiCDThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">anti-CD39</link:label>
    <link:label id="lab_rcus_AntiCDThirtyNineMember_label_en-US" xlink:label="lab_rcus_AntiCDThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti C D Thirty Nine [Member]</link:label>
    <link:label id="lab_rcus_AntiCDThirtyNineMember_documentation_en-US" xlink:label="lab_rcus_AntiCDThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti CD thirty nine.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AntiCDThirtyNineMember" xlink:href="rcus-20230930.xsd#rcus_AntiCDThirtyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AntiCDThirtyNineMember" xlink:to="lab_rcus_AntiCDThirtyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_d3a498de-c86a-467b-9c7e-ca2510bd80c4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0734b2ba-7633-45e9-a4f1-02328cd9b849_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_35e8e772-64b3-412f-ba8a-8ca3d9474db6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_548bd42d-bb4c-4e8e-8716-24f482988e6c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueRevenueRecognized1_ca31b380-cf8b-4923-8f01-9edf2a2b8076_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue recognized</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueRevenueRecognized1_fb248a25-7177-4c5a-8955-81f0bcc4aff8_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts included in deferred revenue at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueRevenueRecognized1_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="lab_us-gaap_DeferredRevenueRevenueRecognized1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_e8f3c3db-ee4a-4cae-9b81-701eb8b9b544_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AmendedInvestorRightsAgreementMember_0867d32a-68ff-4cbf-8fac-bb64de819ef2_terseLabel_en-US" xlink:label="lab_rcus_AmendedInvestorRightsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Investor Rights Agreement</link:label>
    <link:label id="lab_rcus_AmendedInvestorRightsAgreementMember_label_en-US" xlink:label="lab_rcus_AmendedInvestorRightsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Investor Rights Agreement [Member]</link:label>
    <link:label id="lab_rcus_AmendedInvestorRightsAgreementMember_documentation_en-US" xlink:label="lab_rcus_AmendedInvestorRightsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Investor Rights Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AmendedInvestorRightsAgreementMember" xlink:href="rcus-20230930.xsd#rcus_AmendedInvestorRightsAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AmendedInvestorRightsAgreementMember" xlink:to="lab_rcus_AmendedInvestorRightsAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4671ad65-5b09-4aef-80b9-5227123f48b8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_1387960f-675d-405c-8866-3e960168556a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_421bf99e-bb01-4fa4-b0ac-ac03a0f1eab9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d60041d8-d3d6-41ac-ac1a-e15f8d00d134_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AbmunoLicenseAgreementMember_09d7bafd-711a-4399-9628-1a96a4e4d565_terseLabel_en-US" xlink:label="lab_rcus_AbmunoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abmuno License Agreement</link:label>
    <link:label id="lab_rcus_AbmunoLicenseAgreementMember_label_en-US" xlink:label="lab_rcus_AbmunoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abmuno License Agreement [Member]</link:label>
    <link:label id="lab_rcus_AbmunoLicenseAgreementMember_documentation_en-US" xlink:label="lab_rcus_AbmunoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abmuno license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AbmunoLicenseAgreementMember" xlink:href="rcus-20230930.xsd#rcus_AbmunoLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AbmunoLicenseAgreementMember" xlink:to="lab_rcus_AbmunoLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_29304ab6-9ba6-4582-b6bb-0d0cfbce867d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_867d65d5-45d9-4c77-8f9d-165b48ae31d7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6314fcb4-4e3d-4fb2-ac98-7d10f6017435_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9952fa71-e3d5-42c4-bc35-bbbec22c742b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_5fe13fc6-7337-468b-a4e3-823a5559dda2_terseLabel_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Activities for Inflammation Programs</link:label>
    <link:label id="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_label_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Activities For Inflammation Programs [Member]</link:label>
    <link:label id="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_documentation_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development activities for inflammation programs member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" xlink:href="rcus-20230930.xsd#rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" xlink:to="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_PercentageOfPremiumPurchasePriceOfCommonStock_54b7507b-978c-4b61-bca3-ad9f08994591_terseLabel_en-US" xlink:label="lab_rcus_PercentageOfPremiumPurchasePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of premium purchase price of common stock</link:label>
    <link:label id="lab_rcus_PercentageOfPremiumPurchasePriceOfCommonStock_label_en-US" xlink:label="lab_rcus_PercentageOfPremiumPurchasePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Premium Purchase Price Of Common Stock</link:label>
    <link:label id="lab_rcus_PercentageOfPremiumPurchasePriceOfCommonStock_documentation_en-US" xlink:label="lab_rcus_PercentageOfPremiumPurchasePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of premium purchase price of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PercentageOfPremiumPurchasePriceOfCommonStock" xlink:href="rcus-20230930.xsd#rcus_PercentageOfPremiumPurchasePriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_PercentageOfPremiumPurchasePriceOfCommonStock" xlink:to="lab_rcus_PercentageOfPremiumPurchasePriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ProceedsFromSaleOfMarketableSecurities_912868a4-6c1b-4088-9561-c459e12c2f4b_terseLabel_en-US" xlink:label="lab_rcus_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable securities</link:label>
    <link:label id="lab_rcus_ProceedsFromSaleOfMarketableSecurities_label_en-US" xlink:label="lab_rcus_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale of Marketable Securities</link:label>
    <link:label id="lab_rcus_ProceedsFromSaleOfMarketableSecurities_documentation_en-US" xlink:label="lab_rcus_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromSaleOfMarketableSecurities" xlink:href="rcus-20230930.xsd#rcus_ProceedsFromSaleOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ProceedsFromSaleOfMarketableSecurities" xlink:to="lab_rcus_ProceedsFromSaleOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_89159f4d-7249-4aae-b7e4-d7f953bfd7ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_GileadSciencesIncMember_4a372154-5945-4ed0-8657-5e28286e573c_terseLabel_en-US" xlink:label="lab_rcus_GileadSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead</link:label>
    <link:label id="lab_rcus_GileadSciencesIncMember_label_en-US" xlink:label="lab_rcus_GileadSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences Inc [Member]</link:label>
    <link:label id="lab_rcus_GileadSciencesIncMember_documentation_en-US" xlink:label="lab_rcus_GileadSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember" xlink:href="rcus-20230930.xsd#rcus_GileadSciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_GileadSciencesIncMember" xlink:to="lab_rcus_GileadSciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a2aba737-6efe-41eb-8676-db680088b6bb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ebc19688-6184-4e72-8c9c-d0fbd37766ce_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_96a2564a-efab-4493-91ff-8e6ff97244da_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options issued and outstanding</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_453910a3-357f-44f5-98b2-1d37574e38b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c82626ff-54ce-4a8b-8c65-dbd5da74a6fe_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock_d1b4a0c2-fc29-4ba2-b5c7-394077e1b790_terseLabel_en-US" xlink:label="lab_rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes of Liabilities for Sale of Future Royalties</link:label>
    <link:label id="lab_rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock_label_en-US" xlink:label="lab_rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes Of Liabilities for Sale of Future Royalties [Table Text Block]</link:label>
    <link:label id="lab_rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock_documentation_en-US" xlink:label="lab_rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of changes of liabilities for sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock" xlink:href="rcus-20230930.xsd#rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock" xlink:to="lab_rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e5814e70-032b-4072-8e78-cfc0e8d65e2a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1b7c24c1-3a6c-41df-a5a6-0f5bdbc9eb62_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bcf4077c-6989-48da-b91e-97918a7aba9c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_SaleOfStockAuthorizedConsiderationOnTransaction_efd1b9c8-81ec-4dc4-8bde-74fc0cc7852b_terseLabel_en-US" xlink:label="lab_rcus_SaleOfStockAuthorizedConsiderationOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock authorized consideration on transaction</link:label>
    <link:label id="lab_rcus_SaleOfStockAuthorizedConsiderationOnTransaction_label_en-US" xlink:label="lab_rcus_SaleOfStockAuthorizedConsiderationOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Authorized Consideration On Transaction</link:label>
    <link:label id="lab_rcus_SaleOfStockAuthorizedConsiderationOnTransaction_documentation_en-US" xlink:label="lab_rcus_SaleOfStockAuthorizedConsiderationOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Authorized Consideration On Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SaleOfStockAuthorizedConsiderationOnTransaction" xlink:href="rcus-20230930.xsd#rcus_SaleOfStockAuthorizedConsiderationOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_SaleOfStockAuthorizedConsiderationOnTransaction" xlink:to="lab_rcus_SaleOfStockAuthorizedConsiderationOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_80eed93e-d8f9-4b45-aaa8-b05f0560fe6e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_4b404bd2-5119-42a7-8f46-88bfe2d02309_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3ba3b850-2d15-4080-b15c-2696df76f5c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_InflammationTarget2Member_c93579fe-6487-43f4-b46a-91e8fe3932e3_terseLabel_en-US" xlink:label="lab_rcus_InflammationTarget2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflammation target 2</link:label>
    <link:label id="lab_rcus_InflammationTarget2Member_label_en-US" xlink:label="lab_rcus_InflammationTarget2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflammation Target 2 [Member]</link:label>
    <link:label id="lab_rcus_InflammationTarget2Member_documentation_en-US" xlink:label="lab_rcus_InflammationTarget2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflammation target 2 member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InflammationTarget2Member" xlink:href="rcus-20230930.xsd#rcus_InflammationTarget2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_InflammationTarget2Member" xlink:to="lab_rcus_InflammationTarget2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_GileadCollaborationAccessRightsMember_a04657d5-56d0-48b0-b1c1-b2bf1147f81c_terseLabel_en-US" xlink:label="lab_rcus_GileadCollaborationAccessRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access rights</link:label>
    <link:label id="lab_rcus_GileadCollaborationAccessRightsMember_label_en-US" xlink:label="lab_rcus_GileadCollaborationAccessRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Collaboration, Access Rights [Member]</link:label>
    <link:label id="lab_rcus_GileadCollaborationAccessRightsMember_documentation_en-US" xlink:label="lab_rcus_GileadCollaborationAccessRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead collaboration, access rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationAccessRightsMember" xlink:href="rcus-20230930.xsd#rcus_GileadCollaborationAccessRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_GileadCollaborationAccessRightsMember" xlink:to="lab_rcus_GileadCollaborationAccessRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_11b8c51d-e0b3-4204-9d2b-670255971e14_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_8c01c666-f2a1-4f31-a4f2-2b1cdd0d1142_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c5413b2f-f97b-40fb-82f3-16d4c5205222_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionPeriod_891a5cf0-5f15-4383-a907-d95832b16a68_terseLabel_en-US" xlink:label="lab_rcus_OptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option period</link:label>
    <link:label id="lab_rcus_OptionPeriod_label_en-US" xlink:label="lab_rcus_OptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Period</link:label>
    <link:label id="lab_rcus_OptionPeriod_documentation_en-US" xlink:label="lab_rcus_OptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPeriod" xlink:href="rcus-20230930.xsd#rcus_OptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionPeriod" xlink:to="lab_rcus_OptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_94a61653-d2a2-4216-96d4-d2d23adcb527_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_718cb70a-850f-4a5a-9119-91d8b7b9ebeb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6de9a5ef-ba3a-4a3c-bafd-df37f46932aa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_f277fc3c-b464-4c7b-9ebf-1df9e62d3932_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_d327354b-045b-4ea2-98ab-8a44f4d7249c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_40d588a6-37e4-4a93-a0e2-169213dd515c_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_89ae7fc2-0c78-4282-9435-975242307703_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2ddc29e-ee76-4adc-b142-450fa1c43c8b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_4f1edc79-571e-48b2-bd2b-214167eff833_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6e274a93-7464-44f4-9075-4bca78b7b451_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d7e5064c-1897-47fe-8b43-452a5e10e40a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ResearchAndDevelopmentExpenseRecoveries_26f85d03-7c4d-408c-ab87-c7138bb7920b_terseLabel_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentExpenseRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense, net of recoveries</link:label>
    <link:label id="lab_rcus_ResearchAndDevelopmentExpenseRecoveries_label_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentExpenseRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Recoveries</link:label>
    <link:label id="lab_rcus_ResearchAndDevelopmentExpenseRecoveries_documentation_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentExpenseRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentExpenseRecoveries" xlink:href="rcus-20230930.xsd#rcus_ResearchAndDevelopmentExpenseRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ResearchAndDevelopmentExpenseRecoveries" xlink:to="lab_rcus_ResearchAndDevelopmentExpenseRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d8be7f01-a028-45e6-8d97-38d528c15bfe_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums (discounts) on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_186b69c8-336a-4fd6-a732-6a29ec1ce139_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5b812539-b300-4278-b195-05391f068306_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_16db50b4-4033-4094-a9fe-aa2b57742d75_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets ($6 and $2 from a related party)</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1eba2df3-19f8-4812-bbbd-9c09e03b8d3e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9642fcca-8ee3-423a-ab90-75c805085a4c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ba911bbc-59f5-4884-bfaf-f27eadeaf510_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_f419f9cb-f5e0-4ab0-8bfa-e2a9c018bffa_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_PercentageOfOutstandingCommonStockOwned_100b0869-90c6-406c-b884-58661be0418c_terseLabel_en-US" xlink:label="lab_rcus_PercentageOfOutstandingCommonStockOwned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding common stock held</link:label>
    <link:label id="lab_rcus_PercentageOfOutstandingCommonStockOwned_label_en-US" xlink:label="lab_rcus_PercentageOfOutstandingCommonStockOwned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Outstanding Common Stock Owned</link:label>
    <link:label id="lab_rcus_PercentageOfOutstandingCommonStockOwned_documentation_en-US" xlink:label="lab_rcus_PercentageOfOutstandingCommonStockOwned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding common stock owned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PercentageOfOutstandingCommonStockOwned" xlink:href="rcus-20230930.xsd#rcus_PercentageOfOutstandingCommonStockOwned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_PercentageOfOutstandingCommonStockOwned" xlink:to="lab_rcus_PercentageOfOutstandingCommonStockOwned" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember_dfb43af4-5768-4d3c-9b05-9d3690f781f5_terseLabel_en-US" xlink:label="lab_rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quemliclustat, License and R&amp;D services</link:label>
    <link:label id="lab_rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember_label_en-US" xlink:label="lab_rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quemliclustat License And Research And Development Services Agreement [Member]</link:label>
    <link:label id="lab_rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember_documentation_en-US" xlink:label="lab_rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quemliclustat license and research and development services agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember" xlink:href="rcus-20230930.xsd#rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember" xlink:to="lab_rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_RecognitionOfTenantImprovementAllowanceReceivable_41d92325-3ef4-494f-bc0e-c65f05d16f37_terseLabel_en-US" xlink:label="lab_rcus_RecognitionOfTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of tenant improvement allowance receivable included in Other current liabilities</link:label>
    <link:label id="lab_rcus_RecognitionOfTenantImprovementAllowanceReceivable_label_en-US" xlink:label="lab_rcus_RecognitionOfTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of Tenant Improvement Allowance Receivable</link:label>
    <link:label id="lab_rcus_RecognitionOfTenantImprovementAllowanceReceivable_documentation_en-US" xlink:label="lab_rcus_RecognitionOfTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of tenant improvement allowance receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RecognitionOfTenantImprovementAllowanceReceivable" xlink:href="rcus-20230930.xsd#rcus_RecognitionOfTenantImprovementAllowanceReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_RecognitionOfTenantImprovementAllowanceReceivable" xlink:to="lab_rcus_RecognitionOfTenantImprovementAllowanceReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a37fab47-ddef-4d64-afd2-6c4c6091b423_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_e9bfd5e8-3ba0-4d47-a3c2-77fd6cbfbb63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_a0ddd534-16eb-4363-ab72-cedc0fb9f5de_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_0170a7df-c011-4dee-af77-1acedeb22254_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Consolidated Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_710062f7-f8b3-4db5-881b-c50940fcdefc_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OtherCollaborationRevenueMember_5d270a10-08df-4306-bc83-fc88a0626233_terseLabel_en-US" xlink:label="lab_rcus_OtherCollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Revenue</link:label>
    <link:label id="lab_rcus_OtherCollaborationRevenueMember_label_en-US" xlink:label="lab_rcus_OtherCollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Revenue [Member]</link:label>
    <link:label id="lab_rcus_OtherCollaborationRevenueMember_documentation_en-US" xlink:label="lab_rcus_OtherCollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherCollaborationRevenueMember" xlink:href="rcus-20230930.xsd#rcus_OtherCollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OtherCollaborationRevenueMember" xlink:to="lab_rcus_OtherCollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d1bdff9e-8f0d-4ac0-9b63-d2b1d9430e7e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f138dc81-e670-4189-8357-62bbc9ce1f1d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b9e106ff-b4a1-4859-9b85-e29e20c43f52_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_EquityAwardProgramsMember_0f93c004-d246-4e28-be6b-50e91e090972_terseLabel_en-US" xlink:label="lab_rcus_EquityAwardProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award Programs</link:label>
    <link:label id="lab_rcus_EquityAwardProgramsMember_label_en-US" xlink:label="lab_rcus_EquityAwardProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award Programs [Member]</link:label>
    <link:label id="lab_rcus_EquityAwardProgramsMember_documentation_en-US" xlink:label="lab_rcus_EquityAwardProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award Programs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EquityAwardProgramsMember" xlink:href="rcus-20230930.xsd#rcus_EquityAwardProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_EquityAwardProgramsMember" xlink:to="lab_rcus_EquityAwardProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d40b640c-717b-402a-91cf-5c177d52894e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_38ac296d-0679-4698-bec4-9fe0af11a80e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OrganizationTable_1f53867c-e688-457f-8219-17e719faa057_terseLabel_en-US" xlink:label="lab_rcus_OrganizationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization [Table]</link:label>
    <link:label id="lab_rcus_OrganizationTable_label_en-US" xlink:label="lab_rcus_OrganizationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization [Table]</link:label>
    <link:label id="lab_rcus_OrganizationTable_documentation_en-US" xlink:label="lab_rcus_OrganizationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OrganizationTable" xlink:href="rcus-20230930.xsd#rcus_OrganizationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OrganizationTable" xlink:to="lab_rcus_OrganizationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_98ba3b7d-1457-4d06-8b7b-69d2e34f4563_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_17286b7e-6f54-4d03-be81-f4aaf5284275_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_b45dc574-cb91-4a1f-b216-04181fcfdf25_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ee87bcfc-e0be-45a1-8deb-7799029b8e7d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_ba6a5619-f1b1-480c-bb0c-c6e10d29eed8_terseLabel_en-US" xlink:label="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential regulatory approval milestones payment receivable related to domvanalimab</link:label>
    <link:label id="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_label_en-US" xlink:label="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Regulatory Approval Milestones Payment Receivable Related To Domvanalimab</link:label>
    <link:label id="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_documentation_en-US" xlink:label="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential regulatory approval milestones payment receivable related to domvanalimab.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" xlink:href="rcus-20230930.xsd#rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" xlink:to="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CommonStockPurchaseAgreementMember_23a3b9ec-9894-436d-841f-9e89951d2e92_terseLabel_en-US" xlink:label="lab_rcus_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_rcus_CommonStockPurchaseAgreementMember_label_en-US" xlink:label="lab_rcus_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_rcus_CommonStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_rcus_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CommonStockPurchaseAgreementMember" xlink:href="rcus-20230930.xsd#rcus_CommonStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CommonStockPurchaseAgreementMember" xlink:to="lab_rcus_CommonStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_905d2096-a253-4234-bad2-d2856033141e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c37cb360-75fd-4e73-a94d-28eb0f3ceaba_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2ce9415d-bad0-4219-baaa-9f1cf75bbf7c_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_NonRefundablePaymentsReceived_5657966c-cefd-472b-8b1e-468b4a15c4ad_terseLabel_en-US" xlink:label="lab_rcus_NonRefundablePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable payments received</link:label>
    <link:label id="lab_rcus_NonRefundablePaymentsReceived_label_en-US" xlink:label="lab_rcus_NonRefundablePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable Payments Received</link:label>
    <link:label id="lab_rcus_NonRefundablePaymentsReceived_documentation_en-US" xlink:label="lab_rcus_NonRefundablePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable payments received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NonRefundablePaymentsReceived" xlink:href="rcus-20230930.xsd#rcus_NonRefundablePaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_NonRefundablePaymentsReceived" xlink:to="lab_rcus_NonRefundablePaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_0f108b25-dc75-41b0-bc28-412ea050e9a5_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average closing price of our common stock on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_3613599b-8ccb-40d3-bba1-877d891fa9d4_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3561f7a5-4f21-42f3-8c45-f77a4f676221_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_28ea6865-42db-49eb-894f-8af198223231_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_44ec3782-b629-4c9c-b552-cf6aaa21674f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d84a8954-0745-4c82-8998-1be4457c26c8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember_c423d22e-aafc-4b6e-a36a-5b94cde8d9d8_terseLabel_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D and Commercialization Activities for Zimberelimab</link:label>
    <link:label id="lab_rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember_label_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development and commercialization activities for Zimberelimab [Member]</link:label>
    <link:label id="lab_rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember_documentation_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development and commercialization activities for zimberelimab.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember" xlink:href="rcus-20230930.xsd#rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember" xlink:to="lab_rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_9946b626-4833-4375-965b-382cd69fa698_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d3a93055-a900-4e3b-8fc0-8d9b3fd9a583_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9c2761a8-19a1-4221-b59b-5a837378a212_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0a5361c4-c02e-4ed0-99c6-8c333095370d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_ba5fc487-1cbd-4d78-a00b-7c4ace2d2d2e_totalLabel_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and marketable securities</link:label>
    <link:label id="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_label_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Available For Sale Investments</link:label>
    <link:label id="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_documentation_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and available for sale investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:href="rcus-20230930.xsd#rcus_CashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_41dffe4c-7b78-4afb-aea1-a0e316fb5805_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued personnel expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5d52480b-fc98-448f-b4c0-d58765691612_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_07f8f684-7afe-4509-9f30-def77fb563c8_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_dca1bfeb-f843-46c2-ac03-93f984a3d2ca_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation_a699fcaa-541a-4d54-8042-76de8817e00e_terseLabel_en-US" xlink:label="lab_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock allocation to performance obligation</link:label>
    <link:label id="lab_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation_label_en-US" xlink:label="lab_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Determined To Premium On Purchase Of Common Stock And Allocated To Performance Obligation</link:label>
    <link:label id="lab_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation_documentation_en-US" xlink:label="lab_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period value determined to premium on purchase of common stock and allocated to performance obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation" xlink:href="rcus-20230930.xsd#rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation" xlink:to="lab_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_164885d2-3b46-424d-a33f-af2c778e5efb_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit related losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_label_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Loss, Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:to="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_985b1ed7-0060-4650-a6b7-0c3ac0e0e520_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_bc9efd97-a318-42f6-98f3-5569a66d15fc_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_46b99fa7-8190-4aa5-b5d4-ab408a1e4133_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, net, noncurrent</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_fc71234c-3c68-435a-afed-133454d5067b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2a021998-cf6f-49d4-a953-46733032b162_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock share value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_12c0fe87-9b3e-4b54-8e58-72c7710e7958_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45233666-9654-4582-bbc4-b831f31a774e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6807a499-68cb-4bf7-b3f4-0bd0ee45e04a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer, excluding assessed tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d41c74e3-de33-4367-ad79-6c7d1b4020e3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsAbstract_463ec8c1-2525-4313-9586-20f215522a87_terseLabel_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsAbstract_label_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsAbstract_documentation_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsAbstract" xlink:href="rcus-20230930.xsd#rcus_LicenseAndCollaborationAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsAbstract" xlink:to="lab_rcus_LicenseAndCollaborationAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_1a8b6568-f2ad-4204-991a-7736078714ae_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CashReceivedFromTenantImprovementAllowances_6ede6f1b-d935-4f69-8c10-67a9aa23762e_terseLabel_en-US" xlink:label="lab_rcus_CashReceivedFromTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from tenant improvement allowances</link:label>
    <link:label id="lab_rcus_CashReceivedFromTenantImprovementAllowances_label_en-US" xlink:label="lab_rcus_CashReceivedFromTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Received from Tenant Improvement Allowances</link:label>
    <link:label id="lab_rcus_CashReceivedFromTenantImprovementAllowances_documentation_en-US" xlink:label="lab_rcus_CashReceivedFromTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from tenant improvement allowances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashReceivedFromTenantImprovementAllowances" xlink:href="rcus-20230930.xsd#rcus_CashReceivedFromTenantImprovementAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CashReceivedFromTenantImprovementAllowances" xlink:to="lab_rcus_CashReceivedFromTenantImprovementAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5467435f-e501-4241-8c12-7cbd585b9f1f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty_9f2d1d4c-a1f8-4c46-8a8a-0580f788f8c4_terseLabel_en-US" xlink:label="lab_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration reimbursements of in-process research and development</link:label>
    <link:label id="lab_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty_label_en-US" xlink:label="lab_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Reimbursements Of In-Process Research And Development From Related party</link:label>
    <link:label id="lab_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty_documentation_en-US" xlink:label="lab_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration reimbursements of in-process research and development from a related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty" xlink:href="rcus-20230930.xsd#rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty" xlink:to="lab_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_9f8ea729-c732-4d53-a2ff-f8b11b08afcd_terseLabel_en-US" xlink:label="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option payment upon achievement of certain development milestones</link:label>
    <link:label id="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_label_en-US" xlink:label="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Payment Upon Achievement Of Certain Development Milestones</link:label>
    <link:label id="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_documentation_en-US" xlink:label="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option payment upon achievement of certain development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" xlink:href="rcus-20230930.xsd#rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" xlink:to="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_BvfAgreementMember_735fb9bb-5656-40db-9715-146bca22b0be_terseLabel_en-US" xlink:label="lab_rcus_BvfAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BVF Agreement</link:label>
    <link:label id="lab_rcus_BvfAgreementMember_label_en-US" xlink:label="lab_rcus_BvfAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BVF Agreement [Member]</link:label>
    <link:label id="lab_rcus_BvfAgreementMember_documentation_en-US" xlink:label="lab_rcus_BvfAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BVF Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_BvfAgreementMember" xlink:href="rcus-20230930.xsd#rcus_BvfAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_BvfAgreementMember" xlink:to="lab_rcus_BvfAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ProceedsFromSaleOfFutureRoyalties_9b8fbd49-b34c-4635-a14a-5140082a91ee_terseLabel_en-US" xlink:label="lab_rcus_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of future royalties</link:label>
    <link:label id="lab_rcus_ProceedsFromSaleOfFutureRoyalties_label_en-US" xlink:label="lab_rcus_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale of Future Royalties</link:label>
    <link:label id="lab_rcus_ProceedsFromSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_rcus_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromSaleOfFutureRoyalties" xlink:href="rcus-20230930.xsd#rcus_ProceedsFromSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ProceedsFromSaleOfFutureRoyalties" xlink:to="lab_rcus_ProceedsFromSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock_8f231f7a-a5f8-4f1f-bd4f-677eff5acb09_terseLabel_en-US" xlink:label="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash and Non-cash Information Related to Operating Leases</link:label>
    <link:label id="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Cash Flow Disclosures And Non-Cash Financing Activities Related To Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental cash flow disclosures and non-cash financing activities related to operating leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" xlink:href="rcus-20230930.xsd#rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" xlink:to="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_87b30037-90a8-4bda-844e-a3f660f67fdf_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_f64fc1e0-68d3-49e4-9c57-3f89a6721ebf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_081be7be-824a-4724-9d5c-51d3fddafded_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionAndLicenseAgreementMember_8401b0a7-9e89-4e83-82da-0135da94d908_terseLabel_en-US" xlink:label="lab_rcus_OptionAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taiho Agreement</link:label>
    <link:label id="lab_rcus_OptionAndLicenseAgreementMember_label_en-US" xlink:label="lab_rcus_OptionAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option And License Agreement [Member]</link:label>
    <link:label id="lab_rcus_OptionAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_rcus_OptionAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionAndLicenseAgreementMember" xlink:href="rcus-20230930.xsd#rcus_OptionAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionAndLicenseAgreementMember" xlink:to="lab_rcus_OptionAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6953acb1-6f1f-48a2-86bc-522db6595e54_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_TaihoCollaborationAccessRightsMember_eebb74c2-7ded-4913-b16b-db04a2238f29_terseLabel_en-US" xlink:label="lab_rcus_TaihoCollaborationAccessRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access rights</link:label>
    <link:label id="lab_rcus_TaihoCollaborationAccessRightsMember_label_en-US" xlink:label="lab_rcus_TaihoCollaborationAccessRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taiho Collaboration, Access Rights [Member]</link:label>
    <link:label id="lab_rcus_TaihoCollaborationAccessRightsMember_documentation_en-US" xlink:label="lab_rcus_TaihoCollaborationAccessRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taiho collaboration, access rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationAccessRightsMember" xlink:href="rcus-20230930.xsd#rcus_TaihoCollaborationAccessRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_TaihoCollaborationAccessRightsMember" xlink:to="lab_rcus_TaihoCollaborationAccessRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_bb2da030-7180-454d-a889-6c0af001e012_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_e1ba79cd-3fa3-4dfb-a077-f41ff0a3deb4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_bc715208-1ca1-4cd9-9ee8-a147b5103bf8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1127a289-6f17-4c11-a963-62ba19bf307d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_687cf1f6-dfec-4942-99d2-cde69733fbc7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_dfc07064-d292-4e31-80c3-7cc45597820d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_TaihoCollaborationRDServicesMember_2f7f5463-e02b-46b9-bcc4-092072c94659_terseLabel_en-US" xlink:label="lab_rcus_TaihoCollaborationRDServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D services</link:label>
    <link:label id="lab_rcus_TaihoCollaborationRDServicesMember_label_en-US" xlink:label="lab_rcus_TaihoCollaborationRDServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taiho Collaboration, R&amp;D Services [Member]</link:label>
    <link:label id="lab_rcus_TaihoCollaborationRDServicesMember_documentation_en-US" xlink:label="lab_rcus_TaihoCollaborationRDServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taiho Collaboration, R&amp;D Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationRDServicesMember" xlink:href="rcus-20230930.xsd#rcus_TaihoCollaborationRDServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_TaihoCollaborationRDServicesMember" xlink:to="lab_rcus_TaihoCollaborationRDServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d464add1-af7a-48d5-a5e5-0f8a10aa71af_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_609e4b02-f2ae-4e44-ae61-b629e59bbaf2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value On Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_091023be-bb65-4a4b-a7eb-5969ce99fbc4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ae2e2f6f-5a2e-42e7-b816-7649cc2773ed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_fe52b7b4-9d69-4157-88e7-1d4ab8891751_terseLabel_en-US" xlink:label="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option fee per program for all other programs entering clinical development to exercise option</link:label>
    <link:label id="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_label_en-US" xlink:label="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Fee Per Program For All Other Programs Entering Clinical Development To Exercise Option</link:label>
    <link:label id="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_documentation_en-US" xlink:label="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option fee per program for all other programs entering clinical development to exercise option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" xlink:href="rcus-20230930.xsd#rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" xlink:to="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_929f1c9e-7eb6-4b9a-b51e-cc5a441150f0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64da27e6-c7ab-4842-b632-878049f5e3dd_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c1b67020-00dc-4496-afc5-97a9c7e13027_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1e81d0cc-594a-4844-ad6a-e92db3bb3751_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_68828c8b-cf08-42b2-95a3-aaed1b46e037_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost sharing receivable</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_00d781db-1e00-4cf8-9e41-72e0ee7aa0ff_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a2e29bdd-4397-4433-aab6-f7a54e27b5e0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_07a18e5b-90e0-4f46-8cac-a23188bd9f16_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_70c4146b-2e6b-45c6-b2e4-aa1d8aaee0ab_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_RoyaltiesPayableTerm_dacc2a2b-35d9-46eb-b9f7-76f07259b475_terseLabel_en-US" xlink:label="lab_rcus_RoyaltiesPayableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties payable term</link:label>
    <link:label id="lab_rcus_RoyaltiesPayableTerm_label_en-US" xlink:label="lab_rcus_RoyaltiesPayableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Payable Term</link:label>
    <link:label id="lab_rcus_RoyaltiesPayableTerm_documentation_en-US" xlink:label="lab_rcus_RoyaltiesPayableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Payable Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RoyaltiesPayableTerm" xlink:href="rcus-20230930.xsd#rcus_RoyaltiesPayableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_RoyaltiesPayableTerm" xlink:to="lab_rcus_RoyaltiesPayableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_7d3e4f42-7eeb-4294-bb03-5b43f76643ab_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense_98f5f4cd-1496-4ea1-9cf0-3fa1ae18c185_terseLabel_en-US" xlink:label="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of research and development expense</link:label>
    <link:label id="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of Research and Development Expense</link:label>
    <link:label id="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ReimbursementOfResearchAndDevelopmentExpense" xlink:href="rcus-20230930.xsd#rcus_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ReimbursementOfResearchAndDevelopmentExpense" xlink:to="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_c3c3772e-30cf-4958-a7c3-1f132ad46eec_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_PrepaidExpensesAndOtherCurrentAssets_00cb6db4-52e6-47ea-ab2b-2ddd8cff3757_terseLabel_en-US" xlink:label="lab_rcus_PrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_rcus_PrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_rcus_PrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_rcus_PrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_rcus_PrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PrepaidExpensesAndOtherCurrentAssets" xlink:href="rcus-20230930.xsd#rcus_PrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_PrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_rcus_PrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OfficersAndDirectorsTradingArrangementMember_label_en-US" xlink:label="lab_rcus_OfficersAndDirectorsTradingArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officers And Directors Trading Arrangement [Member]</link:label>
    <link:label id="lab_rcus_OfficersAndDirectorsTradingArrangementMember_documentation_en-US" xlink:label="lab_rcus_OfficersAndDirectorsTradingArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officers And Directors Trading Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OfficersAndDirectorsTradingArrangementMember" xlink:href="rcus-20230930.xsd#rcus_OfficersAndDirectorsTradingArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OfficersAndDirectorsTradingArrangementMember" xlink:to="lab_rcus_OfficersAndDirectorsTradingArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_dfd3b1ec-6fa2-466a-9412-e8b3caed13f9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock pursuant to equity award plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_107c121b-de28-44d4-a757-3b368806d46f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3d26357b-856e-4fbb-8a33-becac06659ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionPaymentReceived_2a716d9c-ac56-4e29-9f50-687271e37833_terseLabel_en-US" xlink:label="lab_rcus_OptionPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option payments received</link:label>
    <link:label id="lab_rcus_OptionPaymentReceived_label_en-US" xlink:label="lab_rcus_OptionPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Payment Received</link:label>
    <link:label id="lab_rcus_OptionPaymentReceived_documentation_en-US" xlink:label="lab_rcus_OptionPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentReceived" xlink:href="rcus-20230930.xsd#rcus_OptionPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionPaymentReceived" xlink:to="lab_rcus_OptionPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OrganizationLineItems_73446368-c8a9-45d1-8199-f77dba97fcb0_terseLabel_en-US" xlink:label="lab_rcus_OrganizationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization [Line Items]</link:label>
    <link:label id="lab_rcus_OrganizationLineItems_label_en-US" xlink:label="lab_rcus_OrganizationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization [Line Items]</link:label>
    <link:label id="lab_rcus_OrganizationLineItems_documentation_en-US" xlink:label="lab_rcus_OrganizationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OrganizationLineItems" xlink:href="rcus-20230930.xsd#rcus_OrganizationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OrganizationLineItems" xlink:to="lab_rcus_OrganizationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_GileadCollaborationLicenseAndRDServicesMember_0311bd82-eeec-4a87-8edd-efda949c12c4_terseLabel_en-US" xlink:label="lab_rcus_GileadCollaborationLicenseAndRDServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and R&amp;D services</link:label>
    <link:label id="lab_rcus_GileadCollaborationLicenseAndRDServicesMember_label_en-US" xlink:label="lab_rcus_GileadCollaborationLicenseAndRDServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Collaboration, License and R&amp;D services [Member]</link:label>
    <link:label id="lab_rcus_GileadCollaborationLicenseAndRDServicesMember_documentation_en-US" xlink:label="lab_rcus_GileadCollaborationLicenseAndRDServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead collaboration, license and R&amp;D services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationLicenseAndRDServicesMember" xlink:href="rcus-20230930.xsd#rcus_GileadCollaborationLicenseAndRDServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_GileadCollaborationLicenseAndRDServicesMember" xlink:to="lab_rcus_GileadCollaborationLicenseAndRDServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_14419cff-c9a2-44b9-851e-2a58f9eb486d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities Considered as Available for Sale by Type of Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_LicenseAndDevelopmentServicesRevenueMember_bb82b4ba-0aa7-4c07-85c3-c4875e1ec6f6_terseLabel_en-US" xlink:label="lab_rcus_LicenseAndDevelopmentServicesRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Development Services Revenue</link:label>
    <link:label id="lab_rcus_LicenseAndDevelopmentServicesRevenueMember_label_en-US" xlink:label="lab_rcus_LicenseAndDevelopmentServicesRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Development Services Revenue [Member]</link:label>
    <link:label id="lab_rcus_LicenseAndDevelopmentServicesRevenueMember_documentation_en-US" xlink:label="lab_rcus_LicenseAndDevelopmentServicesRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and development services revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesRevenueMember" xlink:href="rcus-20230930.xsd#rcus_LicenseAndDevelopmentServicesRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_LicenseAndDevelopmentServicesRevenueMember" xlink:to="lab_rcus_LicenseAndDevelopmentServicesRevenueMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>rcus-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:805eb66e-844e-45f5-86a8-527ac86fecd7,g:7538c7a3-a72e-4e53-a8d0-2829fb9c9dc2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://arcusbio.com/role/Cover" xlink:type="simple" xlink:href="rcus-20230930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_576b6238-32ce-4575-beea-9f55625f87be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_DocumentType_576b6238-32ce-4575-beea-9f55625f87be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_6e768175-9424-4d76-ad0f-808925fb988c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_DocumentQuarterlyReport_6e768175-9424-4d76-ad0f-808925fb988c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ef629f16-d208-4d62-8b72-bbd145a2513d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_DocumentPeriodEndDate_ef629f16-d208-4d62-8b72-bbd145a2513d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_aacf88fc-440d-437a-9451-951c056e85fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_DocumentTransitionReport_aacf88fc-440d-437a-9451-951c056e85fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e6fd6f93-fc18-4d8b-b953-788f93c250d3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityFileNumber_e6fd6f93-fc18-4d8b-b953-788f93c250d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a6e73fb6-4145-4cab-ac24-d070323ed0e8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityRegistrantName_a6e73fb6-4145-4cab-ac24-d070323ed0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1fbc5215-3f40-48f8-bda5-133ee1713f58" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1fbc5215-3f40-48f8-bda5-133ee1713f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_14bdb808-7440-421a-92ef-ef40c910ed92" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityTaxIdentificationNumber_14bdb808-7440-421a-92ef-ef40c910ed92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3843de66-79df-4e60-b22d-51e3f45efe7d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityAddressAddressLine1_3843de66-79df-4e60-b22d-51e3f45efe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9e68cad6-eed9-4616-95e1-80bbc783dee1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityAddressCityOrTown_9e68cad6-eed9-4616-95e1-80bbc783dee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_125db29b-dabf-49e3-9c4b-de064a01bd7a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityAddressStateOrProvince_125db29b-dabf-49e3-9c4b-de064a01bd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_793c1532-ee26-4c0f-98be-a71556fbc2d3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityAddressPostalZipCode_793c1532-ee26-4c0f-98be-a71556fbc2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_28176cfa-593a-457d-a745-4355a524ed5e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_CityAreaCode_28176cfa-593a-457d-a745-4355a524ed5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_db794788-7994-4df5-8fe7-d8cbc3906c6f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_LocalPhoneNumber_db794788-7994-4df5-8fe7-d8cbc3906c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9a236b20-9c10-4368-a763-4915a9399425" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_Security12bTitle_9a236b20-9c10-4368-a763-4915a9399425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_899f2cda-4a30-4e4f-af26-dde66254292e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_TradingSymbol_899f2cda-4a30-4e4f-af26-dde66254292e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e2d435b9-d6b2-4707-b99f-13fe96fe23aa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_SecurityExchangeName_e2d435b9-d6b2-4707-b99f-13fe96fe23aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_91de624c-357b-4059-817f-865f83d58270" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityCurrentReportingStatus_91de624c-357b-4059-817f-865f83d58270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_175d1b2d-95e9-458d-a5e5-d20c6b2d1730" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityInteractiveDataCurrent_175d1b2d-95e9-458d-a5e5-d20c6b2d1730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f223930f-00d9-4a50-b5a8-1f525bcb1efb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityFilerCategory_f223930f-00d9-4a50-b5a8-1f525bcb1efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ec797448-6b76-4014-88f9-7028387477bc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntitySmallBusiness_ec797448-6b76-4014-88f9-7028387477bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c95db8b0-ea61-4089-9a87-3cc235354113" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityEmergingGrowthCompany_c95db8b0-ea61-4089-9a87-3cc235354113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6e0d6ec9-3436-4b31-956b-9e2b2be539e8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityShellCompany_6e0d6ec9-3436-4b31-956b-9e2b2be539e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_10eb1d77-8904-4286-b410-c7c0eb488961" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_10eb1d77-8904-4286-b410-c7c0eb488961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_eb723e4a-21ef-4591-8ffd-533783ab5b7e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_EntityCentralIndexKey_eb723e4a-21ef-4591-8ffd-533783ab5b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d509d867-7157-4e5e-9166-aac4ba1ecd85" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_CurrentFiscalYearEndDate_d509d867-7157-4e5e-9166-aac4ba1ecd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_63762718-a7cd-4bef-95f8-1b8369b60f7a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_AmendmentFlag_63762718-a7cd-4bef-95f8-1b8369b60f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c6c87d0f-e757-4606-8883-39427502a525" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_DocumentFiscalYearFocus_c6c87d0f-e757-4606-8883-39427502a525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_72ccd3d7-adc2-4b73-a67e-2103d73404bd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a94f85c0-47f0-47ae-acd3-0b431bef25cf" xlink:to="loc_dei_DocumentFiscalPeriodFocus_72ccd3d7-adc2-4b73-a67e-2103d73404bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_92404605-f0d4-4da2-8a02-6758fbbb690b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_193c7699-ce4a-447a-88c1-f5ead741f06c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_92404605-f0d4-4da2-8a02-6758fbbb690b" xlink:to="loc_us-gaap_StatementTable_193c7699-ce4a-447a-88c1-f5ead741f06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f062fa20-a279-4966-9aa8-d1de083dcdd0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_193c7699-ce4a-447a-88c1-f5ead741f06c" xlink:to="loc_srt_ProductOrServiceAxis_f062fa20-a279-4966-9aa8-d1de083dcdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f01f9433-3795-4ad7-aa10-bb02181af8d5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f062fa20-a279-4966-9aa8-d1de083dcdd0" xlink:to="loc_srt_ProductsAndServicesDomain_f01f9433-3795-4ad7-aa10-bb02181af8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesRevenueMember_0b1bd505-1c4a-46ff-b90c-7c4efb941c54" xlink:href="rcus-20230930.xsd#rcus_LicenseAndDevelopmentServicesRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f01f9433-3795-4ad7-aa10-bb02181af8d5" xlink:to="loc_rcus_LicenseAndDevelopmentServicesRevenueMember_0b1bd505-1c4a-46ff-b90c-7c4efb941c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherCollaborationRevenueMember_0d731bb5-a469-4f42-af30-06e85e5409a1" xlink:href="rcus-20230930.xsd#rcus_OtherCollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f01f9433-3795-4ad7-aa10-bb02181af8d5" xlink:to="loc_rcus_OtherCollaborationRevenueMember_0d731bb5-a469-4f42-af30-06e85e5409a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_193c7699-ce4a-447a-88c1-f5ead741f06c" xlink:to="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_22d63d1e-8a7e-47ea-b689-504d6772e920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_RevenuesAbstract_22d63d1e-8a7e-47ea-b689-504d6772e920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f367fd8-aa03-4b45-bc37-2225af1790bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_22d63d1e-8a7e-47ea-b689-504d6772e920" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f367fd8-aa03-4b45-bc37-2225af1790bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_fa8518ef-a9cc-41b2-94e3-da8c721d4ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_OperatingExpensesAbstract_fa8518ef-a9cc-41b2-94e3-da8c721d4ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e30a2c35-ea0d-48bb-9b5a-2fad8c8c3854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fa8518ef-a9cc-41b2-94e3-da8c721d4ca9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e30a2c35-ea0d-48bb-9b5a-2fad8c8c3854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3ec07ccb-a1e1-4cc0-b782-690c1967efb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fa8518ef-a9cc-41b2-94e3-da8c721d4ca9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3ec07ccb-a1e1-4cc0-b782-690c1967efb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ec9c2de9-3d13-4f79-9147-b6971d944512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fa8518ef-a9cc-41b2-94e3-da8c721d4ca9" xlink:to="loc_us-gaap_OperatingExpenses_ec9c2de9-3d13-4f79-9147-b6971d944512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9282cabd-41c3-42c5-8498-b512f951f44f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_OperatingIncomeLoss_9282cabd-41c3-42c5-8498-b512f951f44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_7e36f0b7-8653-4906-8603-3b378985ac6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_7e36f0b7-8653-4906-8603-3b378985ac6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_d5785810-71b4-4089-a18f-49fe0a0f0ced" xlink:href="rcus-20230930.xsd#rcus_InterestAndOtherIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_7e36f0b7-8653-4906-8603-3b378985ac6c" xlink:to="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_d5785810-71b4-4089-a18f-49fe0a0f0ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties_ff43e319-0bc9-4477-ab7f-de23363f6352" xlink:href="rcus-20230930.xsd#rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_7e36f0b7-8653-4906-8603-3b378985ac6c" xlink:to="loc_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties_ff43e319-0bc9-4477-ab7f-de23363f6352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e22e54a8-715b-441e-a97a-60b5924c03f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_7e36f0b7-8653-4906-8603-3b378985ac6c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e22e54a8-715b-441e-a97a-60b5924c03f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d86fa16-a7c9-40ad-8dc4-698973cca72c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0d86fa16-a7c9-40ad-8dc4-698973cca72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e3949b5e-b722-4ea9-a46f-ab58f0abf0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e3949b5e-b722-4ea9-a46f-ab58f0abf0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_da1e20b7-c552-4a7b-94fc-a80ef69ba08a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_NetIncomeLoss_da1e20b7-c552-4a7b-94fc-a80ef69ba08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_07c27aca-0917-4f44-99fc-f9a4d4e62597" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_07c27aca-0917-4f44-99fc-f9a4d4e62597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_c4810057-e205-43b7-8a99-f52c848a38e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_c4810057-e205-43b7-8a99-f52c848a38e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_64a3989b-014a-49ee-aeb3-b7dbc829eca8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_64a3989b-014a-49ee-aeb3-b7dbc829eca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b330cf5e-bbae-4243-9899-2ecc088e02e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_178c6267-de72-4a18-ac74-e385ce77be93" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b330cf5e-bbae-4243-9899-2ecc088e02e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedStatementsofOperationsParenthetical"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e7bb97d7-1ba7-4306-88d4-b1ceb5be8ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_54ecc98f-5c7f-44c1-8161-f2894f4bbd16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7bb97d7-1ba7-4306-88d4-b1ceb5be8ee6" xlink:to="loc_us-gaap_StatementTable_54ecc98f-5c7f-44c1-8161-f2894f4bbd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1a5fb827-6935-4fc4-a4c3-5203c3510a1a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_54ecc98f-5c7f-44c1-8161-f2894f4bbd16" xlink:to="loc_srt_ProductOrServiceAxis_1a5fb827-6935-4fc4-a4c3-5203c3510a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e7860977-649e-4ff6-8e34-cf8d3b34367a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1a5fb827-6935-4fc4-a4c3-5203c3510a1a" xlink:to="loc_srt_ProductsAndServicesDomain_e7860977-649e-4ff6-8e34-cf8d3b34367a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesRevenueMember_b514578f-77a8-44a9-ac78-0b7c36f53909" xlink:href="rcus-20230930.xsd#rcus_LicenseAndDevelopmentServicesRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e7860977-649e-4ff6-8e34-cf8d3b34367a" xlink:to="loc_rcus_LicenseAndDevelopmentServicesRevenueMember_b514578f-77a8-44a9-ac78-0b7c36f53909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherCollaborationRevenueMember_2ba9a33c-89e1-4a42-92b1-46fd61730330" xlink:href="rcus-20230930.xsd#rcus_OtherCollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e7860977-649e-4ff6-8e34-cf8d3b34367a" xlink:to="loc_rcus_OtherCollaborationRevenueMember_2ba9a33c-89e1-4a42-92b1-46fd61730330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ce5fbe12-f2da-4342-bf2d-2054a73793e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_54ecc98f-5c7f-44c1-8161-f2894f4bbd16" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ce5fbe12-f2da-4342-bf2d-2054a73793e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_01618040-310b-41bf-ad4a-97056a03884f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ce5fbe12-f2da-4342-bf2d-2054a73793e0" xlink:to="loc_us-gaap_RelatedPartyDomain_01618040-310b-41bf-ad4a-97056a03884f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_0bfff693-6456-4986-acb2-dfcbe4d439d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_01618040-310b-41bf-ad4a-97056a03884f" xlink:to="loc_us-gaap_RelatedPartyMember_0bfff693-6456-4986-acb2-dfcbe4d439d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7c2a361f-2a25-47f5-9cd4-24c94bbd69fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_54ecc98f-5c7f-44c1-8161-f2894f4bbd16" xlink:to="loc_us-gaap_StatementLineItems_7c2a361f-2a25-47f5-9cd4-24c94bbd69fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee4347a2-9f61-4307-9e35-65aa86f2e499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c2a361f-2a25-47f5-9cd4-24c94bbd69fd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee4347a2-9f61-4307-9e35-65aa86f2e499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentExpenseRecoveries_01492c6c-da3b-4cee-9a87-679a6fd6ac86" xlink:href="rcus-20230930.xsd#rcus_ResearchAndDevelopmentExpenseRecoveries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c2a361f-2a25-47f5-9cd4-24c94bbd69fd" xlink:to="loc_rcus_ResearchAndDevelopmentExpenseRecoveries_01492c6c-da3b-4cee-9a87-679a6fd6ac86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f0463001-8d9f-4eda-8518-7ab2bd2ac5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6d3e3ffe-684e-4bbf-ad50-52bbeabb639b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f0463001-8d9f-4eda-8518-7ab2bd2ac5b6" xlink:to="loc_us-gaap_NetIncomeLoss_6d3e3ffe-684e-4bbf-ad50-52bbeabb639b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8df26b9c-8b3f-4ef7-9d23-19868231913d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f0463001-8d9f-4eda-8518-7ab2bd2ac5b6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8df26b9c-8b3f-4ef7-9d23-19868231913d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_29bf4584-31b5-4e13-ba28-34390e88330a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f0463001-8d9f-4eda-8518-7ab2bd2ac5b6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_29bf4584-31b5-4e13-ba28-34390e88330a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8840a877-8422-4941-b445-608f3341332b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_fb0d1a7a-597d-49a0-94fe-c5b7b59a752e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8840a877-8422-4941-b445-608f3341332b" xlink:to="loc_us-gaap_AssetsAbstract_fb0d1a7a-597d-49a0-94fe-c5b7b59a752e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7b6038c8-f27a-4928-bc14-eaa51115fef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb0d1a7a-597d-49a0-94fe-c5b7b59a752e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7b6038c8-f27a-4928-bc14-eaa51115fef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e0f008c-7ebd-4cae-9ea7-3501d512d4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b6038c8-f27a-4928-bc14-eaa51115fef9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e0f008c-7ebd-4cae-9ea7-3501d512d4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_98705ec0-2f4f-4f48-aab2-bf8fbcaf614c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b6038c8-f27a-4928-bc14-eaa51115fef9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_98705ec0-2f4f-4f48-aab2-bf8fbcaf614c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_2ea81402-07a9-4332-a8e4-78acd2e3098f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b6038c8-f27a-4928-bc14-eaa51115fef9" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_2ea81402-07a9-4332-a8e4-78acd2e3098f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_88a756a4-0dd4-474a-b5d5-ccbc76abeacd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b6038c8-f27a-4928-bc14-eaa51115fef9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_88a756a4-0dd4-474a-b5d5-ccbc76abeacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9cfe741b-ca57-4960-8f3c-eebbc9f130c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7b6038c8-f27a-4928-bc14-eaa51115fef9" xlink:to="loc_us-gaap_AssetsCurrent_9cfe741b-ca57-4960-8f3c-eebbc9f130c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_76f00488-3ee1-4d65-ba28-6f575a97c27b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb0d1a7a-597d-49a0-94fe-c5b7b59a752e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_76f00488-3ee1-4d65-ba28-6f575a97c27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a4cbb9ca-35af-4c8a-a064-df9e56b10ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb0d1a7a-597d-49a0-94fe-c5b7b59a752e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a4cbb9ca-35af-4c8a-a064-df9e56b10ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ac7325e4-bda3-4984-aa79-e2a0a6c2d507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb0d1a7a-597d-49a0-94fe-c5b7b59a752e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ac7325e4-bda3-4984-aa79-e2a0a6c2d507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bde6f6de-6d7a-4a29-8a54-810f3ec6cc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fb0d1a7a-597d-49a0-94fe-c5b7b59a752e" xlink:to="loc_us-gaap_Assets_bde6f6de-6d7a-4a29-8a54-810f3ec6cc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_0e316288-4898-4255-98b3-4b8f2c803f19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8840a877-8422-4941-b445-608f3341332b" xlink:to="loc_us-gaap_LiabilitiesAbstract_0e316288-4898-4255-98b3-4b8f2c803f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_66c00dec-e9d7-4d16-81f1-a8b96fca3d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0e316288-4898-4255-98b3-4b8f2c803f19" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_66c00dec-e9d7-4d16-81f1-a8b96fca3d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9e6067af-7845-4d06-9374-b141aa128586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_66c00dec-e9d7-4d16-81f1-a8b96fca3d0f" xlink:to="loc_us-gaap_AccountsPayableCurrent_9e6067af-7845-4d06-9374-b141aa128586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dda66b02-6523-4c90-9c73-8227ba7c5066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_66c00dec-e9d7-4d16-81f1-a8b96fca3d0f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dda66b02-6523-4c90-9c73-8227ba7c5066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5985974a-8d2b-4b39-92ff-2072b4920f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_66c00dec-e9d7-4d16-81f1-a8b96fca3d0f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5985974a-8d2b-4b39-92ff-2072b4920f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d3b21518-dc6f-4177-89a4-04359b0fd4be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_66c00dec-e9d7-4d16-81f1-a8b96fca3d0f" xlink:to="loc_us-gaap_LiabilitiesCurrent_d3b21518-dc6f-4177-89a4-04359b0fd4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1f3d0af6-d09e-4f84-9627-548d81f93367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0e316288-4898-4255-98b3-4b8f2c803f19" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1f3d0af6-d09e-4f84-9627-548d81f93367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ea351b28-e200-4318-93de-3c65680164ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0e316288-4898-4255-98b3-4b8f2c803f19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ea351b28-e200-4318-93de-3c65680164ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d7fd3838-0120-42ba-ab53-1329428b383d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0e316288-4898-4255-98b3-4b8f2c803f19" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d7fd3838-0120-42ba-ab53-1329428b383d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_575ff0ce-cef7-4c45-ac61-92ad27438a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8840a877-8422-4941-b445-608f3341332b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_575ff0ce-cef7-4c45-ac61-92ad27438a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_36bf6d0c-1cc5-4948-8b54-e81cbc568b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_575ff0ce-cef7-4c45-ac61-92ad27438a29" xlink:to="loc_us-gaap_PreferredStockValue_36bf6d0c-1cc5-4948-8b54-e81cbc568b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_387535a1-db8e-4af9-b5fd-7eb4fb3e3cda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_575ff0ce-cef7-4c45-ac61-92ad27438a29" xlink:to="loc_us-gaap_CommonStockValue_387535a1-db8e-4af9-b5fd-7eb4fb3e3cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5900be30-720f-4369-b20f-75c34c7db9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_575ff0ce-cef7-4c45-ac61-92ad27438a29" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5900be30-720f-4369-b20f-75c34c7db9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_55ead219-45dc-4593-8496-daa966699e21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_575ff0ce-cef7-4c45-ac61-92ad27438a29" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_55ead219-45dc-4593-8496-daa966699e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e84e1b82-7e63-4e9e-a919-90a160eb8383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_575ff0ce-cef7-4c45-ac61-92ad27438a29" xlink:to="loc_us-gaap_StockholdersEquity_e84e1b82-7e63-4e9e-a919-90a160eb8383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_796ba07d-97a8-4864-9693-02629b0a1c07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_575ff0ce-cef7-4c45-ac61-92ad27438a29" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_796ba07d-97a8-4864-9693-02629b0a1c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fad6c737-1554-4ad1-9aa0-d0747188807d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c4fb16c6-fb61-41b1-8f63-96134686fd76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fad6c737-1554-4ad1-9aa0-d0747188807d" xlink:to="loc_us-gaap_StatementTable_c4fb16c6-fb61-41b1-8f63-96134686fd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca8eb3a-491a-492b-8f32-f560be852a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c4fb16c6-fb61-41b1-8f63-96134686fd76" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca8eb3a-491a-492b-8f32-f560be852a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ef5fd612-61cf-49b1-8584-466dcf0a6398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5ca8eb3a-491a-492b-8f32-f560be852a87" xlink:to="loc_us-gaap_RelatedPartyDomain_ef5fd612-61cf-49b1-8584-466dcf0a6398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_ca0a5d31-72f4-4fc9-aa4e-7a32886ede9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ef5fd612-61cf-49b1-8584-466dcf0a6398" xlink:to="loc_us-gaap_RelatedPartyMember_ca0a5d31-72f4-4fc9-aa4e-7a32886ede9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c4fb16c6-fb61-41b1-8f63-96134686fd76" xlink:to="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_6eb6bc64-7f46-45c8-a654-3e07642363e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_6eb6bc64-7f46-45c8-a654-3e07642363e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c5135878-4fc1-490a-9f7e-2e024a46f123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c5135878-4fc1-490a-9f7e-2e024a46f123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_db6f6f44-79ee-4d34-b068-1f46989cf279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_db6f6f44-79ee-4d34-b068-1f46989cf279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_70c82c4c-919b-4a19-94c3-581c005c0bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_70c82c4c-919b-4a19-94c3-581c005c0bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_42004903-7c6a-4baf-9b53-8c6bb3e13947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_42004903-7c6a-4baf-9b53-8c6bb3e13947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1a8abebc-c4cb-489f-9b8f-99b0fb888f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1a8abebc-c4cb-489f-9b8f-99b0fb888f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f04604a8-e8cd-46df-8242-99403c81a60c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f04604a8-e8cd-46df-8242-99403c81a60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4f4a49c9-8e78-407b-b010-738c059e52c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4f4a49c9-8e78-407b-b010-738c059e52c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8ee1f610-ded0-4f73-bd17-ae6640f60ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8ee1f610-ded0-4f73-bd17-ae6640f60ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a8b23046-54d0-4523-a7dc-dc972ef41dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a8b23046-54d0-4523-a7dc-dc972ef41dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_749f9d80-c413-41fe-93e1-f29b31cd4f48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_CommonStockSharesIssued_749f9d80-c413-41fe-93e1-f29b31cd4f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d14f1f3e-9c68-4c5c-9078-480ec3c61c06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdac9941-df06-486a-8606-de122b4b3e05" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d14f1f3e-9c68-4c5c-9078-480ec3c61c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_49c831ff-55af-441c-85be-10cb9b23ea3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8025f4df-5a94-40ff-a972-3d3315d4062c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_49c831ff-55af-441c-85be-10cb9b23ea3f" xlink:to="loc_us-gaap_StatementTable_8025f4df-5a94-40ff-a972-3d3315d4062c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40efc704-4d00-4424-8711-a74b64c229bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8025f4df-5a94-40ff-a972-3d3315d4062c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40efc704-4d00-4424-8711-a74b64c229bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87e5d0cc-190c-45de-ba38-2122cd67a13f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40efc704-4d00-4424-8711-a74b64c229bd" xlink:to="loc_us-gaap_EquityComponentDomain_87e5d0cc-190c-45de-ba38-2122cd67a13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_064a67ec-3149-4769-976b-047736a3635c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87e5d0cc-190c-45de-ba38-2122cd67a13f" xlink:to="loc_us-gaap_CommonStockMember_064a67ec-3149-4769-976b-047736a3635c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_a3b0c59b-d204-4e7e-bc97-d2bc74cc8cff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87e5d0cc-190c-45de-ba38-2122cd67a13f" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_a3b0c59b-d204-4e7e-bc97-d2bc74cc8cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1803e84a-741d-431c-8e8e-eb5159ec1967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87e5d0cc-190c-45de-ba38-2122cd67a13f" xlink:to="loc_us-gaap_RetainedEarningsMember_1803e84a-741d-431c-8e8e-eb5159ec1967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f52eb671-38b0-46bf-8e04-4cc5e862867a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87e5d0cc-190c-45de-ba38-2122cd67a13f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f52eb671-38b0-46bf-8e04-4cc5e862867a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d8fb6355-d76a-4093-91bb-9ffd00315398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8025f4df-5a94-40ff-a972-3d3315d4062c" xlink:to="loc_us-gaap_PlanNameAxis_d8fb6355-d76a-4093-91bb-9ffd00315398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dd141c39-6371-45b3-b425-85d8a4263e09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d8fb6355-d76a-4093-91bb-9ffd00315398" xlink:to="loc_us-gaap_PlanNameDomain_dd141c39-6371-45b3-b425-85d8a4263e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EquityAwardProgramsMember_f6d0ebbb-4eeb-4678-8e97-c028c3a49e3b" xlink:href="rcus-20230930.xsd#rcus_EquityAwardProgramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dd141c39-6371-45b3-b425-85d8a4263e09" xlink:to="loc_rcus_EquityAwardProgramsMember_f6d0ebbb-4eeb-4678-8e97-c028c3a49e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_116b2611-34e8-4ec1-b688-6149151b23f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8025f4df-5a94-40ff-a972-3d3315d4062c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_116b2611-34e8-4ec1-b688-6149151b23f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3377b0de-e72a-40df-868f-046ff7c72bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_116b2611-34e8-4ec1-b688-6149151b23f2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3377b0de-e72a-40df-868f-046ff7c72bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SecondStockPurchaseAgreementMember_018ca0c1-1197-44d6-81cd-b4fcfdd5c4d9" xlink:href="rcus-20230930.xsd#rcus_SecondStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3377b0de-e72a-40df-868f-046ff7c72bc1" xlink:to="loc_rcus_SecondStockPurchaseAgreementMember_018ca0c1-1197-44d6-81cd-b4fcfdd5c4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1325bbfb-5e26-480a-9105-a7978af5c1d6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8025f4df-5a94-40ff-a972-3d3315d4062c" xlink:to="loc_srt_CounterpartyNameAxis_1325bbfb-5e26-480a-9105-a7978af5c1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31b48067-66ba-456b-80c0-14bc535cfc63" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1325bbfb-5e26-480a-9105-a7978af5c1d6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31b48067-66ba-456b-80c0-14bc535cfc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_87691920-5de5-487b-81fb-a3f44c5f457d" xlink:href="rcus-20230930.xsd#rcus_GileadSciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31b48067-66ba-456b-80c0-14bc535cfc63" xlink:to="loc_rcus_GileadSciencesIncMember_87691920-5de5-487b-81fb-a3f44c5f457d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8025f4df-5a94-40ff-a972-3d3315d4062c" xlink:to="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dbbc2b52-1177-4605-ad2e-0aef25189b62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dbbc2b52-1177-4605-ad2e-0aef25189b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_df0cfc2c-667e-4b35-b239-e7b672420043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_StockholdersEquity_df0cfc2c-667e-4b35-b239-e7b672420043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c3922219-d33d-40b2-8611-60d76bc6fd67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c3922219-d33d-40b2-8611-60d76bc6fd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27581d50-66c9-4c19-af89-0135573c8310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_27581d50-66c9-4c19-af89-0135573c8310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_020cb3c8-ea7f-43be-916b-f810e436aa5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_020cb3c8-ea7f-43be-916b-f810e436aa5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a1aa440a-e7f2-49c4-9f9e-00b9b08a891f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a1aa440a-e7f2-49c4-9f9e-00b9b08a891f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_44cf9f59-d93c-452e-b5c7-688e3d452d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_NetIncomeLoss_44cf9f59-d93c-452e-b5c7-688e3d452d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_81c64402-1c31-4733-ab58-d189a8292b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_81c64402-1c31-4733-ab58-d189a8292b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fb9b230a-90b5-4ce5-bd5a-affe618dcf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bbdb2d48-5baa-4d75-ac6c-4f4e64e2fff5" xlink:to="loc_us-gaap_StockholdersEquity_fb9b230a-90b5-4ce5-bd5a-affe618dcf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c7b42913-d344-45a5-a88c-aaf3700d0606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_255f35fb-674c-4677-af93-6476b8da63fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7b42913-d344-45a5-a88c-aaf3700d0606" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_255f35fb-674c-4677-af93-6476b8da63fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7493cc19-ffd8-474e-9bfa-ffd247ac9643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_255f35fb-674c-4677-af93-6476b8da63fe" xlink:to="loc_us-gaap_ProfitLoss_7493cc19-ffd8-474e-9bfa-ffd247ac9643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c3cf9815-2dd8-4234-b73f-44204f589637" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_255f35fb-674c-4677-af93-6476b8da63fe" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c3cf9815-2dd8-4234-b73f-44204f589637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ddddbf35-4cea-4f0c-8ffd-fc852ed26242" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c3cf9815-2dd8-4234-b73f-44204f589637" xlink:to="loc_us-gaap_ShareBasedCompensation_ddddbf35-4cea-4f0c-8ffd-fc852ed26242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_3ee14a79-1673-42e8-93d3-21e234802b89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c3cf9815-2dd8-4234-b73f-44204f589637" xlink:to="loc_us-gaap_DepreciationAndAmortization_3ee14a79-1673-42e8-93d3-21e234802b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f55dc6ff-eb22-4330-90d6-8a21ac92215e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c3cf9815-2dd8-4234-b73f-44204f589637" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f55dc6ff-eb22-4330-90d6-8a21ac92215e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ddde343a-7844-423d-a82a-065844027162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c3cf9815-2dd8-4234-b73f-44204f589637" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ddde343a-7844-423d-a82a-065844027162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_93019064-0eca-4fd2-80e3-e808f7194db7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c3cf9815-2dd8-4234-b73f-44204f589637" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_93019064-0eca-4fd2-80e3-e808f7194db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07c8011d-a040-4e2d-804a-2f981a0a6c94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c3cf9815-2dd8-4234-b73f-44204f589637" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07c8011d-a040-4e2d-804a-2f981a0a6c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_2b173fcc-9fe9-4444-b6bf-47c6bd23e60f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07c8011d-a040-4e2d-804a-2f981a0a6c94" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_2b173fcc-9fe9-4444-b6bf-47c6bd23e60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7e2c4c18-2c75-43c7-a763-75fbf9ea28d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07c8011d-a040-4e2d-804a-2f981a0a6c94" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7e2c4c18-2c75-43c7-a763-75fbf9ea28d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f91c4b04-e75e-4db7-8ed1-38667a13208a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07c8011d-a040-4e2d-804a-2f981a0a6c94" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f91c4b04-e75e-4db7-8ed1-38667a13208a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_815c5e8d-3351-4dd4-957d-6eede2ee1f09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07c8011d-a040-4e2d-804a-2f981a0a6c94" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_815c5e8d-3351-4dd4-957d-6eede2ee1f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_08d3daff-e439-4709-8650-e395e4ba7f83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07c8011d-a040-4e2d-804a-2f981a0a6c94" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_08d3daff-e439-4709-8650-e395e4ba7f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5f9873d-bf8c-462a-96a7-1b8dbb7df121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_255f35fb-674c-4677-af93-6476b8da63fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5f9873d-bf8c-462a-96a7-1b8dbb7df121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d0be830-73ef-4031-9079-42570ceffc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7b42913-d344-45a5-a88c-aaf3700d0606" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d0be830-73ef-4031-9079-42570ceffc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0120624f-a639-4f71-9a22-88544c7f4746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d0be830-73ef-4031-9079-42570ceffc1c" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0120624f-a639-4f71-9a22-88544c7f4746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromMaturityOfMarketableSecurities_0af44365-5e3a-463d-93aa-354a1032f752" xlink:href="rcus-20230930.xsd#rcus_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d0be830-73ef-4031-9079-42570ceffc1c" xlink:to="loc_rcus_ProceedsFromMaturityOfMarketableSecurities_0af44365-5e3a-463d-93aa-354a1032f752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromSaleOfMarketableSecurities_d2aeb140-751e-4bc3-8711-e483747a898e" xlink:href="rcus-20230930.xsd#rcus_ProceedsFromSaleOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d0be830-73ef-4031-9079-42570ceffc1c" xlink:to="loc_rcus_ProceedsFromSaleOfMarketableSecurities_d2aeb140-751e-4bc3-8711-e483747a898e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eb0d49fc-ae21-4e44-a06a-711bfd3fb221" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d0be830-73ef-4031-9079-42570ceffc1c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eb0d49fc-ae21-4e44-a06a-711bfd3fb221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_81b3470c-e518-4fd7-96c8-ce1f422b69d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d0be830-73ef-4031-9079-42570ceffc1c" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_81b3470c-e518-4fd7-96c8-ce1f422b69d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty_be546189-00a2-4070-896b-ee73b4e677ba" xlink:href="rcus-20230930.xsd#rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d0be830-73ef-4031-9079-42570ceffc1c" xlink:to="loc_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty_be546189-00a2-4070-896b-ee73b4e677ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c2843243-a3f7-4472-a608-5bc3c0866f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0d0be830-73ef-4031-9079-42570ceffc1c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c2843243-a3f7-4472-a608-5bc3c0866f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9df982c-493c-49f1-abf9-254f0ce1a0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7b42913-d344-45a5-a88c-aaf3700d0606" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9df982c-493c-49f1-abf9-254f0ce1a0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_031fa0e1-56ee-4eb2-923a-b4fd94578cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9df982c-493c-49f1-abf9-254f0ce1a0e9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_031fa0e1-56ee-4eb2-923a-b4fd94578cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_843a4ccf-dfd7-412c-a891-076545a80a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9df982c-493c-49f1-abf9-254f0ce1a0e9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_843a4ccf-dfd7-412c-a891-076545a80a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromSaleOfFutureRoyalties_d6e85ce0-e603-4f39-9a97-cdbb8ecdacf1" xlink:href="rcus-20230930.xsd#rcus_ProceedsFromSaleOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9df982c-493c-49f1-abf9-254f0ce1a0e9" xlink:to="loc_rcus_ProceedsFromSaleOfFutureRoyalties_d6e85ce0-e603-4f39-9a97-cdbb8ecdacf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6311b90f-9e75-42c6-858f-d2b56093bac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9df982c-493c-49f1-abf9-254f0ce1a0e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6311b90f-9e75-42c6-858f-d2b56093bac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d615475-7a0f-4d6c-bbec-fd668b006fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7b42913-d344-45a5-a88c-aaf3700d0606" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d615475-7a0f-4d6c-bbec-fd668b006fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1563c993-4d5d-49ed-96b9-ef427af39a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7b42913-d344-45a5-a88c-aaf3700d0606" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1563c993-4d5d-49ed-96b9-ef427af39a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_10c1e052-94a0-4dae-8f62-a9ab48c857b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7b42913-d344-45a5-a88c-aaf3700d0606" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_10c1e052-94a0-4dae-8f62-a9ab48c857b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3b433d60-5635-46e0-a0a3-bdfc14c11043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7b42913-d344-45a5-a88c-aaf3700d0606" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3b433d60-5635-46e0-a0a3-bdfc14c11043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_31d26d82-f23b-42ae-95ec-e3da26241258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_3b433d60-5635-46e0-a0a3-bdfc14c11043" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_31d26d82-f23b-42ae-95ec-e3da26241258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_35955366-e022-40d6-9207-8fc47f5e3815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f7bf5eca-2762-4c11-a9f1-2b76a3786b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_35955366-e022-40d6-9207-8fc47f5e3815" xlink:to="loc_us-gaap_StatementTable_f7bf5eca-2762-4c11-a9f1-2b76a3786b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_30167fff-a1bf-4a37-8f1e-a1d739e95a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f7bf5eca-2762-4c11-a9f1-2b76a3786b4d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_30167fff-a1bf-4a37-8f1e-a1d739e95a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cc76c575-d8cf-4a56-a18f-092ffa0501f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_30167fff-a1bf-4a37-8f1e-a1d739e95a4c" xlink:to="loc_us-gaap_RelatedPartyDomain_cc76c575-d8cf-4a56-a18f-092ffa0501f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_8ae98add-2695-48df-bd6a-d5b2b1989811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cc76c575-d8cf-4a56-a18f-092ffa0501f1" xlink:to="loc_us-gaap_RelatedPartyMember_8ae98add-2695-48df-bd6a-d5b2b1989811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_183e6186-c6b2-4869-8850-7dcd80719602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f7bf5eca-2762-4c11-a9f1-2b76a3786b4d" xlink:to="loc_us-gaap_StatementLineItems_183e6186-c6b2-4869-8850-7dcd80719602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_43b48e2e-b409-48d0-93e8-ccdaf5155ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_183e6186-c6b2-4869-8850-7dcd80719602" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_43b48e2e-b409-48d0-93e8-ccdaf5155ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d2ecd068-e3b7-4609-862f-93c925b9c0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_183e6186-c6b2-4869-8850-7dcd80719602" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d2ecd068-e3b7-4609-862f-93c925b9c0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_36f2a563-31a2-4a2f-9364-d73f34b42df5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_183e6186-c6b2-4869-8850-7dcd80719602" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_36f2a563-31a2-4a2f-9364-d73f34b42df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0c466600-9951-4ebb-bcae-f4990c0f3cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_183e6186-c6b2-4869-8850-7dcd80719602" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0c466600-9951-4ebb-bcae-f4990c0f3cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/OrganizationLiquidityandCapitalResources" xlink:type="simple" xlink:href="rcus-20230930.xsd#OrganizationLiquidityandCapitalResources"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/OrganizationLiquidityandCapitalResources" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3456bf4d-033b-4416-924b-92fdca6784f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_2b2d20d1-dcaa-43cf-8972-f5c889e8323d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3456bf4d-033b-4416-924b-92fdca6784f2" xlink:to="loc_us-gaap_NatureOfOperations_2b2d20d1-dcaa-43cf-8972-f5c889e8323d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="rcus-20230930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8cef45f6-0322-4068-9667-d3da6f9ba49e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e5c1d9ff-17e3-4cab-a5f1-f205006e2b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8cef45f6-0322-4068-9667-d3da6f9ba49e" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e5c1d9ff-17e3-4cab-a5f1-f205006e2b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RelatedPartyGileadSciencesInc" xlink:type="simple" xlink:href="rcus-20230930.xsd#RelatedPartyGileadSciencesInc"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RelatedPartyGileadSciencesInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_73e96968-4e6d-4d00-aa5e-511f880f2ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c87f22f9-9531-4686-89a7-042ec5dab37f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_73e96968-4e6d-4d00-aa5e-511f880f2ce9" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c87f22f9-9531-4686-89a7-042ec5dab37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LicenseandCollaborations" xlink:type="simple" xlink:href="rcus-20230930.xsd#LicenseandCollaborations"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LicenseandCollaborations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsAbstract_df4e67a7-8fb2-4986-a20e-b1d32d2ee064" xlink:href="rcus-20230930.xsd#rcus_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1e45b5af-18f8-4c95-af66-9d67b49f2c75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsAbstract_df4e67a7-8fb2-4986-a20e-b1d32d2ee064" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1e45b5af-18f8-4c95-af66-9d67b49f2c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/Revenues" xlink:type="simple" xlink:href="rcus-20230930.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b40846d0-2179-478b-91d5-6b5b2f6328a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d23d420c-0c0f-4472-9960-c6435cdc0c93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b40846d0-2179-478b-91d5-6b5b2f6328a8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d23d420c-0c0f-4472-9960-c6435cdc0c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="rcus-20230930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_91ecafe6-534e-4d29-a079-77b53f507b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_d0fdef3f-983e-4e57-b4b8-8b107d31a374" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91ecafe6-534e-4d29-a079-77b53f507b2c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_d0fdef3f-983e-4e57-b4b8-8b107d31a374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="rcus-20230930.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6863fcf3-8119-4bbb-8e6a-8ec83758d731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0693b548-2ce0-4ffa-b6d2-a3612c52d216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6863fcf3-8119-4bbb-8e6a-8ec83758d731" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0693b548-2ce0-4ffa-b6d2-a3612c52d216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="rcus-20230930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37f554ea-c40d-4cfc-bbb0-c452f2e89a92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_95c932ea-7d39-4a51-9296-18ea9eed6a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37f554ea-c40d-4cfc-bbb0-c452f2e89a92" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_95c932ea-7d39-4a51-9296-18ea9eed6a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="rcus-20230930.xsd#CashCashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_dba4f590-093d-4b35-b5ab-3f572b12e9d4" xlink:href="rcus-20230930.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_01b008a8-b22c-43c3-aab3-42d64dd57410" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_dba4f590-093d-4b35-b5ab-3f572b12e9d4" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_01b008a8-b22c-43c3-aab3-42d64dd57410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedBalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aef71f3c-b8a4-4b04-aa59-5f9eecc59a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3f5acc00-ef3b-453d-8543-e480b84e3a32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aef71f3c-b8a4-4b04-aa59-5f9eecc59a2b" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3f5acc00-ef3b-453d-8543-e480b84e3a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/Leases" xlink:type="simple" xlink:href="rcus-20230930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ef9bd490-7f65-416e-b52e-5ae2d0952135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_da126f03-240e-4f20-970f-f1dbc8ed696e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef9bd490-7f65-416e-b52e-5ae2d0952135" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_da126f03-240e-4f20-970f-f1dbc8ed696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="rcus-20230930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_b68b9b7f-2dbb-4cbc-9fe2-bbcc8fa9afff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c464c123-da64-45d4-88e0-72878f5ae8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b68b9b7f-2dbb-4cbc-9fe2-bbcc8fa9afff" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c464c123-da64-45d4-88e0-72878f5ae8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="rcus-20230930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0f597f8e-ffbd-48a1-a792-b2ec70f14661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c3c144ab-9ed6-41b2-bd5b-0a6bb8344b09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0f597f8e-ffbd-48a1-a792-b2ec70f14661" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c3c144ab-9ed6-41b2-bd5b-0a6bb8344b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="rcus-20230930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c6a78374-992d-4e3b-b702-1574bb3421a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6e0baba0-cb24-46e1-83f8-82bef032eb37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c6a78374-992d-4e3b-b702-1574bb3421a3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6e0baba0-cb24-46e1-83f8-82bef032eb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0938782f-62d8-4bbd-a14a-6791a64ea403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c6a78374-992d-4e3b-b702-1574bb3421a3" xlink:to="loc_us-gaap_UseOfEstimates_0938782f-62d8-4bbd-a14a-6791a64ea403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_679751d0-0f42-48ec-976d-77e15cc6a650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c6a78374-992d-4e3b-b702-1574bb3421a3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_679751d0-0f42-48ec-976d-77e15cc6a650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesTables" xlink:type="simple" xlink:href="rcus-20230930.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20141dc4-b954-42a9-98d2-2eaed4330923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b408bec0-afd6-4a1e-bc12-9807b28d5b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20141dc4-b954-42a9-98d2-2eaed4330923" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b408bec0-afd6-4a1e-bc12-9807b28d5b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_47a7dc69-e43e-4665-9fab-c1c4c67ceace" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20141dc4-b954-42a9-98d2-2eaed4330923" xlink:to="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_47a7dc69-e43e-4665-9fab-c1c4c67ceace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock_e1c42097-7fc2-4772-ac28-fbb44af69b96" xlink:href="rcus-20230930.xsd#rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_20141dc4-b954-42a9-98d2-2eaed4330923" xlink:to="loc_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock_e1c42097-7fc2-4772-ac28-fbb44af69b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="rcus-20230930.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f36edf71-981b-4997-872c-0e6c17e71b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c4b23dc0-fc40-4d51-9b8b-7ed45e6a28f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f36edf71-981b-4997-872c-0e6c17e71b6f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c4b23dc0-fc40-4d51-9b8b-7ed45e6a28f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="rcus-20230930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03e10706-c43a-4f03-acf6-b6c5b80e0248" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_88fa2eb8-f8c8-425d-9266-5ceb335dbfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03e10706-c43a-4f03-acf6-b6c5b80e0248" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_88fa2eb8-f8c8-425d-9266-5ceb335dbfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="rcus-20230930.xsd#CashCashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_3002779b-2245-4964-b971-0532b2fa4fcf" xlink:href="rcus-20230930.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_9d3da786-3359-4def-8a15-848066f0f012" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_3002779b-2245-4964-b971-0532b2fa4fcf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_9d3da786-3359-4def-8a15-848066f0f012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_fd2e04d4-8ab2-4f1b-be53-88c0e9dec1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_3002779b-2245-4964-b971-0532b2fa4fcf" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_fd2e04d4-8ab2-4f1b-be53-88c0e9dec1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d81d690e-d7e7-4d41-8ce1-e711f1b01b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_3002779b-2245-4964-b971-0532b2fa4fcf" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d81d690e-d7e7-4d41-8ce1-e711f1b01b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_391773f7-d398-4f71-849d-9bf77e204b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_3002779b-2245-4964-b971-0532b2fa4fcf" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_391773f7-d398-4f71-849d-9bf77e204b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedBalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e3a11274-7d49-4e1f-ab19-fa28ee805c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_ef8eea86-6e14-4766-82a3-96e46054d3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e3a11274-7d49-4e1f-ab19-fa28ee805c9c" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_ef8eea86-6e14-4766-82a3-96e46054d3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_d7dc857e-c194-47ba-9f66-a7b9ad891adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e3a11274-7d49-4e1f-ab19-fa28ee805c9c" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_d7dc857e-c194-47ba-9f66-a7b9ad891adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LeasesTables" xlink:type="simple" xlink:href="rcus-20230930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bddf5349-75b3-4ff5-a914-db9a78ae5da3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock_65dd757c-1742-41e5-8172-e5918134ba53" xlink:href="rcus-20230930.xsd#rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bddf5349-75b3-4ff5-a914-db9a78ae5da3" xlink:to="loc_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock_65dd757c-1742-41e5-8172-e5918134ba53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="rcus-20230930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_12af6193-5783-4a51-99c7-5ebc932721c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0ee73272-d62c-460d-9f50-472ba3c0c72e" xlink:href="rcus-20230930.xsd#rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_12af6193-5783-4a51-99c7-5ebc932721c6" xlink:to="loc_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0ee73272-d62c-460d-9f50-472ba3c0c72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock_89eefc85-08c0-4557-bdd9-15abbbee0b0c" xlink:href="rcus-20230930.xsd#rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_12af6193-5783-4a51-99c7-5ebc932721c6" xlink:to="loc_rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock_89eefc85-08c0-4557-bdd9-15abbbee0b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aba4ee48-4516-44c3-8a2d-8ca5a57e1564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OrganizationTable_ee6fb5d8-8c19-4f03-8207-ca11861ede06" xlink:href="rcus-20230930.xsd#rcus_OrganizationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aba4ee48-4516-44c3-8a2d-8ca5a57e1564" xlink:to="loc_rcus_OrganizationTable_ee6fb5d8-8c19-4f03-8207-ca11861ede06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8a1098bf-5769-4e1d-9715-e825e1706c46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_OrganizationTable_ee6fb5d8-8c19-4f03-8207-ca11861ede06" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8a1098bf-5769-4e1d-9715-e825e1706c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8445bcbb-a6b8-4f43-8e85-1dd09bdaa0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8a1098bf-5769-4e1d-9715-e825e1706c46" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8445bcbb-a6b8-4f43-8e85-1dd09bdaa0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_6e71d93a-353c-40ba-ac08-7486c9315be7" xlink:href="rcus-20230930.xsd#rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8445bcbb-a6b8-4f43-8e85-1dd09bdaa0ae" xlink:to="loc_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_6e71d93a-353c-40ba-ac08-7486c9315be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OrganizationLineItems_1540ce45-df18-48ef-99c3-7322d57ec5b5" xlink:href="rcus-20230930.xsd#rcus_OrganizationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_OrganizationTable_ee6fb5d8-8c19-4f03-8207-ca11861ede06" xlink:to="loc_rcus_OrganizationLineItems_1540ce45-df18-48ef-99c3-7322d57ec5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_be1fa21d-925e-43bf-a878-a7dcbb133af0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_OrganizationLineItems_1540ce45-df18-48ef-99c3-7322d57ec5b5" xlink:to="loc_us-gaap_NumberOfReportableSegments_be1fa21d-925e-43bf-a878-a7dcbb133af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_51064459-0c00-41f6-80a5-2f3e012e2161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_OrganizationLineItems_1540ce45-df18-48ef-99c3-7322d57ec5b5" xlink:to="loc_us-gaap_NumberOfOperatingSegments_51064459-0c00-41f6-80a5-2f3e012e2161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_9826e14b-8b16-41f4-ab1c-bf461aa55b17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_OrganizationLineItems_1540ce45-df18-48ef-99c3-7322d57ec5b5" xlink:to="loc_us-gaap_InvestmentsAndCash_9826e14b-8b16-41f4-ab1c-bf461aa55b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#RelatedPartyGileadSciencesIncAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_7d24b748-b19d-44b2-a027-aea36200e201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_456de4ac-1ecb-4e60-91e1-57c6d3fa47a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_7d24b748-b19d-44b2-a027-aea36200e201" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_456de4ac-1ecb-4e60-91e1-57c6d3fa47a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1dde1a24-c476-4699-9fa8-932ac38b37d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_456de4ac-1ecb-4e60-91e1-57c6d3fa47a7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1dde1a24-c476-4699-9fa8-932ac38b37d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_203eda47-0be2-4eed-8e26-b5f97b33d166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1dde1a24-c476-4699-9fa8-932ac38b37d7" xlink:to="loc_us-gaap_RelatedPartyDomain_203eda47-0be2-4eed-8e26-b5f97b33d166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_952dbcfa-22c2-4ab6-9dc0-b3782fed6ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_203eda47-0be2-4eed-8e26-b5f97b33d166" xlink:to="loc_us-gaap_RelatedPartyMember_952dbcfa-22c2-4ab6-9dc0-b3782fed6ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_33ab0d89-d850-4882-87ed-60161e75228a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_456de4ac-1ecb-4e60-91e1-57c6d3fa47a7" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_33ab0d89-d850-4882-87ed-60161e75228a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a85867f1-bebe-4b9d-8f87-60b4e9568f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_33ab0d89-d850-4882-87ed-60161e75228a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a85867f1-bebe-4b9d-8f87-60b4e9568f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CommonStockPurchaseAgreementMember_7ed57a97-78bf-4aff-9502-365ab0bc3160" xlink:href="rcus-20230930.xsd#rcus_CommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a85867f1-bebe-4b9d-8f87-60b4e9568f16" xlink:to="loc_rcus_CommonStockPurchaseAgreementMember_7ed57a97-78bf-4aff-9502-365ab0bc3160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AmendedInvestorRightsAgreementMember_d746b1d2-82c6-4909-a8d7-038a9c845f7c" xlink:href="rcus-20230930.xsd#rcus_AmendedInvestorRightsAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a85867f1-bebe-4b9d-8f87-60b4e9568f16" xlink:to="loc_rcus_AmendedInvestorRightsAgreementMember_d746b1d2-82c6-4909-a8d7-038a9c845f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionLicenseAndCollaborationAgreementMember_dd83fff8-8dd7-4ad5-ac5a-ff69d0337bd9" xlink:href="rcus-20230930.xsd#rcus_OptionLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a85867f1-bebe-4b9d-8f87-60b4e9568f16" xlink:to="loc_rcus_OptionLicenseAndCollaborationAgreementMember_dd83fff8-8dd7-4ad5-ac5a-ff69d0337bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AmendedGileadCollaborationAgreementMember_fd86273e-edc0-4613-b010-38c217955a55" xlink:href="rcus-20230930.xsd#rcus_AmendedGileadCollaborationAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a85867f1-bebe-4b9d-8f87-60b4e9568f16" xlink:to="loc_rcus_AmendedGileadCollaborationAgreementMember_fd86273e-edc0-4613-b010-38c217955a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa973925-0e3c-44a9-98fb-92cd932f9e0b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_456de4ac-1ecb-4e60-91e1-57c6d3fa47a7" xlink:to="loc_srt_RangeAxis_aa973925-0e3c-44a9-98fb-92cd932f9e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e873d81-dbdc-4ccc-88a9-1de9cd3e3a94" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aa973925-0e3c-44a9-98fb-92cd932f9e0b" xlink:to="loc_srt_RangeMember_7e873d81-dbdc-4ccc-88a9-1de9cd3e3a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_43ccd4e5-4fc2-4cb3-ae31-0790774d7a75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7e873d81-dbdc-4ccc-88a9-1de9cd3e3a94" xlink:to="loc_srt_MaximumMember_43ccd4e5-4fc2-4cb3-ae31-0790774d7a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cb32cc10-29f9-4902-b4d0-9dbf96681435" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_456de4ac-1ecb-4e60-91e1-57c6d3fa47a7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cb32cc10-29f9-4902-b4d0-9dbf96681435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a26cf6e8-dd1b-46fb-a9c9-3d8a62182993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cb32cc10-29f9-4902-b4d0-9dbf96681435" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a26cf6e8-dd1b-46fb-a9c9-3d8a62182993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_26d60c8b-2955-432d-91b0-2241421d0e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a26cf6e8-dd1b-46fb-a9c9-3d8a62182993" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_26d60c8b-2955-432d-91b0-2241421d0e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_456de4ac-1ecb-4e60-91e1-57c6d3fa47a7" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2bc46066-1450-4dd1-8a16-00468f431435" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2bc46066-1450-4dd1-8a16-00468f431435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_FundsReceivedForStockPurchaseAgreement_098aa783-7573-4d0c-ba59-3798fa1fac84" xlink:href="rcus-20230930.xsd#rcus_FundsReceivedForStockPurchaseAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_FundsReceivedForStockPurchaseAgreement_098aa783-7573-4d0c-ba59-3798fa1fac84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation_052863c2-e63c-484f-9bc5-f70d17df6fe1" xlink:href="rcus-20230930.xsd#rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation_052863c2-e63c-484f-9bc5-f70d17df6fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e71bc42e-865b-4dd9-85be-eb834fbd9787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e71bc42e-865b-4dd9-85be-eb834fbd9787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage_692f01c8-a855-43c9-9b28-7b90cc8e6dcf" xlink:href="rcus-20230930.xsd#rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage_692f01c8-a855-43c9-9b28-7b90cc8e6dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PercentageOfPremiumPurchasePriceOfCommonStock_9702db27-d13e-4266-b60a-01b457430b8a" xlink:href="rcus-20230930.xsd#rcus_PercentageOfPremiumPurchasePriceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_PercentageOfPremiumPurchasePriceOfCommonStock_9702db27-d13e-4266-b60a-01b457430b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_d7cbe0f8-0a34-467e-adde-df9bd2d9bc32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_us-gaap_SharePrice_d7cbe0f8-0a34-467e-adde-df9bd2d9bc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TrailingDaysAverageClosingPrice_71878ee4-ff4c-4548-90cd-5adaeb973f1f" xlink:href="rcus-20230930.xsd#rcus_TrailingDaysAverageClosingPrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_TrailingDaysAverageClosingPrice_71878ee4-ff4c-4548-90cd-5adaeb973f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LockupPeriod_52a331cf-439a-44da-9cb7-3ef6960fbaf3" xlink:href="rcus-20230930.xsd#rcus_LockupPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_LockupPeriod_52a331cf-439a-44da-9cb7-3ef6960fbaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ExtendedLockupPeriod_b92a5a5e-e80d-4997-ba57-c4c5c9cc509d" xlink:href="rcus-20230930.xsd#rcus_ExtendedLockupPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_ExtendedLockupPeriod_b92a5a5e-e80d-4997-ba57-c4c5c9cc509d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PercentageOfOutstandingCommonStockOwned_a8303d03-2306-44da-ab42-62123091b629" xlink:href="rcus-20230930.xsd#rcus_PercentageOfOutstandingCommonStockOwned"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_PercentageOfOutstandingCommonStockOwned_a8303d03-2306-44da-ab42-62123091b629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_acb652be-7104-4bdf-82de-6da37eedb3c2" xlink:href="rcus-20230930.xsd#rcus_CollaborationTermForCurrentAndFutureClinicalPrograms"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_acb652be-7104-4bdf-82de-6da37eedb3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_20c2ce57-45e3-4624-9921-0d8aa2fae174" xlink:href="rcus-20230930.xsd#rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_20c2ce57-45e3-4624-9921-0d8aa2fae174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_UpfrontCashPayment_b1170fa7-ffb6-4b34-be7b-24354f8973b0" xlink:href="rcus-20230930.xsd#rcus_UpfrontCashPayment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_UpfrontCashPayment_b1170fa7-ffb6-4b34-be7b-24354f8973b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfExerciseOptionToPrograms_0d31608d-3eca-4f36-936d-6b28c9515889" xlink:href="rcus-20230930.xsd#rcus_NumberOfExerciseOptionToPrograms"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_NumberOfExerciseOptionToPrograms_0d31608d-3eca-4f36-936d-6b28c9515889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentReceived_075cc8ff-5f15-4259-b528-822dcb72064f" xlink:href="rcus-20230930.xsd#rcus_OptionPaymentReceived"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_OptionPaymentReceived_075cc8ff-5f15-4259-b528-822dcb72064f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RemoveOptionContinuationPaymentUnderAgreement_6b120b77-a9fb-4cba-8e08-9b609722b490" xlink:href="rcus-20230930.xsd#rcus_RemoveOptionContinuationPaymentUnderAgreement"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_RemoveOptionContinuationPaymentUnderAgreement_6b120b77-a9fb-4cba-8e08-9b609722b490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_e39024de-f320-4889-9d65-ddd876f7bfe4" xlink:href="rcus-20230930.xsd#rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_e39024de-f320-4889-9d65-ddd876f7bfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_57af7d5e-b3b9-428d-b0a8-cb0b096a4097" xlink:href="rcus-20230930.xsd#rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_57af7d5e-b3b9-428d-b0a8-cb0b096a4097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfResearchPrograms_fc4d5ac8-2e1f-4549-b767-036e84b19015" xlink:href="rcus-20230930.xsd#rcus_NumberOfResearchPrograms"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_NumberOfResearchPrograms_fc4d5ac8-2e1f-4549-b767-036e84b19015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities_3233e909-69ae-4305-8a2f-63d5e2bf87a3" xlink:href="rcus-20230930.xsd#rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities_3233e909-69ae-4305-8a2f-63d5e2bf87a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_47a79d88-34a7-4c57-b051-bfff647b9572" xlink:href="rcus-20230930.xsd#rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_47a79d88-34a7-4c57-b051-bfff647b9572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_70ba06c1-af0d-42eb-b3ce-f69e486df05a" xlink:href="rcus-20230930.xsd#rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_70ba06c1-af0d-42eb-b3ce-f69e486df05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_691daf7f-06df-4cf2-8a40-bd0249ed5749" xlink:href="rcus-20230930.xsd#rcus_RegulatoryAndCommercialMilestonePaymentsReceived"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_691daf7f-06df-4cf2-8a40-bd0249ed5749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5291f8cf-1715-4a05-a1f4-943245555b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5291f8cf-1715-4a05-a1f4-943245555b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_ddd98f1c-941b-49dd-b396-9e40f28e020c" xlink:href="rcus-20230930.xsd#rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9e589cce-7786-4050-85a3-7d1d8e2f0643" xlink:to="loc_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_ddd98f1c-941b-49dd-b396-9e40f28e020c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#LicenseandCollaborationsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsAbstract_fa867ee1-061f-463f-b6b4-02e7ef03f559" xlink:href="rcus-20230930.xsd#rcus_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:href="rcus-20230930.xsd#rcus_LicenseAndCollaborationAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsAbstract_fa867ee1-061f-463f-b6b4-02e7ef03f559" xlink:to="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0d9454ee-570f-4f82-a4b3-741272317726" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:to="loc_srt_CounterpartyNameAxis_0d9454ee-570f-4f82-a4b3-741272317726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_481eee06-b5a6-432e-86d3-c9cee1ba2ff8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0d9454ee-570f-4f82-a4b3-741272317726" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_481eee06-b5a6-432e-86d3-c9cee1ba2ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoPharmaceuticalCoLtdMember_a967eac1-af61-4903-9cc5-0b4fbdac48fb" xlink:href="rcus-20230930.xsd#rcus_TaihoPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_481eee06-b5a6-432e-86d3-c9cee1ba2ff8" xlink:to="loc_rcus_TaihoPharmaceuticalCoLtdMember_a967eac1-af61-4903-9cc5-0b4fbdac48fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_WuXiBiologicsLicenseAgreementMember_9d0806a2-f248-4286-87c4-31a266372ca9" xlink:href="rcus-20230930.xsd#rcus_WuXiBiologicsLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_481eee06-b5a6-432e-86d3-c9cee1ba2ff8" xlink:to="loc_rcus_WuXiBiologicsLicenseAgreementMember_9d0806a2-f248-4286-87c4-31a266372ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AbmunoLicenseAgreementMember_19bf1559-d996-4cce-95eb-d3aee84e75ad" xlink:href="rcus-20230930.xsd#rcus_AbmunoLicenseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_481eee06-b5a6-432e-86d3-c9cee1ba2ff8" xlink:to="loc_rcus_AbmunoLicenseAgreementMember_19bf1559-d996-4cce-95eb-d3aee84e75ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0c6975fa-4c9b-4b9d-b32c-3c1449641412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0c6975fa-4c9b-4b9d-b32c-3c1449641412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bc6e364-d944-4217-8847-12007b361743" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0c6975fa-4c9b-4b9d-b32c-3c1449641412" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bc6e364-d944-4217-8847-12007b361743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionAndLicenseAgreementMember_20e921a1-2ba0-467b-8c2b-812eaf6e42d1" xlink:href="rcus-20230930.xsd#rcus_OptionAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bc6e364-d944-4217-8847-12007b361743" xlink:to="loc_rcus_OptionAndLicenseAgreementMember_20e921a1-2ba0-467b-8c2b-812eaf6e42d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AstraZenecaAgreementMember_ffdc022a-ae8a-42c5-a757-f8ac6942f147" xlink:href="rcus-20230930.xsd#rcus_AstraZenecaAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bc6e364-d944-4217-8847-12007b361743" xlink:to="loc_rcus_AstraZenecaAgreementMember_ffdc022a-ae8a-42c5-a757-f8ac6942f147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionLicenseAndCollaborationAgreementMember_8f49f955-c566-4dfa-a390-8f0918655d47" xlink:href="rcus-20230930.xsd#rcus_OptionLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6bc6e364-d944-4217-8847-12007b361743" xlink:to="loc_rcus_OptionLicenseAndCollaborationAgreementMember_8f49f955-c566-4dfa-a390-8f0918655d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b159544-ecb5-4f51-9eb2-f37f0519a8f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:to="loc_srt_RangeAxis_7b159544-ecb5-4f51-9eb2-f37f0519a8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7d076581-d3c8-477e-afdd-29f7da4c1de6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7b159544-ecb5-4f51-9eb2-f37f0519a8f8" xlink:to="loc_srt_RangeMember_7d076581-d3c8-477e-afdd-29f7da4c1de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4f5d92ed-7353-4a1d-a8d5-7e66416c5368" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7d076581-d3c8-477e-afdd-29f7da4c1de6" xlink:to="loc_srt_MinimumMember_4f5d92ed-7353-4a1d-a8d5-7e66416c5368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f5a6547c-94e1-455d-9c88-a3bc649203dd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7d076581-d3c8-477e-afdd-29f7da4c1de6" xlink:to="loc_srt_MaximumMember_f5a6547c-94e1-455d-9c88-a3bc649203dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2c5cc149-cea9-4e9e-9d2f-9cc1da4271a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:to="loc_srt_ProductOrServiceAxis_2c5cc149-cea9-4e9e-9d2f-9cc1da4271a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1acc93e3-7e29-47bc-a768-5209959d9063" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2c5cc149-cea9-4e9e-9d2f-9cc1da4271a8" xlink:to="loc_srt_ProductsAndServicesDomain_1acc93e3-7e29-47bc-a768-5209959d9063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AntiPDOneMember_6db1d61d-24da-4b37-b76b-80ef4234138b" xlink:href="rcus-20230930.xsd#rcus_AntiPDOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1acc93e3-7e29-47bc-a768-5209959d9063" xlink:to="loc_rcus_AntiPDOneMember_6db1d61d-24da-4b37-b76b-80ef4234138b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AntiCDThirtyNineMember_bed55ac7-afec-44d4-b5b4-ac8c414a0f28" xlink:href="rcus-20230930.xsd#rcus_AntiCDThirtyNineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1acc93e3-7e29-47bc-a768-5209959d9063" xlink:to="loc_rcus_AntiCDThirtyNineMember_bed55ac7-afec-44d4-b5b4-ac8c414a0f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_13cc2e8b-c7bc-4bdc-9137-9285b68dd59c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_13cc2e8b-c7bc-4bdc-9137-9285b68dd59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fbc94661-ef06-4e19-9c4d-a1fa496b3d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13cc2e8b-c7bc-4bdc-9137-9285b68dd59c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fbc94661-ef06-4e19-9c4d-a1fa496b3d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f562b10d-2a2a-48c0-8dff-565aa0549d80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fbc94661-ef06-4e19-9c4d-a1fa496b3d0c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f562b10d-2a2a-48c0-8dff-565aa0549d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:href="rcus-20230930.xsd#rcus_LicenseAndCollaborationAgreementsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_5c7724c3-fe4d-455f-8185-13f342518b56" xlink:to="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPeriod_ff8b09e4-5d9a-4aea-95b2-c286114f9442" xlink:href="rcus-20230930.xsd#rcus_OptionPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_OptionPeriod_ff8b09e4-5d9a-4aea-95b2-c286114f9442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NonRefundableAndNonCreditableCashPayments_88865cc3-ba18-48ab-ae39-3ad5eb2e6586" xlink:href="rcus-20230930.xsd#rcus_NonRefundableAndNonCreditableCashPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_NonRefundableAndNonCreditableCashPayments_88865cc3-ba18-48ab-ae39-3ad5eb2e6586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PaymentForOptionExercise_7efe035a-890c-4088-9ae9-bf107565196d" xlink:href="rcus-20230930.xsd#rcus_PaymentForOptionExercise"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_PaymentForOptionExercise_7efe035a-890c-4088-9ae9-bf107565196d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_01ec51e3-4ec3-46ca-80ec-6b78ce7aff1a" xlink:href="rcus-20230930.xsd#rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_01ec51e3-4ec3-46ca-80ec-6b78ce7aff1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContingentMilestonePaymentsReceivable_0daf72ec-0ced-4142-ad2e-d903cf255183" xlink:href="rcus-20230930.xsd#rcus_ContingentMilestonePaymentsReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_ContingentMilestonePaymentsReceivable_0daf72ec-0ced-4142-ad2e-d903cf255183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RoyaltiesPayableTerm_1dd2d123-23a2-4ca0-8fab-b2d592ad468a" xlink:href="rcus-20230930.xsd#rcus_RoyaltiesPayableTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_RoyaltiesPayableTerm_1dd2d123-23a2-4ca0-8fab-b2d592ad468a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_faa780c7-d7af-4647-b12f-ad1933335119" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_faa780c7-d7af-4647-b12f-ad1933335119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ReimbursementOfResearchAndDevelopmentExpense_6902b8d2-36f0-4888-8ebb-37b79f95e37f" xlink:href="rcus-20230930.xsd#rcus_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_ReimbursementOfResearchAndDevelopmentExpense_6902b8d2-36f0-4888-8ebb-37b79f95e37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_969ee8ba-c5e0-4bc2-9edd-d39660f6cca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_969ee8ba-c5e0-4bc2-9edd-d39660f6cca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b65eb925-2c90-4286-b2d8-f2b8959bca87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b65eb925-2c90-4286-b2d8-f2b8959bca87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b849fbe7-f5c3-4c5c-a611-bd0d425bd845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b849fbe7-f5c3-4c5c-a611-bd0d425bd845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_a9b04298-f3c5-4f6b-b02f-e1b3171e8039" xlink:href="rcus-20230930.xsd#rcus_ClinicalRegulatoryAndCommercializationMilestonePayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_a9b04298-f3c5-4f6b-b02f-e1b3171e8039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_499e113f-f656-479e-bde3-d2608884e677" xlink:href="rcus-20230930.xsd#rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_499e113f-f656-479e-bde3-d2608884e677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_MilestoneExpense_aeaff702-2c84-44f0-9f70-88944e145268" xlink:href="rcus-20230930.xsd#rcus_MilestoneExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_d93afd91-f1eb-47b4-bfd9-b1b81fe6f841" xlink:to="loc_rcus_MilestoneExpense_aeaff702-2c84-44f0-9f70-88944e145268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ed609c77-af00-4146-bf5e-828ea1ed333c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_60361001-e0ac-40bc-9f0b-bd43fd09d3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ed609c77-af00-4146-bf5e-828ea1ed333c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_60361001-e0ac-40bc-9f0b-bd43fd09d3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e704328b-96a6-420f-b940-97c11a5fd1e2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_60361001-e0ac-40bc-9f0b-bd43fd09d3ba" xlink:to="loc_srt_ProductOrServiceAxis_e704328b-96a6-420f-b940-97c11a5fd1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f247b0fb-0e76-4d07-93b1-0f68a5b8d6fd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e704328b-96a6-420f-b940-97c11a5fd1e2" xlink:to="loc_srt_ProductsAndServicesDomain_f247b0fb-0e76-4d07-93b1-0f68a5b8d6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationLicenseAndRDServicesMember_5b907266-8fd2-405d-a8b6-8a96e4d33c08" xlink:href="rcus-20230930.xsd#rcus_GileadCollaborationLicenseAndRDServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f247b0fb-0e76-4d07-93b1-0f68a5b8d6fd" xlink:to="loc_rcus_GileadCollaborationLicenseAndRDServicesMember_5b907266-8fd2-405d-a8b6-8a96e4d33c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationAccessRightsMember_3a119fd0-e60e-4982-8a72-f89e5f2843be" xlink:href="rcus-20230930.xsd#rcus_GileadCollaborationAccessRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f247b0fb-0e76-4d07-93b1-0f68a5b8d6fd" xlink:to="loc_rcus_GileadCollaborationAccessRightsMember_3a119fd0-e60e-4982-8a72-f89e5f2843be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationRDServicesMember_ee79149b-e12f-4a38-b8ab-7364a7e104d0" xlink:href="rcus-20230930.xsd#rcus_TaihoCollaborationRDServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f247b0fb-0e76-4d07-93b1-0f68a5b8d6fd" xlink:to="loc_rcus_TaihoCollaborationRDServicesMember_ee79149b-e12f-4a38-b8ab-7364a7e104d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationAccessRightsMember_dcadadf4-94d1-438c-97a8-9b7ed3bc65b4" xlink:href="rcus-20230930.xsd#rcus_TaihoCollaborationAccessRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f247b0fb-0e76-4d07-93b1-0f68a5b8d6fd" xlink:to="loc_rcus_TaihoCollaborationAccessRightsMember_dcadadf4-94d1-438c-97a8-9b7ed3bc65b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsLineItems_f5caf771-2073-463f-8932-a9004af2db89" xlink:href="rcus-20230930.xsd#rcus_LicenseAndCollaborationAgreementsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_60361001-e0ac-40bc-9f0b-bd43fd09d3ba" xlink:to="loc_rcus_LicenseAndCollaborationAgreementsLineItems_f5caf771-2073-463f-8932-a9004af2db89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63d42f86-15ba-4433-a27f-caa6f335a525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_f5caf771-2073-463f-8932-a9004af2db89" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63d42f86-15ba-4433-a27f-caa6f335a525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#RevenuesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RevenuesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f0aed06c-d126-4442-b9da-7150e0ba8041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f0aed06c-d126-4442-b9da-7150e0ba8041" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0d25dac3-445b-4993-a033-9f90d0eae723" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:to="loc_srt_CounterpartyNameAxis_0d25dac3-445b-4993-a033-9f90d0eae723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b4b844f-3577-4835-bd42-dd1fe7af4a6a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0d25dac3-445b-4993-a033-9f90d0eae723" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b4b844f-3577-4835-bd42-dd1fe7af4a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_aec233df-480f-48c9-b1ac-87d07eb29778" xlink:href="rcus-20230930.xsd#rcus_GileadSciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b4b844f-3577-4835-bd42-dd1fe7af4a6a" xlink:to="loc_rcus_GileadSciencesIncMember_aec233df-480f-48c9-b1ac-87d07eb29778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_STAR221DevelopmentActivitiesMember_01cb6781-e61a-4e46-ba62-b0163d11f71a" xlink:href="rcus-20230930.xsd#rcus_STAR221DevelopmentActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b4b844f-3577-4835-bd42-dd1fe7af4a6a" xlink:to="loc_rcus_STAR221DevelopmentActivitiesMember_01cb6781-e61a-4e46-ba62-b0163d11f71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_47baaa1a-b0c9-415d-a0ef-7274d58a189a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_47baaa1a-b0c9-415d-a0ef-7274d58a189a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19266558-e675-4a30-916c-c8ce0a009180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_47baaa1a-b0c9-415d-a0ef-7274d58a189a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19266558-e675-4a30-916c-c8ce0a009180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_04e6c0e7-7003-44d4-b1d8-6a42228aece4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19266558-e675-4a30-916c-c8ce0a009180" xlink:to="loc_us-gaap_SalesRevenueNetMember_04e6c0e7-7003-44d4-b1d8-6a42228aece4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b2ef0120-a763-4507-9e3d-a57d7ddfa300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b2ef0120-a763-4507-9e3d-a57d7ddfa300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_28faad5c-1c09-48c0-8b6a-0c64419585eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b2ef0120-a763-4507-9e3d-a57d7ddfa300" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_28faad5c-1c09-48c0-8b6a-0c64419585eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_887f6502-6ad0-4370-a609-7b705a8f7bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_28faad5c-1c09-48c0-8b6a-0c64419585eb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_887f6502-6ad0-4370-a609-7b705a8f7bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_73694dd2-04e4-4cd3-af79-96e70cf8d41a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:to="loc_us-gaap_TypeOfArrangementAxis_73694dd2-04e4-4cd3-af79-96e70cf8d41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_73694dd2-04e4-4cd3-af79-96e70cf8d41a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionLicenseAndCollaborationAgreementMember_62e60355-a8cf-4fa8-8871-478916883aa4" xlink:href="rcus-20230930.xsd#rcus_OptionLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_OptionLicenseAndCollaborationAgreementMember_62e60355-a8cf-4fa8-8871-478916883aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_2e9d46be-ec42-4d05-8e20-c8eab19c59da" xlink:href="rcus-20230930.xsd#rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_2e9d46be-ec42-4d05-8e20-c8eab19c59da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember_06dd0c88-f20e-4721-af56-aa77d85f2c5e" xlink:href="rcus-20230930.xsd#rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember_06dd0c88-f20e-4721-af56-aa77d85f2c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember_72255d19-2090-48a5-ab89-72107432d5ed" xlink:href="rcus-20230930.xsd#rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember_72255d19-2090-48a5-ab89-72107432d5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember_d3277e75-06ee-494b-aa11-ef56f4e407ab" xlink:href="rcus-20230930.xsd#rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember_d3277e75-06ee-494b-aa11-ef56f4e407ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember_753fde11-5740-49dc-b71c-60487c4e75a6" xlink:href="rcus-20230930.xsd#rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember_753fde11-5740-49dc-b71c-60487c4e75a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember_f08c9082-2ef9-40fa-b96b-fe301d30d3bf" xlink:href="rcus-20230930.xsd#rcus_AccessRightsAndOptionContinuationPeriodsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember_f08c9082-2ef9-40fa-b96b-fe301d30d3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationAgreementMember_4d1692d4-3125-4412-9a1a-43fb42a39655" xlink:href="rcus-20230930.xsd#rcus_TaihoCollaborationAgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70b726d4-b97a-4998-98cd-b769c5795ea0" xlink:to="loc_rcus_TaihoCollaborationAgreementMember_4d1692d4-3125-4412-9a1a-43fb42a39655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_18d7f194-e924-41cf-9467-a7844651fcac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_18d7f194-e924-41cf-9467-a7844651fcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_744ad76f-dd48-4fe3-a44b-d5aec6c866af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_18d7f194-e924-41cf-9467-a7844651fcac" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_744ad76f-dd48-4fe3-a44b-d5aec6c866af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_486b49e6-a26e-4c57-96d0-6a9f5f8e2268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_744ad76f-dd48-4fe3-a44b-d5aec6c866af" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_486b49e6-a26e-4c57-96d0-6a9f5f8e2268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_b54d17a0-b1b4-4f8c-a04e-5e1f0c21c51a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_744ad76f-dd48-4fe3-a44b-d5aec6c866af" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_b54d17a0-b1b4-4f8c-a04e-5e1f0c21c51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_97b02c7f-7741-4839-9fe2-394a592a1106" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8b04f663-45ea-49fa-91f0-fcb5beb7d5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8b04f663-45ea-49fa-91f0-fcb5beb7d5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee984f1f-9ff3-4266-9fe6-84df40d9d1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee984f1f-9ff3-4266-9fe6-84df40d9d1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_13993935-1d37-4f8d-b206-0126c8df19a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_ContractWithCustomerLiability_13993935-1d37-4f8d-b206-0126c8df19a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_UpfrontCashPayment_da6f5aa1-cec6-4839-b9a6-820b1724017a" xlink:href="rcus-20230930.xsd#rcus_UpfrontCashPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_rcus_UpfrontCashPayment_da6f5aa1-cec6-4839-b9a6-820b1724017a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AllocationToPerformanceObligations_18059f5c-80c7-4a7e-8e57-6ca131b312b0" xlink:href="rcus-20230930.xsd#rcus_AllocationToPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_rcus_AllocationToPerformanceObligations_18059f5c-80c7-4a7e-8e57-6ca131b312b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_04c24fb9-c97d-4362-96e0-b07c99df5693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_04c24fb9-c97d-4362-96e0-b07c99df5693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_7245312f-d199-4114-9b66-8162a1caaeaf" xlink:href="rcus-20230930.xsd#rcus_CurrentAndFutureProgramsExclusiveAccessPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_7245312f-d199-4114-9b66-8162a1caaeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContingentMilestonePaymentsReceivable_515cc7fd-f964-4a94-99bb-fdcf4817b20c" xlink:href="rcus-20230930.xsd#rcus_ContingentMilestonePaymentsReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_rcus_ContingentMilestonePaymentsReceivable_515cc7fd-f964-4a94-99bb-fdcf4817b20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_58441cdd-0d46-44e6-8c6b-0003ef2645bf" xlink:href="rcus-20230930.xsd#rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_58441cdd-0d46-44e6-8c6b-0003ef2645bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PerformanceObligationPeriod_30e311d0-e7c2-4264-a9b3-02deb2b9042c" xlink:href="rcus-20230930.xsd#rcus_PerformanceObligationPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_rcus_PerformanceObligationPeriod_30e311d0-e7c2-4264-a9b3-02deb2b9042c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2410be4a-3c58-4747-b4cd-322053032e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2410be4a-3c58-4747-b4cd-322053032e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_19ba808d-ee48-4841-a121-d91d3309bd56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_19ba808d-ee48-4841-a121-d91d3309bd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_22d4cc10-67b2-4e41-a21d-a02ef4ad6833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_22d4cc10-67b2-4e41-a21d-a02ef4ad6833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent_9435c064-eb49-4f59-97a5-8e8b6c7985b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_CapitalizedContractCostNetCurrent_9435c064-eb49-4f59-97a5-8e8b6c7985b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_73f506cd-9b8c-42c1-a568-e0d994610e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b7b00a39-4a1b-4d9f-a690-fae91f76ca47" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_73f506cd-9b8c-42c1-a568-e0d994610e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a87a37bd-ed8f-4d25-a661-ee32e4588aae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_6b190621-ba49-4694-bd93-f91775f08493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a87a37bd-ed8f-4d25-a661-ee32e4588aae" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_6b190621-ba49-4694-bd93-f91775f08493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0e8568bd-f391-46cf-9d50-312d931e7503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1189627e-a07d-472b-a065-b5bf70b08a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0e8568bd-f391-46cf-9d50-312d931e7503" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1189627e-a07d-472b-a065-b5bf70b08a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_65260505-c30d-4757-915c-240691c123a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1189627e-a07d-472b-a065-b5bf70b08a7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_65260505-c30d-4757-915c-240691c123a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1d595712-9f56-4b36-83e8-9fb349346fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_65260505-c30d-4757-915c-240691c123a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1d595712-9f56-4b36-83e8-9fb349346fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InflammationTarget1Member_08273c45-3fe9-4e29-bf95-b868bb58c12a" xlink:href="rcus-20230930.xsd#rcus_InflammationTarget1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1d595712-9f56-4b36-83e8-9fb349346fc6" xlink:to="loc_rcus_InflammationTarget1Member_08273c45-3fe9-4e29-bf95-b868bb58c12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InflammationTarget2Member_a786f319-3f11-4ed2-905a-1e6b95b75a6d" xlink:href="rcus-20230930.xsd#rcus_InflammationTarget2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1d595712-9f56-4b36-83e8-9fb349346fc6" xlink:to="loc_rcus_InflammationTarget2Member_a786f319-3f11-4ed2-905a-1e6b95b75a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsLineItems_c12f2281-e907-4ca3-836c-99301de5c6fc" xlink:href="rcus-20230930.xsd#rcus_LicenseAndCollaborationAgreementsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1189627e-a07d-472b-a065-b5bf70b08a7b" xlink:to="loc_rcus_LicenseAndCollaborationAgreementsLineItems_c12f2281-e907-4ca3-836c-99301de5c6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AllocationToPerformanceObligations_1fe21a38-b88d-474a-b9dd-43668382c485" xlink:href="rcus-20230930.xsd#rcus_AllocationToPerformanceObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_c12f2281-e907-4ca3-836c-99301de5c6fc" xlink:to="loc_rcus_AllocationToPerformanceObligations_1fe21a38-b88d-474a-b9dd-43668382c485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ceb99086-4d2b-42b7-ae6f-c9fcad599dae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11712db9-22f4-4f98-aeb1-ea22e5e31a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ceb99086-4d2b-42b7-ae6f-c9fcad599dae" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11712db9-22f4-4f98-aeb1-ea22e5e31a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ca24c92-5649-47a5-8402-5e33b0101540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ceb99086-4d2b-42b7-ae6f-c9fcad599dae" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ca24c92-5649-47a5-8402-5e33b0101540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d6e1c30d-d497-41b1-a760-cf1689bbf55f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d86dbdf5-5c59-47b1-9104-78b515db15b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d6e1c30d-d497-41b1-a760-cf1689bbf55f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d86dbdf5-5c59-47b1-9104-78b515db15b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a980e966-0114-4b6e-846d-b422162670a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d86dbdf5-5c59-47b1-9104-78b515db15b0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a980e966-0114-4b6e-846d-b422162670a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd6bd39-8d36-4904-8ce2-30de85446d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a980e966-0114-4b6e-846d-b422162670a6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd6bd39-8d36-4904-8ce2-30de85446d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_9168588d-c845-4905-a27b-eb094171f364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd6bd39-8d36-4904-8ce2-30de85446d7b" xlink:to="loc_us-gaap_StockCompensationPlanMember_9168588d-c845-4905-a27b-eb094171f364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a3ce3605-3799-4c52-b82d-5a524d1c0e59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd6bd39-8d36-4904-8ce2-30de85446d7b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a3ce3605-3799-4c52-b82d-5a524d1c0e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2fe6992c-0f4b-4b18-9f07-42029b09964d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cbd6bd39-8d36-4904-8ce2-30de85446d7b" xlink:to="loc_us-gaap_EmployeeStockMember_2fe6992c-0f4b-4b18-9f07-42029b09964d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_56d68774-faec-4ba7-a282-2b51f95a4e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d86dbdf5-5c59-47b1-9104-78b515db15b0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_56d68774-faec-4ba7-a282-2b51f95a4e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c7ae6d51-2790-4245-adf9-02eb6e7f7663" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_56d68774-faec-4ba7-a282-2b51f95a4e98" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c7ae6d51-2790-4245-adf9-02eb6e7f7663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bbf103c0-9339-43b4-91fe-47746f45be19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_211f2568-539f-4d37-a19e-f4ba763178c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bbf103c0-9339-43b4-91fe-47746f45be19" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_211f2568-539f-4d37-a19e-f4ba763178c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_734e292c-8ed3-4786-aa10-5ba825b210a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_211f2568-539f-4d37-a19e-f4ba763178c9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_734e292c-8ed3-4786-aa10-5ba825b210a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3038f968-4e6b-49bd-8e71-d08f778e8b61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_734e292c-8ed3-4786-aa10-5ba825b210a0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3038f968-4e6b-49bd-8e71-d08f778e8b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_50d9788a-9f6f-4c89-b672-2d3bd2b657bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3038f968-4e6b-49bd-8e71-d08f778e8b61" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_50d9788a-9f6f-4c89-b672-2d3bd2b657bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1bcafff7-6e9c-45ca-bf98-e6afcacb7e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3038f968-4e6b-49bd-8e71-d08f778e8b61" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1bcafff7-6e9c-45ca-bf98-e6afcacb7e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ff8add99-dbff-4343-9228-203b188f5628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_211f2568-539f-4d37-a19e-f4ba763178c9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ff8add99-dbff-4343-9228-203b188f5628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d037b9f1-01bb-48a3-b536-a6aed328b003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ff8add99-dbff-4343-9228-203b188f5628" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d037b9f1-01bb-48a3-b536-a6aed328b003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_15635a74-3abd-4dc6-a993-e34991b3d9ae" xlink:href="rcus-20230930.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1bc1ad48-53c5-432c-8049-e89d61e9119f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_15635a74-3abd-4dc6-a993-e34991b3d9ae" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1bc1ad48-53c5-432c-8049-e89d61e9119f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_132aaba9-06c2-4f8a-92f6-0d15d3f7670f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1bc1ad48-53c5-432c-8049-e89d61e9119f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_132aaba9-06c2-4f8a-92f6-0d15d3f7670f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_132aaba9-06c2-4f8a-92f6-0d15d3f7670f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_32c85ebb-2a8a-4781-bf88-3004642ab547" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_32c85ebb-2a8a-4781-bf88-3004642ab547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8973c201-0d71-4875-87fe-f3feca3b1f25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8973c201-0d71-4875-87fe-f3feca3b1f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_ca8a4ca9-f63d-4440-8160-34fad52bb9ff" xlink:href="rcus-20230930.xsd#rcus_CorporateSecuritiesAndCommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:to="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_ca8a4ca9-f63d-4440-8160-34fad52bb9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e29c50f7-10f2-4ce1-9036-bd51a3353b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e29c50f7-10f2-4ce1-9036-bd51a3353b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d8d8b7d3-1617-4373-835c-0405e104db1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b45f2a3a-c886-4222-8e3e-320b26d7ada4" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d8d8b7d3-1617-4373-835c-0405e104db1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa97a8a5-884b-4559-bc12-0bc515afaf69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1bc1ad48-53c5-432c-8049-e89d61e9119f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa97a8a5-884b-4559-bc12-0bc515afaf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1fe0a367-ea27-4675-9e80-ad9a0405f455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa97a8a5-884b-4559-bc12-0bc515afaf69" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1fe0a367-ea27-4675-9e80-ad9a0405f455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_51de150c-1312-4c5b-80e3-7b6c4332c95e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa97a8a5-884b-4559-bc12-0bc515afaf69" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_51de150c-1312-4c5b-80e3-7b6c4332c95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6578f0a2-867d-450b-ab52-5a29a026ff62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa97a8a5-884b-4559-bc12-0bc515afaf69" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6578f0a2-867d-450b-ab52-5a29a026ff62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a35dfd17-48ac-4aa6-b5bc-3ef80251c9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aa97a8a5-884b-4559-bc12-0bc515afaf69" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a35dfd17-48ac-4aa6-b5bc-3ef80251c9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_34dc30ac-0e66-42ba-89e1-ce4705e30b90" xlink:href="rcus-20230930.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_73fac349-4cf0-406e-895e-6659816fa345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_34dc30ac-0e66-42ba-89e1-ce4705e30b90" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_73fac349-4cf0-406e-895e-6659816fa345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b8e37025-c2f1-4439-9cad-347adc184410" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_34dc30ac-0e66-42ba-89e1-ce4705e30b90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b8e37025-c2f1-4439-9cad-347adc184410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_45c8d99e-5966-44a1-85b9-e59dd4075e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_34dc30ac-0e66-42ba-89e1-ce4705e30b90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_45c8d99e-5966-44a1-85b9-e59dd4075e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_2c7f3aa6-e813-4021-a353-216296f4430e" xlink:href="rcus-20230930.xsd#rcus_CashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_34dc30ac-0e66-42ba-89e1-ce4705e30b90" xlink:to="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_2c7f3aa6-e813-4021-a353-216296f4430e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_bc465c1a-0d23-49c7-b8be-e74a8a0e6ace" xlink:href="rcus-20230930.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_dbee2cb8-a6f5-498b-aa03-7792ee6523cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_bc465c1a-0d23-49c7-b8be-e74a8a0e6ace" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_dbee2cb8-a6f5-498b-aa03-7792ee6523cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed_9dad6db3-199d-4779-a7ea-0cc858b6abf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_bc465c1a-0d23-49c7-b8be-e74a8a0e6ace" xlink:to="loc_us-gaap_ProvisionForLoanLossesExpensed_9dad6db3-199d-4779-a7ea-0cc858b6abf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_27c4e130-5f76-4395-b298-b23e48767db2" xlink:href="rcus-20230930.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_953a6055-8121-497e-8f66-971bac2acb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_27c4e130-5f76-4395-b298-b23e48767db2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_953a6055-8121-497e-8f66-971bac2acb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_422b2448-8e2d-4de0-9890-c36eb9302705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_27c4e130-5f76-4395-b298-b23e48767db2" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_422b2448-8e2d-4de0-9890-c36eb9302705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13d848bd-6272-4375-80b6-f3b078ab3306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_27c4e130-5f76-4395-b298-b23e48767db2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13d848bd-6272-4375-80b6-f3b078ab3306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList_66280c9c-1c85-45e4-b095-79c5c2d30c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_27c4e130-5f76-4395-b298-b23e48767db2" xlink:to="loc_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList_66280c9c-1c85-45e4-b095-79c5c2d30c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_afc76c7a-917a-42ef-9843-86097068614a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PrepaidExpensesAndOtherCurrentAssets_0bc9e5b1-7e69-48ca-a85d-3feccce12944" xlink:href="rcus-20230930.xsd#rcus_PrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_afc76c7a-917a-42ef-9843-86097068614a" xlink:to="loc_rcus_PrepaidExpensesAndOtherCurrentAssets_0bc9e5b1-7e69-48ca-a85d-3feccce12944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_3079d773-a4c0-482a-8bd2-f805c9b32525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_afc76c7a-917a-42ef-9843-86097068614a" xlink:to="loc_us-gaap_InterestReceivableCurrent_3079d773-a4c0-482a-8bd2-f805c9b32525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bad6e0d8-86a9-41bf-acce-2eb2dfb78b87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_afc76c7a-917a-42ef-9843-86097068614a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bad6e0d8-86a9-41bf-acce-2eb2dfb78b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f097151a-deff-4180-84f5-6b87af92284a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccruedResearchAndDevelopmentExpensesCurrent_4a023e6f-b953-41bb-b4dc-407345d03ed2" xlink:href="rcus-20230930.xsd#rcus_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f097151a-deff-4180-84f5-6b87af92284a" xlink:to="loc_rcus_AccruedResearchAndDevelopmentExpensesCurrent_4a023e6f-b953-41bb-b4dc-407345d03ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dd7d2e9b-5983-4cc5-bc01-2c82c01c70e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f097151a-deff-4180-84f5-6b87af92284a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dd7d2e9b-5983-4cc5-bc01-2c82c01c70e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f2f5484e-d9b3-40da-b296-a6cebfe76b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f097151a-deff-4180-84f5-6b87af92284a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f2f5484e-d9b3-40da-b296-a6cebfe76b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_48725b36-2101-4932-9bba-bd2e967d6104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f097151a-deff-4180-84f5-6b87af92284a" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_48725b36-2101-4932-9bba-bd2e967d6104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_1828dbc9-70ed-443a-bba9-2752257e5cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f097151a-deff-4180-84f5-6b87af92284a" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_1828dbc9-70ed-443a-bba9-2752257e5cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5af47c40-d4be-4d3b-9554-316b31dae0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f097151a-deff-4180-84f5-6b87af92284a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5af47c40-d4be-4d3b-9554-316b31dae0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7394d4d2-61f2-4be9-b576-ebc9f470883e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_c31fa13b-6707-457b-b0c4-bede946ec3b9" xlink:href="rcus-20230930.xsd#rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7394d4d2-61f2-4be9-b576-ebc9f470883e" xlink:to="loc_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_c31fa13b-6707-457b-b0c4-bede946ec3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashReceivedFromTenantImprovementAllowances_a70192ea-aaac-401c-ac1b-91414a5df605" xlink:href="rcus-20230930.xsd#rcus_CashReceivedFromTenantImprovementAllowances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7394d4d2-61f2-4be9-b576-ebc9f470883e" xlink:to="loc_rcus_CashReceivedFromTenantImprovementAllowances_a70192ea-aaac-401c-ac1b-91414a5df605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_71322b1c-d899-43aa-b1ea-b56e422643bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7394d4d2-61f2-4be9-b576-ebc9f470883e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_71322b1c-d899-43aa-b1ea-b56e422643bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RecognitionOfTenantImprovementAllowanceReceivable_bc1ace28-879f-4f2a-8a93-5fff3a32956e" xlink:href="rcus-20230930.xsd#rcus_RecognitionOfTenantImprovementAllowanceReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7394d4d2-61f2-4be9-b576-ebc9f470883e" xlink:to="loc_rcus_RecognitionOfTenantImprovementAllowanceReceivable_bc1ace28-879f-4f2a-8a93-5fff3a32956e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4225bd76-c494-4a3b-a775-fcf5a2a0bdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_393767ae-95a3-4e2a-94b9-f22b8996c922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4225bd76-c494-4a3b-a775-fcf5a2a0bdc1" xlink:to="loc_us-gaap_SecurityDeposit_393767ae-95a3-4e2a-94b9-f22b8996c922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_c591b990-8a87-41a6-bf16-005f157537c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ec7fb4d9-8913-41e7-ac78-e6c177c5389f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c591b990-8a87-41a6-bf16-005f157537c7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ec7fb4d9-8913-41e7-ac78-e6c177c5389f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8c7d5716-358a-4ee9-ac74-ab2cd7ceb2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ec7fb4d9-8913-41e7-ac78-e6c177c5389f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8c7d5716-358a-4ee9-ac74-ab2cd7ceb2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3e8d43e-dce9-404f-9043-d0588c303b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8c7d5716-358a-4ee9-ac74-ab2cd7ceb2d3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3e8d43e-dce9-404f-9043-d0588c303b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SecondStockPurchaseAgreementMember_1f77c57b-d31a-4fee-8bc2-512103f0fb94" xlink:href="rcus-20230930.xsd#rcus_SecondStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3e8d43e-dce9-404f-9043-d0588c303b0d" xlink:to="loc_rcus_SecondStockPurchaseAgreementMember_1f77c57b-d31a-4fee-8bc2-512103f0fb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e25aad8b-86aa-48e4-88ee-679bb79f99e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ec7fb4d9-8913-41e7-ac78-e6c177c5389f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e25aad8b-86aa-48e4-88ee-679bb79f99e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9a30c48b-dc8c-4acf-b2e1-cfa255dafc52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e25aad8b-86aa-48e4-88ee-679bb79f99e0" xlink:to="loc_us-gaap_RelatedPartyDomain_9a30c48b-dc8c-4acf-b2e1-cfa255dafc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_3933336b-9290-47c5-8db6-9704d3ae22d1" xlink:href="rcus-20230930.xsd#rcus_GileadSciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9a30c48b-dc8c-4acf-b2e1-cfa255dafc52" xlink:to="loc_rcus_GileadSciencesIncMember_3933336b-9290-47c5-8db6-9704d3ae22d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_08f4b474-f659-4088-9fce-b0aa59c7975f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ec7fb4d9-8913-41e7-ac78-e6c177c5389f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_08f4b474-f659-4088-9fce-b0aa59c7975f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_72f2c56e-5599-493c-b17c-467c48d76455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_08f4b474-f659-4088-9fce-b0aa59c7975f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_72f2c56e-5599-493c-b17c-467c48d76455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AtTheMarketFacilityMember_fc00313f-963c-4944-9209-7ac788a1fe46" xlink:href="rcus-20230930.xsd#rcus_AtTheMarketFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_72f2c56e-5599-493c-b17c-467c48d76455" xlink:to="loc_rcus_AtTheMarketFacilityMember_fc00313f-963c-4944-9209-7ac788a1fe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ec7fb4d9-8913-41e7-ac78-e6c177c5389f" xlink:to="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0d29528f-01f0-47d2-b040-bb02cc4e17a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0d29528f-01f0-47d2-b040-bb02cc4e17a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_5bfd94a1-96e2-4772-ae67-a4a174fcfc90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_us-gaap_SharePrice_5bfd94a1-96e2-4772-ae67-a4a174fcfc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0b8c9502-6eb5-401b-8230-23084af7aa22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0b8c9502-6eb5-401b-8230-23084af7aa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d8bcc002-2b03-4c55-9824-968c1e6a7908" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d8bcc002-2b03-4c55-9824-968c1e6a7908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SaleOfStockAuthorizedConsiderationOnTransaction_215988c8-a08f-44e4-af10-c8be09feab99" xlink:href="rcus-20230930.xsd#rcus_SaleOfStockAuthorizedConsiderationOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_rcus_SaleOfStockAuthorizedConsiderationOnTransaction_215988c8-a08f-44e4-af10-c8be09feab99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c7721872-d891-4ca7-a6a5-9b94bc5dd09b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c7721872-d891-4ca7-a6a5-9b94bc5dd09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fdf003c3-ee60-47b0-8c4a-981cd9a2652b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b7190f38-0f24-4f81-8842-621efacb539e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fdf003c3-ee60-47b0-8c4a-981cd9a2652b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7e1036e6-7184-40e2-89ea-f950e183f614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b121ff51-8022-441c-868a-df0aaafef4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7e1036e6-7184-40e2-89ea-f950e183f614" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b121ff51-8022-441c-868a-df0aaafef4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e881ae2c-bfdc-41cc-af7e-6bb08ad24cba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b121ff51-8022-441c-868a-df0aaafef4b1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e881ae2c-bfdc-41cc-af7e-6bb08ad24cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b96de93-a72d-4e1e-8b31-2b49a44ad288" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e881ae2c-bfdc-41cc-af7e-6bb08ad24cba" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b96de93-a72d-4e1e-8b31-2b49a44ad288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bfa02e21-c670-40e9-be52-0ddc8a1b00fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6b96de93-a72d-4e1e-8b31-2b49a44ad288" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bfa02e21-c670-40e9-be52-0ddc8a1b00fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beba0a8c-8ed3-4a11-8504-1444ba6020f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b121ff51-8022-441c-868a-df0aaafef4b1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beba0a8c-8ed3-4a11-8504-1444ba6020f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51a94b2f-6d34-47e2-a20e-88099f8aa632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beba0a8c-8ed3-4a11-8504-1444ba6020f5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51a94b2f-6d34-47e2-a20e-88099f8aa632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4c0a934e-9c81-44ff-881b-f40528bb4bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51a94b2f-6d34-47e2-a20e-88099f8aa632" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4c0a934e-9c81-44ff-881b-f40528bb4bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9d9f3792-bfd9-4130-bdbf-369661b5b7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51a94b2f-6d34-47e2-a20e-88099f8aa632" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9d9f3792-bfd9-4130-bdbf-369661b5b7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f1e443c7-4fa7-4ee0-8bc7-e163aff7ff3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_51a94b2f-6d34-47e2-a20e-88099f8aa632" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f1e443c7-4fa7-4ee0-8bc7-e163aff7ff3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_75bd78a1-361d-4101-90c7-e4d99d209ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b121ff51-8022-441c-868a-df0aaafef4b1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_75bd78a1-361d-4101-90c7-e4d99d209ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_75bd78a1-361d-4101-90c7-e4d99d209ca7" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4b1463a6-a474-4f4f-a948-a935380aee35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4b1463a6-a474-4f4f-a948-a935380aee35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b99c22e7-1c3a-49e9-bd1f-7bb410a919f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b99c22e7-1c3a-49e9-bd1f-7bb410a919f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_88e106b7-a515-40c7-bacb-87a39dfe41df" xlink:href="rcus-20230930.xsd#rcus_CorporateSecuritiesAndCommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:to="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_88e106b7-a515-40c7-bacb-87a39dfe41df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_UsGovernmentAgencyObligationMember_b5f21e6c-c7f2-4abd-8b82-ac90f95dea78" xlink:href="rcus-20230930.xsd#rcus_UsGovernmentAgencyObligationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:to="loc_rcus_UsGovernmentAgencyObligationMember_b5f21e6c-c7f2-4abd-8b82-ac90f95dea78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9e8f7c54-0c08-4a28-b3ab-c4657dbcd697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_9e8f7c54-0c08-4a28-b3ab-c4657dbcd697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_66ee8a2f-9c03-4516-8966-20246567c4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b538e639-506a-4a51-b113-4b93a0e3b2a7" xlink:to="loc_us-gaap_CertificatesOfDepositMember_66ee8a2f-9c03-4516-8966-20246567c4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1997ff5a-6d81-4835-b76f-c786ac697674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b121ff51-8022-441c-868a-df0aaafef4b1" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1997ff5a-6d81-4835-b76f-c786ac697674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_82768542-0f20-45fe-9f9f-bc9d57891dab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1997ff5a-6d81-4835-b76f-c786ac697674" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_82768542-0f20-45fe-9f9f-bc9d57891dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LiabilityForSaleOfFutureRoyaltiesMember_a9e68cf7-c9af-462f-aeed-44cd2e5b0a98" xlink:href="rcus-20230930.xsd#rcus_LiabilityForSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_82768542-0f20-45fe-9f9f-bc9d57891dab" xlink:to="loc_rcus_LiabilityForSaleOfFutureRoyaltiesMember_a9e68cf7-c9af-462f-aeed-44cd2e5b0a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc39747d-07c4-4259-9e5a-4458ad824dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b121ff51-8022-441c-868a-df0aaafef4b1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc39747d-07c4-4259-9e5a-4458ad824dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b7c3ccd8-b242-4bba-bc9b-b76fbfa64eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc39747d-07c4-4259-9e5a-4458ad824dbe" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b7c3ccd8-b242-4bba-bc9b-b76fbfa64eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8ee7eb6b-20b2-4b28-a6a2-2109898ae56a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bc39747d-07c4-4259-9e5a-4458ad824dbe" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_8ee7eb6b-20b2-4b28-a6a2-2109898ae56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f031b1b5-2873-44e8-88a0-9e8016ce8af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4401f4c1-6fb0-4561-82f3-516dbd7a5b75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f031b1b5-2873-44e8-88a0-9e8016ce8af2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4401f4c1-6fb0-4561-82f3-516dbd7a5b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_48e4eb33-27e3-4076-9da2-87e8bc36de00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4401f4c1-6fb0-4561-82f3-516dbd7a5b75" xlink:to="loc_srt_CounterpartyNameAxis_48e4eb33-27e3-4076-9da2-87e8bc36de00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c20c04d-f33b-4b25-8ffc-80d8061c874c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_48e4eb33-27e3-4076-9da2-87e8bc36de00" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c20c04d-f33b-4b25-8ffc-80d8061c874c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_BvfPartnersLPMember_fb85685a-81a2-4326-a0b5-8ca880af2f67" xlink:href="rcus-20230930.xsd#rcus_BvfPartnersLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c20c04d-f33b-4b25-8ffc-80d8061c874c" xlink:to="loc_rcus_BvfPartnersLPMember_fb85685a-81a2-4326-a0b5-8ca880af2f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a0c7197d-7080-44c3-aa8a-dfb6adc2116c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4401f4c1-6fb0-4561-82f3-516dbd7a5b75" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a0c7197d-7080-44c3-aa8a-dfb6adc2116c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_873e3736-d68a-423d-9f81-b1ff5668abbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a0c7197d-7080-44c3-aa8a-dfb6adc2116c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_873e3736-d68a-423d-9f81-b1ff5668abbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_BvfAgreementMember_74a554cb-c39c-4b2f-bc36-2fe946e43be7" xlink:href="rcus-20230930.xsd#rcus_BvfAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_873e3736-d68a-423d-9f81-b1ff5668abbd" xlink:to="loc_rcus_BvfAgreementMember_74a554cb-c39c-4b2f-bc36-2fe946e43be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationAgreementMember_9ec629bd-bbd1-432b-9d1f-3e36e75bb44a" xlink:href="rcus-20230930.xsd#rcus_GileadCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_873e3736-d68a-423d-9f81-b1ff5668abbd" xlink:to="loc_rcus_GileadCollaborationAgreementMember_9ec629bd-bbd1-432b-9d1f-3e36e75bb44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e4e00dcd-09d8-4b86-958d-a148570bb29d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4401f4c1-6fb0-4561-82f3-516dbd7a5b75" xlink:to="loc_srt_RangeAxis_e4e00dcd-09d8-4b86-958d-a148570bb29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27de2269-7ab1-4eff-8df6-48baeb7255c7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e4e00dcd-09d8-4b86-958d-a148570bb29d" xlink:to="loc_srt_RangeMember_27de2269-7ab1-4eff-8df6-48baeb7255c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_702f030a-4e34-4a05-bf56-c66689f154a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_27de2269-7ab1-4eff-8df6-48baeb7255c7" xlink:to="loc_srt_MaximumMember_702f030a-4e34-4a05-bf56-c66689f154a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aa8d980e-01e9-432c-85e1-711252e11f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4401f4c1-6fb0-4561-82f3-516dbd7a5b75" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aa8d980e-01e9-432c-85e1-711252e11f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NonRefundablePaymentsReceived_54383bad-aebe-4528-bca5-6a9f9ee96c62" xlink:href="rcus-20230930.xsd#rcus_NonRefundablePaymentsReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aa8d980e-01e9-432c-85e1-711252e11f20" xlink:to="loc_rcus_NonRefundablePaymentsReceived_54383bad-aebe-4528-bca5-6a9f9ee96c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones_d0c91e3d-5d4e-4778-9dba-807ebf9847ef" xlink:href="rcus-20230930.xsd#rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aa8d980e-01e9-432c-85e1-711252e11f20" xlink:to="loc_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones_d0c91e3d-5d4e-4778-9dba-807ebf9847ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability_2f3df560-2b86-43b7-bd3c-c8a72f30c9bf" xlink:href="rcus-20230930.xsd#rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_aa8d980e-01e9-432c-85e1-711252e11f20" xlink:to="loc_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability_2f3df560-2b86-43b7-bd3c-c8a72f30c9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails" xlink:type="simple" xlink:href="rcus-20230930.xsd#FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_629c5527-3a88-4bdc-8bee-c4fc6a40230b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_59d590df-cd0d-453e-a050-ed1c8b0f777b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_629c5527-3a88-4bdc-8bee-c4fc6a40230b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_59d590df-cd0d-453e-a050-ed1c8b0f777b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_664b4f3f-37a5-4c1b-88b3-9e466f97195e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_59d590df-cd0d-453e-a050-ed1c8b0f777b" xlink:to="loc_srt_CounterpartyNameAxis_664b4f3f-37a5-4c1b-88b3-9e466f97195e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e75a0bc-f08c-40c5-aa78-1f36dc8f9da5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_664b4f3f-37a5-4c1b-88b3-9e466f97195e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e75a0bc-f08c-40c5-aa78-1f36dc8f9da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_BvfPartnersLPMember_40bd70ef-4f89-4234-a57a-506680040c93" xlink:href="rcus-20230930.xsd#rcus_BvfPartnersLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e75a0bc-f08c-40c5-aa78-1f36dc8f9da5" xlink:to="loc_rcus_BvfPartnersLPMember_40bd70ef-4f89-4234-a57a-506680040c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f4b32ef8-1638-480d-ab77-365aff4afcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_59d590df-cd0d-453e-a050-ed1c8b0f777b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f4b32ef8-1638-480d-ab77-365aff4afcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f06d3c4-df69-40ba-9ace-938347cf2ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f4b32ef8-1638-480d-ab77-365aff4afcd9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f06d3c4-df69-40ba-9ace-938347cf2ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_BvfAgreementMember_66853d4d-b342-4089-961b-e4236bb42434" xlink:href="rcus-20230930.xsd#rcus_BvfAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f06d3c4-df69-40ba-9ace-938347cf2ef1" xlink:to="loc_rcus_BvfAgreementMember_66853d4d-b342-4089-961b-e4236bb42434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8c721385-2bd4-4c59-b6a8-ddd85af52200" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_59d590df-cd0d-453e-a050-ed1c8b0f777b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8c721385-2bd4-4c59-b6a8-ddd85af52200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_19781b0a-d327-447a-a704-29088f5a5ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8c721385-2bd4-4c59-b6a8-ddd85af52200" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_19781b0a-d327-447a-a704-29088f5a5ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LiabilityForSaleOfFutureRoyalties_1e4c28c9-bdda-4995-a394-4033c113d92c" xlink:href="rcus-20230930.xsd#rcus_LiabilityForSaleOfFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_19781b0a-d327-447a-a704-29088f5a5ce7" xlink:to="loc_rcus_LiabilityForSaleOfFutureRoyalties_1e4c28c9-bdda-4995-a394-4033c113d92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived_239fde6e-7297-44c9-aa56-2e831767770a" xlink:href="rcus-20230930.xsd#rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_19781b0a-d327-447a-a704-29088f5a5ce7" xlink:to="loc_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived_239fde6e-7297-44c9-aa56-2e831767770a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion_f1c12604-98d0-44cc-929f-6dad92121cb3" xlink:href="rcus-20230930.xsd#rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_19781b0a-d327-447a-a704-29088f5a5ce7" xlink:to="loc_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion_f1c12604-98d0-44cc-929f-6dad92121cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LiabilityForSaleOfFutureRoyalties_a3905f1c-446f-4574-8f63-d6d97255b077" xlink:href="rcus-20230930.xsd#rcus_LiabilityForSaleOfFutureRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_19781b0a-d327-447a-a704-29088f5a5ce7" xlink:to="loc_rcus_LiabilityForSaleOfFutureRoyalties_a3905f1c-446f-4574-8f63-d6d97255b077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OfficersAndDirectorsTradingArrangementMember" xlink:href="rcus-20230930.xsd#rcus_OfficersAndDirectorsTradingArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_rcus_OfficersAndDirectorsTradingArrangementMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_JuanCJaenMember" xlink:href="rcus-20230930.xsd#rcus_JuanCJaenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rcus_JuanCJaenMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>rcus-20230930_g1.jpg
<TEXT>
begin 644 rcus-20230930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$,17AI9@  34T *@    @ ! $[  (
M   6   (2H=I  0    !   (8)R=  $    L   0V.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $)R86YD;VX@
M0V]H96X@*$%R8W5S*0  !9 #  (    4   0KI $  (    4   0PI*1  (
M   #-#@  )*2  (    #-#@  .H<  <   @,   (H@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                 #(P,C,Z,#<Z,3@@,3,Z-3DZ-34
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M@Y&!@$\^I->@U4K23OUO^*L)735NG^=SR>#P7KZ?L]2^&6L,:NQ.+;SH^?\
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MC_OK^= #J*;YL?\ ?7\Z/-C_ +Z_G0 ZBF^;'_?7\Z/-C_OK^= #J*;YL?\
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MISHTD=I"TSHF-S!1G S7G]IX#\2Z3K%GJ6G2:5-+;7=[-LGFD52LY7;R$/(
M.?ZUTUY:ZUXC\):YI][#;VD]PLMM:YW!2NW:'8\G!.2..F.*3;<--[ OBUVN
M95Q\5;*RM7DO]'U"VE^S174,+&,F:*1P@92&('+#@XK<T7Q9#JNJRZ5=6%YI
M>HQ1";[/=JN9(\XW*RD@C/!KF]0^&$(\#-I^BPVL6L2QVZS7-Q-(ZL8V5F 8
MY(4E>@ '3@5H6?@^_P!7UB;4_')T^Y=K3[''9V2OY2H6W$L6Y)) ]A5=?O\
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M:,RBM/RH_P#GFO\ WS1Y4?\ SS7_ +YKA_L.I_.C;ZY'L9E%:?E1_P#/-?\
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MST7\C_A3:* ';!_ST7\C_A1L'_/1?R/^%-HH =L'_/1?R/\ A1L'_/1?R/\
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M\*;10 [8/^>B_D?\*-@_YZ+^1_PIM% #M@_YZ+^1_P *-@_YZ+^1_P *;10
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MG_CW;\/YU1J]<_\ 'NWX?SJC5QV$%%%%4 4444 %%%% !1110 4444 %%%%
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M"Q^4\,PW+RO;&>];^BZ:=(T>"Q,PG,((\P0I$&R2?NH HZ]A5=R5>R+]%%%
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M4_=;^&/'S$<9YK=\$^%=4T3Q#Y^LQS7:C388K:[EG5OLW \R#:#_ 'AD,!C
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MBH&17/\ Q[M^'\ZHU>N?^/=OP_G5&KCL(****H HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J2W_X^%_'^51U
M);_\?"_C_*D]@+]%%%9C*-S_ ,?#?A_*HJEN?^/AOP_E45:+804444P"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@!TO^N?\ WC3:DD*>:V5;.X_Q?_6I
MN8_[K?\ ?7_UJ0#:*=F/^ZW_ 'U_]:C,?]UO^^O_ *U #:*=F/\ NM_WU_\
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M '6_[Z_^M0 VBG9C_NM_WU_]:C,?]UO^^O\ ZU #:*=F/^ZW_?7_ -:C,?\
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MHIV8_P"ZW_?7_P!:C,?]UO\ OK_ZU #:*=F/^ZW_ 'U_]:C,?]UO^^O_ *U
M#:*=F/\ NM_WU_\ 6HS'_=;_ +Z_^M0 VBG9C_NM_P!]?_6HS'_=;_OK_P"M
M0 VBG9C_ +K?]]?_ %J,Q_W6_P"^O_K4 -HIV8_[K?\ ?7_UJ,Q_W6_[Z_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "I+;_CX7\?Y5'4EO_Q\+^/\J3V OT445F,HW/\
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MV!A?YI?>O\BO[0J]E_7S,+^SKK_GE_X\/\:/[.NO^>7_ (\/\:W:*/[ PO\
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M<)"2DI2T\U_D3+,JS5K+\?\ ,****^D/-"BBB@ HHHH **** "BBB@ HHHH
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M>S-#<6UM#)HJ6 QG/FI*K@D 8V87'7/M7H5%-ZN_]=5^HH^ZK+^MO\CR[5_
M'BC7EU*;4)M%BN+O38K-%MC(J*4F5\G*DD84_H,=ZZ#0?"^L0^+)-;U^;3PT
M=@+""/3U<!D#9W-NZ'C@#/Z5V-%']?U][#I;^NG^2/#+%)$U/0O#%K?6-[%8
M:V76.&"5+M5RQ9I0P 4#/49SQZ5UFD?#W5K:?2+#4KG3GT?1IY9K=X5?[1/O
MS\KY^4#YN<$YQ7HV!G..?6EH2TU_K8'JV_ZZ_P"9YE9?#358-)UNUNKRTF>6
MQ;3M*;<_[F NS8<[>#RHXSTJ>7X=ZI))JL O+1+/5M,@MIV^<R1RQ(%4J, %
M"1SD@UZ-12M=6_KK_F'6_P#73_)'E_\ PK/5KJSFFO9["/4H_(^RN+BYN%81
ML&VR&5CA21T5>/4UHWWA'Q)?-9ZLQT*/6;2^-RL4<3K!(NW;AWQN9NX;'%=_
M13L!YOI?P_UJW\06FI:A/IK&/5YM0F6#>!B2,* H*]0P[GWS74^$]"N-!AU1
M+IH6^UZE-=Q^420J.1@'('/%;]%"TV_K;_) ]=_ZW_S84444P"K-G_'^%5JL
MV?\ '^%2]@+5%%%0,BN?^/=OP_G5&KUS_P >[?A_.J-7'8044450!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH\P^B_\ ?(IM% #O,/HO_?(H\P^B_P#?(IM% #O,/HO_ 'R*/,/HO_?(IM%
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MQNB+& Q);<Q.>M3V%SIVH?&F#4=(:*6&[T)I#-$N/-(FVY)[GY0/PH6K^_\
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MO_(_N9HT5G?V]IO_ #\_^0V_PJ_'(LL2R1G*. RG'4&MJ6)H5FU2FI6[-/\
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M+A01ZJZAD//W2/YT_(5S>HKSK5/'?B&TO_$366G:;-8:#*GG&69TED0KDA0
M1N]S@>QJ.W^)NHZAK!.FZ*\^F1W:VKA8)VFYQF3<$,8 S]TMGZ4D[[?U<;T/
M2:*\QM/B'XGFM+"^.D:9+:WU^^GPA;AT?S-S!6.00%^7GJ:KZQXQ\1326%HT
M4-KJEGK\=G-';7++!<AHRP!8C.TY&00?Z4)WM;^MO\T#TW_K?_)GJU%>9S_$
M7Q!;WBZ2VE6$NKQZFEC*D<S>2X="ZE6/(Z<Y!^G:I]0^(6M61U&\&EV3:;HT
MT=M?YG83/(VW<8QC&T%N_6A._P#7I_F@_K^ON/1:*16#*&'0C(S2TP"BBB@
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M /CG_P!>C^Q_^F__ (Y_]>C^Q\=_)^*_S#ZY0_F_!F916G_8_P#TW_\ '/\
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M$4C21L)9"$)!!PI; ')XQCVIL'P[\*VINC!I$:?:XGAD_>/PC?>5?F^0'/\
M#BNFHHL@,V'0-,M[RTNX;;;/9VWV2!_,8[(N/EQG!Z#D\U+I6CV.B:7'IVF0
M>3:1[ML98OC<2QY8D]2:NT4P*<^E6-SI$NER6R+8RQ&%H(_W:[",$#;C'X5C
MVO@#PW9+ MO82 6\JRQ![N9PC*" 1N<]B>.E=)12 Q[7PIHMG;Z9!;6>R/2G
M9[-?-<^4S9!/)YZGKFK>GZ/8Z7]K^PP>5]LN&N9_G9M\C8W-R3C.!P.*NT4
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ML_X_PJM5FS_C_"I>P%JBBBH&17/_ ![M^'\ZHU>N?^/=OP_G5&KCL(****H
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M5)_<;\J/*D_N-^5-HH =Y4G]QORH\J3^XWY4VB@!WE2?W&_*CRI/[C?E3:*
M'>5)_<;\J/*D_N-^5-HH =Y4G]QORH\J3^XWY4VB@!WE2?W&_*CRI/[C?E3:
M* '>5)_<;\J/*D_N-^5-HH =Y4G]QORH\J3^XWY4VB@!WE2?W&_*CRI/[C?E
M3:* '>5)_<;\J/*D_N-^5-HH =Y4G]QORH\J3^XWY4VB@!WE2?W&_*CRI/[C
M?E3:* '>5)_<;\J/*D_N-^5-HH =Y4G]QORH\J3^XWY4VB@!WE2?W&_*CRI/
M[C?E3:* '>5)_<;\J/*D_N-^5-HH =Y4G]QORH\J3^XWY4VB@!WE2?W&_*I(
M(W6=258#U(J&I;;_ (^%_'^5#V O4445F,HW/_'PWX?RJ*I;G_CX;\/Y5%6B
MV$<1J'C_ %"#Q1J6D:7X8N-3_LU4>>6&Y56"LH.0A&2>O /:GS?$S39='TRY
MT6SN=3O=59DM;! $DW+]\.3PH'<\^O3FLJ>S\7:+\1-?U31/#B:C;ZDD*132
M7L<2H50#)4G<1GMQTJG:_#[7O#5OHNL:1]FU'6+&2:2[M2_EI.)?O!&/0CWQ
MZ^QZ(QARJ_9??;_,4KW=C;_X65]FLM536-$GT[5M-MOM36$DRL)8\@;DD P1
MD^G]:L#XCZ>?AM_PEWD'R\;?LOF?-YF[;LSCUYSCIS7.:KX5\4>*/[:UK5=-
MAL;R73#86.FQW*2-RP8LTG"^N.>_MS3A^'.NI=I9- !HWV07I@\Q,?;O(\O9
MU_O?-GI[T.,+:[_U=?=^(+=?UV_7\#L/#_C]-;UC3K&;3FM!J6G_ &VWE,V\
M-@X*8P.1@GZ5:T_QM;WUMK]ZUL8;#197B-P9,^>4&6P,<8X[G.:Y6\\(^(;;
MP+X6GTBS7_A(=$./),J#*L"'7=G;Z=_6I+WP7K47PJTWPMIL6+F\F0ZG<&1?
MW(9M\C')&[!P,#.0*)1@[V?6WX[_ '"BWI?U_#5?>;/A_P"(T.N^$=5UH:=)
M;2Z8C/):/)EF4)O4YQP&'3CM5>#XIV-UX'C\0VMFTC?:DM9K0R@-$S''7'(Q
M@].:QI?!7BC3=5UCR3#JEOK&D/;2R01I;".5$VQ H7.>.,CUYQ69JOPRUQ?#
MVAOH]OLNS%!%JUD)4 <QG*R9)VDCD<'G(]ZM1I.2UT=O^#^7Y$OF4?/7\E;\
M_G8[?QA\1+3PAK%A83VCW/VD;YY$? MH]X7>PP<C)/IT]ZT[KQ0EMXWT_P .
MBU+F]MGN!<"3A0N>-N.>GK7%ZGX$\1^)M=\1W]U<0:;%>)]CMXIH%G,D"X((
M97^3+#//.:A@TOQI::QX9UF7PZU[<Z=ISVES%]MA0ELE0=Q8@Y7!J(Q@XJ[U
M_P T[?<5*]W;^M5?]3:U[XHQZ'<Z[$VE--_8\L$;$3A?-\T$Y^[QC'O5SQ%\
M1]/T'P78>(4@-VE_L\B!9-I.X9.3@],'/'6N/\0>"O$NK7OB6YCTG;_:4]C+
M"AN(CG8O[P9W?PGCG&>U,U'X;Z_+'K=FD GL+2*0:'#YJ#)F<,_4\;0".<=>
M*:C3Y5??3\E?\7^?8=_>TV_S_P CLO%WQ%M_"FG:9</827DNH(9?(CDP8XPH
M9F)P<XR/2I_$?C:32+O1K;2=*.KRZPK-;JERL0( #=6&.0?4=*YNX\$>)->\
M1SW%S-#I=I!IB:=;^=$MSYJLG[T@!QM.<C)[5C7G@[Q5/H_ABWO_  [_ &K_
M &*]Q#+ +Z.$31?+Y9#;LCC\?EYZTU"G=:_UK_P!*]OE^/\ 5STGPEXJ7Q1;
M7F^QEL+JQN&MKFWD</L<>C#@UT%<7\-="U70=,U"/4[--.MY[HRVFGB<3FW4
M]07'7)]Z[2L:B2EH-#I?]<_^\:;3I?\ 7/\ [QIM9C"BBBF 4444 %%%% !1
M110 4444 %%%% !1110 4Y_NI_N_U--IS_=3_=_J:0#:***8!1110 4444 %
M%%% !1110 4444 %.?[J?[O]33:<_P!U/]W^II -IDQ987*%0P4D%^@.._M3
MZ0@$$$9!Z@T/5 MSQ^V\0^)K&UO5U'6;F/5GT^XF2&Y@C>UG*9.^WECZ;5'W
M2#SUK5T7QGXIN+;1]-CMM-N]0FTW^T9YYYGC5H<X X7_ %A[\;176Z?X&\-Z
M7>2W-CI4<<DJ-&<NS*JM]X*I)"@^B@56;X<>$VM;:W;2%,=J6,0\Z3*[NH)W
M9*G^Z<CVI:_U\_\ @?=8>G]?+_@G/:7\0M=UM-*M]+TW3S>W%C)?W/VB5XXQ
M&LA3:A )W''4Y%58OBEK%Y8Z>+'2X)+V:S:\G40SR*5$C($01JQ!.W[S<"M;
MQ%\/DE@TVWT'2=)FMK&.1$BOIIT9-QSPZ$EER3E6!%6]-^&VC#PSIFG:[;1W
MMQ90F,S1N\>0S%F7*D$KD]#Q[4:N]N_^?_ %M_7I_P $JZ]XFU+S?"<UMYVG
M#4A,US;2*-PQ#N"G(SP?I6?\._$VL:QKEG!J5\]Q')H:W+*RJ,R&=EW<#T %
M=S=>'=*O&L3/9J?[/!%J$9D$0*[2 %(&,<<UE2_#[0OL?V>QMWL\PQVQ=)78
MF!9!)Y?S,>ISSUYIK1OU_1H3NTO3]46KW79[;QQIFBK'$8+RUFF9VSN!3& .
M<=ZY#3_B#XDUFZL[32K'2VGN;:XG)G>1$7RYB@Z9)R ./4]17;ZSX8T?Q ;8
MZM9+.UJ286#LA3/!&5(.#Z=*BTSP=H.CW$$VFV @>WB>&(B5SM1VW,,$XY)S
M[=JFS_/]2O\ @?\ !.2L?B1J^J:AI<=CI5L8;G33?7.^4AH0LK(^T_Q<+P,9
MR1S3M!^(NM:M.DAT!I;6[MY9K;[/%.IC*J65'D= C;L8!4D9KK--\):)I%U!
M<:?8^5+;VQM8V\UVVQ%RY7!)!^8DY/-0V/@;PUIUU-/::3"KS1M&P9F=0C?>
M558D*#DY"@53OT\_U_X :?D<B/B?J=OI+F^L+0:E)/#!#:JLZM$TF3^\C9-Y
MQCJ@.X\"K$/Q U^Y>STJ+188=9O+F2&*6Z6:&V=$0.7 =0_?&,=JZ*+X?^&(
M;*>T72U:*X"!_,FD=@$^Z%9F)7';:1BG-X!\,OI*::VE)]F28SKB5Q)YAZMY
MF[?D_6C41S,WB/Q:_CGP_;/'96<%Q;RO=6OF^:&V'YV#*#SMP5'J<&HX/B#K
M]W;Z3?'3M/ATS6;QK>W99G:>-1N'S# &?ESD'CN*Z\^"_#WEZ9&NF1HNE/OL
M]CLOE'.>H/S9(R<YSWJM%\._"L&H+>PZ2D=PLWGJRRR *_J%W8 YZ 8Z<<"D
MUI;^M_Z]/R/Z_ XKPUXU\0VOA70I=7CAN;+4S):QW?VEWNO-^<AV!&,<8QDD
M8Z]JBT7XC:W%X?TVULK1M3NXK$75U).D\KS9=@$4QHV#@?>; [5W6G_#OPKI
M=U%<6.D)'+"C)&3+(VT,,$@%B,D=^OO2S?#SPM/;6L$NDJ8[2/RH@)I =F[=
MM8ALN,\X;(IN[;?]=1);?UV+UWJ,TO@V?4HHY+29K!IU21</$WE[@"#W!KRZ
MQ\2^+7\,3ZG!=ZI);KI#SW%Q?6R1HD^!L,#;1N'7U&*]1M_#EG#<:I(^9$U%
M4B>/[JQQ*FP(N.@ZG\:E_L#3/^$=_L+[-_Q+?)\CR/,;[F,8W9W?CG-*2;;:
MZ_\ !*72_P#6QQ5CK.MZ%K.@Q76I7&NP:Q8R3O;-#&)H72,/E"H7(.=N#^==
MEHVMR:NTPDT?4M-\L#!OHT7?G/W=K-TQ^M0:%X,\/^&IWFT73DMYG7896D>1
MMOH&<D@>PK<JW8E7L%6;/^/\*K59L_X_PJ'L,M4445 R*Y_X]V_#^=4:O7/_
M ![M^'\ZHU<=A!1115 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%!([X!./PKE7\+^+&&BW\;Z-'JFBHT$*%Y7AFB9 I+':&#<=ABDM]?ZW_P"
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M'FM&F(****!A5FS_ (_PJM5FS_C_  J7L!:HHHJ!E74O^0=+^'\Q6!727/\
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M_)?^"']J_P!S\?\ @'%45VM%'^J__3[_ ,E_X(?VK_<_'_@'%45VM%'^J_\
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M%% !1110 4444 .E_P!<_P#O&FTZ7_7/_O&FT@"BBBF 4444 %%%% !1110
M4444 %%%% !1110 4Y_NI_N_U--IS_=3_=_J:0#:***8!1110 4444 %%%%
M!1110 4444 %.?[J?[O]33:<_P!U/]W^II -HHJ*Z:5+29K==\JHQ13W;' _
M.ANRN"U=@ENH()8HIIXXY)FVQ([@&0XS@#N?I4M>%Z;JD^JZQX9>77-0O]6:
MYG-Y:3Q[5M9O*<!4^4;?]W)]>*O1^-+FZTCPW:6^J7G]H16]VNH@EU82+"Q
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MM?H*^O\ 79?YFS1110,**** "BBB@ HHHH **** "K-G_'^%5JLV?\?X5+V
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M3MX_YYK^9_QHWC_GFOYG_&@!M.?[J?[O]31O'_/-?S/^-.9AM3Y%^[[^I]Z
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M_,_XT -HIV\?\\U_,_XT;Q_SS7\S_C0 VBG;Q_SS7\S_ (T;Q_SS7\S_ (T
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M4 <?@*]TBD2:%)8FW(ZAE8=P>E"UBI+J*^K3Z#Z***8PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "K-G_'^%5JLV?\?X5+V M4445 R*Y_X]V_
M#^=4:O7/_'NWX?SJC5QV$%%%%4 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5);?\?"_C_*HZDM_^/A?Q_E2>
MP%^BBBLQE&Y_X^&_#^515+<_\?#?A_*HJT6P@HHHI@%%%% !1110 4444 %%
M%% !1110 4444 %%%% #I?\ 7/\ [QIM.E_US_[QIM( HHHI@%%%% &'XTOK
MG3?!.KWMC*8;B"U=XY  2K <'FL3^V]1'BCP7;&Z;R-0L)9+E<#$KB)6!Z>I
M)XKKM1T^VU73I["_B\VVN$,<J;BNY3U&001^%83_  \\+R:6-/ETUI+99/,1
M9+F5F1L8^5BVY1@#@$"DKIW_ *Z_Y_@#U_KT_P OQ//Y_&/BS[=9C3+DW4C:
MSJ$8MV50)X80K",''IN /J:FB\?:IK6I75OI&IFWMM0U6WM;>ZDB4_9(VB+,
MH!'WB1CG/.:]'MO"6AV9TPVNGI#_ &5O-GL=AY9<88]?F)]6S43>"?#K6^H0
M-I4)BU*4372$MAWY^8<_*>3]W%*UE;^NGYV!Z_UZ_E=&+X+UF[;Q%J.B7]]J
MEV\,8FC&HV*0NBYV_?4_,">1E1TKN*RM"\,Z/X:ADBT2R6V$IW2-N9V<]LLQ
M)./K6K5=$+J%%%% PHHHH *<_P!U/]W^IIM.?[J?[O\ 4T@(I9/*A>0AF"@G
M"C)-0V5]%?VXEA/LRGJIHN=0M;20)<3!&(R 0>E9>;>35$FTBY19I#B2,@[6
M'4GZUPSKR>(C"E.+_FC?5>?R[&_(HTG*::[/IZ%G1)I)4NO-D9]LY W,3@>E
M:E<]>7\>@>%]9U33XWU&2TBEN/(7@NRJ3L''M[UY_P" OBCXK\;V]\MG;>')
M;K[+Y]JD5TZ&)]X&R:-CO(QGYU&W./7C7"T94*,:<W=KJ14J*K-S2LF>PT5Y
M1X+^)/BG6'UJ_P#$=CHUIHN@RW$%_+;O)YH>)<G8&."*D\ ?%B_\5:-KS:OI
MD.GZGIUJ+ZW@&[;-;M'O1N3D]LD=F%=-S,]3HKQ3P5\:M<USQ%X>LM7T_2&M
M]>\U8QI]PS3VQ3/,J$G ...G&3VQ7J6N:T^GZ4;W3OLUV(I4$RF7&%9@O& >
M>>]%P-FBL"XUC5;;6;>WFL;=+>\N7M[<&8F4[8V<2$ $;24QCJ 03S\M7/#^
MI3ZKI/VB[BCAF2YN+=TB8LN8IGBR"0#SLS^- &G17)>*8)=1\7:!I?\ :%]9
MVUQ#=R2_8KEH6<H(MN2O.!N/'O6+XDMKS69X?#7A+4M5%WIB$W=^+^15BS@A
M'8$>9(<< GY0236L87MJ*YZ/3G^ZG^[_ %-9GA^*\M_#.EPZH7-]'9Q+<F1]
M[&0( V6R<G.><G-:;_=3_=_J:S>C&-HHJ*XG6VM99W!*Q(7( Y( S2;25V"U
M=B6BO*3XUU^\N_#.JWT,%GI=[-/,D5G<LTCQK$QV2*0 3QG(/X"IY?B9K=GI
ML%_?Z78I!JEE/=:<(IG=D\M-^V48&<CNM+FW\O\ *X>AZ?17G=KXR\7W5Y9V
M*Z1I'VK4K 7UJ_VJ0)&HQD.-N2>1@#UZGK6SIWC.2^^'\'B-=*NIY9 0UI:+
MYK!@Q4D<CY<C/TIMV3?8%KL=717(>%/%>I^)_!CWZV'V._6#<DEY&8[:5R#\
MRD$DIQR>M<J/%FNZFVB7FK6EFL#ZOY-I-9RS(DZA&R^"1N7(XR.>>*'H[/\
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M+UKX4T6SM],@MK/9'I3L]FOFN?*9L@GD\]3US5O3M(L=)-T=/@\HWEPUS/\
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M"Z_YZ0_]]'_"NAHK#_5_ ]G]YI_:-?R.>_L"Z_YZ0_\ ?1_PH_L"Z_YZ0_\
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MBBB@ HHHH =+_KG_ -XTVG2_ZY_]XTVD 4444P"BBB@ HHHH **** "BBB@
MHHHH **** "G/]U/]W^IIM.?[J?[O]32 ;1113 **** "BBB@ HHHH ****
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MO]0F\ZYN3$(PQ P %'0 >YK=HHI@%%%% !1110 4444 %6;/^/\ "JU6;/\
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M-D_OM^='FR?WV_.FT4 .\V3^^WYT>;)_?;\Z;10 [S9/[[?G1YLG]]OSIM%
M#O-D_OM^='FR?WV_.FT4 .\V3^^WYT>;)_?;\Z;10 [S9/[[?G5FT9FW[F)Z
M=352K-G_ !_A2>P%JBBBH&1W!*P,0<'CD?6J7FR?WV_.KES_ ,>[?A_.J-7'
M80[S9/[[?G1YLG]]OSIM%,!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM^=
M-HH =YLG]]OSH\V3^^WYTVB@!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM
M^=-HH =YLG]]OSH\V3^^WYTVB@!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_
MOM^=-HH =YLG]]OSH\V3^^WYTVB@!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-
MD_OM^=-HH =YLG]]OSH\V3^^WYTVB@!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z
M/-D_OM^=-HH =YLG]]OSH\V3^^WYTVB@!WFR?WV_.CS9/[[?G3:* '>;)_?;
M\Z/-D_OM^=-HH =YLG]]OSH\V3^^WYTVB@!WFR?WV_.CS9/[[?G3:* '>;)_
M?;\Z/-D_OM^=-HH =YLG]]OSH\V3^^WYTVB@!WFR?WV_.CS9/[[?G3:* '>;
M)_?;\Z/-D_OM^=-HH =YLG]]OSH\V3^^WYTVB@!WFR?WV_.I+>1VG4%F(YX)
M]JAJ2W_X^%_'^5#V OT445F,HW/_ !\-^'\JBJ6Y_P"/AOP_E45:+804444P
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!TO^N?_ 'C3:=+_ *Y_]XTV
MD 4444P"BBB@ HHHH **** "BBB@ HHHH **** "G/\ =3_=_J:;3G^ZG^[_
M %-(!M%%%, HHHH **** "BBB@ HHHH **** "G/]U/]W^IIM.?[J?[O]32
M;3)IDMX))IFVQQJ79L= !DFGT4/R QM*\6Z%K8@_LS4H9S<,ZPKRK2% "V 0
M"<9%;->+Z1:ZCH7B?3-1N]$U62W@O]39Q;V,DC!7*A#@#H>Q[U[+$_FPI(%9
M=RAMKC!&>Q'8T+6*8M;M,?1113&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 59L_X_PJM5FS_C_"I>P%JBBBH&17/_ ![M^'\ZHU<O'$=H[-G
MQT^M9?VV/T;\JQGBJ-%\M25F7&G.2O%%BBJ_VV/T;\J/ML?HWY5']H87^=%>
MPJ=BQ15?[;'Z-^5'VV/T;\J/[0PO\Z#V%3L6**K_ &V/T;\J/ML?HWY4?VAA
M?YT'L*G8L457^VQ^C?E1]MC]&_*C^T,+_.@]A4[%BBJ_VV/T;\J/ML?HWY4?
MVAA?YT'L*G8L457^VQ^C?E1]MC]&_*C^T,+_ #H/85.Q8HJI-J,4$S1NKDKU
MP!_C3/[6@_N2?D/\:)9AA82<935T-8>JU=1+U%4?[6@_N2?D/\:/[6@_N2?D
M/\:G^TL'_P _$/ZM6_E+U%4?[6@_N2?D/\:/[6@_N2?D/\:/[2P?_/Q!]6K?
MREZBJ/\ :T']R3\A_C1_:T']R3\A_C1_:6#_ .?B#ZM6_E+U%4?[6@_N2?D/
M\:/[6@_N2?D/\:/[2P?_ #\0?5JW\I>HJC_:T']R3\A_C1_:T']R3\A_C1_:
M6#_Y^(/JU;^4O451_M:#^Y)^0_QHFU6""&*1UD(ESC ';\:?]HX1IOVBLM_R
M_47U>M=+EW+U%9?]OVO_ #SF_P"^1_C1_;]K_P \YO\ OD?XUG_:V!_Y^HOZ
MI7_E9J45E_V_:_\ /.;_ +Y'^-']OVO_ #SF_P"^1_C1_:V!_P"?J#ZI7_E9
MJ45E_P!OVO\ SSF_[Y'^-.BUNVEF2-4E!=@HR!W_ !IK-,%)V51">$KI7<6:
M5%%%>D<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4EO\ \?"_
MC_*HZDM_^/A?Q_E2>P%^BBBLQE&Y_P"/AOP_E452W/\ Q\-^'\JBK1;""BBB
MF 4444 %%%% !1110 4444 %%%% !1110 4444 .E_US_P"\:;3I?]<_^\:;
M2 ****8!1110 4444 %%%% !1110 4444 %%%% !3G^ZG^[_ %--IS_=3_=_
MJ:0#:***8!1110 4444 %%%% !1110 4444 %.?[J?[O]33:<_W4_P!W^II
M-HHJ*ZE,%I-,B&1HT9@@ZL0,XH;LKL$KNQ+17BL/BC5-4U'PKJE[JUCJ$DTU
MQ<#3;6/9);E8FPA(8D@X[C.?6IC\1/$$.FPW8U:POGU+3[FY^SVT"AM->-"R
MYY.1GCYAUI<V_E_E</0]DHKS*QU;QK=:EIVF_P!N6 ?5=+%\LYT_FV(QE0-V
M&SD<GWX[5H6_B_5;OX3P:\K6L.H2$QLSP2R1DB0H2%CRV3C/H*;=DWV_X;]
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M1168RC<_\?#?A_*HJEN?^/AOP_E45:+804444P"BBB@ HHHH **** "BBB@
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M</\ WR?\:/[?NO\ GG#_ -\G_&LNBO-_M;'?\_6=?U2A_*C4_M^Z_P"></\
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MN@&MF# $<<'ZUG>5'_SS7_OFM&Y_X]V_#^=4:/9PEK)7'S-;#/*C_P">:_\
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M .O0 VBG8C_O-_WS_P#7HQ'_ 'F_[Y_^O0 VBG8C_O-_WS_]>C$?]YO^^?\
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MIM^?:2>G48I/8"Q1114#(KG_ (]V_#^=4:OW&/(;/ XZ#WJEB/\ O-_WS_\
M7JX["&T4[$?]YO\ OG_Z]&(_[S?]\_\ UZ8#:*=B/^\W_?/_ ->C$?\ >;_O
MG_Z] #:*=B/^\W_?/_UZ,1_WF_[Y_P#KT -HIV(_[S?]\_\ UZ,1_P!YO^^?
M_KT -HIV(_[S?]\__7HQ'_>;_OG_ .O0 VBG8C_O-_WS_P#7HQ'_ 'F_[Y_^
MO0 VBG8C_O-_WS_]>C$?]YO^^?\ Z] #:*=B/^\W_?/_ ->C$?\ >;_OG_Z]
M #:*=B/^\W_?/_UZ,1_WF_[Y_P#KT -HIV(_[S?]\_\ UZ,1_P!YO^^?_KT
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MA[ 7:***S&4;G_CX;\/Y5%4MS_Q\-^'\JBK1;""BBBF 4444 %%%% !1110
M4444 %%%% !1110 4444 .E_US_[QIM.E_US_P"\:;2 ****8!1110 4444
M%%%% !1110 4444 %%%% !3G^ZG^[_4TVG/]U/\ =_J:0#:***8!1110 444
M4 %%%% !1110 4444 %.?[J?[O\ 4TVG/]U/]W^II -HHIDT?G021!WCWJ5W
MH<,N1U!]:& ^BO)/!FO:Q_PDVD:9<:I=74$EYJ,4IN'WM((@NS)//'MCK7K=
M/=)]Q7U:[!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JS
M9_Q_A5:K-G_'^%2]@+5%%%0,BN?^/=OP_G5&KUS_ ,>[?A_.J-7'8044450!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !4MM_Q\+^/\JBJ2W_ ./A?Q_E2>P%^BBBLQE&Y_X^&_#^515+<_\
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MNQG'RYSG^5;'AGPKJ/AW4;UQK4=Q87=U-=&U^Q[&5W.?]9O/ ^E*.VO];?\
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M 7Z***S&4;G_ (^&_#^515+<_P#'PWX?RJ*M%L(****8!1110 4444 %%%%
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MPDL2V=Q]*[J:>*VA::XE2*)!EGD8*JCW)K)O?%>E6-]IEM).'&J>88)XV4Q
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MHK"\J3_GFW_?-=#<_P#'NWX?SJC7G8K+88N:G*5M+'13KNFK)&9Y4G_/-O\
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M\_']R#^U)_RHY'[%=?\ /M-_W[-'V*Z_Y]IO^_9KKJ*/]6:/_/Q_<@_M2?\
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MW4_W?ZFFTY_NI_N_U-(!M%%%, HHHH **** "BBB@ HHHH **** "G/]U/\
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F2/[QHHHNP#R1_>-'DC^\:**+@2QVZYR>:L@8'%%%)@%%%%(#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>rcus-20230930_g2.jpg
<TEXT>
begin 644 rcus-20230930_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1X>17AI9@  34T *@    @ "  +  (
M   F   (>@$2  ,    !  $   $Q  (    F   (H $R  (    4   (Q@$[
M  (    6   (VH=I  0    !   (\)R=  $    L   1=.H<  <   @,
M;@  $: <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     %=I;F1O
M=W,@4&AO=&\@161I=&]R(#$P+C N,3 P,3$N,38S.#0 5VEN9&]W<R!0:&]T
M;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X-  R,#(S.C W.C$X(#$T.C X.C$T
M $)R86YD;VX@0V]H96X@*$%R8W5S*0  !I #  (    4   12I $  (    4
M   17I*1  (    #,S   )*2  (    #,S   * !  ,    !  $  .H<  <
M  @,   )/@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M #(P,C,Z,#<Z,3@@,30Z,#(Z,34 ,C R,SHP-SHQ." Q-#HP,CHQ-0   $(
M<@!A &X 9 !O &X ( !# &\ : !E &X (  H $$ <@!C '4 <P I      8!
M P #     0 &   !&@ %     0  $>X!&P %     0  $?8!*  #     0 "
M   " 0 $     0  $?X" @ $     0  #!@         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ 2@$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M]/7V]_CY^O_:  P# 0 "$0,1 #\ ]P+L3DL?SI-S>I_.K$&YO4_G1N;U/YT
M+N; Y/YTTN54DL< 9/- &6_B;2DG$#7H$AX VM_A6KN/]X_G0 NXX/S'\Z:)
M,CAL_C0 NYO[Q_.C>?[Q_.@"&]EN8[9WM4$LPQM1FP#SSS]*E#L1U/YT &\G
M^+]:7>?[Q_.@ #D]&/YTH=@<[C^= %S=^ZW>V:H^;DYW_K6;G&.[*46]@\S_
M &_UH\S_ &_UI>VI]Q\C$\X#K(/^^J/.7_GJ/^^J7MZ?</9R[!YR_P#/4?\
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M6%A?XB/^U)O^?5JTHV+QJQ&"0#CTKJP&-J8F34XVL98BA&DDT[CJ*],Y0HH
M**0!13 7L*S;W4+FUE98M-GN% &&C(Y-("N-9O2>=%NP,9SD?E5NSO;BYE*2
MV$UN ,AG(P?:@"_V-9DVMV=O-+'*S QL%.!G.?\ )JDK@64OH9(A(N[:>F1C
M-+]MB^U"WP^\G&=O'3/6H3O)Q[#:TN,U2.26R=([9+ABRXCD.%/S#K].OX57
ML+(M PO-/MH6#Y58_F';GZ\4Q%G^S++S6D-I$79MQ8ISGUH?3+*2%H6M8C&Y
MRPVXR>#_ $'Y4 ']FV7'^B1<=/D%20VEO;DF&".,GJ57% &I_P L/^ U1I(
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M7OG-9]3+_P >LG_71/\ V:CEB!*NK773S.W]U:7^UKK_ )Z?^.K5)>E+1RQ
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M44 %%%% !1110 4444 %%%% !1110 5,O_'K)_UT3_V:H:F7_CUD_P"NB?\
MLU)@0+TI:1>E+0 4444P"BBC\_J.Q]:3=E<:5W8**^>Y/%<NG_M8>,=+NM8-
MK9MX0M_L=G-=F.,SM*XS$CD8D/;'I7C_ ((^)4^L?#?]GO1+7Q5+>>*AXIVZ
MO81Z@SW?D(UP'$\8;>54;"0W& 3VI*7-KYK\[?H9WM]U_P $S[DHK\TM+^*7
MC[PY\"=)MM6U?5-0TWQ1K22Z3JZSN9K.:&^,<]J[ELE'C4.O.#F0#/-==XL\
M=R26OB[Q1XA\1Z]_PFUAXAN;;^RM/\7II$VD6L;+]G%O;2*RS"10/^6;;LD]
MZ.:[3[_I;_,TDN5N/;_@_P"1]_T5F>%]1N-8\,Z1?W=K+8W5U:13RVLY_>0N
MR LC<#D$GH%&<\"M.M):29$=0HHHJ2@HHHH EM_O/_US?_T$U%_$:EM_O/\
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MGU')GM611@:I_P ?\OU'_H(JI1K6IV]OJ4R22[6XXP3_  CTJE_;5G_SV_\
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M0V_^)H_X2K2_^?K_ ,AM_P#$T_[:RS_H(A]Z#ZGBO^?<ON-:BLG_ (2K2_\
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MBBB@ HHHH **** "IE_X]9/^NB?^S5#4R_\ 'K)_UT3_ -FI,"!>E+2+TI:
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MB]BCT'1=2N]4T^T@N[@H9;B*>+ MV.R$JMRX+AI"?O*L6]E/KJYZEMK'GG
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MA)Q@DGBNLU#]FOPOJND^/]-EO=4%MXV>W?43]HC+1>4JJHB+QY ^7G=N)/\
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M\]I/^^J-0(:*F^V7'_/:3_OJC[9<?\]I/^^J-0(:*F^V7'_/:3_OJC[9<?\
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M[2?]]4?;+C_GM)_WU1J!#14WVRX_Y[2?]]4?;+C_ )[2?]]4:@0T5-]LN/\
MGM)_WU1]LN/^>TG_ 'U1J!#14WVRX_Y[2?\ ?5'VRX_Y[2?]]4:@0T5-]LN/
M^>TG_?5'VRX_Y[2?]]4:@0T5-]LN/^>TG_?5'VRX_P">TG_?5&H$-%3?;+C_
M )[2?]]4?;)_^>TG_?5&H$/I]1_.J]7?MD^1^^ESD?Q>]1?;+C_GO)_WU4R
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MG_ZYO_Z":B_B-(84444Q!1110 4444 %%%% !1110 4444 2V_WG_P"N;_\
MH)J+^(U+;_>?_KF__H)J+^(TM>@PHI>?X3SD8XSSG&?U-<AXI^+GA+P7XJT7
MPYK.LQ6&LZR?] M)8F(F^;;G(4@>O.*7-R^ZQ'745F^'/$FE^+M%MM7T6_@U
M/2[H%H;NVDWQR8)4X/3C&/PK2JB0HHHH*"BBB@ HHHH **** "BBB@ HHHH
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M_"06_P#=D_[YH_X2"W_NR?\ ?-<[CWHQ[UQ?ZWYE_-'[C?\ LN@=%_PD%O\
MW9/^^:/^$@M_[LG_ 'S7.X]Z,>]'^M^9?S1^X/[+H'1?\)!;_P!V3_OFC_A(
M+?\ NR?]\USN/>C'O1_K?F7\T?N#^RZ!T7_"06_]V3_OFC_A(+?^[)_WS7.X
M]Z,>]'^M^9?S1^X/[+H'1?\ "06_]V3_ +YH_P"$@M_[LG_?-<[CWHQ[T?ZW
MYE_-'[@_LN@=%_PD%O\ W9/^^:)=?@CLYKDK)LBP&^4=\XZD>E<[CWJ2;_D
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M ,-^B-@= ,8X'7D]/6BEY& >PX!ZXI*KN+L%%%%( HHHI, _S^HKK%Z5R?\
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M\6@"*BI?LS?WH_\ OXM'V9O[T?\ W\6@"*BI?LS?WH_^_BT?9F_O1_\ ?Q:
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M\6@"*BI?LS?WH_\ OXM'V9O[T?\ W\6@"*BI?LS?WH_^_BT?9F_O1_\ ?Q:
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M3+_QZR?]=$_]FJ&IE_X]9/\ KHG_ +-0QD"]*6D7I2T %%%%, HHHH ****
M"BBB@ HHHH **** "BBB@"6W^\__ %S?_P!!-1?Q&I;?[S_]<W_]!-1?Q&D,
M****8@HHHH **** "BBB@ HHHH **** );?[S_\ 7-__ $$U%_$:EM_O/_US
M?_T$U%_$:%OJ,**7GL,MD8^N<_TKYJ_:OT6VM_B'\'=<BWIJBZ[]B$JSL%,/
MEO)AAD#&0#ST(&.]93DX:H$KGTI17B'[&OBP>)?V?_"?VG6!JVLK!,UQ]INO
M.N<^?)@R$DD' P,]AQ7N&>G.>,]<UT2CROE(C/FBI=Q****@H**** "BBB@
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M3J5P-5MHY[>6>-&VPVS.DUPL8?#.H!^4C! K-/FT8VN5H^FZ#M&2V %&2S'
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M HHHH **** "BBB@ HHHH **** "BBB@"6W^\_\ US?_ -!-1?Q&I;?[S_\
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M9"6BNF";\*X!097..>>W0US.L?M(?#7P_#/+?^*[6TCAOYM,):.93Y\.#,@
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M '0^W77_ #VD_P"_E'VZZ_Y[2?\ ?RC[#=?\\9/^_='V&Z_YXR?]^Z/^%/\
MO_B'^S_W0^W77_/:3_OY1]NNO^>TG_?RC[#=?\\9/^_='V&Z_P">,G_?NC_A
M3_O_ (A_L_\ =#[==?\ /:3_ +^4?;KK_GM)_P!_*/L-U_SQD_[]T?8;K_GC
M)_W[H_X4_P"_^(?[/_=#[==?\]I/^_E'VZZ_Y[2?]_*/L-U_SQD_[]T?8;K_
M )XR?]^Z/^%/^_\ B'^S_P!T/MUU_P ]I/\ OY4DUY<+HE_)YTGF*8]K;R<?
M.,]*C^PW7_/&3_OW4DUG<-HE_'Y,GF,8]J[",_.,]*]# _VA[27/SVY9]_Y6
M95/8>[;EW7YHYI=6O]O%Y<$<?\MFI?[7O\_\?=Q_W^:D&D7^.+.X X_Y8M2_
MV3?Y_P"/2X_[\M7S2_M7KSV_[>\CVU]5Z\H?VM??\_=Q_P!_FH_M:^_Y^[C_
M +_-1_9-]_SZ7'_?EJ/[)OO^?2X_[\M1_P *O_3S\1_[+_=#^UK[_G[N/^_S
M4?VM??\ /W<?]_FH_LF^_P"?2X_[\M1_9-]_SZ7'_?EJ/^%7_IY^(?[+_=#^
MUK[_ )^[C_O\U']K7W_/W<?]_FH_LF^_Y]+C_ORU']DWW_/I<?\ ?EJ/^%7_
M *>?B'^R_P!T/[6OO^?NX_[_ #4?VM??\_=Q_P!_FH_LF^_Y]+C_ +\M1_9-
M]_SZ7'_?EJ/^%7_IY^(?[+_=#^UK[_G[N/\ O\U+_:U]_P _=Q_W^:D_LF^_
MY]+C_ORU+_9-]_SZ7'_?EJ%_:EU?VGXA_LO]TTO#>I7<^N6R27$[J=QVF1CT
M4UQ@\0:F./[1N@!P,3L*[/PWIMW#K=L\EO.BC<-QB8=5-<8OA_4VY_LZZ(/(
MQ;M5X_\ M3ZA1Y?:7YY]^T18?ZI]9G?E^%?FQ?\ A(-2_P"@C=_]_P!J/^$@
MU+_H(W?_ '_:C_A']3_Z!MY_X#M1_P (_J?_ $#;S_P':OG?^%G_ *>?B>K_
M +%_=_ /^$@U+_H(W?\ W_:C_A(-3_Z"5W_X$-1_PC^I_P#0-O/_  ':C_A'
M]3_Z!MW_ . [4?\ "U_T\_$?^Q?W?P$;Q!J?_02NR,$?Z]C7HGP[O;B^T>X>
MYN)+EQ<,-TCEOX5]:\[;P_J?_0-NP,$_ZAA7HGP[L[BQT>X2YMY+9S<,=LB%
M?X5]:^]X'_M'^U8_6.?EY7O>Q\]GOU;ZK^[M?RL=31117]%GYP%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 >GU'\ZKU8]/J/YU7J9;@66ZGZG^
M=)2MU/U/\Z2J[ %%%% !1110 4444 %%%% !1110 4444 %%%% !4R_\>LG_
M %T3_P!FJ&IE_P"/63_KHG_LU)@0+TI:1>E+0 4444P"BBB@ HHHH **** "
MBBB@ HHHH **** );?[S_P#7-_\ T$U%_$:EM_O/_P!<W_\ 0347\1I#"BBB
MF(**** "BBB@ HHHH **** "BBB@"6W^\_\ US?_ -!-1?Q&I;?[S_\ 7-__
M $$U%_$:$,4=:^9/V@K?7[C]I;X-?\(Q_91UQ++5WMUUI7-LV(8]RL4^9<KN
M 8 X)'!S7TU2,JL02NXCI465XR87?*XKJ?)WA7]EGX@?#[5]#\5Z+JOA>]\5
M^9J7]JV>HQ7/]GQ"[?S";8 ;P5("X8("IZKWJ^#OV5_B+\-8-&U/1+_PCJ.O
M1:5?:+?VFK1W#6)AGNWN%>%1&68C?AHR K88!ADD_7GOWHIQBHVMT'JXV9Y#
M\4O@_JWBSX4Z'I&A7.CV'BWP[<VFH:9=_9S:V$5S X#XC3<4A(,B@8.,@9XK
MSK5OV5_%%C\-_!NDZ#<Z,?$VEV]X+[5I[V]LKA;FY&^:2&:+[R&3@QR1LKKC
MI@Y^HZ*25G=BD[Z'G?AKPGXSE\/:KX;\6:GI-]I4FCP:=;7^FQ217DDK0%+A
MY5($8!<@IL SW(XKYFU#X0^,/#/B[X,>!_%-WX>?2XEU?2-,NM&MYEN)(WLI
M 9)R^%5L8^1#]Y3\QR*^W:1E5L;EW8Z43@GN.+L[GR=;_LN_$37K7P?HWBC6
M?#<>A^'M#U'08I])%P;F6.XM_(BF8.G+#";E! !5N7_AS5_8[\9ZEX'U[3-2
MN] ;5SH":'I5\NK:I=L5$J,[OY\A2)"(PWEQQ$9S@CO]B454HQ>_];_YL(_"
MD>*_\*-OF^*%WXD8:4UA)X+7PTD*EPXFW[BV/+.(BI X8M_LUXS<_L6^-Y/#
M+:<FIZ MQ_PC^EZ2K&YG51+;7HN')Q%]TH#C_:(RO0U]H44M.92_KK_FS.23
M7+_73_)'DGQP_9G\)_'B;2;K6;<1W^GSQ 7*J[%[99"[VQ D50'#8+<M\W!Z
MBN,_:6\)Z7X!\"_#R_T:^TOPY!X/U>&33H]9M[J?3N4=%CF>)7DB4+TE(X/&
M>:^CJ&4,,$;AZ4G#F6IHFEL?"7P]^$GB'XTV7B+Q?H^HZ9_:%GXVGU.UN+>>
M\T[3]15K9(I_)GA/G( <[9."3NXYX]9^'_[,.L>$?'7P^U^X?1%.CR:K=:O%
M:SWDIDN+M$4/$T[2._"89G89.2%Y-?2BJ%& -H]**<$HM6Z?Y)?H3+6_G_FW
M^I\S6?[,^NZ7\//"&CK/HJ7VB>./^$HGFB,I7[*)Y7*(1$&:8(R+M./N\$UE
M^&O@CXB^(?P1TJ6:VCTC7=6\:_\ "7ZC::P)(9%B^T.WE$!68-Y2( "!UZBO
MJVBI4%RV_KI_DBYR;U_KK_FSYD^(G[,?BGQ#XX\5^*=&U#0X+Z?Q#I>O:1;W
MRRO!(]K;O$R7*JOW6+9! 8^I'4<]JO[+?Q.UGQ%=^(I[_P &Q:W<>++#Q+Y,
M?VHV:^1;O&8F4QECABI^\-P!;<OW:^O**K6*;6W^5O\ )$NSLWT_X/\ F?/_
M ((_9B@UEO%VI?%73]!UW4_$6IQZD=/TQ9?L-IY<)B1U+D$L49BQQU(ZXKVO
MPMX5TGP3H-KHNA6$6F:5:[E@M800D8+%B!DG^(M^=:M%-[<O;]-!)6NP_P _
MJ*ZQ>E<G_G]176+TK*IT&AU-;I^%.IK=/PK$HY[5?^0A-]1_Z"*J5;U7_D(3
M?4?^@BJE=22LB;L****=D 444460!11119 %%%%%D 444460!11119 %%%%+
ME78+L****.5=@NPHHHHY5V"["BBBCE78+L****.5=@NPHHHHY5V"["BBBCE7
M8+L****.5=@NPHHHHY5V"["BBBBR6R"["BBBJ$%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 >GU'\ZKU8]/J/YU7J9;@66ZGZG^=)2MU/U/\Z2J
M[ %%%% !1110 4444 %%%% !1110 4444 %%%% !4R_\>LG_ %T3_P!FJ&IE
M_P"/63_KHG_LU)@0+TI:1>E+0 5Y9\>_C!??".T\*_V?I]A?7.O:Q'I"MJ5X
M;2"#>CMYC2!6P!M].F:]3KSCXS?!>S^,Q\(PW]S EEHFM1:K+9W5DMU%?*J.
MI@96=0 V[[V&_P!TYJ9<UO=&C@+/]JV6Z^#^O^)F\/P2^(M-UP>'+?3;"],U
MKJ5\61$^SS%!E&WD_=Z(U4_%'[8B^'?A5X#\:1^&I+X:[J#:?J.FPS%IK)HP
M_GA $^=E\M@!MZ 5V_Q'_9VTKXA2^#+*UU!_"OA;P_=27J:3H,0LVDGV$121
MRHR^3L.Y@%3/)Z=:Y+0?V05\/ZQIDEMXON[C1M/\4+XGM['4K4SS>88=DL+S
M&4%RYP^\C/KG.2:V?;2WX7_4.GW_ *_\ AUW]L2ST_7O$NG:7HJ^(/(?1[?0
M3:W80ZI-J$9>,,6_U*@ Y(#8ST&>;OB[X]?$'X9?#_Q5KOB_X=6EE<Z3!!/;
MW%EJHFL+KS)DA,9.P/&ZF0'!4[L$CI658_L.Z!I=]XRDT_7KO3[?5KZSU'2%
MMX%\S1;BW9FC*,S8D0%R-A0;4 7)Q6OXB_9H\4^// _BK1O%WQ5U#Q#J&LPP
MP0W"Z:D%E:QQS1RDBTCD >1BA!8MT(XHU;UW_P" O^":+DY]=KJ_K8Y77/VS
M-6\,Z3XF6_\ #>B76IZ*NG2^=INLF>R>*ZD" 23>2#%(IP2I4\$^E=SXB_:$
MU#PS\(;?Q.MGX>\4Z]J6J1Z9I5AX9UDWMI>2,X38MP4'*A9"5V\%:P->_8ZA
MN/"GC#PSH7B6#0]#US4;/58;+^R1,EG<P[/, 'FJ&20HIV-C;@]<UJZG^S'J
M/BR;PHOB?QM(UKX?FN+F.'PMIPT9WFE*JD@>.8E&3GD9SO.2.ZUM9;Z?\$Q]
M>WXZ_P# (/&'[2NLZ=^S_I'Q6T#P_INHZ6UHLNIV=Y?R1S6\QE6(Q1JL)#[7
M9LY*<)D9Y%0>,/VHM3^%?B"ZTKQMX?L+>6U\-2:[(VCZ@]QEOM0@AA0M&A^8
MLOS$ #)X-6O^&4?)^"_C+X;6_BVX;2=<U'[=9375H9Y+)3)'(T1/F#S0S(3N
MPO+G@UM?$K]FG2_BGX[O-<UG59#IUWX9/AV2QA@VR*?M G2Y23<0K*RKA2AQ
MZUH]].[^ZQJN3EE??I^'_!-'X>^/OB3JWB&SM?%_P[AT+3;ZW-S%J6GZHMR+
M1L#$,\9C0AB#G<N1UYKU,-NY_+'3'MW/?FO*?A[\(O&/AOQ):ZGXH^*.J>+;
M2Q@-O8Z9%916%OS_ !3[&)G< #YCC'/J:]6SP!U]"!@$>WZU6G*C/[3"BBBI
M EM_O/\ ]<W_ /0347\1J6W^\_\ US?_ -!-1?Q&A;C"N4\>?%+PK\,FTC_A
M)]7CTG^UKI;&RWQR.99FZ* BDCM\QPHSS75XSCWX)]..OYX_.OESXV_#T?M%
M:E\2K>,!D\+Z6+#2F_NZEQ<R'Z?)%$?]EFK>C"-1^]L(^HE^Z#G@\^V?KT/;
MD<4M>$?"7XS:+\7O@;I*W6M+#K]SIS0W$,%R8YUGB4ASD$8)9"?Q%>3?#KQ/
MX6U#X'6FJZU\1]=M?',MG<OL@UB9[@3)+((PL))#\*O&#FK6'>HN8^T**^4/
M!/CGXA_%6^\ ?#_6[ZZ\-ZFV@MKGB>\MU$-[-'O\N&%6ZPN^49CMR 3ZUZM-
M\*]8\)^+/#&J^%-<U6?3(;LC5=(U#4&F@E@:-AYJ>9E@5)! SSQTJ945!V<@
MYGT/66./;WJC?:]IVFRB*[O8()#_  ,^35"U\<>';[5_[)M]6M9]15FA^S+*
M"^Y6.0<="#QCMBN/GNK?3=8UT75FVIR2MO$D:>84[;6/\(KY?-LQEE\(./6^
MK\M3U<#@XXGF4NAZ7'(DR!T<2*PR&!R#3JY[P#$8?"]HOF+(#N8!'WJF6/R@
M^U<#^T8U[>0_#[1K35]3T6'6?%,%C=SZ1>O:3O";6Z<H)$(*@F->XZ5Z^"J_
M7*4*LM.97MT1QXB"HU94ET/7Z*^;?BKI4\-AIOPB\%>(/%FI>-;B4Z@=1F\0
M7(DTVW^93/=W*ON,?W@EN3AG Z5Z;^SYX=\3^$OA+HVD^,KV\U+Q#;2W8GO-
M0N?M,\R&ZF,+.^]R<Q&+@L2HP.,5W2II04T]SFYCTJW^\_\ US?_ -!-1?Q&
MI;?[S_\ 7-__ $$U%_$:QW&'\0KY/_:QBLKKXX?"BWU72M>UW1Y+#5OMFF^'
M))%NYT$4? $<B,P!.2 <E=P .<'ZP/0_S]JY[5O >BZYXOT7Q1>67FZYHJ3Q
MV5QYK+Y:3(%D^4, V0J]<]*32;C)] O:FXKJ?%&D>"?&4-OX';QKX7\?:QX
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M **** "BBB@ HHHH /3ZC^=5ZL>GU'\ZKU,MP++=3]3_ #I*5NI^I_G2578
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *F7_CUD_P"NB?\ LU0U,O\
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MJ*!$OVEO[L?_ '[6C[2W]V/_ +]K45% R7[2W]V/_OVM'VEO[L?_ '[6HJ*
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MW]V/_OVM'VEO[L?_ '[6HJ* )?M+?W8_^_:T?:6_NQ_]^UJ*B@"7[2W]V/\
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M HHHI, _S^HKK%Z5R?\ G]176+TK*IT&AU,DZ4^HY,]JR*,#5/\ C_E^H_\
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M;?G0#^%N!GWJ.^\ ^&=0BMX;OPYI5W';VC6$*26$;".U<!6MTRN%C(QE1\I
M]J<E+7MK^O\ P/N".EF^EOT_6_WGSG^RQJUQ-X^\;0)9VLDMKX7\.R1R)#%'
M/.6L </+@$@^K9Q^)KH_@;\5OBGXP^*GC+2?%?A"'2]&L[Q$DD_M*&9=)8VZ
M.(1M13.'8JV[/RY [5[CH_A'0_#UW/=:5HVG:==W$<4$MS9VJ0M)'&I2)25
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M8[;["M_';1K.EMG?Y0<@%4SSMZ<UHJ=[$E=IZD8SVZ =#UX]ZTU]U]/^'M^
MG%:KT_3_ ()\C?&K]H'QEH?C+XGVND^,-#\'6OA#3X9++2]2M$N+C5Y)8MY>
M-GDSO!.U2BL,E=PQ7-WG[4GQ,NO$$IT^?3H1I(TR$Z7>?8+>+4FG@BDD=YIK
MN*1&;>QC\F-@< $DY%>U?&O]G'4/BUKUY=)XGT[3["\L/[.DCN?#EO>7=O'@
MA_LEV=DD>]69<'=@[L8[^E6?PN\)VLNBW4GAW3+S4](MXK6SU.XLXI+J%8P
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M-X0\#VNJ(EUI"7C321 AD#>8C NL?4YQC@9Q7(ZQ^U/X[\0Z;X@U*W\6>'O
MW]B^%+'5H]-OK-)FU>:YMO,8PEY 5"-A%"A_F8;MQX'V7-X5T2ZU&ZU"?2+"
M>^O+;[!=7<UI&TEQ;<_NI&VY*<GY3QS65>?"OP7JR67VWPAH-Y]CMS:6WVC3
M(9?)A*LIC3<ORH5+#:.""1WJN5O?^M6_U_ 4;)?UY?Y/[SXH@^*GBO3?'GQ+
M\367CS1/"^K#PSHNM20:K;),=3E&GJY@A0R1K&'9R&94+9=!@9Y^H_"OQ.^(
MWBBQ\,ZA#\.+)]%U2RL[J>^D\0&WFA$L2/+FW,!.5W/\I<%A@\YKL;OX1^!+
M^82W'@GP]<NHA >32[=W'E+MBRVWHBX"C^$' KK%78JJ  H  VC"X[ < X_R
M*OI;^OZ_R&^G]=$OT_$5OO'G=R>?QI***EB#_/ZBNL7I7)_Y_45UB]*RJ=!H
M=3).U/ICGM6,MBCS?Q5QKMS_ ,!_]!%9.X5U&N:-]LU.>4R[-VWY=N?X15'_
M (1O_IO_ .0Z_&,?PYFF)Q=6K3I7BY.SNNY]90QM"G2C&4M48NZC=6U_PCG_
M $W_ /(='_".?]-__(=<'^JV;?\ /G\5_F;_ -HX;^8Q=U&ZMK_A'/\ IO\
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH /3ZC^=5ZL?X5/\ 8ZF6X&GJ&E^<WF1D!CUSWK+>QFCZPM]<9KJ*
M0]#62FT6<F5*]01]1BDKI)(48\KFHUMHN?D%5[1D'/T5T/V6+^X*/LL7]P57
M.!SU%=#]EB_N"C[+%_<%'.!SU%=#]EB_N"C[+%_<%'.!SU%=#]EB_N"C[+%_
M<%'.!SU%=#]EB_N"C[+%_<%'.!SU%=#]EB_N"C[+%_<%'.!SU3(P6W?)Q^\3
M_P!FK;^RQ?W!1]EB_N"DY@<\,[1QBBNA^S1?W!2+;1<_(*7M&!S]%=#]EB_N
M"C[+%_<%5S@<]170_98O[@H^RQ?W!1S@<]170_98O[@H^RQ?W!1S@<]170_9
M8O[@H^RQ?W!1S@<]170_98O[@H^RQ?W!1S@<]170_98O[@H^RQ?W!1S@<]17
M0_98O[@H^RQ?W!2YP,.W8*[$_P!Q_P#T$U&5*D@^IKH/L\7]P4?9XO[@I*HP
M.>HKH?LL7]P4?98O[@JN<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X
M*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%(;:
M+(^04N<#$MS\[?\ 7-__ $$U&S9KHFMXR!\@IOV6+^X*2J,#GJ*Z'[+%_<%'
MV6+^X*KV@'/45T/V6+^X*/LL7]P4N<#GJ*Z'[+%_<%'V6+^X*?.!SU%=#]EB
M_N"C[+%_<%'.!SU%=#]EB_N"C[+%_<%'.!SU%=#]EB_N"C[+%_<%'.!SU%=#
M]EB_N"C[+%_<%'.!SU%=#]EB_N"C[+%_<%'.!SU%=#]EB_N"C[+%_<%'.!SU
M%=#]EB_N"C[+%_<%+G Y\*6X )^@S4\.G3S' C*?[1&*W([>-3PH%6< =JGV
MC&BI8V"6JYZOW-6Z6BLV[E!112-2 AO+=+B$J_'H:Y^XLY;>0@\^]=,*;(H8
M<C-5&7*)G*45T36\9/W!2?98O[@K3VC).>HKH?LL7]P4?98O[@JN<#GJ*Z'[
M+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*
MZ'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X*.<#
MGJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X*
M.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+
M^X*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%'
MV6+^X*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_
M<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ*Z'[
M+%_<%'V6+^X*.<#GJ*Z'[+%_<%'V6+^X*.<#GJ/PS70_98O[@I5MXMWW!2YQ
:HSM.L6E<.PP!6SY*>E.50HX&*=6+=V4?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>rcus-20230930_g3.jpg
<TEXT>
begin 644 rcus-20230930_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $=!-H# 2(  A$! Q$!_\0
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MO_CH_P *IT4678"Y_:UW_P ]?_'1_A1_:UW_ ,]?_'1_A5.BBR[ 7/[6N_\
MGK_XZ/\ "C^UKO\ YZ_^.C_"J=%%EV N?VM=_P#/7_QT?X4?VM=_\]?_ !T?
MX53HHLNP%S^UKO\ YZ_^.C_"C^UKO_GK_P".C_"J=%%EV N?VM=_\]?_ !T?
MX4?VM=_\]?\ QT?X53HHLNP&A<:G<I( LF!L4_='=0?2H_[6N_\ GK_XZ/\
M"H;K_6+_ +B?^@BH:++L!<_M:[_YZ_\ CH_PH_M:[_YZ_P#CH_PJG119=@+G
M]K7?_/7_ ,='^%']K7?_ #U_\='^%4Z*++L!<_M:[_YZ_P#CH_PH_M:[_P">
MO_CH_P *IT4678"Y_:UW_P ]?_'1_A1_:UW_ ,]?_'1_A5.BBR[ 7/[6N_\
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M_P#'1_A1_:UW_P ]?_'1_A5.BBR[ 7/[6N_^>O\ XZ/\*/[6N_\ GK_XZ/\
M"J=%%EV N?VM=_\ /7_QT?X4?VM=_P#/7_QT?X53HHLNP%S^UKO_ )Z_^.C_
M  H_M:[_ .>O_CH_PJG119=@+G]K7?\ SU_\='^%']K7?_/7_P ='^%4Z*++
ML!H2ZG<K'"1)@LF3\H_O$>GM4?\ :UW_ ,]?_'1_A4,W^KM_]P_^A-4-%EV
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M_P">O_CH_P */[6N_P#GK_XZ/\*IT4678"Y_:UW_ ,]?_'1_A1_:UW_SU_\
M'1_A5.BBR[ 7/[6N_P#GK_XZ/\*/[6N_^>O_ (Z/\*IT4678"Y_:UW_SU_\
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M_M:[_P">O_CH_P *IT4678"Y_:UW_P ]?_'1_A1_:UW_ ,]?_'1_A5.BBR[
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MUBS\/Z1<:IJ$PMK"R^-\MS<3$$A(T4LS8 ). ">*47[_ "RVT_\ 2HI_A+\
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M4WU30O UYJMKJFCZM&\EA,C6UO(LUU&>"%8.P)(YR1U'#YG[SVMKKT^!Z_\
M@3^:ZZF?\J[_ (ZR6GI9?)^A]-6?Q4\*:AJGA[3;368;N]\06C7^FQ6Z/)Y]
MN "9<J"%7!ZL1SQUXKJZ^!_ WQ!N/@R^G^.K?PQ \/B6S:#0;/4[J2.6#1[:
M6..WL[?".7N9_,,Q!.#MSWX^]T;<JM@KD9P>HK6VE_7\]O5+?SOT)ZV_KU].
MWD+1112&%%%% !1110 4444 %%%% !1110!<TG_D(1?C_(UT5<[I/_(0B_'^
M1KHJPGN4@HHHK,9R-%4_[8L_^>W_ (ZW^%']L6?_ #V_\=;_  KD_M;+O^@B
M'_@<?\S;ZM7_ .?;^YERBJ?]L6?_ #V_\=;_  H_MBS_ .>W_CK?X4?VMEW_
M $$0_P# X_YA]6K_ //M_<RY15/^V+/_ )[?^.M_A1_;%G_SV_\ '6_PH_M;
M+O\ H(A_X''_ ##ZM7_Y]O[F7**I_P!L6?\ SV_\=;_"C^V+/_GM_P".M_A1
M_:V7?]!$/_ X_P"8?5J__/M_<RY15/\ MBS_ .>W_CK?X4?VQ9_\]O\ QUO\
M*/[6R[_H(A_X''_,/JU?_GV_N9<HJG_;%G_SV_\ '6_PH_MBS_Y[?^.M_A1_
M:V7?]!$/_ X_YA]6K_\ /M_<RY15/^V+/_GM_P".M_A1_;%G_P ]O_'6_P *
M/[6R[_H(A_X''_,/JU?_ )]O[F7**I_VQ9_\]O\ QUO\*/[8L_\ GM_XZW^%
M']K9=_T$0_\  X_YA]6K_P#/M_<RY15&YUNRLXXI)9MB2YV'8QSCKT%5_P#A
M*M+_ .?K_P AO_A1/-LNIOEGB()Z/64=FKKKU6J\BHX3$25XTY/Y,UJ*R?\
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M?A'^JN<?\^/_ ":/_P D?9_VCA?Y_P '_D8U%;/_  CO_3Q_XY_]>C_A'?\
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M %%%% !1110 4444 %%%% !1110 4444 377^L7_ '$_]!%0U-=?ZQ?]Q/\
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M*A1XW&0RD8((]"*^>(_V&?!$/V."/Q%XP72M/U)-3L-(;5@]E92*Y;;%$T9
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M_GJ?/(_8?\#QRHD.N^+(-+AU--6M-%350;"TF5]W[J%D( .<$MEL="*[6/\
M9W\.1V/Q*M!>ZIY?CYW?4R98\PED9#Y'[OY>&/WMW:O4:*GE7+R]+6^6G^2^
MX=[RYNN_Y_YO[SS&X_9Z\-7;?#GS[C498_ ML]II\;R1E;B-H%A87 \OYOE0
M?=V\D_2N"C_89\$0_8X(_$7C!=+L-234]/TAM6#V5E(KEML431D!23R3EN/O
M#)S]%T5?VN;K>_SW%O'EZ6M\M?\ -GGGQN^!OA_X]>%[;1/$$]_9Q6UR+J&Z
MTR5(YT8*RD!F1A@JQ!&*I^)OV?="U[0?#&F6.L:]X7;PY;BTL+S0;X6\PAV!
M"C@JR." ,Y7UQC)KT^BIY59KOK^GY#N]'VT/,/ ?[/F@_#:X\,'0]5UZWL]
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MFC[9/_SWD_[[-&H$-%3?;)_^>\G_ 'V:/MD__/>3_OLT:@0T5-]LG_Y[R?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML=LGM4E<3-4%%%% $UU_K%_W$_\ 014-377^L7_<3_T$5#26P!1113 ****
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M=]3]4**_-KX@:@O]L>.VUB[\31_M"IXB*^&8+0W7_'EYJ>6( @\ORC'OZ\G
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MC"U:7-).]WU[-H[?_A-['_GE<?\ ?*__ !5'_";V/_/*X_[Y7_XJN(HKS/\
M7?-_YH_^ G7_ &)@^S^\[?\ X3>Q_P">5Q_WRO\ \51_PF]C_P \KC_OE?\
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MIV,1@"H/V;?VFM0^.WB/7]!\3:!:Z1!<67]IZ+&%;-]I[2R0LT@9B"00H.,
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M@&#=#GM17YW-X_\ %FB^!O#;^ (;'PK%>?$RYL)X8;Z["W<Y*>6LI9V/DO\
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M]^7\Q_A1_P (_;_WY?S'^%:=%'^K^5?\^(A]=Q/\[,S_ (1^W_OR_F/\*/\
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MYZW'_?2__$UT-%'^K>4?] T0_M+&?\_&<]_PA%C_ ,];C_OI?_B:/^$(L?\
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M_P"[^7EA]W=Q7,_!?]D_5?@UX\\*Z_IX\/R0OH TKQ+#\^\W"KQ<6C>5G+8
M<-LR,DY)X]AF^-WA^*^\96J0WUPWA>WCGN7BA4I<ES(OEVY+#>X>)HSG #_+
MG(..L\3>)+/PGX?O-8O_ #!;6T>\QQ+ODD8D!8T7^)V8A54=20.]1]8E"#UT
M:2]4H\J_#\=2G"[Y.MV_FVI?G8^5&_9'^(S^$V^%K>*/#W_"I6U3[=YWD3?V
MQY/G>=Y.,>7][^+.>_3Y:F\>?L?^+O$&K?$36]&UO2]+UW5-;M=4T"\$\RM;
MHL4D,R3$1';N20_=W D#.*^G/"_C33/%?AK0=:MY#:P:U;1W-I!=LJ3$.@<(
M5#$%@#R 3C!I?&GB=?"7AF]U,1?:KA (K:U4X-Q<.P2*(>[.RK[9K26)JQTE
MOU\W>+U[M\J7_#ARJ4K_ -=?\W_2/F?5/V2/%NB67C33O!NI:+966M>&].\/
M6TEW/,DB)%@7+N%B(RZ[\8)R7.<5L:7^RGJGPP\>> /%7AOQG=:C:>'(6L-0
MM_$MRB(FFE,,D!B@'W<E@KG&0#N'.?9[7XB6VF>+-!\%ZF\E[XEO+$SW%S:0
MA;6.14R58ELJ7VR%%^8[4)..IZVWU"UN]_D7,,VR0Q-Y<@;:XZJ<'@CTI_6J
MO1KK\]U]VK^]F:A%KEZ?\!?C9+[CY_\ V;6D^(7Q3^*/Q4B5AH.L7,&DZ+(Z
M8^T6]JI1YESU1GZ?0^E?1%<KXV^)6D> [W0K34%N)KG6+V.R@CM4#E-[K'YL
MF2-L8>2-2WK(H )-9EU\8+*SUZ[LYM#UA-*M=0BTN7Q!MMS9"YD,:JF!-YWW
MY40MY6T,3D\9K"4_:-**T5DOE9?JOFS2S3<GUU_R^Y+[E<[VBO+KS]H#3-+T
M%]>U'P]KNG^'VNDM;;5)5M7CNMTI0RHB3M((U56D+.BX12<'I6YJ'Q7TRUU>
M_P!(M+'4-7UBUG^SQV%BD9DN7$,<SE&=U0*B2Q[GD9%#.JYR0#BFFKK^MO\
M-?>.VMCM:*\UD^.NGM$L%KX=U[4-?5K@7'AZWCM_MUL(/+\TMNF$;8$T1 CD
M<L)!M#<XLP_&_P /R>+].\./!J$%[?W4UG#+-;[8O,BABE;<<Y7F98QD EU9
M>P)I:[=?ZT[B>FYZ#17GVD_&*W\1:S;Z?HWAK7-65U66>[A^RQPVL+3RPI*_
MF3JS*WD2.!&KMLP< D"O0:6ZN'6P4444P)KK_6+_ +B?^@BH:M7%NTC*P* ;
M$ZR*#]T>IJ/[*_\ >C_[^K_C4W&0T5-]E?\ O1_]_5_QH^RO_>C_ ._J_P"-
M.X$-%3?97_O1_P#?U?\ &C[*_P#>C_[^K_C1<"&BIOLK_P!Z/_OZO^-'V5_[
MT?\ W]7_ !HN!#14WV5_[T?_ ']7_&C[*_\ >C_[^K_C1<"&BIOLK_WH_P#O
MZO\ C1]E?^]'_P!_5_QHN!#14WV5_P"]'_W]7_&C[*_]Z/\ [^K_ (T7 AHJ
M;[*_]Z/_ +^K_C1]E?\ O1_]_5_QHN!#14WV5_[T?_?U?\:/LK_WH_\ OZO^
M-%P(:*F^RO\ WH_^_J_XT?97_O1_]_5_QHN!#4TW^KM_]P_^A-1]E?\ O1_]
M_5_QJ6:V<QP<Q\)C_6+_ 'C[TK@5**F^RO\ WH_^_J_XT?97_O1_]_5_QIW
MAHJ;[*_]Z/\ [^K_ (T?97_O1_\ ?U?\:+@0T5-]E?\ O1_]_5_QH^RO_>C_
M ._J_P"-%P(:*F^RO_>C_P"_J_XT?97_ +T?_?U?\:+@0T5-]E?^]'_W]7_&
MC[*_]Z/_ +^K_C1<"&BIOLK_ -Z/_OZO^-'V5_[T?_?U?\:+@0T5-]E?^]'_
M -_5_P :/LK_ -Z/_OZO^-%P(:*F^RO_ 'H_^_J_XT?97_O1_P#?U?\ &BX!
M-_J[?_</_H35#5N:V<QP<Q\)C_6+_>/O47V5_P"]'_W]7_&E<"K<6\=W;RP2
MKOBD4HZ^JD8(KQC0?V2O"&D^((-2OM4\0^)8+6VNK2QTW7-0^TVUG%<*5F6/
MY0Y!5F7YV;@^O->X_97_ +T?_?U?\:/LK_WH_P#OZO\ C1:-[CN]CYTT?]B3
MP=H^H>';D>)?&%Y#X>U*/4=+L;S5EFMK0H^\1)&T>%C) SCYC@?-USJ:?^Q_
MX*TWQA%K,&H^(ETR'4#JL7A?^TS_ &1'=$Y\T0;<YSSC=CMC'%>[_97_ +T?
M_?U?\:/LK_WH_P#OZO\ C35DTUT_X'^2^XEZIKI_7^;/#)OV1_!TW@&Y\*?V
MCKL5O)KK>(H=0@NTCO+2\;^*)UC  '.,J2,YSG!$/BK]D#PGXLUR^U67Q!XL
MT^YU+3X]/U5=.U8PIJBI%Y:R7(V'S'Q@G/RDCE3DY]Y^RO\ WH_^_J_XT?97
M_O1_]_5_QJ.6*7*MO^!;\M"KN]_ZWO\ GJ?.^H?L7>&[B^T"\L?&OCC0;O1-
M)BT:TN-'U6*VD%NF>K"'.6S\V, X'%6O%G[''A#Q9K.M:C+K_BS3CK=JEOJM
MKIVK>5!?LJ;%FF38=[C[W/RDY)4Y.??OLK_WH_\ OZO^-'V5_P"]'_W]7_&G
M:+O?S_'<2TV_JVQY7X._9\\.^"?&FC^)[&]U26_TOPY#X8ACN)8VB:VB(*NP
M$8)DX&2"!_LBLQOV7/"K?">?X?'4-8_L:;4_[5:?SHOM'F^<)=H;RMNW<,8V
MYQW[U[/]E?\ O1_]_5_QH^RO_>C_ ._J_P"-6W>7,]_^#S?GJ*VEOZVM^6AX
M!XP_8T\&>+]<\1WYUKQ1HUKXAS)J6DZ1JGD6-Q,1_KFBV'<^?F^8E<_P]:BU
M#]C'PI=ZC:ZA:>*/&&B:C:Z-;:%%=Z3JB6T@MX55!DK%\Q95 8'*GLHXQ]"?
M97_O1_\ ?U?\:/LK_P!Z/_OZO^-9\L;6_K9K\FUZ%7=[_P!=/\D>-Z]\#="\
M,?L[ZI\/O#_AK_A(-.6S<1Z7<7H@EO)2V\L9RI"R%OF#8P& ' Z?/7P8^".L
M>(OC-X3U6\\-^-[+P_H&F7=KJ4WQ OEN7F,L+0K:VP& 85#MAE4 @G..!7W3
M]E?^]'_W]7_&C[*_]Z/_ +^K_C5:<[F];_Y-?DQ?8Y%I_2_R/"?!/[(/@SP1
MXGTK5XM4\2:M;:-*\^CZ+JVJ&>PTQV.=T$6T8(SQN)]3D\UM6/[-7A'3_C?<
M_%*)]0.OS!C]D:5/L<<C1")I539N#E1R=W<\5ZY]E?\ O1_]_5_QH^RO_>C_
M ._J_P"--63372_X[BMNNYX9-^R/X.F\ W/A3^T==BMY-=;Q%#J$%VD=Y:7C
M?Q1.L8  YQE21G.<X(77OV3?#.N:W)J:>(_%VE27D<$>K0Z9K#01ZN8E"K)<
M@+EG(7EE*YR3U)->Y?97_O1_]_5_QH^RO_>C_P"_J_XU*48I)>7X*WY)?<AN
M[U?]7=_S/"_&G[(O@WQEXBN=6CU/Q'X=^W10P:G8Z%J9MK;4HX@%C6X3:2V%
M '!'KUYI_B[]DKP;XH\2KK5KJ'B#PQ(]C'IMY;>'M2-I#?VZ*$2.< %F 4!>
M",@#.:]Q^RO_ 'H_^_J_XT?97_O1_P#?U?\ &BT6K/\ K^KA=[_U_6B/%? /
M[*_A3X<ZIX*O]-U#69YO"=K=VEBMU/$RR)<.[R&7;$N2#(V-NW@#.:[+X<?"
MO2?AA)XE?2KB\N#K^K3:S=?;'1MDTN-RIM5<)P, Y/N:[C[*_P#>C_[^K_C1
M]E?^]'_W]7_&KOK?U_%W?XZB_K[E;\B&BIOLK_WH_P#OZO\ C1]E?^]'_P!_
M5_QI7&0T5-]E?^]'_P!_5_QH^RO_ 'H_^_J_XT7 FTG_ )"$7X_R-=%6#IEN
MT=]&Q*$<])%)Z'T-;U8SW&@HHHK,9R-%3?97_O1_]_5_QH^RO_>C_P"_J_XU
MU7)(:*F^RO\ WH_^_J_XT?97_O1_]_5_QHN!#14WV5_[T?\ W]7_ !H^RO\
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M_>C_ ._J_P"-'V5_[T?_ ']7_&BX$-%3?97_ +T?_?U?\:/LK_WH_P#OZO\
MC1<"&BIOLK_WH_\ OZO^-'V5_P"]'_W]7_&BX$-%3?97_O1_]_5_QH^RO_>C
M_P"_J_XT7 AHJ;[*_P#>C_[^K_C1]E?^]'_W]7_&BX$-%3?97_O1_P#?U?\
M&C[*_P#>C_[^K_C1<"&BIOLK_P!Z/_OZO^-'V5_[T?\ W]7_ !HN!#14WV5_
M[T?_ ']7_&C[*_\ >C_[^K_C1<"&BIOLK_WH_P#OZO\ C1]E?^]'_P!_5_QH
MN!#14WV5_P"]'_W]7_&C[*_]Z/\ [^K_ (T7 AHJ;[*_]Z/_ +^K_C1]E?\
MO1_]_5_QHN!#14WV5_[T?_?U?\:/LK_WH_\ OZO^-%P(:*F^RO\ WH_^_J_X
MT?97_O1_]_5_QHN!#14WV5_[T?\ W]7_ !H^RO\ WH_^_J_XT7 AHJ;[*_\
M>C_[^K_C1]E?^]'_ -_5_P :+@0T5-]E?^]'_P!_5_QH^RO_ 'H_^_J_XT7
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M*Y;QA\:-:^'NEV[>)]"T'0[^\U%+&SFO?$HBTR4&*25G:Y: .FT1E2&AY9E
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MD*[(A8 ]"57/H*LUJ[]24%%%%(9-=?ZQ?]Q/_014-377^L7_ '$_]!%0TEL
M4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *FF_U=O_ +A_
M]":H:FF_U=O_ +A_]":D,AHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@":;_ %=O_N'_ -":H:FF_P!7;_[A_P#0FJ&D,**CNDEDM9D@E6&=D(CD
M9-X1L<$KD9P>V17Q1:Z7XB\&?&9=(\._$7Q'XTU#2]%U*[\::A<W;_8HG:)S
M;(D6YEBE#8PH8D #H,BLYU.2]UT;^Y-_I^148\VW]=/^&/MNBO(?V2?$6J>*
M_P!GCP=JNLZA<:IJ=S!*TUW=R&260B>0 LQY/  _"O7JWE'EDX]C*$N>*DNH
M4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7
M-)_Y"$7X_P C715SND_\A"+\?Y&NBK">Y2"BBBLQG(T445UD!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 7-6_Y"$OX?R%4ZN:M_P A
M"7\/Y"J=3'9#.(F^$>D2>(&UN.[O[;57N[B[>ZA= [>=;K;M&<H?D"QQ$#J&
MB0DGD'/L?@K%8>%=&T9?%OB!Y=$E232=3(LEN;)5A,(C4+;"-U*,P/F1N3N)
MSD#$'B_X@>(-)^(MAHMO]@TG3)&@"3ZKIUS+'J.XL98XKJ-A'!(B*=J2*Q<]
M !S7&0?M'ZO??#&34K;2K-_%UYJ7V/3]/8.(4AEDB-M/,"V['E7-MN (W/(%
M&W/!&TM(^2^YI+\]/GYC>FK_ *O=O\OR/0KOX1O<7FCWT?C/Q-;ZCISS.;SS
M;69K@RA ^])8'C08C  A6,#<V -QKI_#?A>T\+V-S;6DDTAN+JXO)9YV#2-)
M-*TC<@#@%L 8X  [5YK/\=V@\>:Q:E+%O"NGZ1J%T+Q7)GEN;-HA/C#8$0\T
MH,C):-^< 9ZOPSXNUK4O$FE:/?PV<=S'H$6HZL(4<>7<RN%C2/+'"9CN>#D_
M*O/7+C:25NOY:_A[OY=Q-.*U_K;\;RL_F12_"&RCTGP[;:9K>KZ+?:%"]O:Z
MM9M ]RZ2!?-$@EB>-MY16/R?> (Q52^^ _AW4(KKSKC4'NKB+:UZTRM.)O.2
M8W(9D.)=\4/;:!$BJH48K,/QPDL?&GCG3KZQ0Z;HR0+I9@SY^H3D8FC&3M^6
M1XTSP!\Q8X&1F^#/BAXW^(7@F36+3_A'_#\VGVL<]_)J%K-<1/*\"W'DHJS1
MF-4BEB!E8MEBWR +S"E&WM%LM;]D_P"OZ=AM-OD?]/1_?K^?F>C>*?AWI/C3
M4].O-7-U<KIZO]GMDN&BC21P 9?DPV_;E0=V &;CDURG_#.OAEO!&H^%WNM4
MDLKRUM;,7!N%%Q;QV^3"(G"#:5)8\@\L>W%9"?'+5KSX9^(/%,>E+92PM9VF
MGV;VTUS)]JGB@+*\<9WRA);C9M0!CY;#J>-'P[XL\;>+EN]/TO4M%2]L4CEN
M=4U#P]>6L;-*"R0"RDN1+&P3:S.\G&]0$/.*E%)N+7];_EK^1*E>TD_Z_K_@
MG5:I\-=-U235&-U?6O\ :&G0:4ZVTJIY=M&SMLC.W*EQ(RLP.< 8*D UA/\
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MRN0><YS[8KFO"_[2'BWQUXSU[2?#OPLGU32=$UN31KW5_P"WK:%8RCX:3RG
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MR+\C_C1_KAE7>7W!_9>)[+[S?HK _P"$@N/[D7Y'_&C_ (2"X_N1?D?\:/\
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MX"']B8SLOO.WHKB/^$WOO^>5O_WRW_Q5'_";WW_/*W_[Y;_XJC_7?*/YI?\
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MC756$;65OQ;_ %"BBBOLCQ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** +FK?\A"7\/Y"J=7-6_Y"$OX?R%4ZF.R&%%%%4(*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":Z_P!8O^XG_H(J&IKK
M_6+_ +B?^@BH:2V ****8!1110!QVI?&3P)H_BM/#-]XOT6TU]V"#3YKV-9=
MYQM0@GACD84\G(P*/%'QD\"^"=<M]&U_Q;H^CZK. 4M+R\2-\'H6!/R@]BV
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M&",L3P%S6"O@W7[SX,Z1\'K;X5:UI_CNSOX6?Q4]BG]G1.EP)'ODO<_,Q3/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9[C04445F,Y?;!_STD_[]C_XJC;!_P ])/\ OV/_ (JH:*ZB2;;!_P ])/\
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M3_OV/_BJAHH FVP?\])/^_8_^*HVP?\ /23_ +]C_P"*J&B@";;!_P ])/\
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MNO\ 6+_N)_Z"*AI+8 HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
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MM745M>Z7DDONT(ZR?=M_>[A1112 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** +FD_P#(0B_'^1KHJYW2?^0A%^/\C715A/<I!111
M68SD:***ZR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M +FK?\A"7\/Y"J=7-6_Y"$OX?R%4ZF.R&%%%%4(**** "BBB@ HHHH ****
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MY?@'VZX_Y[R_]]FC[=<?\]Y?^^S1]BN/^>$O_?!H^Q7'_/"7_O@T?\*/]_\
M\F#]QY?@1:_?W,.GZ<T=Q*C-YFXJY!.",9K#_M>^_P"?VX_[^M_C6YK]C<S:
M?IRQV\KLOF;@J$D9(QFL/^R+[_GRN/\ OTW^%7FW]H_65R<]N2GMS?\ /N-_
MQW\SJP7U?V/O<N\NW\S#^U[[_G]N/^_K?XT?VO??\_MQ_P!_6_QH_LB^_P"?
M*X_[]-_A1_9%]_SY7'_?IO\ "O'_ .%/_IY_Y,=W^R_W?P#^U[[_ )_;C_OZ
MW^-']KWW_/[<?]_6_P :/[(OO^?*X_[]-_A1_9%]_P ^5Q_WZ;_"C_A3_P"G
MG_DP?[+_ '?P#^U[[_G]N/\ OZW^-']KWW_/[<?]_6_QH_LB^_Y\KC_OTW^%
M']D7W_/E<?\ ?IO\*/\ A3_Z>?\ DP?[+_=_ /[7OO\ G]N/^_K?XT?VO??\
M_MQ_W];_ !H_LB^_Y\KC_OTW^%']D7W_ #Y7'_?IO\*/^%/_ *>?^3!_LO\
M=_ /[7OO^?VX_P"_K?XT?VO??\_MQ_W];_&C^R+[_GRN/^_3?X4?V1??\^5Q
M_P!^F_PH_P"%/_IY_P"3!_LO]W\ _M>^_P"?VX_[^M_C1_:]]_S^W'_?UO\
M&C^R+[_GRN/^_3?X4?V1??\ /E<?]^F_PH_X4_\ IY_Y,'^R_P!W\ _M>^_Y
M_;C_ +^M_C1_:]]_S^W'_?UO\:/[(OO^?*X_[]-_A1_9%]_SY7'_ 'Z;_"C_
M (4_^GG_ ),'^R_W?P-#2]2O)+?5"]U,Q2QE==TA.U@!@CG@UR/_  D&J?\
M02O/^_[_ .-==I>FWD=OJ@>UF4O8RHNZ,C<Q P!QR:Y'_A']4_Z!MY_WX?\
MPJ\S_M/ZKAN3VE_>O;F[]1X3ZK[6KS<O3MV#_A(-4_Z"5Y_W_?\ QH_X2#5/
M^@E>?]_W_P :/^$?U3_H&WG_ 'X?_"C_ (1_5/\ H&WG_?A_\*^;_P"%?_IY
M_P"3'J?['_=_ /\ A(-4_P"@E>?]_P!_\:/^$@U3_H)7G_?]_P#&C_A']4_Z
M!MY_WX?_  H_X1_5/^@;>?\ ?A_\*/\ A7_Z>?\ DP?['_=_ /\ A(-4_P"@
ME>?]_P!_\:/^$@U3_H)7G_?]_P#&C_A']4_Z!MY_WX?_  H_X1_5/^@;>?\
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MB@ HHHH **** "IIO]7!_N?^S-4-33?ZN#_<_P#9FI#(:***8@HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/[/7^^?RHYD!2HJ[_9Z_WS^5']GK_?/Y4<R I45=_L]?[Y_*C^SU_OG\J.9
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M/[/7^^?RHYD!2HJ[_9Z_WS^5']GK_?/Y4<R I45=_L]?[Y_*C^SU_OG\J.9
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>rcus-20230930_g4.jpg
<TEXT>
begin 644 rcus-20230930_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1<"17AI9@  34T *@    @ "  +  (
M   F   (>@$2  ,    !  $   $Q  (    F   (H $R  (    4   (Q@$[
M  (    6   (VH=I  0    !   (\)R=  $    L   1=.H<  <   @,
M;@  $: <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     %=I;F1O
M=W,@4&AO=&\@161I=&]R(#$P+C N,3 P,3$N,38S.#0 5VEN9&]W<R!0:&]T
M;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X-  R,#(S.C W.C$X(#$T.C V.C4S
M $)R86YD;VX@0V]H96X@*$%R8W5S*0  !I #  (    4   12I $  (    4
M   17I*1  (    #,S   )*2  (    #,S   * !  ,    !  $  .H<  <
M  @,   )/@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M #(P,C,Z,#<Z,3@@,30Z,#(Z-#8 ,C R,SHP-SHQ." Q-#HP,CHT-@   $(
M<@!A &X 9 !O &X ( !# &\ : !E &X (  H $$ <@!C '4 <P I      8!
M P #     0 &   !&@ %     0  $>X!&P %     0  $?8!*  #     0 "
M   " 0 $     0  $?X" @ $     0  !/L         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ $@$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M#>>*BI( HI@':B@ HH ** "B@ [T4 %% !3X@-XXH NGI5!OO&I0Q**H044
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M%!04%!3_P  1" !+!!,# 2(  A$! Q$!_\0 'P   04! 0$! 0$
M  $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&
M$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ
M0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66
MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3E
MYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<(
M"0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(
M%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*
M4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.D
MI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T
M]?;W^/GZ_]H # ,!  (1 Q$ /P#]4"P1<DX%9D^MJK;8EW?[34W6KKYEA7_>
M:LFM(Q)-#^VKC^['^1H_MJX_NQ_D:SZ*UY8@:']M7']V/\C1_;5Q_=C_ "-9
M]%/EB!H?VU<?W8_R-']M7']V/\C6?12Y8@:']M7']V/\C1_;5Q_=C_(UGT4<
ML0-#^VKC^['^1H_MJX_NQ_D:SZ*.6(&A_;5Q_=C_ "-']M7']V/\C6?11RQ
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M.6(&A_;5Q_=C_(U))JTJQQMM3YEW=/\ :K+J6?\ U</_ %S_ /9FJ>6(%O\
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M54<AS-27[J0GC</;XCH****_H>/PH^'>X44458@HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5K2_\ D(1?\"_]!JK5S24W
MWJM_=J9?",Z*BBBN8HJ7UG]KC_VE^[7/R6\ENVUUVUU=-**X^89^M7&7*!R=
M%;U[:PJH(B4?05E-"G]VM.<DK458\E/[M'DI_=J^9"*]%6/)3^[1Y*?W:.9
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M3^[1S("O15CR4_NT>2G]VCF0%>BK'DI_=H\E/[M',@*]%6/)3^[1Y*?W:.9
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,K8K.4BPHHHK(#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>rcus-20230930_g5.jpg
<TEXT>
begin 644 rcus-20230930_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1=Z17AI9@  34T *@    @ "  +  (
M   F   (>@$2  ,    !  $   $Q  (    F   (H $R  (    4   (Q@$[
M  (    6   (VH=I  0    !   (\)R=  $    L   1=.H<  <   @,
M;@  $: <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     %=I;F1O
M=W,@4&AO=&\@161I=&]R(#$P+C N,3 P,3$N,38S.#0 5VEN9&]W<R!0:&]T
M;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X-  R,#(S.C W.C$X(#$T.C V.C$P
M $)R86YD;VX@0V]H96X@*$%R8W5S*0  !I #  (    4   12I $  (    4
M   17I*1  (    #,S   )*2  (    #,S   * !  ,    !  $  .H<  <
M  @,   )/@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M #(P,C,Z,#<Z,3@@,30Z,#(Z-#8 ,C R,SHP-SHQ." Q-#HP,CHT-@   $(
M<@!A &X 9 !O &X ( !# &\ : !E &X (  H $$ <@!C '4 <P I      8!
M P #     0 &   !&@ %     0  $>X!&P %     0  $?8!*  #     0 "
M   " 0 $     0  $?X" @ $     0  !70         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ $P$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
M   ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!
M!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25
MEI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/D
MY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'
M" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!
M"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)
M2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*C
MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S
M]/7V]_CY^O_:  P# 0 "$0,1 #\ ]NGG6-BTLJH,GEFQ[_R%0B]MF( NHB3T
M D'-:)")\GU-&3ZFD 9..IJI?:E#IZHT[/\ .<*%&: *C^)+%.K3]O\ EF?4
MC'YBK-GJL%]*\<)DW)G.X8Z'% %W)P>34'VZWR1]I0$,5.6QSZ4[ /\ M$>T
M-Y@*GH0<BD>ZBC=4>4*SXV@GKG_]52FF[#L[7$O+M;.W>>0.47&0@R>3CI4N
MXD9R:8A<GU-&3ZF@ R?4T!F!R": +KMMB+9QQ5#SE_OC\ZRE5A#XF4HM["><
MO]\?G1YR_P!\?G2^LTOYA\DNPAN(P<&4?G2K,C'"R GT!H6(I-V3!TY)7L/R
M?4T9/J:V(#)]31D^IH ,GU-&3ZF@ R?4T^)B)!R>: *.I:7:ZFOEW:%U4G #
M$=>#T]OYU2C\-:5%)'(EN0T9#*=YX(Q_@*I2: UZ*0"]JR+C3]2EN6=-258B
MV5C,(.!]:0$)TG5=I']KCG.28!W[U)#IFI1R(SZF& QN B W<@G^HH UV!*,
M%.&(X/I64OAZQ.UYD:27@L^\C+>N*I.VP%\6D0 'S<#'+&FO8P23QS,&WH,+
MACC\JB,4I.7<IRNDA]W'++;ND$HBD.,.5W8Y]*RXM+U5)(F?6'8*P+KY?##C
MC]/UIDDPLM4\Q6.J J%P5\E>3ZTLEGJ;29CU3:N,8,*F@">S@O868W5X+A2.
M!Y87!_"KE %V5=T#*>XK,^S1^A_.N2MA(5W>1K"JX+0/LT?H?SH^S1^A_.L?
M[,HE_6)#&L868D@Y/O2Q6<43[U!R/>G#+:4)J:W0/$S<>4L45Z)SA10 44 %
M/B_UB_6D!;:-&Y*BF^3'_=J;C#R8_P"[1Y,?]VBX!Y4?]VCR8_[M.X!Y,?\
M=H\F/^[2N >3'_=H\F/^[1< \F/^[1Y,?]VG< \F/^[1Y,?]VE< \F/^[1Y,
M?]VBX!Y,?]VE6- <A11<"2HC%'G[M" /)C_NT>3'_=HN >3'_=H\F/\ NT7
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M4607)?M,O_/9_P#OHT?:9?\ GL__ 'T:BHHL@N2_:9?^>S_]]&C[3+_SV?\
M[Z-144607)?M,O\ SV?_ +Z-'VF7_GL__?1J*BBR"Y+]IE_Y[/\ ]]&C[3+_
M ,]G_P"^C45%%D%R7[3+_P ]G_[Z-'VF7_GL_P#WT:BHHL@N2_:9?^>S_P#?
M1H^TR_\ /9_^^C45%%D%RW=74JW4V)' #X W>E0_:9?^>S_]]&B\_P"/R?\
MZZ-453H%R7[3+_SV?_OHT?:9?^>S_P#?1J*BJL@N2_:9?^>S_P#?1H^TR_\
M/9_^^C45%%D%R7[3+_SV?_OHT?:9?^>S_P#?1J*BBR"Y+]IE_P">S_\ ?1H^
MTR_\]G_[Z-144607)?M,O_/9_P#OHT?:9?\ GL__ 'T:BHHL@N2_:9?^>S_]
M]&C[3+_SV?\ [Z-144607)?M,O\ SV?_ +Z-'VF7_GL__?1J*BBR"Y+]IE_Y
M[/\ ]]&IIKJ58X2)'R4R?F[[C_A52I9_]7#_ -<__9FJ=!W#[3+_ ,]G_P"^
MC1]IE_Y[/_WT:BHJK(5R7[3+_P ]G_[Z-'VF7_GL_P#WT:BHHL@N2_:9?^>S
M_P#?1H^TR_\ /9_^^C45%%D%R7[3+_SV?_OHT?:9?^>S_P#?1J*BBR"Y+]IE
M_P">S_\ ?1H^TR_\]G_[Z-144607)?M,O_/9_P#OHT?:9?\ GL__ 'T:BHHL
M@N2_:9?^>S_]]&IIKJ58X2)'R4R?F[[C_A52I9_]7#_US_\ 9FJ=!W#[3+_S
MV?\ [Z-'VF7_ )[/_P!]&HJ*JR%<E^TR_P#/9_\ OHT?:9?^>S_]]&HJ*+(+
MDOVF7_GL_P#WT:/M,O\ SV?_ +Z-144607)?M,O_ #V?_OHT?:9?^>S_ /?1
MJ*BBR"Y+]IE_Y[/_ -]&C[3+_P ]G_[Z-144607)?M,O_/9_^^C1]IE_Y[/_
M -]&HJ*+(+DOVF7_ )[/_P!]&C[3+_SV?_OHU%119!<E^TR_\]G_ .^C1]IE
M_P">S_\ ?1J*BBR"Y+]IE_Y[/_WT:/M,O_/9_P#OHU%119!<E^TR_P#/9_\
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MHT?:9?\ GL__ 'T:BHHL@N2_:9?^>S_]]&C[3+_SV?\ [Z-144607)?M,O\
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MEG_/]!]3Q'\II9'J/SHR/4?G6;_PD%O_ ')?R%'_  D%O_<E_(4?V_EG_/\
M0?4\1_*:61ZC\Z,CU'YUF_\ "06_]R7\A1_PD%O_ ')?R%/^WLL?_+]!]3Q'
M\II[3SD8^M%8FH>*+/3+R2WDCF9X^Z(O/ /<^XJ#_A-['_GE/_WPO^-*IG^6
M49.$ZZNO\S2& Q$X\RB=%17/?\)O8_\ /*X_[X7_ !H_X3>Q_P">5Q_WPO\
MC6?^LF4_\_T5_9^)_D9T-%<]_P )O8_\\KC_ +X7_&C_ (3>Q_YY7'_?"_XT
M?ZR93_S_ $']GXG^1G0[2>@/7%)65I7B*VUBX,,:2JX4N3(B]B!V/N*U:]K#
M8NAC*?M</+F1Q5J,Z$N684445UF(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5O2C_ ,3"+_@7_H-5
M*M:7_P A"+_@7_H-3+X1G24445S%'.ZM_P A";_@/_H-4ZN:M_R$)O\ @/\
MZ#5.NF/PDGPO^V1J$?Q>^+[^"EL-?U>P\+Z)/<;- T^:]*:K<(!;B01ABH"J
MIS_O=S7,?$?XD1?%;2_V<=<U!O#CW>S4+?4AXP7;IHN(8XHW-T/[I(W\D=5K
M[]T[PSH^D:AJ.H6&DV-E?ZD5>]NH+=$ENF48!D8+\Q ^[NW8KG[[X+_#[4H1
M%=^!?#-U%Y[W96XT>WD_?OC=)RF"S;5W-C)VC):N^GB(4XQBX[?\'_/\$*7O
M2YCX6T'3='U#]G_XE:=)K6BZ*+3QO;W5Q?VL4]WX=7+;H5M5AC+>5VP1MY'.
M.*V[F:T\3?#?XU^#9_$_A6[T/1X]+O8_&/A_0A;6LS;_ #/L\\=F)-\:D ':
M&*;F)STK[ETWP/X=T7P_)H6GZ#I=CHDNX2:;;V426[[_ +^8U54.?IS\N:71
M?!/A[PWH\ND:1H.F:7I,P(EL+*SBA@<'[P*(@5MW?*U7UJ.NF_\ P/\ (SL[
MW/SR\1:DUU%\9]2N8O#>I:7)X1LH;M/AW,RV,=Q]I18B9"IW,J@L^5^Z=AXY
MKU3]F6XBM_VEIDN[WPSKNHOX+MTCU#P6R_8+:..9!Y<Z8/[\D*=VY1A1\OS#
M'UMH?@'PQX:TJZTS2?#>CZ7IMV"+BSL;"*&&;*X^=$4*Q(X.13?"OP_\,>!/
M/'AKPYI7A\7!7SO[+LHK7>!_>,:C/4G\_7BOK*Y6K;AR.W]>7^1OT445YQH%
M%%% !1110 4444 %%%% $MY_Q]S?]=&J*I;S_C\G_P"NC5%4H H)"MM)P_7;
MW[]OPHKXL\8_&+6OA'^UGX^\0ZCJ-_-X$TZ"QL;_ $WS9&C@,]EYD,J19V@^
M;$%SC_EK0Y*+U+C%R3:Z'VEZ9QR 2<=<8]2< 9/<GWHX5B"%#'^'@'&<Y(QG
M&>>O'I7Y]:!\6/&/A#X8?&1?$6KWB>+-:U>RL+1/.FD-A+>1&5TBC&6'E1,_
MRH 3LX!XJ]8_%RZ3X1P^&H_%.I74WAGQ_I\(U2[DGMKFZTZ>4R0O,) KJ#\Z
ML& 'R^XI<R7X?C;_ #(4E:_K^%_\C[YW;L,'RK<@YZ[NWT'J#FC.<9)/\7&3
M@<<GOV'4GZU\3_M'?%#7],^+'BZ?PMXBN8]*;PE8//?:;<-.EE$^I>3<72*I
M*[P@*EAR,'YN#7/:]XPA\'WGCK0_!>I^(-3T^?PKJ-Q'JD7C*/5;?$,3.MZ\
M85Y89"VT#]XF<]*CFTV[_@/[7W?B?? 3:PXP>H)7.#C&.O0#( X]J3Y?EP%R
MW.#U/ '![$#'(!/%?"?@7XD>,M-\<? OP?XJU*^FEB=]235UD=8=3TZ2R+()
M3N^9XFWH=^>$1N^:?\(?C]/J7[0MOXDN_$&IW&B^,[^\TP:7/'<I:640\O[!
M(C,HB+/Y;9V.3\_.*M25VNW_  __  !+;^OZZ'W2<,3_ 'R-WJ<,,_-T.,?4
M4G3'8$*JX/!ZXQSSW['KSFOS2TKXK>/O#?P%TRUU;6-4O]+\4:W'+I&K1W$G
MG6DT-\8[BTE?.=KH@D4>[K7K6EZQX=\1R^-O$?Q%^*^N>"?&>F^(;BU@M;75
MV@:PMTD4Q1PVG/G)(N,DHY;/;FJ\_P"NG_ "7NS=-[Z/\_\ (^U0IQR&7GHW
M]3@8^I!H]3[ _@>]?GO\5/%^NR>/O$5K'J^HWEI)X[TJT%JVKRZ6DD+:>[O&
MTJE3 KL >G'?%=-\:%?34\-7+ZV\>DV'AN>ZE\)V?CB>*^MI/.<O>VM\P9;M
MEY7$F22,!2:7-=?UVN$;-Z?UK8^XO?MZ_P"?\BBN=^&^LP^(/ 'AO4K:>^N8
M+K3H)DFU50MVZM'NW2JO E/\6.-U=%6CCRNS%&2DM J6?_5P_P#7/_V9JBJ6
M?_5P_P#7/_V9J@H@DFCACDDD=8XXU+.['"J!U)/8#%?)6AZK9?&SP;\1;6QT
MB?Q-KGCV1S*L)$5OI%@L?EZ?]HE/RHVQ5G6,*[YGW%0#7I'[7WQ /A/X1W&B
MV%TL.N>*[B+0+'YAN!N&*2.1_P!<]_/3)3O7<?"CX<:3\._AKI7AS3+;[/8I
M:JK;#M9RPSN+C^(YY88^;<1C((IUO9M1BM7K\E_GT+C#W7-['SS\,?&GBOQ=
M^R;XZL]<O=/\SPQH.I^'+^S^S2F\6:"U9%\R;S /N[<_)\Q]ZS=2O?%&H_#?
MX9?#[Q9JVFZ%\./&&@:?9IX@L=,<S>=Y<3"RD9YC'"S*,"4HP8GA%KWVS_9E
M^'%A#K,-OH$L46L*ZZ@JZG=_Z6&;+>9^]^8D\[CSRWJ=V_+\&_!UQ\/_ /A"
M+C18[KPMM6,:=<2R2A5&"NV1V9U"D# #9'8UW*O",M#"S/)O@?#;>&_VC_BW
MH^IA;?5VATU])^T<F32XX"JB(D@E$<#?@@%N3QS7K]];Z"WCJ6>RELXO'+:-
M)%&6WMMMA(I0S*C#*>8XQDJ<-($(!:JNO?!3P7XFT?2]-U311=QZ6/\ 0;F2
MYE^U6V>NRY#"9<]\.#[UK>#_ (>^'? $=RN@Z3!8/=,'N+C+23SLOW6DE8EY
M".2"S$\GFL:LU-<U]1E6SU;6?#=A>77BB^TRY''V==*MI(6+?Q*V^1]V<+SQ
MTIOAVSFU;6!K>I^6ER4:.UM%8?N5P3NQW;DUN:OH%CKPC%];^>(SE/G==I_[
MZJMI_@S1M+NX[FUL_*G0X5_-D? VX[M7R6(PF.K8V,YQ3I1L[7UOW:Y>G34]
MNG5HQH.UU4?6W_!Z]3!NO#\=K:ZAJ.FZ]<(Q>2<^5*##N]-O_P!>NC\+ZE-K
M&@65Y<C$TB9;CK52X\"Z//<-*;=E#.7>*.0JC$]3MZ5NPPI;QK'&GEQJ,(J\
M;:67X*KA\0ZJ2C!Z6BVTWOL]B<5BH5*2C>[[M*YY1X\X_:2^%)8E6_LG7NH_
MZ\OFSD&F^)_A5'J7BS7/&?C.\'B/3]+MI1H6A*ABM[&+R09I,9^:=VW 2#E%
MQ@9QMZWX@_"/PI\4?L!\1Z=)=R6#.UK+;W<]G+&6QO\ WD$B/@[5^7=CA?2N
M/;]DWX9R(8WTG5FB8;75O$FIMD8QCFY[BOKHSBTFV>+J=G\);K2K_P"%7@NY
MT.Q?3=%ET2Q>PL9)/-,%NT*-'$6;=NVH57=UXKL;C_5P?]<__9FK/TG2;30M
M)L],T^WCM+"S@2WM[>/.V*-5"JJ_0 5H7'^K@_ZY_P#LS5S5-9:&A%1139)$
MAC9Y&5$4;F9C@*!W)[5.E[@.QSG/)/(^@)SU'<].V:/1B0K-\V6/.<XR,]J^
M%?AO^T#+>?M&6GBFY\1:E+H/BO5[K14TF9+E+.VMMD:V,T;,HB9I'C8$*Y/S
M],5SWP?\7:M:^)OA]J=[K>I6AOO%US8W-[#XEGNYKI/,F5()M-<[8HL[?WH+
MD;>0,U,9)V2Z_P# _P PJ>ZO3_@_Y'Z&+\QPOS'&[Y>>/6CU_P!GK[?YQFOS
M\^#>GVG@_P"(&FVL5SX:U36]=76+:'6M'UB]N+[39E65UFGMG;RE4+M0;8@Q
MVY!R17->%M2F\$Z%XA&F7 TN"Z\"7DVJZCX>UQ]3>]N5FCC2^;<RB!G+L,<,
M%WY(P*CVGY7_ #*Y?SL?I/QN"Y&X]L\]N?ISUI>HSV[GL*^3/V.HX?#WQ \8
M^'[?['9Q'2-/OQIFAZK)J6FJY5_-D,K$%)Y&(W)M[9RPK*^"/QV^(WBC]H2Y
MTW6]8TVXT&]\M(XX]&U."(^7"[$6YD51&V0/,,W!_@W5OU(6SET1]C22+$C.
M[*J*"Q8GC &2<^F.<TRWN(KRVBN;>5)[>50\<T3!DD4XPRL."#D<BOD_QYX\
M\:W_ ,6_&_AZQ^(&EZOX1TO2[VZU32[K2;9/*=H',5C&Q8M<.N SG@ <,2>*
MY#P#\3OB5J&B6ND^%O$6D^'=/T?X>6OB+R&T6*<22C=OC7!78'V]3N [)GYJ
MR51-?UY_Y%.+3_KR_P S[CZ8]S@>]&1SR,>N>.F:^9_A?\6_B'J'COX8GQ'J
M.D:CHOC_ $>XOHM-L=/:W.F-%$DJ[9"[M+OW$,2![9J]>?%CXM1_M,0>&H_!
M*-X:-A(PC_M:##P?:HXS?[MFX.$8CR"V><XXK77F4.KO^!'V>?H?16X=<@C^
M]GCJ!U_$4?@??CTZ_EW].]?-?Q:^,OBRQ^+^M^&]+\:^'/ %EH.EVNIJWB*
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M]%%%4 4444 %:V@_\M_^ UDUK:#_ ,M_^ UG+X1FQ1116!1@^+>=#NO^ _\
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M:'K][#'Y45QJFG0W,B(&)"*\BLR@%BV <<GCGCHK>WBM(4AAC6**-0B1QKL
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M&_K_ ! CD\5O4467;R"[_4P_"W@;P[X'MYH/#N@:9H,$[AYH],M$MP[#H2%
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'HHHJ!G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>rcus-20230930_g6.jpg
<TEXT>
begin 644 rcus-20230930_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !+!-X# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4F8*I).
M.M8UYK+LQ6#Y5_O=S5G6YC';J@.-YY^@K"K6$>K$R8WEP3GSI/\ OHT?;)_^
M>\G_ 'V:AHK6R$3?;)_^>\G_ 'V:/MD__/>3_OLU#118";[9/_SWD_[[-'VR
M?_GO)_WV:AHHL!-]LG_Y[R?]]FC[9/\ \]Y/^^S4-%%@)OMD_P#SWD_[[-'V
MR?\ Y[R?]]FH:*+ 3?;)_P#GO)_WV:/MD_\ SWD_[[-0T46 F^V3_P#/>3_O
MLT?;)_\ GO)_WV:AHHL!-]LG_P">\G_?9H^V3_\ />3_ +[-0T46 F^V3_\
M/>3_ +[-'VR?_GO)_P!]FH:*+ 6VNI_LL9\Z3.]AG<?1:B^V3_\ />3_ +[-
M#?\ 'I'_ +[?R6H:0$WVR?\ Y[R?]]FC[9/_ ,]Y/^^S4-%.P$WVR?\ Y[R?
M]]FC[9/_ ,]Y/^^S4-%%@)OMD_\ SWD_[[-'VR?_ )[R?]]FH:*+ 3?;)_\
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MLG_Y[R?]]FC[9/\ \]Y/^^S4-%%@)OMD_P#SWD_[[-'VR?\ Y[R?]]FH:*+
M3?;)_P#GO)_WV:/MD_\ SWD_[[-0T46 F^V3_P#/>3_OLT?;)_\ GO)_WV:A
MHHL!-]LG_P">\G_?9H^V3_\ />3_ +[-0T46 F^V3_\ />3_ +[-'VR?_GO)
M_P!]FH:*+ 3?;)_^>\G_ 'V:/MD__/>3_OLU#118";[9/_SWD_[[-'VR?_GO
M)_WV:AHHL!-]LG_Y[R?]]FC[9/\ \]Y/^^S4-%%@)OMD_P#SWD_[[-'VR?\
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MD'IZ5=I["WU04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\YV$)DYX [Y)Z#Q3\%]$\3?$#2?&T=UJ.B>)=/A:U^W:5,L1N8"0?*F#*P=
M<X!'&>O QU1K4XQ45ND];>;_  :?R,+.]SBOV)VTV;]F_P +3V#K+<3>?+J,
MF<RO>&9_-,I/)?..O.-O;%=Y;Z)#X<F\2#P.NER:Q?:FM_JEG>7;+''-)"BE
MBJ!C&SJB-C'S9+=\U@2?LYZ'8^)-4UGPWKOB+P9)JTIGU"TT"]6*UN92,-(8
MGC=5<]V3::[GP=X)T?P'I36&CVIA221IYYY9&EGN9F^]+-*Q+2.<<LQ)X Z
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M[C HK?\ ^$?M_P"_+^8_PH_X1^W_ +\OYC_"C_4_->T?O#^U,-W?W&!16_\
M\(_;_P!^7\Q_A1_PC]O_ 'Y?S'^%'^I^:]H_>']J8;N_N#P__P >;_\ 70_R
M%:=06=FEC&40L03N^:IZ_8,IPU3!X&EAZOQ15F?+XFI&K6E..S"BBBO7.4**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K7T'_EO_P !_K616OH/_+?_ (#_ %J);#0:_P#\L/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MKZ#_ ,M_^ _UK(K;T.,K"[G^(_RJ)[#1I,H92",@\&L:\T9U8M!\R_W>XK:H
MK%2:*.7:UG3[T3C_ (":B.5Z\5UC $<BJKV\;$DH#S6G.*QSF:,UT/V6+^X*
M/LL7]P4^<+'/9HS70_98O[@H^RQ?W!1SA8Y[-&:Z'[+%_<%'V6+^X*.<+'/9
MHS70_98O[@H^RQ?W!1SA8Y[-&:Z'[+%_<%'V6+^X*.<+'/9HS70_98O[@H^R
MQ?W!1SA8Y[-&:Z'[+%_<%'V6+^X*.<+'/9HS70_98O[@H^RQ?W!1SA8PV8?9
M8QD9WL<?@M1X.,XXKH/LL7]P4OV>/IL&*7,%CG<T9KH?LL7]P4?98O[@I\X6
M.>S1FNA^RQ?W!1]EB_N"CG"QSV:,UT/V6+^X*/LL7]P4<X6.>S1FNA^RQ?W!
M1]EB_N"CG"QSV:,UT/V6+^X*/LL7]P4<X6.>S1FNA^RQ?W!1]EB_N"CG"QSV
M:,UT/V6+^X*/LL7]P4<X6.>S1FNA^RQ?W!1]EB_N"CG"QSV:,UT/V6+^X*/L
ML7]P4<X6.>S4J<VT@')WJ<?@U;GV6+^X*/L\:]$%+F%8YZC-=#]EB_N"C[+%
M_<%/G"QSV:,UT/V6+^X*/LL7]P4<X['/9HS70_98O[@H^RQ?W!1SA8Y[-&:Z
M'[+%_<%'V6+^X*.<+'/9HS70_98O[@H^RQ?W!1SA8Y[-&:Z'[+%_<%'V6+^X
M*.<+'/9HS70_98O[@H^RQ?W!1SA8Y[-'7IS70_98O[@H^RQ#^ 4<X6,0$+;2
M*3AMZG'?HU0YKH?LT1ZH*/LL7]P4N8+'/9HS70_98O[@H^RQ?W!3YPL<]FC-
M=#]EB_N"C[+%_<%'.%CGLT9KH?LL7]P4?98O[@HYPL<]FC-=#]EB_N"C[+%_
M<%'.%CGLT9KH?LL7]P4?98O[@HYPL<]FC-=#]EB_N"C[+%_<%'.%CGLT9KH?
MLL7]P4?98O[@HYPL<]FC-=#]EB_N"C[+%_<%'.%CGLT9KH?LL7]P4?98O[@H
MYPL<]FC-=#]EB_N"C[+%_<%'.%CGLT9KH?LL7]P4?98O[@HYPL<]FC-=#]EB
M_N"C[+%_<%'.%CGU4MT&?I5B'3[B8\1D#U;BMR.WC4@A *L=*ES"Q5L;!;-3
MSN<]6JW116=[C"BBBD!#=6ZW4)1OP]JYZXLY+=B",CUKIZCEC5EY&:N,K".5
MHS70FUB_N"C[+%_<%:<XK'/9HS70_98O[@H^RQ?W!1SCL<]FC-=#]EB_N"C[
M+%_<%'.%CGLT9KH?LL7]P4?98O[@HYPL<]FC-=#]EB_N"C[+%_<%'.%CGLT9
MKH?LL7]P4?98O[@HYPL<]FC-=#]EB_N"C[+%_<%'.%CGLT9KH?LL7]P4?98O
M[@HYPL<]FC-=#]EB_N"C[+%_<%'.%CGLT9KH?LL7]P4?98O[@HYPL<]FC-=#
M]EB_N"C[+%_<%'.%CGLT9KH?LL7]P4?98O[@HYPL<]FC-=#]EB_N"C[+%_<%
M'.%CGLT9KH?LL7]P4?98O[@HYPL<]FC-=#]EB_N"C[+%_<%'.%CGLT9KH?LL
M7]P4?98O[@HYPL<]FC-=#]EB_N"C[+%_<%'.%CGLT9KH?LL7]P4?98O[@HYP
ML<]FC-=#]EB_N"C[+%_<%'.%CGLT9KH?LL7]P4?98O[@HYPL<]FC-=#]EB_N
M"C[+%_<%'.%CGLT9KH?LL7]P4?98O[@HYPL<]FC-=#]EB_N"C[+%_<%'.%CG
MLT9KH?LL7]P4?98O[@HYPL<]FC-=#]EB_N"C[+%_<%'.%CGLT9KH?LL7]P4?
M98O[@HYPL<]FC-=#]EB_N"C[+%_<%'.%CGLT9KH?LL7]P4?98O[@HYPL<]FC
M-=#]EB_N"C[+%_<%'.%CGLT9KH?LL7]P4?98O[@HYPL<]FBNA^RQ?W!0+6+^
AX*.<5C&M;-[AP,$+ZUT4$0AC"CM1%&JKP,5)6<I7&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398404490240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arcus Biosciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3898435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3928 Point Eden Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hayward<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">694-6200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RCUS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,855,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001724521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398405288544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 32,000,000<span></span>
</td>
<td class="nump">$ 33,000,000<span></span>
</td>
<td class="nump">$ 86,000,000<span></span>
</td>
<td class="nump">$ 78,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (Net of recoveries of $22, $27, $89 and $93 from a related party)</a></td>
<td class="nump">82,000,000<span></span>
</td>
<td class="nump">77,000,000<span></span>
</td>
<td class="nump">247,000,000<span></span>
</td>
<td class="nump">208,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="nump">88,000,000<span></span>
</td>
<td class="nump">76,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">112,000,000<span></span>
</td>
<td class="nump">103,000,000<span></span>
</td>
<td class="nump">335,000,000<span></span>
</td>
<td class="nump">284,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(80,000,000)<span></span>
</td>
<td class="num">(70,000,000)<span></span>
</td>
<td class="num">(249,000,000)<span></span>
</td>
<td class="num">(206,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_InterestAndOtherIncomeExpenseNonoperatingNet', window );">Interest and other income, net</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties', window );">Effective interest on liability for sale of future royalties</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income, net</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(69,000,000)<span></span>
</td>
<td class="num">(65,000,000)<span></span>
</td>
<td class="num">(221,000,000)<span></span>
</td>
<td class="num">(199,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (71,000,000)<span></span>
</td>
<td class="num">$ (65,000,000)<span></span>
</td>
<td class="num">$ (226,000,000)<span></span>
</td>
<td class="num">$ (200,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
<td class="num">$ (3.07)<span></span>
</td>
<td class="num">$ (2.78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
<td class="num">$ (3.07)<span></span>
</td>
<td class="num">$ (2.78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute net loss per share, basic (in shares)</a></td>
<td class="nump">74.6<span></span>
</td>
<td class="nump">72.2<span></span>
</td>
<td class="nump">73.6<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute net loss per share, diluted (in shares)</a></td>
<td class="nump">74.6<span></span>
</td>
<td class="nump">72.2<span></span>
</td>
<td class="nump">73.6<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesRevenueMember', window );">License and Development Services Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="nump">$ 58,000,000<span></span>
</td>
<td class="nump">$ 48,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember', window );">Other Collaboration Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest on liability for sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_InterestAndOtherIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and other income (expense) nonoperating net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_InterestAndOtherIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398406986080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ResearchAndDevelopmentExpenseRecoveries', window );">Research and development expense, net of recoveries</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesRevenueMember', window );">License and Development Services Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesRevenueMember', window );">License and Development Services Revenue | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember', window );">Other Collaboration Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember', window );">Other Collaboration Revenue | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ResearchAndDevelopmentExpenseRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Recoveries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ResearchAndDevelopmentExpenseRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398404440928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (71)<span></span>
</td>
<td class="num">$ (65)<span></span>
</td>
<td class="num">$ (226)<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (70)<span></span>
</td>
<td class="num">$ (67)<span></span>
</td>
<td class="num">$ (222)<span></span>
</td>
<td class="num">$ (208)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398400676112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Receivable from collaboration partners ($22 and $39 from a related party)</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets ($6 and $2 from a related party)</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,191<span></span>
</td>
<td class="nump">1,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue ($96 and $97 to a related party)</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent ($309 and $355 to a related party)</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value per share; 10.0 shares authorized; no shares issued and outstanding.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 74.8 shares in 2023 and 72.9 shares in 2022 issued and outstanding</a></td>
<td class="nump">1,291<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(768)<span></span>
</td>
<td class="num">(542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">657<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,191<span></span>
</td>
<td class="nump">$ 1,345<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398405172992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Receivable from collaboration partners, current</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">$ 326<span></span>
</td>
<td class="nump">$ 355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="nump">400,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">74,800,000<span></span>
</td>
<td class="nump">72,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">74,800,000<span></span>
</td>
<td class="nump">72,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Receivable from collaboration partners, current</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398399511456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Second Stock Purchase Agreement </div>
<div>Gilead</div>
</th>
<th class="th"><div>Equity Award Programs</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Second Stock Purchase Agreement </div>
<div>Gilead</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Equity Award Programs</div>
</th>
<th class="th"><div>Common stock and additional paid-in capital</div></th>
<th class="th">
<div>Common stock and additional paid-in capital </div>
<div>Second Stock Purchase Agreement </div>
<div>Gilead</div>
</th>
<th class="th">
<div>Common stock and additional paid-in capital </div>
<div>Equity Award Programs</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (275)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(343)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(475)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(343)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(410)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(475)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">72.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(542)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(622)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">72.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(542)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="nump">74.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(768)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(622)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(697)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive gain (loss)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="nump">74.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (768)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398404007136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (226)<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Noncash lease expense</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums (discounts) on marketable securities</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other items, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Receivable from collaboration partners ($17 and $718 from a related party)</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets (($4) and ($2) from a related party)</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue (($47) and ($73) to a related party)</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(218)<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(673)<span></span>
</td>
<td class="num">(1,085)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ProceedsFromMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">837<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ProceedsFromSaleOfMarketableSecurities', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Purchases of in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty', window );">Collaboration reimbursements of in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">166<span></span>
</td>
<td class="num">(460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock ($20 and $&#8212; from a related party)</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock pursuant to equity award plans</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ProceedsFromSaleOfFutureRoyalties', window );">Proceeds from sale of future royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid portion of property and equipment purchases included in Accounts payable and Other current liabilities</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration reimbursements of in-process research and development from a related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ProceedsFromMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturity of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ProceedsFromMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ProceedsFromSaleOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ProceedsFromSaleOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398408612512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Receivable from collaboration partners</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Receivable from collaboration partners</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398495432304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Liquidity, and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization, Liquidity, and Capital Resources</a></td>
<td class="text">Organization, liquidity and capital resources<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arcus Biosciences, Inc. (referred to as "Arcus," "we," "our," "us," or the "Company") is a clinical-stage, biopharmaceutical company focused on creating best-in-class therapies. Using our robust and highly efficient drug discovery capability, we have created a significant portfolio of investigational products which are in clinical development, with our most advanced molecule, an anti-TIGIT antibody, now in four Phase 3 registrational studies targeting lung and gastrointestinal cancers. Our deep portfolio of novel small molecules and enabling antibodies allows us to create highly differentiated therapies, which we are developing to treat multiple large indications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate and manage our business as one reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, we had cash, cash equivalents and marketable securities of $950 million, which we believe will be sufficient to fund our planned operations for a period of at least twelve months following the date of filing of this report.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398495594528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2022 included in our Annual Report on Form 10-K filed with the SEC on February&#160;28, 2023. There have been no significant changes to our accounting policies as described in Note 2, Summary of significant accounting policies, in the notes to Consolidated Financial Statements in Item 8 of Part II of the Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and include all adjustments consisting of normal recurring adjustments that management believes are necessary for a fair presentation of the periods presented. The Condensed Consolidated Balance Sheet as of December&#160;31, 2022 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating results for the nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023 or for any future period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed and updated each period to reflect current information. Actual results may differ materially from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements issued or adopted during the period with a significant impact to our financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398407619824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party - Gilead Sciences, Inc.<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party - Gilead Sciences, Inc.</a></td>
<td class="text">Related party - Gilead Sciences, Inc.<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we and Gilead Sciences, Inc. (Gilead) entered into an Option, License and Collaboration Agreement (the Gilead Collaboration Agreement), Common Stock Purchase Agreement (the Stock Purchase Agreement), and Investor Rights Agreement (Investor Rights Agreement). In 2021, we amended the Gilead Collaboration Agreement (the First Gilead Collaboration Agreement Amendment) and the Stock Purchase Agreement (the First Stock Purchase Agreement Amendment), and in 2022 we amended the Investor Rights Agreement (Amended Investor Rights Agreement). In the second quarter of 2023, we expanded our collaboration to include research-stage inflammation programs (the Second Gilead Collaboration Agreement Amendment) and further amended the Stock Purchase Agreement (the Second Stock Purchase Agreement Amendment). We refer to these agreements collectively as the Gilead Agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase Agreement and Investor Rights Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, under the Stock Purchase Agreement, Gilead purchased 6.0 million shares of our common stock for a total cost of $200 million, of which $91 million was allocated to the revenue related performance obligations created by the Gilead Collaboration Agreement (See Note 5, Revenues for more information).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, under the First Stock Purchase Agreement Amendment, Gilead purchased 5.7 million shares of our common stock for a total cost of $220 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, under the Second Stock Purchase Agreement Amendment, Gilead purchased 1.0 million shares of our common stock for a total cost of $20 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead has the right, at its option until July 2025, to purchase up to a maximum of 35% of the Company&#8217;s then-outstanding voting common stock, at a purchase price equal to the greater of a 20% premium to market (based on a trailing five-day average closing price at option exercise) or the $33.54 initial purchase price. Based on the value of our common stock at each contract closing, the right to purchase additional shares had no value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Investor Rights Agreement, Gilead has the right, which they have exercised, to designate two members of our Board of Directors. This agreement also included a three-year standstill and a two-year lockup, provided Gilead with registration rights commencing at the end of the lockup period and provides Gilead with pro rata participation rights in certain future financings. In October 2022, we registered Gilead&#8217;s shares and entered into the Amended Investor Rights Agreement, primarily to extend the two-year lockup period to three-years which expired on July 13, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, Gilead held approximately 19.8% of the Company&#8217;s outstanding common stock arising from purchases in our May 2020 public offering and purchases under the Stock Purchase Agreement and the First and Second Amended Stock Purchase Agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into the Gilead Collaboration Agreement, which gave Gilead an exclusive license to develop and commercialize zimberelimab (the anti PD-1 program) in certain markets and time-limited options to acquire exclusive licenses to develop and commercialize any of our then-current and future clinical programs arising during the 10-year collaboration term, contingent upon $100 million option continuation payments payable on each of the second, fourth, sixth and eighth anniversaries of the agreement. Upon closing of the transaction in July 2020, Gilead made an upfront payment of $175 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we entered into the First Gilead Collaboration Agreement Amendment pursuant to which Gilead exercised its option to three programs&#8212;providing Gilead with exclusive licenses to develop and commercialize domvanalimab and AB308 (collectively, the anti-TIGIT program), etrumadenant (the adenosine receptor antagonist program) and quemliclustat (the CD73 program), in certain markets&#8212;for a total payment of $725 million that was received in 2022. The amendment also (i) provided for a slight reduction in the royalties for these three programs, such that Gilead will pay us tiered royalties as a percentage of revenues ranging from the mid-teens to the low twenties; and (ii) removed the $100 million option continuation payment that was otherwise due on the second anniversary of the Gilead Collaboration Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead's option, on a program-by-program basis, will expire after a prescribed period following the achievement of a clinical development milestone in such program and our delivery to Gilead of the requisite data package. Gilead may exercise its option to any program at any time prior to expiration of the option and will pay Arcus an option fee of $150 million per program. With respect to domvanalimab, we are also eligible to receive up to $500 million in potential U.S. regulatory approval milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each program that Gilead opts in to, both companies will co-develop and equally share global development costs, subject to certain opt-out rights that we have, and caps on our spending and related subsequent adjustments. For each program, provided we have not exercised our opt-out rights, we have the option to co-promote in the United States with equal sharing of related profits and losses. Gilead has the right to exclusively commercialize outside of the U.S., subject to the rights of our existing partners in any territories and will pay us tiered royalties as a percentage of revenues ranging from the high teens to the low twenties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, Gilead also has option rights to two immuno-oncology research programs for which we will lead discovery and early development activities. With respect to these two research programs, Gilead has the right to exercise its option, on a program-by-program basis, either (i) upon our completion of certain IND-enabling activities for an option payment of $60 million or (ii) following the achievement of a clinical development milestone for an option payment of $150 million. These research programs were not determined to be performance obligations at contract inception, due to the very early stages of the programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we entered into the Second Gilead Collaboration Agreement Amendment pursuant to which we expanded our collaboration to provide Gilead with options to license up to four jointly selected research-stage programs that target inflammatory diseases for which we will lead discovery and early development activities. We will receive an upfront payment of $17.5 million for each initiated program and Gilead will have an option to license each program at two separate, prespecified time points. For the first two research programs, Gilead has the right to exercise its option, on a program-by-program basis, either (i) upon our completion of certain IND-enabling activities for an option payment of $45 million or (ii) following the achievement of a clinical development milestone for an option payment of $150 million. If Gilead exercises its option at the earlier time point for the first two programs, we would be eligible to receive up to $375 million in regulatory and commercial milestone payments as well as tiered royalties for each optioned program. For any other program option exercise by Gilead, the parties would have rights to co-develop and share global development costs and to co-commercialize and share profits in the US for that program. We received a total upfront payment of $35 million for an initial two research programs in June 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, Gilead has licenses to domvanalimab, AB308, etrumadenant, quemliclustat and zimberelimab.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2023 and 2022, we recognized revenue under the Gilead Agreements of $28 million and $31 million, respectively, and net reimbursements from Gilead recognized as reductions in research and development (R&amp;D) expense of $22 million and $27 million, respectively. For the nine months ended September&#160;30, 2023 and 2022, we recognized revenue under the Gilead Agreements of $82 million and $73 million, respectively, and net reimbursements from Gilead recognized as reductions in R&amp;D expense of $89 million and $93 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more detailed discussion on revenues recognized under the Gilead Agreements, see Note 5, Revenues.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398495264656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaborations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsAbstract', window );"><strong>License and Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaborations</a></td>
<td class="text">License and collaborations<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into licensing agreements, strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain investigational products. These arrangements may be collaborative and involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include: non-refundable upfront payments; payments for options to acquire certain rights; potential development and regulatory milestone payments and/or sales-based milestone payments; royalty payments; revenue or profit-sharing arrangements; expense reimbursements; and cost-sharing arrangements. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Condensed Consolidated Statements of Operations, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant arrangements are discussed below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gilead Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3, Related party - Gilead Sciences, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taiho Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an agreement with Taiho Pharmaceutical Co., Ltd (Taiho) under which we granted Taiho exclusive options to programs arising over a five-year period which ended in September 2022 (the Option Period) for an upfront payment of $35 million. Upon an option exercise of a program, Taiho would obtain exclusive development and commercialization rights to investigational products under the program for Japan and certain other territories in Asia (excluding China) (the Taiho Territory). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each option that Taiho exercises, they will be obligated to make a payment of $3 million to $15 million, depending on the development stage of the optioned program. Upon exercise, Taiho is solely responsible for continued development and commercialization in the Taiho Territory. In addition, for each optioned program we would be eligible to receive clinical and regulatory milestones of up to $130 million and commercial milestone payments of up to $145 million with the achievement of certain sales thresholds in the Taiho Territory. We will also receive royalties ranging from high single-digits to mid-teens on net sales of licensed products in the Taiho Territory. Royalties will be payable by product and country commencing on the first commercial sale and ending upon the later of: (a) 10 years; and (b) expiration of the last-to-expire valid claim of our patents covering the manufacture, use or sale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, Taiho opted to participate in two global Phase 3 trials of domvanalimab and zimberelimab combinations, STAR-121 and STAR-221, and is obligated to make certain milestone payments contingent upon successfully satisfying the related clinical milestones. During the three months ended September 30, 2023, the clinical milestones for domvanalimab and zimberelimab for the STAR-221 study were met and Taiho became obligated to pay us $28 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, Taiho has licenses for the Taiho Territory to (i) etrumadenant (the adenosine receptor antagonist program); (ii) zimberelimab (the anti PD-1 program); and (iii) domvanalimab and AB308 (collectively, the anti-TIGIT program).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2023 and 2022, we recognized revenue of $4&#160;million and $2 million, respectively, and we recognized net reimbursements from Taiho as a reduction in R&amp;D expense of $2 million for the three months ended September&#160;30, 2023. For the nine months ended September 30, 2023 and 2022, we recognized revenue of $4&#160;million and $5 million, respectively and we recognized net reimbursements from Taiho as a reduction in R&amp;D expense of $4&#160;million for the nine months ended September 30, 2023. For a more detailed discussion on revenues see Note 5, Revenues.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a collaboration with AstraZeneca to evaluate domvanalimab, our investigational anti-TIGIT antibody, in combination with AstraZeneca&#8217;s durvalumab in a registrational Phase 3 clinical trial in patients with unresectable Stage 3 non-small cell lung cancer (NSCLC), known as the PACIFIC-8 trial. Under the collaboration, each company will retain existing rights to their respective molecules and any future commercial economics. AstraZeneca will conduct the trial, and each company will supply their respective investigational product to support the trial. Under the terms of the agreement, we will reimburse AstraZeneca for its share of the trial costs upon the achievement of certain milestones or under certain circumstances if the agreement is terminated early. The portion of the costs that we consider to be unavoidable are accrued in advance of the achievement of the milestone.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2023 and 2022, we recognized as R&amp;D expense $1 million and $1 million, respectively, before expected recoveries from our cost-sharing agreement with Gilead. For the nine months ended September&#160;30, 2023 and 2022, we recognized as R&amp;D expense $6 million and $3 million, respectively, before expected recoveries from our cost-sharing agreement with Gilead. At September&#160;30, 2023 and December&#160;31, 2022, we have recognized a liability of $11 million and $5 million, respectively, related to our obligation to AstraZeneca which is recorded in Other noncurrent liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PACIFIC-8 trial forms part of the Arcus and Gilead joint development program for domvanalimab and our portion of the trial costs are shared with Gilead. At September&#160;30, 2023 and December&#160;31, 2022, we have recognized a receivable due from Gilead for these shared costs of $6 million and $2 million, respectively, which is recorded in Other noncurrent assets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WuXi Biologics License - anti-PD-1 </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an agreement with WuXi Biologics Ireland Limited (WuXi Biologics) which, as amended, provides us with exclusive rights to (i) develop, use and manufacture products that include an anti-PD-1 antibody, including zimberelimab, worldwide and (ii) commercialize any such products worldwide, except in Greater China. Under the agreement, as of September&#160;30, 2023, we may incur (i) clinical and regulatory milestone payments, and commercialization milestone payments of up to $375 million, (ii) tiered royalties that range from the high single-digits to low teens on net sales of the licensed products and (iii) fees related to any sublicenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2023 and 2022, we did not have any transactions nor were any amounts due under this arrangement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WuXi Biologics License - anti-CD39</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into an agreement with WuXi Biologics, under which we obtained the exclusive worldwide license to develop and commercialize anti-CD39 antibodies discovered under the agreement. As of September&#160;30, 2023, we may incur additional clinical and regulatory milestone payments of up to $14 million and royalty payments in the low single digits on net sales of the licensed products under this agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2023 and 2022, we incurred no development milestones nor were any amounts due under this arrangement. For the nine months ended September&#160;30, 2023 and 2022, we incurred development milestones under this arrangement of $1&#160;million and $2 million, respectively, which were recognized as R&amp;D expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Abmuno License</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into an agreement with Abmuno Therapeutics LLC (Abmuno), under which we obtained the exclusive worldwide license to develop, use, manufacture, and commercialize products that include an anti-TIGIT antibody, including domvanalimab. As of September&#160;30, 2023 we may incur additional clinical, regulatory and commercialization milestone payments of up to $88 million under this agreement.</span></div>For the three and nine months ended September&#160;30, 2023 and 2022, we did not have any transactions nor were any amounts due under this arrangement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_LicenseAndCollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_LicenseAndCollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398407813424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">Revenues <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenues by collaboration, category of revenue, and the method of recognition (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Over time</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Point in time</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Collaboration</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License and R&amp;D services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Access rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taiho Collaboration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Access rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from Gilead accounted for 88% and 94% of Total revenues for the three months ended September&#160;30, 2023 and 2022, respectively and 95% and 94% for the nine months ended September&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue recognized as a result of changes in the deferred revenue balance (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from amounts included in deferred revenue at the beginning of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the nine months ended September&#160;30, 2023 includes a net $1&#160;million cumulative catch-up of revenue due to changes in the total estimated effort to be incurred in the future to satisfy the Gilead license and R&amp;D services performance obligations, primarily related to lower estimated late-stage clinical trial costs for etrumadenant, partially offset by higher estimated late-stage clinical trial costs for quemliclustat.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $429 million and $452 million of deferred revenue remaining on our Condensed Consolidated Balance Sheets at September&#160;30, 2023 and December&#160;31, 2022, respectively, allocated between current and noncurrent based on the expected timing of future recognition. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from the Gilead Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for performance obligations under this arrangement for the periods presented herein was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflammation Programs - R&amp;D Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we entered into the Second Gilead Collaboration Agreement Amendment pursuant to which we expanded our collaboration to provide Gilead with options to license up to four jointly selected research-stage programs that target inflammatory diseases for which we will lead discovery and early development activities (see Note 3, Related party - Gilead Sciences, Inc., for more information). In June 2023, we received a total upfront payment of $35 million for an initial two jointly selected research-stage programs. We determined that the Second Gilead Collaboration Agreement Amendment represented a separate contract and, at the amendment closing date, we allocated the transaction price of $35 million to the performance obligations created as of the date of this amendment. The following table summarizes the allocation of the transaction price to the distinct performance obligations (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation to performance obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Distinct</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflammation target 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflammation target 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total allocated transaction price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that we have separate performance obligations to perform R&amp;D services for Gilead related to discovery and early development activities for each research program for which they have made an upfront payment. The standalone selling price of these obligations was determined using an expected cost-plus margin approach. We recognize the amounts allocated to these services as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. The options to acquire additional licenses or services did not result in additional performance obligations because they did not provide a material right at contract inception, primarily due to the very early stages of the programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue of $2 million and $3 million for the three and nine months ended September&#160;30, 2023, respectively, within Other collaboration revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $32 million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to these performance obligations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Etrumadenant - License and R&amp;D Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, Gilead has an exclusive license and we are also obligated to perform further R&amp;D services for Gilead related to etrumadenant. We determined that the license and R&amp;D services were combined based on an evaluation of the delivery of the license, due to the early stage of the technology and the specialized nature of our know-how. We allocated arrangement consideration of $219 million to the combined license and R&amp;D services performance obligation and recognize the amounts allocated as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue of $21 million and $3 million for the three months ended September&#160;30, 2023 and 2022, respectively, and $39 million and $21&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively, within License and development service revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $146 million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to this performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Quemliclustat - License and R&amp;D Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, Gilead has an exclusive license and we are also obligated to perform further R&amp;D services for Gilead related to quemliclustat. We determined that the license and R&amp;D services were combined based on an evaluation of the delivery of the license, due to the early stage of the technology and the specialized nature of our know-how. We allocated arrangement consideration of $176 million to the combined license and R&amp;D services performance obligation and recognize the amounts allocated as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a reversal of revenue of $4 million for the three months ended September&#160;30, 2023 due to changes in the total estimated effort to be incurred in the future to satisfy the performance obligations, primarily related to revised clinical trial assumptions and revenue of $12 million for the three months ended September 30, 2022. We recognized revenue of $11 million and $16 million for the nine months ended September&#160;30, 2023 and 2022, respectively, within License and development service revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $138 million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to this performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Domvanalimab - R&amp;D Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, we have an obligation to perform further R&amp;D services for Gilead related to domvanalimab. We determined that these services are distinct based on an evaluation of the delivery of the related license, noting that the program was in the later stages of development and license met the criteria for being distinct from the R&amp;D services required. We allocated arrangement consideration of $34 million to the R&amp;D services performance obligation and recognize the amounts allocated as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue of $1 million for the three months ended September&#160;30, 2023, and $3 million and $2 million for the nine months ended September&#160;30, 2023 and 2022, respectively, within License and development service revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $27 million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to this performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zimberelimab - R&amp;D and Commercialization Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, we have an obligation to perform further R&amp;D and commercialization services for Gilead related to zimberelimab, as a monotherapy and in combination with other agents. We determined that these services are distinct based on an evaluation of the delivery of the related license, noting that the program was in the later stages of development and license met the criteria for being distinct from the R&amp;D and commercialization services required. We allocated arrangement consideration of $11 million to the R&amp;D and commercialization services performance obligation and recognize the amounts allocated as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized no revenue for the three months ended September&#160;30, 2023 and $8 million for the three months ended September 30, 2022. We recognized $1 million and $9 million for the nine months ended September 30, 2023 and 2022, respectively, within License and development service revenue in our Condensed Consolidated Statements of Operations. As of December 31, 2022, substantially all the revenue related to this performance obligation had been recognized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Access Rights and Option Continuation Periods</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, Gilead has exclusive access to our current programs as well as the future programs for a period of ten years, contingent upon option continuation payments totaling $300 million, consisting of a $100 million payment on each of the fourth, sixth, and eighth anniversaries of the agreement. We allocated arrangement consideration of $121 million to this performance obligation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a time-elapsed input method to measure progress toward satisfying this obligation, which is the method we believe most faithfully depicts our performance in transferring the promised services during the time period in which Gilead has access to our R&amp;D pipeline. Accordingly, the revenue allocated to this performance obligation is being recognized using this input method over the minimum four-year period. We have determined that Gilead is not obligated to pay the remaining $300 million due over the remainder of the term and excluded these payments from the transaction price. Failure to pay the non-obligatory option continuation payments will result in Gilead&#8217;s loss of certain rights to access and obtain licenses to the programs arising from our R&amp;D pipeline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue of $8 million associated with the performance of this obligation for each of the three months ended September&#160;30, 2023 and 2022, and $25 million for each of the nine months ended September&#160;30, 2023 and 2022, within Other collaboration revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $62 million of deferred revenue on our Condensed Consolidated Balance Sheet related to this performance obligation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from the Taiho Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, under the Taiho collaboration, certain clinical milestones for domvanalimab and zimberelimab were met through the STAR-221 study and Taiho became obligated to pay us $28&#160;million, which is recorded in Receivable from collaboration partners at September&#160;30, 2023 on our Condensed Consolidated Balance Sheet. We determined that we have a performance obligation to perform R&amp;D services for Taiho related to the global development activities for the STAR-221 study in support of the Taiho Territory. We allocated the $28&#160;million to this single performance obligation and recognize the amounts allocated to this service as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue of $4&#160;million for both the three and nine months ended September&#160;30, 2023 within License and development service revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $24&#160;million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to this performance obligation, allocated between current and noncurrent based on the expected timing of future recognition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalized Costs to Obtain Contracts</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred certain costs to obtain the Gilead Collaboration Agreement in 2020 and the First Gilead Collaboration Agreement Amendment in 2021, which consisted of consultant and legal fees. We allocated these costs to the various performance obligations, to be recognized as the underlying performance obligations are satisfied and revenue is recognized. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2023 and 2022, the recognized expense was not significant. For each of the nine months ended September&#160;30, 2023 and 2022, we recognized $1&#160;million expense related to these capitalized costs in G&amp;A expense. At September&#160;30, 2023, we had $3 million in capitalized costs to obtain the contracts, of which $1 million was recorded as Prepaid expenses and other current assets and $2 million was recorded as Other noncurrent assets in our Condensed Consolidated Balance Sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398407619824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income taxes<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision or benefit for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into consideration in the relevant period. Each quarter, we update the estimate of the annual effective tax rate, and if the estimated tax rate changes, we record a cumulative adjustment to the provision or benefit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense was $2 million for the three months ended September&#160;30, 2023, with an effective tax rate of (2.4%). We did not record a provision for income taxes for the three months ended September&#160;30, 2022. The income tax expense was $5 million and $1 million for the nine months ended September&#160;30, 2023 and 2022, with an effective tax rate of (2.2%) and (0.5%), respectively. The year-over-year increase in the income tax provision was due to an increase in taxable income. We have taxable income compared to book losses before income taxes due to the timing of recognition of deferred revenue for tax purposes and the effects of the mandatory capitalization and amortization of research and development expenses starting in 2022, as required by the 2017 Tax Cuts and Jobs Act. The effective tax rate differs from the U.S. statutory tax rate primarily due to the valuation allowances on our deferred tax assets and state income taxes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023 and December&#160;31, 2022, we have provided a valuation allowance against U.S. federal and state deferred tax assets. We continue to evaluate the realizability of deferred tax assets and the related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties associated with uncertain tax benefits as part of the income tax provision. To date, we have not recognized any interest and penalties, nor have we accrued for or made payments for interest and penalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been audited by the Internal Revenue Service, or any state or foreign tax authority. We are subject to taxation in the United States and in Australia. Due to net operating loss and research credit carryforwards, all of our tax years, from 2015 to 2022, remain open to U.S. federal and California state tax examinations. In addition, our fiscal years from 2018 to 2022 are open to examination in Australia.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398407787488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net loss per share<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potentially dilutive securities excluded from the computation of diluted net loss per share calculations because they would have been antidilutive (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock options issued and outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total potential dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.8</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also excluded the effect of Gilead&#8217;s right to purchase additional shares of our common stock from the calculation as these rights had no intrinsic value at either September&#160;30, 2023 or 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398407787488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-based compensation <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Condensed Consolidated Statements of Operations (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398495432304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text">Cash, cash equivalents and marketable securities <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, gross unrealized gains and losses and the fair value of our cash, cash equivalents and marketable securities, all of which are considered available for sale, by type of securities (in millions): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Types of securities as of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">953&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Types of securities as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair values of our cash, cash equivalents and marketable securities by location in the Condensed Consolidated Balance Sheets and contractual maturity (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Location in Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">206&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between one and three years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses recognized on the sale of available-for-sale marketable securities were not material for the three and nine months ended September&#160;30, 2023 and 2022. Realized gains and losses are included in Interest and other income, net, in the Condensed Consolidated Statements of Operations. The cost of a security sold is determined using the specific-identification method.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We limit the credit risk associated with our investments by placing them with banks and institutions we believe are highly credit worthy and investing in highly rated investments. We held a total of 159 and 219 positions in securities which were in unrealized loss positions as of September&#160;30, 2023 and December&#160;31, 2022, respectively. We do not intend to sell our securities with unrealized loss positions and have concluded we will not be required to sell the securities before recovery of the amortized cost for the investment at maturity. No credit related losses have been recognized for any of the periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-615"><span style="-sec-ix-hidden:f-616">Restricted cash (included in Other noncurrent assets)</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398408919632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Condensed Consolidated Balance Sheet Components</a></td>
<td class="text">Condensed consolidated balance sheet components<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398495458064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash and non-cash information related to our operating leases (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from tenant improvement allowances</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of tenant improvement allowance receivable included in Other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023 and December&#160;31, 2022, we have provided deposits for letters of credit totaling $3 million to secure our obligations under our leases, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398405354992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gilead Stock Purchase</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, under the Second Stock Purchase Agreement, Gilead purchased 1.0 million shares of our common stock at the closing day purchase price of $19.26 per share for a total cost of $20 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Facility</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we entered into an equity distribution agreement pursuant to which we may, from time to time, sell shares of our common stock, par value $0.0001 per share, having an aggregate offering price of up to $200&#160;million. In August 2023, we issued and sold 0.2&#160;million shares of our common stock under this agreement for total net proceeds of $5&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398407677904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair value measurements<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1 inputs include unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement as of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">840&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">950&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability for sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities measured at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">969&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,138&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability for sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities measured at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability for Sale of Future Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we entered into an agreement with BVF Partners L.P. (BVF), under which BVF funded the discovery and development of compounds for the treatment of inflammatory diseases (the BVF Program) for $15 million in non-refundable payments which were paid in 2021 and 2022. In return, we are obligated to: perform research and development activities in the Program; make contingent payments upon the achievement of certain clinical and regulatory milestones of up to $73 million or $160 million depending on whether the program is solely developed by us or with Gilead if they opt-in under the Gilead Collaboration Agreement; and pay mid- to high-single digit royalties on any net product sales generated by the BVF Program. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the BVF Agreement as a liability primarily because we have significant continuing involvement in generating the cash flows due to BVF. The liability is recorded at fair value by using probability-adjusted discounted cash flows and is revalued each reporting period until the related contingencies have been resolved. The fair value measurement is based on significant unobservable inputs that are reviewed quarterly by management and include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair value of this liability related to interest accretion are recognized in Non-operating income (expense) in the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2023, new preclinical information from our BVF Program led to revised assumptions which decreased the estimated probabilities of success and delayed the projected timing of achieving specified development, regulatory and commercial milestones and commercial sales. These changes in estimates are accounted for prospectively and resulted in a decrease in the imputed effective interest rate on the unamortized portion of the liability to 10.1% commencing with the quarter ended June 30, 2023, compared to 20.6% for the quarters ended March 31, 2023 and prior. The impact of this change on the non-cash interest expense for the quarter and nine months ended September&#160;30, 2023 was not material when compared to the prior year periods. The liability for sale of future royalties is reported in Other noncurrent liabilities in the Condensed Consolidated Balance Sheets and changes were as follows (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398404378192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (71)<span></span>
</td>
<td class="num">$ (75)<span></span>
</td>
<td class="num">$ (80)<span></span>
</td>
<td class="num">$ (65)<span></span>
</td>
<td class="num">$ (67)<span></span>
</td>
<td class="num">$ (68)<span></span>
</td>
<td class="num">$ (226)<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398405304880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Juan C. Jaen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President and Director<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rcus_JuanCJaenMember', window );">Juan C. Jaen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">August 8, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">458 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">300,000,000,000<span></span>
</td>
<td class="nump">300,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=rcus_OfficersAndDirectorsTradingArrangementMember', window );">Officers And Directors Trading Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption, modification or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended September&#160;30, 2023, which are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:37.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.877%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.003%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name and Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Action</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Shares to be Sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Juan C. Jaen</span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">President and Director</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adopted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 8, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">300,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 8, 2024</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rcus_JuanCJaenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rcus_JuanCJaenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=rcus_OfficersAndDirectorsTradingArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=rcus_OfficersAndDirectorsTradingArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398405347968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2022 included in our Annual Report on Form 10-K filed with the SEC on February&#160;28, 2023. There have been no significant changes to our accounting policies as described in Note 2, Summary of significant accounting policies, in the notes to Consolidated Financial Statements in Item 8 of Part II of the Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and include all adjustments consisting of normal recurring adjustments that management believes are necessary for a fair presentation of the periods presented. The Condensed Consolidated Balance Sheet as of December&#160;31, 2022 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.</span></div>Operating results for the nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023 or for any future period.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed and updated each period to reflect current information. Actual results may differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements issued or adopted during the period with a significant impact to our financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398408566816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenues by collaboration, category of revenue, and the method of recognition (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Over time</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Point in time</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Collaboration</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License and R&amp;D services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Access rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taiho Collaboration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Access rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Summary of Revenue Recognized as a Result of Changes in Deferred Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue recognized as a result of changes in the deferred revenue balance (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from amounts included in deferred revenue at the beginning of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock', window );">Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations</a></td>
<td class="text">The following table summarizes the allocation of the transaction price to the distinct performance obligations (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation to performance obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Distinct</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflammation target 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflammation target 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total allocated transaction price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of transaction price and allocated to transaction price to performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398404372032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potentially dilutive securities excluded from the computation of diluted net loss per share calculations because they would have been antidilutive (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock options issued and outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total potential dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.8</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398407705856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Condensed Consolidated Statements of Operations (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398404383104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities Considered as Available for Sale by Type of Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, gross unrealized gains and losses and the fair value of our cash, cash equivalents and marketable securities, all of which are considered available for sale, by type of securities (in millions): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Types of securities as of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">953&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Types of securities as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loss </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Fair Values of Our Cash, Cash Equivalents and Marketable Securities by Location in Condensed Consolidated Balance Sheets and Contractual Maturity</a></td>
<td class="text">The following table summarizes the fair values of our cash, cash equivalents and marketable securities by location in the Condensed Consolidated Balance Sheets and contractual maturity (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Location in Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">206&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between one and three years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-615"><span style="-sec-ix-hidden:f-616">Restricted cash (included in Other noncurrent assets)</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-615"><span style="-sec-ix-hidden:f-616">Restricted cash (included in Other noncurrent assets)</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398405218672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid and Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Summary of Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398407705856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock', window );">Summary of Cash and Non-cash Information Related to Operating Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash and non-cash information related to our operating leases (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from tenant improvement allowances</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of tenant improvement allowance receivable included in Other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow disclosures and non-cash financing activities related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398404301872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement as of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">840&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">950&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability for sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities measured at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">969&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,138&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability for sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities measured at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock', window );">Summary of Changes of Liabilities for Sale of Future Royalties</a></td>
<td class="text">The liability for sale of future royalties is reported in Other noncurrent liabilities in the Condensed Consolidated Balance Sheets and changes were as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value assets and liabilities measured on recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of changes of liabilities for sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398408691216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Liquidity, and Capital Resources - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OrganizationLineItems', window );"><strong>Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember', window );">Cash, Cash Equivalents and Investments in Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OrganizationLineItems', window );"><strong>Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash and investments | $</a></td>
<td class="nump">$ 950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OrganizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OrganizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398400388016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party - Gilead Sciences, Inc. - Additional Information (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>Program </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>Program</div>
</th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Program </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock share value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=rcus_AmendedInvestorRightsAgreementMember', window );">Amended Investor Rights Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LockupPeriod', window );">Lockup period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ExtendedLockupPeriod', window );">Extended lockup period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=rcus_OptionLicenseAndCollaborationAgreementMember', window );">Gilead Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities', window );">Option payment upon completion of certain IND-enabling activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones', window );">Option payment upon achievement of certain development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=rcus_AmendedGileadCollaborationAgreementMember', window );">Amended Gilead Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_NumberOfExerciseOptionToPrograms', window );">Number of exercise option to programs | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionPaymentReceived', window );">Option payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 725,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_RemoveOptionContinuationPaymentUnderAgreement', window );">Removal of option continuation payment under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones', window );">Option payment upon achievement of certain development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments', window );">Number of programs, eligible to receive regulatory and commercial milestone payments | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PercentageOfOutstandingCommonStockOwned', window );">Percentage of outstanding common stock held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts', window );">Reimbursement from related party for shared costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="nump">$ 89,000,000<span></span>
</td>
<td class="nump">$ 93,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_FundsReceivedForStockPurchaseAgreement', window );">Funds received for stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation', window );">Purchase price of common stock allocation to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock share value</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PercentageOfPremiumPurchasePriceOfCommonStock', window );">Percentage of premium purchase price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average closing price of our common stock on grant date (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_TrailingDaysAverageClosingPrice', window );">Trailing days average closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage', window );">Right to purchase additional outstanding voting common stock percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Gilead Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms', window );">Collaboration term for current and future clinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement', window );">Option continuation payment due upon sixth anniversary of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption', window );">Option fee per program for all other programs entering clinical development to exercise option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_NumberOfResearchPrograms', window );">Number of research programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="nump">$ 31,000,000<span></span>
</td>
<td class="nump">$ 82,000,000<span></span>
</td>
<td class="nump">$ 73,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Gilead Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab', window );">Potential regulatory approval milestones payment receivable related to domvanalimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Amended Gilead Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_NumberOfResearchPrograms', window );">Number of research programs | Program</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities', window );">Option payment upon completion of certain IND-enabling activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Amended Gilead Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_RegulatoryAndCommercialMilestonePaymentsReceived', window );">Regulatory and commercial milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration term for current and future clinical programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CollaborationTermForCurrentAndFutureClinicalPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ExtendedLockupPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended lockup period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ExtendedLockupPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_FundsReceivedForStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds received for stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_FundsReceivedForStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_LockupPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lockup period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_LockupPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_NumberOfExerciseOptionToPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of exercise option to programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_NumberOfExerciseOptionToPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of programs, eligible to receive regulatory and commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_NumberOfResearchPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of research programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_NumberOfResearchPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option continuation payment due upon Sixth anniversary of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option fee per program for all other programs entering clinical development to exercise option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option payment upon achievement of certain development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option payment upon completion of certain IND-enabling activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_PercentageOfOutstandingCommonStockOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding common stock owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_PercentageOfOutstandingCommonStockOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_PercentageOfPremiumPurchasePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of premium purchase price of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_PercentageOfPremiumPurchasePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential regulatory approval milestones payment receivable related to domvanalimab.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_RegulatoryAndCommercialMilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory and commercial milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_RegulatoryAndCommercialMilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction reimbursement from related party for shared costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_RemoveOptionContinuationPaymentUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remove option continuation payment under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_RemoveOptionContinuationPaymentUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to purchase additional outstanding voting common stock percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value determined to premium on purchase of common stock and allocated to performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_TrailingDaysAverageClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trailing days average closing price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_TrailingDaysAverageClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rcus_AmendedInvestorRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rcus_AmendedInvestorRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rcus_OptionLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rcus_OptionLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rcus_AmendedGileadCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rcus_AmendedGileadCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rcus_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rcus_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398398079600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaborations - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 32,000,000<span></span>
</td>
<td class="nump">$ 33,000,000<span></span>
</td>
<td class="nump">$ 86,000,000<span></span>
</td>
<td class="nump">$ 78,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">145,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets ($6 and $2 from a related party)</a></td>
<td class="nump">108,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rcus_AstraZenecaAgreementMember', window );">AstraZeneca Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Development cost recorded within research and development expenses</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rcus_OptionLicenseAndCollaborationAgreementMember', window );">Gilead Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets ($6 and $2 from a related party)</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember', window );">Taiho Pharmaceutical Co., Ltd | Taiho Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionPeriod', window );">Option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_NonRefundableAndNonCreditableCashPayments', window );">Non refundable and non creditable cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PaymentForOptionExercise', window );">Payment for option exercise</a></td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_RoyaltiesPayableTerm', window );">Royalties payable term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ReimbursementOfResearchAndDevelopmentExpense', window );">Reimbursement of research and development expense</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember', window );">Taiho Pharmaceutical Co., Ltd | Taiho Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PaymentForOptionExercise', window );">Payment for option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember', window );">Taiho Pharmaceutical Co., Ltd | Taiho Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PaymentForOptionExercise', window );">Payment for option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Additional clinical and regulatory milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember', window );">WuXi Biologics License Agreement | anti-CD39 | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_MilestoneExpense', window );">Development milestone expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember', window );">WuXi Biologics License Agreement | Maximum | anti-PD-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments', window );">Clinical, regulatory and commercialization milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember', window );">WuXi Biologics License Agreement | Maximum | anti-CD39</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments', window );">Additional clinical, regulatory and commercialization milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_AbmunoLicenseAgreementMember', window );">Abmuno License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments', window );">Additional clinical, regulatory and commercialization milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional clinical and milestone payments received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional clinical regulatory and commercialization milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical regulatory and commercialization milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ClinicalRegulatoryAndCommercializationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ContingentMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ContingentMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_MilestoneExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_MilestoneExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_NonRefundableAndNonCreditableCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non refundable and non creditable cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_NonRefundableAndNonCreditableCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_PaymentForOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for option exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_PaymentForOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ReimbursementOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of research and development expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ReimbursementOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_RoyaltiesPayableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties Payable Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_RoyaltiesPayableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_AstraZenecaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_AstraZenecaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_OptionLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_OptionLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_OptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_OptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_AntiCDThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_AntiCDThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_AntiPDOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_AntiPDOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_AbmunoLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_AbmunoLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398405329264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_GileadCollaborationLicenseAndRDServicesMember', window );">License and R&amp;D services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_GileadCollaborationAccessRightsMember', window );">Access rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_TaihoCollaborationRDServicesMember', window );">R&amp;D services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_TaihoCollaborationAccessRightsMember', window );">Access rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_GileadCollaborationLicenseAndRDServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_GileadCollaborationLicenseAndRDServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_GileadCollaborationAccessRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_GileadCollaborationAccessRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_TaihoCollaborationRDServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_TaihoCollaborationRDServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_TaihoCollaborationAccessRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_TaihoCollaborationAccessRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398400205168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="nump">$ 429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_AllocationToPerformanceObligations', window );">Total allocated transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rcus_OptionLicenseAndCollaborationAgreementMember', window );">Gilead Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember', window );">R&amp;D Activities for Domvanalimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember', window );">R&amp;D and Commercialization Activities for Zimberelimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rcus_AccessRightsAndOptionContinuationPeriodsMember', window );">Access Rights and Option Continuation Periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Capitalized contract cost, amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Cost sharing receivable</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead | Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetCurrent', window );">Capitalized contract cost, net, current</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead | Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetNoncurrent', window );">Capitalized contract cost, net, noncurrent</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead | Gilead Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_AllocationToPerformanceObligations', window );">Total allocated transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod', window );">Current and future programs exclusive access period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement', window );">Option continuation payment receivable upon sixth anniversary of agreement</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PerformanceObligationPeriod', window );">Performance obligation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead | R&amp;D Activities for Inflammation Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead | Etrumadenant License and research and Development Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead | Quemliclustat, License and R&amp;D services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead | Revenue Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_STAR221DevelopmentActivitiesMember', window );">STAR-221 Development Activities | Taiho Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_AllocationToPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allocation to performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_AllocationToPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ContingentMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ContingentMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current and future programs exclusive access period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CurrentAndFutureProgramsExclusiveAccessPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option continuation payment receivable upon sixth anniversary of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_PerformanceObligationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance obligation period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_PerformanceObligationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_OptionLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_OptionLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_AccessRightsAndOptionContinuationPeriodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_AccessRightsAndOptionContinuationPeriodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_STAR221DevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_STAR221DevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_TaihoCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_TaihoCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398405302048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Amounts included in deferred revenue at the beginning of the period</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398401914992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_AllocationToPerformanceObligations', window );">Total allocated transaction price</a></td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rcus_InflammationTarget1Member', window );">Inflammation target 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_AllocationToPerformanceObligations', window );">Total allocated transaction price</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rcus_InflammationTarget2Member', window );">Inflammation target 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_AllocationToPerformanceObligations', window );">Total allocated transaction price</a></td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_AllocationToPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allocation to performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_AllocationToPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rcus_InflammationTarget1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rcus_InflammationTarget1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rcus_InflammationTarget2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rcus_InflammationTarget2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398409226752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information - (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(2.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398400151296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">15.8<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Common stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">13.7<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398401905104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398400242512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities Considered as Available for Sale by Type of Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 953<span></span>
</td>
<td class="nump">$ 1,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">950<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rcus_CorporateSecuritiesAndCommercialPaperMember', window );">Corporate securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rcus_CorporateSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rcus_CorporateSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398404001232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities - Schedule of Fair Values of Our Cash, Cash Equivalents and Marketable Securities by Location in Condensed Consolidated Balance Sheets and Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 950<span></span>
</td>
<td class="nump">$ 1,138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398404008288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of positions in securities in unrealized loss | position</a></td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForLoanLossesExpensed', window );">Credit related losses | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLoanLossesExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of credit loss expense (reversal of expense) for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLoanLossesExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398406986432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash (included in Other noncurrent assets)</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other noncurrent assets ($6 and $2 from a related party)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other noncurrent assets ($6 and $2 from a related party)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398400002896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Summary of Prepaid and Other Current Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_PrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_PrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398401915248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Summary of Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued personnel expenses</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398404358304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Cash and Non-cash Information Related to Operating Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashReceivedFromTenantImprovementAllowances', window );">Cash received from tenant improvement allowances</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_RecognitionOfTenantImprovementAllowanceReceivable', window );">Recognition of tenant improvement allowance receivable included in Other current liabilities</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashReceivedFromTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashReceivedFromTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_RecognitionOfTenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition of tenant improvement allowance receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_RecognitionOfTenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398408518752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Deposits for letters of credit</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398396369600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rcus_AtTheMarketFacilityMember', window );">At-the-Market Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_SaleOfStockAuthorizedConsiderationOnTransaction', window );">Sale of stock authorized consideration on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rcus_SecondStockPurchaseAgreementMember', window );">Second Stock Purchase Agreement | Gilead</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_SaleOfStockAuthorizedConsiderationOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock Authorized Consideration On Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_SaleOfStockAuthorizedConsiderationOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rcus_AtTheMarketFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rcus_AtTheMarketFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_SecondStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_SecondStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rcus_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rcus_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398398457648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value On Recurring Basis - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 950<span></span>
</td>
<td class="nump">$ 1,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Liability for sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Liability for sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">840<span></span>
</td>
<td class="nump">969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Liability for sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Liability for sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=rcus_LiabilityForSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=rcus_LiabilityForSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=rcus_CorporateSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=rcus_CorporateSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=rcus_UsGovernmentAgencyObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=rcus_UsGovernmentAgencyObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398401895232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - BVF Partners L.P. - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_BvfPartnersLPMember', window );">BVF Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_NonRefundablePaymentsReceived', window );">Non-refundable payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability', window );">Imputed effective rate of interest on unamortized portion of liability</a></td>
<td class="nump">10.10%<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_BvfPartnersLPMember', window );">BVF Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones', window );">Contingent payments upon achievement of certain clinical and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_BvfPartnersLPMember', window );">Gilead Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones', window );">Contingent payments upon achievement of certain clinical and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent payments upon achievement of certain clinical and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Imputed effective rate of interest on unamortized portion of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_NonRefundablePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_NonRefundablePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_BvfPartnersLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_BvfPartnersLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_BvfAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_BvfAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_GileadCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_GileadCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140398404289264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes of Liabilities for Sale of Future Royalties (Details) - BVF Partners L.P. - BVF Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LiabilityForSaleOfFutureRoyalties', window );">Beginning balance</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived', window );">Cash received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion', window );">Interest accretion</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LiabilityForSaleOfFutureRoyalties', window );">Ending balance</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in liability for sale of future royalties cash received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in liability for sale of future royalties interest accretion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_LiabilityForSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability for sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_LiabilityForSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_BvfPartnersLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_BvfPartnersLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_BvfAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_BvfAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>rcus-20230930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rcus="http://arcusbio.com/20230930"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rcus-20230930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2023-11-01</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:SecondStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:SecondStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:SecondStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rcus:CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedInvestorRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiPDOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:AbmunoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationLicenseAndRDServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationLicenseAndRDServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationLicenseAndRDServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationLicenseAndRDServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationAccessRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationAccessRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationAccessRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:GileadCollaborationAccessRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationRDServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationRDServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationRDServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationRDServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationAccessRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationAccessRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationAccessRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:TaihoCollaborationAccessRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rcus:InflammationTarget1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rcus:InflammationTarget2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForInflammationProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForInflammationProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForInflammationProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForDomvanalimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForDomvanalimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForDomvanalimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForDomvanalimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR221DevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR221DevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR221DevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR221DevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:SecondStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:SecondStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rcus:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rcus:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:UsGovernmentAgencyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:UsGovernmentAgencyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:UsGovernmentAgencyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:UsGovernmentAgencyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">rcus:LiabilityForSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:BvfPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:BvfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">rcus:OfficersAndDirectorsTradingArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:JuanCJaenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:JuanCJaenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>rcus:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="program">
        <measure>rcus:Program</measure>
    </unit>
    <unit id="position">
        <measure>rcus:position</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001724521</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="c-1" id="f-27">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q3</dei:DocumentFiscalPeriodFocus>
    <us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList contextRef="c-69" id="f-615">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList contextRef="c-26" id="f-616">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList>
    <ecd:TrdArrDuration contextRef="c-322" id="f-754">P458D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38419</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Arcus Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">47-3898435</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">3928 Point Eden Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Hayward</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">94545</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">694-6200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">RCUS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">74855565</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-3" decimals="-6" id="f-30" unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="-6" id="f-31" unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-6" id="f-32" unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-6" id="f-33" unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-6" id="f-34" unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-6" id="f-35" unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-6" id="f-36" unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-6" id="f-37" unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-6" id="f-38" unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-6" id="f-39" unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-6" id="f-40" unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-6" id="f-41" unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-6" id="f-42" unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-6" id="f-43" unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-6" id="f-44" unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-18" decimals="-6" id="f-45" unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-19" decimals="-6" id="f-46" unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-20" decimals="-6" id="f-47" unitRef="usd">33000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-48" unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-21" decimals="-6" id="f-49" unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <rcus:ResearchAndDevelopmentExpenseRecoveries contextRef="c-22" decimals="-6" id="f-50" unitRef="usd">22000000</rcus:ResearchAndDevelopmentExpenseRecoveries>
    <rcus:ResearchAndDevelopmentExpenseRecoveries contextRef="c-23" decimals="-6" id="f-51" unitRef="usd">27000000</rcus:ResearchAndDevelopmentExpenseRecoveries>
    <rcus:ResearchAndDevelopmentExpenseRecoveries contextRef="c-24" decimals="-6" id="f-52" unitRef="usd">89000000</rcus:ResearchAndDevelopmentExpenseRecoveries>
    <rcus:ResearchAndDevelopmentExpenseRecoveries contextRef="c-25" decimals="-6" id="f-53" unitRef="usd">93000000</rcus:ResearchAndDevelopmentExpenseRecoveries>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-19" decimals="-6" id="f-54" unitRef="usd">82000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-20" decimals="-6" id="f-55" unitRef="usd">77000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-6" id="f-56" unitRef="usd">247000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-21" decimals="-6" id="f-57" unitRef="usd">208000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-19" decimals="-6" id="f-58" unitRef="usd">30000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-20" decimals="-6" id="f-59" unitRef="usd">26000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-60" unitRef="usd">88000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-21" decimals="-6" id="f-61" unitRef="usd">76000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-19" decimals="-6" id="f-62" unitRef="usd">112000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-20" decimals="-6" id="f-63" unitRef="usd">103000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-6" id="f-64" unitRef="usd">335000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-21" decimals="-6" id="f-65" unitRef="usd">284000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-19" decimals="-6" id="f-66" unitRef="usd">-80000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-20" decimals="-6" id="f-67" unitRef="usd">-70000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-6" id="f-68" unitRef="usd">-249000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-21" decimals="-6" id="f-69" unitRef="usd">-206000000</us-gaap:OperatingIncomeLoss>
    <rcus:InterestAndOtherIncomeExpenseNonoperatingNet contextRef="c-19" decimals="-6" id="f-70" unitRef="usd">12000000</rcus:InterestAndOtherIncomeExpenseNonoperatingNet>
    <rcus:InterestAndOtherIncomeExpenseNonoperatingNet contextRef="c-20" decimals="-6" id="f-71" unitRef="usd">5000000</rcus:InterestAndOtherIncomeExpenseNonoperatingNet>
    <rcus:InterestAndOtherIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-6" id="f-72" unitRef="usd">30000000</rcus:InterestAndOtherIncomeExpenseNonoperatingNet>
    <rcus:InterestAndOtherIncomeExpenseNonoperatingNet contextRef="c-21" decimals="-6" id="f-73" unitRef="usd">8000000</rcus:InterestAndOtherIncomeExpenseNonoperatingNet>
    <rcus:EffectiveInterestOnLiabilityForSaleOfFutureRoyalties contextRef="c-19" decimals="-6" id="f-74" unitRef="usd">1000000</rcus:EffectiveInterestOnLiabilityForSaleOfFutureRoyalties>
    <rcus:EffectiveInterestOnLiabilityForSaleOfFutureRoyalties contextRef="c-20" decimals="-6" id="f-75" unitRef="usd">0</rcus:EffectiveInterestOnLiabilityForSaleOfFutureRoyalties>
    <rcus:EffectiveInterestOnLiabilityForSaleOfFutureRoyalties contextRef="c-1" decimals="-6" id="f-76" unitRef="usd">2000000</rcus:EffectiveInterestOnLiabilityForSaleOfFutureRoyalties>
    <rcus:EffectiveInterestOnLiabilityForSaleOfFutureRoyalties contextRef="c-21" decimals="-6" id="f-77" unitRef="usd">1000000</rcus:EffectiveInterestOnLiabilityForSaleOfFutureRoyalties>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-19" decimals="-6" id="f-78" unitRef="usd">11000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-20" decimals="-6" id="f-79" unitRef="usd">5000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-80" unitRef="usd">28000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-21" decimals="-6" id="f-81" unitRef="usd">7000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-19" decimals="-6" id="f-82" unitRef="usd">-69000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-20" decimals="-6" id="f-83" unitRef="usd">-65000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-84" unitRef="usd">-221000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-21" decimals="-6" id="f-85" unitRef="usd">-199000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-19" decimals="-6" id="f-86" unitRef="usd">2000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-20" decimals="-6" id="f-87" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-88" unitRef="usd">5000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-21" decimals="-6" id="f-89" unitRef="usd">1000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-6" id="f-90" unitRef="usd">-71000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-6" id="f-91" unitRef="usd">-65000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-92" unitRef="usd">-226000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-6" id="f-93" unitRef="usd">-200000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-19"
      decimals="2"
      id="f-94"
      unitRef="usdPerShare">-0.94</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-19"
      decimals="2"
      id="f-95"
      unitRef="usdPerShare">-0.94</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-20"
      decimals="2"
      id="f-96"
      unitRef="usdPerShare">-0.90</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-20"
      decimals="2"
      id="f-97"
      unitRef="usdPerShare">-0.90</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-98"
      unitRef="usdPerShare">-3.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-99"
      unitRef="usdPerShare">-3.07</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-21"
      decimals="2"
      id="f-100"
      unitRef="usdPerShare">-2.78</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-21"
      decimals="2"
      id="f-101"
      unitRef="usdPerShare">-2.78</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-19" decimals="-5" id="f-102" unitRef="shares">74600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-19" decimals="-5" id="f-103" unitRef="shares">74600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-20" decimals="-5" id="f-104" unitRef="shares">72200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-20" decimals="-5" id="f-105" unitRef="shares">72200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-106" unitRef="shares">73600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-107" unitRef="shares">73600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-21" decimals="-5" id="f-108" unitRef="shares">71800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-21" decimals="-5" id="f-109" unitRef="shares">71800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-6" id="f-110" unitRef="usd">-71000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-6" id="f-111" unitRef="usd">-65000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-112" unitRef="usd">-226000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-6" id="f-113" unitRef="usd">-200000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-19" decimals="-6" id="f-114" unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-20" decimals="-6" id="f-115" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-6" id="f-116" unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-21" decimals="-6" id="f-117" unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-19" decimals="-6" id="f-118" unitRef="usd">-70000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-20" decimals="-6" id="f-119" unitRef="usd">-67000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-6" id="f-120" unitRef="usd">-222000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-21" decimals="-6" id="f-121" unitRef="usd">-208000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-26" decimals="-6" id="f-122" unitRef="usd">184000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-27" decimals="-6" id="f-123" unitRef="usd">206000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-26" decimals="-6" id="f-124" unitRef="usd">615000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-27" decimals="-6" id="f-125" unitRef="usd">803000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-28" decimals="-6" id="f-126" unitRef="usd">22000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-29" decimals="-6" id="f-127" unitRef="usd">39000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-26" decimals="-6" id="f-128" unitRef="usd">52000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-27" decimals="-6" id="f-129" unitRef="usd">39000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-26" decimals="-6" id="f-130" unitRef="usd">31000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-27" decimals="-6" id="f-131" unitRef="usd">19000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-26" decimals="-6" id="f-132" unitRef="usd">882000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-27" decimals="-6" id="f-133" unitRef="usd">1067000000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-26" decimals="-6" id="f-134" unitRef="usd">151000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-27" decimals="-6" id="f-135" unitRef="usd">129000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-26" decimals="-6" id="f-136" unitRef="usd">50000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-27" decimals="-6" id="f-137" unitRef="usd">35000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-28" decimals="-6" id="f-138" unitRef="usd">6000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-29" decimals="-6" id="f-139" unitRef="usd">2000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-26" decimals="-6" id="f-140" unitRef="usd">108000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-27" decimals="-6" id="f-141" unitRef="usd">114000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-26" decimals="-6" id="f-142" unitRef="usd">1191000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-27" decimals="-6" id="f-143" unitRef="usd">1345000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-26" decimals="-6" id="f-144" unitRef="usd">17000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-27" decimals="-6" id="f-145" unitRef="usd">20000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-28" decimals="-6" id="f-146" unitRef="usd">96000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-29" decimals="-6" id="f-147" unitRef="usd">97000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-26" decimals="-6" id="f-148" unitRef="usd">103000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-27" decimals="-6" id="f-149" unitRef="usd">97000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-26" decimals="-6" id="f-150" unitRef="usd">80000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-27" decimals="-6" id="f-151" unitRef="usd">76000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-26" decimals="-6" id="f-152" unitRef="usd">200000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-27" decimals="-6" id="f-153" unitRef="usd">193000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-28" decimals="-6" id="f-154" unitRef="usd">309000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-29" decimals="-6" id="f-155" unitRef="usd">355000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-26" decimals="-6" id="f-156" unitRef="usd">326000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-27" decimals="-6" id="f-157" unitRef="usd">355000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-26" decimals="-6" id="f-158" unitRef="usd">145000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-27" decimals="-6" id="f-159" unitRef="usd">140000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="c-26" id="f-160" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-27" id="f-161" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-26"
      decimals="INF"
      id="f-162"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-27"
      decimals="INF"
      id="f-163"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-27"
      decimals="INF"
      id="f-164"
      unitRef="shares">10000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-26"
      decimals="INF"
      id="f-165"
      unitRef="shares">10000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-166"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-26"
      decimals="INF"
      id="f-167"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-26"
      decimals="INF"
      id="f-168"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-27"
      decimals="INF"
      id="f-169"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-26" decimals="-6" id="f-170" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-27" decimals="-6" id="f-171" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-26"
      decimals="INF"
      id="f-172"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-27"
      decimals="INF"
      id="f-173"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-27" decimals="-5" id="f-174" unitRef="shares">400000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-26" decimals="-5" id="f-175" unitRef="shares">400000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-26" decimals="-5" id="f-176" unitRef="shares">74800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-26" decimals="-5" id="f-177" unitRef="shares">74800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="-5" id="f-178" unitRef="shares">72900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-27" decimals="-5" id="f-179" unitRef="shares">72900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-26" decimals="-6" id="f-180" unitRef="usd">1291000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-27" decimals="-6" id="f-181" unitRef="usd">1206000000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-26" decimals="-6" id="f-182" unitRef="usd">-768000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-27" decimals="-6" id="f-183" unitRef="usd">-542000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-26" decimals="-6" id="f-184" unitRef="usd">-3000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-27" decimals="-6" id="f-185" unitRef="usd">-7000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-6" id="f-186" unitRef="usd">520000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-6" id="f-187" unitRef="usd">657000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-26" decimals="-6" id="f-188" unitRef="usd">1191000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-27" decimals="-6" id="f-189" unitRef="usd">1345000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-30" decimals="-5" id="f-190" unitRef="shares">70800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-6" id="f-191" unitRef="usd">1118000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-6" id="f-192" unitRef="usd">-275000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-6" id="f-193" unitRef="usd">-1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-6" id="f-194" unitRef="usd">842000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-35" decimals="-5" id="f-195" unitRef="shares">800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-36" decimals="-6" id="f-196" unitRef="usd">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-37" decimals="-6" id="f-197" unitRef="usd">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-38" decimals="-6" id="f-198" unitRef="usd">17000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-39" decimals="-6" id="f-199" unitRef="usd">17000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-40" decimals="-6" id="f-200" unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-39" decimals="-6" id="f-201" unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-41" decimals="-6" id="f-202" unitRef="usd">-68000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-39" decimals="-6" id="f-203" unitRef="usd">-68000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-5" id="f-204" unitRef="shares">71600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-6" id="f-205" unitRef="usd">1145000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-6" id="f-206" unitRef="usd">-343000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-6" id="f-207" unitRef="usd">-5000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-6" id="f-208" unitRef="usd">797000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-47" decimals="-5" id="f-209" unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-48" decimals="-6" id="f-210" unitRef="usd">4000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-49" decimals="-6" id="f-211" unitRef="usd">4000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-50" decimals="-6" id="f-212" unitRef="usd">15000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-51" decimals="-6" id="f-213" unitRef="usd">15000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-52" decimals="-6" id="f-214" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-51" decimals="-6" id="f-215" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-53" decimals="-6" id="f-216" unitRef="usd">-67000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-51" decimals="-6" id="f-217" unitRef="usd">-67000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-54" decimals="-5" id="f-218" unitRef="shares">72100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-6" id="f-219" unitRef="usd">1164000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-6" id="f-220" unitRef="usd">-410000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-57" decimals="-6" id="f-221" unitRef="usd">-7000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-58" decimals="-6" id="f-222" unitRef="usd">747000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-59" decimals="-5" id="f-223" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-60" decimals="-6" id="f-224" unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-61" decimals="-6" id="f-225" unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-62" decimals="-6" id="f-226" unitRef="usd">16000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-6" id="f-227" unitRef="usd">16000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-63" decimals="-6" id="f-228" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-20" decimals="-6" id="f-229" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-64" decimals="-6" id="f-230" unitRef="usd">-65000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-6" id="f-231" unitRef="usd">-65000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-65" decimals="-5" id="f-232" unitRef="shares">72400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-66" decimals="-6" id="f-233" unitRef="usd">1183000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-67" decimals="-6" id="f-234" unitRef="usd">-475000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-68" decimals="-6" id="f-235" unitRef="usd">-9000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-69" decimals="-6" id="f-236" unitRef="usd">699000000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-70" decimals="-5" id="f-237" unitRef="shares">72900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-71" decimals="-6" id="f-238" unitRef="usd">1206000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-72" decimals="-6" id="f-239" unitRef="usd">-542000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-73" decimals="-6" id="f-240" unitRef="usd">-7000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-6" id="f-241" unitRef="usd">657000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-74" decimals="-5" id="f-242" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-75" decimals="-6" id="f-243" unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-76" decimals="-6" id="f-244" unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-77" decimals="-6" id="f-245" unitRef="usd">19000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-78" decimals="-6" id="f-246" unitRef="usd">19000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-79" decimals="-6" id="f-247" unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-78" decimals="-6" id="f-248" unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-80" decimals="-6" id="f-249" unitRef="usd">-80000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-78" decimals="-6" id="f-250" unitRef="usd">-80000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-81" decimals="-5" id="f-251" unitRef="shares">73100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-82" decimals="-6" id="f-252" unitRef="usd">1226000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-83" decimals="-6" id="f-253" unitRef="usd">-622000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-84" decimals="-6" id="f-254" unitRef="usd">-4000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-85" decimals="-6" id="f-255" unitRef="usd">600000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-86" decimals="-5" id="f-256" unitRef="shares">1000000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-87" decimals="-6" id="f-257" unitRef="usd">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-88" decimals="-6" id="f-258" unitRef="usd">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-89" decimals="-5" id="f-259" unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-90" decimals="-6" id="f-260" unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-91" decimals="-6" id="f-261" unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-92" decimals="-6" id="f-262" unitRef="usd">18000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-93" decimals="-6" id="f-263" unitRef="usd">18000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-94" decimals="-6" id="f-264" unitRef="usd">-75000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-93" decimals="-6" id="f-265" unitRef="usd">-75000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-95" decimals="-5" id="f-266" unitRef="shares">74500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-96" decimals="-6" id="f-267" unitRef="usd">1267000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-97" decimals="-6" id="f-268" unitRef="usd">-697000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-98" decimals="-6" id="f-269" unitRef="usd">-4000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-99" decimals="-6" id="f-270" unitRef="usd">566000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-100"
      decimals="-5"
      id="f-271"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-101" decimals="-6" id="f-272" unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-19" decimals="-6" id="f-273" unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-102"
      decimals="-5"
      id="f-274"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-103" decimals="-6" id="f-275" unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-104" decimals="-6" id="f-276" unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-101" decimals="-6" id="f-277" unitRef="usd">18000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-19" decimals="-6" id="f-278" unitRef="usd">18000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-105" decimals="-6" id="f-279" unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-19" decimals="-6" id="f-280" unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-106" decimals="-6" id="f-281" unitRef="usd">-71000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-6" id="f-282" unitRef="usd">-71000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-107"
      decimals="-5"
      id="f-283"
      unitRef="shares">74800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-108" decimals="-6" id="f-284" unitRef="usd">1291000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-109" decimals="-6" id="f-285" unitRef="usd">-768000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-110" decimals="-6" id="f-286" unitRef="usd">-3000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-6" id="f-287" unitRef="usd">520000000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-288" unitRef="usd">-226000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-21" decimals="-6" id="f-289" unitRef="usd">-200000000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-6" id="f-290" unitRef="usd">55000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-21" decimals="-6" id="f-291" unitRef="usd">48000000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-6" id="f-292" unitRef="usd">5000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-21" decimals="-6" id="f-293" unitRef="usd">5000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-6" id="f-294" unitRef="usd">6000000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-21" decimals="-6" id="f-295" unitRef="usd">6000000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-6" id="f-296" unitRef="usd">13000000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-21" decimals="-6" id="f-297" unitRef="usd">-2000000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-1" decimals="-6" id="f-298" unitRef="usd">2000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-21" decimals="-6" id="f-299" unitRef="usd">3000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-24" decimals="-6" id="f-300" unitRef="usd">-17000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-25" decimals="-6" id="f-301" unitRef="usd">-718000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-1" decimals="-6" id="f-302" unitRef="usd">-15000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-21" decimals="-6" id="f-303" unitRef="usd">-716000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-24" decimals="-6" id="f-304" unitRef="usd">-4000000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-25" decimals="-6" id="f-305" unitRef="usd">-2000000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-6" id="f-306" unitRef="usd">12000000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-21" decimals="-6" id="f-307" unitRef="usd">4000000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-6" id="f-308" unitRef="usd">-3000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-21" decimals="-6" id="f-309" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-24" decimals="-6" id="f-310" unitRef="usd">-47000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-25" decimals="-6" id="f-311" unitRef="usd">-73000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-6" id="f-312" unitRef="usd">-51000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-21" decimals="-6" id="f-313" unitRef="usd">-78000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-6" id="f-314" unitRef="usd">4000000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-21" decimals="-6" id="f-315" unitRef="usd">10000000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-316" unitRef="usd">-218000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-21" decimals="-6" id="f-317" unitRef="usd">508000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-6" id="f-318" unitRef="usd">673000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-21" decimals="-6" id="f-319" unitRef="usd">1085000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <rcus:ProceedsFromMaturityOfMarketableSecurities contextRef="c-1" decimals="-6" id="f-320" unitRef="usd">837000000</rcus:ProceedsFromMaturityOfMarketableSecurities>
    <rcus:ProceedsFromMaturityOfMarketableSecurities contextRef="c-21" decimals="-6" id="f-321" unitRef="usd">491000000</rcus:ProceedsFromMaturityOfMarketableSecurities>
    <rcus:ProceedsFromSaleOfMarketableSecurities contextRef="c-1" decimals="-6" id="f-322" unitRef="usd">20000000</rcus:ProceedsFromSaleOfMarketableSecurities>
    <rcus:ProceedsFromSaleOfMarketableSecurities contextRef="c-21" decimals="-6" id="f-323" unitRef="usd">143000000</rcus:ProceedsFromSaleOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-324" unitRef="usd">18000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-21" decimals="-6" id="f-325" unitRef="usd">6000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="c-1" decimals="-6" id="f-326" unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="c-21" decimals="-6" id="f-327" unitRef="usd">6000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <rcus:CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty contextRef="c-1" decimals="-6" id="f-328" unitRef="usd">0</rcus:CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty>
    <rcus:CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty contextRef="c-21" decimals="-6" id="f-329" unitRef="usd">3000000</rcus:CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-330" unitRef="usd">166000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-21" decimals="-6" id="f-331" unitRef="usd">-460000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-24" decimals="-6" id="f-332" unitRef="usd">20000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-25" decimals="-6" id="f-333" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-6" id="f-334" unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-21" decimals="-6" id="f-335" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-6" id="f-336" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-21" decimals="-6" id="f-337" unitRef="usd">17000000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <rcus:ProceedsFromSaleOfFutureRoyalties contextRef="c-1" decimals="-6" id="f-338" unitRef="usd">0</rcus:ProceedsFromSaleOfFutureRoyalties>
    <rcus:ProceedsFromSaleOfFutureRoyalties contextRef="c-21" decimals="-6" id="f-339" unitRef="usd">5000000</rcus:ProceedsFromSaleOfFutureRoyalties>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-340" unitRef="usd">30000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-21" decimals="-6" id="f-341" unitRef="usd">22000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-6" id="f-342" unitRef="usd">-22000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-21" decimals="-6" id="f-343" unitRef="usd">70000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-27" decimals="-6" id="f-344" unitRef="usd">209000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-34" decimals="-6" id="f-345" unitRef="usd">151000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-26" decimals="-6" id="f-346" unitRef="usd">187000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-69" decimals="-6" id="f-347" unitRef="usd">221000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-6" id="f-348" unitRef="usd">6000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-21" decimals="-6" id="f-349" unitRef="usd">1000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-350">Organization, liquidity and capital resources&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arcus Biosciences, Inc. (referred to as "Arcus," "we," "our," "us," or the "Company") is a clinical-stage, biopharmaceutical company focused on creating best-in-class therapies. Using our robust and highly efficient drug discovery capability, we have created a significant portfolio of investigational products which are in clinical development, with our most advanced molecule, an anti-TIGIT antibody, now in four Phase 3 registrational studies targeting lung and gastrointestinal cancers. Our deep portfolio of novel small molecules and enabling antibodies allows us to create highly differentiated therapies, which we are developing to treat multiple large indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate and manage our business as one reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, we had cash, cash equivalents and marketable securities of $950 million, which we believe will be sufficient to fund our planned operations for a period of at least twelve months following the date of filing of this report.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-351"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-352"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:InvestmentsAndCash contextRef="c-111" decimals="-6" id="f-353" unitRef="usd">950000000</us-gaap:InvestmentsAndCash>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-354">Summary of significant accounting policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim financial statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2022 included in our Annual Report on Form 10-K filed with the SEC on February&#160;28, 2023. There have been no significant changes to our accounting policies as described in Note 2, Summary of significant accounting policies, in the notes to Consolidated Financial Statements in Item 8 of Part II of the Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and include all adjustments consisting of normal recurring adjustments that management believes are necessary for a fair presentation of the periods presented. The Condensed Consolidated Balance Sheet as of December&#160;31, 2022 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating results for the nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023 or for any future period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed and updated each period to reflect current information. Actual results may differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no new accounting pronouncements issued or adopted during the period with a significant impact to our financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-355">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim financial statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2022 included in our Annual Report on Form 10-K filed with the SEC on February&#160;28, 2023. There have been no significant changes to our accounting policies as described in Note 2, Summary of significant accounting policies, in the notes to Consolidated Financial Statements in Item 8 of Part II of the Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and include all adjustments consisting of normal recurring adjustments that management believes are necessary for a fair presentation of the periods presented. The Condensed Consolidated Balance Sheet as of December&#160;31, 2022 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;Operating results for the nine months ended September&#160;30, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023 or for any future period.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-356">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed and updated each period to reflect current information. Actual results may differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-357">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no new accounting pronouncements issued or adopted during the period with a significant impact to our financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-358">Related party - Gilead Sciences, Inc.&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we and Gilead Sciences, Inc. (Gilead) entered into an Option, License and Collaboration Agreement (the Gilead Collaboration Agreement), Common Stock Purchase Agreement (the Stock Purchase Agreement), and Investor Rights Agreement (Investor Rights Agreement). In 2021, we amended the Gilead Collaboration Agreement (the First Gilead Collaboration Agreement Amendment) and the Stock Purchase Agreement (the First Stock Purchase Agreement Amendment), and in 2022 we amended the Investor Rights Agreement (Amended Investor Rights Agreement). In the second quarter of 2023, we expanded our collaboration to include research-stage inflammation programs (the Second Gilead Collaboration Agreement Amendment) and further amended the Stock Purchase Agreement (the Second Stock Purchase Agreement Amendment). We refer to these agreements collectively as the Gilead Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Purchase Agreement and Investor Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, under the Stock Purchase Agreement, Gilead purchased 6.0 million shares of our common stock for a total cost of $200 million, of which $91 million was allocated to the revenue related performance obligations created by the Gilead Collaboration Agreement (See Note 5, Revenues for more information).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, under the First Stock Purchase Agreement Amendment, Gilead purchased 5.7 million shares of our common stock for a total cost of $220 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, under the Second Stock Purchase Agreement Amendment, Gilead purchased 1.0 million shares of our common stock for a total cost of $20 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead has the right, at its option until July 2025, to purchase up to a maximum of 35% of the Company&#x2019;s then-outstanding voting common stock, at a purchase price equal to the greater of a 20% premium to market (based on a trailing five-day average closing price at option exercise) or the $33.54 initial purchase price. Based on the value of our common stock at each contract closing, the right to purchase additional shares had no value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Investor Rights Agreement, Gilead has the right, which they have exercised, to designate two members of our Board of Directors. This agreement also included a three-year standstill and a two-year lockup, provided Gilead with registration rights commencing at the end of the lockup period and provides Gilead with pro rata participation rights in certain future financings. In October 2022, we registered Gilead&#x2019;s shares and entered into the Amended Investor Rights Agreement, primarily to extend the two-year lockup period to three-years which expired on July 13, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, Gilead held approximately 19.8% of the Company&#x2019;s outstanding common stock arising from purchases in our May 2020 public offering and purchases under the Stock Purchase Agreement and the First and Second Amended Stock Purchase Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into the Gilead Collaboration Agreement, which gave Gilead an exclusive license to develop and commercialize zimberelimab (the anti PD-1 program) in certain markets and time-limited options to acquire exclusive licenses to develop and commercialize any of our then-current and future clinical programs arising during the 10-year collaboration term, contingent upon $100 million option continuation payments payable on each of the second, fourth, sixth and eighth anniversaries of the agreement. Upon closing of the transaction in July 2020, Gilead made an upfront payment of $175 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we entered into the First Gilead Collaboration Agreement Amendment pursuant to which Gilead exercised its option to three programs&#x2014;providing Gilead with exclusive licenses to develop and commercialize domvanalimab and AB308 (collectively, the anti-TIGIT program), etrumadenant (the adenosine receptor antagonist program) and quemliclustat (the CD73 program), in certain markets&#x2014;for a total payment of $725 million that was received in 2022. The amendment also (i) provided for a slight reduction in the royalties for these three programs, such that Gilead will pay us tiered royalties as a percentage of revenues ranging from the mid-teens to the low twenties; and (ii) removed the $100 million option continuation payment that was otherwise due on the second anniversary of the Gilead Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead's option, on a program-by-program basis, will expire after a prescribed period following the achievement of a clinical development milestone in such program and our delivery to Gilead of the requisite data package. Gilead may exercise its option to any program at any time prior to expiration of the option and will pay Arcus an option fee of $150 million per program. With respect to domvanalimab, we are also eligible to receive up to $500 million in potential U.S. regulatory approval milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each program that Gilead opts in to, both companies will co-develop and equally share global development costs, subject to certain opt-out rights that we have, and caps on our spending and related subsequent adjustments. For each program, provided we have not exercised our opt-out rights, we have the option to co-promote in the United States with equal sharing of related profits and losses. Gilead has the right to exclusively commercialize outside of the U.S., subject to the rights of our existing partners in any territories and will pay us tiered royalties as a percentage of revenues ranging from the high teens to the low twenties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the First Gilead Collaboration Agreement Amendment, Gilead also has option rights to two immuno-oncology research programs for which we will lead discovery and early development activities. With respect to these two research programs, Gilead has the right to exercise its option, on a program-by-program basis, either (i) upon our completion of certain IND-enabling activities for an option payment of $60 million or (ii) following the achievement of a clinical development milestone for an option payment of $150 million. These research programs were not determined to be performance obligations at contract inception, due to the very early stages of the programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, we entered into the Second Gilead Collaboration Agreement Amendment pursuant to which we expanded our collaboration to provide Gilead with options to license up to four jointly selected research-stage programs that target inflammatory diseases for which we will lead discovery and early development activities. We will receive an upfront payment of $17.5 million for each initiated program and Gilead will have an option to license each program at two separate, prespecified time points. For the first two research programs, Gilead has the right to exercise its option, on a program-by-program basis, either (i) upon our completion of certain IND-enabling activities for an option payment of $45 million or (ii) following the achievement of a clinical development milestone for an option payment of $150 million. If Gilead exercises its option at the earlier time point for the first two programs, we would be eligible to receive up to $375 million in regulatory and commercial milestone payments as well as tiered royalties for each optioned program. For any other program option exercise by Gilead, the parties would have rights to co-develop and share global development costs and to co-commercialize and share profits in the US for that program. We received a total upfront payment of $35 million for an initial two research programs in June 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, Gilead has licenses to domvanalimab, AB308, etrumadenant, quemliclustat and zimberelimab.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September&#160;30, 2023 and 2022, we recognized revenue under the Gilead Agreements of $28 million and $31 million, respectively, and net reimbursements from Gilead recognized as reductions in research and development (R&amp;amp;D) expense of $22 million and $27 million, respectively. For the nine months ended September&#160;30, 2023 and 2022, we recognized revenue under the Gilead Agreements of $82 million and $73 million, respectively, and net reimbursements from Gilead recognized as reductions in R&amp;amp;D expense of $89 million and $93 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a more detailed discussion on revenues recognized under the Gilead Agreements, see Note 5, Revenues.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-112"
      decimals="-5"
      id="f-359"
      unitRef="shares">6000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <rcus:FundsReceivedForStockPurchaseAgreement contextRef="c-112" decimals="-6" id="f-360" unitRef="usd">200000000</rcus:FundsReceivedForStockPurchaseAgreement>
    <rcus:StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation contextRef="c-112" decimals="-6" id="f-361" unitRef="usd">91000000</rcus:StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-113"
      decimals="-5"
      id="f-362"
      unitRef="shares">5700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-113" decimals="-6" id="f-363" unitRef="usd">220000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-114"
      decimals="-5"
      id="f-364"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-114" decimals="-6" id="f-365" unitRef="usd">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <rcus:RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage contextRef="c-115" decimals="2" id="f-366" unitRef="number">0.35</rcus:RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage>
    <rcus:PercentageOfPremiumPurchasePriceOfCommonStock contextRef="c-116" decimals="2" id="f-367" unitRef="number">0.20</rcus:PercentageOfPremiumPurchasePriceOfCommonStock>
    <rcus:TrailingDaysAverageClosingPrice contextRef="c-116" id="f-368">P5D</rcus:TrailingDaysAverageClosingPrice>
    <us-gaap:SharePrice
      contextRef="c-117"
      decimals="2"
      id="f-369"
      unitRef="usdPerShare">33.54</us-gaap:SharePrice>
    <rcus:LockupPeriod contextRef="c-118" id="f-370">P2Y</rcus:LockupPeriod>
    <rcus:ExtendedLockupPeriod contextRef="c-118" id="f-371">P3Y</rcus:ExtendedLockupPeriod>
    <rcus:PercentageOfOutstandingCommonStockOwned contextRef="c-28" decimals="3" id="f-372" unitRef="number">0.198</rcus:PercentageOfOutstandingCommonStockOwned>
    <rcus:CollaborationTermForCurrentAndFutureClinicalPrograms contextRef="c-119" id="f-373">P10Y</rcus:CollaborationTermForCurrentAndFutureClinicalPrograms>
    <rcus:OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement contextRef="c-120" decimals="-6" id="f-374" unitRef="usd">100000000</rcus:OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement>
    <rcus:UpfrontCashPayment contextRef="c-119" decimals="-6" id="f-375" unitRef="usd">175000000</rcus:UpfrontCashPayment>
    <rcus:NumberOfExerciseOptionToPrograms
      contextRef="c-121"
      decimals="INF"
      id="f-376"
      unitRef="program">3</rcus:NumberOfExerciseOptionToPrograms>
    <rcus:OptionPaymentReceived contextRef="c-121" decimals="-6" id="f-377" unitRef="usd">725000000</rcus:OptionPaymentReceived>
    <rcus:RemoveOptionContinuationPaymentUnderAgreement contextRef="c-121" decimals="-6" id="f-378" unitRef="usd">100000000</rcus:RemoveOptionContinuationPaymentUnderAgreement>
    <rcus:OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption contextRef="c-122" decimals="-6" id="f-379" unitRef="usd">150000000</rcus:OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption>
    <rcus:PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab contextRef="c-123" decimals="-6" id="f-380" unitRef="usd">500000000</rcus:PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab>
    <rcus:NumberOfResearchPrograms contextRef="c-122" decimals="INF" id="f-381" unitRef="usd">2</rcus:NumberOfResearchPrograms>
    <rcus:OptionPaymentUponCompletionOfCertainIndEnablingActivities contextRef="c-124" decimals="-6" id="f-382" unitRef="usd">60000000</rcus:OptionPaymentUponCompletionOfCertainIndEnablingActivities>
    <rcus:OptionPaymentUponAchievementOfCertainDevelopmentMilestones contextRef="c-124" decimals="-6" id="f-383" unitRef="usd">150000000</rcus:OptionPaymentUponAchievementOfCertainDevelopmentMilestones>
    <rcus:UpfrontCashPayment contextRef="c-125" decimals="-5" id="f-384" unitRef="usd">17500000</rcus:UpfrontCashPayment>
    <rcus:OptionPaymentUponCompletionOfCertainIndEnablingActivities contextRef="c-125" decimals="-6" id="f-385" unitRef="usd">45000000</rcus:OptionPaymentUponCompletionOfCertainIndEnablingActivities>
    <rcus:OptionPaymentUponAchievementOfCertainDevelopmentMilestones contextRef="c-126" decimals="-6" id="f-386" unitRef="usd">150000000</rcus:OptionPaymentUponAchievementOfCertainDevelopmentMilestones>
    <rcus:NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments
      contextRef="c-126"
      decimals="INF"
      id="f-387"
      unitRef="program">2</rcus:NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments>
    <rcus:RegulatoryAndCommercialMilestonePaymentsReceived contextRef="c-127" decimals="-6" id="f-388" unitRef="usd">375000000</rcus:RegulatoryAndCommercialMilestonePaymentsReceived>
    <rcus:UpfrontCashPayment contextRef="c-128" decimals="-6" id="f-389" unitRef="usd">35000000</rcus:UpfrontCashPayment>
    <rcus:NumberOfResearchPrograms
      contextRef="c-128"
      decimals="INF"
      id="f-390"
      unitRef="program">2</rcus:NumberOfResearchPrograms>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-129" decimals="-6" id="f-391" unitRef="usd">28000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-130" decimals="-6" id="f-392" unitRef="usd">31000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts contextRef="c-131" decimals="-6" id="f-393" unitRef="usd">22000000</rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts>
    <rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts contextRef="c-132" decimals="-6" id="f-394" unitRef="usd">27000000</rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-133" decimals="-6" id="f-395" unitRef="usd">82000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-134" decimals="-6" id="f-396" unitRef="usd">73000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts contextRef="c-135" decimals="-6" id="f-397" unitRef="usd">89000000</rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts>
    <rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts contextRef="c-136" decimals="-6" id="f-398" unitRef="usd">93000000</rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-399">License and collaborations&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into licensing agreements, strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain investigational products. These arrangements may be collaborative and involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include: non-refundable upfront payments; payments for options to acquire certain rights; potential development and regulatory milestone payments and/or sales-based milestone payments; royalty payments; revenue or profit-sharing arrangements; expense reimbursements; and cost-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Condensed Consolidated Statements of Operations, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our significant arrangements are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Gilead Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 3, Related party - Gilead Sciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Taiho Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we entered into an agreement with Taiho Pharmaceutical Co., Ltd (Taiho) under which we granted Taiho exclusive options to programs arising over a five-year period which ended in September 2022 (the Option Period) for an upfront payment of $35 million. Upon an option exercise of a program, Taiho would obtain exclusive development and commercialization rights to investigational products under the program for Japan and certain other territories in Asia (excluding China) (the Taiho Territory). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each option that Taiho exercises, they will be obligated to make a payment of $3 million to $15 million, depending on the development stage of the optioned program. Upon exercise, Taiho is solely responsible for continued development and commercialization in the Taiho Territory. In addition, for each optioned program we would be eligible to receive clinical and regulatory milestones of up to $130 million and commercial milestone payments of up to $145 million with the achievement of certain sales thresholds in the Taiho Territory. We will also receive royalties ranging from high single-digits to mid-teens on net sales of licensed products in the Taiho Territory. Royalties will be payable by product and country commencing on the first commercial sale and ending upon the later of: (a) 10 years; and (b) expiration of the last-to-expire valid claim of our patents covering the manufacture, use or sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2022, Taiho opted to participate in two global Phase 3 trials of domvanalimab and zimberelimab combinations, STAR-121 and STAR-221, and is obligated to make certain milestone payments contingent upon successfully satisfying the related clinical milestones. During the three months ended September 30, 2023, the clinical milestones for domvanalimab and zimberelimab for the STAR-221 study were met and Taiho became obligated to pay us $28 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, Taiho has licenses for the Taiho Territory to (i) etrumadenant (the adenosine receptor antagonist program); (ii) zimberelimab (the anti PD-1 program); and (iii) domvanalimab and AB308 (collectively, the anti-TIGIT program).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September&#160;30, 2023 and 2022, we recognized revenue of $4&#160;million and $2 million, respectively, and we recognized net reimbursements from Taiho as a reduction in R&amp;amp;D expense of $2 million for the three months ended September&#160;30, 2023. For the nine months ended September 30, 2023 and 2022, we recognized revenue of $4&#160;million and $5 million, respectively and we recognized net reimbursements from Taiho as a reduction in R&amp;amp;D expense of $4&#160;million for the nine months ended September 30, 2023. For a more detailed discussion on revenues see Note 5, Revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AstraZeneca Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into a collaboration with AstraZeneca to evaluate domvanalimab, our investigational anti-TIGIT antibody, in combination with AstraZeneca&#x2019;s durvalumab in a registrational Phase 3 clinical trial in patients with unresectable Stage 3 non-small cell lung cancer (NSCLC), known as the PACIFIC-8 trial. Under the collaboration, each company will retain existing rights to their respective molecules and any future commercial economics. AstraZeneca will conduct the trial, and each company will supply their respective investigational product to support the trial. Under the terms of the agreement, we will reimburse AstraZeneca for its share of the trial costs upon the achievement of certain milestones or under certain circumstances if the agreement is terminated early. The portion of the costs that we consider to be unavoidable are accrued in advance of the achievement of the milestone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September&#160;30, 2023 and 2022, we recognized as R&amp;amp;D expense $1 million and $1 million, respectively, before expected recoveries from our cost-sharing agreement with Gilead. For the nine months ended September&#160;30, 2023 and 2022, we recognized as R&amp;amp;D expense $6 million and $3 million, respectively, before expected recoveries from our cost-sharing agreement with Gilead. At September&#160;30, 2023 and December&#160;31, 2022, we have recognized a liability of $11 million and $5 million, respectively, related to our obligation to AstraZeneca which is recorded in Other noncurrent liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The PACIFIC-8 trial forms part of the Arcus and Gilead joint development program for domvanalimab and our portion of the trial costs are shared with Gilead. At September&#160;30, 2023 and December&#160;31, 2022, we have recognized a receivable due from Gilead for these shared costs of $6 million and $2 million, respectively, which is recorded in Other noncurrent assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;WuXi Biologics License - anti-PD-1 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we entered into an agreement with WuXi Biologics Ireland Limited (WuXi Biologics) which, as amended, provides us with exclusive rights to (i) develop, use and manufacture products that include an anti-PD-1 antibody, including zimberelimab, worldwide and (ii) commercialize any such products worldwide, except in Greater China. Under the agreement, as of September&#160;30, 2023, we may incur (i) clinical and regulatory milestone payments, and commercialization milestone payments of up to $375 million, (ii) tiered royalties that range from the high single-digits to low teens on net sales of the licensed products and (iii) fees related to any sublicenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2023 and 2022, we did not have any transactions nor were any amounts due under this arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;WuXi Biologics License - anti-CD39&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into an agreement with WuXi Biologics, under which we obtained the exclusive worldwide license to develop and commercialize anti-CD39 antibodies discovered under the agreement. As of September&#160;30, 2023, we may incur additional clinical and regulatory milestone payments of up to $14 million and royalty payments in the low single digits on net sales of the licensed products under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September&#160;30, 2023 and 2022, we incurred no development milestones nor were any amounts due under this arrangement. For the nine months ended September&#160;30, 2023 and 2022, we incurred development milestones under this arrangement of $1&#160;million and $2 million, respectively, which were recognized as R&amp;amp;D expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Abmuno License&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, we entered into an agreement with Abmuno Therapeutics LLC (Abmuno), under which we obtained the exclusive worldwide license to develop, use, manufacture, and commercialize products that include an anti-TIGIT antibody, including domvanalimab. As of September&#160;30, 2023 we may incur additional clinical, regulatory and commercialization milestone payments of up to $88 million under this agreement.&lt;/span&gt;&lt;/div&gt;For the three and nine months ended September&#160;30, 2023 and 2022, we did not have any transactions nor were any amounts due under this arrangement.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <rcus:OptionPeriod contextRef="c-137" id="f-400">P5Y</rcus:OptionPeriod>
    <rcus:NonRefundableAndNonCreditableCashPayments contextRef="c-137" decimals="-6" id="f-401" unitRef="usd">35000000</rcus:NonRefundableAndNonCreditableCashPayments>
    <rcus:PaymentForOptionExercise contextRef="c-138" decimals="-6" id="f-402" unitRef="usd">3000000</rcus:PaymentForOptionExercise>
    <rcus:PaymentForOptionExercise contextRef="c-139" decimals="-6" id="f-403" unitRef="usd">15000000</rcus:PaymentForOptionExercise>
    <rcus:AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="c-139" decimals="-6" id="f-404" unitRef="usd">130000000</rcus:AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <rcus:ContingentMilestonePaymentsReceivable contextRef="c-140" decimals="-6" id="f-405" unitRef="usd">145000000</rcus:ContingentMilestonePaymentsReceivable>
    <rcus:RoyaltiesPayableTerm contextRef="c-141" id="f-406">P10Y</rcus:RoyaltiesPayableTerm>
    <rcus:PaymentForOptionExercise contextRef="c-141" decimals="-6" id="f-407" unitRef="usd">28000000</rcus:PaymentForOptionExercise>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-141" decimals="-6" id="f-408" unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-142" decimals="-6" id="f-409" unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <rcus:ReimbursementOfResearchAndDevelopmentExpense contextRef="c-141" decimals="-6" id="f-410" unitRef="usd">2000000</rcus:ReimbursementOfResearchAndDevelopmentExpense>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-143" decimals="-6" id="f-411" unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-144" decimals="-6" id="f-412" unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <rcus:ReimbursementOfResearchAndDevelopmentExpense contextRef="c-143" decimals="-6" id="f-413" unitRef="usd">4000000</rcus:ReimbursementOfResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-145" decimals="-6" id="f-414" unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-146" decimals="-6" id="f-415" unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-147" decimals="-6" id="f-416" unitRef="usd">6000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-148" decimals="-6" id="f-417" unitRef="usd">3000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-149" decimals="-6" id="f-418" unitRef="usd">11000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-150" decimals="-6" id="f-419" unitRef="usd">5000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-151" decimals="-6" id="f-420" unitRef="usd">6000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-152" decimals="-6" id="f-421" unitRef="usd">2000000</us-gaap:OtherAssetsNoncurrent>
    <rcus:ClinicalRegulatoryAndCommercializationMilestonePayments contextRef="c-153" decimals="-6" id="f-422" unitRef="usd">375000000</rcus:ClinicalRegulatoryAndCommercializationMilestonePayments>
    <rcus:AdditionalClinicalRegulatoryAndCommercializationMilestonePayments contextRef="c-154" decimals="-6" id="f-423" unitRef="usd">14000000</rcus:AdditionalClinicalRegulatoryAndCommercializationMilestonePayments>
    <rcus:MilestoneExpense contextRef="c-155" decimals="INF" id="f-424" unitRef="usd">0</rcus:MilestoneExpense>
    <rcus:MilestoneExpense contextRef="c-156" decimals="INF" id="f-425" unitRef="usd">0</rcus:MilestoneExpense>
    <rcus:MilestoneExpense contextRef="c-157" decimals="-6" id="f-426" unitRef="usd">1000000</rcus:MilestoneExpense>
    <rcus:MilestoneExpense contextRef="c-158" decimals="-6" id="f-427" unitRef="usd">2000000</rcus:MilestoneExpense>
    <rcus:AdditionalClinicalRegulatoryAndCommercializationMilestonePayments contextRef="c-159" decimals="-6" id="f-428" unitRef="usd">88000000</rcus:AdditionalClinicalRegulatoryAndCommercializationMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-429">Revenues &lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenues by collaboration, category of revenue, and the method of recognition (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License and R&amp;amp;D services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Access rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Taiho Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Access rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from Gilead accounted for 88% and 94% of Total revenues for the three months ended September&#160;30, 2023 and 2022, respectively and 95% and 94% for the nine months ended September&#160;30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the revenue recognized as a result of changes in the deferred revenue balance (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from amounts included in deferred revenue at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue for the nine months ended September&#160;30, 2023 includes a net $1&#160;million cumulative catch-up of revenue due to changes in the total estimated effort to be incurred in the future to satisfy the Gilead license and R&amp;amp;D services performance obligations, primarily related to lower estimated late-stage clinical trial costs for etrumadenant, partially offset by higher estimated late-stage clinical trial costs for quemliclustat.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $429 million and $452 million of deferred revenue remaining on our Condensed Consolidated Balance Sheets at September&#160;30, 2023 and December&#160;31, 2022, respectively, allocated between current and noncurrent based on the expected timing of future recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from the Gilead Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for performance obligations under this arrangement for the periods presented herein was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inflammation Programs - R&amp;amp;D Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, we entered into the Second Gilead Collaboration Agreement Amendment pursuant to which we expanded our collaboration to provide Gilead with options to license up to four jointly selected research-stage programs that target inflammatory diseases for which we will lead discovery and early development activities (see Note 3, Related party - Gilead Sciences, Inc., for more information). In June 2023, we received a total upfront payment of $35 million for an initial two jointly selected research-stage programs. We determined that the Second Gilead Collaboration Agreement Amendment represented a separate contract and, at the amendment closing date, we allocated the transaction price of $35 million to the performance obligations created as of the date of this amendment. The following table summarizes the allocation of the transaction price to the distinct performance obligations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation to performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Distinct&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inflammation target 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inflammation target 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total allocated transaction price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that we have separate performance obligations to perform R&amp;amp;D services for Gilead related to discovery and early development activities for each research program for which they have made an upfront payment. The standalone selling price of these obligations was determined using an expected cost-plus margin approach. We recognize the amounts allocated to these services as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. The options to acquire additional licenses or services did not result in additional performance obligations because they did not provide a material right at contract inception, primarily due to the very early stages of the programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue of $2 million and $3 million for the three and nine months ended September&#160;30, 2023, respectively, within Other collaboration revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $32 million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to these performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Etrumadenant - License and R&amp;amp;D Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the First Gilead Collaboration Agreement Amendment, Gilead has an exclusive license and we are also obligated to perform further R&amp;amp;D services for Gilead related to etrumadenant. We determined that the license and R&amp;amp;D services were combined based on an evaluation of the delivery of the license, due to the early stage of the technology and the specialized nature of our know-how. We allocated arrangement consideration of $219 million to the combined license and R&amp;amp;D services performance obligation and recognize the amounts allocated as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue of $21 million and $3 million for the three months ended September&#160;30, 2023 and 2022, respectively, and $39 million and $21&#160;million for the nine months ended September&#160;30, 2023 and 2022, respectively, within License and development service revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $146 million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to this performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Quemliclustat - License and R&amp;amp;D Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the First Gilead Collaboration Agreement Amendment, Gilead has an exclusive license and we are also obligated to perform further R&amp;amp;D services for Gilead related to quemliclustat. We determined that the license and R&amp;amp;D services were combined based on an evaluation of the delivery of the license, due to the early stage of the technology and the specialized nature of our know-how. We allocated arrangement consideration of $176 million to the combined license and R&amp;amp;D services performance obligation and recognize the amounts allocated as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized a reversal of revenue of $4 million for the three months ended September&#160;30, 2023 due to changes in the total estimated effort to be incurred in the future to satisfy the performance obligations, primarily related to revised clinical trial assumptions and revenue of $12 million for the three months ended September 30, 2022. We recognized revenue of $11 million and $16 million for the nine months ended September&#160;30, 2023 and 2022, respectively, within License and development service revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $138 million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to this performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Domvanalimab - R&amp;amp;D Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the First Gilead Collaboration Agreement Amendment, we have an obligation to perform further R&amp;amp;D services for Gilead related to domvanalimab. We determined that these services are distinct based on an evaluation of the delivery of the related license, noting that the program was in the later stages of development and license met the criteria for being distinct from the R&amp;amp;D services required. We allocated arrangement consideration of $34 million to the R&amp;amp;D services performance obligation and recognize the amounts allocated as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue of $1 million for the three months ended September&#160;30, 2023, and $3 million and $2 million for the nine months ended September&#160;30, 2023 and 2022, respectively, within License and development service revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $27 million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to this performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zimberelimab - R&amp;amp;D and Commercialization Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the First Gilead Collaboration Agreement Amendment, we have an obligation to perform further R&amp;amp;D and commercialization services for Gilead related to zimberelimab, as a monotherapy and in combination with other agents. We determined that these services are distinct based on an evaluation of the delivery of the related license, noting that the program was in the later stages of development and license met the criteria for being distinct from the R&amp;amp;D and commercialization services required. We allocated arrangement consideration of $11 million to the R&amp;amp;D and commercialization services performance obligation and recognize the amounts allocated as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized no revenue for the three months ended September&#160;30, 2023 and $8 million for the three months ended September 30, 2022. We recognized $1 million and $9 million for the nine months ended September 30, 2023 and 2022, respectively, within License and development service revenue in our Condensed Consolidated Statements of Operations. As of December 31, 2022, substantially all the revenue related to this performance obligation had been recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Access Rights and Option Continuation Periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the First Gilead Collaboration Agreement Amendment, Gilead has exclusive access to our current programs as well as the future programs for a period of ten years, contingent upon option continuation payments totaling $300 million, consisting of a $100 million payment on each of the fourth, sixth, and eighth anniversaries of the agreement. We allocated arrangement consideration of $121 million to this performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a time-elapsed input method to measure progress toward satisfying this obligation, which is the method we believe most faithfully depicts our performance in transferring the promised services during the time period in which Gilead has access to our R&amp;amp;D pipeline. Accordingly, the revenue allocated to this performance obligation is being recognized using this input method over the minimum four-year period. We have determined that Gilead is not obligated to pay the remaining $300 million due over the remainder of the term and excluded these payments from the transaction price. Failure to pay the non-obligatory option continuation payments will result in Gilead&#x2019;s loss of certain rights to access and obtain licenses to the programs arising from our R&amp;amp;D pipeline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue of $8 million associated with the performance of this obligation for each of the three months ended September&#160;30, 2023 and 2022, and $25 million for each of the nine months ended September&#160;30, 2023 and 2022, within Other collaboration revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $62 million of deferred revenue on our Condensed Consolidated Balance Sheet related to this performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from the Taiho Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2023, under the Taiho collaboration, certain clinical milestones for domvanalimab and zimberelimab were met through the STAR-221 study and Taiho became obligated to pay us $28&#160;million, which is recorded in Receivable from collaboration partners at September&#160;30, 2023 on our Condensed Consolidated Balance Sheet. We determined that we have a performance obligation to perform R&amp;amp;D services for Taiho related to the global development activities for the STAR-221 study in support of the Taiho Territory. We allocated the $28&#160;million to this single performance obligation and recognize the amounts allocated to this service as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue of $4&#160;million for both the three and nine months ended September&#160;30, 2023 within License and development service revenue in our Condensed Consolidated Statements of Operations. At September&#160;30, 2023, we had $24&#160;million of deferred revenue remaining on our Condensed Consolidated Balance Sheet related to this performance obligation, allocated between current and noncurrent based on the expected timing of future recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capitalized Costs to Obtain Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred certain costs to obtain the Gilead Collaboration Agreement in 2020 and the First Gilead Collaboration Agreement Amendment in 2021, which consisted of consultant and legal fees. We allocated these costs to the various performance obligations, to be recognized as the underlying performance obligations are satisfied and revenue is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September&#160;30, 2023 and 2022, the recognized expense was not significant. For each of the nine months ended September&#160;30, 2023 and 2022, we recognized $1&#160;million expense related to these capitalized costs in G&amp;amp;A expense. At September&#160;30, 2023, we had $3 million in capitalized costs to obtain the contracts, of which $1 million was recorded as Prepaid expenses and other current assets and $2 million was recorded as Other noncurrent assets in our Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-430">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenues by collaboration, category of revenue, and the method of recognition (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License and R&amp;amp;D services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Access rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Taiho Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Access rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-160" decimals="-6" id="f-431" unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-161" decimals="-6" id="f-432" unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-162" decimals="-6" id="f-433" unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-163" decimals="-6" id="f-434" unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-164" decimals="-6" id="f-435" unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-165" decimals="-6" id="f-436" unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-166" decimals="-6" id="f-437" unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-167" decimals="-6" id="f-438" unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-168" decimals="-6" id="f-439" unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-169" decimals="-6" id="f-440" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-170" decimals="-6" id="f-441" unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-171" decimals="-6" id="f-442" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-172" decimals="-6" id="f-443" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-173" decimals="-6" id="f-444" unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-174" decimals="-6" id="f-445" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-175" decimals="-6" id="f-446" unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-19" decimals="-6" id="f-447" unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-20" decimals="-6" id="f-448" unitRef="usd">33000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-449" unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-21" decimals="-6" id="f-450" unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-176" decimals="2" id="f-451" unitRef="number">0.88</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-177" decimals="2" id="f-452" unitRef="number">0.94</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-178" decimals="2" id="f-453" unitRef="number">0.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-179" decimals="2" id="f-454" unitRef="number">0.94</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock contextRef="c-1" id="f-455">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the revenue recognized as a result of changes in the deferred revenue balance (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from amounts included in deferred revenue at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c-19" decimals="-6" id="f-456" unitRef="usd">28000000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c-20" decimals="-6" id="f-457" unitRef="usd">33000000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c-1" decimals="-6" id="f-458" unitRef="usd">79000000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c-21" decimals="-6" id="f-459" unitRef="usd">78000000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-180" decimals="-6" id="f-460" unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-26" decimals="-6" id="f-461" unitRef="usd">429000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-152" decimals="-6" id="f-462" unitRef="usd">452000000</us-gaap:ContractWithCustomerLiability>
    <rcus:UpfrontCashPayment contextRef="c-181" decimals="-6" id="f-463" unitRef="usd">35000000</rcus:UpfrontCashPayment>
    <rcus:AllocationToPerformanceObligations contextRef="c-182" decimals="-6" id="f-464" unitRef="usd">35000000</rcus:AllocationToPerformanceObligations>
    <rcus:ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock contextRef="c-1" id="f-465">The following table summarizes the allocation of the transaction price to the distinct performance obligations (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation to performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Distinct&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inflammation target 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inflammation target 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total allocated transaction price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</rcus:ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock>
    <rcus:AllocationToPerformanceObligations contextRef="c-183" decimals="-6" id="f-466" unitRef="usd">18000000</rcus:AllocationToPerformanceObligations>
    <rcus:AllocationToPerformanceObligations contextRef="c-184" decimals="-6" id="f-467" unitRef="usd">17000000</rcus:AllocationToPerformanceObligations>
    <rcus:AllocationToPerformanceObligations contextRef="c-1" decimals="-6" id="f-468" unitRef="usd">35000000</rcus:AllocationToPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-185" decimals="-6" id="f-469" unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-186" decimals="-6" id="f-470" unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-187" decimals="-6" id="f-471" unitRef="usd">32000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c-188" decimals="-6" id="f-472" unitRef="usd">219000000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-189" decimals="-6" id="f-473" unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-190" decimals="-6" id="f-474" unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-188" decimals="-6" id="f-475" unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-191" decimals="-6" id="f-476" unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-192" decimals="-6" id="f-477" unitRef="usd">146000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c-193" decimals="-6" id="f-478" unitRef="usd">176000000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-194" decimals="-6" id="f-479" unitRef="usd">-4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-195" decimals="-6" id="f-480" unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-193" decimals="-6" id="f-481" unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-196" decimals="-6" id="f-482" unitRef="usd">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-197" decimals="-6" id="f-483" unitRef="usd">138000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c-198" decimals="-6" id="f-484" unitRef="usd">34000000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-199" decimals="-6" id="f-485" unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-198" decimals="-6" id="f-486" unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-200" decimals="-6" id="f-487" unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-201" decimals="-6" id="f-488" unitRef="usd">27000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c-202" decimals="-6" id="f-489" unitRef="usd">11000000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-203" decimals="-6" id="f-490" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-204" decimals="-6" id="f-491" unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-202" decimals="-6" id="f-492" unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-205" decimals="-6" id="f-493" unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <rcus:CurrentAndFutureProgramsExclusiveAccessPeriod contextRef="c-206" id="f-494">P10Y</rcus:CurrentAndFutureProgramsExclusiveAccessPeriod>
    <rcus:ContingentMilestonePaymentsReceivable contextRef="c-207" decimals="-6" id="f-495" unitRef="usd">300000000</rcus:ContingentMilestonePaymentsReceivable>
    <rcus:OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement contextRef="c-207" decimals="-6" id="f-496" unitRef="usd">100000000</rcus:OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c-206" decimals="-6" id="f-497" unitRef="usd">121000000</us-gaap:DeferredRevenueRevenueRecognized1>
    <rcus:PerformanceObligationPeriod contextRef="c-206" id="f-498">P4Y</rcus:PerformanceObligationPeriod>
    <rcus:ContingentMilestonePaymentsReceivable contextRef="c-207" decimals="-6" id="f-499" unitRef="usd">300000000</rcus:ContingentMilestonePaymentsReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-208" decimals="-6" id="f-500" unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-209" decimals="-6" id="f-501" unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-210" decimals="-6" id="f-502" unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-211" decimals="-6" id="f-503" unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-212" decimals="-6" id="f-504" unitRef="usd">62000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-213" decimals="-6" id="f-505" unitRef="usd">28000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-213" decimals="-6" id="f-506" unitRef="usd">28000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-214" decimals="-6" id="f-507" unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-215" decimals="-6" id="f-508" unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-216" decimals="-6" id="f-509" unitRef="usd">24000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-217" decimals="-6" id="f-510" unitRef="usd">1000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-218" decimals="-6" id="f-511" unitRef="usd">1000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-219" decimals="-6" id="f-512" unitRef="usd">3000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNetCurrent contextRef="c-220" decimals="-6" id="f-513" unitRef="usd">1000000</us-gaap:CapitalizedContractCostNetCurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent contextRef="c-221" decimals="-6" id="f-514" unitRef="usd">2000000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-515">Income taxes&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax provision or benefit for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into consideration in the relevant period. Each quarter, we update the estimate of the annual effective tax rate, and if the estimated tax rate changes, we record a cumulative adjustment to the provision or benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense was $2 million for the three months ended September&#160;30, 2023, with an effective tax rate of (2.4%). We did not record a provision for income taxes for the three months ended September&#160;30, 2022. The income tax expense was $5 million and $1 million for the nine months ended September&#160;30, 2023 and 2022, with an effective tax rate of (2.2%) and (0.5%), respectively. The year-over-year increase in the income tax provision was due to an increase in taxable income. We have taxable income compared to book losses before income taxes due to the timing of recognition of deferred revenue for tax purposes and the effects of the mandatory capitalization and amortization of research and development expenses starting in 2022, as required by the 2017 Tax Cuts and Jobs Act. The effective tax rate differs from the U.S. statutory tax rate primarily due to the valuation allowances on our deferred tax assets and state income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023 and December&#160;31, 2022, we have provided a valuation allowance against U.S. federal and state deferred tax assets. We continue to evaluate the realizability of deferred tax assets and the related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize interest and penalties associated with uncertain tax benefits as part of the income tax provision. To date, we have not recognized any interest and penalties, nor have we accrued for or made payments for interest and penalties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not been audited by the Internal Revenue Service, or any state or foreign tax authority. We are subject to taxation in the United States and in Australia. Due to net operating loss and research credit carryforwards, all of our tax years, from 2015 to 2022, remain open to U.S. federal and California state tax examinations. In addition, our fiscal years from 2018 to 2022 are open to examination in Australia.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-19" decimals="-6" id="f-516" unitRef="usd">2000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-19" decimals="3" id="f-517" unitRef="number">0.024</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-20" decimals="INF" id="f-518" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-519" unitRef="usd">5000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-21" decimals="-6" id="f-520" unitRef="usd">1000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-521" unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-21" decimals="3" id="f-522" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-523">Net loss per share&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potentially dilutive securities excluded from the computation of diluted net loss per share calculations because they would have been antidilutive (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total potential dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also excluded the effect of Gilead&#x2019;s right to purchase additional shares of our common stock from the calculation as these rights had no intrinsic value at either September&#160;30, 2023 or 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-524">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potentially dilutive securities excluded from the computation of diluted net loss per share calculations because they would have been antidilutive (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total potential dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-222"
      decimals="-5"
      id="f-525"
      unitRef="shares">13700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-223"
      decimals="-5"
      id="f-526"
      unitRef="shares">12300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-224"
      decimals="-5"
      id="f-527"
      unitRef="shares">1900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-225"
      decimals="-5"
      id="f-528"
      unitRef="shares">1400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-226"
      decimals="-5"
      id="f-529"
      unitRef="shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-227"
      decimals="-5"
      id="f-530"
      unitRef="shares">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-5" id="f-531" unitRef="shares">15800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-21" decimals="-5" id="f-532" unitRef="shares">13800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-533">Stock-based compensation &lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the components of stock-based compensation expense recognized in our Condensed Consolidated Statements of Operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-534">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the components of stock-based compensation expense recognized in our Condensed Consolidated Statements of Operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-228" decimals="-6" id="f-535" unitRef="usd">8000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-229" decimals="-6" id="f-536" unitRef="usd">8000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-230" decimals="-6" id="f-537" unitRef="usd">26000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-231" decimals="-6" id="f-538" unitRef="usd">24000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-232" decimals="-6" id="f-539" unitRef="usd">10000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-233" decimals="-6" id="f-540" unitRef="usd">8000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-234" decimals="-6" id="f-541" unitRef="usd">29000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-235" decimals="-6" id="f-542" unitRef="usd">24000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-19" decimals="-6" id="f-543" unitRef="usd">18000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-20" decimals="-6" id="f-544" unitRef="usd">16000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-6" id="f-545" unitRef="usd">55000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-21" decimals="-6" id="f-546" unitRef="usd">48000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-547">Cash, cash equivalents and marketable securities &lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, gross unrealized gains and losses and the fair value of our cash, cash equivalents and marketable securities, all of which are considered available for sale, by type of securities (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Types of securities as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Types of securities as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair values of our cash, cash equivalents and marketable securities by location in the Condensed Consolidated Balance Sheets and contractual maturity (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Location in Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between one and three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains or losses recognized on the sale of available-for-sale marketable securities were not material for the three and nine months ended September&#160;30, 2023 and 2022. Realized gains and losses are included in Interest and other income, net, in the Condensed Consolidated Statements of Operations. The cost of a security sold is determined using the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We limit the credit risk associated with our investments by placing them with banks and institutions we believe are highly credit worthy and investing in highly rated investments. We held a total of 159 and 219 positions in securities which were in unrealized loss positions as of September&#160;30, 2023 and December&#160;31, 2022, respectively. We do not intend to sell our securities with unrealized loss positions and have concluded we will not be required to sell the securities before recovery of the amortized cost for the investment at maturity. No credit related losses have been recognized for any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-615"&gt;&lt;span style="-sec-ix-hidden:f-616"&gt;Restricted cash (included in Other noncurrent assets)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-548">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, gross unrealized gains and losses and the fair value of our cash, cash equivalents and marketable securities, all of which are considered available for sale, by type of securities (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Types of securities as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Types of securities as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-236" decimals="-6" id="f-549" unitRef="usd">110000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-236" decimals="-6" id="f-550" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-236" decimals="-6" id="f-551" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-236" decimals="-6" id="f-552" unitRef="usd">110000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-237" decimals="-6" id="f-553" unitRef="usd">246000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-237" decimals="-6" id="f-554" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-237" decimals="-6" id="f-555" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-237" decimals="-6" id="f-556" unitRef="usd">245000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-238" decimals="-6" id="f-557" unitRef="usd">493000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-238" decimals="-6" id="f-558" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-238" decimals="-6" id="f-559" unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-238" decimals="-6" id="f-560" unitRef="usd">491000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-239" decimals="-6" id="f-561" unitRef="usd">96000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-239" decimals="-6" id="f-562" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-239" decimals="-6" id="f-563" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-239" decimals="-6" id="f-564" unitRef="usd">96000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-240" decimals="-6" id="f-565" unitRef="usd">8000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-240" decimals="-6" id="f-566" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-240" decimals="-6" id="f-567" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-240" decimals="-6" id="f-568" unitRef="usd">8000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-26" decimals="-6" id="f-569" unitRef="usd">953000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-26" decimals="-6" id="f-570" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-26" decimals="-6" id="f-571" unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-26" decimals="-6" id="f-572" unitRef="usd">950000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-241" decimals="-6" id="f-573" unitRef="usd">169000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-241" decimals="-6" id="f-574" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-241" decimals="-6" id="f-575" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-241" decimals="-6" id="f-576" unitRef="usd">169000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-242" decimals="-6" id="f-577" unitRef="usd">317000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-242" decimals="-6" id="f-578" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-242" decimals="-6" id="f-579" unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-242" decimals="-6" id="f-580" unitRef="usd">314000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-243" decimals="-6" id="f-581" unitRef="usd">635000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-243" decimals="-6" id="f-582" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-243" decimals="-6" id="f-583" unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-243" decimals="-6" id="f-584" unitRef="usd">631000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-244" decimals="-6" id="f-585" unitRef="usd">20000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-244" decimals="-6" id="f-586" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-244" decimals="-6" id="f-587" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-244" decimals="-6" id="f-588" unitRef="usd">20000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-245" decimals="-6" id="f-589" unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-245" decimals="-6" id="f-590" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-245" decimals="-6" id="f-591" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-245" decimals="-6" id="f-592" unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-27" decimals="-6" id="f-593" unitRef="usd">1145000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-27" decimals="-6" id="f-594" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-27" decimals="-6" id="f-595" unitRef="usd">7000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-27" decimals="-6" id="f-596" unitRef="usd">1138000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-597">The following table summarizes the fair values of our cash, cash equivalents and marketable securities by location in the Condensed Consolidated Balance Sheets and contractual maturity (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Location in Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between one and three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-26" decimals="-6" id="f-598" unitRef="usd">184000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-27" decimals="-6" id="f-599" unitRef="usd">206000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-26" decimals="-6" id="f-600" unitRef="usd">615000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-27" decimals="-6" id="f-601" unitRef="usd">803000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-26" decimals="-6" id="f-602" unitRef="usd">151000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-27" decimals="-6" id="f-603" unitRef="usd">129000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rcus:CashCashEquivalentsAndAvailableForSaleInvestments contextRef="c-26" decimals="-6" id="f-604" unitRef="usd">950000000</rcus:CashCashEquivalentsAndAvailableForSaleInvestments>
    <rcus:CashCashEquivalentsAndAvailableForSaleInvestments contextRef="c-27" decimals="-6" id="f-605" unitRef="usd">1138000000</rcus:CashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-26"
      decimals="INF"
      id="f-606"
      unitRef="position">159</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-27"
      decimals="INF"
      id="f-607"
      unitRef="position">219</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:ProvisionForLoanLossesExpensed contextRef="c-21" decimals="INF" id="f-608" unitRef="usd">0</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:ProvisionForLoanLossesExpensed contextRef="c-1" decimals="INF" id="f-609" unitRef="usd">0</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:ProvisionForLoanLossesExpensed contextRef="c-246" decimals="INF" id="f-610" unitRef="usd">0</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-611">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-615"&gt;&lt;span style="-sec-ix-hidden:f-616"&gt;Restricted cash (included in Other noncurrent assets)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-612">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-615"&gt;&lt;span style="-sec-ix-hidden:f-616"&gt;Restricted cash (included in Other noncurrent assets)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-26" decimals="-6" id="f-613" unitRef="usd">184000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-69" decimals="-6" id="f-614" unitRef="usd">218000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-26" decimals="-6" id="f-617" unitRef="usd">3000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-69" decimals="-6" id="f-618" unitRef="usd">3000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-26" decimals="-6" id="f-619" unitRef="usd">187000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-69" decimals="-6" id="f-620" unitRef="usd">221000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-621">Condensed consolidated balance sheet components&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued personnel expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-622">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <rcus:PrepaidExpensesAndOtherCurrentAssets contextRef="c-26" decimals="-6" id="f-623" unitRef="usd">27000000</rcus:PrepaidExpensesAndOtherCurrentAssets>
    <rcus:PrepaidExpensesAndOtherCurrentAssets contextRef="c-27" decimals="-6" id="f-624" unitRef="usd">15000000</rcus:PrepaidExpensesAndOtherCurrentAssets>
    <us-gaap:InterestReceivableCurrent contextRef="c-26" decimals="-6" id="f-625" unitRef="usd">4000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent contextRef="c-27" decimals="-6" id="f-626" unitRef="usd">4000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-26" decimals="-6" id="f-627" unitRef="usd">31000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-27" decimals="-6" id="f-628" unitRef="usd">19000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-629">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued personnel expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <rcus:AccruedResearchAndDevelopmentExpensesCurrent contextRef="c-26" decimals="-6" id="f-630" unitRef="usd">41000000</rcus:AccruedResearchAndDevelopmentExpensesCurrent>
    <rcus:AccruedResearchAndDevelopmentExpensesCurrent contextRef="c-27" decimals="-6" id="f-631" unitRef="usd">45000000</rcus:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-26" decimals="-6" id="f-632" unitRef="usd">22000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-27" decimals="-6" id="f-633" unitRef="usd">25000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-26" decimals="-6" id="f-634" unitRef="usd">9000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-27" decimals="-6" id="f-635" unitRef="usd">3000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-26" decimals="-6" id="f-636" unitRef="usd">3000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-27" decimals="-6" id="f-637" unitRef="usd">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-26" decimals="-6" id="f-638" unitRef="usd">5000000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-27" decimals="-6" id="f-639" unitRef="usd">3000000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-26" decimals="-6" id="f-640" unitRef="usd">80000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-27" decimals="-6" id="f-641" unitRef="usd">76000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-642">Leases&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash and non-cash information related to our operating leases (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received from tenant improvement allowances&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognition of tenant improvement allowance receivable included in Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023 and December&#160;31, 2022, we have provided deposits for letters of credit totaling $3 million to secure our obligations under our leases, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock contextRef="c-1" id="f-643">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash and non-cash information related to our operating leases (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received from tenant improvement allowances&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognition of tenant improvement allowance receivable included in Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock>
    <rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-1" decimals="-6" id="f-644" unitRef="usd">12000000</rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-21" decimals="-6" id="f-645" unitRef="usd">8000000</rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <rcus:CashReceivedFromTenantImprovementAllowances contextRef="c-1" decimals="-6" id="f-646" unitRef="usd">8000000</rcus:CashReceivedFromTenantImprovementAllowances>
    <rcus:CashReceivedFromTenantImprovementAllowances contextRef="c-21" decimals="-6" id="f-647" unitRef="usd">8000000</rcus:CashReceivedFromTenantImprovementAllowances>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-6" id="f-648" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-21" decimals="-6" id="f-649" unitRef="usd">3000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <rcus:RecognitionOfTenantImprovementAllowanceReceivable contextRef="c-1" decimals="-6" id="f-650" unitRef="usd">4000000</rcus:RecognitionOfTenantImprovementAllowanceReceivable>
    <rcus:RecognitionOfTenantImprovementAllowanceReceivable contextRef="c-21" decimals="-6" id="f-651" unitRef="usd">6000000</rcus:RecognitionOfTenantImprovementAllowanceReceivable>
    <us-gaap:SecurityDeposit contextRef="c-26" decimals="-6" id="f-652" unitRef="usd">3000000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="c-27" decimals="-6" id="f-653" unitRef="usd">3000000</us-gaap:SecurityDeposit>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-654">Stockholders' Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Gilead Stock Purchase&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, under the Second Stock Purchase Agreement, Gilead purchased 1.0 million shares of our common stock at the closing day purchase price of $19.26 per share for a total cost of $20 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the-Market Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, we entered into an equity distribution agreement pursuant to which we may, from time to time, sell shares of our common stock, par value $0.0001 per share, having an aggregate offering price of up to $200&#160;million. In August 2023, we issued and sold 0.2&#160;million shares of our common stock under this agreement for total net proceeds of $5&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-247"
      decimals="-5"
      id="f-655"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="c-248"
      decimals="2"
      id="f-656"
      unitRef="usdPerShare">19.26</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-247" decimals="-6" id="f-657" unitRef="usd">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-249"
      decimals="INF"
      id="f-658"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <rcus:SaleOfStockAuthorizedConsiderationOnTransaction contextRef="c-250" decimals="-6" id="f-659" unitRef="usd">200000000</rcus:SaleOfStockAuthorizedConsiderationOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-251"
      decimals="-5"
      id="f-660"
      unitRef="shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-251" decimals="-6" id="f-661" unitRef="usd">5000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-662">Fair value measurements&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1 inputs include unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability for sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability for sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability for Sale of Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we entered into an agreement with BVF Partners L.P. (BVF), under which BVF funded the discovery and development of compounds for the treatment of inflammatory diseases (the BVF Program) for $15 million in non-refundable payments which were paid in 2021 and 2022. In return, we are obligated to: perform research and development activities in the Program; make contingent payments upon the achievement of certain clinical and regulatory milestones of up to $73 million or $160 million depending on whether the program is solely developed by us or with Gilead if they opt-in under the Gilead Collaboration Agreement; and pay mid- to high-single digit royalties on any net product sales generated by the BVF Program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for the BVF Agreement as a liability primarily because we have significant continuing involvement in generating the cash flows due to BVF. The liability is recorded at fair value by using probability-adjusted discounted cash flows and is revalued each reporting period until the related contingencies have been resolved. The fair value measurement is based on significant unobservable inputs that are reviewed quarterly by management and include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair value of this liability related to interest accretion are recognized in Non-operating income (expense) in the Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2023, new preclinical information from our BVF Program led to revised assumptions which decreased the estimated probabilities of success and delayed the projected timing of achieving specified development, regulatory and commercial milestones and commercial sales. These changes in estimates are accounted for prospectively and resulted in a decrease in the imputed effective interest rate on the unamortized portion of the liability to 10.1% commencing with the quarter ended June 30, 2023, compared to 20.6% for the quarters ended March 31, 2023 and prior. The impact of this change on the non-cash interest expense for the quarter and nine months ended September&#160;30, 2023 was not material when compared to the prior year periods. The liability for sale of future royalties is reported in Other noncurrent liabilities in the Condensed Consolidated Balance Sheets and changes were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-663">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability for sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability for sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-252" decimals="-6" id="f-664" unitRef="usd">110000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-253" decimals="-6" id="f-665" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-254" decimals="-6" id="f-666" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-255" decimals="-6" id="f-667" unitRef="usd">110000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-256" decimals="-6" id="f-668" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-257" decimals="-6" id="f-669" unitRef="usd">245000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-258" decimals="-6" id="f-670" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-259" decimals="-6" id="f-671" unitRef="usd">245000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-260" decimals="-6" id="f-672" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-261" decimals="-6" id="f-673" unitRef="usd">491000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-262" decimals="-6" id="f-674" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-263" decimals="-6" id="f-675" unitRef="usd">491000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-264" decimals="-6" id="f-676" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-265" decimals="-6" id="f-677" unitRef="usd">96000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-266" decimals="-6" id="f-678" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-267" decimals="-6" id="f-679" unitRef="usd">96000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-268" decimals="-6" id="f-680" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-269" decimals="-6" id="f-681" unitRef="usd">8000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-270" decimals="-6" id="f-682" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-271" decimals="-6" id="f-683" unitRef="usd">8000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-272" decimals="-6" id="f-684" unitRef="usd">110000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-273" decimals="-6" id="f-685" unitRef="usd">840000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-274" decimals="-6" id="f-686" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-275" decimals="-6" id="f-687" unitRef="usd">950000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-276" decimals="-6" id="f-688" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-277" decimals="-6" id="f-689" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-278" decimals="-6" id="f-690" unitRef="usd">19000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-279" decimals="-6" id="f-691" unitRef="usd">19000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-272" decimals="-6" id="f-692" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-273" decimals="-6" id="f-693" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-274" decimals="-6" id="f-694" unitRef="usd">19000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-275" decimals="-6" id="f-695" unitRef="usd">19000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-280" decimals="-6" id="f-696" unitRef="usd">169000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-281" decimals="-6" id="f-697" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-282" decimals="-6" id="f-698" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-283" decimals="-6" id="f-699" unitRef="usd">169000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-284" decimals="-6" id="f-700" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-285" decimals="-6" id="f-701" unitRef="usd">314000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-286" decimals="-6" id="f-702" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-287" decimals="-6" id="f-703" unitRef="usd">314000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-288" decimals="-6" id="f-704" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-289" decimals="-6" id="f-705" unitRef="usd">631000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-290" decimals="-6" id="f-706" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-291" decimals="-6" id="f-707" unitRef="usd">631000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-292" decimals="-6" id="f-708" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-293" decimals="-6" id="f-709" unitRef="usd">20000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-294" decimals="-6" id="f-710" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-295" decimals="-6" id="f-711" unitRef="usd">20000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-296" decimals="-6" id="f-712" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-297" decimals="-6" id="f-713" unitRef="usd">4000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-298" decimals="-6" id="f-714" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-299" decimals="-6" id="f-715" unitRef="usd">4000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-300" decimals="-6" id="f-716" unitRef="usd">169000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-301" decimals="-6" id="f-717" unitRef="usd">969000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-302" decimals="-6" id="f-718" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-303" decimals="-6" id="f-719" unitRef="usd">1138000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-304" decimals="-6" id="f-720" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-305" decimals="-6" id="f-721" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-306" decimals="-6" id="f-722" unitRef="usd">17000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-307" decimals="-6" id="f-723" unitRef="usd">17000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-300" decimals="-6" id="f-724" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-301" decimals="-6" id="f-725" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-302" decimals="-6" id="f-726" unitRef="usd">17000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-303" decimals="-6" id="f-727" unitRef="usd">17000000</us-gaap:LiabilitiesFairValueDisclosure>
    <rcus:NonRefundablePaymentsReceived contextRef="c-308" decimals="-6" id="f-728" unitRef="usd">15000000</rcus:NonRefundablePaymentsReceived>
    <rcus:NonRefundablePaymentsReceived contextRef="c-309" decimals="-6" id="f-729" unitRef="usd">15000000</rcus:NonRefundablePaymentsReceived>
    <rcus:ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones contextRef="c-310" decimals="-6" id="f-730" unitRef="usd">73000000</rcus:ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones>
    <rcus:ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones contextRef="c-311" decimals="-6" id="f-731" unitRef="usd">160000000</rcus:ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones>
    <rcus:ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability contextRef="c-312" decimals="3" id="f-732" unitRef="number">0.101</rcus:ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability>
    <rcus:ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability contextRef="c-313" decimals="3" id="f-733" unitRef="number">0.206</rcus:ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability>
    <rcus:ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability contextRef="c-314" decimals="3" id="f-734" unitRef="number">0.206</rcus:ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability>
    <rcus:ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability contextRef="c-315" decimals="3" id="f-735" unitRef="number">0.206</rcus:ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability>
    <rcus:SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock contextRef="c-1" id="f-736">The liability for sale of future royalties is reported in Other noncurrent liabilities in the Condensed Consolidated Balance Sheets and changes were as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</rcus:SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock>
    <rcus:LiabilityForSaleOfFutureRoyalties contextRef="c-316" decimals="-6" id="f-737" unitRef="usd">17000000</rcus:LiabilityForSaleOfFutureRoyalties>
    <rcus:LiabilityForSaleOfFutureRoyalties contextRef="c-317" decimals="-6" id="f-738" unitRef="usd">5000000</rcus:LiabilityForSaleOfFutureRoyalties>
    <rcus:IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived contextRef="c-318" decimals="-6" id="f-739" unitRef="usd">0</rcus:IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived>
    <rcus:IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived contextRef="c-313" decimals="-6" id="f-740" unitRef="usd">5000000</rcus:IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived>
    <rcus:IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion contextRef="c-318" decimals="-6" id="f-741" unitRef="usd">2000000</rcus:IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion>
    <rcus:IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion contextRef="c-313" decimals="-6" id="f-742" unitRef="usd">2000000</rcus:IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion>
    <rcus:LiabilityForSaleOfFutureRoyalties contextRef="c-319" decimals="-6" id="f-743" unitRef="usd">19000000</rcus:LiabilityForSaleOfFutureRoyalties>
    <rcus:LiabilityForSaleOfFutureRoyalties contextRef="c-320" decimals="-6" id="f-744" unitRef="usd">12000000</rcus:LiabilityForSaleOfFutureRoyalties>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-321" id="f-745">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adoption, modification or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended September&#160;30, 2023, which are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.003%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Name and Title&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Action&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total Shares to be Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:7.37pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Juan C. Jaen&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:7.37pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;President and Director&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adopted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;August 8, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;300,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;November 8, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-19" id="f-746">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-19" id="f-747">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-19" id="f-748">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-19" id="f-749">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrIndName contextRef="c-19" id="f-750">Juan C. Jaen</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-19" id="f-751">President and Director</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-322" id="f-752">August 8, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-323"
      decimals="INF"
      id="f-753"
      unitRef="shares">300000000000</ecd:TrdArrSecuritiesAggAvailAmt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MDO7V6\]KD2#/M$QVP5"")$JW__G3KB*>![": +8+8*\":-TON+L MP#=EJS
M>LLU'UXJN2;*? UJYJ*HFR(::*+4I'&B%;R-($X/?;D2BK1)MN!*9)<=#9KF
M32?8Q5]OXUE-_(!\D*E>9.0F#47X,KX#92D+Q/8%NF:HX$0LSXGKG!'F,-=2
M'A\/OY>K<^)06_B+XKAE_;B%GHO6S]^C::85-+E_;#6T5?#L"J8?OLF6/!!7
M+>AHF5 KT1K^\A/M.;_;\'Z0V M8KX3U,/7A6QGDT$4U>=PLA8T4#Z=.^Y,-
M"8UJB-0MD;K'(7W*N=)"Q1OR()92:1L>+J55;JL4'XUJB-<K\7K'X8V%BF1H
M>B&!<<":/%RI['>U'0^-;\AY47)>'-DR%8<II)@!ZO.(:\UXG%D3B88U!.R7
M@'VT4#>ICO2&W$:Q(/=Y,A7*!H9K. YMNWV/#FQP:&A#N$$)-S@&[D',(S.,
M0AKO>6)MH[C.2,&,2*XCF0612 .1G9&[-#BWX:)"#7&I4TVJSC' 4#BIH)%R
MTU[/R$1#SR12$5_FJ58;^!]::^& ^ML;&S$>U!3YF8^@QR _\B=R%T)/C691
M4' CS?F I'<!S7G0]]RNE1<-;LK+*EYV#.\H#$$=&N+N@KR'[\C'U)Y77-(=
ML#X9RPCZQPU4(?G*-U9P5*4I>&6(*&I!_@?NFSMHU(]RG5JA<;EW?+/F*K2"
MGL(+T<H,4=S.O 8MN^]8R54$PX^5%M?T1U;04S@D6EDDBAN;UZ!CF6D>D[^B
M9?T(A2L.O*YG[[2G,$NT<DL4-SE%6QW!<K<>#!?H4L>*=0IO1"MS1'%'\UX&
MD*_Q0J:8>3@@TAMX[1ZL_JU\I[!&M/)&%#<VCY$&6R1GA+)?I[^1B0AR!9FT
M0N)*ODP2F)(F6@;?H:%S1;[P.!?D9^?< ?MD;#29F*6PM19.X:%H9:(H[G[
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M!*$!>'_+N7H>: ?5,=WJ/U!+ P04    " !R@6=7 Q/ 6^H"  "<"0  &
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M]O8Q$PO&]\-]T-0&\KP&M&>NUYCK'37W3:4@2+QWW&35%CS5IM_97%>2O9U
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M[H@_:7WR,]];OU#YP N%,K8!MV \ _[R\ GS<*/%SGX%O!=:B]Q>;AD%X,8
M?M\(H5]NS(?%^D/RZC]02P,$%     @ <H%G5R]<*ZG5 P  M@\  !@   !X
M;"]W;W)K<VAE971S+W-H965T-BYX;6RMEVV/VC@0Q[^*E:NJ76F[B</S%I"Z
MK$Z]%]6A1>V]-LD UCIQ:AMH[]/?.,F&!$Q8>N4%Q,G,^/>W)\QXO)?J16\
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M^XJ]&.!]Y5S</TB Z8MM\S=02P,$%     @ <H%G5]A7>K&0!0  < T  !D
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MXIS#FRNGYQ5\+/P*+E7E5-DFPZZ-M#F]>:LM -!8H-R'A78M. (=7-,"<HK
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MK12T)(H!, E14;U!;<+25!FX?<KYW]KS;=H.7$$&[V+MVG>,H7 H&_!W6<K
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MYJ5(O(AA[<\D7M')&3J]02[HCC<>SZD@^:PY4[;%@*R<4,3IT#K&O.]4A'-
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M=2Z2MR<B[[61]T[1_^LCG20=CK/&+P,^V\/#;8&P,HH:5^HU>+%4R(W('>7
MTR%;&TV7Y\"LP!WCX /+[)N9M99_Z%QJ,!M+V5"QZ#HO[8R2N?"D+#P]RAWW
M:X4V@!R\(+]2*L7*RR$%:!&?U!U0U9#K$FTHG2^4_ZES+BU>TCWIANY%V*P
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M%!J=G T"T-4%4$VL*GW3392E%NZ'.=V9J)T#K2^5LON)(VANX<E?4$L#!!0
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M5X/0)6BCC\-&ZMC&L:.4("R!3!#F-K=\P5@J&G@D-1><4BSK'I_!>Z9Q+^?
M&2-L<K1#VOPK@PMOJ16R9'X61&,Z38Y-%ZKS:AZ6+706N;<)S#H:!"5%+I4D
MR;:/8)SQ:Q:Q+!;(K<MXUC1 J 7KR::UYC9B"!\&H8N@.0M/F"['9GW<,;1P
M#IF"R8FG5*2 =T4M=(6!H^;A\9?_?]%Y^&"6C;,7O)K -1:FTC($D=D?XM-3
M#\G9#< 'JCEL16>M%[]O:LK/*9P[C[TGQ#Z?+QDUGH[#:?8$-@BUN$7P)*2W
M4F)KG&2OO8,*B= &R,)B*8FS3D)Y;X\FVRS[2G#(I# 61*YD%4K%0<<)M^$T
M%@?;JV7!Q67W^<7EMG6MCSQ?\0U<&,;1CF5YY8R29:C E5 A6#=^BKF3?;V5
M[DRX!FT5YKB#PM=6'';#Z?"K.(\3\H]X_,]<"EM)]DGAFE5')\^>)F#C[(X;
M,FV8E[DAGKYA6?/O#JT7X/NU,;3=> /##W3Y&U!+ P04    " !R@6=7UEO4
MCAP#   0!P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R55=]OTS 0
M_E=.88*7TJ3I-L9H*W7 ^"&!IE7  ^+!3:Z)-<<.]GG=_GO.3IH5,2IX:6S?
MW7??=SY?9UMC;UR-2'#7*.WF24W4GJ>I*VILA!N;%C5;-L8V@GAKJ]2U%D49
M@QJ5YEEVFC9"ZF0QBV=7=C$SGI34>&7!^:81]OX"E=G.DTFR.[B654WA(%W,
M6E'A"NE+>V5YEPXHI6Q0.VDT6-S,D^7D_.(X^$>'KQ*W;F\-0<G:F)NP^5#.
MDRP00H4%!03!GUM\C4H%(*;QL\=,AI0A<'^]0[^,VEG+6CA\;=0W65(]3\X2
M*'$CO*)KLWV/O9Z3@%<8Y>(O;#O?Z8L$"N_(-'TP,VBD[K[BKJ_#7L!9]I>
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MAGB"QF7-+8HV.+!]8_CM]YN08/@37/P"4$L#!!0    ( '*!9U=Y0TYGNPD
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MX%J@[B\9D_N!#E#UR?$K4$L#!!0    ( '*!9U>8\)4ZG00  -<3   9
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M^".:E4L? .DAV#I>NC,;<(6/PQ(*),<+,+^P.,W;!]Z@^PJ;_@-02P,$%
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M=WT@M0"JA5 M@FH$JE&HQCIMOS[<R1L% FI8+Q"55;O6L&^74?2?B=CAWE4
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MF>/\<HTD0J8,Y.=+2L7A1@6HOCJ9_ ]02P,$%     @ <H%G5^>'1/?7#0
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M09.^S_J)%I7K;0NA3:=TP\+<35#:#69]*83>36R YK:3_@%02P,$%     @
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MP.<;B6-7=6-?4$_XBW\ 4$L#!!0    ( '*!9U>_SF=QAP,  -40   9
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;,U876_;-A3]*X0:#"W01K+\D3BS
M!<26M@98L"!>VX>B#XQT;1&A1)6D[;2_OB2E*)9#>^G&A[Y$%'7.N5_TE6XF
M6\;O10X@T4-!2S'U<BFK"]\7:0X%%J>L@E(]63)>8*EN^<H7%0><&5)!_3 (
M1GZ!2>E%$[-WPZ,)6TM*2KCA2*R+ O-O,Z!L._5ZWN/&+5GE4F_XT:3"*UB
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M&?WVW/2-7O^ 7E)4E'T#0 O@&Y*J:XXY(,L1N:24I?7R[R6ZA92M2O)=H6Z
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M_2L6.UK-2&W!-J30!:0.W9D=::JMANWLPVH?3&)*U"3.V :F^^O7"6E,8L>
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M!C?(H=I!V09&UF[6+*3!R>66)7Y;0-D$?+^4TFP#.[[ZKU7Z%U!+ P04
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M%SL<D+FA>EM!^)X8BQ]_L"?6SUTV0<)<2)@'"?.!8"U[1[6](QU]\2A$AM.
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M),7A#J=<D'D _KX10K^<Y!>H]QLG_P%02P,$%     @ <H%G5SE1W4D2 P
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MS7MP[WT4KM]3X>:_8Y-'4$L#!!0    ( '*!9U>7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ <H%G5Y,BB4=C!
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M   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-VCM.PT 4A>&M1%X
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M              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ <H%G5RK%]$?.!0  R1X  !@              ("!# @  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( '*!9U<$OH0]0 8  %$B   8
M              " @1 .  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " !R@6=7^EVY+O #  "R$P  &               @(&&%   >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ <H%G5P,3P%OJ @
MG D  !@              ("!K!@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( '*!9U>]4AJ;<@4  %06   8              " @<P;
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !R@6=7+UPK
MJ=4#  "V#P  &               @(%T(0  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ <H%G5^N% :6<#@  F\\  !@
M ("!?R4  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( '*!
M9U<LCE0&RP8  $T>   8              " @5$T  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " !R@6=7MA;(D2(#   V"@  &
M        @(%2.P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ <H%G5P"O%AB#!   O0D  !D              ("!JCX  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !R@6=7V%=ZL9 %  !P#0
M&0              @(%D0P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( '*!9U>$;W')"@P  %(E   9              " @2M)  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ <H%G5_!'D^C:
M"P  ZR,  !D              ("!;%4  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " !R@6=7H$T Q5 -  !>.   &0
M@(%]80  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( '*!
M9U?0 :4]R 4  !P.   9              " @01O  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ <H%G5\:,XK4T P  "P<  !D
M         ("! W4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " !R@6=7W?)0UK\"  !0!@  &0              @(%N>   >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( '*!9U=_&4,\* 8  $(1
M   9              " @61[  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ <H%G5SZ*[[@1 P  D0<  !D              ("!PX$
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !R@6=7?:PD
M'$(#  !,!P  &0              @($+A0  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( '*!9U?66]2.' ,  ! '   9
M  " @82(  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M<H%G5WE#3F>["0  DQH  !D              ("!UXL  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " !R@6=70]E*4- "   S"P  &0
M            @(')E0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( '*!9U>8\)4ZG00  -<3   9              " @="8  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ <H%G5VH:.REK!0
MD0T  !D              ("!I)T  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " !R@6=7 ##.&.D#  #5"@  &0              @(%&
MHP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( '*!9U<+
M<*^+^@(  ) &   9              " @6:G  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ <H%G5\"^*I#/ @  4P8  !D
M     ("!EZH  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M" !R@6=7HRR<M0X%  #H$0  &0              @(&=K0  >&PO=V]R:W-H
M965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( '*!9U=/X%\K(@,  - '   9
M              " @>*R  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L!
M A0#%     @ <H%G5^%H&!3S @  I@8  !D              ("!.[8  'AL
M+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !R@6=7]=+=6T $
M   )#   &0              @(%EN0  >&PO=V]R:W-H965T<R]S:&5E=#,R
M+GAM;%!+ 0(4 Q0    ( '*!9U<M_N5EOP(  %L'   9              "
M@=R]  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ <H%G
M5\^W>"DE#@  H*X  !D              ("!TL   'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " !R@6=7XYO_I>\(   '6P  &0
M        @($NSP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( '*!9U=('63W)P0  $89   9              " @538  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ <H%G5^>'1/?7#0  SJT
M !D              ("!LMP  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " !R@6=7UC0$<\X"   U"   &0              @(' Z@
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( '*!9U=#<E[.
MS (  /D(   9              " @<7M  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ <H%G5T.HV ^^ @  %PD  !D
M ("!R/   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !R
M@6=7RXB)6)L#  #M#P  &0              @(&]\P  >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( '*!9U>_SF=QAP,  -40   9
M          " @8_W  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#
M%     @ <H%G5UT"(0Q1!0  ZQT  !D              ("!3?L  'AL+W=O
M<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !R@6=7IDJ/T]@"  #G
M!P  &0              @('5  $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;%!+ 0(4 Q0    ( '*!9U=>5)#6S0(  #T(   9              " @>0#
M 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ <H%G5SG)
MAMU* P  Q L  !D              ("!Z 8! 'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6Q02P$"% ,4    " !R@6=7DP6#@:0"  "Y!@  &0
M    @(%I"@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M '*!9U<P*%1>_ (  '0(   9              " @40- 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ <H%G5ZJO78L: P  90@  !D
M             ("!=Q ! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " !R@6=7QQPELR4"   !!0  &0              @('($P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( '*!9U?%^VW4L 0
M $P=   9              " @206 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ <H%G5P,7.8)'"0  TF0  !D              ("!
M"QL! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !R@6=7
MW"&L$Y8$  !['   &0              @(&)) $ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( '*!9U<Y4=U)$@,  !L(   9
M      " @58I 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ <H%G5P)+:Z4R P  *A,   T              ( !GRP! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !R@6=7EXJ[',     3 @  "P
M@ '\+P$ 7W)E;',O+G)E;'-02P$"% ,4    " !R@6=7DR*)1V,$   /)
M#P              @ 'E, $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M<H%G5P^45$C: 0  62   !H              ( !=34! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ <H%G5R%=IR;- 0  )"   !,
M             ( !AS<! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #X
,/@#I$   A3D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>323</ContextCount>
  <ElementCount>232</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Organization, Liquidity, and Capital Resources</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/OrganizationLiquidityandCapitalResources</Role>
      <ShortName>Organization, Liquidity, and Capital Resources</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Related Party - Gilead Sciences, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RelatedPartyGileadSciencesInc</Role>
      <ShortName>Related Party - Gilead Sciences, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - License and Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LicenseandCollaborations</Role>
      <ShortName>License and Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Cash, Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Condensed Consolidated Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://arcusbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/Revenues</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/NetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/StockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/Leases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Organization, Liquidity, and Capital Resources - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails</Role>
      <ShortName>Organization, Liquidity, and Capital Resources - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Related Party - Gilead Sciences, Inc. - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails</Role>
      <ShortName>Related Party - Gilead Sciences, Inc. - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - License and Collaborations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails</Role>
      <ShortName>License and Collaborations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Revenues - Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails</Role>
      <ShortName>Revenues - Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Revenues - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RevenuesAdditionalInformationDetails</Role>
      <ShortName>Revenues - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Revenues - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails</Role>
      <ShortName>Revenues - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails</Role>
      <ShortName>Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Income Taxes - Additional Information - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities Considered as Available for Sale by Type of Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities Considered as Available for Sale by Type of Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Schedule of Fair Values of Our Cash, Cash Equivalents and Marketable Securities by Location in Condensed Consolidated Balance Sheets and Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities - Schedule of Fair Values of Our Cash, Cash Equivalents and Marketable Securities by Location in Condensed Consolidated Balance Sheets and Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Condensed Consolidated Balance Sheet Components - Summary of Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Summary of Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Condensed Consolidated Balance Sheet Components - Summary of Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Summary of Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Leases - Summary of Cash and Non-cash Information Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Cash and Non-cash Information Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rcus-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Fair Value Measurements - Summary of Changes of Liabilities for Sale of Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Changes of Liabilities for Sale of Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="rcus-20230930.htm">rcus-20230930.htm</File>
    <File>rcus-20230930.xsd</File>
    <File>rcus-20230930_cal.xml</File>
    <File>rcus-20230930_def.xml</File>
    <File>rcus-20230930_lab.xml</File>
    <File>rcus-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>rcus-20230930_g1.jpg</File>
    <File>rcus-20230930_g2.jpg</File>
    <File>rcus-20230930_g3.jpg</File>
    <File>rcus-20230930_g4.jpg</File>
    <File>rcus-20230930_g5.jpg</File>
    <File>rcus-20230930_g6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="605">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rcus-20230930.htm": {
   "nsprefix": "rcus",
   "nsuri": "http://arcusbio.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "rcus-20230930.htm"
     ]
    },
    "schema": {
     "local": [
      "rcus-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "rcus-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rcus-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "rcus-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rcus-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 172,
   "keyCustom": 60,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 24,
   "memberCustom": 40,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/ecd/2023": 1,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://fasb.org/us-gaap/2023": 2
   },
   "contextCount": 323,
   "entityCount": 1,
   "segmentCount": 71,
   "elementCount": 474,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 605,
    "http://xbrl.sec.gov/dei/2023": 29,
    "http://xbrl.sec.gov/ecd/2023": 10
   },
   "report": {
    "R1": {
     "role": "http://arcusbio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
     "longName": "0000002 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
     "longName": "0000003 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Operations (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "rcus:ResearchAndDevelopmentExpenseRecoveries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "0000005 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-30",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-35",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
     "longName": "0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncreaseDecreaseInContractWithCustomerAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:IncreaseDecreaseInContractWithCustomerAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://arcusbio.com/role/OrganizationLiquidityandCapitalResources",
     "longName": "0000010 - Disclosure - Organization, Liquidity, and Capital Resources",
     "shortName": "Organization, Liquidity, and Capital Resources",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://arcusbio.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://arcusbio.com/role/RelatedPartyGileadSciencesInc",
     "longName": "0000012 - Disclosure - Related Party - Gilead Sciences, Inc.",
     "shortName": "Related Party - Gilead Sciences, Inc.",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://arcusbio.com/role/LicenseandCollaborations",
     "longName": "0000013 - Disclosure - License and Collaborations",
     "shortName": "License and Collaborations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://arcusbio.com/role/Revenues",
     "longName": "0000014 - Disclosure - Revenues",
     "shortName": "Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://arcusbio.com/role/IncomeTaxes",
     "longName": "0000015 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://arcusbio.com/role/NetLossPerShare",
     "longName": "0000016 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://arcusbio.com/role/StockBasedCompensation",
     "longName": "0000017 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities",
     "longName": "0000018 - Disclosure - Cash, Cash Equivalents and Marketable Securities",
     "shortName": "Cash, Cash Equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents",
     "longName": "0000019 - Disclosure - Condensed Consolidated Balance Sheet Components",
     "shortName": "Condensed Consolidated Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://arcusbio.com/role/Leases",
     "longName": "0000020 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://arcusbio.com/role/StockholdersEquity",
     "longName": "0000021 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://arcusbio.com/role/FairValueMeasurements",
     "longName": "0000022 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "ecd:TrdArrIndName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ecd:MtrlTermsOfTrdArrTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "ecd:TrdArrIndName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ecd:MtrlTermsOfTrdArrTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://arcusbio.com/role/RevenuesTables",
     "longName": "9954472 - Disclosure - Revenues (Tables)",
     "shortName": "Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://arcusbio.com/role/NetLossPerShareTables",
     "longName": "9954473 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://arcusbio.com/role/StockBasedCompensationTables",
     "longName": "9954474 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables",
     "longName": "9954475 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)",
     "shortName": "Cash, Cash Equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables",
     "longName": "9954476 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)",
     "shortName": "Condensed Consolidated Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://arcusbio.com/role/LeasesTables",
     "longName": "9954477 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://arcusbio.com/role/FairValueMeasurementsTables",
     "longName": "9954478 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails",
     "longName": "9954479 - Disclosure - Organization, Liquidity, and Capital Resources - Additional Information (Details)",
     "shortName": "Organization, Liquidity, and Capital Resources - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails",
     "longName": "9954480 - Disclosure - Related Party - Gilead Sciences, Inc. - Additional Information (Details)",
     "shortName": "Related Party - Gilead Sciences, Inc. - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-118",
      "name": "rcus:LockupPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
     "longName": "9954481 - Disclosure - License and Collaborations - Additional Information (Details)",
     "shortName": "License and Collaborations - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-145",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails",
     "longName": "9954482 - Disclosure - Revenues - Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition (Details)",
     "shortName": "Revenues - Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-160",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
     "longName": "9954483 - Disclosure - Revenues - Additional Information (Details)",
     "shortName": "Revenues - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-152",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://arcusbio.com/role/RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails",
     "longName": "9954484 - Disclosure - Revenues - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details)",
     "shortName": "Revenues - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:DeferredRevenueRevenueRecognized1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails",
     "longName": "9954485 - Disclosure - Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details)",
     "shortName": "Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rcus:AllocationToPerformanceObligations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "rcus:AllocationToPerformanceObligations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://arcusbio.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9954486 - Disclosure - Income Taxes - Additional Information - (Details)",
     "shortName": "Income Taxes - Additional Information - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails",
     "longName": "9954487 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)",
     "shortName": "Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails",
     "longName": "9954488 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails",
     "longName": "9954489 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities Considered as Available for Sale by Type of Securities (Details)",
     "shortName": "Cash, Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities Considered as Available for Sale by Type of Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails",
     "longName": "9954490 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Schedule of Fair Values of Our Cash, Cash Equivalents and Marketable Securities by Location in Condensed Consolidated Balance Sheets and Contractual Maturity (Details)",
     "shortName": "Cash, Cash Equivalents and Marketable Securities - Schedule of Fair Values of Our Cash, Cash Equivalents and Marketable Securities by Location in Condensed Consolidated Balance Sheets and Contractual Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails",
     "longName": "9954491 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)",
     "shortName": "Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "position",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "position",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "longName": "9954492 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Cash, Cash Equivalents and Marketable Securities - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-69",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails",
     "longName": "9954493 - Disclosure - Condensed Consolidated Balance Sheet Components - Summary of Prepaid and Other Current Assets (Details)",
     "shortName": "Condensed Consolidated Balance Sheet Components - Summary of Prepaid and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "rcus:PrepaidExpensesAndOtherCurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "rcus:PrepaidExpensesAndOtherCurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails",
     "longName": "9954494 - Disclosure - Condensed Consolidated Balance Sheet Components - Summary of Other Current Liabilities (Details)",
     "shortName": "Condensed Consolidated Balance Sheet Components - Summary of Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "rcus:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "rcus:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails",
     "longName": "9954495 - Disclosure - Leases - Summary of Cash and Non-cash Information Related to Operating Leases (Details)",
     "shortName": "Leases - Summary of Cash and Non-cash Information Related to Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://arcusbio.com/role/LeasesAdditionalInformationDetails",
     "longName": "9954496 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:SecurityDeposit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:SecurityDeposit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails",
     "longName": "9954497 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-249",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9954498 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-275",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-275",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "longName": "9954499 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-308",
      "name": "rcus:NonRefundablePaymentsReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-308",
      "name": "rcus:NonRefundablePaymentsReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails",
     "longName": "9954500 - Disclosure - Fair Value Measurements - Summary of Changes of Liabilities for Sale of Future Royalties (Details)",
     "shortName": "Fair Value Measurements - Summary of Changes of Liabilities for Sale of Future Royalties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-316",
      "name": "rcus:LiabilityForSaleOfFutureRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-316",
      "name": "rcus:LiabilityForSaleOfFutureRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20230930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r84"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r614",
      "r624",
      "r649"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_InvestmentsAndCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAndCash",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and investments",
        "label": "Investments and Cash",
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r764"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r361",
      "r389",
      "r390",
      "r391",
      "r559",
      "r560",
      "r569",
      "r570",
      "r571"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r614",
      "r624",
      "r641",
      "r649"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r608",
      "r618",
      "r643"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r604",
      "r615",
      "r625",
      "r650"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used to compute net loss per share, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r161"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r614",
      "r624",
      "r649"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits for letters of credit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r606",
      "r614",
      "r624",
      "r641",
      "r649",
      "r653",
      "r661"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r604",
      "r615",
      "r625",
      "r650"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r606",
      "r614",
      "r624",
      "r641",
      "r649",
      "r653",
      "r661"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r614",
      "r624",
      "r649"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used to compute net loss per share, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r161"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r614",
      "r624",
      "r649"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails",
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r596",
      "r607",
      "r617",
      "r642"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid portion of property and equipment purchases included in Accounts payable and Other current liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r365"
     ]
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueRevenueRecognized1",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue recognized",
        "verboseLabel": "Amounts included in deferred revenue at the beginning of the period",
        "label": "Deferred Revenue, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r609",
      "r619",
      "r644"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r605",
      "r616",
      "r626",
      "r651"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r512"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r596",
      "r607",
      "r617",
      "r642"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r281",
      "r286",
      "r361",
      "r390",
      "r559",
      "r560",
      "r569",
      "r570",
      "r571"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r281",
      "r286",
      "r361",
      "r389",
      "r569",
      "r570",
      "r571"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r114",
      "r136",
      "r167",
      "r173",
      "r177",
      "r213",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r343",
      "r347",
      "r366",
      "r439",
      "r502",
      "r577",
      "r590",
      "r717",
      "r718",
      "r753"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-operating income (expense):",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r602",
      "r613",
      "r623",
      "r648"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r610",
      "r620",
      "r645"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r361",
      "r391",
      "r559",
      "r560",
      "r569",
      "r570",
      "r571"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r21",
      "r107",
      "r125",
      "r126",
      "r127",
      "r142",
      "r143",
      "r144",
      "r146",
      "r151",
      "r153",
      "r165",
      "r214",
      "r215",
      "r263",
      "r322",
      "r323",
      "r324",
      "r334",
      "r335",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r377",
      "r461",
      "r462",
      "r463",
      "r479",
      "r532"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r142",
      "r143",
      "r144",
      "r146",
      "r151",
      "r153",
      "r214",
      "r215",
      "r322",
      "r323",
      "r324",
      "r334",
      "r335",
      "r349",
      "r351",
      "r352",
      "r354",
      "r357",
      "r461",
      "r463",
      "r479",
      "r768"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r610",
      "r620",
      "r645"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r600",
      "r611",
      "r621",
      "r646"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Values of Our Cash, Cash Equivalents and Marketable Securities by Location in Condensed Consolidated Balance Sheets and Contractual Maturity",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r63",
      "r64",
      "r78",
      "r492",
      "r508",
      "r533",
      "r534",
      "r577",
      "r590",
      "r689",
      "r713",
      "r751",
      "r768"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r601",
      "r612",
      "r622",
      "r647"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "rcus_ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ResearchAndDevelopmentAndCommercializationActivitiesForZimberelimabMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D and Commercialization Activities for Zimberelimab",
        "label": "Research and development and commercialization activities for Zimberelimab [Member]",
        "documentation": "Research and development and commercialization activities for zimberelimab."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r107",
      "r125",
      "r126",
      "r127",
      "r142",
      "r143",
      "r144",
      "r146",
      "r151",
      "r153",
      "r165",
      "r214",
      "r215",
      "r263",
      "r322",
      "r323",
      "r324",
      "r334",
      "r335",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r377",
      "r461",
      "r462",
      "r463",
      "r479",
      "r532"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33",
      "r53",
      "r54",
      "r181",
      "r547"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10",
      "r23",
      "r350",
      "r353",
      "r377",
      "r461",
      "r462",
      "r682",
      "r683",
      "r684",
      "r690",
      "r691",
      "r692"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r614",
      "r624",
      "r649"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails",
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average closing price of our common stock on grant date (in dollars per share)",
        "verboseLabel": "Purchase price per share (in dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Current",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r38"
     ]
    },
    "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueByArrangementDisclosureTextBlock",
     "presentation": [
      "http://arcusbio.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Revenue Recognized as a Result of Changes in Deferred Revenue",
        "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other items, net",
        "label": "Other Operating Activities, Cash Flow Statement",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails",
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock",
        "terseLabel": "Common stock share value",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r60",
      "r61",
      "r82",
      "r479",
      "r532",
      "r545",
      "r589"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://arcusbio.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r119",
      "r136",
      "r213",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r343",
      "r347",
      "r366",
      "r577",
      "r717",
      "r718",
      "r753"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://arcusbio.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities Considered as Available for Sale by Type of Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total liabilities measured at fair value",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r165",
      "r418",
      "r468",
      "r480",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r509",
      "r511",
      "r512",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r532",
      "r583"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails",
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r60",
      "r61",
      "r82",
      "r469",
      "r532",
      "r545"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r222",
      "r438"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://arcusbio.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r328",
      "r331",
      "r332",
      "r333",
      "r336",
      "r338",
      "r339",
      "r340",
      "r474"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r52"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 74.8 shares in 2023 and 72.9 shares in 2022 issued and outstanding",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r442",
      "r577"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails",
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r325"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value per share; 10.0 shares authorized; no shares issued and outstanding.",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r441",
      "r577"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r490"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r61",
      "r490",
      "r508",
      "r768",
      "r769"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan shares",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent assets ($6 and $2 from a related party)",
        "verboseLabel": "Other noncurrent assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "rcus_GileadCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "GileadCollaborationAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gilead Collaboration Agreement",
        "label": "Gilead Collaboration Agreement [Member]",
        "documentation": "Gilead collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_EffectiveInterestOnLiabilityForSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "EffectiveInterestOnLiabilityForSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Effective interest on liability for sale of future royalties",
        "label": "Effective Interest on Liability for Sale of Future Royalties",
        "documentation": "Effective interest on liability for sale of future royalties."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations",
        "label": "Schedule Of Transaction Price and Allocated To Transaction Price to Performance Obligations [Table Text Block]",
        "documentation": "Schedule of transaction price and allocated to transaction price to performance obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r290"
     ]
    },
    "rcus_AmendedInvestorRightsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "AmendedInvestorRightsAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Investor Rights Agreement",
        "label": "Amended Investor Rights Agreement [Member]",
        "documentation": "Amended Investor Rights Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_CorporateSecuritiesAndCommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "CorporateSecuritiesAndCommercialPaperMember",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails",
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate securities and commercial paper",
        "label": "Corporate Securities And Commercial Paper [Member]",
        "documentation": "Corporate securities and commercial paper."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Investments in Marketable Securities",
        "label": "Cash Cash Equivalents And Investments In Marketable Securities [Member]",
        "documentation": "Cash, cash equivalents and investments in marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash (included in Other noncurrent assets)",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r679",
      "r687"
     ]
    },
    "rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of programs, eligible to receive regulatory and commercial milestone payments",
        "label": "Number Of Programs, Eligible To Receive Regulatory And Commercial Milestone Payments",
        "documentation": "Number of programs, eligible to receive regulatory and commercial milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cash and Non-cash Information Related to Operating Leases",
        "label": "Schedule Of Supplemental Cash Flow Disclosures And Non-Cash Financing Activities Related To Operating Leases [Table Text Block]",
        "documentation": "Schedule of supplemental cash flow disclosures and non-cash financing activities related to operating leases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_LockupPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "LockupPeriod",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lockup period",
        "label": "Lockup Period",
        "documentation": "Lockup period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails",
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government agency securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r569",
      "r762"
     ]
    },
    "rcus_WuXiBiologicsLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "WuXiBiologicsLicenseAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WuXi Biologics License Agreement",
        "label": "Wu Xi Biologics License Agreement [Member]",
        "documentation": "WuXi Biologics license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "rcus_OptionLicenseAndCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "OptionLicenseAndCollaborationAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gilead Collaboration Agreement",
        "label": "Option License And Collaboration Agreement [Member]",
        "documentation": "Option, license and collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r665"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option continuation payment due upon sixth anniversary of agreement",
        "label": "Option Continuation Payment Due Upon Sixth Anniversary of Agreement",
        "documentation": "Option continuation payment due upon Sixth anniversary of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r9",
      "r83",
      "r121",
      "r124"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r665"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Current Liabilities",
        "label": "Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_InflammationTarget1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "InflammationTarget1Member",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inflammation target 1",
        "label": "Inflammation Target 1 [Member]",
        "documentation": "Inflammation target 1 member."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r181"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r665"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest receivable",
        "label": "Interest Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "rcus_OptionAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "OptionAndLicenseAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taiho Agreement",
        "label": "Option And License Agreement [Member]",
        "documentation": "Option and license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "rcus_StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "StockIssuedDuringPeriodValueDeterminedToPremiumOnPurchaseOfCommonStockAndAllocatedToPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of common stock allocation to performance obligation",
        "label": "Stock Issued During Period Value Determined To Premium On Purchase Of Common Stock And Allocated To Performance Obligation",
        "documentation": "Stock issued during period value determined to premium on purchase of common stock and allocated to performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "rcus_EquityAwardProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "EquityAwardProgramsMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award Programs",
        "label": "Equity Award Programs [Member]",
        "documentation": "Equity Award Programs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock ($20 and $\u2014 from a related party)",
        "verboseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "rcus_EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "EtrumadenantLicenseAndResearchAndDevelopmentServicesAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Etrumadenant License and research and Development Services Agreement",
        "label": "Etrumadenant License And Research And Development Services Agreement [Member]",
        "documentation": "Etrumadenant License And Research And Development Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential regulatory approval milestones payment receivable related to domvanalimab",
        "label": "Potential Regulatory Approval Milestones Payment Receivable Related To Domvanalimab",
        "documentation": "Potential regulatory approval milestones payment receivable related to domvanalimab."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ProceedsFromSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ProceedsFromSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of future royalties",
        "label": "Proceeds From Sale of Future Royalties",
        "documentation": "Proceeds from sale of future royalties."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "rcus_ProceedsFromMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ProceedsFromMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds From Maturity of Marketable Securities",
        "documentation": "Proceeds from maturity of marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_CommonStockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "CommonStockPurchaseAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Agreement",
        "label": "Common Stock Purchase Agreement [Member]",
        "documentation": "Common stock purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "terseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r103",
      "r152",
      "r153",
      "r170",
      "r329",
      "r337",
      "r453"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "rcus_OrganizationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "OrganizationLineItems",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization [Line Items]",
        "label": "Organization [Line Items]",
        "documentation": "Organization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of positions in securities in unrealized loss",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r224"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r74"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]",
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r74",
      "r133"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r576"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets (($4) and ($2) from a related party)",
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r513",
      "r514",
      "r517"
     ]
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesInc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party - Gilead Sciences, Inc.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r382",
      "r385",
      "r475",
      "r476",
      "r477",
      "r515",
      "r516",
      "r517",
      "r536",
      "r538"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r517"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r172",
      "r176",
      "r178",
      "r556"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r364"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails",
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificate of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r584",
      "r585",
      "r586",
      "r587"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails",
      "http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r517"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails",
      "http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails",
      "http://arcusbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r517"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r89",
      "r91",
      "r130",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r157",
      "r159",
      "r160",
      "r358",
      "r435",
      "r765"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r130",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r157",
      "r159",
      "r160",
      "r161",
      "r358",
      "r435",
      "r765"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Receivable from collaboration partners ($17 and $718 from a related party)",
        "negatedTerseLabel": "Receivable from collaboration partners",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue ($96 and $97 to a related party)",
        "verboseLabel": "Deferred revenue, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r277"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, noncurrent ($309 and $355 to a related party)",
        "verboseLabel": "Deferred revenue, noncurrent",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r277"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r277"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue (($47) and ($73) to a related party)",
        "verboseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r685"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails",
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r381",
      "r382",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r507",
      "r509",
      "r539",
      "r752"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails": {
       "parentTag": "rcus_CashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r222"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue from contract with customer, excluding assessed tax",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r171",
      "r174",
      "r175",
      "r179",
      "r180",
      "r181",
      "r275",
      "r276",
      "r418"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Consolidated Balance Sheet Components",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "rcus_AtTheMarketFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "AtTheMarketFacilityMember",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-Market Facility",
        "label": "At-the-Market Facility [Member]",
        "documentation": "At-the-Market Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r246",
      "r260",
      "r355",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r451",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r709",
      "r710",
      "r711",
      "r712"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForLoanLossesExpensed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForLoanLossesExpensed",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit related losses",
        "label": "Financing Receivable, Credit Loss, Expense (Reversal)",
        "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r432"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r418",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r550",
      "r562",
      "r578",
      "r670",
      "r715",
      "r716",
      "r720",
      "r766"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_CashReceivedFromTenantImprovementAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "CashReceivedFromTenantImprovementAllowances",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received from tenant improvement allowances",
        "label": "Cash Received from Tenant Improvement Allowances",
        "documentation": "Cash received from tenant improvement allowances."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock options issued and outstanding",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r577"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r418",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r550",
      "r562",
      "r578",
      "r670",
      "r715",
      "r716",
      "r720",
      "r766"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option continuation payment receivable upon sixth anniversary of agreement",
        "label": "Option Continuation Payment Receivable Upon Sixth Anniversary Of Agreement",
        "documentation": "Option continuation payment receivable upon sixth anniversary of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of premiums (discounts) on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_AccessRightsAndOptionContinuationPeriodsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "AccessRightsAndOptionContinuationPeriodsMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Access Rights and Option Continuation Periods",
        "label": "Access Rights and Option Continuation Periods [Member]",
        "documentation": "Access rights and option continuation periods."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r752"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development (Net of recoveries of $22, $27, $89 and $93 from a related party)",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r326",
      "r761"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r88",
      "r445",
      "r577",
      "r689",
      "r713",
      "r751"
     ]
    },
    "rcus_TaihoCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "TaihoCollaborationAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taiho Collaboration Agreement",
        "label": "Taiho Collaboration Agreement [Member]",
        "documentation": "Taiho Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-operating income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33",
      "r53",
      "r54",
      "r181",
      "r547"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33",
      "r53",
      "r54",
      "r181",
      "r467",
      "r547"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r166",
      "r248",
      "r249",
      "r250",
      "r252",
      "r255",
      "r260",
      "r262",
      "r469",
      "r470",
      "r471",
      "r472",
      "r561",
      "r667",
      "r688"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of revenues",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33",
      "r53",
      "r54",
      "r181"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails": {
       "parentTag": "rcus_CashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r82",
      "r444",
      "r464",
      "r466",
      "r473",
      "r491",
      "r577"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock pursuant to equity award plans",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r223",
      "r225",
      "r226",
      "r246",
      "r260",
      "r355",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r451",
      "r558",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r709",
      "r710",
      "r711",
      "r712"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r668"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostAmortization",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized contract cost, amortization",
        "label": "Capitalized Contract Cost, Amortization",
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResources"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Liquidity, and Capital Resources",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r104"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued personnel expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r37"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r110",
      "r136",
      "r213",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r344",
      "r347",
      "r348",
      "r366",
      "r577",
      "r717",
      "r753",
      "r754"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r120",
      "r123",
      "r131",
      "r136",
      "r145",
      "r152",
      "r153",
      "r167",
      "r172",
      "r176",
      "r178",
      "r213",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r342",
      "r345",
      "r346",
      "r358",
      "r366",
      "r436",
      "r448",
      "r478",
      "r510",
      "r530",
      "r531",
      "r556",
      "r574",
      "r575",
      "r589",
      "r684",
      "r717"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r162",
      "r163",
      "r164"
     ]
    },
    "rcus_RemoveOptionContinuationPaymentUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "RemoveOptionContinuationPaymentUnderAgreement",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Removal of option continuation payment under agreement",
        "label": "Remove Option Continuation Payment Under Agreement",
        "documentation": "Remove option continuation payment under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized contract cost, net, current",
        "label": "Capitalized Contract Cost, Net, Current",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_CapitalizedContractCostNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostNetNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized contract cost, net, noncurrent",
        "label": "Capitalized Contract Cost, Net, Noncurrent",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r165",
      "r418",
      "r468",
      "r480",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r509",
      "r511",
      "r512",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r532",
      "r583"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r87"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r437",
      "r446",
      "r577"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails",
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r244",
      "r250",
      "r384",
      "r553",
      "r554"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r111",
      "r551"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails",
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r381",
      "r382",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r507",
      "r509",
      "r539"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive gain (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r15",
      "r121",
      "r124",
      "r128",
      "r367",
      "r368",
      "r373",
      "r433",
      "r450",
      "r682",
      "r683"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r85",
      "r764"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r749"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of in-process research and development",
        "label": "Payments to Acquire in Process Research and Development",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r749"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r749"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r381",
      "r382",
      "r383",
      "r384",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r507",
      "r509",
      "r539"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Loss",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://arcusbio.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r291",
      "r319",
      "r320",
      "r321",
      "r573"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Collaborations",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r99",
      "r106"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r68",
      "r90",
      "r167",
      "r172",
      "r176",
      "r178",
      "r436",
      "r447",
      "r556"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r135",
      "r247",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r263",
      "r356",
      "r535",
      "r537",
      "r546"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r280",
      "r288",
      "r314",
      "r315",
      "r316",
      "r392",
      "r416",
      "r460",
      "r481",
      "r482",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r548",
      "r549",
      "r557",
      "r561",
      "r572",
      "r579",
      "r582",
      "r714",
      "r719",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760"
     ]
    },
    "rcus_PercentageOfOutstandingCommonStockOwned": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "PercentageOfOutstandingCommonStockOwned",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding common stock held",
        "label": "Percentage Of Outstanding Common Stock Owned",
        "documentation": "Percentage of outstanding common stock owned."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r248"
     ]
    },
    "rcus_UpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "UpfrontCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront cash payment",
        "label": "Upfront Cash Payment",
        "documentation": "Upfront cash payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r288",
      "r416",
      "r460",
      "r481",
      "r482",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r548",
      "r549",
      "r557",
      "r561",
      "r572",
      "r579",
      "r719",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r280",
      "r288",
      "r314",
      "r315",
      "r316",
      "r392",
      "r416",
      "r460",
      "r481",
      "r482",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r548",
      "r549",
      "r557",
      "r561",
      "r572",
      "r579",
      "r582",
      "r714",
      "r719",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails",
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r288",
      "r416",
      "r460",
      "r481",
      "r482",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r548",
      "r549",
      "r557",
      "r561",
      "r572",
      "r579",
      "r719",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r490"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units issued",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r490",
      "r508",
      "r768",
      "r769"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r581",
      "r582",
      "r584",
      "r585",
      "r586",
      "r587",
      "r690",
      "r691",
      "r750",
      "r767",
      "r768"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails",
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r244",
      "r250",
      "r384",
      "r552",
      "r554"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r248"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r364"
     ]
    },
    "rcus_GileadSciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "GileadSciencesIncMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gilead",
        "label": "Gilead Sciences Inc [Member]",
        "documentation": "Gilead Sciences, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://arcusbio.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r389",
      "r390",
      "r391",
      "r559",
      "r560",
      "r569",
      "r570",
      "r571"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_PrepaidExpensesAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "PrepaidExpensesAndOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets",
        "label": "Prepaid Expenses and Other Current Assets",
        "documentation": "Prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_RecognitionOfTenantImprovementAllowanceReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "RecognitionOfTenantImprovementAllowanceReceivable",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of tenant improvement allowance receivable included in Other current liabilities",
        "label": "Recognition of Tenant Improvement Allowance Receivable",
        "documentation": "Recognition of tenant improvement allowance receivable."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost sharing receivable",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r266",
      "r277"
     ]
    },
    "rcus_OptionPaymentUponCompletionOfCertainIndEnablingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "OptionPaymentUponCompletionOfCertainIndEnablingActivities",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option payment upon completion of certain IND-enabling activities",
        "label": "Option Payment Upon Completion of certain IND-enabling Activities",
        "documentation": "Option payment upon completion of certain IND-enabling activities."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "IncreaseInLiabilityForSaleOfFutureRoyaltiesInterestAccretion",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest accretion",
        "label": "Increase in Liability for Sale of Future Royalties Interest Accretion",
        "documentation": "Increase in liability for sale of future royalties interest accretion."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_CollaborationTermForCurrentAndFutureClinicalPrograms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "CollaborationTermForCurrentAndFutureClinicalPrograms",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration term for current and future clinical programs",
        "label": "Collaboration Term For Current And Future Clinical Programs",
        "documentation": "Collaboration term for current and future clinical programs."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_PerformanceObligationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "PerformanceObligationPeriod",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligation period",
        "label": "Performance Obligation Period",
        "documentation": "Performance obligation period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://arcusbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r134"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "rcus_TaihoCollaborationAccessRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "TaihoCollaborationAccessRightsMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Access rights",
        "label": "Taiho Collaboration, Access Rights [Member]",
        "documentation": "Taiho collaboration, access rights."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_AbmunoLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "AbmunoLicenseAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Abmuno License Agreement",
        "label": "Abmuno License Agreement [Member]",
        "documentation": "Abmuno license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r80",
      "r81",
      "r82",
      "r115",
      "r116",
      "r117",
      "r166",
      "r248",
      "r249",
      "r250",
      "r252",
      "r255",
      "r260",
      "r262",
      "r469",
      "r470",
      "r471",
      "r472",
      "r561",
      "r667",
      "r688"
     ]
    },
    "rcus_RegulatoryAndCommercialMilestonePaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "RegulatoryAndCommercialMilestonePaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory and commercial milestone payments received",
        "label": "Regulatory And Commercial Milestone Payments Received",
        "documentation": "Regulatory and commercial milestone payments received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash lease expense",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Fair Value Assets and Liabilities Measured On Recurring Basis [Table Text Block]",
        "documentation": "Fair value assets and liabilities measured on recurring basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_AntiCDThirtyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "AntiCDThirtyNineMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "anti-CD39",
        "label": "Anti C D Thirty Nine [Member]",
        "documentation": "Anti CD thirty nine."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "rcus_NonRefundablePaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "NonRefundablePaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable payments received",
        "label": "Non-refundable Payments Received",
        "documentation": "Non-refundable payments received."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "rcus_AllocationToPerformanceObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "AllocationToPerformanceObligations",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total allocated transaction price",
        "label": "Allocation To Performance Obligations",
        "documentation": "Allocation to performance obligations."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ImputedEffectiveRateOfInterestOnUnamortizedPortionOfLiability",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Imputed effective rate of interest on unamortized portion of liability",
        "label": "Imputed Effective Rate of Interest on Unamortized Portion of Liability",
        "documentation": "Imputed effective rate of interest on unamortized portion of liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockIncludingAdditionalPaidInCapitalMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock and additional paid-in capital",
        "label": "Common Stock Including Additional Paid in Capital [Member]",
        "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock)."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities [Abstract]",
        "label": "Cash, Cash Equivalents and Marketable Securities [Abstract]",
        "documentation": "Cash, cash equivalents and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option fee per program for all other programs entering clinical development to exercise option",
        "label": "Option Fee Per Program For All Other Programs Entering Clinical Development To Exercise Option",
        "documentation": "Option fee per program for all other programs entering clinical development to exercise option."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_InterestAndOtherIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "InterestAndOtherIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other income, net",
        "label": "Interest And Other Income Expense Nonoperating Net",
        "documentation": "Interest and other income (expense) nonoperating net."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "rcus_GileadCollaborationAccessRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "GileadCollaborationAccessRightsMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Access rights",
        "label": "Gilead Collaboration, Access Rights [Member]",
        "documentation": "Gilead collaboration, access rights."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "rcus_AstraZenecaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "AstraZenecaAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AstraZeneca Agreement",
        "label": "Astra Zeneca Agreement [Member]",
        "documentation": "AstraZeneca Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_LicenseAndCollaborationAgreementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "LicenseAndCollaborationAgreementsTable",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License And Collaboration Agreements [Table]",
        "label": "License and Collaboration Agreements [Table]",
        "documentation": "License and collaboration agreements."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "rcus_AccruedResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development",
        "label": "Accrued Research And Development Expenses Current",
        "documentation": "Accrued research and development expenses current."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_GileadCollaborationLicenseAndRDServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "GileadCollaborationLicenseAndRDServicesMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and R&amp;D services",
        "label": "Gilead Collaboration, License and R&amp;D services [Member]",
        "documentation": "Gilead collaboration, license and R&amp;D services."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_NumberOfExerciseOptionToPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "NumberOfExerciseOptionToPrograms",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of exercise option to programs",
        "label": "Number of Exercise Option to Programs",
        "documentation": "Number of exercise option to programs."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_AntiPDOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "AntiPDOneMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "anti-PD-1",
        "label": "Anti P D One [Member]",
        "documentation": "Anti PD one."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "rcus_NumberOfResearchPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "NumberOfResearchPrograms",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of research programs",
        "label": "Number Of Research Programs",
        "documentation": "Number of research programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r577"
     ]
    },
    "rcus_QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "QuemliclustatLicenseAndResearchAndDevelopmentServicesAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quemliclustat, License and R&amp;D services",
        "label": "Quemliclustat License And Research And Development Services Agreement [Member]",
        "documentation": "Quemliclustat license and research and development services agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "rcus_LicenseAndCollaborationAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "LicenseAndCollaborationAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License And Collaboration Agreements [Abstract]",
        "label": "License and Collaboration Agreements [Abstract]",
        "documentation": "License and collaboration agreements."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "RightToPurchaseAdditionalOutstandingVotingCommonStockPercentage",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right to purchase additional outstanding voting common stock percentage",
        "label": "Right To Purchase Additional Outstanding Voting Common Stock Percentage",
        "documentation": "Right to purchase additional outstanding voting common stock percentage."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "OptionPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option payments received",
        "label": "Option Payment Received",
        "documentation": "Option payment received."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r76",
      "r92",
      "r108",
      "r120",
      "r123",
      "r127",
      "r136",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r152",
      "r153",
      "r158",
      "r167",
      "r172",
      "r176",
      "r178",
      "r213",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r358",
      "r366",
      "r449",
      "r510",
      "r530",
      "r531",
      "r556",
      "r588",
      "r717"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails": {
       "parentTag": "rcus_CashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term marketable securities",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r182",
      "r222"
     ]
    },
    "rcus_AmendedGileadCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "AmendedGileadCollaborationAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Gilead Collaboration Agreement",
        "label": "Amended Gilead Collaboration Agreement [Member]",
        "documentation": "Amended gilead collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ResearchAndDevelopmentActivitiesForInflammationProgramsMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D Activities for Inflammation Programs",
        "label": "Research And Development Activities For Inflammation Programs [Member]",
        "documentation": "Research and development activities for inflammation programs member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r222",
      "r431",
      "r696"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesConsideredasAvailableforSalebyTypeofSecuritiesDetails",
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r569",
      "r571",
      "r762"
     ]
    },
    "rcus_SecondStockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "SecondStockPurchaseAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Stock Purchase Agreement",
        "label": "Second Stock Purchase Agreement [Member]",
        "documentation": "Second Stock Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_LicenseAndCollaborationAgreementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "LicenseAndCollaborationAgreementsLineItems",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails",
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License And Collaboration Agreements [Line Items]",
        "label": "License and Collaboration Agreements [Line Items]",
        "documentation": "License and collaboration agreements."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_PercentageOfPremiumPurchasePriceOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "PercentageOfPremiumPurchasePriceOfCommonStock",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of premium purchase price of common stock",
        "label": "Percentage Of Premium Purchase Price Of Common Stock",
        "documentation": "Percentage of premium purchase price of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in measurement of lease liabilities",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities",
        "documentation": "Cash paid for amounts included in measurement of lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_TaihoPharmaceuticalCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "TaihoPharmaceuticalCoLtdMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taiho Pharmaceutical Co., Ltd",
        "label": "Taiho Pharmaceutical Co Ltd [Member]",
        "documentation": "Taiho Pharmaceutical Co., Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "rcus_LiabilityForSaleOfFutureRoyaltiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "LiabilityForSaleOfFutureRoyaltiesMember",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for sale of future royalties",
        "label": "Liability for Sale of Future Royalties [Member]",
        "documentation": "Liability for sale of future royalties."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_LicenseAndDevelopmentServicesRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "LicenseAndDevelopmentServicesRevenueMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Development Services Revenue",
        "label": "License and Development Services Revenue [Member]",
        "documentation": "License and development services revenue."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_FundsReceivedForStockPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "FundsReceivedForStockPurchaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funds received for stock purchase agreement",
        "label": "Funds Received For Stock Purchase Agreement",
        "documentation": "Funds received for stock purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "rcus_CashCashEquivalentsAndAvailableForSaleInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "CashCashEquivalentsAndAvailableForSaleInvestments",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesScheduleofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesbyLocationinCondensedConsolidatedBalanceSheetsandContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents and marketable securities",
        "label": "Cash Cash Equivalents And Available For Sale Investments",
        "documentation": "Cash, cash equivalents and available for sale investments."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_STAR221DevelopmentActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "STAR221DevelopmentActivitiesMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STAR-221 Development Activities",
        "label": "STAR-221 Development Activities [Member]",
        "documentation": "STAR-221 Development Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "rcus_LiabilityForSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "LiabilityForSaleOfFutureRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Liability for Sale of Future Royalties",
        "documentation": "Liability for sale of future royalties."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ResearchAndDevelopmentActivitiesForDomvanalimabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ResearchAndDevelopmentActivitiesForDomvanalimabMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D Activities for Domvanalimab",
        "label": "Research And Development Activities For Domvanalimab [Member]",
        "documentation": "Research and development activities for domvanalimab."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "rcus_RoyaltiesPayableTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "RoyaltiesPayableTerm",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties payable term",
        "label": "Royalties Payable Term",
        "documentation": "Royalties Payable Term"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_JuanCJaenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "JuanCJaenMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Juan C. Jaen [Member]",
        "documentation": "Juan C. Jaen"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development cost recorded within research and development expenses",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "rcus_IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "IncreaseInLiabilityForSaleOfFutureRoyaltiesCashReceived",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received",
        "label": "Increase in Liability for Sale of Future Royalties Cash Received",
        "documentation": "Increase in liability for sale of future royalties cash received."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_BvfPartnersLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "BvfPartnersLPMember",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BVF Partners L.P.",
        "label": "BVF Partners L.P. [Member]",
        "documentation": "BVF Partners L.P."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_CurrentAndFutureProgramsExclusiveAccessPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "CurrentAndFutureProgramsExclusiveAccessPeriod",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current and future programs exclusive access period",
        "label": "Current And Future Programs Exclusive Access Period",
        "documentation": "Current and future programs exclusive access period."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ContingentMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ContingentMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent milestone payments receivable",
        "label": "Contingent Milestone Payments Receivable",
        "documentation": "Contingent milestone payments receivable."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ClinicalRegulatoryAndCommercializationMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ClinicalRegulatoryAndCommercializationMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical, regulatory and commercialization milestone payments",
        "label": "Clinical Regulatory And Commercialization Milestone Payments",
        "documentation": "Clinical regulatory and commercialization milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_TaihoCollaborationRDServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "TaihoCollaborationRDServicesMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D services",
        "label": "Taiho Collaboration, R&amp;D Services [Member]",
        "documentation": "Taiho Collaboration, R&amp;D Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Prepaid and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "CollaborationReimbursementsOfInProcessResearchAndDevelopmentFromRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration reimbursements of in-process research and development",
        "label": "Collaboration Reimbursements Of In-Process Research And Development From Related party",
        "documentation": "Collaboration reimbursements of in-process research and development from a related party."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OfficersAndDirectorsTradingArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "OfficersAndDirectorsTradingArrangementMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers And Directors Trading Arrangement [Member]",
        "documentation": "Officers And Directors Trading Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_TrailingDaysAverageClosingPrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "TrailingDaysAverageClosingPrice",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trailing days average closing price",
        "label": "Trailing Days Average Closing Price",
        "documentation": "Trailing days average closing price."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "OptionPaymentUponAchievementOfCertainDevelopmentMilestones",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option payment upon achievement of certain development milestones",
        "label": "Option Payment Upon Achievement Of Certain Development Milestones",
        "documentation": "Option payment upon achievement of certain development milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r66",
      "r118",
      "r443",
      "r465",
      "r466"
     ]
    },
    "rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement from related party for shared costs",
        "label": "Related Party Transaction Reimbursement From Related Party For Shared Costs",
        "documentation": "Related party transaction reimbursement from related party for shared costs."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_SaleOfStockAuthorizedConsiderationOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "SaleOfStockAuthorizedConsiderationOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock authorized consideration on transaction",
        "label": "Sale Of Stock Authorized Consideration On Transaction",
        "documentation": "Sale Of Stock Authorized Consideration On Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_InflammationTarget2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "InflammationTarget2Member",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inflammation target 2",
        "label": "Inflammation Target 2 [Member]",
        "documentation": "Inflammation target 2 member"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ExtendedLockupPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ExtendedLockupPeriod",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extended lockup period",
        "label": "Extended Lockup Period",
        "documentation": "Extended lockup period."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ContingentPaymentsUponAchievementOfCertainClinicalAndRegulatoryMilestones",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent payments upon achievement of certain clinical and regulatory milestones",
        "label": "Contingent Payments Upon Achievement Of Certain Clinical And Regulatory Milestones",
        "documentation": "Contingent payments upon achievement of certain clinical and regulatory milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_MilestoneExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "MilestoneExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestone expense",
        "label": "Milestone Expense",
        "documentation": "Milestone expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r57",
      "r440",
      "r489"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from collaboration partners ($22 and $39 from a related party)",
        "verboseLabel": "Receivable from collaboration partners, current",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r266",
      "r277"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "rcus_SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "SummaryOfChangesOfLiabilitiesForSaleOfFutureRoyaltiesTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Changes of Liabilities for Sale of Future Royalties",
        "label": "Summary of Changes Of Liabilities for Sale of Future Royalties [Table Text Block]",
        "documentation": "Summary of changes of liabilities for sale of future royalties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r122",
      "r124",
      "r129",
      "r434",
      "r452"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "AdditionalClinicalRegulatoryAndCommercializationMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional clinical, regulatory and commercialization milestone payments",
        "label": "Additional Clinical Regulatory And Commercialization Milestone Payments",
        "documentation": "Additional clinical regulatory and commercialization milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_PaymentForOptionExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "PaymentForOptionExercise",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for option exercise",
        "label": "Payment For Option Exercise",
        "documentation": "Payment for option exercise."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ResearchAndDevelopmentExpenseRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ResearchAndDevelopmentExpenseRecoveries",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense, net of recoveries",
        "label": "Research And Development Expense, Recoveries",
        "documentation": "Research And Development Expense, Recoveries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r98",
      "r100",
      "r101",
      "r102"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://arcusbio.com/role/Revenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r279"
     ]
    },
    "rcus_ProceedsFromSaleOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ProceedsFromSaleOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of marketable securities",
        "label": "Proceeds From Sale of Marketable Securities",
        "documentation": "Proceeds from sale of marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OtherCollaborationRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "OtherCollaborationRevenueMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Collaboration Revenue",
        "label": "Other Collaboration Revenue [Member]",
        "documentation": "Other Collaboration Revenue [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "rcus_NonRefundableAndNonCreditableCashPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "NonRefundableAndNonCreditableCashPayments",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non refundable and non creditable cash payments",
        "label": "Non Refundable And Non Creditable Cash Payments",
        "documentation": "Non refundable and non creditable cash payments."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional clinical and regulatory milestone payments receivable",
        "label": "Additional Clinical And Milestone Payments Received Under License Agreement",
        "documentation": "Additional clinical and milestone payments received under license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_BvfAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "BvfAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://arcusbio.com/role/FairValueMeasurementsSummaryofChangesofLiabilitiesforSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BVF Agreement",
        "label": "BVF Agreement [Member]",
        "documentation": "BVF Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33",
      "r53",
      "r54",
      "r181",
      "r547",
      "r669"
     ]
    },
    "rcus_OrganizationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "OrganizationTable",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization [Table]",
        "label": "Organization [Table]",
        "documentation": "Organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value On Recurring Basis",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r365"
     ]
    },
    "rcus_UsGovernmentAgencyObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "UsGovernmentAgencyObligationMember",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government agency obligations",
        "label": "US Government Agency Obligation [Member]",
        "documentation": "US Government agency obligation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "rcus_ReimbursementOfResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "ReimbursementOfResearchAndDevelopmentExpense",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement of research and development expense",
        "label": "Reimbursement of Research and Development Expense",
        "documentation": "Reimbursement of research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcusbio.com/20230930",
     "localname": "OptionPeriod",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option period",
        "label": "Option Period",
        "documentation": "Option period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Noncurrent Assets",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001724521-23-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001724521-23-000021-xbrl.zip
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M;@!^XJB$:JZC&<* ><D#F4H[)6+PU+"TWAP8'<[\4ED27>"XKL3<5PX5I2Z
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MQOW<V?/G]6.Q<L]N#E)7&)OS+CP 3DN[VN4S5_.J3W]+<,_=3OPO4$L#!!0
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M17'F96>>>3PSVO["9.E)?\$(/?FA_Z/GP:F,EQD3!F+%B&$4EIJ+.7RF3-^
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M4[DG:8)C^)9N77$\LM1.2._1A"R0J+G>-OF76Y'RL[B@:=B+H;\!4$L#!!0
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M&4P1.*S59 >-O<9>,1E[7DJIIG,K@S [),K;%&&OV3[OLMZ$IQ'W16:DST-
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ML*77%3Z"'1[R$.1-/_E;!>#;X<H&U<*/!IN7'YRW.VU@-!5V=T^IYONTW1^
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M'7%6'BC-@>>6>^!Y?C^1+$X>^&?7->Z"5#R;J&=YT$A[BEL8KP6JO^D&)=I
MU:FI4@=PE!93\3R;TH=1U[:)^<+@O?31 851TYAA?_1L=4P<VGVQ*;NMR"1;
MW!JB:GHU1"T1H,>&3L%4):> Y2XQ0<""!UAPR\^(M:,,X-#..^MSP6M'6<"%
M6_KIDH4B^*F<"_#D9%9.QB'OW-+YER"RD%*!TDU.S?2E5=G=YHX.RY.)/Y%,
M\LX(G7L)(K6!YX[9R-\21&JRX*SD(L6NR94"Q<:G]T0R.%I<KG ;CN9A6N1"
M@MS&KH*.S 0/><_KN& ^,A.\<$L97+14\DX1<)$$G(GD\DXTG)^"RT1,>><>
MSLC!I56"+U?RSCMP1,*E)Q1N\QFX,5@G&GDY[_0(!S3<X<+P3-V71/#QN2PF
ME#B>37V/,[@8OB.\%OZ.+]DF76ZIE2\$/&N5#L:4NM\LE:#U6G*R>\09X_^C
M[%^)P<1N@F%[I8Z+7W+ZYG=B_P2M&QIT0%7/!OM'<Z1VW#(F3Y3ITB/F]CW;
MQ'2(NBZ;Q01TLGSE+:UPOLR6KZS;X,65$SN,E?AE8Y75'2..<AAE;GD5@9H8
MJ)'CHT9.$S7<LBL"-?&"T\;Y\T-DF5OV)UO48/[[$^:@^]_#7[^3=WWB38J+
MQ]3=7=/#MFQXN\$[X,=#?%UN22]AYN*9N025^*EQ<#*W')Q S7DC,FYYP?U
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M@(<'XZH!1P#BEC6^P%FG6J[48LXZ<&MC:6NXXV8=;NGA"\1 (N]S97O XS#
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M/U@X-<%"$@S@(TS[("SG&1[\8K"=8$((U")"@=IF*##P)C J,Y3$LMM$YI\
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M4J@M)$:/*C-__8V(S-0#28! @(#<L].V :4R(R,B(R,^$<%'%5L!VR.XF?U
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M;U<AI01Q"UO)@QPK.9)PU,BR'&)IKLK!VB#*=DO=-3@V'-[<==8$NO&J&7=
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MJOU8[KH6H\XZ&)86 =K(H9\>BLZC]=20P1*Y=."$8++D>3ISQH65;\68&2!
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MP/]\9Q5!X!-2A\$VPVR @'!T.*Z//QPSI%I [DSQXVG@!RZ-XL%[O.F2/A7
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MHO=0Z<-,]_6EH"E3N,GSC3%FA&U>$:;RPJ+@2YY+/'+4I4%'&$L209\8N*A
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MD?P@]LM',AV :N]-;^%XNO4K[,P"GL!L6$?4Q(NP!5EZ:X07NG0=U;T,S;,
MT)5SXU,:06F$ ]P93Z@1VDVX>K;+RLBI@D;8HN)JUK_3=3210IO+$_:[-^N#
M@JWV$2*SV=[T3X[/M%8SQ&EL&\X.%@N+0J*Z):*K%%R-BBYDQ- 1WK%2F!4^
M2Q=FC:*P1CP*.Q917 ]?!%_-%X[-7>#K"J!F5VWD[]VI,.>^VT$CWII .-/8
M8H.^N&RA _\+P 8W7KE70.3Z:O?D$M@#&/&>31D,1?U6O =]09/[%YN(=X.R
MH!?R]T1;G+'#EP%7D#1G<9IS0&?2#4,,:GK(G0*P$J$<%#9 80/*Q :<::E
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M0&_KYJBP^72?O3V"_A/TK<6V!7?"L&!+@40\6 #< -^BGG,9L-*87(X.CQ3
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M!*3S+#?*"HZC]?47'5Z,"A5X):!L,8$@GXB6YIN9EA/A=08\H47+XT1-9 ;
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MDJ^$2N8M6^98H=Z+\UIX<(AJ\F$R@.W8L=YGP0)^*-K<A(7RH]9CLA(6'TY
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MLKZQ6B"&>06A6,M6?IE1]O_RV)/J$:_>[\D9KGKEN'G7P#<;6 )%6M(:GD,
M"C,+2R!MX^_>>Q&#P2X*N"#8W14,:D[S4]',,3H/[HD(E )7$EG-<-; FJAP
M-7]Y H;#=L2JJ.YHN/B$Q4&M<2AKGX3.8#. O69D3@K&=2? DQ!NT5(5;XI
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MB 1'9T:6DR!<N?KZA!4)SDOYC[.4OWAV7Y'!AUO.#R2@\%''_R4GS/_QX^D
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MLL*!8U#9^XP,G02]I4>:?85& A_S%1B=-(C\"+A<,*RXV$G#0)GS23\FK'6
M<!Y5_4+ZFX'N&E(.(>[\ D5UI]ARK!;2JV%_JZ:EA&6L$G<6?&5B2&4\_60[
MQ"A2G364T,,V13H!NQ-!(6'=3X*.Z[5C4V-J*.P<WSAFM6BO*,!86WVLRP#3
M"1U+,/&&PX,!5QI!#XG4B;M#T+6 :W!+V"V^AF*4*+&X[&J]?)]F0YF:O4
ML610RZOI2W%'(7X#S1:YT]JN0]^AJ-'I4YX ?]B/_1&G-DZ=#T^85]5'SO#E
M['6?9T_ 28.)Q$[4W/"HAV8U[@+JS1^7/QPE=P"MF1D?\/_=T=\@*.\:^(6\
M-?:4O/1O2IWS: /=\QLS&"N#N !,PI>@\,$]6FR)W/.%A39&<"HE<V&P.[P2
MD<DTE=%!7LTMM=1,M->Q0@0.#X]-S,"K;T! 0-\F&TU_LU8">XPP30 W93!B
M!X]?#+98'3WQ*]V46EV>WIR\G^/.%:14C:GZS0:?-:DF$6Y79X3;&>'V*7@7
M;U$8"$-#A9[<L@?O9?R\<%_(R#H0B^C9Y]EA>FTI.N9X((.1000,%RVCYM9Z
M1AO"?-6X_\+[R"B'Q48\ZI0<9;Y72>6$4W/PZ7RWIT O.;N#2 &O\2)D+^26
M'L08D%S+4K2 B1)*F2>&7,7XS+?5PE[2?8.?^N\!"X!Y:NQH@5?^L&<[A4CK
MFA(;AHESZN 'Z=\M&A[AC8J:?*8 E,T';"JWG?HRF,3!1OTD%/'@I$L&<(X<
MQ4H+<7"-"IC%;PD,Q=#K 5^MAMBMD[HCK"#':AS17'_0RXW+>Z*C4K!'@81-
M<)F$_QV0<O1P3H=4&/!C.5)X#"$?NIRI4-0!0HE<Y';!O;H3=O9,.=D'F@&)
M$+OY=S)-$J1QK7FW82&R),FO%KY$S\MFK"7A4.3.A^=A?FGBD$[VR(3V&H.3
M_J6(H3'P(F%=6!,UI!WL@N9FD=JC!.[SMW!MC$2P^-4J[V/$0JX"@IF(GPZF
M/EZVT0#=X012?&[UO#T:9VGITR')C-BD1/*G'*']NEM7M"N8TU]B)+K"!NG!
MF7R'-ZK(QF28#<U-@)>_)F1"+U?W>3/B;=][?%$B ZDS=?R60O)E?+W6![Y7
MSH6/2F,,="8LG:&N/"QVICF3J.Y5KE>:O57!NR=O_O+J[5/:Y_QI)NIA^L:>
M.3@^9HFXH:>GCIQ;JEU'":<FLQRC'C*."^$D3I(?/$0W6@H\3A2S2KI*0U?A
M<_$=@2[[:AG34?K+4 BDDHL&XMN*:#K<QBERO>:B2/--PSD[8QDA,8TZ(PDV
M9MJ:C.3BF.\4)BUBU\'S($X=[#T>1-.I&77#I-JOAUK#FBYJ$7;3QV PAI2P
M#]Y"ZL@<;)*+B$$BT.L0TR.>-CBK/O]VYG_X2-68/?*@6GMWZI)*%"S3?RZB
M/I*I&E$2ODMKI."RP(GD$,X3]I 3-NX%+8@K%86PS(N;W71H:ZNN+9@W31/'
M8<=%QIAX0KTSX_SG\Q0_DCVI#N@QZ0SA9#[;U(^P11>FL=L)Y_$ZPS1=;HR]
MY'J* Q3M-/SR>;8>ENFDSK8=;R(70Y^"SQ]%/YR6ZI$Q=J+MYM ,M;&IA\2K
M9IP<6V^0B9N.V?.5T78GCAOQ0#TM\05!A[0B#*"5VDZ".O%:LBN(IR;/:E08
M3E! FCCR[0%NZ(_B)DV1=#2F5L$&3P2F* F;?3!-S4.<REF Y> M6\S?D1 \
M198KS7I0@4$3 V-@EI&"Q"GLO9][\IC)!^2'T_[R<(GO,<'03WZ=#'G,<=/_
M!#.6I[/O\ZI9D-Z&RMM(9Q S0M8X^$UTKQ%)@"><T"-,PHI)K^%1O";"4]Z$
MOW;_)\=;DK@V]H^E.U@33V<OR\7E[$G\Z=/+D6?D&\@#D2*W/ +<[Z>?WUX\
M$X+]W"9N3)F#T WZ=9B/%^N\3"]GOV:J2FGJFE@ST^[<0?)\;)<E'F#6,T&M
ME^FURP8TXG#I';6_X9>1_ 1.MNB\S6YSEQ",OI4V>W%YOX[&1 (Y&<[+?^]M
MQ'VI;5E,]^UFCM+&,,R;RO+L+?8O4B,"T@-SU6J!I,*C5,&]D;!W7:4+M!E@
MMM):HCH^QJEEGX5Y"+/CKA6L@]%T3>Y<L!\_Y515QB7R+LW7E=<!P-MDOV$Q
MQ6*-6/*BVAHX.M[>G[Y=_Y&GB8S3U!8\<@/RT'DS[1A0?U>K.O S+)'N%DYH
M[C]N<\?,S"YW?HRB^"12=55TR"[<2N<OPU;/U&&3P*KG9V#5&5CU2<0ZL_<9
M'!M%YNGZ&RW+YLT8HW^.': 7>)##X9-327"NY!Q4IKYCI#:VF3;= GO"5UW!
M?BNCB$B0SYE5CD(#G?Q>4TOP56H:(D+3%EN"$.A@KJ]I,C1.E %=2F'!;SJD
M.PJ"">@4%D) 5OEL'6)8$))P$_>"N_<5V6"66^Q)(CC.?1E0%,^A2BJ5[>XT
M'X5:&.@@G<)!?'@]5;-YE^/)-9O758H-A+J.]O&Z,&8Y1\%&:M]00;I[+<U?
M41:^H%FAZ\UW?A$2_@A#%PG&]F"5R,] +(KZ&'+JVKT8-E\W'<5*G'/!BNS:
MR=0GX#2B.-_?L\&A;35TRQ/%+_)OU1UBCY*1#]7]P:X5].$9RB,=+-K6@#0>
M#-0 )YAG9];L2@AA"?,4-&_2FQ15LF");KJ2XRKT0,BO:9+H6O_DW262W8NL
MGE-5)8X6!G2WI:7$IH5<<#(HUTOM'8SM2;>[1$561D<IR(,*) 6C)=61A._D
MXXJVU)!(1TG7AU%@\6#$-14AQ6%Q/X@Q#D9JUQ/1(PV',:P8-U["N##4@.7Z
MRFGP$RK$E;+8"1'"C0 <K.9&TA/ALF*I\:B= %\YNEYX;=%$U#U1AMH7IFTP
MO]!_1EI S$5 T9T-R@DTY"A.\$Y[GZ+3--BNB4VC#6[X9X<^.XKT>5' IG)J
MD5G.V:\"'-;E+B@_5D%/)T7M,_=DC-T4*4A><_T4-UQ,SOM]-E#:ZX:O*.GG
MR;3YQ-E[&GGJ'^*S;WR 9- ;<HPJH6X*#-Z!3YSFJ7><>A,=KGD"^^K5,?1Z
MN.JYD8R/\J4PS-HHAZ-&(<!.%_$(]5_6[5D>.XUST3KGL^,WGK$1)VA\UFBK
ML X$PK8D*R>>%0H,-M@&Z\^ZHRVPGA)ROA/,+UM*OL[:^<>$E[4]SKTSYA41
M.8M-8>\P1>MH Z1K[KT*C6'-2H*'R22H'[)$+D8U-/I[K^U;@([D*A)@<H0N
MAV1L) %I*MB,86S9&E+_G!W730M/2(PKD:KV^#SW/@@.)Q\"$,_F2\XRI<L-
M/'N#J#YB0EZ\QT H'?,*>$QE62 @/*1IH\Q^I[J,LS_YJ]1=D?TIL9RK#LDJ
M9R8N;4!)X2^_9<N+916[I+8\NI)@\[2$C*J20C1JS:D:(9H-7D=#R/>26['?
M\]N5$1IFN-X"?P0\B,2&O5L^23>H%)\H)![K0,N.\P1/Z:ZP5'6A2O)4G2[T
M:H@5*G0>P#JMX"=MWJQVXI''K$TZ<NUNBXO-[SZGL,.H\EQ:9_&1:'W+; =!
M2GM-@6F;H#V^)(V?'.,C<R!;*F]<I1B[\&L(5,@?YE>\08E6=JP1(*ZY35$0
MX%90W'K8@[';;-MJ8Z11>4-Y<V9H8VO(9@X'8(T+D8K6>#54(,LS+BW0(H(7
MX)XF-YBS_DJ$\-&V'UVP:<GO)SL6CZ$SG%U)DK'PP9/L\N827&,47V6-(QJS
M]Z4L-(C&:3DW77V;P_XE?CC\(Y'&X05:DM.5"[<5KLURY\E7F>6:]4J'T[K)
M4L-^L=E98/<[V1@K!SSM#1HU'+L7#3ZWRA8JDY=4-'9;;G.SY44R]5496LZL
MSUW2)1CX18I OFMCW[G0A% +?(%\B2IT*>\:OY1DM\JI,+3\E[-78)(KC6NG
M6&)9RL:S0XR:O'Y7\P)W/#,3RG^>@!OSDC<LN[^A]_R 7T--+YC4/RJ^C<]K
MT@1,F0\@)^#*87L\,4=<DLLD#Z8D=H90=[H (Q5HK@S*.X_JS"=1D2[AY!$Q
M4N(SSN&\G,M@;4*=9>)4EO"+W$!8TC[)V97';)%!]?1^0[7;.U#E6$F=N92R
ML;@X2A:$]3-\(3 Y%9WP8W\N7;1&)QKJ._)W4#,LB7LX(IA02'TZ!@1$'&7+
M<[/^9$WILW--Z5Q3^A3R$B]8E?:H)GMM:" 41XG&:9FG-V7%K;<8;\O%@@99
M4(TF5]%28H5E\Q/P+(M\27EBY+#B3*I#A2R*+*U3H1N*\JID*S$QJ@5V T*.
MZ29;88,XS/=EMO#Y]J:W3KG)_<7HY/;(G()2@&?6E<K@D:2Z%.=J;RU,5+X(
M-0]=:4V&%VNSD6O\76,E+%]PDCY6N+Z<Z=H>Y/>5QZHV)YZ*G,IZAU/,7=3/
M9]=O7EQ\I22JHIRL'=;XV=4S_C#QV5<,[C@9%2!#N:.]HUP4N  _7_VW__+U
MU\^^^.Z+9_]U]M>W+WY^H2UWF2^^I&XJN!  [[O.BFWP*\!3N:' 0N]Q.?NE
ML_2&JR-0<(+7_;"+1A4+Q>_XKD)PCJJZA['1"]* !*8@C"BQ77B1%84Y'2T,
M&X4?9*XI'6/@*.$.6.=;*=+MDN";:>2DU;!J#AO@E@=^C+*<+FRQ>BX=/?8L
M?V:E WX<ZT;0"M06 R6.FN9Y164?QBDV&?**DW6RV:;D59&_)PJ]BD!>57FH
M7=L7#KE^J5&G+&I=Q.0JNXR7<S6E+30\82()Q/BO?(G0%8RP53=C$M[5%6PU
MW(H1>>,A(A-]2E$_B4F]"XA8\72N]!G<:[A#8==?J8VC%%4PW?B,2+.7OLXI
MV.=?,\U?XAE:47:/=B&-0I'R[M&N_I&1HTBMP);L7]D$4HJ$2LX!]EBI.E&#
MBPT)1"KK(] H4ZC$I^<T+GMI;?U@&M^J51H6$0,&V<PT5.1'O1!ZR42<B*@.
M.X9:X?0?C0M%B?QO11+&@=28ZS+A"$GV<2\D@2)D$?+*'"?FLB)9KRH9JQ4<
MPX+4QQA*]]0XF?RP;!V=K8=?!+P[+B>BC1N@:K3S!>X/3X2-[K@C$1;2]"N(
M,KP),X@>+O>07;$&V_&UH":ES>D8$@I96^+=%L\P+G<OLGS;,JFI9/TG'0Y-
M6"L-T-*S,+!'&@%2-1TN+SQ\S"@R#WF\JAR$Z9HKAI,P0S#5["9#>.IV3=2-
MUT[R)5B X%[KMA GBQN4)N>>)HVUR2B'-S'$&:<X:*CWT?J=1 WW7:ACR=$7
M-)QEP5;E3:4@.7&^QM <C+;;"J5C'S1R"L=4/%;1.*7]2MZ"BME*#'2WSACX
M0+09#$2A]34]8+RU5T5Z9WODV'L'J\BTG%O8MV0=C :S]X-<;1@+M!/C*),J
M(?@JY=X:KCH( 9)WC]'G57N!V;XA+$E?>9ZU=P@*<^U#KI_E4/^1L;IW8%O0
MR196:$?I85=>9$Z5W%CZ(1Q"M!N9N]W6-2TREZGC\DKDK;",O5SS%8U+CT6(
MP)K"XBH#<$QO,]0H:%7VFOBPJFW5M=+^T=<34#W94HOS]Y;,X[I#0T)83GJ=
M+L\+J+&@SQ!2QI<7N'1)0:-'EER-D(U[A!"-% X3T@Q8>F-)8?!-CE_\0"%
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MR$7Z-)F]?7?]YN+J^=7L"=_0]!L$&6$:#$]INNCKSY]?]11HX]-YL%/XQO%
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MT2]=P;M@UH$?VK$,-M./G=("-7D?>= 2G-D"&R:( D$9K"-WW_B(\@TV=0M
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MMOI^(EHV2K1T99LP8MZET[4QT^Q;8IDM95+@4CX# 7IWVH,/V*3OU:9@'8G
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MD'EVT\&WI"S5N_.?.EPC8*F*W9_&IT=MNR\<#+SCT-5-S';4O=XOF;F.E?V
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MV\P&M'7 <NO1ATG<\S3A%*5'@9>C3F<Y0Q/M,R3%#!+K8&>'/-"4GT[+V;S
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MUN-]\^EDV2+Q_IL4$+ =IRE4JP98&/.0TN'6\SC8]<<L3=.J8%3-!L)C>MF
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M^(:ZU-H5:C/NVUVE)XF]:%!:UZBTYNCHAO8<&"6^LX'+0&-';I'799$A])
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M'TQI#^[[H@)6XW=GXY<(,%;@-TAFP^>/K54VBUY]QM9]>YF(KK@D]^'GQJ[
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M\00H"L$/<&C>%\*(08.'6LQ)T= ![,;Y.K-V?0"()3R.CME9EP\JQ/K5'F"
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M?R#\/AP"O1/%))QS^X^]<22;KR.L?,TYMCB=FHSAF%%NV_-F0EPHM]L0T[J
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M!3B<+?3JXL(X-.V)R<T,#*P2SO#G=-Y VK/>*68[BV)JATJM@F0%TFAC*(R
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MZU9[!M$7E\@5 &VVF>$854D%Z3F%QYTI+O7#PTY=ZTY!"@8;<;"::@D2+79
M/AXX UT.NXD.VZXN3@U:J*[Y /+'Q46.M1)_%"4#3Z)_W=2(=([&[N#"W."E
MK+"RCG:%;^(L*^)ZX)B[?GMDR2X>1^!#G"5,#U-_^=;E0VN7).*@-2- 6/?(
MNL;8 &1'#;!/G/Z LWE>9 UTIG)Z0Y"H:Z[/DBZ^=D>J:M?4&16"VZ+(N8K
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MKAR)UN@]3+.*CB3DTM*LI-OU51YAV!E5&U5_CNC^XTA#D'FYJ@BR LI([F'
M5N@\'2ZD#U\62@*YW.%,T5)08/\A/(X(%\V=,XZ.W>\%=G*.&PXT;?$GJP4$
MHE""4ZJ6JE@LF()YSH9"5TPZX4B/11,!EPBGP35(,\KSH.%2"I4!7E0)S@L
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MI#D:'6T1#78"^R%H[%+NA8KBX,%4QP-RFS@:,">41TW.''+@^DA<#O)7\\4
ME7']-F5RCG46N3VP4Z/I713C1FA) +DLH](#V'7!]"-3N!8)$?*NS)V2@F9>
M<I^V1 ,T1I )3+&32=-3Y\#FC3Z=/C9+?5@0 XT5DX,[H^CG #92,^5<(!]$
M9TE@9MLHU\W%$DM(ZN,0*LPX5QE?P=#D@;M^D59&SK,T#E$1JDHX-EM1NA:$
M>U>&XI&DH<55=,+IYOW=@TT#\3TDR5P91-*)ZN':26Y-8$X1G8(H O:@6J"D
M<'!/U4 HSO'H0(Z&,\H4L(<?\)8PSTGLFG)4?![)"X_Z<Q0P_F*!U-NT"FGE
MIP?VN?F,V1WU2Z >P2*N]!399]9J! +1<\(88V3VRY=_AR@F,&I%L8FT%308
M1S]9%7F.ICP74T"M'Y$,]TYG&\X['4#%H_KWTX2CM<D.^%V0G%1)0WODPUP&
MGL&PGJ+LD8-5OT1:+;#M02=*>RGH()<3[@W6:R128((6DF!V]SF/WA=S2;1T
MOC#)YAE0@L"1@E3.Z1!1.*:DC ?O#T4%+5P.M5%$HZ[ BU;7/V+W*!7>+0 ^
MJ,E31]?5YZ&6QI[;OPQSV&*2K[=.9COJ&-]^D9G*I9Q\C&#]C^U2HL0X/@-;
MI%R*2D"(9_C!W8&TBL(HK-V)9DXG7U>GHN$.L$\-V",34U\ *0K3Q'6+H70X
M8N-"2[Y#L;5OS^WD('3ZASW=&(;QPW*#$$W!1T=="RD(A#\YSJMMD)=?=D!D
MBU@&NF+GKWM<" P Z:/A#QP*)8$#='$@8R8E,*!Y@GMS%F?84[Z4SQ-_%UF3
MGMIYEEH;,P4"X:2IERN_@'Q@FODK+I%ZNU-A>)EI1+GVR]2Z6E.>_R9CPF6W
MZTALD#Y3@04%8(%801JG +%73.L2L7-"0+K"%4I8,X$-8H8L,T*)!AU:0/"V
MP#MD5R%I [)#\C>N95YYA;*^)EL,Z@.!:["!S@#LW :=:% -@6N O5R*CCV(
M(%:CM8=M9A)<\20EE'A^H!RY$(L>ZS4G9N69 [ UTEX((@$^%/#)A1L0,[.=
M; Z?"6KRQ6/N 8^.J-AQ[]G! 1G@=-D<+=E9P9J-QM RG4G2!8Z6<W*4G)N4
M^F@,Y8ZKRAT/AW+'H=QQM5*^H6.)%DK++B&97D-S5%(I\^4+[!62J)ZI4Z"]
M5%2&;/%ZN:!@*<C9)D5VW#.H90@4'$M7="A=G4;BQ+%^3D>DP?<AU(CVG[7
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M!!7!9T.O.#:*"VDWY)T@.P0:%<-_L)?.D>5@*-\EY0 1(@B"%334V09GU,[
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M>U!?N^>=^*TKQ+-WR3T>+1_'&:S85)%%=E)W&M&"S$ZL&DBM9*PKYQ^+PTX
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MH0KRB -(N]0N]AV+GT3B<4#NB1<)*BW#TP[8C-(Z6946('X7)X0%_'K3S6=
M^12[)$53S12TFS/@UU9*L 5T1CF>5N1H47]%^0P[),8;HER17? :CS0QOU_)
MT6/ '>+I>L7J-6K1_6I.O=MUYBM,Q=]Q$)'O2N<41^:V[J<>T,C_2K8,>)!&
MA(J8=D@$=N6B[1>@; I1IZ?''SY\VJ 0A7Y-/^U2+3C-?Q\@VNF4;"<01I'4
M5)UB!.C7&,4NL7LER;/G>CV@D?F5VE(U1]Q%,=2G?/;2:(4W"J52A&I*''=1
M-/8YG[VX.N,TBK!2Y^J:3>ZD:.WSP ZR[8S4*-Q*8:UCBKF+LHT307NQE<8;
M)5(IM<7@N\CHVFS&GN]MX$8Q5&IH#2G1+LK%MA%BX/MZ2AQ<,WBL60-<JOV!
M!EMMN&B=QRCI2I6M6S.& LCG1P4"T*\)";ND&JW']IOJP_K(34IP4JGV6?4+
MO,G>IJ5@4[&OA=<H\4KYI+D5X4W,=664K)Z5?C%>EMAVH>QGR@L#( \A<L9]
M^,;CTYBB3O;_(C,;5:6YK%,JNF7?CI=E!8)D*::H,"S.ES15\;<973NM59OO
M$19XC!*OU)(*$G]S!497D"CS?XB/0ZPBI2B0?'(QPVQ*0JJD,"%"$#\9O 4'
ML-9\1B5H;*"J-7N4$X%PB#"*Z="=V#$EB#*4TI)!O:F-$N.#P"S$'J ?";4-
M*]<X"(+D5HCJSY++&1D1H8U/16/#<4"G\5:]B3)MGPJCBE5J:_4J5I@:Z;GU
MYI$35S]&<GVY5(%$5*!Q)S6OT."WZ49CB\JH Y427+&/L'F_Z>VD %?.AC+;
M'482;D3R]4FJ5.NC. B6ES2()'TL%+V_/GM!Y!-_(O@<JIB13*Q;#R5^@G^1
MX.^@#Z]$F5&]*O7$FF.QDK,I$(P*%*.4Y&)E/R4: =6H0#8@2@C/)USDYW [
MJ+KU!VEY5T#MSU^?X6,7/=S&-$:EJE1'&X_URFT)3:.2^7=2+^Q/[.#"13\*
M")\,YEQ("#4O>"B_"65</Y@@.("OOF'*  .8'($/61T<G)&PGPX.@*A/!$35
M@T<E%OA9;4#W"FJ\!/J5.F6C.ZCHGVS%1FNI]G%V/4%55I1P LPHXP4"9KQ#
MFATHYP?2#-'H8I;HCX4##.WE17<R<OY BI-Q""D6(> 15#ZT7H.M%\Y_WZS:
M2L<SM0T[ZNUXF5ZA1YGY$@A=2&52J&0APL%W+ '+\H7MUXFUF2SUM'(,L*&E
MYC87KFUTRJ92#D %P>X.CKB(G3$"I9QXL\569=LT*=S23$8]K1Q>K*&G;W7,
M-10$BGS,HP%-DK-ZR#L22D$]99?PVXOHSR:$&-6K<N"QAGJ5"4POI&A DM,9
M_[Z32FC?W95E<R-!%EB-9/Y0SHBXB 3<\S%0,9_L%)"_T-1&1:N<LW1M/RNE
MEPE)6J,T42BA"L5DO:F5I6R+$KVA>*RLN&N*M_U9C<I4.:_92)G*"E2@9R>U
M*&Y"S$0%3EI9V:WR\.I3(7Q(VF8D3V[:9-,8LDN[QY:F,NI+Y? EZ;0LJ8'>
MCL"A* )Z0$$I6$J[A"1'&159P^;.JLG&#3]F+$;A5DY5,N&^Q;TM3WAN*KJ.
M&(UBK+]X8.7)T#>A&KNF"X54'0I!M33?TI*1:GO,*Z?*OZIH7BB']@6'M(L#
M?UD"C"ICW;F]4E2-0T1=-"UL]BEE",M2!15\?T(>TO2]Z5K*V$U]2'>D1IVH
M5.";=>+-DQ@\21:8Q5U-?%(PE^2LA$^N(JD [O@2!QTSA^U/:M".XX-*U;?%
M8Q0BPZ2K2WTL.HSL+ 3*OYH@E%'T9]>BW_;+[]Z)_RZ]GP?>SI.\Y$SK&,C_
M7R,B/%C@E R+_1(J-9MSIG?\X1.#]Y_A<:A+VN=[$QS .T;@34/G>];PC ;Z
MQ.I\3XH(7E$"[Y8[4Y$[Y?Z#?HE(_&8M> %3I.:B,@+"OPD>+<[WXM%4DOD>
MBE\YDK]K#I  #=?J5\"4OY^HLMKX48)2A_!@*H@>]9W,Q_"&DGRA,:'Q.FT@
MS4OTHQBT^QI]/L>462SQZV1"/&@6N6:2*.V50Y;:R/(J-M?AJKDV2G<]9%WX
M$/\VCNL"Z@<RIK8:$'^CU$P9MEA:L":-.8:5AL)!UF](_ >^^NL#K^\UU(^?
M/9!G^46!_FQDXDM/^Y)J)]-I+-@[4'_ZQ+]FCTI1N+B#MV>&EN9E!^N$@5UP
ML0 /4#Q1@J//^5RY(8J#$58$M:^V$PHW%ET]XU 4Q^+2&_0UJSLJ,;!A,Z1.
M,.8V F*&DY'@4X'GX5=EIA3LDZLDA2C/>4>F$ =PL2R)^+O:3Y2F,S+"R^2.
MH0;WL<49MLZQY!NU.4R)Z.2![Z/%(OX5!^G=['D@"'IP"T\3J1\H4_Y/A10#
MV(B2 [@@]I@KY<?._OB/(,(5[WRCAD6+D9ZWD37E02^D+BF0!=&%1[/4[DF4
M$.3U?"'XHQX'>^<3;(ZQ(0"IC2M; Y.K84QRUI8T;H*65H\!F^-U*^ .P?H?
MNO*Z>,B@TJTPKZ_APX6F)W;1/Q;*W7!XE6*LIQ=$2-B&F/^5*3)+_J=QP1M@
MW$#C/4'\EQ-\?:10V]R3,*5;S-&.Z86T!/HNV-0FL&:27EP^S*B0RUO*B"&4
M;ACM1+@T\#PU.33'$"R\F6+])7DD 5_ L-0I)<ZH4<.[(5G?E[VL3O]?1.8!
M]8)(32Z3)^ 'K&%5]T0\4KAOPRZ=V@YN)S0F#7^_/D-8&Y+8O:G<. F'C7%S
M,^"KA\,E5YU$\\T[6<-H5\.4>^A"\W4)<!0II5/!L:7VVD ZH9O&6EC[.JW!
MG5CL Z8S/IIA%4MY)-*OL[K@-])O7Z,)RHFEU0<%V4,6B7@*A8E&&UT#DZ.Q
M]I?'"5S PX@(;T;M,JX=ZH1@AY.)VMD$R."2"N))+L('@>&$8B $'"*9O5$W
M'"^W;/M5Q[Y$^\]!)&=<Q ]OQ0\0Z;F'K%!L;BZ4=,7CZE:DB*20ZUSB93AX
M5+1/R47 0W@N& KMC0PPPKU^_OCU6>K*N55YIW[PZR\B/_B_4.R&/:*AIIE<
M#6=?/-T"9E>56L6Q'B%^>"7X/+;4^A>@-!:"[,!=77YK]@?5/F6O;>NWAG>V
M*'(+?5J3B/E 75*KUA/"WQ"$F(\6[#$XRX6JA4,]9]6,TW3IAW)_(DV(TYRB
M@_=8 [>K!J2B-LM\K&ZD$^'=C_ ;F"G3)?PI8=XR+_&V+\D&THDE)DE_^[Y>
M'O3Z^WGEAE";WIJ:X4Y(H-3S\T#$7"5QZ7$)\^.,/74/QJ+4>LA>7Z)9:V!\
M0C2H;2$>KO0-6Y[';@6W*\>LNMY1;A/SE%*'<4>+1:W$".N$4>07H#5U*35O
MJA:@SD8;L:>](G#[7&*?RH+5DO0I:M:B =URT 696'(AP'S@Y7JTP:=O=29G
MN5K77&EM-9; 3IA-?A13WTD:N[7F>K$=]!:6ZLNSV1+Z:J,QN5[_Y+)&-H73
MJ,OTY*FS@-N0."%H.(0=70YMSFI+PYP@WJAGID/V#@A>^VR]E *O9G1VB7,5
MREE'JUVBVG;34[4LORVT[O^=RW(#?][BWUQ,V12O$T\'Q!4/ZL,^.X<7]T$N
MHB]9O&:%AU&&$]WI5PA26X^#UL3HK@[5%L[R-B*UUFLV"? \?GPKC53:'>&&
M2)UPFUJIK\,P(OYE!.XG3LAU:G-)5)PVIPP:1D=*Z#2:#UEJ+L-)P2K*SP34
M!LC-!S9_' 7.JF<<[,(%7)1%N- Q<1D1Z(:[I\]2J1E3GEJ$"N5P8JX#;H33
MT?/=?T2_TR^4!WQ*O7"U:MENK%:@3IAD349MMT0+0!=.>HN)#K3R5O54DV-P
MOEVQ."':1IO,6[BW;NX=4#MJ]1"0I'$JG/PU=\*W!S76.%P]_1C(AQF)3SRO
ML*>[L Q&T@S@@B?XJJ:>8U^+8LO-I%M![0*/JD?>ML_!6D"ZJNA%TM.K2#=H
M%3"A<)4-R8TX3UCX=AE)"X!#^Y^ITF)H;>N$PXEE-R2*-:T\I>3QGQ360 (Z
MQ^.U,M%U)G""83\6$Z$BF4(W1Z.=UPUU/,_3AX5=<A<CF!-"*]8Z'K"8$GG8
MOJP6 "<6=$?F*CAL#*QUZXPY,.^(Q=6]J%@#[?9DA VD$_+.WEY3:+=<0()0
M>"X]K&15V3/5EWS^B!G6WK0Y+-GF'([F:^M?W;*5>UI>Y\FX/""IR2R2U[29
MGJRQQ^"$O6124?H:=[:(>;,;K!W\^DU"JXU,69,"O*HJI(\D+C09FMDZ8G%@
MV<6H^8ZH0# 287S..9Q<,YT]A6%]7 DI5?'=VG:-8QM/XN[.")OZ%':S^B[;
MUCL>+*$==?5%"16>JBG)>E62X-OAK6[ZU4QMO>Z;HW8V$<BEG@H;BK,#;T;)
M8W*ZFMQZ4&CBSD.&/%2PT*N-9W!UR\UH3!Z :.1%=:"KOB2Y+W*87EPY+%Y<
MV104V5XAM W<KK2L)DJMR(XSJ[1ML#GP;@1P51?B.V[*6ZA%&&D$<R)V'(HI
M9DE-JK5_L&:@.ZV"I<UH.&E]/*MEH^N"Q-DMK2BH&\HT6T,;J18&OW9CW353
M/,(AN3;?&)I>+@KWNI#6!I?-D+KJG0;C><1XMSIF.XP3?LGV7D)CMV5W1,Y:
M=J:5R;UK\0O'$X]TRQE/+Q.\)<UET&Y(W.4%O+*:^-D=PW<J]X!<-KUI^(=:
M;?*VU1'\"_>796;?S)S-L+ZDY=AWH@Y@:?\DC'C8UA^T0#CA#=+KF-(]V?K^
MIBK J]_;E-Q6O/YMXAT0."&\4>&6]Z1Y-#U_T#=AE/I'K>Z*M\#BABD:GV4P
M!FA=,+QVU';_,+CK]P]K>[ -EW990+K0!&31:5X\&=JX;;T.F1,V_;<(LXN_
M86)X4KXRS 4A=L@#BMV*V\@KROA<32FN(N9G\3 LI?;(N/F1;$MP9V/+;=\C
M]*>[/:C:X&[[.*8-I L^HG(/<EW!ON"U+0X"-D'IK*E46X?Z77N-^J^SL>EW
M'(7>C,SQYU_^'U!+ P04    " !R@6=7_ 1_KC(5  "=Q0  %0   ')C=7,M
M,C R,S Y,S!?8V%L+GAM;-U=67,;.9)^[U^A];XN6KB/CNZ>\-GA"/?88;MW
MYHV!(V$QFB*U547;FE^_"5*4*(FR2!%%E6U'R!95*GR)_) 'CL2O__AZ.CGZ
M#$T[GDU_>\)^ID^.8!IG:3S]]-N3OSZ^(O;)/W[_Z:=?_XN0?S][_^;HQ2S.
M3V':'3UOP'>0CKZ,NY.C[@2._C5K_AY_]D?O)K[+L^:4D-\7O_9\=G;>C#^=
M=$><<K%Z;/73YA=+%02M@5@I@4B5%;':6Z*X\='J##&9__GTBU'"1N,%\8;C
M8Z#P?S91PBUW.;CH4N2+ET[&T[]_*5^";^$(Q9NVBV]_>W+2=6>_'!]_^?+E
MYZ^AF?P\:SX=<TK%\>KI)Q>/?[WU_!>Q>)HYYXX7/[U\M!UO>A!?RX[__>>;
M#_$$3CT93]O.3V-IH!W_TBX^?#.+OEOT^KVXCNY\HGQ'5H^1\A%AG CV\]<V
M/?G]IZ.C97<TLPF\AWQ4_OWK_>O+)GT3YVT8SWZ.L]/C\L/CY[-I@FD+"?_3
MSB;C5)3\H<.O1>OM++\]@V:!NT5A%B_OSL_@MR?M^/1L JO/3AK(OSTI;R=%
MZ]0)6B#]]RZO/[["'_TDSB>+S]_@]Q>-%,!]B )?.\!?77;@"L)D%J\]-"GJ
MFS6KWYSX )/%IR.4^9/W9Z.+UT\_O?QZ5G"THP0T9N0K80&U)$62)*CLB8Z.
M>ADBCR)<[\$B7(O2+;2>?1L6JK]HX;AT[3%,NG;UR:*S%QU])XAEMSY<JC]@
MBF^</)VFI^ET/!VW77G_9[AX_XBZH RS@ABC4$9/(W$^.)*#DDE);K36E66\
M!])UB=>H]+2)1[,F08.&[\G1%RA&ZL(&+O$AIZYQ[/;XNWCBN)V?GB[>2<9(
MK]7OYV9V6I,3W:P_72SUC_+L2Y#WT *^Y@11O8#/,)F=E>&V@@0A1J-T)#JY
M2*1#F0,(2E*0'H"YE**O3(]O MJ&'/R[)$<]/52CQFN,+$[AS:QM7Z'P:)91
MV#G*>V6(GP&&#K!\[J/_"NW+K\AIU,-XZIOSU]A][3]G^--IASV+S7QZ/>V@
M@;8;I< EAA&,F*P%D3P9$H)AQ!F;1!(.PP9>F5@]BK-O3U]2Z0KC2%I/3<J4
M& !-9!8ET&*")&.8=S10EWKS/E<PAF2-A\+'FT-W7^U5&[ HV^PZEI7]T#Y3
MRS%@9X%;%,]Z$J*/)%EO)8O6&T4KD^E.,$.RX4.E5!U-'H!8@ANEI%8D:<N(
MI Y(R"81A>Z))VMC#.IQB+6]E"45&;W,F+J6:&REO[>8N_@PGHR[\U>SYH.?
MP-O\:M[-&W@_._>3;HP./X?@M;6):"91Q3%GXED4)"K-HPU6477#B]W.L1[<
M^HZFF?0ZD.HP9#4,#J.1O8?' N8*'09N;[L3:*Y)O]XM_X1N)+F#F 00<-@/
M&!)F8CU($H660E(M&-V.,+NT.B2#VP-/>E- /?,)W5IHH*(+!HT_\=$9(JU,
MQ(>4"<_2,(YLY<S6-IGK .JD!>@++[KX&::U>=R-N,@<5 0BI,"AIUG H<<\
M$25U$0Z%LZ:7D/X6E&%9Q@<K_V904*/COXODT .+V;M0AB9FNR%AMHMQ,Y%,
M")HC=9'UPZ0#)(>/;'XKD_'Q]5^-T)NR..H!>%"6<)4#D8DJ$BP#DKP2'##L
MIL8=.@>O,;.-&41P@CMBG4AE.BD1%V,DW$+&SN4!5.U9WWMFMA_92.^K_#NG
M!![4Y14G=S_#= ZK$=KXV/UKW)T\G[<=2MF\_!HG\[)V^+1%B"TD'*8C)[+5
M*I4(FGLB30C$)4/11F2= */KZ%GU*=^=80[)J-8F3]]:NT&O7X\W+=KULAKY
M?'9ZUL )/H-IW<*T];$H>;N5WM<F[Q&LTA+EM5:69$.'_C87 D!4R8@8"/51
MH2_WF03F)&%1:QV=#A)J3\1\ \[>+JLD<AO>7[IVU<:[6;,8\%W7C,.\\V$"
M'V?O?(,:&7&KG4S&DD M6EL5</@IQPC#)--X3RG/4-O![0=Y2!/MM7AVRRL>
M4*L])>_6VBBCM02B0SNKR[R^0#OK;.9*@<A,Y\,E[X_K]_JBR<-[_+">[9F?
ME%U"'TX NGJ>[/I;>_%<WP!>R5.5T*1KG\^;Q;B53DCA&5) !\PS=9;$)Y>(
MS5J#U9Z#K;W8>PW OB;@N6_+NGSYY^7_S<>?_:1X_:?=<]\TYQB(_:^?S&$$
M5EJC*:;/DJN2JRKDJ/2$)^F3S!!IB+4]\#; AN19'LZ+FT:BODZJ>8RGG_UX
M4AS7Q2K%!XCS9ER6)UY Z*Z^6W6#-8K%D 6)9>^(]%(0!XX2Y@0SBO,L6:H]
M/':#."2O4X]"?>JI&IDV98"++D ON0(6C+!!"T94P Q04@3FM=,D2.EL%)1&
M4=N^;@%K&]*([XXTM?51C2CO&CCSXW0QX;1:#+LNN)?*FD 3ALU1HCFTFE@>
M C'*0TXJJ1QJ[RG: M8V1)'?'5%JZZ,:45:+Z&C9$-6';A;_/IE-L)?;XDB[
M\U&R+#K\0Y(H6TPR-<27N2OEG0_>91VA=O)\'Z:*,J_ZGE.C5/:R9!.9H)HQ
MKY#&$(KZR#:K3)7H3\H=J'^HV*PJ+VZ.ACT5T*L[O=Q54I:C+L"Y2!/FFA9E
MQ9A1XE O:ZJ&9)#>,<93JK[[<DMH0XK%>J5,'ZJJMUI8C/F:^&MX=,@&I'"$
MBA30^R= ?X%=X+A$DDO!6*H=C=V-9DA!6*]LJ:20:@39()[A*AOJ&&8-&8DJ
M ,536F$Z$1SFH]Y2J#UW>)\G?=Q@JU="[*F BA[G]'3<+=:)RGS%8J/$)YC&
MLEL1K1,+3G@"RF.B4+;U8K0IB))6*"A[TG)M1GP#SC;44#\"-6JII$]C$4!%
MYE$T)[(FTC)&;#E%BY*"=!Q2JAZ$UP^[WT/GQU-(+WTSQ2YNG\8X/RVD@O0"
M\CB.T7MGBPFQ=T1P'8J<FK@L,\D,1RO'M)FYVD/@?E1#"LOWY,;MS05555)S
M^B(#^NOE6%_.WB9'4U B$"X%)=(I2H+$L<B%SYQ+%22MG:)M@#&D@+LR&?;M
M]*I.<C9=0\&,3#I2;#93262*BCC/#0D6G,*@S=)4>X?:30Q#"ITKZWVO[JZW
M3G)E>K;9&3!B8"((6G(\:<K9#@2I$&[(.5K#:/:F]F'D'2$.*;BN3)D^E56/
M48O9U9&(1C,:&!&FQ' :,.)GV';B@MDHE*+58Z=ERW7P7RXC.)T4DY$H95%=
M7F<2C%($L =U,ER(5/O0YL[S\H==.-Y)L[<8_.#./?C*\-KD!=7@,,4)!$UP
MV4A3-G:J( AEB<5,O8JV=@RT.\HAA4@UF-*OFBK&S.5L6W?^;N*GY?A;,?.+
MLA'EI%OB^"<:Q"$1EE08Q5MA(W: !>IE0M[+ZL'SW7B&%$U5H$BUKJ\[([V4
M;(V7J4Q9Q)+&>>,PFH^66*4R(LO4*6>U3K59L!'(D"*C"NK?O[/[6,Y=^385
M@DG&&!)=V:B2M"#>&46RHYC(&VTPHC_PTN;^*RQ7RX8\F7)XUY;9/^D]8'ZJ
M<'"!0Q.,T:90M;?9W0%E2/'1GBRX;S7E(9U_F#7;%3(3HJ16:6*\P]$L:2#!
M Q"JA/(YR.1"[3.CV^ :4F14F2/5U5)S8F$VGW;M.W]>HK@5%NVYR5P&(ES(
MF))R54JG%&&-U=P(";YZ/K41R9!BH<JDJ-#UCW@\S;<GKR:S+ST=2[M\>__'
MT38+4FES?]GIB U@"/QYC&][=OX70GD]?36>^FDLYQ)+U98%HT:AG-<&=!54
M H9%AC/T%_B%EME%*YW6KO9>B.W154B_(D!:'(!_W;;S<J;B;?YPXAMH_\)^
M+I5(4!_CSV7WW^+C9WZAM-.R)7"A\Y(^M/C8\D#G8LKN[=GB]/PHLDAQQ"AB
M4RQ5'5(@'K/,<A(^<!!>Z^IKP[T*-*1HJ2<&;T@2!T*0FE,.&T1:6T\8L8!1
MH,7 4*3LB>20B3>1(BR=E(_!!5;;R]X+:DA1V*-R[Z&*JE,J:QW3YO)=#&D;
M%-48':2(H0=$XBRFT<JF))0UT3!_GR/>KJDAQ6 ]4Z*'OJ]YNG:3Z)<E%=9$
M3P:"\]X2JX$3&7@F(=$RS\*85XH:4?V$^_;H*I13:@"-_PM8_OMZ^LWT:F08
M)$H9Q40J4>1!1!XXBWF5T 85)F)TM:MT[ CQ._#W^[)L0TVDWI18=YYX@^2K
MG.$RCQAQQ46V#AU$%*XL%V/NCN(3EF)0RM&4=>T!MS6X[\"CUV97/XJK61#N
M!OD7@*^FQ]=F&D;.)JFST\29@+Z&:D]LL&67I=2!*Y%<]>1F%WS?07#0O^VJ
MI+Z:LWH-+)1P6FJ$_&?1>6_SBW&[G'+"'.I= Z?C^2DF3)^A76[P'?&DI"_U
MD)1D9<HZ:N*5M(1'$,Y:"*G^+HH'(=UQB:SWJI6'8-T!='HX W>QKHBV5V,D
MS@BCF%Q)[PUQM.RBC,%281V-J8?JE=M VW&#_P_!L#ZT5K_FY)L"[7WI]K<9
M^V&!:7U(K(HDF[(Q.ZA$,%:41&:)AI?'3 R-@$-",U-]1_2N&+<AF?ZQ?&>O
M:NS1?MU9RV"DLS12^;(=CF7L \FQ-[(@PN0(.DH0MG:-ZAW@;4,Q\\/;L3K:
MJSDSG,?=HF27B08,0\]L9"R7GWAL/XA,6 Y1IT!==K4+VERUO@TY[(]E?Q[8
M]=54_P+.&HCC92]/T[K%&P&3/H20"#>E A, FCIE#%&:.>DS];;Z!2'?@+,-
M.=R/18Y:RJEWV''C0M<HIBB\ D4RIYA3>A>)YXA*AR05MRI:73NTV8QDJXE+
M^F.1I().>HQ3;FPJ&3D3:*!EOB'XO+R#-C#KB?8F,2&8X[3_Z.0&J*U8\\//
M=^^CJ7K[!5'T&W4!WT/;->/80;JH&WC]@[4GWT$SGJ7;DEVLP+_\&D_\]!.\
M]QTL+R@:I0B>FS(9IG4YZ20HP8PQ$Y"9A00*O*Y>*N:@$AYPC2]$RW,Q,UR%
M<KLTMZ4FD,8.531Z*4'IVIM['[K&]\@EFH?+\0WE?/M0?]]+T,OYQNOXHLZ)
MZ2#0.J*=E%X%@@%UV> OF9&2B\AKQRC;HQO2DMCW3\]]U=\W/3=M#M',9!8C
M)RDO-NY"(,'J2((/G@<<7%G6WA3PT-V6C[NF]OW3<U_U/X;UE+Z4/Y624*TT
M9IL4B,/Q0R)E!J+4D-2!-O#<:ST?,/WESQ=K4Q]G3R-RI8$_??,W+.XON#HP
M6DJ1T4@QEZ)14R*9*C>$)UK\G<9$2Z:@:I],WPK8H"YCZHE2MV;-JFNLWESJ
M36AW'C<=I:2L1UB$BEANAE>&6(O?"BU]Y"8F7?U"BNW1[1B2_)BTJJ.[_KCU
M>KK8&]H6%PC80'%^+^ S3&9+E%GRI+TM%YA33J1@@5A(DMB ^#W/P?G>;=8]
M&'>,+7Y,GM748U_[O3>:V)RS=25D8:G<V6PIAM6,)2*-$R:GF&BZ,9VW]:;O
MA_JZ0QU%[YDK?6FA/CW^]%T!<GX'.&8X<P(2"8R5Z_30"WLE&-I,*H*TTEIJ
M=J;(M]L<4C7,0].DHC;J4.7Y;((?S98WR[Z'\6F8-^WRM./;?(_A*P*]AT7E
MJG<>_?#(<FUBN8HS95$.HUI!G/".9!LQB]<I9.>V(E--5-_!MIFJ='LTC?9W
MO/CVI(*?IDT#Z$,\@32?P"Q?K,:69;>V^Z.9M>U?TP;\I'STAQ]/RQO*NCZ4
M_[SRXV91KF^6W\Z;[9LKIX11CPTDWUZ6-LK+TD;A_"/VQRROESCJ\)&''8'^
ML7I@[V/:/U9W7"-$K7OBMJRTA=$)%Q:,)<6@E;N7//&.!^*#D\PD%274GMK<
M%EOMHG#7WWZ-$,]\.VY':%C1NJ&A"\$".EWGB5-"$<8< ^NMT[[V@N.N&(>T
M5-8+Q^XK&5=5B;W5'[R!\JK$YPW+4RS.LV(A8''7- OXUSJB35G4ERR2("$3
M06U&=Z^5Y+47::L ']("V1!(V8.Z'YVIQ4=>0<\\,.."(BKGLIZ,0@0M4))R
M[I++'/'K0)AZ#?B@YK,&3=6'ZWM0><!E)-?N&,J%\S=E+"'<\?3^NW[]\K:+
MLFM\[B>K+/_ $?\@9'V,V'X0@M>,XI>)_&TQRC;C&^-Y_?0>%3K83#D1294:
M%@FS]6 M44'D(&C,,NKMYE]V;?K0-_N"XRZ7)7AE+2WG9#FQ609"F<PILVQ2
MZ-O_5+C9M^] _0 TVO?JWUT4^9C5PCGC"H6W1&J!?>(T$ <@B1?6&0X",.5X
M),(-JUKX@#GW0'56W3Y]^V;U2^=5SF9/9NV\@9'(S&J.D5:*P96]XYIX"Y0H
MH-Y34$%57QG>&MP0MIL] LGZ4=X 8N7W$'%<C"?+@TS+$I>W?_/ZIKV#!+;[
M #M<%%JM^RI-_.ZU _-RKR72^6S6^@DFA?.SLD94ZD:4V_SFD"[VEY=*B<ZP
M -H!"<%HI#J+Q$LPA$>M<RJ[NU+U:Q8/*%\_!O]I]]PWS3FB6%X1I3"G-E92
MX@1X(F/BY4(?1ZR-+'BE+6;>!S'V-X -(8(=/*NW<Q/[J+Q:^'&]?]:"(0,:
M79/)1,E2GY#E2(**G+!H9(S9&+"UDZF[L PA@OWN.%=%L8<M#KX^KU(.QLZF
MI=,^%,TTY[/\KH$SCT].+ZY$6R\HLT_LT1.47LJ.U^ZB2O'%1;L7!5>>7C1_
M_0HP+G6R"1CA3)>]*TR2P#@E7(O$E,C 0_TR%??"VO_X= <-#C6,^ "'^5H1
M_F1QT!J7B76!74QB:"4)3<Q(2)9)5O_8]!U@AN2U:W/E]C'I&AJIM>=R7=;V
MZ:9Q.;*)6NK*G:\LE7-NIIP)5Y;H[,J]2#P[%^XS8ENW-B1?VA<3^NGZ0?G"
M=5G62D4>V W>@^(Q/. N'5/)^=UU>Y/TVGB7RZW.OIPW$6ANDO"+BUD5$L_'
M4#L/WNKJK =*^&$^3<WY!CE-=#D+M*CEY%:9.Q7$1L>)ITHYKIBPJK:C^R:@
M(3F[&MS86)FXBC9ZJJQXZUHJ(1@-WE!BRCRKE &E#6C$0TXVJN"%U;5#OV\C
M&I(7[(4B]?11)Q JE6<QM]V\P7SEHR_A61W0L5.2I'1$8A),'(-$4&B).2H%
MGK<[?K)+JT-8P>B#$OUV?]5RT_-R[*%<;?[1?[V"PSP%L"&7)6",T0)$XLOM
M=@%2S-I('U+UZ\7O C.DPVQ]V(TZ6JA&BI<8N,[. 2Y.GVP05J=(G=5 J*1E
MW19C=^M16"ER0'$E6H3:&]7O!36DHVQ]D*2N5K9,JRX^+U\"NK3??_I_4$L#
M!!0    ( '*!9U<1H#*Q[$D   @N P 5    <F-U<RTR,#(S,#DS,%]D968N
M>&UL[;U9<UM)DB;ZWK\B;\[K1&7L2UE7CS&E5(W&E$E=2=G=-B^T6#Q$W (!
M%1:E6+_^>AP )$@"Q $0!P"A+*M2B8MPOG#_3H2[AR___K^^W?1_^ JC<6\X
M^-N/["_TQQ]@$(>I-_C\MQ]___2&V!__UW_\V[_]^_]#R'___.'=#Z^'<7H#
M@\D/KT;@)Y!^^*,WN?YA<@T__-=P](_>5__#^[Z?Y.'HAI#_:/[9J^&7VU'O
M\_7D!TZY6/S:XJ>COUJJ(&@-Q$H)1*JLB-7>$L6-CU9GB,G\S\]_-4K8:+P@
MWG#\-5#X-YLHX9:['%QT*?+F0_N]P3_^6OX(?@P_X/(&X^;+O_UX/9E\^>M/
M/_WQQQ]_^19&_;\,1Y]_XI2*GQ:__>/\U[\]^?T_1//;S#GW4_/3NU\=]U;]
M(GXL^^F_?WWW,5[#C2>]P7CB!_'^ ?CX-+G[A\MHU$^S'^*OCGM_'3?__MTP
M^DFCH(U+^&'M;Y2OR.+72/D689P(]I=OX_3C?_S;#S_,).='<33LPP?(/\S_
M^ON'MT^1]@:3GU+OYJ?Y[_SD^WU$W'S"Y/8+_.W'<>_F2Q\6W[L>05Z+?K'D
M DH5./^C?-I/>V.Z1B"C. U \+LP*!2OB''5I^^/^>ZS2(+LI_U)1<1//[LJ
MWN&-[]44\)./KH"V^2!R S<!1C6A/OC<)9P+D(\1(J#I./2&?XG#FY\::*^&
M@X3+A81_&0_[O51VUX\3_+-LM^-AOD2Z-;O >#/P\NFD;+?4"=H@W.;CE_ C
M47J#7OGV._QR_HR"MXN5P+<)X#^=[48+!/UA?/!+_;(7#N^4U_<!^LUWKW#)
MG[W_<G7W*(0,;_&OXRMF;-1<&R2^X41Z9HF/1A(05D4P)H 33U4_7E I^W%H
ME#]_Q$]%M#]!?S)>?*<1=B/H]2AF<MU]71_@*PRF,+X(X\G(Q\D5YTF+Q/#D
M] :/1 .>!&T=450F;?"8=)Q67M5C# _7=,^6B]%B=?-7;\=W,X^&-U6U.QE6
M%.I,<[B 'W\8CA*,_O8CK:3D-[AN?'T:2/^%%M:KZ7@RO('1+]]B?UJ,LXOQ
M&/"_Z9/_=J6RT"8G7+7'0UT&J4B(PA#.N?*9&4=#[(8'V\ \/%7VT^UJHG2F
MF*=<8OMR:;[/#C[_\NU+V9#O!9&]5<Q")M[%2"0+G#@)@B2/-C9G24;O*C-F
M+9@7OX74$7,'^O\ 8\ /O+X8I-?(WO[P2UGT'.45".IY%(J IXE(&P)Q07G"
MLT\VVH@KE]5WC6< '9X'E13W9*.H)?4.*/%W&.":^XCM(MV@@,MZ)[VOL( G
M(%(38R"> 2,R1DJ"L9QH1R-SVD .JC(I-D Z%UK4E/Q38O#J9\451!=Y D?P
MQ,3#*QM''),&3TQG6')2*L:[/B/.1?G[2?>IND4U=;\=H-\&[X;C\97CED<?
M<%=B$2'QJ(B5SI* 4+)3+$N9NU+X/8SS,0=V%&T7+_?D&D:_#0?#A]#F9+QC
MN &A,PV&6*T0I:,:_X:&JPC"6&>5C[JV']$.V<OG1'T%5-P42@3GZNU@ B,8
M3_" :M ^0+@,_3>87"5EK+*,$L."))*B#X7RR @Y _4TTPAI4T1JZZ<>X3#H
M0&W#0\B\HN78 /TE9XC%6ED@OAR\Z_G0Z_<FMV^&HX^^#Y?YS70R'<&'X:WO
M3WIXQ.4L!0CF"'JYCDAI#/'!9'Q_N!!:9"T4;T6279Y^?F3I7 <='#QKQ7$%
MG(.2WB*;54!@#-"N,IYH&I3C,E*1:SL::\&<%5?JBKX#T_/>+%K$TGJ#*8*\
MOQ7X&?)P!+/?^^2_P?B7;R@/?'YOX$>WS6F,JXLE"C?L]YOUS=Z(*YJLSIYI
MXDVA._6)V!0E.E'6&1&C-[RV!=/A<EZ\V7,JJG[*8EF'Q0AY_E;]C.Y][DVN
M0#CI@@)TWCF*"SR>TE*CTQB4S=2'3*OO:VN@G E[]A/Q4\VKO<\TF"QY=LDS
MX&6+CDJ5!9I G,R1>$LA:Q<\M;[V.;8,X,5K>7=Q/M6M[OYL>@^CG_VX%S]>
M^Q%<41-+EI(GU#%#)+KQQ#F$FYV728+FRIF#GS</(+YX?G2IDJ<,,@=AT.M>
M?UIR(AK 4:)31Y4A2'Q%I"CFGG>.9,6CE=8+"_88'%H&^7VP:&>U/.61W9='
M_P4E91+2Q5<$^!E^FQ9Q7>8&V_AR.BGYA.6ZN6'^E99>H-T3"&72HZ, :-)#
M$'A"IA M=Q!];0YM!?#%\Z<[=3SECNN(.\OT7L9\%82@,1>#*G@@DDM!$+TC
M'&*DU@+E4#L[:DN(Y\J?*BI9$>S;.PWI;OF??.C#%7,B&HW/CU (+8TGUD:&
MFR'X9"3+M/K-P$,$%0FPE*G<N=KW$..J$.X/L[S3O\;^< SI;S].1E.X_R8>
M:O!M\DN_>>#??AS#Y_*779DP'DVNWH^&:1HGEZ./,/K:BW#QK3>^0I \>TZ)
MYP8=;Z<U<=Y;DE@":D6**;7*.L0'+/$ O[KGP+IG5V3!,[GAS[!B!S4.*XJS
M8EA_"<_X8I#FB,:OF]VQ%:BK1PGJ^^OZ*9":^_ZZQ/I[==?1T5.%5Q+P ;7/
MLI-"$&$<FK[(:>(]HW@64<XL\]FF5C&LT]+Z@_*$(RF]O5QKW^"]0QSE:N%!
M4MH"WSRW]=?&)KJB@86DT.EAL6QO.F<2'(W$1 DY.,GBX\3 -?=V[9]Y./NN
MHH:&W8NW8H)Y [.Y=WHU[./WAS._]Q&V9 0+096 JBO!$TY\%I10#5:!DM1Y
MUDKU&Q[TXO5=4Y!K7_5__^F1>- H_4?'M47OT1,9X.(FO>A;5/3M56CT\%F'
MJSIZ9HW=E2"9R+W0+!/N.5+-9$5<3))P&9T,(6F74YM#]11*D+8J@@"0 DUD
M3ES6C$A!#7$@%-$*3U.=.4A7N];@152G[,F1&O4IVZBF]E'T;)K\!XC#KS J
M&2R42<>CCB1Y$8B, &B&64.T<5[GI$N->*LCJ>4#7RP1.I-J!V4(CQQJ)2%&
M9S-1T61TJ-&7M@P9F;EU>';B@IGN:F\\=GAIGW=^#S&>;'B)>96#Y4A%ASN1
MS%&B#14%49R**!2CGK6Z4'^YX:6MU+@IO+2-. \68&@#ZCL*+VVEHU:1AET$
M?##M@[&:.H/@I ,$ES6Q("2)Z&V)(*30IN(;?JKAI?I*WT:N1PPO!<6D,KB]
M&>,M;F\E?2L:2V@P4>BLA*.NE4'W\L)+6VEHQ_#2-N(]='B)!^^\$)%85VH<
MO43/@P=6@F!),R.H$+25ZE](>&EG?=<49">%Y?T277GO1Y/;3R,_&*.SV63S
MWB[_I-GF(N V!XRC]9(\NIB(-.!?4:=*>B.,$U"_1TE;="_8X.M8%1W4@BSC
MF;\?;1!M8P?N2))C&(-=Z^\9FNPA_([WDCDRBN2W5%(B& VETCH3GZ0GSE"E
M/1765B]$/A0=UEB)QV?#-C+OF 5W]V09#TPG\/!4FDAG-1HR@9.48P"9I'")
M=<B"0UL2M73SC*IW$.Q:"[';NZF??;^TR_QX#3#IZ$KJF4=T<1/5=D7=74#%
MY*-SDJ&>*:K=:E^*"34>48SS( /N%[4KD^I?0*VZVB@W&I/?8/)J.BIBO=(0
M=(A:$I,E+E1%2[Q6DN "C99<Z/HF9PM8)W&OL T''N\DM47?0?.\QFUJ,#55
M@W-043&A++K ,J-E+1W%G3,;(!PHEZ5RC/':Z<TK@;QX!NPOW@XLAU6TO*N+
M7_ R!9UU*04R)1=?)O3! ]66,*2ILRYF;FK?0;?!]>(945WX'?B=SV)<XK&A
MT?(H(W',A9+G[8AK K*614I5I+BQ'9(C9[1Q=*&"#CH3O$>M B))'R?#^ \T
MTBY'C2#2?_K^%-[#:%89)CFEN,T)8B(*00:?2PL_06S4 <7 A).UBS[;(7OQ
M/.E  1V4_C]$.:O=N9A.KH>CWK\@73%O\=^$2)#(2&+K"CJ+?[A <[#69EO;
M_'P>T9G18B^!=] /8!6ZM^/Q%)%E*C4MG5; QD2D3IE87F+U3E(1+?.:UBZ;
M6H_F+&FP@Z [:!NP"MER-9_,: B[Z(B%8B=3$] "*IV\A(U4.5 \UFZEN0'2
M69)A5Y%WT ;@U?#F9CAX_ABS "QKQ)0@T=("5)"0F"$>M)8T:^I#[0!G"U@O
MGAFU1=]!<?\2Q">GF;>!"]S.B)(%FN)EXE&*)$5G.&3)$M0^,YZ!<TYLV$O4
M'93I/X$V/\R,=-DE2]&>*:V!60;BT*HEF;L@6$RXM=5NYK &ROEI?P<1=U%>
M_P37\M&5F,PL"X04-1Y=4:$_3,LA9BE$$37ZPO4#$>OQG!\)=A7V"B;4SH2/
M,@>FHR8YE(H,%ABQ60OB-!-26YV3.=M,^'UTO(<8CYT)O\/=OXK>0A"EM0PK
M?_" RQ.<9*5I *NXM[4C4"\NJ6HK"NR>5+6-*@Z3/=,&T9])53OI;W,:S2["
M/PPM(*N2&\H)'FFE:7AY'Y251&J=8J9>"U?;JGQY2565V;"-S ^35!4]]2H)
M1@S/LMS8.N*]!&*\X-9J2.#"]Y%4M95N-B=5;2/8(R55+1?#-];P];"/3Q__
M\L]I;W);+;%JPV.Z+O/?M++N$JQ"2($G:8D*'C>/9!0I#=I+]P?0$GC.U5L_
M=Y%@]9RS%$+D07'"F#'XIE!<8>) J(?,%;,NZ-IQ[)/W3+?1^G:>Z1;"[B"7
MZNE[=(5^6<R11Z)U&9\9A"*!"T? !&UX<RM;?XKNZ@WD!2M]3\%V4HV/B&:1
ML=?3$7+O/8QZPWE7RM_@C^9'Z)\+QSEGCB0A$I$T</3/&2.:HBL58BD]JNUU
MMD-V'I2HJX .$JG6H&QN5NY!<J,L2XHBE\M<AHAP?;:.4":4,B):P6JG/[0"
M=JXDV4/\':107:3_;SJ>-*;8I^%%2HV(??^][Z6W@U?^2V_B^PVM@V]LN)O2
MF&1>X(A[X;@W@7D-Y6QUI67)YYFBFH5>44YCP&40\*563@0@CNE LF44I-#>
MJ]KS%KI>TXMGYDDIO8.$KWDU[LV7$5R7F,-7N&\G_QM,+G/II>09^GN2>CRT
M,T=_,DKBLD-SC087J/76L>K3,UO@>O'DJB[\SD?"2!FSRPJ/:2=BN58&$E0T
M1%L+(N'7R9W_2)A]5+Z[.#O([7K61[,L:N0=^FA1,"*-$,T4(I+0/?.6.QZJ
M3_]I[Q!7\?DROD!<E)H.&E1I%(:N25(>C8H,FMD4,ZO?^?UYGV_O2U9+N<HR
M9:*\*Y,T<YGI;#@1:%<SE235U:?$G<PEZWX6Z,YB/)5+UKLES(A5SI7AH!@N
M3?A?4LC14%Q,HI1(R26Q!ATL;V30,G+N0F<].E<!.I&KU*T4O8XS>PN\@\#'
M(TSSFX$VH#JZ0%T)Z#AWJ!45-^Q*Z@>CA#6@$HV1L-*I6ZJ$-H@7EG#&>4S:
M>"9J&_<'I,*&^]-#,V$;87=24'IG8"T:)FCIM8%(!),.K3SMB#/H?E)I##J?
M0@O584KNL>Y,*RAG_77'#I+MX(YC"1 Z'//^R*OC%W/ 7@0:E0LD\4)Y,+C\
MZ Q^&:*1,=J8:V\$6X,\,ZITH)E.<BTFN&9(O_C1 +&.YZB8I0*L],1(EH@4
M+!(+%@@$Q92#R%SU.Y/52,Z!%!5DW,&UR$6,TYMIDQ"R+E8U!YH5AZ -(\(&
M/"IUR BTD#5&!59SV[+QZ3:QZ[;@SH$?W6BBBT+SOA_\YF]FC6"3S0'/.462
M*=7,U GB6 C$Y8P6%3I8]1/SEI]_!C[FSN+L8#=88)G3N0V:CGS)ATB.XT3N
MKIDU*MY#K!T<^H]1)299%(YH@5N+5&7BJ^2*6)6LE[PT/ZK=9>802M[@'G:F
MXRVD6;N=]>QLNOC#C]+[T?#SR-\LC(VL$X6 *Y( ^(<V%D\.-#,CY38*+QV(
M1PFT:UH8KWW$X4_B?00_K"ZU#OR\3_A[E_EB-/*#S\V9,^O SG3@)7]&2+"(
M+#(2M+5$HR_*% M<Y-K9C"N!G,$)O+^ N\A%N8=3>G/_AI[C_7>6"P$6?D0+
MN!V=U5M"/<YA7D')CPWV VBH@V-_6]A"&!,H>C)@>#D42W<2;3.A9?BCB8:'
M6+O1PTD0:H/A<'P^;:.8VB;&1XC#P;S1U704K_T8+CZ/H(&ZB(XR&SU% 3"&
M9Z6421/+8L+3.,><DHHRM9N4L?E9AS<Z.M75L#M!5S1/RO"(5\/I8 *C+Z64
MZ,Z*9H*K$'(@"GBIA"[I%ZSD_QMGK,\JLM2J"GS#A)Q5SW[!QD@5<59,'RQX
M/L"7QYQ[#'$QLJD%R(HSL5H#._R,K/UU.#R4 BK/S&H/5K" "+4A6@?<#94.
MQ-)("9,A*J%BCKI5*<YIL^29F5I'(LDV<J]M,?R]UP>?/L8>#"*,WP[B_/2R
M1COF."4J@<)5&\3$4 A>9"DC;J/*I%9FPIH'''::4D>Z&%86Y G4\+[RX^LW
M_>$?!YC9O>917=?RMEEA=_6\S(J2XJI)1(^D]*-QQ%I%B4DQ66J8T[1V?*A^
M/2^R>P3X,KV&V?^_':SMXW\E!;Y04/*K)76XX$1+5RQ+8DRX>3*E/-2^B=H"
MWDFDM6_#B<?>:5>JZ"!@^A1J<Z%ZWZI[-@7@*G&(J?1R!Q&:&F44A^89L4:'
M1[&+U-=N5]42VAFR97\5=! +:T?JNV;O5T)G[I461#"/(O$-4BU),B(+&21/
MU9LD; GQ#)E33R5=W)B/AA$@C=^@7$H1:QF3=)F7$L"N:)1::XI;H%.,2 B!
MA.B!9.D<&GQ91%^[:<U&4"^>)77%WL'US:.(4#8A*XB><*-Y*6QFQ+O," ]&
M>V&L#K*SVHQC%^WLH^<]Q'@J13M;-/ 2E&F32[2P3,F3N")B,P/\$G<S!TYY
M63M5^\5U1MR* KMW1MQ&%8=I@=<&T9^=$7?2W^9>>+L(_S"TB-'HJ(PBR99.
M<&@*(:ARL^1XSIXJRG*7@T9?1F?$RFS81N:'Z8QH/3CK4R)<NQ+\2YF$I#U)
M*O# G'66?2?C9K?2S>;.B-L(MONHZN7HLQ_T_N5GG_'/:2^A"^0':5Y,\@'&
MP^DHPOB^V.3M( ]'-\T_>%T*$/KC74*L59Z[9[RU_MKW#+XVT?B'J.Y,7B5I
M!(DDS*QT8X<RSRD*8@3G21F(*JA-,E__\7LW_)@6:E_F#_!E.)H4J^KCS-0=
M7P5@V7.6B.,*2J\:W#++=,PR62($)H3/M?M?K4=SN/VDDBJ?M *I(^@.0J0+
M9)=HB.."!Y_O@"E&M93*$722:1DNH8FE7A&>!5#&@3-=^R19"^9L"+"?F#L)
M?'Z%>=.KB[*%CJ^OG.4:F S$!J8+(DE\8)&$+#7S7JG :A?[/47QXC6^IV K
M1BB?+'#F/P/H'%2RQ);N>C)302RGAD3/F-4,$CR>S]+B:#I(B*FRQBK(YU1"
M3#_[?@F ?KP&F+PKOUVD7OP>ZQEU%L\658K3)93SQC!%P.*IPPS54=:^X5J'
MY=#AHQKJ'78@Y@XV\U6X%@6I+9!U%#1:C^HXP:,ZVFM!B3U$?V!RH $2T-HD
M7@=;>FB)4GJN"$N)NI"\IQY>."DVA) .SHDM)%X[ :_8(N5_I<[MJ^_/+90E
M>^7MX%<_^@?,_90X':'\89' KL&PY(0G0I4^AC1XXB.UQ$BKHQ-,!3"MS(:]
M8!P^PE1+F<.C:*+[B-1RR.Q)9F+M,-3N#]LS]E1IE96R_=8$ON_-80?*NAB!
M&&/1XZ"*$JL\FL.))0L\H^M9>]3!)DP'ZO+/ V[,5&O")"Y:IL0(;N6:4"JU
MQ3>425%_BLEI=OFORI(=>_YOHXZ*4:YFEWTS':3Q!XC0^PKIS7"TNH;J"H]Y
M[XW%92LC2ALX=,R]<D089[-GV4<K6QUL[9YW)CSH2L+5ZQ2?&3N 6S2,;DI+
MID_#]R.XZ4UO+@<+^ ^2B?!TON@W3VI^%T;--E]2CD*_][G9[Z^HXE:+R GH
M<BQ;F8D+49%L:&(F99V!M>+1P2"?$Q5/4\]'&V.")B+NO!R(U2J4?=>A'$-I
M*F:%S"$Y4WW$ZHF.,3G&*;B',BIF(C;OQ8?>Y^L)4GFQ*=^9JDM]U_]S6&XF
MEEX#7$7$C=M_ABOM4 (L6N*M4D2*Z)#M')V-X&B,%LJTP5:[VIY SH0X!]=)
MQ8+@!OL]C,L\WTL7ZW@_ZCW.P76&\A2X(8D)()*C(1@T]82R()61@CX9,+"&
M/5L]]IRXTIV\.Q@DTEC_#:RK9&( FBVA7I2II :(3PE(RBXDGO#$%-6KS^Z>
M?B8$V%.L%:>)-%3$=?7P!Y]?^]OQQ5<8(2=?]8?C<NHUV RSQ@)(DK,LO2^E
M);@?):)\\A"<$?GQ"*$U+_N&!YV)=JO+]*F^S5[Z?H<[RO3+S**Y4MP+T8P:
M%LZ7'B.>N!@,$9"UTS0'GT4KY2Y_ZCEI<F=I/56;W:_YWSS&^ !0<-PKK]#F
MM#01Z9PI+K@A4485<;V*NG9%]JL^_9S4N+?TGJK353.XENS#I5/_\@_T;*^\
M%50D*@AJ3,\HYX/D1'-6=,B"YNVZ+;5\X#DIO0L9KPAD[1?.?#7LX[>&HUDN
M XQNW@Q'K^:UM(/T9CJ9CO#L0"U$WU_TK[SR,6C%T=<TK/2'#J7M%$=[02<O
M#$ *(O)6K-CEZ>=$D<ZEOX(O^T4^+[\4J*5VMC>8-K#?^]L2CWT]A=^_(*][
MWR;7%X-!#\V.L1_=7N;[B"VGD4? '4XJ$&AF<DF<XXS09+WGV0,S[6+B>X X
M)_8<2A<K2+1?^N#O7U!,@TFYK)XCO@J,&9J]09,TZ#+M6Y( )A NA9+9HDT:
M:"MN//WL<U+YGI);H<G] H&+3.1?ON%AUQO#C)(E(#[?K&@23%.;T$B-:+-F
MH4L=?2(Z<!N=8LK:=@;$IB>=DY:K2G6%SO<+ULW0S.FWN*>[HD;%:',F*C-%
M)%>.!,4M'DT\H9/"<;'M_/25'W].VMU??BM4NG.4;18[AIOA5UA[GOR.OLOH
M_NS0@7$:C"D5TH'(&'P9%&*)"YHZPWF0KMU>O=5CSXD"W<E[!37VB\_-0+Z!
M,H9\OO^@D7K1[S>==Q8[TB^E%UUQ;N;&ZFOX"OWAEZ:^?OAP&[L"X2B7:+!F
MP2F1N%41E[0B*25K="G$AVW,P(K0SHEBQ]7;"AKN%S9\/YP@IEXIR/Q<IAD-
M1[<77[Z,AE]]_]=>'\:3X0#&#_;4DN4X%^^GX>OAS5<_\/W>C0]7ROALD@(2
M1'"XU>(Y&JBW) 8:J-->XEO5+JA1#]0Y4>]8NEI!NOV"GO>%EF/ C[V^L[]R
ME$GY: D'EDL '0]KHPVA0H.5@3G*VA7BKGO".=&ABA17Z':_".@#*ZQXRV4P
M6A_*-R_S*QB5J7IO!^F7 7*SS%E$:7QM\J6O!!<"''5$.U]J;*DBMO0'TP)Y
MRD.VQK>[M-@9PCFQXS!Z6)$RM5_<] GLBWC=P\.S?'F'>^DTO=_XKJ3QQB5K
MB9#HM<NH#&YIBI&0<];2!*=,N^CI[AC.FD#=:&(%@_:+I"ZVQ3M3K-_[W,-S
M\--P[A,NG9Z#5&X-BC6V=(3.ESR^,C1XJB,C/I>+) X!3TN49-8.I-4I4]4N
M'Z8:I'/BUW'TM()N^\5<VZ*\"TAHQQ+:7IE01(8O1^:XO4I*0D(OP$%21K:+
MW&W[Y',B3Z=27\&1O1M,/ML5]0/NHH,I$CX./P]Z_X*2DN!8+AV16"ECE+[,
M%2B=")P47"K\3["UNY!NA_!,R'0 ]:Q@TWYQXC6"^ "]FS =C9L#NC1:7?Z]
M4NY1\M+P71F7/LXI.9M91, L$.D2>G_":8+[)<W< N4TMMR#]L5R)D0ZAF96
M,&O_I-!X#6G:A^)6MNG7-VO3()5.('TD#&*9NZDI<0P842;J)+(O!F'M_-%=
M@!ZJK6ZW"::=J^A4&J5LT3*2I03,<TFB-"A0[1QQV5OB!/=1V"!,JLW %]"+
MMWNF[-ZR=QN-':8W:QM$?[;LW4E_FYNT[B+\P]""4P$)64]H %Z&2B=BR\BO
MH+(S08C$=.VN3"^O96]E-FPC\\.T['6*IQ"S)YS',K@BH$V6(CJ0PEB>(6G?
MZ0%S0BU[M]+-YI:]VPBV@]:::S@^ZT,M?*#).I+*  1I+2?6X'(U99J!49P_
M+HCKRJCXTXK812<=%'2O@;;H.]\"W $LB"? 3LJ8V%Z-[>BQAPXZ/D*>@O16
M66TR(P'P)93!X1Z:K4&008)3VF;6I4UQ((+L9EYTS(]M1%^]J=M2A?B:\>"F
MQ**],\389O9!SL0IRHG0"B428DE0;5D#LNE9)Q-ZVT4SP^[$6KNUT<5-4Z0V
MZQ@W'#4-!<:/ 28C=6 ):<XC&M#E_MW;5)(VK'?12I5-NY!LFZ>=C>:KB[;V
M&S^[17_7BV7V;'-7M529] 1HLB+G;(E-"$_ZI(B/RI.<M4M4"!-2NZO!;9YZ
M-ESH3-2UNWS/23OK3/@LRIRLYD8 @>(12<T$"911(FSDS#BEO&J7#]?ZD6?#
MAFZ$7+'A3S-_W \^SZ;)>SR;A..*4"A]JJ1WQ-D<B.,Q.<&S ]KJPA<_=<D8
MQ*_N#<$'#SQ_9W)W^7:AY#G7VL#8QD%LH^[Z+_9F%W /X3]6WQZ2JWB8/X9C
MP!J1+",I)(038R06K0G"$KB8! COY$M0X!H7K;[^MA%89;W]ZK_U;J8W<R!2
MQ)@D*")SB3?&((@'P0@UCAHC$VXEK7K.;M#<@X<>[E3=2^S#&C+K9D+\\ ;N
M9]4NMWY'+#Q&/*ZYRZX8]YP$62;8IY"=UK:#%L+/P#G_8[6V3BJVO-L ;3%Q
ML 6XCF*TSP([3HRVFAK;T6,/'70R5NLYD)[KF#58DE))Q=)XX'D7'<'MU&O.
M+'>N=EOV(Q!D0XSV./S81O2=Q.YG%547@[14X/#+MR\ELC _$KE.FD8;</%-
M6T^><.\,* LNF>0L4:"USYT6L [OOE=4Y),P?ETM=#]=8QY[\H]B3]7GN^[T
MG#UG:NR_MAKS6S=%]\;O[E(LR]"5G!PCF0%2SP1) GY- @N69=#9RG8=WML_
MLT;EVZR'7<XV4 >2J%1:$GKPQ*G 2>16,R:SDW*K6K8#=_[K4E>KBM2V%UKM
M.Y[?2IIWG@Y2,:QQR?CUJQ'@JU&^7FHK-+ZRUFH5HR#!-\,/?2B^%&Z)/BD(
M'+2R[28ZMG[D&>J]&W'7OOR9@W@S',UXNFC\@%YY!BJ4)];1,A3*6N(\X+HS
MHT9IQ9QNU^!SW1/.4.55A%G]*N?N]%MT^D 9K*U":_K/+&1U/W %O6_%2K<X
MB*5E7,254(A$!V,C&)\S:U=F6@',&?+FT"JJ/1-BUL?H\W*%]4/032B'ENI&
MCI!HA$2*\4M\XD"2HR)FKA2S[9HGM'K<&=*DOIAK#W/X,+SU_=*A 7$5,*6O
M:<F[YHGQTN36E\BLI\1F/.,"3\IQGZ1N.;-AU:>?H9KW%F('@QCF]:6E,G!5
M'>HOWV)_6CH<7XS'@/]-G_RWJUQF=-%H2,+=!W<D:7#M/",;F1/X'\78HU21
M"N&'K6&>%X$.I:_:HR >U)_>]PM:&5>YTH[R8%/)C,M-XJ4E%D(@P@3CLE,@
M3,L10EL\];QXTJW0*PZ.:!5INZ=S_.>T-RK)=N]'PXC,+A7+5TX[ !L\B0H0
M>HB<.$B)).&TIEG'Z%M=A->*@SX/][R(=FC]51Q^L8#>=$U<=%K 8QD=^3AK
MU'X5-#KH)>N 1T=+BSI=#F1+,KXJ3KD0??6I>.O1G"=Q*DF_XA2-!\C* 3IY
M ,I*EP,8DE7QPZ**Q&O&2A>7)+D*R<K:ERXK@9PQ&_:2>?TQ&G.7?4V_G]Z_
M&D$\;0GE7:"2.Z2KB"5K1:,Q3]'< A8$,PPL%>TRJ7<$<%X$.9@JJH_5>!K\
MV1:^= X8$YEDK33*RP$R'P1)7%.TTR1HTZZI[=Y0SI!3AU5/]7D;=W 6=KP'
MG[.A' ]-*XF4:,P[_)I8ZZ0$)A77MA59'G_R&>I^+^%5'[BQ<<6SC#D5C>$2
MS\$,,A&I5":66460@0(/0V:#:G=YU^YY7?<K.IBR.Q#OL9L4E2S95\-I:?3^
MI:14_N9O9MG2-#FI) !1AF8\\"PG7@9!C&3<<#SS#&]5V[LAP7C5LP^=?MJ9
M;H<595R["@"^/*XQ?0QQGOS4!F3-8H^VP Y?"K*_#H>'4L#1V"(M P!:^JAX
M75+9R@3Z)$AT$=!6]CQG^_)9\DR]R9%(LHW<:R>(?/*]Z^'[:S^Z\1&FDV(
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M"YQK6YD;[=$=WO*HI=/A013207)%@^N^5OX!M*#0&C*>DL""+!V&(_%4 E'
M,HV<154]Q>(9.&=#CEHB7[N1=#>Z=\D6?S_JQ3*"]K[/[=,?3X:XU-7-;VN.
M\:V/JO9(WX[E=N#QOI'QS'FI?'/4X);E!;%"1^)<<91!19W;->'K?KQOZU;,
MZ"NPV>P?FTK[LN+[IZ;=KK;"\BAM.^_ZE)I<=ZG7K7M=;R'@#HZYC_$:TK0/
MQ6M<&5N\CS<L^LC<+>7-<-1LV>.9I\F8=9H;P(VY]&,V/.#?M")!A6QHH-:;
MVOG)]="?VES?72AW9)T>NR?,8OE[+'HIG5PKKJFBBD1!R\J+^<E4)%Q2[1BJ
M1_A6HX.W8',5X,<*0AV+=$]&R1Q:^1VXK?M(\#[SO<TB.@J%55G <:)F1R!0
M/0KOJ?V3I3)+RBE3KAQ*/H\,0N-I"!:_#$(Z(?$PK-T+[H0IO"'&=RX,WD;I
MM3,'EQ,:/_G19YBP19*9Y49$J8C(X(@$[DC(#@\GJVT(RJ)DVJ6;KGW$X>,Y
M1]#7L+JP:V<E/T7%%^V-C-59,(>H&$-4"9=,E2<,=' JE-2)=FEZ:Q_Q)P5V
M$G;W@;_?2L"SF3/S\=J/X"Z.=3F=C"=^4(84OA].4%P]] )O7_?ZTTGO*WR$
M.!TUR3BS48:0<C/J\.;+=#*/=#6_"FG^^5_FG[]',/!(2/<,$)Z"?"L-XKU
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M.-KH.:%IS6(D/AL@.@2*XN4RAMJ;: M8QXJ*'8DOZUA;26]=;JBK "[N=5I
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M/S'&G_0G_4E_TI_T)_V_31S/.#CYG_'RLS^G8>?DY^;CY^;^A_?0: 2P!PP
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M!&)17\M:;M-R*AT0OK4?QB:BXUI\?/C3M5^>_>\YYO?O\NROCOWA%Q3 Q<1
M#Q[F/4 $N) (84B[]HL/Y8-3^"8\V0ZU.MZQKO._XQG6T8'2,VTW^'^"@U\U
M'"9V34!E Q--%SUZ'J8L"D\]/7#2X&=;:$=^+MF;'VRK;K#9OIC>%W(..>8\
MY/%BDS@8_V*<-0/W;R<+3+[3UD;A^YSAMLD[*NGK)Q=1FBFT\(BY1W#C)8W8
M\6VQ":XA!OEW1@^7;ZJ2J@/4ALW;^W)ZVY:EDG/F+M5+[E>$:VHHX!XK5Q%^
M&QEK3):.J[]N_<A"C>O+):&"U;!R/JQHT6UXRI>&'(06Q.A@KP1<.*EC'I?
M^6%OAR3(J]_VJSQISW*5<!(D>M7*&04$WA^?,P6#W.8"#L60*$ =LELY=&O>
MG >:X&_NLD8:4PZQQ>;QCQJJV1TP=U7O0@$'G\QK=^=/;:; WYY$LZ1XHP!>
M,WH^*,\Z%8SEJ*!IJ[G26=(8Y)K=L)S8]&#*E5B]0K.BLGX<5VFZPUZ#HS"D
MANY&M_![=9E\3^5Z77V5RH.F@#WN/B^:* _'ZFN/)4B[%2MB._&;L,(<Y+.;
MQH=@=TZ1U?I?-T;5Y ,0DL9+0WC3EF36A[@+JQ0&4;XMRB?<1;+9R?&?:A1!
M!($$BB" 0$T]Q-JD_""PS,&2%L3%PRE-7J+ZYKV?"-FQ$/52UI[_ CZVSE:L
M.MGL>!G787TH*QVY"?19G=QR(( ;\9D%C-^) E8$!.BWX51M(#=D\*'HGJ<R
M3\"2U36O:ZM6T#7:IZTO-M+*Z %#'WE2BGO0[UXN2W-?BUW%-1-E#CJS;GX>
M%GRV==C7*_*BXP6YA+Q"%T'BM^O%0Z:L^;V%S427:2D5E8L)3K/A70CFVTZ)
MEG578@L]J[I>%<6M=!2E3#)'DG80K$>UVD.A9VQ>N=1X<*5C#0C7E&=!XL;J
M]*"M<S&DQEN(;T&5VZ8!>1TTOZ<?O#FJCK%$'5)U8<3_4HLURJG 0JO>^QT1
M[9E<:!+ES'T\49*N@Q1+'NK0A/"U,K?TG/>L13!FCR=)+2S=^/6 LV]YE/_'
M^2P99]G3IL7OEMINR)Q<SNM*_6*YI'0I-QAH?$2[A6Z58 U[&N2[?EK$:T !
MM[V3G7*GQ *0,]77'K#/Q8<9W%+B7T\ZZ7"ZYRE>>; >),B9X>HB5CM:2;Y]
M:[4:,K+\A*$7!1 $N&V W^/ABZI:>E.'HX#NS_MP)!$*X!QE*!&"-#)WN7S=
M'IG;@&A87%"PL'0F<M674K;M;D*J[2:X/WMSSXIG:U@2I^ U^(-JWT2ZFUYG
M=H'R(-HB;D^GF#LA:\-@[HQEW=_:OTFXT.8:"Z=!<H'T$ 8TOPN(Y6&HB[_V
M L:5^*T&+[W1=1@ANV1S=VY6AC>26/P05]V#=J1DHJ=J*K4NZ5Y2]#-108^U
M6GD"U_U.?LGV67I9?QFW4>WP4[6C\+@]A5BCMU\4<D1T*Z7UYMY<G%-U@>RU
MB"/P*I<'#-MDLZ^2-J,*OB"NYDR<#ZO-NN9@0LQ/V$)C91:O/%1'N=:K91^=
M3-&9\YS6>'YD/PIO$#K@5/9@1J" %UIUGDW*/S9*, ^'VBD]U$I_C*^+C];S
M'.ME1G736\7=NP>A81RB]6,>J=#_H#@/S] ?YK;$R);-8/S\O>;X^C!>R9G$
M<R:/JRTO8130.K_&O)T3MPP^$F!BCC^@#ET]K/)_4@@U@.SV[U)@9!_CYC=H
M[X4Y=/)M6.9D0\2Q&=(_WB!0?''C7U\YLE,Z=CH#M&I1E$8*W2V?3VA6R(Y1
MP$T+AVTP9N-LB0P+(AJJZ[8S8N5&P.5/'B1WDU-G/@A)H^'*MM@4N#)R@I-G
M5<F<EWZ7?(A#Y>&!E !@[]#JTS2>5R#=<5*]Q#+BW>2[4Z&.F89XG7+6*=Z6
M\NA@MS/ Y:F$I>'35M%'/O+/,2DP(4*W"GL:V6?J>=VS/RT*U.WC:PZLRN3A
M^+Q?..JCFI,4;M)1PAPUR^?1:BC.2NLHT'R5/>YZ_;#G(?1:5&HB9'ZD'KPX
M5U0,KU/]I&!#+HV78>XXY)+]*O]TWR8*68@9YH1NMW!F=4,OM6G\Z183 ^N;
MNJ"!RA2^C!6;\#;<*Y#G>A8\IYU7CW 4UM-(AT,^3:HCGC5(:UJ#C4%RHWQ0
MZC+3[IQY3T!7!YU&CE7@62Y809Y\),.9HPC)PNE@M4[B>W<R1/CH*-,6HKI>
MGW3(&Q_:]SC.FB- 63/F9!%A&#5EIO<Y]VA8.Y?YZ#SL\:3RW7GJO-\7*7FA
M .4?F[S%5XF!"YS5@DOU$?O+WEDY9J466I&^^RP+M7:GFE3;]WHS'R1//Q>Z
M1;)BM!Y2P<W".K0L7.Y&%<<W^F98%M)O W9>>)3\E<?6SC<IJM-.>K,I=:%8
MZ!196;;EJ!Y%WT4^\>/K>)!?B=R7)N..'S6]$BZ&JP+"UK/.88?[ZM;"G%>Q
M>[UKVVUD 4U!^T;WVO+[IUU,X56&.>"&:+[3')-9_ZPAA?0:(9<EH;'J$/H?
MGBR+4[#+ON?OJXWI[V:^\'G1@T6/E;.:8LE_MBS[F0JW?*+(,3C'S::QP\[D
M^)TKM;GA(*0NAY(S99:1114%%#>?"/&$'.^R+7GUSW%6_N!& ;BS&]E7,IH#
M7%_K!SEX@9N0KK>VMOA%[G<H62G?_8K[_S_6DSPDUQY=A.=EFI6Z9B$$<G0F
MOSRI>?KUGN]'/Y>[?% L+?Y)Y^'&KF)%/0RV,.[->M)E*QY9ITHSQR;:G82&
MIKVIZM=IX7T3M#,G@E&Z>)&';X]!PY[\M?.!^Q"9[X'DX%VW[)ZH4T#?&D^4
M)D6;SF%7EGEW%1Z\48Q>SCC@+]NCZBF6U 3K_AT3_,2!"$Z7$J$/-X\TZ*"T
MFQ]O0I),OU.$>8SIBBR#BN8#G!KLUR52H$*LC@$/CZL%^U<"AGIY'->+A;:L
MBVRW#2%FQ?1M<T*C;'N/Y>_!3=9!OE:R4+W; 1UU$C?EC!2 Y^M4LP4X2&+N
M[F]D$%>)$U>SH=4[,KLX=:2=^VQ4]4Z=KH.N.>,M(^MYPSHV[1JLW. @%V(H
M:[E#CE<*K><GJ #C%R*>AQRW:"C\X8Z9<$D/IUP$VTAQ)<Z7XF+J@?FG1\3.
M[<4WI5<.V&59$+X["5O.CHH@&FR&PBMW<Y9ZWCQYS/C5D!%U24J5]W1D2IYY
M95DNAF(AYXW4I*Y^?<VG<X\CE[ '\LZGM4'Q$COJ;A1AZR2D&\^%W-7EV4(K
MZ]C"/E46)X+S9.PR7_9D@=A5I$GO!?,MOE@QI73=5[6RNK*RM[GRW/&0)5QW
MU^^X$EYOA7;F%6Q.D#F-1]*$K+57G<ZU!P +]E*T']G]-2::R"M9V*2JFT81
M^&Y6E-.1Y8)Q&A$O:?EFR_TAF!1A28=BZLXG"&?2[0KUU.VF^_M/$<I.7UU=
MVI0MU7F>W=[SJ=5XY8?1RGC]>QM>TB59HB8\GNM2B$J \N;%ON;8: 6_3D9W
MM*#M= \6A?]TTH/FK)$%%Q5UZH5]*G3<E<Z?WX!FQ["&%TX"(U!IFH\$(NV%
MP)#B=$T+=[?%=L'&//6)ADCU_GK9&.DZCXGI/0F>TJEJYUO+0C>HS5D7T;.Q
M9%COP:(\]78M:")XJ?P'C.V^-%$6<]D#RMC#:VW 8H3K<P4!]4(X;T>L-]?!
M#'^E'Y=H?&;I][Z7R_GK30JB)X\"\FN/$*(;.P-0AG0?;(9BMJ7Q(G"Z)V]3
MXXAU9F5M^-+MIZ;734!8)UR)I2/?H8IZA 9+#3:@0_J \:'.GB7'L967]:78
M$>.75>N/I6G"NR![QU$RB_I4V[6<\-QILX3(#XU#N3VT934/6=*OAUT3I^I:
MQ4P;4(: 1=!9YY7+=-]ATSG5)LAM%05T7'%,MY!9UYD;"(T-YCT,G)97:_M"
ML.C[7! SX@5?]W*"7]=2QTG*TY%ZH0+XJVV9NB81OI3E]Q2+<2OG75B0FW':
M^%E#K]+K![N65O?R[!X/QBWB;,\2"924"ZU6M$I_1@&NS?G:).LERRG,XKKP
M2">K);<3:AQ7>R_OH\&'+',][<RW:.YRB/:T;';E"/X0L#2L3_\^?Q/>.M'9
M2,T?'L9F\]3:( 5J> RBH;R]QT>!3"[H09AGNQ:TUCX[O%FVM#T$ERIF:X5.
M:>J451MM5SS$S,EF__%F+2BC'%G\./_'63X3N63,3II'S!2G1#;HY)V]"']"
MHIKS?1?UGQFU-:3$>Y<JT7[CU;?65:D=6\MU2Q$25S^V:]3WP:UM*" X2=F*
M3+"5UYS8EA0J9^>?6@>-@97NI@M'I=?++7?RCU(35O3%GUQN;Y9P,622O;X?
MH\\W&BTER$"Q$M7A>*'><<EX(F2]KSNRQU700)!;4VXRUZ^QJY#IVV/-1Z'L
M;K,.%[AM"?=F6D\?U@.Y'#8I02HTN%DDF\]B#W2?7SZ-=/JPJG1[<#>)ZCVN
M/8=#A_5VZ@/6'80L:\#B_IV^PCEM;9S$&&(9O#$:GKMW99*>;0X)W0'<;Q"V
M;E,_4)8=K@A^\V-_;0SFS&R3V9M-JNK;9DUGB[%A-Z27%$IU__!R&PI;\RTR
M.S9+&,B_+5L1':P*B5#U(=T2$<Y)<!YO;8Q#0Y,^[R>;D#:O)^5+^,1SFV1D
MG0\KJB#5!167TN15?GBVLQYOC- [G5:/!I/+Q;& K@_&;GMT3PUC)6;VB;R5
MNKYO3R09<F7D>XO'AKLE)__"+W\PE>42]77][29B(N32D',P3\2I@_P:?6\_
MA:&U"_CN.F$7U)/E4/- _L,#E:I+N1(Z6XW-PR_+*"#2=47MN=4DL&!KZZWO
M?I;/J"V_C4:\ZD=DSB[(6G"TH+?-#7AUVT5D4+W,8AVS1]^E[A-R\EEA\Q@I
M)E\Y<AKJYM/]A#R[@_V.A&+_I0%#M0H?R]JE#@I^S_O%M*I1M_N(II-H]MS=
MD]0KAV6WIF$(I[=:VKWS@5T?ME-Q8/9SU&,9/W9AV=4C"^6-(SFU1Q\<7UNK
MXV)1Z\T>=R2*O(<&H  ?IU#M(@&Y86[R=<GJZNJH&1H)NJ=AFKZ#4LLY>N[X
MQNE!1>@4-+A04;9.1?9IR:KS:_:4!=0K(BI[2B+/X7G48X^/]9YI[% I3 @I
M/;2T IVN7,]:S^;H1BJ$.'KWY<96HZ5*LFI4CZHQ$7P]SY]WLJ? 2XS2@SVF
MSY$T%=,794M$(OB>BO@!"$+S)U^"3QHT]U@AN_>\MS@?E;[;:UEP).76UX1K
M%YHCZ<96RPXJ(S_L5I(F6&H'[^/*FFE$B[/"9B=.*$Y+7-(CMX]0 (T6,U@7
MW-]\(!\TW:9'4 E9#8&2=AI]8>%UL]BQ%]NC0_*M0ZLWTA-=7.ZKB8((E$C0
M&SV,+TO:?##\VUOCSL%K.CJ:L@32'WDY'P)&!WQ"VSV[WM3P!"'BQ1W\[+>Z
MY JQEJN7+_6_B_/7B'BLG8N*L%I"-W*(>_?JF_#A=O,R[DBFKB_PDA;^[(9#
M%_E14!Z_R*E151SQ(Y4;.%U,5R,NU(W\>+ !;;CADE[B@I=XBUJM[/MQDH^2
MGM8$7!^Z'JL0;<FYO6%/_5IBEYX-U;Z80P&Y,XDN@LZ0YA3:"/D@"5D!3!"'
M5]/9(7*=]1:2+=$7P9<Y@A XQ&E6LDB0?W_2QWR),_U)J&&G/#^>LZN_L/F3
MCP!5\H5ZV;"JRSF2_V.T?M""FWY(/>WRK<I]?'BU)%%M575.RXINLU0PW>!.
M3 \FB3.EZ(:7!1L^W+33!4Q$=T@?PK7M(<7ZE(QB>C"B=/7%+8G=]HN4%-@V
MEU+U-CQ2O^] 4%GZ0#_L9#^(ZN&!Y\7K^R\7&I+[U1F1'U<A843G$AB"OFK&
M!Y*A7 (EN/!/;54*NEMJ9$;.Z@F.$*83)3QR 7GE^=).![T.D$##E0A.R:B:
M-EAK&A%)57U '>+$+$)L>;%;>,]2:^R3MO;FP:M,FN:MJ6D$\_QX$=R_)>'J
MK#F<MZVJBARF<5W8N"F99+HB"=%1A:S<&E6I2*C.6<R%E#>5H)<CKAKDH8?7
MDQ'2N'=1S1_:^%JP,0JX%%5F9]MC8OQ"&#*?9;YY]3''G-8_XG.% M8'>$:K
M_EU!<2N[C*T+HIC\U\<E4X@79 PI#"T4;PSJ[-EG8$M5@I(+\P3FM4/O8:EX
MHGB5=NE3H=*&"0:D]@3%B#(*BI3SS?$&K1"B1'>D#TPP>[MMCO/@K...>+LP
MV<@NMX#76T+-EQ,XU%/3.$DK?B^84S"ZSPJU]0.\Z48]<9981-1"F*U>>2GH
M:U4G9/-]N$Y=*_?#A<(TAW"/0*DJ%EE=X]0$JXS$/Z0*..3M)"+CTBKV-[6A
M2K4/V[S3[[%"\Z;;'HZ)F<;7LRG9.4#E=!@8:?=5?G6+?U0V1P8[Q5CL1<]I
MVYM4 [U%#6+A.Q ;04NK)8^<FMC3$3:F6U-=,20MI#AAZVN":RF[^I:S5_.Y
ML<'3E:$7-R-M%E$ _I0Y3^I6T4.-EJXYV@)J>WLPV8_T$*NJO19F9IKT$$9<
MAO00@)FSO<IAB^K!6.'N@_Z:FF\)#)]HK$W$@)X%>X_Q9(*$VM*E<RVS(_F;
MDZ[;T@?V<"5T? XFS)DJ-KRT.7W_>CI)@&&2!&:"<S'N5(+.<0^Z%O4Q-1O1
M0:)(=H_MP:\@P?#&H0XKHNU)P[>01M.!@0GYEIF46!C"47"[/>7^6*5\&)2J
M\D[*%=-<SV)-TBM_@T>*X9E[(JZ.E-N^\N^AR,^033M7>9FQ,_EX[N!]4D):
M^@P)2CF[#8&4RA-*0F;Y[<%57A>'Z'%!:NZ)UIYZMAP9PHK.80,)V3ZJ!5':
M:"DE44IYK 8WX_VV>=)M+9.X'/%%2Q:\?3F?Z<8"RJ,2*"U45$V%#C&UD@03
MPN ^N4$@I.W57B'-&L1^<-IY+', BDW,W5B73AD6S X=E"82'^W&_G063.<_
MZ  KH:^$BQ3C7^L1,%=H6Q*059C1EMA_<)5.0=_;]=CNHQ2N![76V05CU4Q2
M+0IHJ6&A[8-<H #.;H3+@JYA>W4M?;"RF-_1%H[!G=-@H>X7[JDQ8V4MA@C=
M(#V0,5L;G[R?TSFLCI*VM<0VGR5N]^G+%\_?/(Y**KZ-_1R&8)ZQ:/R: ]VJ
M]3SE?X\C5-E*$,N[T3S:D!Q8K2[L?#B['U;L369.A'SX#5)TLO$DY#E]=8VF
MWL&'25K63H-J,SZA'I(2T=16_I6F^]Q%6@(4D[,;+.:XC19W1CXK5I-VKU!)
M=>A#A+%=963&WX[>8V,5C)N_4]F^F![F'^7K(R^<.9$V]FI$[LH&7G!;E]LZ
M==VA9^% KS&U?+21U!+78D>.I7[C' 5(X9]56UW6P[(.(_U@5^H+$T$GS#CX
MO$KEE@Z"5(Z6Y>_>%1T38=M*;5B.;>3T[X.YD(L=1[OK\!3FI?G A'17=&C5
M*CM8S0FVXB; VCG6C2>#Z@!R+JR25#DE[TP^*<*-BW-\3A(%6)X,V*" RNBC
MO;E>W;S[UYG')04^+#\7>;W,O>NHTC5;6=^$96_T/;9I/%80!72FD(S!;(+U
M[H\Y7LKS]\G%)&SI<Q/WD?MN2-'GO+'\P9 >D.GF!;[78#QP9?;W.TW"-233
M 6CB@_>SC83DN3C"O8 ;GT".(]\([URV8HC9NQEO,(\P9!1U>9'MV0GS'-C+
M'/2I_$#09DYW<'>VQIYN16$9/(J6?D[:O"5OL5YOM]  UH!++@X0RY4>5^(\
MM#G]X+DQ83+YJKI? ]//KH5[ZT19;MX=;$MOTW4H&%//NVR#!;]4&ZU_F#VU
M%:LU=5_Z--C/#3_:K>_:BZ>SG!^]+$H"ZN\M70FT(AG]%2!</265.)5?'C8R
M/R5^0<3B4Q2SXL<99@?)/7W%9)75*+8-3ETT[/2D/[C4Y9^%ITH)$PVSGIRS
M%#_]I'#Y:H V3W>+PRYL/26^>5#60-.3X?#.MXY,F<4[CQ9'#.NT$PY[N=Q0
M0(K%8CG<>7.NT3\]53M(AD1K+9(6(=(X7-'MW^NX7N7WS#E06&^,E#ZR?0P_
MD)_UZ^)^D+OUET+MJY0C?-[^4/?&F>Y^/B5),8$)371N\40!"R@@WE&F%)WU
M?9@BOENQK ?!R"V-Y[G&OTF2K>"6*0$]RT5ZZ9_C.,S,IV:.FP+G\0HKP-@:
MO!\0(D:UHZP[1U)1O5LNT3FVW8/L$:YY.PCN M#A( IHY] RE$F4N_NX*SZI
MJ:=S9F_'K9.Y(3VOKB_Q MJ>96RS[9'"S-NZZZ(6UV6GTUP5FJ];-)C,W!OV
M+29JTHCQL2@N%FU3I?*A2% C@VMUJY9W##A-LSW!,Z_=1?'\4XS2UW.O-(Q1
M4[J4F\RSN5G4SN-'"&SKHS480IX.'K!XQT%C/#N6^M8FM%\>T-;N\RCYIC,M
M_ SW?2,=<$*"*!#0@>LN"131MR4$K#QS#5*"I#W3F]+1^7S\HX[#]XDD$TG8
M>NFVWA2(G!FL/YXN.+\8Y[?/)?OJ3&VT@E)$W$VYQP\*-8T%B8D*S-0Q;O![
MQQBV-Y*.P?##A$G'=W8%!_@[GV@'UX^2WYZ/_)R4DI'&O4&@O)5JX&CY?0G*
M&G[(W,KI&BA++%9>&ZK4$"TU8AG?5BP]37/>W(DOYM E5SF-8#T(F/ 7I'CJ
M1"Q17Y-<;'K+/K<?@.)[$WCS%?>&*)ZI-NK;SI4<8O_<ARXC&3>T(C\@J>8V
M$UB:H#:/74,D&Y1II#*/VO%\SHI;0V1US"?7$&P+L^1B9=]2*(EZ)Y1DC*1-
MI-1=K=)X^X6.?QSKK/LB& LW+DS#'HV^0\2-%J]%C[KESKW]5HKE9S?JU.$N
M1+"^/W=EW7@H.5M92T6,U49-T'*  D1CH>//*Z_P%:+7!*2-Q;XQ<Y2>^UL-
MJMA%=5HJ;.B)'&*UI^+!_?6'B]X5%0:K1>"\MZ%QZ/.<>BN]\7VIP2_$94QX
M_J!UTV;[^Z)[DX^GKEM17-G!8&JVA;[E7"WRB^>;R+[]>)D'GT8_<L*VU>JU
M#R"J\N3ZECS>5!6'H.(TGWB3VF?<]35 ]9R.GX3=IXDJ3KTQD&P%2&]OG?I@
MOXU8F/"@H,/)U-C2RW;-G*:<U5#9!W@<OW+8@T7=?XX@PVK_XFF, FZS?E^L
M$U([8H.?A&BO:!2!9Q1FO88F2KCW")0O==JG9U<?5;BM?//=6]8H)N/FZ,QY
MJ$WAX[$P6J$H?N/GRL'UN^!-E*\)88]S_:)BFD<SD8S@@%N:9[EJS2/O-^%K
M@BV[!!K/H_GB<1$YMG3@ '== A;R-S!I"G*XC:H(Q?+A+?0V(5@#(NAOMT8_
MW[-L[>+]O,/^(K*-Q49[0M!N7:RJU")%>U)',%]-4@(7 XC&Z.2CW)YBR%O5
M<M,_''6Y$L%L%91<G ^AHC]0#0SR2-/LHDJE,V2?E5R3KWP5>'GY K-$3)J$
MTM*E"WEO@MM*N5\>O3)FGDP^;NCGU3>JK?H(8#BS!0$KOI%]346**K#Y41D9
M-RKF(@3;X>.S@'I>._=22_?BS\5Q:NK$UV\OFW2+HM?(\T')B0@7;S+XDS/I
M"598N$Q;K;<?K@FSI1F]6Q:P_#C53<=N,S6;[P3*F&,R#\LMRHH4.G2D$O1O
MY^S+T)B"A[ZL]7\#*7ZM>)5\&#[UCHCR(B73KJ6(.F".:%20=B'^Y$KWQTS]
M$*<DN;5&M>$JUL$0A1&2>W)8VBP0AAV>HS"M0L2W_D/AN#.UX],&7X>2\!OZ
M]7.-E0.^-)RY=^!Y_<&0C+6!J_D^ZD70,RZS=+\76W:P3 P0[T#DY?;Y\%K7
M%0RQ@3&J[#F) AJ;DJE^/>)#^9]>SM7MLU"[OBV92'TV<9R&I2A[;(B\0#JZ
ME:$ +S _X$0PSR.R7[+^GUX>G_I?X^_OY?3_O>[^6\N#_^+.W^(1Y=<?^+]%
MYF7\<N@'9F[V^5^4"/[%8X _Q.:7EC\K_.=72$M1K$@_DM<7?9U@HM[_DEK/
M/+_Y:BGMK$/IQ;/B.7\44")'NF>VZDL[_IDBPAPPNO1641I^\6" [7/C>I:B
MJ2F?84+L9CD[E=_7?"E1$($J@ [C_RIO@B=$+CL3Y>*N'%! O7F%#WHS]^9?
MOA3YC=<O\Y#[,"ZHP]4H"G"Y2'C!$\*0C0$B4/@7+ >N3=U# <JR.2*S\F?@
MO$Q,LW^F^.]8F"^!LV5YI"0#2Z'OQ[B5=OF[ GQQ9;H;(0SI:08JZS6LK[ZV
MH@#^,@&K@ \G^82*+] /:?C]]1N,_QR^<3VO.T^UFD5<3OQ8I?0)@B'[S44(
MTTUBD<.#^:"CW'SM5#C<INU<135]$MWMRK^]1/Z'C#&" HK!9^$\R6P7ZRC
M%6+^<S":?VZD"_*V>* 2<7:Y^GPR'F;]T<^4I!0G?%7!BX\@X<@OIFO5R?EB
M$*WBMF.FW+?2NRV4%OBDYF?\)7XP2YQ;]=.)H:81=#/$#O>:>VCP.[\30Q"*
MZZXN&D%MX:=%]^DK/4C9WM[AK["H&VMA>B8I/D 'F[B81P(")\@J%.#G&-2%
MI-3.I8D^Z3PCCM:4T.,!>M_?5++K>LJW.2#KLFR%W6Q!;5G/C@),^S^^QGTG
M'=6IJH(12^>N?C,5CYM%3)?"4HWAA[P'V"57XA/C)5M2QALL6KOK>"H49!%M
MS8U/*VIK1ZTS0BXN^I1#MF9DF/+GTR64^7HF)UOZ\"HJJYK&)ZY$S\':TT>2
M&1MZC".(EY"N'!F:E,E(_CE7+4;:(3%5G^?"E64ZZOY<J7?;BO0MW'?BJL:/
MLKL=+PL.'7NGO^DS7?/] 7#.U6D5?] 50P^9P;\V%=._UX0,CE@F!MW&91B1
MZH*KX'XZQWXC W+C#3*M'Q:F,4]HS.Z/<FV=A8K2VA%\#6UMG*]C\''_I L.
M@\WJBZ5*DBE^,QJU62IC=L ID_!$G*M3X#IV+6O56DG3,2>K$G;INW[2/MBK
MRX!N!^?,3EM4BQBKETN&+SG\B#'AT]>+S^-J &L=*L_,PCUVU-Q5E"J>S>B]
M.&H85O;KS>\FY&SFH_=OSCNUGM@@YH<R/VA+B,US=\+Q<H:2>]0)I#YU(Z^2
M)@49V\KKK%RQ1XQ]=7E3'58(D:4:#I.8'#!4'<295??.:@$UN4T1;10*D-R:
MH#1(,7]43<WG/*@19HBX4%LU""S>[NCI'+=RF1RIY):3IO=B)5!G7P3?WT(^
M"IR#G9 4<?7%]T?I>-4(1$TSEAJ*Z#%%!GAZV2U1$^IL3)"]=$Z_1:7H=&<]
ME2(L+*0WYZV_'^*C_&MUF_+81@EB :W?XX,5'W(+7'<E:\)>T9.\["<9(L(#
M4E(37+;KPA0JET\/Q")=W/\09>DRKL9+9C3NHNZ@\_+!@"81YRWR;Q)"'N[J
MLH5;=ANUC]=R^+FBH&(0_B>\SQ23<"=2H:[X[;5R9:9YYB/FRC)6+AX\/6M1
M*H6KSD=WCP ^9"5$3VM;C_8@]GO.7)N-N5!KGY5E<LNK72AE)/WUE0A^PQ#9
MZCN\I6RANL7&.IZJW[Y5NK&=>(E!]<M!3KA/#9^89=KZ?@ZDL6_S#YD9]M3$
M*\COR]+5T#-W#U.\W3CD7/"%=I"7F9$F[, R<5281$P0%^H=>J=0J[ULNG""
M]X'45B>/VAN2E8#'[@"6W TS3;@P"E ??S**L'>\C+.4+^LR-2I992*:D2%:
MB7YQ2JCKC0+@U\;G71 //-JI:/S;AC4:^CE>L=G0ELNS43,+V\IYV*D^.GQ9
MM+SIR<V3,(QA?II;'-8<K$[C]8.#C\[>0TW^@^"UU,EQM3F\BK*RZ'GED*MH
M$V-)!GQ;DO4LG6\_N(,%G:R6*%4FLV=9BAZ'0"5M4@>>8N\IQG3R'Z>,LL".
M$4W].=6P>41H+!5SB)6">4)QJEN67OGG#SJ2\<5X.-Y[JKW5F,_IJ*V96?6I
M=%! JRF/OV6&)$>;[4>N_=R.!Y2]A:\Z)TV:K?V%F*P>M#ELNB_/-8;FU$/X
M.+:4+91T=.^%X5J_-PR[\]6GPP0>U.P>4;9$:N)_224@$/K!-'IG^IX'<:QH
M:^G".DD/[;5LWMJ:E,&.$KB&_Z5-+[(K]9)V%P5,S4.]+99W23OGV?:MALCS
M3O7O.U["1:O+:\Q7OD?,W2*,2A [IWTNPJB062I8LJR"Y0.+RL=AJYX"M_)S
MR^^^2"3?)3^S/D(!==4NWI4NN@<I1?F6ZOPQ#?UWN1BB-@^[F-M?/,7=&2SX
M[(+YQGCP!O:I.K+JRKKI7L-L4Q$*D.&L2,_=J)J(=7^<U9ACRVJ]_.'I-S^Y
MM8N/MR]2*MUS/Z*C.LG?)E;51)%E!%.E9CE2I#5KYT8^.G,9J8L<[LT''>=S
M6U_U.RMQ+--2>J>7-4[3IR-5N_2I)>^PODK<L\3FS"VY#R.4W/WFSK8J.6UT
MHM];BIQL/0/;Y8Q9$.?FBUA]&@8S"?]\2@7\SL"CJ4:X0*$!I'CY+B7T7/%T
M2HCX*./2$&?VJ@6F%;#%%/E+0V15ST93#/4TB=[^'G[^*)NBBO<O!5Y5\B!$
M[B_UMEYJ7]U#,OZBX"_&3SN)ZR[]MRIQ1M6LYC*>$LN3,=VMZ10]N1@5@4)0
M@+U(-PH()^0,8^&KD:[+L0JBH-0$23OQ,!2"=\U1P'?J%7!GY%^EC$L;K-FK
M#B^)LC*0(0JPE+]"/TV+Y +_(5DM7**]R="83$=#HLH<Y HX"@60B?PA51UX
MS<]0*Q:^4]1  7\T@?IOQ&E78;2+N>/_2BLB=^NI7<ZP1BW)"=1$3M%[TYG(
M(Y%E&:?\H1M%]1_*/K'NK%!U;:N4)]&&9;F8%30(CER!8$P3,M]+0 [STV?Z
MQX/4ERN_[/PA&R!+WZ"' 7+)WQ3U8UCG[/1J G$<A#P769;\&_&BQ7</N8 <
M+%EQY%(7NFIR0@&"BVC()P\?C;V8[:]6E.BYB[<HA['G7:DX5*H<'6*C_U"P
ML5;=F1>-G,XB_AF<^,59\O6,C,/%Y]=23N+O6YUQ*2,^GUS)$A*34@XA/'D7
M$?E,L>M(8?(#I"JAUK\7H##QK8= L5*65$(81LM[:&^H8N;1G1 ^=J"^6Y$X
M8-E2353KJ&\68Q2A5CT;*:38QF$Z@RT[=8>L5OU#A9=M-Y>7W#@L_7(;]VO(
M9=3FOER0[DCQ?5C:*,N*]C70L";&D5W2WDDG_JK.>ZVA>!LG6?KFZG&'J4F.
M+L%3/T9=%!!(%R[*RAGACJO^.-N,BO8 0?QLZ*M<7O[&!-$9OO7:0H\MX:R1
M;<'1IYI<+!$M612@#S[W?DCHW #N10%?M@N*S6UN)/7D:E>H#WT;:_<)3AR6
M=VC)?70H$<!3Z%A3Z4'?>*=Z9YL_=G;6+J5QUK)G5_#QTATNUU?CXW,;F\<R
ME#-?PD,GY0RGGRPBF*1GA\039@YF6 RR-E,H&@Y8!CJ_F@L;UT43:MN*/U@/
M/N_IQ.,_S=^VX6#+Z=XC[A2FL Q.T[7H[@.<8ZZW,1#O/]@,HQB]T/]P8F4U
MRQ6N- Y;)G7R4^B0S,.L=%,-R"XC"EHJXI'Q,B,OJ>;B"9(1EHGM4;N_.R.]
MP^FO/8<Y7"F@3TB'I E<&,"+PE5S8*F.NQOFHTFQ?/6VM//VYB"CI+9^]3D*
M^#@7!T.OK9'<]!##7P=J?Y^9:<AU)#M8+"A%VJJ@CIWR\(29K+I"$:]T+$??
M%UM2Y.Q;2W7N1QN55IP=Z/4795@;Z.'U:-ZX>$KT?N^4J3&LF5Q.B/'X.;V
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ME[__1 I4?^/0>,8:QIY)1]6%]D1,H9>"#?J0LTR\4^C&QWHQ01TU69IR$4=
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MY?Q38Z0HP4<AA9EIXBA!<:^F0"]S5Z+&+53'U[7T,X0;'Y6[&"T!/0?0:9D
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MC=3E,N")'$C^%6I%J]X?8.^>C2&]Y9*8D>"\JK[\'BRRRIH11V&FNS<'M;>
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M03L6C[ ,AT@2K (W%5[_.+>/D8+.RN!'LQ$*[1W$RIT.,N ]M O9)#// FS
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M%*-AE&&C>2F#1%[IO1IP8N2SQ.&OZEQNDI[:(MAS&VM9;%W0#*XFSW#G6XO
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MT^!USXT:0FI\ !-[WI;I$Z..ZKY\:TM]7?KYSBILO%=2PCW-6J#]"4\X(8U
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M;P@\[[[ _PC2W[C/7,U(U[Z-*C56AFMMUE9C.OU!X:PBU2>>F85BV-*2"G$
M=?#J]HF/2^@F< L+VB$R@:QF)!_CQT8Z- !#@NW';L_C ( EL[P8"&AX^LCC
M /R5^/\ ]7?WF:O,N>3B9D_I!N?4QKO%L ^Q??L?*IT1>Y;EGYH5=7/)6K'9
M.,#@-B8:>[$<E;\/ AZ<)Y-T+E'\E7P!;($#..SB -YV*NJ6DL UZ+$87HT%
MSP3\M>CV87C5]CI^;B\#'Y$9CB3V:ZG-YEM22,/'([5G$;;0C\K=;C0)C%OH
MPSOC;8@.MKZ5/#!2 9L 7H >%^:C>K\3CU?4"\"7F?!;F>CGV#'L\DDK(3JV
M2G" PW-:> &$%/LPIU^O134"!S!]JKR\5%4&.]9L#FKUM&"QAT^!=TY#F/-?
M(1[^'WCYO*KP;-BJ)-'&=IGD.,VI_ V)K!O%#!$HX3%$WN,)1.Y@:E-BM2/?
M\<LU T+NFE,]TFF6]#H[2^G9TW*.Y<XK]%RY.7?]O%6=WH=/J@8RKQ!?JD->
M:7V3MUP-6=\D22F:YBVO)V\J<//I/P]T=;,+<?T*UKKQ$42O*J*>*MK<=':K
M?_,C0YH<9;_J.\"59@##%@4 \1FB(:*<W,L;%A@=VJENR+ C2VI%,@NISE #
M(%GEE2OZ;!=+/]"/'PZN2>WI]HS+B*/#!C-8R+T"\E]9 L^L.:,4;Z"%)[39
MQ72X];L=:'+"V0K9UPC%(:&1-V@OG@<HJ:\12Z3B &^R9:\^W>;=/3PEQU 6
M05]@ D]]EF%Z]BT@0R0F:KQ)V'CP45C/.D/1QRBA%ZX3@@_1FAJGT\V8WG.S
M42OU.W6BU^7E9P?A2Q=)/-]/"@8;*FD?FT;)79OCV0<T&$ZE5>\TP2$!=:XQ
MVH&C6W<?\C#+#%\Z-+.+"/O*1$DX*4B*)/#JV:)&JU26VN^T=P@I"1 KQD\%
M)-) XM\#LDY[ R@ SJEI_VC-2_#+J.&'E</ /P;E^<ML&Y(@D-54.=F829>.
MC&;2?:N7(&%JO/RCZZN=<3.*.2U><.%365/(#"41C_?]A%0YO1MI:Q%K5:W^
M>KH.SZ##,4L.;N8B'FHP6Y9ZE4.IZ7U[3]?L_H.!I769G<G4NDRWXT2R6OC:
MS6BU:^SL#^S=WTM)#Z3'M-=-+]S7'459L+5S($4-&Z=(=I8#G:Y8H)^5&USY
MQBW001\NPDF0!R.(:&?,YL_,&:U[!WQ7(Y&Y&K7O3.Q>/.Z[>:=33.UZI,WI
MJWN&P#C^33#G@1V':J^>@-JZ<UFNR,/9]U4-.K9L:S?R1-<L=@*UC[50XPJU
MD*4U3\4:'N?V>P;&[$R"-Y$]9_5V;X0PUOG+.E[16^\,;,0:EEBMG)E3.8,(
M*CCCZ[DJA/\D00TXP )O'@Z0SXD038/L]1:N6\^QQ=&XEJN3\(=4A44X>CV/
M%JR_[_H4+256&L 4Z*1=;<8(JQ'/,+>"L_8^9Y^;VWMUSV!4.>*S78MPD'+$
M]W##<OKK@YA>\QO.F\ZP;!&I697[#VEL+WE$XM>YF!J:M:RJ&O6J_+=.5[AE
M7PE8+2V-DKNEKA'P#[B!GGSK=L>/Z;S2R],7S*.%.R+KHB:UGG>61*Q)&T@1
MB:[E0J,/2X\N'>$ NM&'L;S_>'W^W[I"G_][Y(/6$^]F*G\:..&O>GY-7LF_
M;(-E-\X>_8<#7@R%WT-H+R@C@/J[:=M 1#>8!WOB/F1S'NN6OP1N"?[Q>Q(V
MQQ4'B+<\3-A-_@E\.=?_= JT'(,UQ9C]_#U5HEP>>K@$_80#4 G\! #_(8(_
MM'C;']PMO2@5DSR)5#_E39\45P/NY</T'O3_^.TC,$O_B?CS%P!G&6_%(/2[
M<(!@ZI_ 27P;_)(E,H( S4O]!$X"C_R["/[<4/A50X=[\(3;Q]-@Y>T'5_]+
M&N7_&L'?1+N,7TC%9N+3?I<'T\Q%O0O__AN9H'DP1KGZ]6B8X\?+>?<O_#/%
MC__>-O_+._%_"/Y7$OPU;<G_&',6<L[GG!J8]RG_WXG<8UG5$K1W3U4QRD00
MX#Z8F??NQ"4T+069\8OWXAMF7@_$+3,UIJ7H6O:F%BG>4U&J?J7/:.,SJ:%O
MK/*/PVL,9&;[-P8EC8W/)6:ES=W+$'MV'NB=[PAY%$,:Q3@1DA@9\-+]62DD
M?(UM;7!%[&<DPG_U_,%-UM\C<"%_1BK0<291E"1[\*_:\*]XR.Z4_V\<3_G^
ML#_YL^?/9;M3 ?-RZW$"7X5K-X/2J-]RZ,Z_!SPNH*&SO(ZV5:1CWM$MK+*E
M?U80)1=9WY1W6^U\>B839+V45FQ<=3"] !K8758A09-9D;<H*B5^QHOL#5ZE
M%^%DC.(]=(2%CQDAKAI51GZBICC4*%ND(/!^D)(7AP/D09</"$:.ON$ G$V(
M0XSA7&^Y9C#WPJ0,O">1HMSX&9,_20[]>;I8;[&TM,!6>%IIIJ[V*M6G\K(A
M/FT/;8_,V\HH&?CMKB]7]]]1+(LLU=*--VC1?AJ\DA?_'@<PMN7WH V(TGD1
MJO\Q0:W[T=3%G77M-1+^R(N!2A_D'=^4T1X>!H!8%HXGE$HCH7D)<2?Q@;#J
M4IR^R-BR7?+D)/UIBVA;0@.SEF2#]U5WG8^1H'M,89&T;!4YN9<;A4'^B>$<
MU]JMWZ0[!E?&?49U<C',KVN5ZI)4^?T,L_O/=^XNI$9T^"W<^LC,=(E;7L+8
MD^RX(NKZ1H=[9M+RL]*2]W>:OE($>8NO:KJ51ZC(E@1^T$P1#.<F@M'*'HT0
MKK?/T5]2#L2:3:LN[VW8MB7+=ICG]:8GFCZ*D55:[PY+L%JXTO7T?*J%NJ@;
MF,YGUM-497#>4TI.)K5B[X;O1M;3KZWEM7AUV[N.^2"_!;7?:6H]VVY3U[D,
M3U%_ZL\T=:X]V; FR'19L5P0.:_#0?DLF<K!Q3*3C)6UV.%Q>WRCI)NT+Y;A
M(%W#$Z^5-CD+\Z4%?NFT.XLIVV:*H;O3/DHQ XFH!Y)S8E23+;NS5]^O'L7'
M67#FSE"7==OT;TLM+*#::3^JRW?U*B?5*'_5IRKM=FC2HRL:_G9\*Q>YS6=(
MY=G(BVKFZ<J0K1><3Z<4+=1+S;-42%^5VG^*YAN%J%QGB:90>U[SG,YM6[)^
M+*G@+E^PVKAF>7E,RR3']EV]J0G*=Q\V@S_+/#AC?8<KY N) HA#9P>;*I:=
M<IRTQ3S[Z:X-Q^1M@\Z/::Y%%P&(8E PP+Q?)QKR/%IQU]D'_U&8Z6N.ZTBX
M,$ -*LTT.RZ4+>0+4H?2(0/GY"R[35Q?\<URR*G><#>X[N+%N: :*'B+UH?.
M*(#FM-<S6;Z<%QX6;/&A/[M9,QX(V9MN%-813G3PI/TL9V_DN6%T@<"XR-XA
MWMY!R_8WQPX"R7_NV"&I)N5@1+^F>J<GVY.0W%UW8[ K3'.B6&8WYXFS3 I
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M5,DKD<XLSQH':"]VV2R#(A#$QQA2S[(1K-<+' #J6TG%%GALDHL#B(U,=>,
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M1;+V!ZUERWX;1S#FT#^UN><B'=.[\T9V5I]DY>4Z0H(<FL5WW)1M(\ :16@
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M=80J^ZC:B#&.I[]EGRLIBT$_J1X4&Z,L*7-C,IE2M^GO Q Y#-*:XP#ZL3C
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M([QQ; _0E^0]:?9$R@NKL]ZB7IXN$+J/ SSNV'5Y5R/Q16-U1X,_VB6G*V0
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M%;%*^Z@2'& B= \T+_T+4C%+1LM1X@ @"D^MT+UH:&DZ=@$<A@-0@7Y!R9)
MN$;OX4'CVA#X0^UQ+FB?'A-Z<F3S&S!,Q?P;#T"U9$SJ]J8Y#E )7 "W1*VK
MQE_6=KMJR*@[UB8:"LM0+B4^V"GZ'NB!2ZN5J[E*5;_$11:OAYZ&',NZNHOL
MZE1#^T.QTR<F72_Q*P83OAY_\\?R+@0!+BV<1B#CP"J)F(RA?X4)^HX8,,P,
M9N4#E6]!ES^#]MOQ=0F?UJZ,6F,>NWUJ@J5>M!=6N.;!B?_N\6IQ7C9F74LH
MC5_5($ZZZK;KXTL<&<EY21"V;X.+#?]WU&KY]%\&'O_R /F?3:#^;*+Z)[.J
M4K*^R%Q&\B;V9@HIA0>C\\A,L\3L[-/.+B(2LOVE"IM73GWI1X[RN9I\7KL1
MG23ED\95H'XFO*)'[#E@L_MAE5@5W"$M+M6R3Q]L,GFW],[TQW8WEH?7.SMI
M-ZL3%0=J89!X70P.T-%8N2CLXO/:DDHR96>M\X5;LNV0RD3/U67JES3+OMQ>
M>L*.N:*<3T>0Q*]A9<J,7_@>:%ZJ'=1Z0F;\G'M1MJ5/L/5V+1$D+2]F&VO]
MSOS831M[<5F,9&<J<;87L!9%1U]87:UP,[2HT=T4$7TE\IT* 9U#T&E[MSQU
MR;Z[+P)DHWIE8!Q;0#7-K;DHV/.HW0W/C-1#UMK+=,NK>K.2U]1=OF'.1$:&
M4O6]HG2,T7\3;^EI<'%K(896Y6+ZP]N'D.P@3.![49Z8-1&^5(LH[-5=NO#"
MZ2\0[!RMD%%<(ICI<K%1SD6"/.J8;;-D: *&>'VII:0\&@-<7W";;@R]M%Y'
M4S$$+E4STO;=IO24[I7O&EOD#XT=1O2FVNUHZHZOQ0-#E0M@-V$)ZBR>+D[T
MQ_$S<6AGX[)RVDLA +'AK<C'.(!LT=!2<10*R+61?H.$=L'J_>E3,XBO(G3,
MI?!#+X.5@34WO4_D-3 QTH'D?J2<93>K]IOX)4O[6X2*#;33397T\9&QZ69Z
MM[!=0PCK'$F7XVAA/7HMN;(UI13.GD&!CX<+%'UVJWK+DG>UR] X0*1_29$N
M,<M@#2&UQ@ '4X":]N5N:J^DM*67H8+CWLLB5R/V=@=3';A7L(R5_8T3JU4I
MY6RSAQR-HC5^^Y>+2X5-G>N)A.=C]CM82AVQX& <H,ON5?86AN-PU+=9TQ'M
M]%+BP@<2Z9MSZ4F0M*VMQVIJ^%'\ON'/)OS;5:=R/]X[8_?U".82"<0@]-%+
M)38_)'TSU,NH(G4@CS;A7O*)1PL<X%7_HO2)GP'L87J_=&$Z)GN+R-R%\F=:
M<D<HUBW_&*&0%&JH<*@^03.PQ?,C2?H'[01)NI:$O?P*H=0)TQ])H:R@PR7H
M?K<81#08M*C_TD&NHO='$IT*&-$-WH[Q)/6@ G?4S2Q%V\7_2!+)P &68_#S
M$>\1,XH7WZJ>7[OO+EB?>=H<SV#@'OYEP#.&^' >>+S#JL7L:%[N0K9_7J0Z
M[&<B,YH7B&@!H6=42I10O-!(S\;E:'O.8G%\/0QQ@+JS0)/76-=6?'TO1>&Y
MXCSAJK/RQM@7?"MPX<L\'?H[JAR^1M$G-5J<"-SH _=2X&5A'^G?45/QC2%W
MTAA[6Y(H,]!R$'B_/OD7HA*^&5-/FM'-Y?9/GI[!^H2S:K@*]+R_"&::I6^8
M;W;4S>++/S^:"UZ& ]$H9C19/@8M@0-X-2M(*@ROX "WT>^/4]!%Q(5:.$!O
M"6A_0Q'%IG^("L >XT5OL7SIPQL3K^$*U3=_?Y$5KLUV3MO5Y_S--S0J0\HH
MTN@Q?7MB<[$-_ 0YZOUON4/XZZ-F_K31L9 ][98;9;4%:L0!1M+F0-L"QP@\
ME$)@EF[P\T_R51S #;J=@*T]\8!!CT6 IT''[ES _5CL(0ZPWO=?C?M3@ R2
M/CZQMP ??5NZ6"IF@H9.[HM].T5+NO$K_=?K)YYAFL!3MFA\I?.E?A8%L/[/
MPOVQ=E&$HKOQHQH'0*YV7;=XU;T/KM[R7#DMS#+Z*V/EU^LGKDG>X@ UT_N]
M.(#>[Y4#P/\_1/_-^]3O[;/6G3:=8,Z4K@A1>,[^?:+\_31AGV*/6H1(F-@]
M]?<BOGO<^8,.2?OO/'#_!_?_ NY/HT9ENY]I0^_/($8(F]#Y^'$44'"B[OTE
M1^SF)=[_<@_G#VRA_L3(ZH_.03_Q>CE>>T0[/Y7JDMAX5_J9I]ES,<B>PCE+
M>"N& 2[UR2Y+5U?\SE(R:=KL?HGOS6IN!1$/PUSW2=$!SV9/K0W2/W($]]_<
M,=PX^+OND?27^H7+L;V^ONMJ*AZM&'6CPM@XA)EDII.>AG6YG"G7JO.[@L(7
M.4=[:;PIA@%N/=].U:8:KA%"): <^6+K0J9+V6LI_H"YVH?+.A%/1JQ*T+*/
MC!NU+10[5$(><[^L]^EY<#O3%3P'0@VL;<!UP@+O.U<7/[+N=@.8Z-8;OHYL
M$5WC.[!U8A^)KO*O*Z=*@0UH-[K0)="(/;/S=[X@[M)*R10T5 8BG!DHI::N
MY=0:NL4/Z[68TR2,33:NOQCQ=F?Z7CV]:,;(#E[!/3BM/W+BJU6$9U[4M@G&
M(V^<MFKSA(U=@2ZY\EE$EY)W]7!]>\\ $9NH&/TZ4T.9\$*,5 *-L-\:_$':
M;IV2YE!QW&> <IDK7^GL]!GYY .(KJ7B,+3D[M3X1E:G18&QBZG#3-QV_6%%
MUO1.'KWM>7,Z8,(S3</!_.;Q:FVCIP+5I&S5WB[S0J+"JN!ZO%;49@%SP>+5
M<.X2T+4\1G\YF6\9>7ROP2B*6^55TV=RR^WL[O;[$>13KJY_!>]>5^PWK"J!
ME;@F#G-T$5UC"]Z5)PTM=B_CON=Q52WYP+[LB%5#<VU FR]R?7+5H?7"I'DU
MZ-:9L-M[[O,0W^W9''A<[5!5'?3.4J;]CG^-I:JDS+SG+#F?B!%2*)5Z4K_S
MV['MT76VL?%>Y/&EY+F&RZ"K;C$O0[9EPIJX2@*L!]A]+IZG(9%I6\[(E7VE
M.'=U+E;W]A7.IR]<;&R2PK9I#.X]$*+3;'08#-M6<>+T(Z]*",AW/"R]5GY]
MC7M:PKG @?BCU$K'UJ'_.>&0UE+'Y$;774G_0E3^ :+0$L34B4:_O5\<+[;]
MQ(N/+5;NT$L!63 =C<PZONL@K-X4FRLA-U1*8)HN/-K(FV#@>U ZZ&8=]/%_
M=7>=44VFVSJ*%60\(B =!E!0JK0(!*(R(2)2A0#21&I FB!%"%% Q2@M"@H(
M2$+O&(K4B(STWIM$5#JA!0(A[89QQKGGK+GWG+O6N??'_96UWNS][+W?]CW[
M2][]DFGYR/KG*%SF3H?MT*9,+=46>/75Q:=*'3]A:]1LLY)^XGY;L]YH(Q*<
M,R^ROZ&W:*4(.W*]-=5Y?,U2]GIS]P1N=D6]<1EB@ GB,E#Z:E;;, 3;()E4
M\'9)!CS=?W^?8))9:E>/E$K]BKUFV&DX4H9QD(^&R&_!SM<\7$EPBU\Z>>YR
MF0V.^_+#MV.7>OC>]PP7P--Y3YKV%LJ/&)ZPLW$W'C.XO2$:+]D]QOUU]L#Q
M3H&1E/=V 1'3GX!4?='1F*+98-&ETH?WO"CWYO(*9W>NW[Y=IU&0FU#;)VGJ
M=4#(!E/MDQ7HV_;YVU>IX7+[D\2[V_Q+S@L[R1(M]VF7F8!(Y#)R/H310R;2
M$%@7)D"!;W-[Z488[SK'#FK".%'_;L1R(,GJ?E&MCT[TU-AFL3>#QY3^2I^.
M#Z;GD5>KZ-ATJ2Y";>#S6OZ6CM=S%%C+HU"9W)U DWK?(JBO0^!=U;X*JDBS
MA5_Z5DH/V\)530^Z)VOEY'GG;.%I;'G_\!JAEXT_@1L7EX^53!N,6I)T7R]U
M=HB#WI.,=HY&0XX5*EY:M5*$^&9.R9XOZ'%5=KCXK1GYH7K1K$"@["KPZ:<M
M(UHT5T2$YUA)"^.HAUX]FM':I6CN.>.#1=7;$+OS/#Z7')ER3Z:E&11ED"2=
M!&,EI0$_?8L#"WPHWVG$3,UOOUR':VS4I^B>QGF"*%2G X4/+C6:'O)+B[R'
MLK0<>GBD&5=75))K_N*TVD*1AC"=IY&5CIRB:17NA)B.B%<,R943-=@T)VW&
ME_5TKTSPMQT;XVN^-U2UDS$]L^,#NIT]:R#C8YK'IU00G&;'/A>1'O9Z1"]I
MM,^F)#),W*U!N:[N[0"VOJ(>9QY<Y%W4J730*SK6:%VDHB O"-5RM<9-ONZ+
M8Y2!)I1#HY%?\O =C6,%2(+DYH'>0T4\:(9DF8%)H:^/K?,&J(^#K[,62'&H
M\9K8<7TVAZK(6O1Q)^]?Z;TBH:3'S]5LDA#?KBBVH=@. ; F!_[$XGA70W7F
MPHW#HZ8>\W/Q,_71G\R@N/L\#]H(NS"+IW4&7X3WMQB%-Y;7UKLX!23V7I+P
M9D,OD:*C#MVQ3!LMXA:L>E4<J/+]":N:-$V_;&O=I&&']<G%V5E]!#WE^UE'
MXY"84YJ2A\%W8JX#"^ ;E\ZN+73K_G8NMTVJ-/,P$-S4<\QF60G>?>Q.A]);
MV\Y(4.0I=8O#KW^2P:)4'W&CSD="V-^\7M/J\F$"UG">"G=3Q0GZX0[P$%#4
MMD5 CP#(+?)E=.P!IYMS&P4F-*->R1@X.P$J<.GTKUSZ[JU5;A&RMZ3VE6J_
M> [KE<MC=;D3DEM%[Z(9;JBSYTC:$23N&\'G\4Y<(-O(@U7KN* <Z+NUR1MK
M#2@Y#?/V+N4CS7[1.0&*=\['WO"&^$R.8$K]T_G@R81'!,M^6D=6C(*2_I7]
M;1I")TLQSTE"_L5!-+T(D_JR6,,8\J^<O]RPA08[/[IE_N02B9;IF&XH?4]3
M<<$/CWF78H2J.3@9L%(YGB_77S665"CT9%*(^W+U),%0:RGPRCHLH= -O5C:
MZ5E$_(3^2G1L=^,/6_.Y=R+YYNT^RS"1];#8+W??,3IKHM.FH-"HUJS* L>P
M?>"SRR'#OQ"XRO.*O&.27\I)P@8ZX"!R9^6V 1>Z472G%*IU%NCLFQ7H%.!O
MP9,1JM^_NKDC"+-:EA=H(7IM3(!\6GGN,*Q%ZPXO3:A0PJ3F860@$&CLKM;\
MB4OG #E+$@V\62 >'FP3OTHT*GKRR68YMUC-""4@I.\C63Z$MK91Z55+%POZ
M"MX8>B D54W+1^A\47N0TYU7L[AXGMU(A5S)VA;7W[671R)ZH=KEC^[ZPZXQ
M)$LKAV7]*?HK^ =S5:_VS;Q]T\;?8R.TN6#91]/KRT9U?:X8S ;&ER\)P1[I
M7HEX0>(["Y:_M/"<>%$8P8UJ?*&T*2&>^.I?N>*.R\(H+D]LO747]8'DQ 2D
M13,!"(M45&=&9'(D%B'O?_W-HDPVO,\J[78ZJ0^_F@\: \]AD03S-GJU$84_
M9W!F<@"#^[W1+/@MLD=WK[038S*']DP[1WXVE2=IMHT)T!+<J[KTG'$/2-^"
MDF? WQRVU -5Y@M[U(PH\X2]JDO?T<%59YD B>-Y'=4Y$)<?:#\<,]DSRH<P
MM.W2D%'^ RY%BK;I35V,);8C6YL6[ZS ^RQ'2.TOWYZ[NGA(D>W$J#FRG)6C
M:66RD+IX<.W^^5=3(OHJMD\=.Y;%([/BKV*A14YB N;*T[?'L$1E)J '#E[%
M63$!A=SX^ 1ZNL*LAH!,&O4:$T :-Z(N]_TI3+^917L&QLW06G0@?@1X.B-$
MC^5CLO8 F$9^SJ"J(/<0'I-#\:_FW8I#?D!#QUU9X?0C"2ZQ6^$O-Q09/2])
MPIP\/8AL)(4H12>[_6F+46K*T!4=VV X9F"J5_\,0VZK<\'9K4T%91UVY99R
M:[[5%O"H43PUGPE V><V9,@[55<Q 3*I!WE:Z95+C##60PS_*+;R$[*GD["]
M-@+<[8(R$/AZ0:1S#R5^Q,0F=L(+/S?K3=UQHWJ.T&BL)!C)*;JD*DHA,S9%
MQ_P83G<'+23($R442@J#(: ]<9?%^)21A";H[T"'R2PZGB1\]R_-]3%P)DQ
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M$ <")ZS^.:'? \^3W$>CT!:8ASG']0E8H*?G Q:(_H!<59HS7D3S]!R&@ T
M 7*O])?$86S*;CJJ'=URY [224T%*Y7=GW6QR,N]!7IPQ@@+#'?"EWCOS<V8
M.(-3BLP$8L"B%*SGT3HXR1)D*^);!^&H;.^"LM5$.>RV3$^V;SOAUI!=_ /'
M5@NN'^UQJZZ8A\^3'KPRTF.,"=LXAAPP[&@I^/WP(?K3X[J_/;Q\E9#YNQ;]
M*]!D_;SXZ7L..2OPY$N\/Y\5\-3_TZ*Z?WHRD,_P&CXWI'FXE'HD>AF/N"\^
MVDO[*XX"M98WX/I^5S;9MWRT86Z6<&US:W/V;259Y6P)R?6\%94+\H\O)=)S
MR#E1:O(-6FI%UAV8-%4N[6A7[A(;S5U$"4^_<EVNC)ZI)QQ@Z>.#NLQ]";GF
MX5Q*<6$MDO#H*9R)1&<+_AZ*@R+6K4)\K: IK:LL\^5G'M91S;/CF'2)?N3.
M6YEE[LGD,%M_R!-E,LIBR+G6LM6DB2_PG+'Y,?^SZDA?9L2HU03)IK^!Y)W]
MMW*F==_F4@9,_+[ 238:.',\'J/,^':2I=9+UC,J&FJ>#GW/TXO+CI#;^*AR
MU!4PE5:BG9$3=^\M85+DR!1H;<1Z4Z= Q,^Z9B533H^;&GU9?[A ]Z-%.LR=
MT%Q^@WSC*F]]GTB!/;%J17_A8%]?WZ7JYY;Q*HSF3^CX+E[1D.C@V!X8K.,N
MR+9Z!PZ]MTX>PYS]ZV/A[+^N(AJ$G7W?XQ7.-T1O&>7PY57W)CC4&:LH, 2!
M+O?]?WP:I ;;3\74(C#^M@*SHGQ_N-R(H#X<_=BPZ12<?0[R[1)!5-YVQMQ[
M65;0QTWS,$&VF7 -FB5N3*E7U;R8H)R\ G.+UZ9F4?PJ='>+M]_=GL=K^GLD
M<K=$!I6ZI:2"2L^U87AVV%0Y4^2LKG*_>A -]>++N9M]F_E"6=G+^W221F$D
M%*H^PS]XI!'"[:X"H\YM#.X?^8P?-= 7KB0RESPOVLV3ACJ]NV>TO/C%[-JM
MOB?MYW*(ZH/'B2YP#$6&01W(25#V%9NER]JV5SNR#>WH'JQJ5[R+(;HL]RFZ
M_<KKE/NRYM'?+9B^#Z?;0,L1@2)=FKI-+_8-XN=TMPY13A;N;ISP\IG(UPL2
M5_IBL #<F2Q5@":<<RUS)L[X(CBL?I2BCC>PJHJ3KI-]6_5CA?8=Q7S66FD8
M10"R[?S,*Y:,G,FRZMU&Q V+>L1N-9HJ;@ +/)JOCFT=WI/%&70U)5ZB'&G$
M5,(\SSQ_,<OA\?U\/0'G@FF4I4_.@LDA0^#Z4YN9CLIZ34H/3L.OHM?LU+S7
MA34]+R8:J_(&^^0ZEMTH+742>I9T/\:CN/SV<2):(']9%MIOU3B(7QV>,K%+
MM1?4J3#/DQ\4VAXE:^+NP($%:-3F2D;JFU,I=@L:U>XEZ-J%)K,Q<U[M+A51
M8YIT<5:4&R\_>]7=,H*<:5!U7V_L$#&'PG-SGSH\)C8])RL$;>6#F6[ME<[4
M]YSU*)"_6KD0YRJM3V3^6JV=PZE-M895S-M?T"06%;N<JCK=1.=#W^=':V2[
M7W487UIBYU6O.%S7AO!P<,BF*/[VM6H01Y<6YT;$0;==X]X'@,19E^\&V'S-
M%$[^B/&_.+3O0Q9W:88$5+^#8^<*;Z%)7)Q&@'Q>4?]6CHYASLS=L@CO.^"D
M_6P*''?30O+T=DT/B-1W(8=$^7%#53>?@WWC^M\3_L\[EG<AW06#D9JY&%>3
MMX9/K7XNOKTL&CC61&;EK_W3HCH":*\.L"-288$'N;:M0B*/)?6M[)?W-61L
MKO(*J!K$P?C% A954O?S_$8<L8!,ULG?Z1\@LLYK^B-Y9-6.WHO%'&;>OICQ
M]O?$>@($.:IYM!(N]R+DS6^)R"HC>(\-=#-?] P##^RWA.Q_+FD<OK^,0X4M
MKL+"#^Z1;TP5P,ML4A\EL5P&B63G?OI;I)S<H/]ZX2C_O)+W15Q'6,PJ"K-^
M6'UT^?5>QX?9$S(&87^'Y!7T7ZW<_W+2>=>>DA\<*[B&]M6F5FJ,>_99'&]Z
M+0^5YXKPB=;Y4:_885X5JDJNZV-N4/G^7(DS'2BVBCB\<\]84>ES#J29IWJ,
M$PND],&G[@Q4W8SJU?$MF\-XJYS\PY"]SLB#=<[C74VM\W]W63%-7D']MX32
M&#]TL2)U?Y#A*2F-^&\)R*.:7VCKVN*)Z$[]GOJ#6.XIZ?^;2<-_(_'+&#M5
MI1E]M.P<C3;9I3LIW  6OO5$;\4OYZ!/^Y=7'TK>_4?>>;CNGF>PO'Z^MN[%
M2+9]:; 1M]L._:H<+5=N,7]Z^1WA+B:>K@IZ)GP2+YR(BLYCC1XUBLKY[[1-
M=I[6#AQ$QI'W-8N NQEYXW8,ODEON3>+,EY[6']_?:>Q)CM0O[2VYH=94U7\
M'&-#[@*)\N$YH%I!+U:[/.+'-6[^&;41Q:7UT?O,3W9TADM6Y6W=0CGC]V\3
MCE-9**=7LSR)['Y%:YW?;SOD5L*FZ4ZBD235P?/"Z'  NA5E\R@=45&XYT+8
MHZ5,O'.'N[)("M?A$J+JV;C8)UR-S"[9(&C0#ZB4BFNC%'TBMT 1I97O"V$A
M_Z)O%*MR=+GYV[9NY9^B/[J2Q A>U);4+:<89AG(@S_J_;SJ?#:"\N8SB6:6
M[]%]KZAZ;U>E/RK]R&YT@U(;S\$T<.?#9NJR3M*A19(W[K(<I>'Q(JA*T*9,
M2PQ%A?_9?A1Y 5J4@G]7&91C_WJARJ6K&0FI,]+?+<*020]W13]YY,PN/FN@
MFRVB:TGL+J=Y45Z8ND.L8FY^^:!J\:(R2\-L@KA 7:OK@![LKR^T\?^+%]IR
MHWY;:?HGQRU<-":C[N.R4>HO@U]9WE=KUU\&/!<T+ZU6CRWBQ_DW*] =BCL\
MDP58X.+9IDS0TJ;1KAOZ!-+G#OK?T/\/'S*RF0>#7J4_^\5 Y^,K?WGQQ_C)
M/RO*8X4%(N]!5S/@:X.D?W2(6-)/U.@<5A8IED71K9QVA:\[)<%3E*:S+,EO
M5Q@VTH9Z/<S0ZG:>,B]''X<**=CMF=4Z2$^>_23)22)94C><S7<SW=WI\"X:
M@TH6#_;CM68AW&*>>K:[+. ")>O(GUBN8ZOX<<_D2Q%M$J=W<,-'BERR#Z]3
MWQ%60.FD;=)\KF]A 7\,JYWVR(1M+,I$[6R% *6-LYJ9NR/3JY1K=D$C)I-;
M=6)?">2XWV\>DBOH\TW4K^Y78^!/,LM,A^6_0VE\H%LE01A>O^[R%1:"=V4,
MZ^'+ R[KJOBU<<^\7$R,](64"W^(R)'0?3\O25_"$MGB..%S9TBA[4W6TJ'T
M%/6#*BSPK-8,MDXJ:SUB<LV*YS.MY&-JWVEB0=[W);VCW+N:PTC3[V3Z69GS
M,-!_?WVP.TN$IK>;*0F2@H97%-W8GUN?S',;M4RUJ/%>#?;IV9'DX[AI=?[Y
M.3D\X'P8B;[H+!8@66GBVT[&!!3:4MVU2YB\]G6Z%E'-JD;:VV\DDLG<\OUP
M :&:FQ?FX@?/1GP*5ESW]*O& L*@IQ@87XTXWW01[5B!"I\YDMQMY)4K]U_F
M-[N7[AW$]NK2^/6G;>A@Z@@YKSGI.S.;I"C#&8&U.;\ZV'.7]%QVS=SQ50/'
MF&9/V2]I,GU*E5FRJ1]K(@V.J3+*739+O/U($6WS)2$81(C:5NG!P78?E'#Y
M,"*XY, /,JR^^.)*>O46>E1]@,%U38V+PX;N?-61)S$EWL,TB_K<$N,FE/.,
MC,5>UM:U20]Q]< C^>8$J;C!Y/4D;96][!CF$N[[Q*H-X8M\R8.[HC09+ZJ1
ML"VJY:6$\0T_6Y1I\^AP2!.7M1B&8>"-VC9?2NULZ+K87%23C]#-9>HGR-+M
M=ZF*1<R,[<,8'I3C')2,/S#W<OD<(L@=\NAKX7F9[V*YI9K>E/YRXP"7DUPG
M4[1IIH@6T6B2OA6L;1]_&V%X?$S>H^S':N@!:X:32U^;Y:C;0OL1H,+Q[%G>
M/>6L[L]2R:ZRD>-X'%[MK]3Q071_.%!:X2VJ7+YL2,2[9I=4Z(<@7^. J9NN
MS 5OO7 :FU$>Z% G&D%IORD^A2$^5OF3LWUSHLTQ11@U +8A3RRP^@8++%TN
M,%;^^D$DF.K62E90_Z;XNZQJ7BNGQJ92>]=<XU&%J^)Z[0*T8E'D3%Z#FN=6
MD':)RG7)6J9=,8+S8:3YK><^)*H5>6N7)EGOUZFO:7/1(2Y^2VTE8J[!3378
M,AV=FPL,P@(/-XE1>"B'=1>BRF2'V:$]=04^2Y>PFQMBC:VE-S,?$RY&*YDX
M/S6"T=AB6A(<TL\YN1Q7BT6F[_K2;"E6'AEY8 $UU*A+/83)XP'F,SFM]2B>
M++DA4==>MIT['OFE 2$E7N;<[E8:[;34!H]NI9:2,;M9PB#1+I;9S58OA>.A
M1INB+O& M9W<?0_/(LJYS_>LD%_F!YHC,);>]YCL'WPH;C*#I _H=V*!TM1U
MFEE(F"GQ^N[4^0Z!X$K#T*6BM^J7>:_<)0AF% HJ9HX3%\0"=VFO5_AM2A"6
MOYE]6YXY)C][+7BCDE>%<X#2GJ%[\MM'NI$A)[Z7%:$2-:8<PE7,&DQX0)BL
MW=/U"OUH(Q_+X<)*M7 Q8\C-FIJ(H3;DE[+!2>M;[A23M6>/HMGM:9.U((%"
MST?#,F2$9Q."*DFU9[\9+E>+#3,\_ZP@+5PFTUCHMJW!1!K&X73I-@[K>2</
MMG"Y/0;>+C\6G]M-V^8VVNHV%OB- YU6R"GR*OJ/N<FO6B_>85UDY0;R].<V
M2K)+OL ;DQSK7] OIZ"/D$/A.SA<)7^_Z"KQ<]'5R&AL7)V=1C=D>*-<<(:"
MP,G6=&1X9JJU"W?6,H5]FS]SEG8KHBC32$2*O[I$W>?0YZV=\[DO'%&8@V@K
M\TZ6\_,2'UV/^"8^=CDOC_W#NX&ORF4U-%\NOI7*DXYHR\"P&]FL]%XWH3K2
M\+"[LTT8)$NM]M9&/S'F'BI*W66H:I/+7X#M>NWG@%+G"H?=]B+O2NJ<_] ;
M@C;<SK+_ ]X05/?Z6%! [7@X5$I:G"/]B..*8!))A'\>O/DZ['@$NIF8/5MR
M0&:$!=[#=RCN753>-(VVJ,FYVC*;W_<B1,C&Y_7.CM,A#7>;TT0R!,U!BP4F
M8C$'F1A*8O@&Z*[[#%^+]!+<-#)=];-"]QZ%8X&R)6:Z?S6?TN'4:[B(WS2F
M,\W%="O*$ NX:1XM1**4^;! /><QTFA#9JF]$?(+L8 C_J>]O[,)G6&MQJRE
M[G<YU^QGLNS BPX2D$H;Y&MUA I8X"P^8A\T8)NLP;G+?^JH##XEVCTW&>;=
MBZE>,.V"U$#_PE6&L1_1VD(M[^5/[QCGF9$165[Z('<QL /@E^6(]69'/3,#
MI[!Y1J>.]5&^USW\Z8Q0T8.$R(@KI9&7Y]R$]_6Q0$@FALI;X& .] Y]2K
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MK-+2T8H/]1J/&+69)]*_E*I+R=?=>H_QB]/7JDALK.3G[[N%JFXWP=GJ>4^
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MTJYWZHK.\2"E)8U%2K9A.<< MJ5:*@-5J,\4XC$=7=>9KQ*+144<B9!/KD5
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M"<+R'B7?,7%14HB-WSE4.)8=,&7JL)2Y]P4G4R:F%]"&!D5:<;=P"0L+%?4
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MN\2^*L +0<F+WPEB&1--^6-2L=LI84T.00$Z(JT" ;NB2WB)9=_VEFJ=N6,
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M. :<;<D?=RUN:JY["+,5A<P;U5C>U&8P]^?VQHR3V'7M0]8ZN1'!=G9$W6,
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M4X]NV:5UX:_^J^9DDILO'2^'^#1GU<_13'#;W%>3[K$W[\__*WN^S2$ >_$
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M@H7[-!?'Z5,<G!R_!J&AHYYSA/XX/?UQCI-,)SG^;V^4+P ; PW_D5$ZFO,
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MV,CWS J_XE[N:K7!>L5"6SG<T75JDS491[Z5-]AE1;YUB@SZ9J(PI'B.GL/
M^&Q&I"CP#QHM%+GSBCP#7SK_,:\8/21]^)("?(@,C_])&RF:0Z/&<?>OS6\*
MRQGDF1-X#$^:2&NN3+[KG&RHIL1L,'N/G;6CZ?7-=?$6;W1$KWG3H;QK*>'C
MN3Y5"9ZN65= =4'YJ5B59-T9B>/[A\\,NHI0,VB<\##&SC^H#TY@U,?7['AS
M[F.1OHC6ADN$*.0T@FL\KP&_GB4;@*Q42C)C.IEE*&%]=>CY9_%6LT615,_
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M;_6J<81S&*@!_[%9]\'GSG'/$J.]3+J7P9NLK_!D]5JQKP%O0B-%"UL]9$W
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MF3/.Z9Y)1MI&S?U:6+\VB.ZM:Q+&[PRR16#", -S\)\EJ1@WJ%Z V" ^$Z$
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M WXND35\AP*XNKQJGRN?VAIHK.N03O?AZ/9;M4U34T%-^%"7)DV;Z_X/_=[
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MCM#U])<KT+U0[O!4(>C]5P<9+O&R)\3TNI*8P5$#7>=X&W#'5%)(/9$"=%.
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M"3S]!=?STF&X@A?!VR)<VIO]_?%81V^>E6]SQYDX[NCQN;F$'_1=&]6[[I#
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MAA3)?-=N>\HPSM++*DI#*$Q!70"N:0!=G=@C65X3K[]?70(3W](@C2F/9S5
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MA]TB7_B[Q9JGRO>3K$\!*//SF;52  J2P'D^!)F(>O];.I:_FT-9,3NPZQ1
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M'4#I,8E<N^J$2#(+.+@$$\,$:\YQ?K(VZQ4GN]N1L.(]JWUKB;2!Z?/=WG<
M\_IWD,7PITKP+"8#5?7BFF,>6BYC3[^+G]@2,<EJ$Y04;+WON:[!-#--1R-7
MFJ<HOJ EV>;/^=VCR)NQF'.DTDLFUJS\<^MMVM-/;YU\K?A:^Z8]U![C@4L.
M 7O<8I^$GSM=4O)T;MI4X43XY?6^[H:)$J&P(AXA%$@64N^+Z$XFRKD5/*0
MQD!;L$%EVQ&@50S;CR1SJ2$D5X%=M8'Q6,CV!I.)AI=B%[^@$;O8O(6 6!T^
MP,UTA;4LA]SMD]?"Q NA:3/GPJ>/9MO/=QJW/$;@1;OYKZ0\.1-[\2.?EU#
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M)0R\O)R5^WL;ZG\H)';TC;0U;$.= H 9$NU^+Z3:&!*>^H?6^7XO5'/NG[G
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MZ$]&KK2Q^]=Z,%G+_Q'(,LZ>)+ZI*-P$+&<*5&3&^(D81CS%7REQSGZX]>-
MK*20XY=4AV7Z=]7*YY'XFLPG";W.1N1><^8ALNPT42]LAZ;TVT527(Y.68?
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MSZ:618I.I#/6[ST;0HL@4?9DLVRB\62129P7JA=[4"H2MKJAC Y!Y\TLLE$
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MTQ-:YS*NS3]?%;2RDHAK.N%VNA@42E8>:!"&:/>T9O#5^)9<P75>3GJ0(J/
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M$TR:^MU2E'-?^3GT]<:\)8]R?/?'Y=+R6L!'^Z=YJPYH^&^\[?S)<_%YT9D
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M38F!C,(H=+X5\&D66FLM=KN]UI#*=V&^P-V3HSE^XK7@3>8 E#Z4[YB"F?$
M?1D6EB]=4GL]Z+D]!U5_M&N)D+GT9!2AGCU,8,E"+3A6?#AF#9J"7\/H:2R?
M=YQU)>7D"J/[VWW!@;/F[7KK*FYQ5E9P=F^I718A2*?< 0H=F(->Y=%)]-MZ
M$^'S7O,AHGFDG;.K<;)'NKI.:_<[?IEJQ2F[D>K QH"(%=)FSO5OS7:K?=)1
ME9?]PYU'PVW_.6SRH26!%/7V!+Q_*U%Y30VID" R8<G("L"6>P+T*(!;8MM)
M0HU^2Q7494^Z(:?J?40#S*FT!2<20(+0L9P2:/A<B*UB0^=_?!\UO"\45HB&
M)8C:-J3O I8BC"6++8*QE@/<>-M_EY/OC8J3FIW SG$-P-E 43A-+$B#1,:Q
M26PHTD&"B-E@^10&,M\, ZU"\K+A54!\%Q4Z+)3K@<E44P5=V1PF<JK?1S39
M/JN'G1LT 'F!HG4T,2\-$AH#]0MW=[X["=+2!I ?U:+V!5\:6 RTQ/_-FV-#
M9O4VY(VWJ3?FMXV$Z+Y>>\D0UP Q:R4(? ]6-,]B>^# J\^ZXS**>EHG:P,&
M\NU5-JD04)/)W+F%X$[40]"ZJ/)9+,-MBT7E-DZ;!&')!FB 4>'2&<"/&\;=
MSGK6(/(604 (BCL!7$5V"UA3(I@YX"$.A)H7:M'#BJ99@[:S-@+QG"? @O7,
M%7P)8M 1R@1>TR)$!@( \2$=V]D:@1CJ!5B,A4!GQ0;4T58V!)H*G<'KL7#E
M;DC!.+4>*SPB0>3AYW8 Q; ,X,ESSG/GP 6V1,@80+, .H<&@AA^MDA+!,60
M4-R70 *R2YDUM1!,*RY]80P24/-1$L1-N7_J%P#2U@ZOR-KE'2O[OGCZV>GP
M/LV][E*7S :8F^#]D&R!!&&E1Q=!$@3;ZUQ:;K\MYI%<V3V'SM;DJIVFAM*(
MT!:2+:0 'H$NEN,%\")=3S:"7LZ35&]V^_375#Z>T5C[II9!-C4XW!</*:XZ
M EURPPO@V;QPBFN7X_QR;X E>!_1#MF!&E.%*<4A%]W-CBZXFXV"0H!'3H?I
M N_I:N2)D'!_P?GQ"_FW1V$D8.%@V:^ ;6<<YV7[ =;E17^W7P'_#"3W1^)(
M8^JBGX+,Q*^&<+,C@>EQ+O;';XE3HM=Z9WG[#-1H0,Q&2EB;W]E/'*@&VE\\
MLCRH;D=V(H\AY:$2,.W(A&=O?[O8K:;R%"MK;E3A/(I(ZSK16XAQZX158-!X
M[N2#I*V(CTQ+/K@$PHNA1)RZ*=ZG,.=;<)3FO^/#H(2_E7[WZ9(Z:!1ZUK'J
M%[O2M>; !TF^_],$\%LFH,8(]_;[G;KY+0&[$=$,_;34&-."XS7#^"O&CPL/
M)) TAE0[^W==,709CC^Y=>.E:'^%$QNJC'&'WFBEG;OXQ%5%FV.^0K@25NQ+
MCI7)3<;G>HY#:U[IQ_B8$-).0/=WE1 YG%NFBKZ:,@]#GKSKU9'EU+2,F-UG
MG<8\[>'US:T+5KXO02P%:*='8MDY0MH^IG%4>*RIY\OP5;KZ30X3'A7#%TU2
M*%[VSA>9F;KJ2%K_>O[2IS6U:4,66UPRAS89&QYGV>@YK-=6=B+8.UFIJ'V-
M'M3W&* GFMOS!$,ZQ$',\LCD@T4U:"F3^*B<AFP@B"9S\:'"B0-A!-DHR)Q_
M\[KK"&]>6,[.&;[<P)7Z$K62&^XHY=T0E/?F6,$IXY>G7S[K))P+:7HR*L,.
MG7GX^D5(=]<XTZY<V-UL[\-C=N0(/443-GS\9;']^:@S#]%5(041 3TAP9/D
M33@[^>Q'-XZ":-_:#4(CGLBI&E;I[_BL%NLS(/6V00?[+/YA<H%[LEV9K*%,
M-S:C-^1K6JB*:MV8D4\8@_%"P)4@Y,>::ZF,3.]\>-RM/^K__P=."J7A^C'?
M LNT(7?2=Q_<IC*NU#29]RCC")IPX?^8\7]"*J9L;UV_>EF;)F[^/K:;_0EU
M0CF/6G:R^)8O88>M$YJ0GUN6Q ;]O^P7CA2E$(SN/"C/?1$\*W[DQM]E5=H!
MS8D+#_MK):R+$%D M8 NJH0I&GV7?4_J\Z3'8":5A;J-[)H I^:<GUW(L?&"
MZ#Y<?"MV<@8NEC^RSV4A?L,9LH ^;#L;#6\"H*-G-VYS=@,6,18!S:XIY1=2
M%S$6 =6:5QQU92UB+ *F^B_5U>7^# $L NY<LI(\DPP- 6-:641IOY$=^II;
M$-^H?[<UUBRR0<%VI[3E7T[P]L=TVH+!3EZ F@V !=/[UPKBZE64E+<$/F'W
MXLRNJ93^837]WM8?>7G8.ZRQ_=F%PE^N'0ZT2#T7KUF?LEJ.!!"-?KO#5CO2
M,J6?0SJ1+A)$0Z96L9>U78U3<;U[0;/F[=L79=;LVXC]G TI0S]!RD(WLA>:
M$G&BJ9+4ZY&,XEA$@Z31I-XU![;:21W9>(ZNCF:B/F2H="/"([[C^*T_<Y#^
M^(E3</#G)S8;P@K.K<C6GEY2%CQ=D<Y59.4$6:/74>=+72UKQLVR.HFY[N"-
MG72HJ$ITWO7-5H)'I96-DHNTLEN1GN8]6>O801"]O:K):>+2;L)CHHE%EQSF
M15E*E:$[[0%9W<R6CV^]N4BGUE_K+VKKW['__^'TWS_Q0RX-VP_!G"B,D2&G
M[+SH,8;^(\28K.Y>#SL.<WA=0/$MDI&DZU]02P,$%     @ <H%G5\)$S#%$
M*0  678  !0   !R8W5S+3(P,C,P.3,P7V<T+FIP9^U\"513R;;V05041,0&
M44"BH(@R1&9%)(TV(-(T@C(/:80 (8;(&.:T$R@T(M 2@5845&0(-$(($"2M
M(*@0D2D!(B"C,B<@))#I'6R[O>M>U[_N^^_]WUOO?]E))?O4V57?WOO4J=K[
MA$+8(WP';#EI:6T)B(F) 3^"+T XI+#&(A+I!P"VML !   V@"\I8 W(J8,'
MT6); 7&0%P-?@)CN7_5WQ?0^\7(@WR1VY!._#>3[$I' VD_RP ;FK[=7OP$M
M ) -FU0&),"Z3>!Q$'A\5WGR$Y:(1"0B$8E(1"+Z7TK.R"!?##9TUZD 3!AF
MEX4O,@P3LDOWH,Y!'=V#!W5U=72-] \9_)-2>@?U]$T.&IOH'MJE:V!RT,C$
M4!\X%N(--@W:=1P3@ C:I6$>XA,>NA\ UM\0_S.&D3UY8^U?O%=ZVB=>7/\@
M *2G?^'OBGV)A;[$,QO-5FT0Q3,B$I&(1"0B$?WOIK^+0?1,#(R^6@< QX 0
MP!L( GP!#/BY"S@.?@< B$^\!F .GO4!PH%08/]JM^O%Q#_''^O!#T5@W2<>
MD)T54_J+7Q+3^"P#1BUKQ/Y\%B,K6+/F3WXM][.:/_YQ_,>WL$?( .$WK%\O
ML7[=!@D)B8T;-TANDI/>)"6U:<?6;V3D=BI"5'8J*BOOVJ.S;Y>JEIJRLH;Q
M?JV#N@8&!I!]AX\>TC/5T3?06^U$;./&C9ND-FV7EMZNMUMYM]Y_FH2_ [(;
M@*U@M"6V&U@C*R8N*R9L!""@ENO$/M&?CA9;([YVW7J)#1LEI4 !XA;08G'Q
M-6O%UZU;"QHK%@>>!];*KMNZ6]=\_3?VWA*JP7)Z%]+N;5 [5OY4WJ&=N4?_
M;,C%C9+;%+;O4-RKOD]C_P$#0R/C0X=-CG]G86EUPOKDZ3..3LXNKFX^O@@_
M_P!D8&A8> 0V,BKZTN4K"8E7KR6E9_QR,Q-_*RL[+__^@X<%CPJ+'E=4$JM(
MU36USQH:GS<UOWCYJJ.SJYM&[^GM&QH>&1T;?_]A8I(UO_!Q<8G-65Y9M6O5
MSC_IJW;)@G:M6;M6?*W$JEUB:["K K)KU^W67;_5W%["._@;5;T+&^2.I=TK
M?[I13=^!*7\VI%URVQZ#H;VL5=,^6?;/&7;Q_\JROPS[8E<?L$D<'(2RXK(
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M.OH'#4RA?R?WI1TFY P&<\[LGWJ&\#?=?&YF"OT[@_\;O&YFZNMCXO.'4G_
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M'B&@YOKQ]-A510C#&=*?.F_P^2PM3J[F[/K$I>YFM@\OY?-)PUP+Y7+QX]S
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M5?(\CRI@EF)F0-D%%H3/*URA*GK-6(?<G!Z#7<Y.2OSK1/Y?7,'B6QB/ESH
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MSM#<1Q)J04AZ[: %3@LO9(2]_P%02P,$%     @ <H%G5W))K9PZ*0  O'<
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M_]WT-S&(H*2PZ%_6 8 <X *8 8Z )>"$NC("-U&_-H#5#YX#N(%JM0#< 5>
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M91JW(8C5KH\9> UBVAH.23-7^.UZC5R'F-&0=1$ <!\3%R@.C*J296W!MF>
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MNC\4EZ&.[TL[BP4$IJH%M[3*ZW*\LW2=O3<OCJW:@G5AO3L1/\EP*@2@N9P
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M4R[4:B;,[@5-Q+/K%RL.PMB_ %!+ P04    " !R@6=72>_MVQ?6  !>[@@
M%0   ')C=7,M,C R,S Y,S!?;&%B+GAM;-2]>7/<.+8G^O]\"KR^'7=<$4(5
M%W#KNTRHO/3UA,O2L^7NF>=XD8&-$J=2237)=%G]Z1_ )9.9RB0!)$CSQ;WM
MDBT2..<'XH<#X"S__C^^/Z[!-UZ46;[YCS^Y/SM_ GQ#<Y9M[O_C3U_NWL'X
M3__C/__;?_OW_PO"__7KIP_@34ZWCWQ3@=<%QQ5GX(^L>@#5 P=_SXO?LV\8
MW*YQE>;%(X3_6;_V.G]Z+K+[APIXCN=WCW6_+?X2.P$G8<AAC!"'*$@#&(<X
MAH$781J'*:<LNKK_2Q3X,8VP#W'DB<=X('Z*F0.]V$M2DM"$4:]N=)UM?O^+
M_(/@D@.AWJ:L__H??WJHJJ>__/++'W_\\?-W4JQ_SHO[7SS'\7_IGOY3^_CW
M%\__X==/NTF2_%+_=O=HF9UZ4#3K_O*_?OOPF3[P1PRS35GA#94=E-E?ROH?
M/^045S7JHW*!LT_(O\'N,2C_";H>]-V?OY?L3__YWP!HX"CR-?_$4R#_^^73
M^[-=)K_()W[9\'LYMK>\R'+VN<)%]0$3OA;2UZU5ST_\/_Y49H]/:][]VT/!
MT]/-KHOBH%4I92*E=$,IY;^<Z^R7"\2W)&_U4E8+PM7J?K0EXQ"F'ZV)>R<8
M@D\O<*^;BT5N/JBW&S;7M[OKZF+1IY?8UF>15W@]PV>Q[Z8G\EK^PP?Q4]N-
M;&B 3.M^6NKNB<J_5WS#>,.6!TV#C/W'G\1/JX)NR]6'C/)-R:\W['6^%O^:
M%S5[7]\7G,L%L122\/<5?RQ7GH<#%,04)G&*('(C"@EB%#)'+&8)#1W'25?5
M[E-?\0W\\KF3JN[:J-\_:>!0G9G/!2_S;4'W*^'C^M3R)E8VN1;&OVSP(R^?
M</N"$%Z:#8T^_]E*#H3HX$!VL!<>?)7B@UK^__???]DC8&\TUC\*X_4\\.(?
M"R]K#<+Z@1\!\X$ \\!-#^#&._E_/@MQ3@\$6TO;+R^.@<JI*5 -Q<J7H;2R
MG<1W:@+5;>Z7%Q_&==&)C@LZ,A[M$[_07-BZ3Q4\F %ID3]>I&.57_0M-<@+
M$?\$\H+Q0NQV3JB[FP<"R7N,GU:?JYS^?OWT5'":U5U\DGN9\O/UI\^_\4?"
M"Q4F5VYL:1Q>"PSZ$H-&9/!*"%W^I,8IZE@.D_4D,$Y,TV,(@J^-R.?I69D[
MM.'9&V:ET*S&)L4EJ95K&_M%TLDO?%V5W;_4!%.3BWI_L]"*MOH=H>B_J$<E
MG++5+7[^6RGV"?)D1)X$O,E*NL[+;<%5+17%5A;TZ0MIP;<2].0%>X'53!/E
M;U\3G1-??LGIS_?YMU]$2^U'3]G^6U=M?Y8O75/9[CO7?4WO*R^+:O5)##]O
MJ3R.<40(2F&2> Y$GIO"V,$I))A&-'59[))(9>T\:G=Y*Z2@BK+**%Z#WSB6
M2$K[0VUA/,9LF $N0&+R1>XD".#KF_P19QL+\_N,[D,KF'BEMWJ)O^UG\W%K
ML\S:,RITL_/<K\W,UC<\Y47!V2?^C6^V_-?GZZ*0C<MAV<_Y._Z]^E7(]OL*
M^S'W41I +T($(D(22'P?0<83'* HPAAS'4M7L__%S>KMXR,NGD&>@E8#\5^:
MWV^R?W(&< FP^'NY75?RB=</4K,29!O0J=V]I6<?ZPZ:FK4\X5!,3"O':%X!
M\@QZTE\=V!-WF*PYD'J 6A&+%K4AA);L:]W>9[6V#:$YMKU-FS%C1S%WN7CI
MX7K#WH@.U_F3[.?M]R=YIK *B>^X* E@$+  (DX3B#GSH<<)\6,6(>9@'2X<
M[&UIS-<)6Q]TL;VXX-5'7K.=V!WEWWB1"<(3?_NSYUV)/R+Q1YS4[_PY\8'\
M3 1%%GQ=WQ$_X:)ZUCPK&!XB->:S!OS$/'> >4]2T(IJC\B4$+%$6\-]S4I2
M2FH?4Y+:2V8$]'Y#"V$G\S>\^>_[S<T3ET>8F_O7^"FK\/J:E%6!:;7B2>S$
M'D(PBDDH++.0PA@C'](P"),@Y1$/B0X;J7>]-&KJV5EY)[*PQ4I>E?7,66>8
M9.NL$M3T%SVRT1@.->:9!N2)::@3&KSJQ/Y)8KV3'+2B@Z^=\!9-+'W$+-&4
M1L>S<I8^(,<$9M""_L'FEPTKUL_WGSG=%EGU_-OOU6V14?[Z87-_*Z:+ C&-
MM[(T(A+2<B&NG!*=Q. W7/PN#*1:['9'J,9!"B".'PS;PV]BCE&$[DJ>&M.A
M<S2MDV$U>(P.A4>:GNT\6$W%_E&PXANF.ZS:]+^5EO^=V,F5@F6R?+._[ C2
M*&&N,&L"'"00^2B",4H(3!D.(APA["!/;Y,UW.'2.*25%]0"@Y[$!CX;RJ"K
M;IOL03GYSNDB% WV3VK06-M"C70W\RY*3?F7&RG%]PP]-!YPP7\5]@U[G3_*
MS5GC";(_/RI_?=X_<XN?Y;]=_X$+5O]Q)WH56[Q;\5U]%%]:<V.AY=0Q0?]+
M8ZOK]1K4T@(I;JGI]C'% *E1V8\>FXGI;S\D%J_:YL#.EN?)%"+.ZZPR(<@O
M_%NF[$M_YU@W^E?1>?5&+ _O<%;\#:^W2K>, Z\OC3FE8*"63%X;YBFH1092
M9O7]X3FHQC>&%E":A</VJ( ]8G8V?R,0&.WZSK4YVW9O1*G^/F_L43.K2U#(
M8[ZI7>;>;^AZ*R,&KQG+)*7@]2W.V/M->\K4.K<X'G-(3#WH$4?L^"A!$'.7
MP8#2! 6(AY&G=:VF+<'2J*%1 )2UAZ@\P,8[Z<&3$!]F&T ;!?0,+OVQ4;.F
M)D5\8IIIP6[<<7?2@[WX0,HOS[MWI]S6'7.-\;-D+NGW/ZLM9 S/L:%CWI!I
MC( @5FDLW:1UIP_Y6KQ<OOW'-JN>=S=')/4X0DX /2^((.)Q"+&#.8PCUW4B
M&C*'A7K!! J]+HWS=D)+4Z@O]G\'C> JETL7#(+BMM$VM!.3FQ54#>(,-%"R
M%FN@TN?,\08:,+R,.=!Y68^>ZD"IU[A\D/^3+7[#:[G+$YNX]YMOO*SJ/=_[
M37/_(KWGVKN C)>M7<!H$*8$88A2WX'(\0C$@<,A]B/F1I[G(!0HA[)>),K2
MB$PJ<@7DGZ"G3VW&]322]L1>)[!72B,8\[(1'":\><=E:A-/#L:+$;D^&I'W
M9T9DW-ZS/KG40V=G&Z*9HFF;V4/E6/&CV9,=SI['_5B5.[UL!=I:@74P]O:R
M'N8+Q[6"Q$&$KIT6#0UR^L#9=LUOTM-2?'[(B^J.%X\]<6KW\;UO?>H&*'60
M--0)A<BM3RMX")W(P4[*DHC'6FYWEXNTM!6PTTC:G/LSN_J,\V9;@($%\C3_
MDF?0Y42JM^'YADE/2YG=8%/FZXS5-[V_XG4=2?CY@7=^?^+WM9FTE=%'N*J]
M&33W#I=_+XH;BUF_@AG66P43:,K #'MXVMJ?7"[0O)L7:P"^V-G8:UG_;NFW
MS5,FPT;NLD?.WN6%O/ 2]/1NC>]5[Y<&FE@:$__V\?9]/Q2J%AFDN2#AWD7?
MR)V*%H;C%T^6X)N8PG20 U^E\)9BU17@,;J8&FIWMLLI!>7Z%U0JCYO9@=>4
MYEO!*[?X63++ZVU1")I9Q:D7N3QP($DYA\C!"8Q1F$"/1H&PWYW X8F.;7>Z
MFZ6Q1"<E>&K$U#.1SD"I9O9<#M#4E] =-JV$PJQI9+1GJ@QC8,G\.-/)K";%
ML*+'9L+(TV;S_K;@\@*UC=62UL9-]<"+MO'K.F2H.X2)$I=37]"H3P.(4B^&
MB?@1>FY(G2A->8J53CCUNUX:/[22=T&'C2%?"]]-!M"(KT<<&F.A1B;3(#PQ
MP2B#.\&ULSY@EMA(H^-9&4H?D&/6,FA!?Q/S26R+VMLAZ;ES_3TK53<O)UY=
M&MWT1 1ON.CQ,=LTUK:46#& \QQ,X_N3"Q&:F"Z&P0%?I;B6=B(#0!CM0$ZU
M-]O.8T"9_HYCZ#%K =V2$#X*D1M.^+ /3EYQQR<L#BB,.?%D@@D*"8T22),Z
MH!MSST<7AG2?[7QI--"L@;W0[8LCM\_CKF9?3(7FQ)1Q+GJ[QG<O//B@ +6-
MZ.U1S*:+WS[?]8^.X!X%12&&>[P-,PH3;>[2*HAN\T?>95MQ7$P"$L60Q"2"
MR(_ER8G+Q98)IY1S'R<H7%6[).VC,^QL3UKD=";WO,TY52>>!YM\ _<))[):
MX"NPX8I)_L;Q5>,E*ZA-3$)]&4$C)'C5BGD^ 9 VW8Q"88E;SO<S*Y&,JGO,
M&N,OF#O]9\U539UY>R,[X!LJ%U<6<D2#U(,DDOD^41I#[*<1C$.?4R2L&L1C
M7??^,WTMS8;IB:KOJ'\.3S52L(32U#?%>REW-_8[.>WZUX^ 8=&3_EQ/L_O,
MCZA\RCM^[!7]PXKWFS(33]X56'K;W^;K3#9X6^3T@T:":X56%O19M]*"5ES0
MR5M_XU)HSK8%5ZS"H;5IU\#):!.OTOYLFWH-9?N;?)W7# [GMFON.B1PKPO1
MQ>.F8CK.!:??7MJZ)J4$4DSH]M.N@KOV/(HSC5.ZTW@I'-1=#-749W6C*%GU
M'!C&P^S([G23\YW:#:IT<' W_*1AKNRLQ/?WA:PUEN6;F[3-0;M?MSP/(9Y$
M,@HB""%B 8-)[! 8IEZ8<N2%C&F9MF,=+HT'#N7M)\4VSU4T"KJ:_6L3RHEY
MXD(4]9-6*T)C*TOU6'?SIJ565/Y%'FK5]PQ"L=YOTC5^?*Q;OL/%/:_<]N*;
MLS@45.)+1HD@<E (L2=8)@P0<7D:N-A3<D@:[F9IM-(7%%2UI,#5B+XYC^<P
M=]A#:?+]10^@NQ8@DSBE\TAIQ"!906RF^**3GQ9XK,6U%3PTBL=@8-#YM^<+
M^AG5X""@9_SIRUP<<EY^S*M/,AZLX)^:+///^P + \^'X1:71H?].W\F1 >;
MO )%(SSHI#=SBQB!5F$3-@FJ4V_,^DX4$E A-OAT!"CX:C4PQ0RLBQTM1KKY
M(?X7:JJ?<\M0?/N"HIX'H?:B+WZJQ$Z:^&GL1#YT(C>%R"=<;OUB8:C1,$E\
M7QAG3+L"J$K/2V.G4UDE#*I_*H&NMO6;!,J)*:G+QC%-,)PN(#;K?RKU.W\=
M4!TX3M8#U6K U%L]IYRS\IU0X7U9;F5\ZTW:2V*T<FF"HMB+8>JQ6 8C$T@<
M'D&7(L>E*?6)HU1+4;G'I;%/)W!362AK199G*+2?1.W5GSVG*4+TK_\2>Z[W
M;S8J$2D,C^,D8G0H=)#K012X%,:)C\1*02/BIBYU7'<EUB^2_Y !ZO?\HX?(
M-O1J2X55."=>(@YQ?-_#L9_"SF9T@"(VUH("QOJ;.19 4?V7(0"J+T[D4=Q$
M&:PB-W%]FF#H$6FA4NY $K,0)G[H!VG@>FGJKS;R0),S-?)1[%EISB3-G.GW
M/]W4:7Q=VXI0KU[]&?U4+P9B5?C)QD*@.B(^XR3 00B)V") %), $HP<R"A-
M@E@LY#''W8C<6?3R-AZ6N]G\O+%! )DJ[&I+@4T4E^78/1*<9]^G^Q"IN=RY
MVUZ7Y<E]"(6V$_?1ZP9W2[]^2V5]C8V8R1]NV[/])$K\*(P3Z%#,( HCP4C,
MCZ&'Q<K@A#&/0J42.^<Z6-HFX=>_O0.=C.##S[?G#_K5\%.X1;H0E8F9XP4@
M)G='IY#1N#6Z$*&9[HO4/QV].Z(![0=OATZ]-]^]T(#4!S="0\^9&;VRQL1-
MVO.BJJ,Y.::4L3B&B>,Q&7\BMM8>P=!QXY2D"0LBIG7\<;*7I;'9ZWPM9,ZE
M$_\W?N!8)FW:_M\;2Z!ZP#)I6N\E/3/K-/1J1M7%@$Y,A)=C:2WD5@DR2[;4
MZ3YFM9P&U3RVDX8?-MY&YX_\#G\_==' 2>H3QT401XD'44I3F,2^ QV<ND%
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M) PJ-X78(S+9EK"F A:XGF?FT7^BLZ5M/'N1R3UI5;R']'%68P!;Z$W,!>;
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MZ0*>&F5J:V<KU &EU ?@O4+2[L'&U^)F(ZA\2S[YN,QS:=Y7 [1Z *$(D)J
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M&0R+&F%-"_;$_"4=H6JL._&EX^<KJ8& _">P4P+LM0!?.STLDIHYB)8XSD"
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M%[>FOR_]7/U^6]";XJXLVJQ0XN/]C5</.=N[XREN4E7:6MK*4Q?. +=%1KG
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M'+2\-%9MA5.O]'"(TS!17J3]Q)38RF7QX/.LMA?48CAL;[9Z"R?5Z-=4./V
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M>JE8\5/$&$1BZD&2Q@&,4I:Z+DUC$FN%O)[I9VGS<B<FV,LY]DUJX:JVJ%M
M:^+Y:P*4?O&381ALU3 YT\N\I4B&57U1463D<=,RIVN97.KS ^?5A[PY96\#
M) F.Q:1/4NC*@B"(.@3&ON=!&@7$)Q$FD1X?G.]J:9302@IJ44$GJVX]T[/
MJA&"';@FYH332$T0A#J.AK7:I&<[FKD>Z9C"+VN0CKYA>I/^?B.F77VXQ-_@
M"G=IT"./>3'G!#+*J; 8PA02[KLP=BAV$.>IYRK%HH]UM#1^:&^%>\("*>UH
M[G0]=(=IPB9F$Y.$*5P&=^C#6%QPA7ZFX9EOT(?5>WF!/O*\L>\B;N.,!</<
MI)_X-[[9\J;*8! Y(65A N,4R:H3A$#LA0PR+_*1BSP:8*U:'D.=+8T6#F65
M!X>MM&85( =Q5K,A;*$W,4&8 V?B(3B*B#W_O_-=S>W=-ZKT"=^]\7<,"823
M:G^">/T-9VO9ZKN\^(S7[?<=,9>YU ]AFC*Q^>""1TCB!3 E7-!($@:AK^?A
M/-[GXNA$B-P['+\".ZEAFA=0RFU(+ KX*_*+752GIAD+@.H3CCI$MGA'H<=Y
MZ4<=@A<LI/&J?F1872NJ=D!^R-?BE4_51B,([/3;2V.1IAY63TRQME;;8J,=
MV'4&K&&BL(/3Q+Q@"I%67-8P"D8A6&>:G"W::EBE?F#5R).FQQ*OZW3X=7QY
MD__[9EN5%=[(K*XK[,8TC-,4.@(S84'$"4S<*( A\7B2A!Z.XD3O<&*HNZ5-
M^W;/W8C<9#[HTMN#GMBZ1Q6#B*L>6-C"<9YC"V,(#8XO5)"YX!!CL/F9CS)4
M5'UYH*'TED$J/O9_[O);GLL@I7<;_>Q[IU]?&B<(,;=E55_;W>7@]NW-06ZX
M*_ NSZM-7IW/.ZN,V[A18 &RB:>_*EI3)- ;!L<L9]Z9-N=+DS>LU$%FO)%'
M#?T>NO2\OS[O?OROC!?2$_/Y@_3#K*_K49I$A) 4)HAX$)'8A4D2<.BZON.E
M+.*,:87^J'6[-*[H):3>"5N[&W^\_INF6X0:[&H'#O;!G)A%AG"T[SRAA8XM
M7PJU3N=UK= "XH6GA=[;!@% ,JA(6"QB;?DM6_.RRC>\\[;<5RY<^0[FOI<F
MD(:) U$J';(8B2'#V$^C('%=IK2#4>]R:2RT%QH\=E*#I\Z=N-C)K1%DH@;]
M,!M- ^C$3-3#<B<PV+EF?YH.2XT '>N8SA20H_J=V@K"T<)I,.A&K:7Y@FRT
M-#L(JM%[T[0>0X5E?N:WN-B(OLIK*CZO;9W,X@U/,YI5JX PUX_#%'JA])J+
M22CSD+HPH*'C,A(&#DWUZC.,=;DTTNY)"%@CHFZQAE&4U:Q%N]A-S,^=L*"3
M%KSJ(]D*?+[4IT%=!U5TK-5Y&.UPYKH/J@"\K .A_*;^850;&U'OBA0/H'JO
M+(T-6M'^HGZH]/]1]Z[+<>M*FNBK(&(Z^JP=(>S@!;Q-_Y)E>Q_'>%D:6VOW
MF5D_*G"5.5TBU625EM5/?P"25<6ZD 18(,69GNUE6220^8'XD$@D,MOZ#SN2
M1JH^\61NI+*VP^O0=)0GJ-W.;-Z?"\*W/3Z7?FT^<UK.X%T.OR\9^R;'27<B
M=;>PM'FE9-*?4SW(#$\Q.Z!,/.-:0N[S;MX *6?ZFK(M7H->P(PFXC >H^9E
M3[.S3=-AU=JS5N/I\1'G-"]>\J+:N*F;@_Q.G<47;W<YXRN/)31B6)WM!CY$
MB1M $G('$A0D6(0Q\X36E-?L;VES?Q]0W9+Y!E122YA!(SE0HIO'HO?AWL\5
M$Z Y,6G8 ')4E+H&/%<%J_>U/WO,NH:RET+7=5X;MXV_+4N^*9MH^%9273?
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M)3%$7)W<<M>#*,1Q&!+NA9YG5 )6M^>ED55+<)!767YH6_019[#Z@Z#'4Y-
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M6BTRJ&16Y_:/Z7.5,>[W;P]?V@DN;T"EAT':# U8^Q>G"1"=>/'1!1/\6:D
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M"!(48IBX/!;<3WR/^]INI,YNEL<9K<H8FTI2W?)V WAJN'ZLH#0Y0[0 >FP
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M3GR('>Y!-TP\UV<L< .C>7YH>FG36SF^U6&"<8S1#BJ]F3L.@(DGK-+]Y!Q
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M&IU! ''B.!!QG\!84 ?*?3_Q!4MP$/OCL@I>*]K26&>?2C!7*0&O+^=P;?[
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MA2(O8'6-]D\E/:C$'YW81V=@-+EK*KBGWE;;0OJ*M#L&B%G/K*/3]SLESS&
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MS78(\6,7XF[5D]MQ(=8Q\T:">BKSS]I7K6D9&L V;#'J##BA)6D@Y[Z%:3*
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M&X]+H7M@T6XX&'VT\7!&C@(';\YQ^9FNO+\L%W^LO[Q:G'\-\Q^3Y'6.+C+
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MZ>-]FUJ_A%F8)_SX!7'=SK2Z_:G]F%)/4-[(=+J"UKORZW1.BTW#[/UB-=T
M_!)MSBE&!K<%IVJYB5<<HE+DN#%7I%1<2M':WNA"U[%*J/JFZQL]2"++/-@
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M_D2GH1B!AZ 4"V2BE#JK+"GPQ9-YRZ*/S 7G>>NDR68#2T[9AN088#87Q C
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MSKMG*Q/V6&^4MESOL&K$_S'>F;1-,DW7/VJ[X_79/-=RGJ^;ET>,+"M?R-I
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MNP+,BU("TXPWSP^X3\6PT.E+WD_ Z@#FCPP^EX.I WH7<@9A?!U,G0M9ER9
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M6F=%.&2BXT3OXVGI!L(7^+)Q8C&-<5[.KBMAN-.5L/D0[X/6.7I*SO&[.W)
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MQ^R4[@-/=PD9:%CER:%TE "&MM4NXS"/-!R=_O>&;_?[V08?F1*>CH9,M<;
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MG(>,\S!?WZBH>'#_EVFS=P\A,SFS.I2OB)H[;P6G*T4;",':['0127<K3FA
MS,N:EWPP0$\MMJ%A^K\N\'PV33/RE<+!&[9":)VY)^35/DHNT+41'7E2@C.K
MI,@:N_7F;D'-L)[(R8!Z<L$-C=0.5\?KQ?FW, ^SZ7F(ET4"4EB+5@,S6,N/
M5*1CR.L4&&T*&>K,AFZC_0Y:?ICFRV.\U8\4S4C!]T GG%N[_L]IW2G>W+75
MLF2D;6JKZ,CYG(B_/(%ARMFDB!^AVQR,9B0-T_YY+"#M681# _=FW13M=>L#
M;INF7VQ-[,W0F4ON%N:29TZ P.)!L1*(SR9"0<EXEBS+V*T][W[K#M,$^N00
M[%$80^/L@8J].[:&RMQX05R37&A0B@OP-0U"R1*5"-(;K3M!Z]FEAFGW?'(T
MM67Y".+4OX19F"?\^ 7QSFA(EVWA7@%ZH4#Q5, K8R%8IY31O*30NA_38[0,
M:]'U]L[1A/4CA=#N*=$J%;(U!7)6#A0I40B*;,ZL R:3G#&AG !$8WC$;R/M
M#A Z@/4C -'[)7X-T[QK8;BYJ6OCWU?;?K_;_K^7&M:9J#P:",)@[?UKP9O,
MP 1?='$H[C6*/!I4W:D;'\@.P</B),(9 >PV^[CN*WUK*U'376X#JQTXZ6 6
MER PA:"1%Y8$3[KY,_\3Y S[6-$3L%JQ?P1(>L1,^.VJA#V2J<#(_@,5> 25
M?8%@/(,2T/-B30JJ]0R"YV@:-@K1FV'55!0C@-:]9"IR6>LWPF?D$Q>9*F:3
M^X?5E2&'E?9 >TE11XPVZ]BIE=\QB9(WZ!EE7>V!DG\N7?)0,8P 4H?TQ$#T
M3A5.YNG_W]Z7-;>5(VN^SW_!#/;E92)DEUW7-UR6PK([8IX46&U.43QJDG*7
MYM=/@J0D2N)RR ,*4$5U1%?9)1LGEP^)S$0B,R7@,[>D@RTID>8A<1Q,(+'T
M>7BJ?B:O_<BI# !/K;2"C4P&&;L7G-U/DKF[(LP89IA )#"5G8* ',4284+!
MU0@01]G2/75V$M3D(X-BYJZ0(FKG2;_?@.@F\[7YW%?!RB2L)<B#C[IT+YRQ
ML"TH=D11CL'S[)48?;EVDU6YPR!10HJU07 V'J_BEF\='-R+9D)PGI^[\6@I
MJYR)P0*B5(\64R!S_T.D(P2P(!/"\G 7ZOKUF=S_K293F@5 4EC*#7A*OZT^
MNY+1P[\6PQ/^7PSD"G-/>7(&>:,"XDS27'\,<2M6WIB0A#2EWY;L):K)R*[,
MN516(;7-TGT.;1(^WLYOI_&^^G+AS,U&O^+R_G)Y27D%-E6PW*DU$)/?,1..
MC,NMH8F$D-C;//FEEX4ZZ+-U;XI/9ZQ.)_OJJ.HUH5T0X;U* 24C.4C/ $?&
M.92"3UP3!0Z=[X>F/I^K>T-\0A05EW5M]&RHD5@R],C/]YMN<CGZ:_[S;#*!
MC3*=V>G=>7JX"[\2FG/B0T X\-SR+D><7CJ$@=:8J.2B9TW+<%KJS/@]/>Y>
M64NU0;G1FUR99H8C(R3WNU>>YB0'1]8XAC -T5%G,*?]#-F.CU2:VGMZ')42
M; .^^LZ4Q0M'\8IR@EWD%C$O-.***^2X#XA1B@7#C$9V@AX#!U!8:;QO_?32
M,%VU@$1[,YKGXM88[AG-(]7/KKOI?%7Q>D5,;OVJ XHQ7YQJ3I EE*!@2&!@
MF%P0I7OI]B"KTM3?U\%<8:VT +1-C8?S-?J7.+^B-'#O"482_,O<4P]XH23W
MOJ(Q<1ND9L6[7NR@I]( WVKF["@]M("IS=L$.%E%S%>&,^$Q> /1<1!7$B:/
M <DO0[637ADMG'D=T_5(5*4QOS4-UY$::1IBC]5 5XHE@24<\L9I#]ZGAVTC
MI$81!V.X)#B6[W/8@ZY^0'M;R?N3Z>4MS9=^=#?MS'Z-L]OQO$OO?^9W!+/1
MY%G>^013I8_Z_LEF20^7QBN/Y+!:6:8<>&Y!)\ ]%8![2<"1@^B "ZVMC87-
MQ6N-Y-A[Y2$=,5B"F^IL-O_2<.2"82@9HI1(6/-&[Z"J#^<X!#6'7T4=HI>V
MYP@]F(>UYU07TY'/(^4?;WU?_GC>S7_&S5?!)4UH>:K*&]832^Z5S2V<\G#H
MP\9)S!" =GZW$@3.[]X X20J@4N;G%<RMY?^9PRWXYA]JXWOEQ_?%MZ3\5#M
M\+&;+HK:9\LR9D*TD51%"/7R5;2B#GXE!7+")84=UE:53C&6H_YM&/!#</BB
M)7,=33<0@ W@=ZW[K!148H$%\@QGIO-K'R(\HAQ+0SRAS-+B-J  X76170MU
M+\J)7QL";QOW:RUR21!&J/RT._>8XHY)I%G4\%O'P*/C,OG2J?LBA->VZ*\.
MN'*0/U+[M:_-USO[?;/3'W%.[CNF::J8YP*Q%"$TB=0@EPR8#@VGJ1,:)-FO
M!'KK)]XLVH[5=5=<\.W!A]Y/^E):)D8,<$' [8H!1(2%121*9X3+_7CZ]9_;
M^HFZ+WF:@\\Q@J\-GP,F/ /J$Z5Y_I?!"G%O&4A*>F1,;KP3A0=1]<+36QG!
M7MD+/*5^:L.NSRN$%"FQ3(/5U5ED//=Y"HMJ<:F9II[K?IV1"KWUJ#YA_2#]
M'OKDXP!AMWAA]&D"OXS?[%_EQZGW77IP-O(H'@JE%!^^_=MHYL?=['8:'](W
M/CICL)8Y]>X0ITXA&V5"WB1OX?0TH?BMS0YRAH:7#TNO>J6\BY.81G.PT. $
M!&<0I2DWLS :N'2PV2RE440&NZ/TN]4MI-1URDLAX7E@5T+N#60G/J04<R/,
M^,#/5SN/JQKOT>3'^4V<KFPJ6&C*O:%(R'RSM*CUX!A^&QESF& B>.GBB/[4
MU?6L3@6R$VGG<-R9)>XFN08DAF^G._B^Y&X_BQ=0ES]!] \W6>>W\]G<3G*S
M@8L.CHCYR(['=[^-QK=9/)?1WTX7O5R7+0EB2(LD_O7-[7QUU[7XHS&LUK]9
MK3_@'*U$Z>!CN04)%SKE/]CI!,A]X.5ASP49R2)9%[@!UY* _;5*8N03D=HX
MEX0HW05P&RWEK@;/0"5AJSH^/E7'>7I.T#)P"UH&%Y) PHML)D RAF".E':"
MB."(>/[BO.#U8 D.ZGH311"W_4[PU57<@ <RD.=W=YL76&3NK=$X&IF;A!!P
MQIR,<"C*@!RGE$@J%7[>AGWXC+/3L=/*'>+KH_3Y(+5&(-/L[OEBK^_SP=X%
MZ0(S2 <&/J@!$6N?V]KA$+7@P%KQ>I!]-%6>Q-8*>'J!^DA--H#,RWGG_\RB
MA.AX^<)S;">K&X4\7$[DS)S77&16!+)4.10=-AP"Z,1D\=GOV\EI$8_'ZOVY
M:U%("0W@Z6L$5VOD(<)8,/5],IK/OEY^O[^C8CXR"2PPE7ME>$&1TS0@807E
M@7@<1>GW03L)JCSI[Y28*J>(!E#U 4+][B[&!2OW PA3E,90CW#B#JPXR;>G
M^8H"(&!@<QC)2S<XW4!&Y5%\IT304*$W@)N!7L3C+9B006JE>'XLY8%OJ\ *
MYVDPX 8G(RR/IG1O^5*TMW*;_=;CD>/ \/8WP=EU=SN97WEEHPR"(*KR>$(*
MSH@-R2!,(SC0*BDI2Y?U%R&\1;?QU)@K"_PC -#B9?WB&'MG9_D%ZZ.G_9!8
MW_SCU;7A@ N($I\=?)M0G/="5P./%W'G:?W37^,XWV#E)\:S!09=)NZ^?=I#
M.M>Y1##S&!F6GS4SQW-S]3SF5W&9N'"1E XGAE%<[IKAP3E;3I-=)CV>:_"Q
M!"<7D]V_/ESV<%I0NCQ4*2&)YH?:@IG\U)&!;2$FHI3-C&1$:5]:C"=AI/J,
M@=?"\O:KB5JP:,#-65Z^7X+"%R5LG]=G:2F6RZDA;-$Q,!"IS@/ "4;"64V%
MHP3;TO=I.\AIY8:@&E@V%ND,UUR[(%Q%XPPSG0P(B4<)T;-Q =A2! 6LDU*+
MEBSD=6#80HJ_F-K[P>D('30 J,TUX"O7;)64$3@8I;5%)DG8>UX;Y*2"V" P
M%ZB30A4?]=.#K";!=0P(>KT5.UXC34Q7^3U.XM2.@:>S<#V:C&:+<4:_XE.V
MB/,VI:20C :"4.%M?J&D490V3Z-T*M+2%T*]"&NAK/ 44"NOE08L6AFOXS$S
MDI*V(1B#@DNPUQAGR%"J 4K,$:V3D+1T:K8P"ZUD:%OQ!VLBI($-LN(LALV,
MKS;_5<!,.9,(PL2!8=&6(2<8^$G2@L]$M</%^ZSTHZQR[5]-\#Q/O);79)O-
MH/+PI_S_#_^^'?VRXYS8L)/PAYW^&>?9'#QFG>^M39=6W767F9'?I]UL]GTR
MC<L>@[_#R9E7R"7*,?_BHQU-_V7'MS%70$_[?^Y]-YF- '"Y6=W9+SL:YQ^G
M;GH)?\LM>@=TZ?%/#TCS_LTD,#CC_#>31\GD]W(ZR$N"SS83_) A)$(R815'
MS((3R8,'"V$,0Y%Q8XACP3Q_$;=M+,O!WQ[>J-#-UU:]%_O'I=A7CY6=)S:/
MBA;,"S"T.?C'W*"H39 D&D),Z=< /<BJ^$CWQ!!YV;2PK(X:\*0^CB9VXD?Y
M/2L(Z';Q>CYGEPBCUCIK$)9Y?$7*@3I-$N% 1&!)285+0VT+*96O+$JKO"LO
M_P9@M&C "%_.VV_I5N9'?6D#=XL6'[/-/UKE QP7B5IFD=?YM2&E%.G((F(4
M.RJ#LL&6SJ&4I+\N8(L JFM$NPT@^X]N$N^6)\K'VTF8K3)*L,FUB!"+4 N2
MY$H3Y)+6B&',):?6B<=.X84PNIF2NFBKAXRNN)H: -OWRV_@S<]NIW>/9\Z*
M$VT4\Q1#!!P4@0A8":15BBBQ%+V%0#O1TFT0ME-3-QW7#.@*J:MVSY_WW?0F
MM[=9=Y=SVYOKZSC-0KNP-W&ZXLO#/N(>CI$D&;C/G.,\Q1,CQI,-@CIG4L\Q
MJOT_6K> O#K:3JJC)HS>[]VO.)TL7)4?$227DPKK;O>*KTB-%S@I1' "%\9'
M@@QF$KD@B&5,,,=*][OI2UO=R?75(7I2538 T?=Q.A^E44Y4@_!^BS?=;#1?
ML1)TT$X%AH@D"J(_E;M_"8\PQR(2S(,CMC J=Y#3"X@G&[#3#!!+*:P![*T]
M#WF6?7C<58]W,=8:!>8?O V=7Q\)89#SA"+LO"#")IODZ0I5>Q!8UW,\=3;G
M=+IJ (C/67HFS/6;B7=V-EKT+L26295;AL%&D^ #FZ@QLL'8O-D2L%SZ^O5
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M/H6^&G3LMYVG]W/JG8Y,P?F)/$T$<<X,,MX&Q+BRP1/-.2G]0O= $NO$H35
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M>6XXXA:\)JN40,DG8:G%+OC20^K+>.GWJZV*1N]6C;&OF&%**ALAMK4,\0B
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MR[J5\5WL#JP3=QS<Q"1%/N&U1B;YB!RV5ABOC!+%TP#;B&EEZ$S9HZF,[%L
MT2/Y7^PU_'+-\*[VF:*)>B$C$B+?^!GFD2/*YT%FL/V"DN5'S^VGJG)FH(SZ
MGX.JK"YJ'U1G\V\_XVJ,O/6+V^.5H4T>OD48Q!T2&."&<S"YV""5]Y^V)$4N
M>QU56S]1&1Z%%=D5EVH#EF=AB5=2^OPP5,DI8G!B&N%$.020FN3Q2A1)2F*R
MW@EF2A?M;22DE4%498^MX3)O #@+ZC_-9K<Q_'8['4U^7,3IJ N7/T&TLR_Q
M/XL?@24.U BJ$\(D3S!1@8(1YA@YAZG/37V4/<G%SU[*ZMJF A!X?FR5U\?1
M*/L5IZXKA;/,P,5TY..5<"F8/,3!R$AS_UV*;)2P\>"_*9Y\\L]'- W'TL/7
MZR9W3H"7X^3:!B8V8WW1,G0-ZDY[(S"((SJ1*S@=TN"Z(/B_YC8I:\N7@/0A
MK&XL]FJ69X VF@#9^^[ZNILL\^QV>CY=M(I;<@4,+K;/5=#.@[]'$74X/U 6
M AD- C12>Q*E50:7?B37@ZRZ7E-Y@)761.V0;#U:O9W_[*;+0>43"&97#37/
M)VNQRA4EPFCM-;(0UR+.(T<V$8R\=A&;%*TS_9Z2'/CAND\NR^'HY$)OP1U?
M"W97 S*6KM_2,']ZPIN'(YYH..8#1"^P62R<]=+"CG&&.R]"P*9T]_-#Z*O[
M-/,$!^2I=-,6[IYLIOMG-D\W50H):/ ,Q2AS].$PTIY;,-7$!V.I%/2$P-M/
M8"_DJ3>)O,+::;&P]V&"ZMJ[P+51Q\MV;W:RWFEF]2>#G3_\Y85T;J?9D7UG
M9Z,A[X5/2]#@LN%7E%>A*N,-,W+7GLM$@IF,$BFB8:-@B&6UB18E"#LBT2Q)
M4KH+RBYZAEK6A[67>CC;J(?S1^$OBXZF3W2QS%4Z0DE* NP&IA#?<^*1EMHB
MV.[6VA03=Z4?=Q0COFZ:KAC>GAOF.LIMP%]X8/S=W9K5^3B-_[Z-$[\J*]&:
MV$@]<BDWE2/>@^NM(I+.86T#Y=Z5[G#8@ZQ&D/BZ@-D&VT+::PF0FQA:71-*
M9V2(AB&K\KR82'(])2.(.FXLY\"4+IWFZ4%6(X L!85M4"NDET:A-GO8L:O[
M8Y<LII$2Y*7"^50QR$5!$0[!:TL<QJETB-2'KD; 5@H,/< V2#,MH>W=W<,O
M_VL$ >#4_[S[G)N[+O:HB\YBJ^$0B($A;DF>D8XY(IQS9R6F.)6N*^I'6=T+
MM^;.VU(Z; F9Z[OM)7^K?2V(-=S1A&1@X&8K<+,MQ;"Y-38F:6LE*WV-=Q"!
MC5C&@@CI8QR+J*LE+'Z:W-S.9PN)D97!YQY;PWA$QFL".S<EX((XE#@65#O'
M72A=P+N#G$9P5AX$V^ V4".-@HNN6#'!)*8,S;YQ'C?!,'+!)<2DD9(XX=3I
M@MR7Y#1RV%8!US$::11<[+X(E43.F5>()ZOR@U6<'P J%(ED-B65$BO]S'<'
M.74+7NJ"ZQB-M 2N=W<+!WAQ-;7P)%3N(P/A#FP+ F%6[G1M<&:$!V,"Q<87
M+^C<2DPCP&HE1!B@J98@MQ3G!@$N)/9]TKE9G"[:EBWV66YV-LDE^ O%KTMA
MM:6=8#I*9I# TH+O"W)V)!=M.\,LCLS1TR&V,"^-^(##H+;[*J2.WAO _Q_=
M)-ZMGI3<3L)]GP#8^AR."(EL?L_$$T\(3B@-_V# '[8QLM+YF<V4-(*]JBCI
MBJNL >!]O_PV78CS[G'R\GW*TQA/:52(> ;",3GE&4A""D(M J$8,:FTZ=Q.
M32,Q2DL +*2ZV@6Q[[OI33>U\_71WY.0RW[C=#&1V][$Z8HOK2/!TBD$@LIU
MY'#*..L=TLHR$U+DY'E29EOWZ_X?;<K/K(N\D^JK-@Z_SW[O?L7I9-'XZ4>^
M6SIWX]&/A?SNMY5(E$3ID5>Y)Z]U >(X#4&B-S@9$:)5NA?\]G^K;AE_>Z@K
MK)TF3MYG'"TFC+KY"V-NHD[*"XZPQQKXHAHY9AWR7 H5G _2E#^'^]%6]Y%
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MR4>Y \^1) 0"DU$)YSBWO3"R_UMU#[I7PTQAH=<.T;*(EOV:. 01P0>$3=
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MNOF*U#(W;?V_4BV=653/.^1W>HN^^D'^AX/(^'__C_\/4$L! A0#%     @
M<H%G5_RU"LL*"   I"@  !4              ( !     &$R,#(S<3-E>&AI
M8FET,S$Q+FAT;5!+ 0(4 Q0    ( '*!9U?2IH,<!@@  +4H   5
M      "  3T(  !A,C R,W$S97AH:6)I=#,Q,BYH=&U02P$"% ,4    " !R
M@6=7&N#X79,$   6$@  %0              @ %V$   83(P,C-Q,V5X:&EB
M:70S,C$N:'1M4$L! A0#%     @ <H%G5RVK7UZ/!   'Q(  !4
M     ( !/!4  &$R,#(S<3-E>&AI8FET,S(R+FAT;5!+ 0(4 Q0    ( '*!
M9U>(1'C?NPT  +Q8   >              "  ?X9  !E>&AI8FET,3 Q87)C
M=7-T86EH;VUE;6]R82YH=&U02P$"% ,4    " !R@6=7'8U+<!ZP 0 LQQ(
M$0              @ 'U)P  <F-U<RTR,#(S,#DS,"YH=&U02P$"% ,4
M" !R@6=7#P;FCO83   4V   $0              @ %"V $ <F-U<RTR,#(S
M,#DS,"YX<V102P$"% ,4    " !R@6=7_ 1_KC(5  "=Q0  %0
M    @ %G[ $ <F-U<RTR,#(S,#DS,%]C86PN>&UL4$L! A0#%     @ <H%G
M5Q&@,K'L20  ""X# !4              ( !S $" ')C=7,M,C R,S Y,S!?
M9&5F+GAM;%!+ 0(4 Q0    ( '*!9U>=]OQK[M\  ,9  0 4
M  "  >M+ @!R8W5S+3(P,C,P.3,P7V<Q+FIP9U!+ 0(4 Q0    ( '*!9U>@
M:U4BL'\  &[G   4              "  0LL P!R8W5S+3(P,C,P.3,P7V<R
M+FIP9U!+ 0(4 Q0    ( '*!9U<#S<S)%)$  +C!   4              "
M >VK P!R8W5S+3(P,C,P.3,P7V<S+FIP9U!+ 0(4 Q0    ( '*!9U?"1,PQ
M1"D  %EV   4              "  3,]! !R8W5S+3(P,C,P.3,P7V<T+FIP
M9U!+ 0(4 Q0    ( '*!9U=R2:V<.BD  +QW   4              "  :EF
M! !R8W5S+3(P,C,P.3,P7V<U+FIP9U!+ 0(4 Q0    ( '*!9U>F,RWEE1H
M *XG   4              "  160! !R8W5S+3(P,C,P.3,P7V<V+FIP9U!+
M 0(4 Q0    ( '*!9U=)[^W;%]8  %[N"  5              "  =RJ! !R
M8W5S+3(P,C,P.3,P7VQA8BYX;6Q02P$"% ,4    " !R@6=76T P,P!]  #O
MH@4 %0              @ $F@04 <F-U<RTR,#(S,#DS,%]P<F4N>&UL4$L%
3!@     1 !$ ;@0  %G^!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
